PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
10373522-2	1999	PI 3-kinase also regulates the activity of p70(s6k), the 40S ribosomal protein S6 kinase, a response that is abrogated by the macrolide rapamycin.	Sirolimus	136-145	ribosomal protein S6 kinase B1	Homo sapiens	43-50
10373483-5	1999	TNFalpha inhibited p70(s6k) activation by glucose-stimulated beta-cells of the islets of Langerhans in a dose- and time-dependent manner, with maximal inhibition observed at approximately 20-50 ng/ml, detected after 24 and 48 h of exposure.	Glucose	42-49	ribosomal protein S6 kinase B1	Homo sapiens	19-26
10206976-7	1999	Leucine also stimulated phosphorylation of the ribosomal protein S6 kinase, p70(S6k), resulting in increased phosphorylation of S6.	Leucine	0-7	ribosomal protein S6 kinase B1	Homo sapiens	80-83
10212283-1	1999	To understand the mechanisms of prostaglandin F2alpha (PGF2alpha)-induced protein synthesis in vascular smooth muscle cells (VSMC), we have studied its effect on two major signal transduction pathways: mitogen-activated protein kinases and phosphatidylinositol 3-kinase (PI3-kinase) and their downstream targets ribosomal protein S6 kinase (p70(S6k)) and eukaryotic initiation factor eIF4E and its regulator 4E-BP1.	Dinoprost	32-53	ribosomal protein S6 kinase B1	Homo sapiens	341-348
10212283-1	1999	To understand the mechanisms of prostaglandin F2alpha (PGF2alpha)-induced protein synthesis in vascular smooth muscle cells (VSMC), we have studied its effect on two major signal transduction pathways: mitogen-activated protein kinases and phosphatidylinositol 3-kinase (PI3-kinase) and their downstream targets ribosomal protein S6 kinase (p70(S6k)) and eukaryotic initiation factor eIF4E and its regulator 4E-BP1.	Dinoprost	55-64	ribosomal protein S6 kinase B1	Homo sapiens	341-348
10212283-2	1999	PGF2alpha induced the activities of extracellular signal-regulated kinase 2 (ERK2) and Jun N-terminal kinase 1 (JNK1) groups of mitogen-activated protein kinases, PI3-kinase, and p70(S6k) in a time-dependent manner in growth-arrested VSMC.	Dinoprost	0-9	ribosomal protein S6 kinase B1	Homo sapiens	183-186
10212283-4	1999	Whereas inhibition of PI3-kinase by wortmannin completely blocked the p70(S6k) activation, it only partially decreased the ERK2 activity, and had no significant effect on global protein synthesis and bFGF-2 expression induced by PGF2alpha.	Wortmannin	36-46	ribosomal protein S6 kinase B1	Homo sapiens	70-77
10212283-5	1999	Rapamycin, a potent inhibitor of p70(S6k), also failed to prevent PGF2alpha-induced global protein synthesis and bFGF-2 expression, although it partially decreased ERK2 activity.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	37-40
10200280-7	1999	FRAP also is shown to phosphorylate PP2A in vitro, consistent with a model in which phosphorylation of PP2A by FRAP prevents the dephosphorylation of 4E-BP1 and p70(s6k), whereas amino acid deprivation or rapamycin treatment inhibits FRAP"s ability to restrain the phosphatase.	Sirolimus	205-214	ribosomal protein S6 kinase B1	Homo sapiens	161-168
10085104-6	1999	Similarly, although p70(s6k) was activated during GH priming, pretreatment of cells with rapamycin, which prevented the activation of p70(s6k), had no effect on GH priming.	Sirolimus	89-98	ribosomal protein S6 kinase B1	Homo sapiens	134-141
10200280-2	1999	Depriving cells of amino acids or treating them with the small molecule rapamycin inhibits FRAP and results in rapid dephosphorylation and inactivation of the translational regulators 4E-BP1(eukaryotic initiation factor 4E-binding protein 1) and p70(s6k) (the 70-kDa S6 kinase).	Sirolimus	72-81	ribosomal protein S6 kinase B1	Homo sapiens	246-253
10200280-5	1999	A calyculin A-sensitive phosphatase is required for the rapamycin- or amino acid deprivation-induced dephosphorylation of p70(s6k), and treatment of Jurkat I cells with rapamycin increases the activity of the protein phosphatase 2A (PP2A) toward 4E-BP1.	Sirolimus	56-65	ribosomal protein S6 kinase B1	Homo sapiens	122-129
10082559-3	1999	Data accumulated thus far support a model whereby p70S6K activation requires sequential phosphorylations at proline-directed residues in the putative autoinhibitory pseudosubstrate domain, as well as threonine 389.	Proline	108-115	ribosomal protein S6 kinase B1	Homo sapiens	50-56
10082559-3	1999	Data accumulated thus far support a model whereby p70S6K activation requires sequential phosphorylations at proline-directed residues in the putative autoinhibitory pseudosubstrate domain, as well as threonine 389.	Threonine	200-209	ribosomal protein S6 kinase B1	Homo sapiens	50-56
10082559-12	1999	This work provides evidence for a link between a phorbol ester-insensitive PKC isoform and p70S6K.	Phorbol Esters	49-62	ribosomal protein S6 kinase B1	Homo sapiens	91-97
10226782-4	1999	In that study we found that PD098059, an inhibitor of MEK activation, inhibited the proliferative response, but dramatically enhanced IGF-stimulated differentiation which was associated with elevation of p70s6k activity.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	28-36	ribosomal protein S6 kinase B1	Homo sapiens	204-210
10029080-14	1999	To examine the rate at which the mTOR pathway recovered, the ability of IGF-I to stimulate p70S6K activity was followed in cells treated for 1 h with rapamycin and then allowed to recover in medium containing > or =100-fold excess of FK506 (to prevent rapamycin from rebinding to its cytosolic receptor FKBP-12).	Sirolimus	150-159	ribosomal protein S6 kinase B1	Homo sapiens	91-97
9895282-8	1999	However, inhibition of p70S6 kinase (p70(s6k)) with rapamycin or of mitogen-activated protein kinase (MAPK) with PD098059 does not preclude insulin effects on GLUT4 gene expression or glucose uptake.	Sirolimus	52-61	ribosomal protein S6 kinase B1	Homo sapiens	37-44
9914383-2	1998	In mammalian cells, rapamycin selectively inhibits phosphorylation and activation of p70 S6 kinase (p70(S6K)), a protein involved in the translation of a subset of mRNAs, without affecting other known kinases.	Sirolimus	20-29	ribosomal protein S6 kinase B1	Homo sapiens	107-108
9873015-5	1999	A partial decrease in the fold activation of GS was, however, observed when p70(S6k) activation was blocked with rapamycin, suggesting a contribution of this pathway to the control of GS by either hormone.	Sirolimus	113-122	ribosomal protein S6 kinase B1	Homo sapiens	80-83
10427963-3	1999	Bau is a splice form of Neurabin-I, one of two related F-actin-binding proteins that are proposed to link cadherin-based cell-cell adhesion sites with the growth regulatory kinase p70S6K.	5-benzylacyclouridine	0-3	ribosomal protein S6 kinase B1	Homo sapiens	180-186
10427963-8	1999	We suggest that Bau may link Bin1 to the Neurabin-I/p70S6K system in muscle and other cells, perhaps providing a mechanism to influence adhesion-dependent signals which affect cell fate.	5-benzylacyclouridine	16-19	ribosomal protein S6 kinase B1	Homo sapiens	52-58
9852118-7	1998	These findings support the interpretation that increasing cAMP attenuates the effects of insulin on PHAS-I, p70(S6K), and other downstream targets of the mTOR signaling pathway by inhibiting the phosphorylation and activation of mTOR.	Cyclic AMP	58-62	ribosomal protein S6 kinase B1	Homo sapiens	112-115
9914383-6	1998	In quiescent mammalian cells (human lymphocytes and CHEF cells) induced with growth factor to re-enter the cell cycle, rapamycin was effective when cells were exposed at the time of p70(S6K) activation.	Sirolimus	119-128	ribosomal protein S6 kinase B1	Homo sapiens	182-185
9804755-6	1998	Similarly to p70alpha, the catalytic activity of p70beta toward ribosomal protein S6 could be rapidly activated by serum, insulin, and phorbol ester in transiently transfected cells.	Phorbol Esters	135-148	ribosomal protein S6 kinase B1	Homo sapiens	13-21
9774438-12	1998	We propose that amino acids, in particular branched-chain amino acids, may promote beta-cell proliferation either by stimulating phosphorylation of PHAS-I and p70(s6k) via the mammalian target of rapamycin pathway and/or by facilitating the proliferative effect mediated by growth factors such as insulin and IGF-I.	Amino Acids, Branched-Chain	43-69	ribosomal protein S6 kinase B1	Homo sapiens	159-166
9751223-2	1998	Full activation of MAPK requires tyrosine and threonine phosphorylation whereas that of p70S6K requires serine phosphorylation.	Serine	104-110	ribosomal protein S6 kinase B1	Homo sapiens	88-94
9774384-5	1998	PECAM-1/CD31-dependent recruitment of PI3K was suggested by the finding that the serine/threonine kinase p70 S6 kinase (S6K), a signaling protein downstream of PI3K, is activated in neutrophils upon PECAM-1/CD31 cross-linking, based on the appearance of serine phosphorylation in S6K immunoprecipitates.	Serine	81-87	ribosomal protein S6 kinase B1	Homo sapiens	120-123
9774384-5	1998	PECAM-1/CD31-dependent recruitment of PI3K was suggested by the finding that the serine/threonine kinase p70 S6 kinase (S6K), a signaling protein downstream of PI3K, is activated in neutrophils upon PECAM-1/CD31 cross-linking, based on the appearance of serine phosphorylation in S6K immunoprecipitates.	Serine	81-87	ribosomal protein S6 kinase B1	Homo sapiens	280-283
9751223-3	1998	In the present study, okadaic acid, which inhibits serine/threonine protein phosphatase activity, was used to explore the linkage of MAPK and p70S6K activation to down-stream effects of prolactin in Nb2 cells.	Okadaic Acid	22-34	ribosomal protein S6 kinase B1	Homo sapiens	142-148
9751223-5	1998	Addition of okadaic acid alone a) stimulated and sustained p70S6K activity (5- to 8-fold) and MAPK (3.5- to 5-fold); and b) increased protein synthesis with the maximum effect being about equal to that of prolactin (2.1-fold with 1 nMokadaic acid versus 2.3-fold with 0.2 nMprolactin).	Okadaic Acid	12-24	ribosomal protein S6 kinase B1	Homo sapiens	59-65
9675059-8	1998	The third step of purification consists of a single affinity chromatography column in which the ligand is a 20-residue peptide containing the structural motif required for recognition and binding by p70(S6k).	Peptides	119-126	ribosomal protein S6 kinase B1	Homo sapiens	203-206
9768361-3	1998	Recent reports have also shown that the phosphoinositide-dependent protein kinase-1 (PDK-1), which binds with high affinity to the PI 3-kinase lipid product phosphatidylinositol-3,4,5-trisphosphate (Ptdins-3,4,5-P3), phosphorylates and potently activates two other PI 3-kinase targets, the protein kinases Akt/PKB and p70S6K.	phosphatidylinositol 3,4,5-triphosphate	157-197	ribosomal protein S6 kinase B1	Homo sapiens	318-324
9768361-3	1998	Recent reports have also shown that the phosphoinositide-dependent protein kinase-1 (PDK-1), which binds with high affinity to the PI 3-kinase lipid product phosphatidylinositol-3,4,5-trisphosphate (Ptdins-3,4,5-P3), phosphorylates and potently activates two other PI 3-kinase targets, the protein kinases Akt/PKB and p70S6K.	phosphatidylinositol 3,4,5-triphosphate	199-214	ribosomal protein S6 kinase B1	Homo sapiens	318-324
9733756-2	1998	Biochemical and confocal microscopy analyses at the level of the cardiocyte revealed that p70(S6K) is present predominantly in the cytosol, substantially activated in 1-h RVPO (>12 fold), and phosphorylated in the pseudosubstrate domain at the Ser-411, Thr-421, and Ser-424 sites.	Serine	247-250	ribosomal protein S6 kinase B1	Homo sapiens	90-97
9733756-2	1998	Biochemical and confocal microscopy analyses at the level of the cardiocyte revealed that p70(S6K) is present predominantly in the cytosol, substantially activated in 1-h RVPO (>12 fold), and phosphorylated in the pseudosubstrate domain at the Ser-411, Thr-421, and Ser-424 sites.	Threonine	256-259	ribosomal protein S6 kinase B1	Homo sapiens	90-97
9733756-2	1998	Biochemical and confocal microscopy analyses at the level of the cardiocyte revealed that p70(S6K) is present predominantly in the cytosol, substantially activated in 1-h RVPO (>12 fold), and phosphorylated in the pseudosubstrate domain at the Ser-411, Thr-421, and Ser-424 sites.	Serine	269-272	ribosomal protein S6 kinase B1	Homo sapiens	90-97
9733756-3	1998	p85(S6K), which was localized exclusively in the nucleus, showed activation subsequent to p70(S6K), with a sustained increase in phosphorylation for up to 48 h of RVPO at equivalent sites of p70(S6K), Thr-421 and Ser-424, but not at Ser-411.	rvpo	163-167	ribosomal protein S6 kinase B1	Homo sapiens	0-7
9733756-3	1998	p85(S6K), which was localized exclusively in the nucleus, showed activation subsequent to p70(S6K), with a sustained increase in phosphorylation for up to 48 h of RVPO at equivalent sites of p70(S6K), Thr-421 and Ser-424, but not at Ser-411.	rvpo	163-167	ribosomal protein S6 kinase B1	Homo sapiens	4-7
9733756-3	1998	p85(S6K), which was localized exclusively in the nucleus, showed activation subsequent to p70(S6K), with a sustained increase in phosphorylation for up to 48 h of RVPO at equivalent sites of p70(S6K), Thr-421 and Ser-424, but not at Ser-411.	Threonine	201-204	ribosomal protein S6 kinase B1	Homo sapiens	0-7
9733756-3	1998	p85(S6K), which was localized exclusively in the nucleus, showed activation subsequent to p70(S6K), with a sustained increase in phosphorylation for up to 48 h of RVPO at equivalent sites of p70(S6K), Thr-421 and Ser-424, but not at Ser-411.	Threonine	201-204	ribosomal protein S6 kinase B1	Homo sapiens	4-7
9733756-3	1998	p85(S6K), which was localized exclusively in the nucleus, showed activation subsequent to p70(S6K), with a sustained increase in phosphorylation for up to 48 h of RVPO at equivalent sites of p70(S6K), Thr-421 and Ser-424, but not at Ser-411.	Serine	213-216	ribosomal protein S6 kinase B1	Homo sapiens	0-7
9733756-3	1998	p85(S6K), which was localized exclusively in the nucleus, showed activation subsequent to p70(S6K), with a sustained increase in phosphorylation for up to 48 h of RVPO at equivalent sites of p70(S6K), Thr-421 and Ser-424, but not at Ser-411.	Serine	213-216	ribosomal protein S6 kinase B1	Homo sapiens	4-7
9733756-3	1998	p85(S6K), which was localized exclusively in the nucleus, showed activation subsequent to p70(S6K), with a sustained increase in phosphorylation for up to 48 h of RVPO at equivalent sites of p70(S6K), Thr-421 and Ser-424, but not at Ser-411.	Serine	233-236	ribosomal protein S6 kinase B1	Homo sapiens	0-7
9733756-3	1998	p85(S6K), which was localized exclusively in the nucleus, showed activation subsequent to p70(S6K), with a sustained increase in phosphorylation for up to 48 h of RVPO at equivalent sites of p70(S6K), Thr-421 and Ser-424, but not at Ser-411.	Serine	233-236	ribosomal protein S6 kinase B1	Homo sapiens	4-7
9733756-5	1998	Further studies to determine potential upstream elements of S6K activation revealed: (i) similar time course of activation for protein kinase C isoforms (alpha, gamma, and epsilon) and c-Raf, (ii) absence of accompanying phosphatidylinositol 3-kinase activation, (iii) activation of c-Src subsequent to p70(S6K), and (iv) similar changes in adult cardiocytes after treatment with 12-O-tetradecanoylphorbol-13-acetate.	Tetradecanoylphorbol Acetate	380-416	ribosomal protein S6 kinase B1	Homo sapiens	60-63
9858932-0	1998	Evidence that phosphatidylinositol 3-kinase and p70S6K protein are involved in differentiation of HL-60 cells induced by calcitriol.	Calcitriol	121-131	ribosomal protein S6 kinase B1	Homo sapiens	48-54
9465032-4	1998	RAFT1 phosphorylates p70(S6k) on Thr-389, a residue whose phosphorylation is rapamycin-sensitive in vivo and necessary for S6 kinase activity.	Threonine	33-36	ribosomal protein S6 kinase B1	Homo sapiens	25-28
9578588-3	1998	We have shown earlier that different vanadium salts stimulate the MAP kinase pathway and ribosomal-S-6-kinase (p70s6k) in chinese hamster ovary cells overexpressing human insulin receptor (CHO-HIR cells) [Pandey, S. K., Chiasson, J.-L., and Srivastava, A. K. (1995) Mol.	vanadium salts	37-51	ribosomal protein S6 kinase B1	Homo sapiens	111-117
9578588-8	1998	Treatment of CHO-HIR cells with VS resulted in increased glycogen synthesis and PI3-k activity which were blocked by pretreatment of the cells with wortmannin and LY294002, two specific inhibitors of PI3-k. On the other hand, PD98059 and rapamycin, specific inhibitors of the MAP kinase pathway and p70s6k, respectively, were unable to inhibit VS-stimulated glycogen synthesis.	Wortmannin	148-158	ribosomal protein S6 kinase B1	Homo sapiens	299-305
9578588-8	1998	Treatment of CHO-HIR cells with VS resulted in increased glycogen synthesis and PI3-k activity which were blocked by pretreatment of the cells with wortmannin and LY294002, two specific inhibitors of PI3-k. On the other hand, PD98059 and rapamycin, specific inhibitors of the MAP kinase pathway and p70s6k, respectively, were unable to inhibit VS-stimulated glycogen synthesis.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	163-171	ribosomal protein S6 kinase B1	Homo sapiens	299-305
9528776-5	1998	Treatment of mammalian cells with rapamycin abolishes in vivo S6 phosphorylation by p70s6k; however, ectopic expression of AtS6k2 rescues the rapamycin block.	Sirolimus	34-43	ribosomal protein S6 kinase B1	Homo sapiens	84-90
9614117-1	1998	The carboxyl terminus of p70 S6 kinase (p70(s6k)) has a set of Ser and Thr residues (Ser411, Ser418, Ser424, and Thr421) phosphorylated in vivo by an unidentified kinase(s).	Serine	63-66	ribosomal protein S6 kinase B1	Homo sapiens	40-48
9614117-1	1998	The carboxyl terminus of p70 S6 kinase (p70(s6k)) has a set of Ser and Thr residues (Ser411, Ser418, Ser424, and Thr421) phosphorylated in vivo by an unidentified kinase(s).	Threonine	71-74	ribosomal protein S6 kinase B1	Homo sapiens	40-48
9531494-4	1998	CPPD crystals induced a robust, transient activation (peak activity at 2 min) of p70(S6K) that was fully inhibited by pretreatment with rapamycin.	Sirolimus	136-145	ribosomal protein S6 kinase B1	Homo sapiens	85-88
9468542-8	1998	Furthermore, although PI3K in anti-phosphotyrosine immunoprecipitates is only very weakly activated by ionomycin, the calcium-induced stimulation of p70(S6k) is completely inhibited by the specific PI3K inhibitor wortmannin.	Calcium	118-125	ribosomal protein S6 kinase B1	Homo sapiens	153-156
9468542-8	1998	Furthermore, although PI3K in anti-phosphotyrosine immunoprecipitates is only very weakly activated by ionomycin, the calcium-induced stimulation of p70(S6k) is completely inhibited by the specific PI3K inhibitor wortmannin.	Wortmannin	213-223	ribosomal protein S6 kinase B1	Homo sapiens	153-156
9468542-11	1998	p70(S6k) requires a separate calcium-dependent and wortmannin-sensitive process that is likely to be independent of type IA PI3K family members.	Calcium	29-36	ribosomal protein S6 kinase B1	Homo sapiens	4-7
9468542-11	1998	p70(S6k) requires a separate calcium-dependent and wortmannin-sensitive process that is likely to be independent of type IA PI3K family members.	Wortmannin	51-61	ribosomal protein S6 kinase B1	Homo sapiens	4-7
9492293-3	1998	In mammals, activation of p70 ribosomal S6 kinase (p70S6k) has been implicated in translational control, in particular the selective up-regulation of translation of mRNAs with polypyrimidine tracts at their 5" start sites.	polypyrimidine	176-190	ribosomal protein S6 kinase B1	Homo sapiens	51-57
9458731-3	1998	The stimulation of protein synthesis was accompanied by increased phosphorylation of p70S6k, an effect that was blocked by rapamycin and wortmannin but not PD-98059.	Sirolimus	123-132	ribosomal protein S6 kinase B1	Homo sapiens	85-91
9458731-3	1998	The stimulation of protein synthesis was accompanied by increased phosphorylation of p70S6k, an effect that was blocked by rapamycin and wortmannin but not PD-98059.	Wortmannin	137-147	ribosomal protein S6 kinase B1	Homo sapiens	85-91
9427627-4	1998	RESULTS: When equipped with an amino-terminal plasma membrane localization sequence and expressed in HEK293 cells, these chimeric receptors could signal to downstream targets as indicated by the FK1012-dependent activation of p70 S6 kinase (p70(S6k)) and mitogen-activated protein (MAP) kinase.	FK 1012	195-201	ribosomal protein S6 kinase B1	Homo sapiens	241-248
9388274-7	1997	The role of PI 3-kinase in regulating heat shock activation of MAPK and p70 S6K was investigated using wortmannin, a specific pharmacological inhibitor of PI 3-kinase.	Wortmannin	103-113	ribosomal protein S6 kinase B1	Homo sapiens	72-79
9468542-0	1998	Differential regulation by calcium reveals distinct signaling requirements for the activation of Akt and p70S6k.	Calcium	27-34	ribosomal protein S6 kinase B1	Homo sapiens	105-111
9468542-6	1998	Depletion of intracellular calcium stores by EGTA pretreatment has no effect on growth factor-induced Akt activation but completely abolishes p70(S6k) stimulation.	Calcium	27-34	ribosomal protein S6 kinase B1	Homo sapiens	146-149
9468542-6	1998	Depletion of intracellular calcium stores by EGTA pretreatment has no effect on growth factor-induced Akt activation but completely abolishes p70(S6k) stimulation.	Egtazic Acid	45-49	ribosomal protein S6 kinase B1	Homo sapiens	146-149
9468542-7	1998	Increase of intracellular calcium induced by ionomycin or thapsigargin results in a full activation of p70(S6k), whereas little or no activation of Akt is observed.	Calcium	26-33	ribosomal protein S6 kinase B1	Homo sapiens	107-110
9468542-7	1998	Increase of intracellular calcium induced by ionomycin or thapsigargin results in a full activation of p70(S6k), whereas little or no activation of Akt is observed.	Ionomycin	45-54	ribosomal protein S6 kinase B1	Homo sapiens	107-110
9468542-7	1998	Increase of intracellular calcium induced by ionomycin or thapsigargin results in a full activation of p70(S6k), whereas little or no activation of Akt is observed.	Thapsigargin	58-70	ribosomal protein S6 kinase B1	Homo sapiens	107-110
9388274-8	1997	The results demonstrated that wortmannin inhibited heat shock activation of p70 S6K but only partially inhibited heat activation of MAPK.	Wortmannin	30-40	ribosomal protein S6 kinase B1	Homo sapiens	76-83
9299479-4	1997	These effects were completely reversed by a commonly used PI-3-kinase inhibitor, wortmannin, suggesting that p70S6K may be a downstream target of PI-3-kinase in a signaling cascade induced by gastrin.	Wortmannin	81-91	ribosomal protein S6 kinase B1	Homo sapiens	109-115
21528277-0	1997	Rapamycin inhibits substance P-induced protein synthesis and phosphorylation of PHAS-I (4E-BP1) and p70 S6 kinase (p70(S6K)) in human astrocytoma cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	100-103
21528277-6	1997	Further, we demonstrate that SP is potent in stimulating PHAS-I protein (also known as 4E-BP1) phosphorylation and p70 S6 kinase (p70(S6K)) phosphorylation and enzymatic activity, and that this stimulation is inhibited by subnanomolar concentrations of rapamycin.	TFF2 protein, human	29-31	ribosomal protein S6 kinase B1	Homo sapiens	115-118
9266970-5	1997	Moreover, Dex-induced apoptosis is associated with a significant decrease in the activities of mitogen activated protein kinase (MAPK) and p70S6K, whereas IR-treatment does not alter the activity of these kinases.	Dexamethasone	10-13	ribosomal protein S6 kinase B1	Homo sapiens	139-145
9248697-7	1997	Incubating 3T3-L1 adipocytes with rapamycin and wortmannin inhibited insulin-stimulated phosphorylation of PHAS-I at concentrations similar to those that inhibited activation of p70S6K.	Sirolimus	34-43	ribosomal protein S6 kinase B1	Homo sapiens	178-184
9245714-6	1997	We also demonstrated that gastrin precursors activate the serine/threonine kinase, p70 kDa S6 kinase (p70S6K), through a wortmannin sensitive pathway.	Wortmannin	121-131	ribosomal protein S6 kinase B1	Homo sapiens	83-100
9245714-6	1997	We also demonstrated that gastrin precursors activate the serine/threonine kinase, p70 kDa S6 kinase (p70S6K), through a wortmannin sensitive pathway.	Wortmannin	121-131	ribosomal protein S6 kinase B1	Homo sapiens	102-108
9242178-3	1997	Our purpose was to determine whether p70S6K plays a role in cardiomyocyte hypertrophy induced by the alpha 1-adrenergic receptor (alpha 1-AR) agonist phenylephrine (PE).	Phenylephrine	150-163	ribosomal protein S6 kinase B1	Homo sapiens	37-43
9242178-3	1997	Our purpose was to determine whether p70S6K plays a role in cardiomyocyte hypertrophy induced by the alpha 1-adrenergic receptor (alpha 1-AR) agonist phenylephrine (PE).	Phenylephrine	165-167	ribosomal protein S6 kinase B1	Homo sapiens	37-43
9242178-4	1997	PE stimulated the activity of p70S6K > 3-fold, and this increase was blocked by rapamycin, an immunosuppressant macrolide that selectively inhibits p70S6K.	Phenylephrine	0-2	ribosomal protein S6 kinase B1	Homo sapiens	30-36
9242178-4	1997	PE stimulated the activity of p70S6K > 3-fold, and this increase was blocked by rapamycin, an immunosuppressant macrolide that selectively inhibits p70S6K.	Phenylephrine	0-2	ribosomal protein S6 kinase B1	Homo sapiens	151-157
9242178-4	1997	PE stimulated the activity of p70S6K > 3-fold, and this increase was blocked by rapamycin, an immunosuppressant macrolide that selectively inhibits p70S6K.	Sirolimus	83-92	ribosomal protein S6 kinase B1	Homo sapiens	30-36
9242178-4	1997	PE stimulated the activity of p70S6K > 3-fold, and this increase was blocked by rapamycin, an immunosuppressant macrolide that selectively inhibits p70S6K.	Sirolimus	83-92	ribosomal protein S6 kinase B1	Homo sapiens	151-157
9242178-4	1997	PE stimulated the activity of p70S6K > 3-fold, and this increase was blocked by rapamycin, an immunosuppressant macrolide that selectively inhibits p70S6K.	Macrolides	115-124	ribosomal protein S6 kinase B1	Homo sapiens	30-36
9242178-4	1997	PE stimulated the activity of p70S6K > 3-fold, and this increase was blocked by rapamycin, an immunosuppressant macrolide that selectively inhibits p70S6K.	Macrolides	115-124	ribosomal protein S6 kinase B1	Homo sapiens	151-157
9242178-9	1997	LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (PI3-K) activity, inhibited PE-stimulated increases in p70S6K activity and the incorporation of labeled precursors into myocyte protein and RNA.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	ribosomal protein S6 kinase B1	Homo sapiens	119-125
9242178-9	1997	LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (PI3-K) activity, inhibited PE-stimulated increases in p70S6K activity and the incorporation of labeled precursors into myocyte protein and RNA.	Phenylephrine	92-94	ribosomal protein S6 kinase B1	Homo sapiens	119-125
9242178-11	1997	The data suggest that p70S6K activation may be required for PE-stimulated hypertrophy of cardiac myocytes.	Phenylephrine	60-62	ribosomal protein S6 kinase B1	Homo sapiens	22-28
9248697-7	1997	Incubating 3T3-L1 adipocytes with rapamycin and wortmannin inhibited insulin-stimulated phosphorylation of PHAS-I at concentrations similar to those that inhibited activation of p70S6K.	Wortmannin	48-58	ribosomal protein S6 kinase B1	Homo sapiens	178-184
9218810-2	1997	In parallel, rapamycin blocks mitogen-induced p70 ribosomal protein S6 kinase (p70s6k) phosphorylation and activation.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	46-77
9202301-0	1997	Ganglioside GM1 activates the mitogen-activated protein kinase Erk2 and p70 S6 kinase in U-1242 MG human glioma cells.	Gangliosides	0-11	ribosomal protein S6 kinase B1	Homo sapiens	72-85
9202301-0	1997	Ganglioside GM1 activates the mitogen-activated protein kinase Erk2 and p70 S6 kinase in U-1242 MG human glioma cells.	G(M1) Ganglioside	12-15	ribosomal protein S6 kinase B1	Homo sapiens	72-85
9202301-6	1997	GM1 treatment stimulated another distinct signaling pathway leading to activation of p70 S6 kinase (p70s6k), and this was prevented by pretreatment with rapamycin.	G(M1) Ganglioside	0-3	ribosomal protein S6 kinase B1	Homo sapiens	85-98
9202301-6	1997	GM1 treatment stimulated another distinct signaling pathway leading to activation of p70 S6 kinase (p70s6k), and this was prevented by pretreatment with rapamycin.	G(M1) Ganglioside	0-3	ribosomal protein S6 kinase B1	Homo sapiens	100-106
9202301-6	1997	GM1 treatment stimulated another distinct signaling pathway leading to activation of p70 S6 kinase (p70s6k), and this was prevented by pretreatment with rapamycin.	Sirolimus	153-162	ribosomal protein S6 kinase B1	Homo sapiens	85-98
9202301-6	1997	GM1 treatment stimulated another distinct signaling pathway leading to activation of p70 S6 kinase (p70s6k), and this was prevented by pretreatment with rapamycin.	Sirolimus	153-162	ribosomal protein S6 kinase B1	Homo sapiens	100-106
9218810-2	1997	In parallel, rapamycin blocks mitogen-induced p70 ribosomal protein S6 kinase (p70s6k) phosphorylation and activation.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	79-85
9049301-5	1997	However, inhibition of PI3K and p70S6k by wortmannin and rapamycin, respectively, failed to antagonize AChR alpha-subunit gene expression stimulated by HRG, despite the fact that the activities of the kinases were inhibited.	Wortmannin	42-52	ribosomal protein S6 kinase B1	Homo sapiens	32-38
9109413-6	1997	However, treatment of cells with a specific p70S6k pathway inhibitor, rapamycin, markedly attenuated FBS-stimulated PHAS-I phosphorylation.	Sirolimus	70-79	ribosomal protein S6 kinase B1	Homo sapiens	44-50
9045696-6	1997	In sharp contrast, LY294002, an inhibitor of phosphatidylinositol 3-kinase, and rapamycin, an inhibitor of the activation of p70 S6 kinase (p70(S6k)), completely abolished IGF stimulation of L6A1 differentiation.	Sirolimus	80-89	ribosomal protein S6 kinase B1	Homo sapiens	140-147
9175775-3	1997	Following insulin treatment, there was a retardation in mobility nuclear p70S6K in SDS-PAGE indicative of a change in phosphorylation of the enzyme, but no change in the amount of enzyme.	Sodium Dodecyl Sulfate	83-86	ribosomal protein S6 kinase B1	Homo sapiens	73-79
9175775-7	1997	Tetradecanoylphorbol acetate (TPA) and fetal calf serum also stimulated nuclear p70S6K as judged by gel mobility shift.	Tetradecanoylphorbol Acetate	0-28	ribosomal protein S6 kinase B1	Homo sapiens	80-86
9175775-7	1997	Tetradecanoylphorbol acetate (TPA) and fetal calf serum also stimulated nuclear p70S6K as judged by gel mobility shift.	Tetradecanoylphorbol Acetate	30-33	ribosomal protein S6 kinase B1	Homo sapiens	80-86
9175775-8	1997	TPA also promoted a decrease in cytosolic p70S6K and an increase in nuclear enzyme suggestive of translocation of the enzyme.	Tetradecanoylphorbol Acetate	0-3	ribosomal protein S6 kinase B1	Homo sapiens	42-48
9175775-9	1997	Rapamycin, a selective inhibitor of p70S6K, and the casein kinase II inhibitor DRB blocked insulin-stimulated nuclear and cytosolic p70S6K.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	132-138
9175775-10	1997	Thus, nuclear p70S6K is regulated by insulin, serum and TPA.	Tetradecanoylphorbol Acetate	56-59	ribosomal protein S6 kinase B1	Homo sapiens	14-20
8999881-3	1997	In GN4 cells, increasing intracellular calcium stimulated p70(S6K) activity in a rapamycin- and wortmannin- sensitive manner, but did not affect p90(RSK) activity.	Calcium	39-46	ribosomal protein S6 kinase B1	Homo sapiens	58-61
8999881-3	1997	In GN4 cells, increasing intracellular calcium stimulated p70(S6K) activity in a rapamycin- and wortmannin- sensitive manner, but did not affect p90(RSK) activity.	Wortmannin	96-106	ribosomal protein S6 kinase B1	Homo sapiens	58-61
8999881-4	1997	In contrast, 12-O-tetradecanoylphorbol-13-acetate strongly activated p90(RSK) but only weakly stimulated p70(S6K).	Tetradecanoylphorbol Acetate	13-49	ribosomal protein S6 kinase B1	Homo sapiens	109-112
8999881-5	1997	The ability of calcium to activate p70(S6K) was confirmed by blocking the A23187-dependent activation through chelation of extracellular calcium with EGTA; the effect of thapsigargin was inhibited by the cell permeant chelator bis-(o-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid tetraacetoxymethyl ester (BAPTA-AM).	Calcium	15-22	ribosomal protein S6 kinase B1	Homo sapiens	39-42
8999881-5	1997	The ability of calcium to activate p70(S6K) was confirmed by blocking the A23187-dependent activation through chelation of extracellular calcium with EGTA; the effect of thapsigargin was inhibited by the cell permeant chelator bis-(o-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid tetraacetoxymethyl ester (BAPTA-AM).	Calcimycin	74-80	ribosomal protein S6 kinase B1	Homo sapiens	39-42
8999881-5	1997	The ability of calcium to activate p70(S6K) was confirmed by blocking the A23187-dependent activation through chelation of extracellular calcium with EGTA; the effect of thapsigargin was inhibited by the cell permeant chelator bis-(o-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid tetraacetoxymethyl ester (BAPTA-AM).	Calcium	137-144	ribosomal protein S6 kinase B1	Homo sapiens	39-42
8999881-5	1997	The ability of calcium to activate p70(S6K) was confirmed by blocking the A23187-dependent activation through chelation of extracellular calcium with EGTA; the effect of thapsigargin was inhibited by the cell permeant chelator bis-(o-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid tetraacetoxymethyl ester (BAPTA-AM).	Egtazic Acid	150-154	ribosomal protein S6 kinase B1	Homo sapiens	39-42
8999881-5	1997	The ability of calcium to activate p70(S6K) was confirmed by blocking the A23187-dependent activation through chelation of extracellular calcium with EGTA; the effect of thapsigargin was inhibited by the cell permeant chelator bis-(o-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid tetraacetoxymethyl ester (BAPTA-AM).	Thapsigargin	170-182	ribosomal protein S6 kinase B1	Homo sapiens	39-42
8999881-5	1997	The ability of calcium to activate p70(S6K) was confirmed by blocking the A23187-dependent activation through chelation of extracellular calcium with EGTA; the effect of thapsigargin was inhibited by the cell permeant chelator bis-(o-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid tetraacetoxymethyl ester (BAPTA-AM).	bis-(o-aminophenoxy)ethane-n,n,n",n"-tetraacetic acid tetraacetoxymethyl ester	227-305	ribosomal protein S6 kinase B1	Homo sapiens	39-42
8999881-5	1997	The ability of calcium to activate p70(S6K) was confirmed by blocking the A23187-dependent activation through chelation of extracellular calcium with EGTA; the effect of thapsigargin was inhibited by the cell permeant chelator bis-(o-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid tetraacetoxymethyl ester (BAPTA-AM).	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	307-315	ribosomal protein S6 kinase B1	Homo sapiens	39-42
8999881-6	1997	Similarly, BAPTA-AM prevented the activation of p70(S6K) by Ang II, suggesting that this signal was largely calcium-dependent.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	11-19	ribosomal protein S6 kinase B1	Homo sapiens	48-51
8999881-6	1997	Similarly, BAPTA-AM prevented the activation of p70(S6K) by Ang II, suggesting that this signal was largely calcium-dependent.	Calcium	108-115	ribosomal protein S6 kinase B1	Homo sapiens	48-51
8999881-8	1997	These results show that in GN4 cells, Ang II selectively activates p70(S6K) through effects on calcium, p90(RSK) through effects on protein kinase C. The activation of p70(S6K) by calcium stimuli or Ang II was independent of calmodulin but correlated well with the activation of the recently identified, nonreceptor calcium-dependent tyrosine kinase (CADTK)/PYK-2.	Calcium	95-102	ribosomal protein S6 kinase B1	Homo sapiens	71-74
8999881-8	1997	These results show that in GN4 cells, Ang II selectively activates p70(S6K) through effects on calcium, p90(RSK) through effects on protein kinase C. The activation of p70(S6K) by calcium stimuli or Ang II was independent of calmodulin but correlated well with the activation of the recently identified, nonreceptor calcium-dependent tyrosine kinase (CADTK)/PYK-2.	Calcium	95-102	ribosomal protein S6 kinase B1	Homo sapiens	168-171
8603539-8	1996	Rapamycin, a macrolide immunosuppressant, inhibited completely growth factor-induced synovial fibroblast proliferation and P70S6k activation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	123-129
8939971-3	1996	The effects of insulin were attenuated by rapamycin and wortmannin, two agents that block activation of p70(S6K).	Sirolimus	42-51	ribosomal protein S6 kinase B1	Homo sapiens	108-111
8939971-3	1996	The effects of insulin were attenuated by rapamycin and wortmannin, two agents that block activation of p70(S6K).	Wortmannin	56-66	ribosomal protein S6 kinase B1	Homo sapiens	108-111
8887654-2	1996	Recent reports have focused on the role of the amino terminus of the p85(s6k) isoform in mediating kinase activity, with the observation that amino-terminal truncation mutants are activated in the presence of rapamycin while retaining their sensitivity to wortmannin.	Sirolimus	209-218	ribosomal protein S6 kinase B1	Homo sapiens	69-76
8887654-2	1996	Recent reports have focused on the role of the amino terminus of the p85(s6k) isoform in mediating kinase activity, with the observation that amino-terminal truncation mutants are activated in the presence of rapamycin while retaining their sensitivity to wortmannin.	Wortmannin	256-266	ribosomal protein S6 kinase B1	Homo sapiens	69-76
8806686-6	1996	This difference in cell cycle progress after rapamycin treatment is reflected in ribosomal S6 protein kinase (p70S6k) by both a downward mobility shift on SDS-PAGE and inhibition of activity.	Sirolimus	45-54	ribosomal protein S6 kinase B1	Homo sapiens	110-116
8806686-6	1996	This difference in cell cycle progress after rapamycin treatment is reflected in ribosomal S6 protein kinase (p70S6k) by both a downward mobility shift on SDS-PAGE and inhibition of activity.	Sodium Dodecyl Sulfate	155-158	ribosomal protein S6 kinase B1	Homo sapiens	110-116
8752154-0	1996	Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	32-38
8752154-3	1996	Rapamycin inhibited growth of H 69, H 345, and H 510 cells in liquid culture at similar concentrations to those required for inducing dephosphorylation of p70s6k.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	155-161
8633019-2	1996	However, the immunosuppressant rapamycin blocks serum-induced 4E-BP1 phosphorylation and, in parallel, p70s6k activation, with no apparent effect on p42mapk activation.	Sirolimus	31-40	ribosomal protein S6 kinase B1	Homo sapiens	103-109
8633019-5	1996	Anisomycin, which, like insulin, does not activate p42mapk, promotes a small parallel increase in 4E-BP1 phosphorylation and p70s6k activation.	Anisomycin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	125-131
8633019-6	1996	The insulin effect on 4E-BP1 phosphorylation and p70s6k activation in both cell types is blocked by SQ20006, wortmannin, and rapamycin.	Wortmannin	109-119	ribosomal protein S6 kinase B1	Homo sapiens	49-55
8633019-6	1996	The insulin effect on 4E-BP1 phosphorylation and p70s6k activation in both cell types is blocked by SQ20006, wortmannin, and rapamycin.	Sirolimus	125-134	ribosomal protein S6 kinase B1	Homo sapiens	49-55
8633019-7	1996	These three inhibitors have no effect on p42mapk activation induced by phorbol 12-tetradecanoate 13-acetate, though wortmannin partially suppresses both the p70s6k response and the 4E-BP1 response.	Wortmannin	116-126	ribosomal protein S6 kinase B1	Homo sapiens	157-163
8615823-4	1996	Pretreatment of cells with wortmannin, a specific inhibitor of PI 3-kinase, prevented the activation of p70s6k and partially inhibited the activation of p42 and p44 MAP kinases by GH.	Wortmannin	27-37	ribosomal protein S6 kinase B1	Homo sapiens	104-110
8999881-8	1997	These results show that in GN4 cells, Ang II selectively activates p70(S6K) through effects on calcium, p90(RSK) through effects on protein kinase C. The activation of p70(S6K) by calcium stimuli or Ang II was independent of calmodulin but correlated well with the activation of the recently identified, nonreceptor calcium-dependent tyrosine kinase (CADTK)/PYK-2.	Calcium	180-187	ribosomal protein S6 kinase B1	Homo sapiens	71-74
8999881-8	1997	These results show that in GN4 cells, Ang II selectively activates p70(S6K) through effects on calcium, p90(RSK) through effects on protein kinase C. The activation of p70(S6K) by calcium stimuli or Ang II was independent of calmodulin but correlated well with the activation of the recently identified, nonreceptor calcium-dependent tyrosine kinase (CADTK)/PYK-2.	Calcium	180-187	ribosomal protein S6 kinase B1	Homo sapiens	168-171
8999881-9	1997	Both calcium- and Ang II-dependent activation of p70(S6K) were attenuated by the tyrosine kinase inhibitor genistein, and activation of p70(S6K) was higher in GN4 than WB cells, correlating with the increased expression and activation of CADTK/PYK-2 in GN4 cells.	Calcium	5-12	ribosomal protein S6 kinase B1	Homo sapiens	49-52
8999881-9	1997	Both calcium- and Ang II-dependent activation of p70(S6K) were attenuated by the tyrosine kinase inhibitor genistein, and activation of p70(S6K) was higher in GN4 than WB cells, correlating with the increased expression and activation of CADTK/PYK-2 in GN4 cells.	Calcium	5-12	ribosomal protein S6 kinase B1	Homo sapiens	53-56
8999881-9	1997	Both calcium- and Ang II-dependent activation of p70(S6K) were attenuated by the tyrosine kinase inhibitor genistein, and activation of p70(S6K) was higher in GN4 than WB cells, correlating with the increased expression and activation of CADTK/PYK-2 in GN4 cells.	Genistein	107-116	ribosomal protein S6 kinase B1	Homo sapiens	49-52
8999881-9	1997	Both calcium- and Ang II-dependent activation of p70(S6K) were attenuated by the tyrosine kinase inhibitor genistein, and activation of p70(S6K) was higher in GN4 than WB cells, correlating with the increased expression and activation of CADTK/PYK-2 in GN4 cells.	Genistein	107-116	ribosomal protein S6 kinase B1	Homo sapiens	53-56
8999881-10	1997	In summary, these results demonstrate that intracellular calcium selectively activates p70(S6K) in GN4 cells, consistent with increased CADTK/PYK-2 signaling in these cells.	Calcium	57-64	ribosomal protein S6 kinase B1	Homo sapiens	91-94
8641294-5	1996	Rapamycin, a macrolide immunosuppressant which blocks the signalling pathway leading to the stimulation of the 70/85 kDa ribosomal protein S6 kinases, substantially blocks the activation of elongation, the fall in eEF-2 phosphorylation and the decrease in eEF-2 kinase activity, suggesting that p7O S6 kinase (p70s6k) and eEF-2 kinase may tie on a common signalling pathway.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	310-316
8603539-10	1996	Our data demonstrate that growth factor-mediated P70S6k activation is closely related to the growth of synovial fibroblast, and suggest the efficacy of rapamycin for controlling synovial hyperplasia in RA.	Sirolimus	152-161	ribosomal protein S6 kinase B1	Homo sapiens	49-55
7592897-0	1995	The phosphodiesterase inhibitor SQ 20006 selectively blocks mitogen activation of p70S6k and transition to S phase of the cell division cycle without affecting the steady state phosphorylation of eIF-4E.	SQ 20006	32-40	ribosomal protein S6 kinase B1	Homo sapiens	82-88
7498520-5	1995	p70S6K (but not p90S6K) tolerated Thr at position n and absence of any residue at n + 2.	Threonine	34-37	ribosomal protein S6 kinase B1	Homo sapiens	0-6
7592897-4	1995	We now show that the p70S6k pathway can be selectively blocked by the aminopurine analogue, SQ 20006.	2-Aminopurine	70-81	ribosomal protein S6 kinase B1	Homo sapiens	21-27
7566123-1	1995	When complexed with the intracellular protein FKBP12, rapamycin is a potent immunosuppressant and an inhibitor of a mitogen-stimulated signalling pathway that leads to activation of p70 S6 kinase (p70S6k) and cyclin-dependent kinases (CDKs).	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	182-195
7566123-1	1995	When complexed with the intracellular protein FKBP12, rapamycin is a potent immunosuppressant and an inhibitor of a mitogen-stimulated signalling pathway that leads to activation of p70 S6 kinase (p70S6k) and cyclin-dependent kinases (CDKs).	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	197-203
7534292-3	1995	AII potently stimulated the phosphotransferase activity of p70S6K, which reached a maximal value at 15 min and persisted for at least 4 h. This response was completely abolished when the cells were incubated in the presence of the AT1-selective receptor antagonist losartan.	Losartan	265-273	ribosomal protein S6 kinase B1	Homo sapiens	59-65
7566093-5	1995	Translational activation is prevented by rapamycin and mimicked by anisomycin, which suggests that translation of the 6.0-kb mRNA is regulated by the p70S6k/85S6k kinase signalling pathway.	Sirolimus	41-50	ribosomal protein S6 kinase B1	Homo sapiens	150-156
7566093-5	1995	Translational activation is prevented by rapamycin and mimicked by anisomycin, which suggests that translation of the 6.0-kb mRNA is regulated by the p70S6k/85S6k kinase signalling pathway.	Anisomycin	67-77	ribosomal protein S6 kinase B1	Homo sapiens	150-156
7629182-8	1995	Rapamycin abolished the effects of insulin on increasing phosphorylation of ribosomal protein S6 and on activating p70S6K.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	115-121
7534292-4	1995	The enzymatic activation of p70S6K was associated with increased phosphorylation of the enzyme on serine and threonine residues.	Serine	98-104	ribosomal protein S6 kinase B1	Homo sapiens	28-34
7534292-4	1995	The enzymatic activation of p70S6K was associated with increased phosphorylation of the enzyme on serine and threonine residues.	Threonine	109-118	ribosomal protein S6 kinase B1	Homo sapiens	28-34
7534292-5	1995	The immunosuppressant drug rapamycin was found to selectively inhibit the activation of p70S6K by AII, but not the activation of mitogen-activated protein kinase or the induction of c-fos mRNA expression.	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	88-94
7540859-7	1995	cAMP-responsive element binding protein Ser133 phosphorylation in response to synergistic growth factors was due probably to the activation of p90RSK and, to a lesser extent, to p70S6K.	Cyclic AMP	0-4	ribosomal protein S6 kinase B1	Homo sapiens	178-184
8090223-7	1994	The critical autophosphorylation site for p70s6k/p85s6k activation within this domain is a tyrosine at residue 751.	Tyrosine	91-99	ribosomal protein S6 kinase B1	Homo sapiens	42-48
7840614-4	1995	The results show that MAPK stimulation is transient (peak activity, 30 min) and precedes that of S6K, which reaches a maximum at 1.5-2 h, and slowly returns towards control levels at 6 h. Both staurosporine which inhibits GH receptor-associated kinase (JAK2) and genistein (GEN), an inhibitor of membrane-associated and cytoplasmic TKs, abrogate Prl-stimulated TK, MAPK, and S6K.	Staurosporine	193-206	ribosomal protein S6 kinase B1	Homo sapiens	97-100
7826337-0	1995	Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3-L1 adipocytes: evidence for the involvement of phosphoinositide 3-kinase and p70 ribosomal protein-S6 kinase.	Wortmannin	87-97	ribosomal protein S6 kinase B1	Homo sapiens	196-227
7826337-1	1995	We have investigated the involvement of phosphoinositide (PI) 3-kinase and p70 ribosomal protein-S6 kinase (p70s6k) in mediating insulin stimulation of glycogen synthesis in 3T3-L1 adipocytes using specific inhibitors.	Glycogen	152-160	ribosomal protein S6 kinase B1	Homo sapiens	108-114
7840614-4	1995	The results show that MAPK stimulation is transient (peak activity, 30 min) and precedes that of S6K, which reaches a maximum at 1.5-2 h, and slowly returns towards control levels at 6 h. Both staurosporine which inhibits GH receptor-associated kinase (JAK2) and genistein (GEN), an inhibitor of membrane-associated and cytoplasmic TKs, abrogate Prl-stimulated TK, MAPK, and S6K.	Staurosporine	193-206	ribosomal protein S6 kinase B1	Homo sapiens	375-378
7840614-4	1995	The results show that MAPK stimulation is transient (peak activity, 30 min) and precedes that of S6K, which reaches a maximum at 1.5-2 h, and slowly returns towards control levels at 6 h. Both staurosporine which inhibits GH receptor-associated kinase (JAK2) and genistein (GEN), an inhibitor of membrane-associated and cytoplasmic TKs, abrogate Prl-stimulated TK, MAPK, and S6K.	Genistein	263-272	ribosomal protein S6 kinase B1	Homo sapiens	97-100
7840614-4	1995	The results show that MAPK stimulation is transient (peak activity, 30 min) and precedes that of S6K, which reaches a maximum at 1.5-2 h, and slowly returns towards control levels at 6 h. Both staurosporine which inhibits GH receptor-associated kinase (JAK2) and genistein (GEN), an inhibitor of membrane-associated and cytoplasmic TKs, abrogate Prl-stimulated TK, MAPK, and S6K.	Genistein	274-277	ribosomal protein S6 kinase B1	Homo sapiens	97-100
7923380-0	1994	Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression.	Cyclic AMP	27-31	ribosomal protein S6 kinase B1	Homo sapiens	65-78
7923380-3	1994	We show that Ser-117 is also phosphorylated by the mitogen-activated p70 S6 kinase (p70S6K) in vitro.	Serine	13-16	ribosomal protein S6 kinase B1	Homo sapiens	69-82
7923380-3	1994	We show that Ser-117 is also phosphorylated by the mitogen-activated p70 S6 kinase (p70S6K) in vitro.	Serine	13-16	ribosomal protein S6 kinase B1	Homo sapiens	84-90
7923380-4	1994	Activation of cellular p70S6K by serum factors enhances Ser-117 phosphorylation and CREM transactivation.	Serine	56-59	ribosomal protein S6 kinase B1	Homo sapiens	23-29
7923380-6	1994	The macrolide rapamycin, a potent and specific inhibitor of p70S6K in vivo, completely blocks CREM activation induced by serum and by p70S6K.	Macrolides	4-13	ribosomal protein S6 kinase B1	Homo sapiens	60-66
7923380-6	1994	The macrolide rapamycin, a potent and specific inhibitor of p70S6K in vivo, completely blocks CREM activation induced by serum and by p70S6K.	Macrolides	4-13	ribosomal protein S6 kinase B1	Homo sapiens	134-140
7923380-6	1994	The macrolide rapamycin, a potent and specific inhibitor of p70S6K in vivo, completely blocks CREM activation induced by serum and by p70S6K.	Sirolimus	14-23	ribosomal protein S6 kinase B1	Homo sapiens	60-66
7923380-6	1994	The macrolide rapamycin, a potent and specific inhibitor of p70S6K in vivo, completely blocks CREM activation induced by serum and by p70S6K.	Sirolimus	14-23	ribosomal protein S6 kinase B1	Homo sapiens	134-140
8344891-2	1993	The four sites of phosphorylation associated with p70s6k/p85s6k activation all display Ser/Thr-Pro motifs and are closely clustered within a putative autoinhibitory domain of the enzyme.	Serine	87-90	ribosomal protein S6 kinase B1	Homo sapiens	50-56
8344891-2	1993	The four sites of phosphorylation associated with p70s6k/p85s6k activation all display Ser/Thr-Pro motifs and are closely clustered within a putative autoinhibitory domain of the enzyme.	Threonine	91-94	ribosomal protein S6 kinase B1	Homo sapiens	50-56
8344891-2	1993	The four sites of phosphorylation associated with p70s6k/p85s6k activation all display Ser/Thr-Pro motifs and are closely clustered within a putative autoinhibitory domain of the enzyme.	Proline	95-98	ribosomal protein S6 kinase B1	Homo sapiens	50-56
8344891-6	1993	Peptide maps reveal that rapamycin abolishes the activity of the overexpressed p70s6k through the dephosphorylation of a novel set of sites distinct from those associated with mitogenic activation.	Sirolimus	25-34	ribosomal protein S6 kinase B1	Homo sapiens	79-85
1551899-1	1992	The late phase of the time-dependent epidermal growth factor (EGF)-induced biphasic activation of the p70s6k is selectively attenuated by the specific PKC inhibitor, CGP 41,251, a staurosporine derivative.	Staurosporine	180-193	ribosomal protein S6 kinase B1	Homo sapiens	102-108
1380801-0	1992	Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	42-55
33777154-13	2021	Conclusion: Baicalein, a medicine agent screened from natural flavonoids targeting TGFbeta pathway, could suppress mTOR/p70S6K pathway-mediated cell proliferation and EMT pathway-related migration via TGFbeta pathway in cervical cancer HeLa cells.	baicalein	12-21	ribosomal protein S6 kinase B1	Homo sapiens	120-126
33802884-6	2021	Western bolt assay showed that Serine/threonine Kinase (Akt) signaling related proteins including Ataxia telangiectasia mutated kinase (ATM), Phosphatase and tensin homolog (PTEN), Akt, Mammalian target of rapamycin (mTOR), Ribosome S6 protein kinase (p70S6K) and e IF4E-binding protein 1(4E-BP1) were regulated, and Hypoxia inducible factor-1alpha (HIF-1alpha) protein expression was decreased by TSE1 in OVCAR-3 cells.	Serine	31-37	ribosomal protein S6 kinase B1	Homo sapiens	252-258
25283693-5	2015	Topical application of 0 5% axitinib effectively suppressed the PDL-induced increase in mRNA levels of the examined angiogenic genes and activation of AKT, P70S6K and ERK from days 1 to 7 post-PDL exposure.	Axitinib	28-36	ribosomal protein S6 kinase B1	Homo sapiens	156-162
33235618-11	2021	Furthermore, combination treatment of erlotinib and LY294002 resulted in a significant reduction of phosphorylated p70S6K levels in NCI-H661 [PI3K catalytic subunit alpha (PI3KCA) wild-type] cells.	Erlotinib Hydrochloride	38-47	ribosomal protein S6 kinase B1	Homo sapiens	115-121
33235618-11	2021	Furthermore, combination treatment of erlotinib and LY294002 resulted in a significant reduction of phosphorylated p70S6K levels in NCI-H661 [PI3K catalytic subunit alpha (PI3KCA) wild-type] cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	52-60	ribosomal protein S6 kinase B1	Homo sapiens	115-121
32882752-5	2020	Glucose starvation decreased the phosphorylation of p70 S6 kinase (p70S6K), a bonafide marker for protein translation initiation.	Glucose	0-7	ribosomal protein S6 kinase B1	Homo sapiens	52-65
32882752-5	2020	Glucose starvation decreased the phosphorylation of p70 S6 kinase (p70S6K), a bonafide marker for protein translation initiation.	Glucose	0-7	ribosomal protein S6 kinase B1	Homo sapiens	67-73
32882752-6	2020	Following re-addition of glucose, phosphorylation of p70S6K markedly increased only in glucose-starved cells.	Glucose	25-32	ribosomal protein S6 kinase B1	Homo sapiens	53-59
32882752-6	2020	Following re-addition of glucose, phosphorylation of p70S6K markedly increased only in glucose-starved cells.	Glucose	87-94	ribosomal protein S6 kinase B1	Homo sapiens	53-59
32882752-7	2020	Inhibiting autophagy using pharmacological inhibitors diminished the effect of glucose re-addition on the phosphorylation of p70S6K, whereas inhibition of the ubiquitin-proteasome system did not exert any effect.	Glucose	79-86	ribosomal protein S6 kinase B1	Homo sapiens	125-131
25283693-7	2015	CONCLUSIONS: Topical application of 0 5% axitinib can systematically suppress the PDL-induced early stages of angiogenesis via inhibition of the AKT/mammalian target of rapamycin/p70S6K and Src homology 2 domain containing transforming protein-1/mitogen-activated protein kinase kinase/ERK pathway cascades.	Axitinib	41-49	ribosomal protein S6 kinase B1	Homo sapiens	179-185
34191518-6	2022	WRX606 inhibited the phosphorylation of not only the ribosomal protein S6 kinase 1 (S6K1) but also eIF4E-binding protein-1 (4E-BP1).	wrx606	0-6	ribosomal protein S6 kinase B1	Homo sapiens	84-88
17360108-0	2007	An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.	Sirolimus	125-134	ribosomal protein S6 kinase B1	Homo sapiens	18-24
34847624-0	2022	Alnustone inhibits the growth of hepatocellular carcinoma via ROS- mediated PI3K/Akt/mTOR/p70S6K axis.	Alnustone	0-9	ribosomal protein S6 kinase B1	Homo sapiens	90-96
34717917-7	2022	The phosphorylation levels of ribosomal protein S6 kinase (p70S6K) and eIF4E binding protein-1 (4E-BP1) were significantly suppressed by digitoxin.	Digitoxin	137-146	ribosomal protein S6 kinase B1	Homo sapiens	59-65
34105096-14	2022	The results also found that the levels of phosphoinositide (PI3K), p-PI3K, AKT, p-AKT, mammalian target of rapamycin (mTOR), p-mTOR, and p-p70S6K all decreased after EDC treatment (P<0.05).	ethylene dichloride	166-169	ribosomal protein S6 kinase B1	Homo sapiens	139-145
34847624-0	2022	Alnustone inhibits the growth of hepatocellular carcinoma via ROS- mediated PI3K/Akt/mTOR/p70S6K axis.	ros	62-65	ribosomal protein S6 kinase B1	Homo sapiens	90-96
34731371-9	2022	The mechanism was that PP242 abrogated the promoting effects of SFN on p-p70S6K (Thr389) and p-Akt (Ser473) in ESCC.	PP242	23-28	ribosomal protein S6 kinase B1	Homo sapiens	73-79
34847624-6	2022	Alnustone inhibited the expression of proteins related to apoptosis and PI3K/Akt/mTOR/p70S6K pathways and generated ROS production in BEL-7402 and HepG2 cells.	Alnustone	0-9	ribosomal protein S6 kinase B1	Homo sapiens	86-92
34731371-9	2022	The mechanism was that PP242 abrogated the promoting effects of SFN on p-p70S6K (Thr389) and p-Akt (Ser473) in ESCC.	sulforaphane	64-67	ribosomal protein S6 kinase B1	Homo sapiens	73-79
34930601-13	2022	Treatment of intestinal I/R mice with petroselinic acid alleviated intestinal injury in vivo and decreased cell apoptosis by mediating AMP-activated protein kinase-mammalian target of rapamycin-P70S6K signaling in vitro.	petroselinic acid	38-55	ribosomal protein S6 kinase B1	Homo sapiens	194-200
34931585-0	2022	Falcarindiol Stimulates Apoptotic and Autophagic Cell Death to Attenuate Cell Proliferation, Cell Division, and Metastasis through the PI3K/AKT/mTOR/p70S6K Pathway in Human Oral Squamous Cell Carcinomas.	falcarindiol	0-12	ribosomal protein S6 kinase B1	Homo sapiens	149-155
34882068-10	2021	Immunoblot analyses of MKN-45 and KATO-III cells revealed that dovitinib decreased phospho-FGFR, phospho-AKT, phospho-ERK, phospho-p70S6K, phospho-4EBP1, Bcl-2 and increased cleaved PARP-1, cleaved-caspase-3, p27, Bax, Bim, with an additive effect from combination therapy.	4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one	63-72	ribosomal protein S6 kinase B1	Homo sapiens	131-137
34944053-6	2021	The activation of the S6K signaling pathway was evaluated by immunohistochemical staining of its downstream effector phospho-S6 in tissue sections.	phospho-s6	117-127	ribosomal protein S6 kinase B1	Homo sapiens	22-25
34916779-9	2021	The expression of Rictor and the phosphorylation of Akt and p70s6k were inhibited by GO-PEI-PEG-CPP/siRNA.	go-pei-peg	85-95	ribosomal protein S6 kinase B1	Homo sapiens	60-66
34813306-4	2021	BDMC showed the potent inhibitory effects on TNBC proliferation through suppressing GPR161-mediated mammalian target of rapamycin (mTOR)/70 kDa ribosomal protein S6 kinase (p70S6K) activation.	bisdemethoxycurcumin	0-4	ribosomal protein S6 kinase B1	Homo sapiens	173-179
34848467-0	2021	Flaccidoxide Induces Apoptosis Through Down-regulation of PI3K/AKT/mTOR/p70S6K Signaling in Human Bladder Cancer Cells.	flaccidoxide	0-12	ribosomal protein S6 kinase B1	Homo sapiens	72-78
34848467-8	2021	CONCLUSION: Flaccidoxide-induced apoptosis in BFTC-905 and T24 cells is mediated by mitochondrial dysfunction and down-regulation the PI3K/AKT/mTOR/p70S6K signaling pathway.	flaccidoxide	12-24	ribosomal protein S6 kinase B1	Homo sapiens	148-154
34047671-8	2021	Further investigation revealed that HUCMSCs noticeably suppressed the AKT-mTOR-S6K1 pathway in the pancreatic tissue of DBTC-induced CP.	Stains-all	120-124	ribosomal protein S6 kinase B1	Homo sapiens	79-83
34781168-0	2021	TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.	ly2780301	71-80	ribosomal protein S6 kinase B1	Homo sapiens	84-90
34718921-6	2021	Moreover, modulating S6K1 expression counteracted the effects of miR-506-3p on glucose uptake and PI3K/AKT pathway activation.	mir-506-3p	65-75	ribosomal protein S6 kinase B1	Homo sapiens	21-25
34738031-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) integrates various types of signal inputs, such as energy, growth factors, and amino acids to regulate cell growth and proliferation mainly through the 2 direct downstream targets, eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 (S6K1).	Sirolimus	26-35	ribosomal protein S6 kinase B1	Homo sapiens	341-345
34718921-6	2021	Moreover, modulating S6K1 expression counteracted the effects of miR-506-3p on glucose uptake and PI3K/AKT pathway activation.	Glucose	79-86	ribosomal protein S6 kinase B1	Homo sapiens	21-25
34934919-3	2021	By modulating lactate metabolism, ITV induced the concomitant acidification of the intra- and extracellular environment, which synergistically suppressed S6K1 activity in cancer cells through protein phosphatase-2A-mediated dephosphorylation via G-protein-coupled receptor(s).	Lactic Acid	14-21	ribosomal protein S6 kinase B1	Homo sapiens	154-158
34858182-4	2021	Methods and Results: Immunoblotting analyses revealed that short-term exposure to rapamycin (6h) significantly reduced phosphorylation of p70S6K (mTORC1-specific) in hPASMCs but had no effect on the phosphorylation of AKT (p-AKT S473, considered mTORC2-specific).	Sirolimus	82-91	ribosomal protein S6 kinase B1	Homo sapiens	138-144
34921503-0	2022	Inhibition of TRIM32 by ibr-7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway.	gemcitabine	78-89	ribosomal protein S6 kinase B1	Homo sapiens	99-105
34687482-10	2021	Mechanistically, fucoidan induced autophagy in breast cancer cells by down-regulating m-TOR/p70S6K/TFEB pathway.	fucoidan	17-25	ribosomal protein S6 kinase B1	Homo sapiens	92-98
34687482-11	2021	In conclusion, our research revealed that fucoidan could induce autophagy of breast cancer cells by mediating m-TOR/p70S6K/TFEB pathway, thus inhibiting tumor development.	fucoidan	42-50	ribosomal protein S6 kinase B1	Homo sapiens	116-122
34827970-6	2021	beta-sitosterol (0.1, 1, 10 muM) increased the mRNA and protein expression levels of signal transducer activator of transcription 5 (STAT5), mammalian target of rapamycin (mTOR), and ribosomal protein S6 kinase beta-1 (S6K1) of the JAK2/STAT5 and mTOR signaling pathways.	gamma-sitosterol	0-15	ribosomal protein S6 kinase B1	Homo sapiens	219-223
34830011-6	2021	Our finding shows that Cy can block the MET/AKT/mTOR axis by decreasing the phosphorylation level of AKT, mTOR and P70S6K.	luteolin-7-glucoside	23-25	ribosomal protein S6 kinase B1	Homo sapiens	115-121
34727092-0	2021	MiRNA-30e downregulation increases cancer cell proliferation, invasion and tumor growth through targeting RPS6KB1.	mirna-30e	0-9	ribosomal protein S6 kinase B1	Homo sapiens	106-113
34718921-7	2021	In conclusion, miR-506-3p altered IR in adipocytes by regulating S6K1-mediated PI3K/AKT pathway activation.	mir-506-3p	15-25	ribosomal protein S6 kinase B1	Homo sapiens	65-69
34607979-7	2021	Metformin diminished the phosphorylation of mTOR, p70S6K and 4E-BP1 by accelerating adenosine monophosphateactivated kinase (AMPK) in HeLa cancer cells, but it did not affect other cell lines.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	50-56
34675258-7	2021	Akt phosphorylation and activation was indispensable for rapamycin-induced TCTP degradation and PLK1 activation, and depended on S6K inhibition, but not mTORC2 activation.	Sirolimus	57-66	ribosomal protein S6 kinase B1	Homo sapiens	129-132
34551966-8	2021	Our results show that TLR-4-induced IFN-gamma production is regulated by the ribosomal protein S6 kinase (p70S6K) through the activation of PI3K, the mammalian target of rapamycin complex 1/2 (mTORC1/2), and the JNK MAPK pathways.	Sirolimus	170-179	ribosomal protein S6 kinase B1	Homo sapiens	106-112
34542136-0	2021	Amentoflavone inhibits tumor necrosis factor-alpha-induced migration and invasion through AKT/mTOR/S6k1/hedgehog signaling in human breast cancer.	amentoflavone	0-13	ribosomal protein S6 kinase B1	Homo sapiens	99-103
34669780-0	2021	Poricoic acid A induces apoptosis and autophagy in ovarian cancer via modulating the mTOR/p70s6k signaling axis.	poricoic acid A	0-15	ribosomal protein S6 kinase B1	Homo sapiens	90-96
34669780-13	2021	In conclusion, our data suggested that PAA induced apoptosis and autophagy in ovarian cancer via modulating the mTOR/p70s6k signaling axis.	poricoic acid A	39-42	ribosomal protein S6 kinase B1	Homo sapiens	117-123
34481987-0	2021	Discovery of 4-Aminopyrimidine Analogs as highly Potent Dual P70S6K/Akt Inhibitors.	4-aminopyrimidine	13-30	ribosomal protein S6 kinase B1	Homo sapiens	61-67
34481987-3	2021	A scaffold docking strategy based on an existing quinazoline carboxamide series identified 4-aminopyrimidine analog 6, which showed a single-digit nanomolar and a micromolar potencies in p70S6K and Akt enzymatic assays.	quinazoline carboxamide	49-72	ribosomal protein S6 kinase B1	Homo sapiens	187-193
34481987-3	2021	A scaffold docking strategy based on an existing quinazoline carboxamide series identified 4-aminopyrimidine analog 6, which showed a single-digit nanomolar and a micromolar potencies in p70S6K and Akt enzymatic assays.	4-aminopyrimidine	91-108	ribosomal protein S6 kinase B1	Homo sapiens	187-193
34596404-0	2021	Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.	M2698 free base	37-42	ribosomal protein S6 kinase B1	Homo sapiens	51-57
34596404-1	2021	Herein, we report the discovery of a novel class of quinazoline carboxamides as dual p70S6k/Akt inhibitors for the treatment of tumors driven by alterations to the PI3K/Akt/mTOR (PAM) pathway.	quinazoline carboxamides	52-76	ribosomal protein S6 kinase B1	Homo sapiens	85-91
34596404-2	2021	Through the screening of in-house proprietary kinase library, 4-benzylamino-quinazoline-8-carboxylic acid amide 1 stood out, with sub-micromolar p70S6k biochemical activity, as the starting point for a structurally enabled p70S6K/Akt dual inhibitor program that led to the discovery of M2698, a dual p70S6k/Akt inhibitor.	-quinazoline-8-carboxylic acid amide	75-111	ribosomal protein S6 kinase B1	Homo sapiens	223-229
34596404-2	2021	Through the screening of in-house proprietary kinase library, 4-benzylamino-quinazoline-8-carboxylic acid amide 1 stood out, with sub-micromolar p70S6k biochemical activity, as the starting point for a structurally enabled p70S6K/Akt dual inhibitor program that led to the discovery of M2698, a dual p70S6k/Akt inhibitor.	M2698 free base	286-291	ribosomal protein S6 kinase B1	Homo sapiens	145-151
34596404-2	2021	Through the screening of in-house proprietary kinase library, 4-benzylamino-quinazoline-8-carboxylic acid amide 1 stood out, with sub-micromolar p70S6k biochemical activity, as the starting point for a structurally enabled p70S6K/Akt dual inhibitor program that led to the discovery of M2698, a dual p70S6k/Akt inhibitor.	M2698 free base	286-291	ribosomal protein S6 kinase B1	Homo sapiens	223-229
34596404-2	2021	Through the screening of in-house proprietary kinase library, 4-benzylamino-quinazoline-8-carboxylic acid amide 1 stood out, with sub-micromolar p70S6k biochemical activity, as the starting point for a structurally enabled p70S6K/Akt dual inhibitor program that led to the discovery of M2698, a dual p70S6k/Akt inhibitor.	M2698 free base	286-291	ribosomal protein S6 kinase B1	Homo sapiens	300-306
34680283-3	2021	We were able to design the first potent and highly isoform-specific S6K2 inhibitor from a known S6K1-selective inhibitor, which was merged with a covalent inhibitor engaging a cysteine located in the hinge region in the fibroblast growth factor receptor kinase (FGFR) 4 via a nucleophilic aromatic substitution (SNAr) reaction.	Cysteine	176-184	ribosomal protein S6 kinase B1	Homo sapiens	96-100
34685438-5	2021	It was shown that the level of sterol-regulatory element-binding protein-1 (SREBP-1), a critical transcription factor involved in lipid synthesis and metabolism, would be upregulated through Akt and p70S6K signaling pathways while CRC cells are cultured in ACM, which subsequently decreases the cell sensitivity to 5-FU cytotoxicity.	Fluorouracil	315-319	ribosomal protein S6 kinase B1	Homo sapiens	199-205
34628069-7	2022	RESULTS: HL strengthened ALA-PDT"s inhibition of SCL-1 cell viability, migration, as well as NRF2 related beta-catenin, p-Erk1/2, p-Akt and p-S6K1 expression.	Alanine	25-28	ribosomal protein S6 kinase B1	Homo sapiens	142-146
34692691-0	2021	TEOA Promotes Autophagic Cell Death via ROS-Mediated Inhibition of mTOR/p70S6k Signaling Pathway in Pancreatic Cancer Cells.	triethanolamine	0-4	ribosomal protein S6 kinase B1	Homo sapiens	72-78
34692691-0	2021	TEOA Promotes Autophagic Cell Death via ROS-Mediated Inhibition of mTOR/p70S6k Signaling Pathway in Pancreatic Cancer Cells.	ros	40-43	ribosomal protein S6 kinase B1	Homo sapiens	72-78
34692691-8	2021	Notably, our further experiments showed that TEOA induced autophagic cell death in pancreatic ductal adenocarcinoma cells by inactivating the ROS-dependent mTOR/p70S6k signaling pathway.	triethanolamine	45-49	ribosomal protein S6 kinase B1	Homo sapiens	161-167
34692691-8	2021	Notably, our further experiments showed that TEOA induced autophagic cell death in pancreatic ductal adenocarcinoma cells by inactivating the ROS-dependent mTOR/p70S6k signaling pathway.	ros	142-145	ribosomal protein S6 kinase B1	Homo sapiens	161-167
34542136-8	2021	In summary, amentoflavone abrogated Gli1 activation in TNFalpha-induced mammary tumor cells, resulting in a decrease of invasiveness in human breast cancer cells via mediating AKT/mTOR/S6K1 signaling.	amentoflavone	12-25	ribosomal protein S6 kinase B1	Homo sapiens	185-189
34329824-0	2021	Improved tumor-suppressive effect of OZ-001 combined with cisplatin mediated by mTOR/p70S6K and STAT3 inactivation in A549 human lung cancer cells.	oz-001	37-43	ribosomal protein S6 kinase B1	Homo sapiens	85-91
34329824-4	2021	Moreover, our findings showed that mechanistic target of rapamycin (mTOR), ribosomal protein S6 kinase (p70S6K), and signal transducer and activator of transcription (STAT3) inactivation was required for apoptosis induced by the combination of OZ-001 and cisplatin in in vitro and in vivo experiments.	oz-001	244-250	ribosomal protein S6 kinase B1	Homo sapiens	104-110
34329824-4	2021	Moreover, our findings showed that mechanistic target of rapamycin (mTOR), ribosomal protein S6 kinase (p70S6K), and signal transducer and activator of transcription (STAT3) inactivation was required for apoptosis induced by the combination of OZ-001 and cisplatin in in vitro and in vivo experiments.	Cisplatin	255-264	ribosomal protein S6 kinase B1	Homo sapiens	104-110
34329824-5	2021	Our results suggest that combined treatment with OZ-001 and cisplatin could potentiate antiproliferative effects via suppression of the mTOR/p70S6K and STAT3 pathways and may be considered a potential therapeutic agent for NSCLC.	oz-001	49-55	ribosomal protein S6 kinase B1	Homo sapiens	141-147
34329824-5	2021	Our results suggest that combined treatment with OZ-001 and cisplatin could potentiate antiproliferative effects via suppression of the mTOR/p70S6K and STAT3 pathways and may be considered a potential therapeutic agent for NSCLC.	Cisplatin	60-69	ribosomal protein S6 kinase B1	Homo sapiens	141-147
34329824-0	2021	Improved tumor-suppressive effect of OZ-001 combined with cisplatin mediated by mTOR/p70S6K and STAT3 inactivation in A549 human lung cancer cells.	Cisplatin	58-67	ribosomal protein S6 kinase B1	Homo sapiens	85-91
34641511-5	2021	Similar in CRPC, para-toluenesulfonamide inhibited the Akt/mTOR/p70S6K pathway in NSCLC cell lines NCI-H460 and A549, leading to G1 arrest of the cell cycle and apoptosis.	4-toluenesulfonamide	17-40	ribosomal protein S6 kinase B1	Homo sapiens	64-70
34565342-12	2021	Mechanistically, the co-treatment of JQ1 or OTX-015 with temsirolimus significantly downregulated the expression levels of phosphorylated 4EBP1/p70-S6K/eIF4E (mTOR components) and BRD4 (BET protein)/MYCN proteins.	temsirolimus	57-69	ribosomal protein S6 kinase B1	Homo sapiens	148-151
34549269-8	2021	In addition, digoxin inhibited the phosphorylation of Akt, mTOR and p70S6K, signalling molecules of the PI3K/Akt pathway that are known to be involved in tumour cell survival, proliferation, metastasis and autophagy.	Digoxin	13-20	ribosomal protein S6 kinase B1	Homo sapiens	68-74
34332284-14	2021	We found that DMBQ increased the phosphorylation of AKT and mammalian target of rapamycin (mTOR), as well as downstream S6K and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) in skeletal muscle.	2,6-dimethoxy-1,4-benzoquinone	14-18	ribosomal protein S6 kinase B1	Homo sapiens	120-123
34323596-8	2021	Phosphorylation of Akt (P = 0.002), rpS6 (P <0.001) and p70S6K (P < 0.001) increased over time in both LEU and DILEU conditions.	Leucine	103-106	ribosomal protein S6 kinase B1	Homo sapiens	56-62
34432732-0	2021	miR-19-3p Promotes Autophagy and Apoptosis in Pelvic Organ Prolapse Through the AKT/mTOR/p70S6K Pathway: Function of miR-19-3p on Vaginal Fibroblasts by Targeting IGF-1.	mir-19-3p	0-9	ribosomal protein S6 kinase B1	Homo sapiens	89-95
34432732-11	2021	miR-19-3p negatively regulated the Akt/mTOR/p70S6K pathway and inhibited COL-1 secretion.	mir-19-3p	0-9	ribosomal protein S6 kinase B1	Homo sapiens	44-50
34266234-5	2021	We found that p70S6K and 4EBP1 differentially correlated with fatty acid uptake.	Fatty Acids	62-72	ribosomal protein S6 kinase B1	Homo sapiens	14-20
34407844-2	2021	We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies.	M2698 free base	16-21	ribosomal protein S6 kinase B1	Homo sapiens	31-37
34439466-2	2021	Here, we found that an ethanol extract of tartary buckwheat (TBE) potently induced autophagy flux in HeLa cells by suppressing mTORC1 activity, as revealed by dephosphorylation of the mTORC1 substrates Ulk1, S6K, and 4EBP, as well as by the nuclear translocation of transcriptional factor EB.	Ethanol	23-30	ribosomal protein S6 kinase B1	Homo sapiens	208-211
34439466-2	2021	Here, we found that an ethanol extract of tartary buckwheat (TBE) potently induced autophagy flux in HeLa cells by suppressing mTORC1 activity, as revealed by dephosphorylation of the mTORC1 substrates Ulk1, S6K, and 4EBP, as well as by the nuclear translocation of transcriptional factor EB.	tbe	61-64	ribosomal protein S6 kinase B1	Homo sapiens	208-211
34367129-7	2021	TGEV-induced mTOR and its downstream p70 S6K and 4E-BP1, STAT1 and ISGs downregulation were blocked by an mTOR activator-MHY1485 but not by an mTOR inhibitor-RAPA.	4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine	121-128	ribosomal protein S6 kinase B1	Homo sapiens	37-55
34367129-9	2021	Furthermore, Leu reversed the inhibition of STAT1 and ISGs by activating mTOR and its downstream p70 S6K and 4E-BP1 in TEGV-infected cells.	Leucine	13-16	ribosomal protein S6 kinase B1	Homo sapiens	97-111
34336098-5	2021	H2O2 inhibited phosphorylation of S6 kinase Thr 389 (p-S6K1 (T389)), 4E-BP1 Thr 37/46 and ULK1 Ser 757, the downstream of mTORC1, in mammary epithelial cells.	Hydrogen Peroxide	0-4	ribosomal protein S6 kinase B1	Homo sapiens	55-59
34336098-5	2021	H2O2 inhibited phosphorylation of S6 kinase Thr 389 (p-S6K1 (T389)), 4E-BP1 Thr 37/46 and ULK1 Ser 757, the downstream of mTORC1, in mammary epithelial cells.	Threonine	44-47	ribosomal protein S6 kinase B1	Homo sapiens	55-59
34281282-8	2021	Acrolein suppressed the phosphorylation of glucose metabolic signals IRS1, Akt, mTOR, p70S6K, and GSK3alpha/beta.	Acrolein	0-8	ribosomal protein S6 kinase B1	Homo sapiens	86-92
34281282-8	2021	Acrolein suppressed the phosphorylation of glucose metabolic signals IRS1, Akt, mTOR, p70S6K, and GSK3alpha/beta.	Glucose	43-50	ribosomal protein S6 kinase B1	Homo sapiens	86-92
34258253-0	2021	Cryptotanshinone Prevents the Binding of S6K1 to mTOR/Raptor Leading to the Suppression of mTORC1-S6K1 Signaling Activity and Neoplastic Cell Transformation.	cryptotanshinone	0-16	ribosomal protein S6 kinase B1	Homo sapiens	41-45
34258253-0	2021	Cryptotanshinone Prevents the Binding of S6K1 to mTOR/Raptor Leading to the Suppression of mTORC1-S6K1 Signaling Activity and Neoplastic Cell Transformation.	cryptotanshinone	0-16	ribosomal protein S6 kinase B1	Homo sapiens	98-102
34258253-3	2021	Here, we propose a plausible molecular mechanism, wherein cryptotanshinone represses rapamycin-sensitive mTORC1/S6K1 mediated cancer cell growth and cell transformation.	cryptotanshinone	58-74	ribosomal protein S6 kinase B1	Homo sapiens	112-116
34258253-3	2021	Here, we propose a plausible molecular mechanism, wherein cryptotanshinone represses rapamycin-sensitive mTORC1/S6K1 mediated cancer cell growth and cell transformation.	Sirolimus	85-94	ribosomal protein S6 kinase B1	Homo sapiens	112-116
34258253-4	2021	We investigated the various effects of cryptotanshinone on the mTORC1/S6K1 axis, which is associated with the regulation of cell growth in response to nutritional and growth factor signals.	cryptotanshinone	39-55	ribosomal protein S6 kinase B1	Homo sapiens	70-74
34258253-5	2021	We found that cryptotanshinone specifically inhibited the mTORC1-mediated phosphorylation of S6K1, which consequently suppressed the clonogenicity of SK-Hep1 cells and the neoplastic transformation of JB6 Cl41 cells induced by insulin-like growth factor-1.	cryptotanshinone	14-30	ribosomal protein S6 kinase B1	Homo sapiens	93-97
34221237-6	2021	Investigation of the mechanism underlying this effect revealed that BT increased the production of reactive oxygen species (ROS) and inhibited the phosphorylation of 4EBP1 and S6K1.	brusatol	68-70	ribosomal protein S6 kinase B1	Homo sapiens	176-180
34407844-0	2021	Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer.	M2698 free base	17-22	ribosomal protein S6 kinase B1	Homo sapiens	26-32
34249433-10	2021	The anti-proliferative effects of GDC-0980 as evidenced by a decreased p-AKT (Ser473, The308), p-P70S6K, p-S6RP, and p-4EBP1, along with blockade of clonogenic 3D growth was accompanied by the initiation of apoptotic activity (annexin V, CASPASE3, cleaved PARP1 and mitochondrial depolarization); and was significantly superior when GDC-0980 combined with T-DM1.	1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one	34-42	ribosomal protein S6 kinase B1	Homo sapiens	97-103
35417269-5	2022	Under normal condition, Cr supplementation enhanced protein synthesis rate as well as upregulated the total and phosphorylated P70S6K expressions.	Creatine	24-26	ribosomal protein S6 kinase B1	Homo sapiens	127-133
34067570-6	2021	These effects of proline (0.5 mmol/L) were accompanied by the enhanced protein abundance of p-mTORC1, p-p70S6K, p-S6, and p-4E-BP1.	Proline	17-24	ribosomal protein S6 kinase B1	Homo sapiens	104-110
35428493-10	2022	WB results showed that LC3-II/I expression was significantly elevated in KHE primary cells treated with rapamycin, while the level of p-mTOR, p-S6K1, and p-4E-BP1 expression was reduced.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	144-148
35276694-7	2022	Tumor cells previously exposed to GZ17-6.02 in vivo had elevated their expression of ERBB2 and ERBB3, and increased phosphorylation of ERBB1, ERBB3, PDGFRbeta, AKT T308, ERK1/2, p70 S6K T389, STAT5 Y694 and c-SRC Y416.	gz17	34-38	ribosomal protein S6 kinase B1	Homo sapiens	178-185
35525984-5	2022	(3) We analyzed the psychiatric adverse events (AEs) of patients treated with M2698 (p70S6K/AKT1/AKT3 inhibitor) and with other PI3K/AKT/mTOR pathway inhibitors.	M2698 free base	78-83	ribosomal protein S6 kinase B1	Homo sapiens	85-91
35417269-10	2022	The present result indicates that at normal state, Cr stimulated protein synthesis via the mTOR/P70S6K pathway.	Creatine	51-53	ribosomal protein S6 kinase B1	Homo sapiens	96-102
34249433-10	2021	The anti-proliferative effects of GDC-0980 as evidenced by a decreased p-AKT (Ser473, The308), p-P70S6K, p-S6RP, and p-4EBP1, along with blockade of clonogenic 3D growth was accompanied by the initiation of apoptotic activity (annexin V, CASPASE3, cleaved PARP1 and mitochondrial depolarization); and was significantly superior when GDC-0980 combined with T-DM1.	1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one	333-341	ribosomal protein S6 kinase B1	Homo sapiens	97-103
34064340-6	2021	The results showed that DHMBA protected mitochondrial function mainly during cold preservation, and suppressed cell death after rewarming, as shown by the MTT, ATP, mitochondrial membrane potential, LDH, and lipid peroxidation assays, together with enhanced survival signals (PI3K, Akt, p70S6K) and induction of antioxidant proteins (HO-1, NQO-1, TRX-1).	3,5-dihydroxy-4-methoxybenzyl alcohol	24-29	ribosomal protein S6 kinase B1	Homo sapiens	287-293
35484006-0	2022	Corrigendum to "Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors" (Bioorgan.	4-aminopyrimidine	29-46	ribosomal protein S6 kinase B1	Homo sapiens	77-83
35176419-3	2022	p70S6K is a critical downstream effector of the oncogenic PI3K/Akt/mTOR pathway and its activation is tightly regulated by an ordered cascade of Ser/Thr phosphorylation events.	Serine	145-148	ribosomal protein S6 kinase B1	Homo sapiens	0-6
35176419-3	2022	p70S6K is a critical downstream effector of the oncogenic PI3K/Akt/mTOR pathway and its activation is tightly regulated by an ordered cascade of Ser/Thr phosphorylation events.	Threonine	149-152	ribosomal protein S6 kinase B1	Homo sapiens	0-6
35176419-8	2022	Currently, the only clinically available p70S6K inhibitors are rapamycin analogs (rapalogs) which target mTOR.	Sirolimus	63-72	ribosomal protein S6 kinase B1	Homo sapiens	41-47
35176419-8	2022	Currently, the only clinically available p70S6K inhibitors are rapamycin analogs (rapalogs) which target mTOR.	temsirolimus	82-90	ribosomal protein S6 kinase B1	Homo sapiens	41-47
35341775-0	2022	Metformin alleviates dexamethasone-induced apoptosis by regulating autophagy via AMPK/mTOR/p70S6K in osteoblasts.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	91-97
35341775-0	2022	Metformin alleviates dexamethasone-induced apoptosis by regulating autophagy via AMPK/mTOR/p70S6K in osteoblasts.	Dexamethasone	21-34	ribosomal protein S6 kinase B1	Homo sapiens	91-97
35341775-12	2022	Treatment with the autophagy inhibitor 3-methyladenine (3-MA) attenuated the effect of metformin on apoptosis, autophagy, and the AMPK/mTOR/p70S6K signaling pathway.	3-methyladenine	39-54	ribosomal protein S6 kinase B1	Homo sapiens	140-146
35341775-12	2022	Treatment with the autophagy inhibitor 3-methyladenine (3-MA) attenuated the effect of metformin on apoptosis, autophagy, and the AMPK/mTOR/p70S6K signaling pathway.	3-methyladenine	56-60	ribosomal protein S6 kinase B1	Homo sapiens	140-146
35341775-12	2022	Treatment with the autophagy inhibitor 3-methyladenine (3-MA) attenuated the effect of metformin on apoptosis, autophagy, and the AMPK/mTOR/p70S6K signaling pathway.	Metformin	87-96	ribosomal protein S6 kinase B1	Homo sapiens	140-146
35341775-15	2022	The AMPK/mTOR/p70S6K signaling pathway plays a role in metformin-mediated apoptosis suppression and autophagy promotion.	Metformin	55-64	ribosomal protein S6 kinase B1	Homo sapiens	14-20
35341775-16	2022	In conclusion, metformin can alleviate Dex-induced osteoblast apoptosis by inducing autophagy via the AMPK/mTOR/p70S6K pathway.	Metformin	15-24	ribosomal protein S6 kinase B1	Homo sapiens	112-118
35341775-16	2022	In conclusion, metformin can alleviate Dex-induced osteoblast apoptosis by inducing autophagy via the AMPK/mTOR/p70S6K pathway.	Dexamethasone	39-42	ribosomal protein S6 kinase B1	Homo sapiens	112-118
35286973-8	2022	The levels of phosphorylated mTOR and ribosomal protein S6 kinase 1 (p70S6K) were increased after GLUT1 inhibition and decreased by an mTOR inhibitor (rapamycin, Rapa) during the odontogenic induction of hDPSCs.	Sirolimus	151-160	ribosomal protein S6 kinase B1	Homo sapiens	69-75
35524821-6	2022	The first node (pS312-IRS-1, pY-IRS-1) and downstream pathway which affects glucose and lipid homeostasis (phosphorylated proteins: pS473-AKT, pS9-GSK3beta, pS2448-mTOR, pT389-p70S6K; total proteins AKT, GSK3beta, mTOR, p70S6K) were analyzed by electrochemiluminescence (ECL) in neuronal extracellular vesicles (nEVs) enriched for L1 neural cell adhesion molecule (L1CAM) expression.	Glucose	76-83	ribosomal protein S6 kinase B1	Homo sapiens	176-182
35174920-7	2022	Akt, p70S6K, and 4EBP1 levels, in general, tend to decrease following CaFB, while PTEN and TSC2 levels have been found to increase.	calcium fructoborate	70-74	ribosomal protein S6 kinase B1	Homo sapiens	5-11
35122700-0	2022	Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study.	ly2780301	72-81	ribosomal protein S6 kinase B1	Homo sapiens	54-60
35122700-2	2022	The phase IB/II TAKTIC trial (NCT01980277) has shown that combining a dual AKT and p70 ribosomal protein S6 kinase (p70S6K) inhibitor (LY2780301) taken orally with weekly paclitaxel in HER2-negative advanced breast cancer is feasible, with preliminary evidence of efficacy.	ly2780301	135-144	ribosomal protein S6 kinase B1	Homo sapiens	83-114
35122700-2	2022	The phase IB/II TAKTIC trial (NCT01980277) has shown that combining a dual AKT and p70 ribosomal protein S6 kinase (p70S6K) inhibitor (LY2780301) taken orally with weekly paclitaxel in HER2-negative advanced breast cancer is feasible, with preliminary evidence of efficacy.	ly2780301	135-144	ribosomal protein S6 kinase B1	Homo sapiens	116-122
35447117-4	2022	Furthermore, conditioned media derived from calpain-activated ECs facilitated the phosphorylation of ribosomal protein S6 kinase (S6K) and de novo lipogenesis in hepatocytes, which were abolished by the amino acid transporter inhibitor, JPH203, and the mTORC1 inhibitor, rapamycin.	2-amino-3-(4-((5-amino-2-phenylbenzo(d)oxazol-7-yl)methoxy)-3,5-dichlorophenyl)propanoic acid	237-243	ribosomal protein S6 kinase B1	Homo sapiens	130-133
35398238-0	2022	Acetyltanshinone IIA reduces the synthesis of cell cycle-related proteins by degrading p70S6K and subsequently inhibits drug-resistant lung cancer cell growth.	acetyltanshinone IIA	0-20	ribosomal protein S6 kinase B1	Homo sapiens	87-93
35398238-6	2022	First, ATA could bind p70S6K at its ATP-binding pocket to prevent phosphorylation, and second by increasing the ubiquitination of p70S6K to cause its degradation.	acetyltanshinone IIA	7-10	ribosomal protein S6 kinase B1	Homo sapiens	22-28
35398238-6	2022	First, ATA could bind p70S6K at its ATP-binding pocket to prevent phosphorylation, and second by increasing the ubiquitination of p70S6K to cause its degradation.	acetyltanshinone IIA	7-10	ribosomal protein S6 kinase B1	Homo sapiens	130-136
35398238-6	2022	First, ATA could bind p70S6K at its ATP-binding pocket to prevent phosphorylation, and second by increasing the ubiquitination of p70S6K to cause its degradation.	Adenosine Triphosphate	36-39	ribosomal protein S6 kinase B1	Homo sapiens	22-28
35398238-6	2022	First, ATA could bind p70S6K at its ATP-binding pocket to prevent phosphorylation, and second by increasing the ubiquitination of p70S6K to cause its degradation.	Adenosine Triphosphate	36-39	ribosomal protein S6 kinase B1	Homo sapiens	130-136
35398238-7	2022	Since phosphorylation of S6 ribosome protein (S6RP) by p70S6K can induce protein synthesis at the ribosome, the dramatic reduction of p70S6K after ATA treatment led to great reductions of new protein synthesis on several cell cycle-related proteins including cyclin D3, aurora kinase A, polo-like kinase, cyclin B1, survivin; and reduced the levels of EGFR and MET.	acetyltanshinone IIA	147-150	ribosomal protein S6 kinase B1	Homo sapiens	134-140
35447117-4	2022	Furthermore, conditioned media derived from calpain-activated ECs facilitated the phosphorylation of ribosomal protein S6 kinase (S6K) and de novo lipogenesis in hepatocytes, which were abolished by the amino acid transporter inhibitor, JPH203, and the mTORC1 inhibitor, rapamycin.	Sirolimus	271-280	ribosomal protein S6 kinase B1	Homo sapiens	130-133
35485300-0	2022	Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.	Everolimus	0-10	ribosomal protein S6 kinase B1	Homo sapiens	285-289
35387990-7	2022	These results imply that the PDK1-mediated activation of effector kinases, including Akt, PKC, Sgk, S6K and RSK, many of whom are not directly regulated by phosphoinositides, is also likely to be dependent on PIP3 or PI(3,4)P2.	PIP3	209-213	ribosomal protein S6 kinase B1	Homo sapiens	100-103
35387990-7	2022	These results imply that the PDK1-mediated activation of effector kinases, including Akt, PKC, Sgk, S6K and RSK, many of whom are not directly regulated by phosphoinositides, is also likely to be dependent on PIP3 or PI(3,4)P2.	phosphoinositide-3,4-bisphosphate	217-226	ribosomal protein S6 kinase B1	Homo sapiens	100-103
35318320-3	2022	Here we report that ribosomal protein S6 kinase beta 1 (S6K1), a member of AGC kinases and downstream target of mechanistic target of rapamycin complex 1 (mTORC1), directly phosphorylates PDK1 at its pleckstrin homology (PH) domain, and impairs PDK1 interaction with and activation of AKT.	Sirolimus	134-143	ribosomal protein S6 kinase B1	Homo sapiens	56-60
35318320-4	2022	Mechanistically, S6K1-mediated phosphorylation of PDK1 augments its interaction with 14-3-3 adaptor protein and homo-dimerization, subsequently dissociating PDK1 from phosphatidylinositol 3,4,5 triphosphate (PIP3) and retarding its interaction with AKT.	phosphatidylinositol 3,4,5-triphosphate	167-206	ribosomal protein S6 kinase B1	Homo sapiens	17-21
35318320-4	2022	Mechanistically, S6K1-mediated phosphorylation of PDK1 augments its interaction with 14-3-3 adaptor protein and homo-dimerization, subsequently dissociating PDK1 from phosphatidylinositol 3,4,5 triphosphate (PIP3) and retarding its interaction with AKT.	PIP3	208-212	ribosomal protein S6 kinase B1	Homo sapiens	17-21
35399709-8	2022	The transfection of cells with active P-AKT rescued hinokitiol-induced downregulation of P-gp, suggesting the involvement of Akt/mTOR/p70s6K signaling in P-gp expression.	beta-thujaplicin	52-62	ribosomal protein S6 kinase B1	Homo sapiens	134-140
33891090-12	2021	Resveratrol increased the phosphorylation of adenosine monophosphate (AMP)-activated protein kinase and decreased the phosphorylation of mammalian target of rapamycin (mTOR) and its downstream substrates p70S6K and 4EBP1 in a dose-dependent manner, leading to autophagy.	Resveratrol	0-11	ribosomal protein S6 kinase B1	Homo sapiens	204-210
35149085-8	2022	Moreover, treatment with DIO caused an increase in p-LKB1/LKB1 and p-AMPK/AMPK expressions and a decrease in p-mTOR/mTOR, p-ULK1(Ser757), p-P70S6K and p-4EBP1 expressions.	Diosgenin	25-28	ribosomal protein S6 kinase B1	Homo sapiens	140-146
35149934-10	2022	CONCLUSION: We demonstrated that rapamycin attenuated podocyte apoptosis via upregulation of nestin expression through the mTOR/P70S6K signaling pathway in an Ang II-induced podocyte injury.	Sirolimus	33-42	ribosomal protein S6 kinase B1	Homo sapiens	128-134
35226448-7	2022	Tetrazole-treatment of A549 and NCI-H1819 cells caused a prominent raise in LC3-II and p-ERK1/2 expression at 72 h. The SQSTM1/p62 level, p-mTOR and p-p70S6K expression was lowered significantly in A549 and NCI-H1819 cells on exposure to tetrazole.	1H-tetrazole	0-9	ribosomal protein S6 kinase B1	Homo sapiens	151-157
35078109-0	2022	Nuclear S6K1 regulates cAMP-responsive element-dependent gene transcription through activation of mTOR signal pathway.	Cyclic AMP	23-27	ribosomal protein S6 kinase B1	Homo sapiens	8-12
35078109-5	2022	S6K1 nuclear localization was serum dependent and serum deprivation or rapamycin treatment inhibited S6K1 Thr389 phosphorylation and, thereby, S6K1 was retained in the cytoplasm.	Sirolimus	71-80	ribosomal protein S6 kinase B1	Homo sapiens	101-105
35078109-5	2022	S6K1 nuclear localization was serum dependent and serum deprivation or rapamycin treatment inhibited S6K1 Thr389 phosphorylation and, thereby, S6K1 was retained in the cytoplasm.	Sirolimus	71-80	ribosomal protein S6 kinase B1	Homo sapiens	143-147
35159037-4	2022	Advanced macrolides, such as azithromycin, reduce the phosphorylation of p70 ribosomal protein S6 kinase (p70S6K), a downstream mammalian target of rapamycin (mTOR) effector, and suppress the proliferation of T-cells.	Macrolides	9-19	ribosomal protein S6 kinase B1	Homo sapiens	73-104
35159037-4	2022	Advanced macrolides, such as azithromycin, reduce the phosphorylation of p70 ribosomal protein S6 kinase (p70S6K), a downstream mammalian target of rapamycin (mTOR) effector, and suppress the proliferation of T-cells.	Macrolides	9-19	ribosomal protein S6 kinase B1	Homo sapiens	106-112
35159037-4	2022	Advanced macrolides, such as azithromycin, reduce the phosphorylation of p70 ribosomal protein S6 kinase (p70S6K), a downstream mammalian target of rapamycin (mTOR) effector, and suppress the proliferation of T-cells.	Azithromycin	29-41	ribosomal protein S6 kinase B1	Homo sapiens	73-104
35159037-4	2022	Advanced macrolides, such as azithromycin, reduce the phosphorylation of p70 ribosomal protein S6 kinase (p70S6K), a downstream mammalian target of rapamycin (mTOR) effector, and suppress the proliferation of T-cells.	Azithromycin	29-41	ribosomal protein S6 kinase B1	Homo sapiens	106-112
34874016-9	2022	On the other hand, rapamycin abolished the effects of T-induced cardiac hypertrophy, decreased the systolic and diastolic blood pressure of SHR, and inhibited the activation of mTOR/ S6K1/4EBP1 signaling pathway in a concentration-dependent manner.	Sirolimus	19-28	ribosomal protein S6 kinase B1	Homo sapiens	183-187
35095503-7	2021	Indeed, TA-mediated suppression of tumor cell viability is associated with multiple biochemical actions, including inhibition of protein synthesis, reduced activating phosphorylation of STAT3 and S6K1, decreased expression of the MYC oncoprotein, and suppression of Lys acetylation.	Tranexamic Acid	8-10	ribosomal protein S6 kinase B1	Homo sapiens	196-200
35524821-6	2022	The first node (pS312-IRS-1, pY-IRS-1) and downstream pathway which affects glucose and lipid homeostasis (phosphorylated proteins: pS473-AKT, pS9-GSK3beta, pS2448-mTOR, pT389-p70S6K; total proteins AKT, GSK3beta, mTOR, p70S6K) were analyzed by electrochemiluminescence (ECL) in neuronal extracellular vesicles (nEVs) enriched for L1 neural cell adhesion molecule (L1CAM) expression.	Glucose	76-83	ribosomal protein S6 kinase B1	Homo sapiens	220-226
35226448-0	2022	Lung cancer growth inhibition and autophagy activation by tetrazole via ERK1/2 up-regulation and mTOR/p70S6K signaling down-regulation.	1H-tetrazole	58-67	ribosomal protein S6 kinase B1	Homo sapiens	102-108
35197970-10	2022	Zinc sulfate significantly increased the levels of P-mTOR Ser2448, P-p70S6K Thr389, and P-tau Ser356 and decreased the levels of nuclear factor erythroid 2-related factor-2 (Nrf2) and heme oxygenase-1 (HO-1) in SH-SY5Y cells and in zinc-treated rats compared with the control groups.	Zinc Sulfate	0-12	ribosomal protein S6 kinase B1	Homo sapiens	69-75
33422633-8	2021	Interestingly, inhibition of mTORC1-S6K1 pathway using rapamycin significantly restored the IRS-1/Akt/eNOS activation, suggesting a feedback regulation of IRS-1/Akt signal through S6K1.	Sirolimus	55-64	ribosomal protein S6 kinase B1	Homo sapiens	36-40
34004440-8	2021	Inhibition of mTOR with rapamycin or knockdown of mTOR enhanced metformin"s suppression of hsBAFF-induced phosphorylation of S6K1, PTEN, Akt, and Erk1/2, as well as B-cell proliferation/viability.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	125-129
34004440-8	2021	Inhibition of mTOR with rapamycin or knockdown of mTOR enhanced metformin"s suppression of hsBAFF-induced phosphorylation of S6K1, PTEN, Akt, and Erk1/2, as well as B-cell proliferation/viability.	Metformin	64-73	ribosomal protein S6 kinase B1	Homo sapiens	125-129
33861751-8	2021	In ER+ breast cancer cells, combined treatment with TAM and CSNK1G2 knockdown further enhanced the TAM-mediated decrease in phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase (S6K) signaling but not extracellular signal-regulated kinase (ERK) signaling.	Tamoxifen	52-55	ribosomal protein S6 kinase B1	Homo sapiens	231-234
33861751-8	2021	In ER+ breast cancer cells, combined treatment with TAM and CSNK1G2 knockdown further enhanced the TAM-mediated decrease in phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase (S6K) signaling but not extracellular signal-regulated kinase (ERK) signaling.	Tamoxifen	99-102	ribosomal protein S6 kinase B1	Homo sapiens	231-234
33861751-10	2021	The CK1 inhibitor, D4476, partly mimicked the CSNK1G2 knockdown effect in ER+ breast cancer cells, but with a broader repression ranging from PI3K/AKT/mTOR/S6K to ERK signaling.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	19-24	ribosomal protein S6 kinase B1	Homo sapiens	156-159
33609687-6	2021	Interestingly, the expression of mTOR signal proteins, which were suppressed by TVX, disrupted the negative feedback of the PI3K/AKT pathway and TNFalpha rebounded p70S6K phosphorylation.	trovafloxacin	80-83	ribosomal protein S6 kinase B1	Homo sapiens	164-170
33609687-7	2021	Co-treatment with TVX and TNFalpha inhibited protective autophagy by maintaining p70S6K activity, which enhanced TVX-induced cytotoxicity.	trovafloxacin	18-21	ribosomal protein S6 kinase B1	Homo sapiens	81-87
33609687-8	2021	Phosphorylation of p70S6K was inhibited by siRNA knockdown and rapamycin to restore TNFalpha-inhibited autophagy, which prevented the synergistic effect on TVX-induced cytotoxicity.	Sirolimus	63-72	ribosomal protein S6 kinase B1	Homo sapiens	19-25
33609687-8	2021	Phosphorylation of p70S6K was inhibited by siRNA knockdown and rapamycin to restore TNFalpha-inhibited autophagy, which prevented the synergistic effect on TVX-induced cytotoxicity.	trovafloxacin	156-159	ribosomal protein S6 kinase B1	Homo sapiens	19-25
33956370-0	2021	p70S6K on astrocytes protects dopamine neurons from 1-methyl-4-phenylpyridinium neurotoxicity.	Dopamine	30-38	ribosomal protein S6 kinase B1	Homo sapiens	0-6
33956370-0	2021	p70S6K on astrocytes protects dopamine neurons from 1-methyl-4-phenylpyridinium neurotoxicity.	1-Methyl-4-phenylpyridinium	52-79	ribosomal protein S6 kinase B1	Homo sapiens	0-6
33938392-3	2021	We also show that this interaction is sufficient to overcome rapamycin sensitivity and mTORC1 dependence of S6K1.	Sirolimus	61-70	ribosomal protein S6 kinase B1	Homo sapiens	108-112
33909501-9	2021	MPS and the phosphorylation of Akt, p70S6K and eEF2 were increased in myotubes treated with young serum in response to leucine treatment, with a blunted response identified in cells treated with old serum (P < 0.05).	Leucine	119-126	ribosomal protein S6 kinase B1	Homo sapiens	36-42
33861751-0	2021	CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells.	Tamoxifen	31-40	ribosomal protein S6 kinase B1	Homo sapiens	75-78
33422633-8	2021	Interestingly, inhibition of mTORC1-S6K1 pathway using rapamycin significantly restored the IRS-1/Akt/eNOS activation, suggesting a feedback regulation of IRS-1/Akt signal through S6K1.	Sirolimus	55-64	ribosomal protein S6 kinase B1	Homo sapiens	180-184
33649826-6	2021	Western blotting results indicated that curcumin dose-dependently suppressed the phosphorylation of AKT, PRAS40, 4E-BP1, P70S6K, RAF-1 and p27 in AML cell lines (ML-2 and OCI-AML5).	Curcumin	40-48	ribosomal protein S6 kinase B1	Homo sapiens	121-127
33073679-8	2021	We observed that cisplatin induced mTOR and S6K1 phosphorylation, increased the number and size of MEC salispheres, and induced Bmi-1 expression and the fraction of CSCs in MEC models in vitro.	Cisplatin	17-26	ribosomal protein S6 kinase B1	Homo sapiens	44-48
33694332-6	2021	Utilising models of glutamate receptor overactivation in primary neurons, we demonstrated that induction of miR-210-3p was accompanied by sustained suppression of p70S6K activity and that this effect was reversed by miR-210-3p inhibition.	mir-210-3p	108-118	ribosomal protein S6 kinase B1	Homo sapiens	163-169
33865602-11	2021	The expression of p-mTOR, p-4EBP1, and p-P70S6K decreased and the ratio of LC-3 II/LC-3 I elevated after treatment of sirolimus.	Sirolimus	118-127	ribosomal protein S6 kinase B1	Homo sapiens	41-47
33758209-0	2021	Erianthridin suppresses non-small-cell lung cancer cell metastasis through inhibition of Akt/mTOR/p70S6K signaling pathway.	erianthridin	0-12	ribosomal protein S6 kinase B1	Homo sapiens	98-104
33694332-6	2021	Utilising models of glutamate receptor overactivation in primary neurons, we demonstrated that induction of miR-210-3p was accompanied by sustained suppression of p70S6K activity and that this effect was reversed by miR-210-3p inhibition.	mir-210-3p	216-226	ribosomal protein S6 kinase B1	Homo sapiens	163-169
33660929-2	2021	In particular, mTOR complex 1 (mTORC1) promotes protein synthesis in ribosomes by activating the downstream effectors, p70S6K and 4EBP1, in skeletal muscle and is highly sensitive to rapamycin, an mTOR inhibitor.	Sirolimus	183-192	ribosomal protein S6 kinase B1	Homo sapiens	119-125
33691148-5	2021	By pairing sub-effective doses of the US (rapamycin) as reminder cues simultaneously with the CS (taste stimulus) at retrieval, conditioned pharmacological responses of rapamycin persisted peripherally and centrally, reflected as suppressed interleukin-10 production and T cell activity as well as diminished activity of the mTOR target protein p70s6k in the amygdala.	Sirolimus	42-51	ribosomal protein S6 kinase B1	Homo sapiens	345-351
33691148-5	2021	By pairing sub-effective doses of the US (rapamycin) as reminder cues simultaneously with the CS (taste stimulus) at retrieval, conditioned pharmacological responses of rapamycin persisted peripherally and centrally, reflected as suppressed interleukin-10 production and T cell activity as well as diminished activity of the mTOR target protein p70s6k in the amygdala.	Sirolimus	169-178	ribosomal protein S6 kinase B1	Homo sapiens	345-351
33548371-11	2021	Also, oxidative stress, autophagy and phosphorylation of p70 S6k induced by FB1 was inhibited by MHY1485, an activator of mTOR.	4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine	97-104	ribosomal protein S6 kinase B1	Homo sapiens	57-64
33011370-9	2021	Exposure to TUA decreased PI3K, AKT, mTOR, P70S6K, Survivin mRNA, inhibited the phosphorylation of major receptors involved in autophagy and apoptosis, such as PI3K, AKT, mTOR and P70S6K, while reduced the expression of Survivin in BGC cells.	Prednisolone	12-15	ribosomal protein S6 kinase B1	Homo sapiens	43-49
33011370-9	2021	Exposure to TUA decreased PI3K, AKT, mTOR, P70S6K, Survivin mRNA, inhibited the phosphorylation of major receptors involved in autophagy and apoptosis, such as PI3K, AKT, mTOR and P70S6K, while reduced the expression of Survivin in BGC cells.	Prednisolone	12-15	ribosomal protein S6 kinase B1	Homo sapiens	180-186
33416466-5	2021	A77 1726 also inhibits the activity of p70 S6 kinase (S6K1), a serine/threonine kinase that phosphorylates and activates carbamoyl-phosphate synthetase (CAD), a second rate-limiting enzyme in the de novo pathway of pyrimidine nucleotide synthesis.	Serine	63-69	ribosomal protein S6 kinase B1	Homo sapiens	54-58
33416466-5	2021	A77 1726 also inhibits the activity of p70 S6 kinase (S6K1), a serine/threonine kinase that phosphorylates and activates carbamoyl-phosphate synthetase (CAD), a second rate-limiting enzyme in the de novo pathway of pyrimidine nucleotide synthesis.	Pyrimidine Nucleotides	215-236	ribosomal protein S6 kinase B1	Homo sapiens	54-58
33718039-0	2021	Triptolide inhibits epithelial-mesenchymal transition phenotype through the p70S6k/GSK3/beta-catenin signaling pathway in taxol-resistant human lung adenocarcinoma.	triptolide	0-10	ribosomal protein S6 kinase B1	Homo sapiens	76-82
33597638-6	2021	Gene set enrichment analysis, peptide substrate-based kinase profiling assay, and western blot analysis identified Aurora kinase, S6K, p38, and beta-catenin as key signaling proteins involved in dexamethasone resistance.	Dexamethasone	195-208	ribosomal protein S6 kinase B1	Homo sapiens	130-133
33597638-7	2021	Deep learning-enabled drug synergy prediction followed by in vitro drug synergy analysis identified kinase inhibitors against Aurora kinase, JAK, S6K, and mTOR that displayed synergy with dexamethasone.	Dexamethasone	188-201	ribosomal protein S6 kinase B1	Homo sapiens	146-149
33399091-10	2021	In contrast, MYC and RPS6KB1 amplifications were associated with responsiveness to CPIs (P < 0.05).	cpis	83-87	ribosomal protein S6 kinase B1	Homo sapiens	21-28
33718039-0	2021	Triptolide inhibits epithelial-mesenchymal transition phenotype through the p70S6k/GSK3/beta-catenin signaling pathway in taxol-resistant human lung adenocarcinoma.	Paclitaxel	122-127	ribosomal protein S6 kinase B1	Homo sapiens	76-82
33718039-12	2021	Additionally, triptolide reversed epithelial-mesenchymal transition (EMT) through repression of the p70S6K/GSK3/beta-catenin signaling pathway.	triptolide	14-24	ribosomal protein S6 kinase B1	Homo sapiens	100-106
33718039-13	2021	Conclusions: Our study provides evidence that triptolide can reverse EMT in taxol-resistant lung adenocarcinoma cells and impairs tumor growth by inhibiting the p70S6K/GSK3/beta-catenin pathway, indicating that triptolide has potential to be used as a new therapeutic agent for taxol-resistant lung adenocarcinoma.	triptolide	46-56	ribosomal protein S6 kinase B1	Homo sapiens	161-167
33718039-13	2021	Conclusions: Our study provides evidence that triptolide can reverse EMT in taxol-resistant lung adenocarcinoma cells and impairs tumor growth by inhibiting the p70S6K/GSK3/beta-catenin pathway, indicating that triptolide has potential to be used as a new therapeutic agent for taxol-resistant lung adenocarcinoma.	Paclitaxel	278-283	ribosomal protein S6 kinase B1	Homo sapiens	161-167
33289516-0	2021	Bortezomib limits renal allograft interstitial fibrosis by inhibiting NF-kappaB/TNF-alpha/Akt/mTOR/P70S6K/Smurf2 pathway via IkappaBalpha protein stabilization.	Bortezomib	0-10	ribosomal protein S6 kinase B1	Homo sapiens	99-105
33278383-8	2021	SIGNIFICANCE: The p70 ribosomal S6 kinase (S6K1) is a serine/threonine protein kinase, and it plays a significant role in different cellular processes.	Serine	54-60	ribosomal protein S6 kinase B1	Homo sapiens	43-47
33179842-0	2021	CBS and MAT2A improve methionine-mediated DNA synthesis through SAMTOR/mTORC1/S6K1/CAD pathway during embryo implantation.	Methionine	22-32	ribosomal protein S6 kinase B1	Homo sapiens	78-82
33494833-10	2021	Moreover, the neuro-reparative role of SKP-SC-EVs was implicated in the activation of PI3K/Akt, mTOR, and p70S6k, as well as the reduction of Bax/Bcl-2 ratio, that was compromised by LY294002 to some extent.	skp-sc-evs	39-49	ribosomal protein S6 kinase B1	Homo sapiens	106-112
32951587-5	2021	In this review, we summarize the chemosensitization effects of metformin and focus primarily on its molecular mechanisms in enhancing the sensitivity of multiple chemotherapeutic drugs, through targeting of mTOR, ERK/P70S6K, NF-kappaB/HIF-1alpha, and mitogenactivated protein kinase (MAPK) signaling pathways, as well as by down-regulating the expression of CSC genes and pyruvate kinase isoenzyme M2 (PKM2).	Metformin	63-72	ribosomal protein S6 kinase B1	Homo sapiens	217-223
33231372-11	2021	RESULTS: Periplocin inhibited the proliferation of PANC1 and CFPAC1 cells and induced their apoptosis by activating the AMPK/mTOR pathway and inhibiting p70 S6K.	periplocin	9-19	ribosomal protein S6 kinase B1	Homo sapiens	153-160
33189285-11	2021	Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	106-110
33189285-11	2021	Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG.	Acetates	55-62	ribosomal protein S6 kinase B1	Homo sapiens	106-110
33296752-8	2021	We found that ABA regulates an increase of PPARgamma receptor expression and suppressed phosphorylation of mTOR/p70S6K signaling and resulting in the induction of the cellular dormancy.	Abscisic Acid	14-17	ribosomal protein S6 kinase B1	Homo sapiens	112-118
33179842-10	2021	CONCLUSIONS: Taken together, these studies demonstrate that CBS and MAT2A improve methionine-mediated DNA synthesis through SAMTOR/mTORC1/S6K1/CAD pathway during embryo implantation.	Methionine	82-92	ribosomal protein S6 kinase B1	Homo sapiens	138-142
33260158-6	2020	Moreover, autophagy inhibition reversed the upregulation of AMPK phosphorylation and downregulation of mTOR and p70S6K phosphorylation elicited by ISO.	isoquercitrin	147-150	ribosomal protein S6 kinase B1	Homo sapiens	112-118
33240434-12	2021	Phosphorylation of S6K was reduced by Ev in both Li-7 and HuH-6 cells.	Everolimus	38-40	ribosomal protein S6 kinase B1	Homo sapiens	19-22
33142217-5	2020	From a cellular perspective using fluorescence lifetime imaging microscopy AZD2014 was found to interact directly with GFP-tagged mTORC1 proteins including the downstream target, S6K1.	vistusertib	75-82	ribosomal protein S6 kinase B1	Homo sapiens	179-183
33260158-0	2020	Isoquercitrin induces apoptosis and autophagy in hepatocellular carcinoma cells via AMPK/mTOR/p70S6K signaling pathway.	isoquercitrin	0-13	ribosomal protein S6 kinase B1	Homo sapiens	94-100
33260158-4	2020	We found that ISO exposure inhibited cell viability and colony growth, activated apoptotic pathway, and triggered dysregulated autophagy by activating the AMPK/mTOR/p70S6K pathway.	isoquercitrin	14-17	ribosomal protein S6 kinase B1	Homo sapiens	165-171
33339133-9	2020	Resveratrol activated Akt by regulating Mammalian Target of Rapamycin (mTOR) Complex 2 (mTORC2) via phosphatase and tensin homolog (PTEN) and ribosomal protein S6 kinase beta-1 (S6K1).	Resveratrol	0-11	ribosomal protein S6 kinase B1	Homo sapiens	178-182
33307758-8	2021	These findings were associated with an increase in ERK, Akt, and mTOR phosphorylation, whereas autophagy induction through mTOR/p70S6K inhibition by rapamycin significantly suppressed NO-induced cell apoptosis.	Sirolimus	149-158	ribosomal protein S6 kinase B1	Homo sapiens	128-134
33490152-8	2020	Finally, it was shown that the application of SKP-SC-EVs could activate the Akt/mTOR/p70S6K signaling pathway that can be abolished by rapamycin.	skp-sc-evs	46-56	ribosomal protein S6 kinase B1	Homo sapiens	85-91
33490152-8	2020	Finally, it was shown that the application of SKP-SC-EVs could activate the Akt/mTOR/p70S6K signaling pathway that can be abolished by rapamycin.	Sirolimus	135-144	ribosomal protein S6 kinase B1	Homo sapiens	85-91
33490152-9	2020	Conclusions: In summary, the addition of SKP-SC-EVs could regulate the cell growth and death signaling pathway mediated by Akt/mTOR/p70S6K, owing to the transmission of cargos in EVs to damaged motoneurons, which leads to axonal regrowth and neuronal resurrection.	skp-sc-evs	41-51	ribosomal protein S6 kinase B1	Homo sapiens	132-138
33273827-7	2020	The loss of PC4 in PDAC inhibits cell growth by inducing cell cycle arrest at the G1/S transition and suppressing the mTOR/p70s6k pathway.	pdac	19-23	ribosomal protein S6 kinase B1	Homo sapiens	123-129
33658929-0	2020	Dihydroartemisinin Inhibits the Proliferation of Esophageal Squamous Cell Carcinoma Partially by Targeting AKT1 and p70S6K.	artenimol	0-18	ribosomal protein S6 kinase B1	Homo sapiens	116-122
33222668-7	2021	At the molecular level, OSI-027 simultaneously blocked mTORC1 and mTORC2 activation, and resulted in the downregulation of phosphor-Akt, phpspho-p70S6k, phosphor-4EBP1, cyclin D1, and cyclin-dependent kinase4 (CDK4).	OSI 027	24-31	ribosomal protein S6 kinase B1	Homo sapiens	145-151
33658929-9	2020	We then explored the proteins targeted by DHA to inhibit the mTOR-p70S6K-RPS6 pathway.	artenimol	42-45	ribosomal protein S6 kinase B1	Homo sapiens	66-72
33658929-11	2020	In vivo, DHA inhibited the tumor growth of ESCC patient-derived xenografts and weakened p-mTOR, p-p70S6K, and p-RPS6 expression in tumor tissues.	artenimol	9-12	ribosomal protein S6 kinase B1	Homo sapiens	98-104
33658929-12	2020	Altogether, our results indicate that DHA has antiproliferative effects in ESCC cells and can downregulate mTOR cascade pathway partially by binding to AKT1 and p70S6K.	artenimol	38-41	ribosomal protein S6 kinase B1	Homo sapiens	161-167
33124469-4	2021	Mechanistically, Sert potentially binds to and antagonizes the mitochondrial VDAC1 (voltage dependent anion channel 1), resulting in reduced cellular ATP (adenosine triphosphate) level, activation of AMP-activated protein kinase (AMPK) and inhibition of its downstream, MTOR (mechanistic target of rapamycin kinase)-RPS6KB1 (ribosomal protein S6 kinase B1) signaling pathway.	Sertraline	17-21	ribosomal protein S6 kinase B1	Homo sapiens	316-323
33199776-8	2020	The QIAGEN Ingenuity Pathway Analysis (IPA) shows that high levels of ethanol in binge drinkers cause a shift in the microbiome that leads to the development of AD through the activation of eIF2, regulation of eIF4 and p70S6K signaling, and mTOR signaling pathways.	Ethanol	70-77	ribosomal protein S6 kinase B1	Homo sapiens	219-225
33124469-4	2021	Mechanistically, Sert potentially binds to and antagonizes the mitochondrial VDAC1 (voltage dependent anion channel 1), resulting in reduced cellular ATP (adenosine triphosphate) level, activation of AMP-activated protein kinase (AMPK) and inhibition of its downstream, MTOR (mechanistic target of rapamycin kinase)-RPS6KB1 (ribosomal protein S6 kinase B1) signaling pathway.	Sertraline	17-21	ribosomal protein S6 kinase B1	Homo sapiens	325-355
33159013-5	2020	In A172 cells and primary human glioma cells, XL388 inhibited Akt-mTORC1/2 activation by blocking phosphorylation of Akt and S6K1.	XL388	46-51	ribosomal protein S6 kinase B1	Homo sapiens	125-129
33204396-14	2020	We found seven putative genes predicted to be modulated by Rsv in the context of Doxo treatment: CCND1, CDH1, ESR1, HSP90AA1, MAPK3, PTPN11, and RPS6KB1.	Resveratrol	59-62	ribosomal protein S6 kinase B1	Homo sapiens	145-152
31912905-4	2020	Neratinib reduced the phosphorylation of PAK1, Merlin, LATS1/2, AKT, mTOR, p70 S6K, and ERK1/2 which required expression of Rubicon, Beclin1, and Merlin.	neratinib	0-9	ribosomal protein S6 kinase B1	Homo sapiens	75-82
33204396-14	2020	We found seven putative genes predicted to be modulated by Rsv in the context of Doxo treatment: CCND1, CDH1, ESR1, HSP90AA1, MAPK3, PTPN11, and RPS6KB1.	Doxorubicin	81-85	ribosomal protein S6 kinase B1	Homo sapiens	145-152
33116125-6	2020	Furthermore, ZJQ-24 significantly blocked AKT/mTOR signaling by down-regulation of mTORC1 molecules, including phospho-p70S6K (Thr389) and phospho-4EBP-1 (Ser65, Thr37/46, Thr70) and phospho-AKT (Ser473) in HCC cells.	zjq-24	13-19	ribosomal protein S6 kinase B1	Homo sapiens	119-125
32396921-7	2020	In addition, mPFC infusion of 8-OH-DPAT increased the phosphorylation of signaling proteins downstream of BDNF, including mTOR, ERK, 4EBP1, and p70S6K.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	ribosomal protein S6 kinase B1	Homo sapiens	144-150
33149612-10	2020	Additionally, Butorphanol treatment significantly reduced the expression of p-AKT, p-mTOR and P70S6K without affecting the expression of AKT and mTOR in ES-2 and SKOV3 cells.	Butorphanol	14-25	ribosomal protein S6 kinase B1	Homo sapiens	94-100
31983282-7	2020	Taken together, our data suggest that PRKDC-mediated phosphorylation of PRKAG1 primes AMPK complex to the lysosomal activation by STK11 in cancer cells thereby linking DNA damage response to autophagy and cellular metabolism.Abbreviations: AXIN1: axin 1; 3-MA: 3-methyladenine; 5-FU: 5-fluorouracil; AA mutant: double alanine mutant (S192A, T284A) of PRKAG1; ACACA: acetyl-CoA carboxylase alpha; AICAR: 5-Aminoimidazole-4-carboxamide ribonucleotide; AMPK: AMP-activated protein kinase; ATG: autophagy-related; ATM: ataxia telangiectasia mutated; ATR: ATM serine/threonine kinase; AV: autophagic vacuole; AVd: degradative autophagic vacuole; AVi: initial autophagic vacuole; BECN1: beclin 1; BSA: bovine serum albumin; CBS: cystathionine beta-synthase; CDK7: cyclin dependent kinase 7; CDKN1A: cyclin dependent kinase inhibitor 1A; EGFP: enhanced green fluorescent protein; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GST: glutathione S transferase; H2AX/H2AFX: H2A.X variant histone; HBSS: Hanks balanced salt solution; IP: immunopurification; IR: ionizing radiation; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP3K9: mitogen-activated protein kinase kinase kinase 9; mRFP: monomeric red fluorescent protein; mCh: mCherry; MCM7: minichromosome maintenance complex component 7; MTORC1: mechanistic target of rapamycin kinase complex 1; NHEJ: non-homologous end joining; NRBP2: nuclear receptor binding protein 2; NTC: non-targeting control; NUAK1: NUAK family kinase 1; PBS: phosphate-buffered saline; PIK3AP1: phosphoinositide-3-kinase adaptor protein 1; PIK3CA: phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; PIKK: phosphatidylinositol 3-kinase-related kinase; PRKAA: protein kinase AMP-activated catalytic subunit alpha; PRKAB: protein kinase AMP-activated non-catalytic subunit beta; PRKAG: protein kinase AMP-activated non-catalytic subunit gamma; PRKDC: protein kinase, DNA-activated, catalytic subunit; RLuc: Renilla luciferase; RPS6KB1: ribosomal protein S6 kinase B1; SQSTM1: sequestosome 1; STK11/LKB1: serine/threonine kinase 11; TP53: tumor protein p53; TSKS: testis specific serine kinase substrate; ULK1: unc-51 like autophagy activating kinase 1; WIPI2: WD repeat domain, phosphoinositide interacting 2; WT: wild type.	Adenosine Monophosphate	86-89	ribosomal protein S6 kinase B1	Homo sapiens	1983-1990
32562591-5	2020	Moreover, MAC stimulated AMP-activated protein kinase (AMPK) phosphorylation and suppressed phosphorylation of the mTOR, p70S6K, and 4EBP1.	4-O-methylascochlorin	10-13	ribosomal protein S6 kinase B1	Homo sapiens	121-127
33029288-9	2020	Furthermore, we found that AMPK and its downstream acetyl-CoA carboxylase (ACC) were phosphorylated, while mammalian target of rapamycin (mTOR) and its downstream p70S6 kinase (p70S6K) were dephosphorylated by morusin.	morusin	210-217	ribosomal protein S6 kinase B1	Homo sapiens	163-175
33029288-9	2020	Furthermore, we found that AMPK and its downstream acetyl-CoA carboxylase (ACC) were phosphorylated, while mammalian target of rapamycin (mTOR) and its downstream p70S6 kinase (p70S6K) were dephosphorylated by morusin.	morusin	210-217	ribosomal protein S6 kinase B1	Homo sapiens	177-183
33101052-6	2020	Conversely, ouabain (50 nM) increased the phosphorylation of ERK1/2, Akt, p70S6K, and S6 ribosomal protein, indicating activation of the ERK1/2 and the Akt-mTOR pathways.	Ouabain	12-19	ribosomal protein S6 kinase B1	Homo sapiens	74-80
32974014-5	2020	Mechanistically, formate induces mechanistic target of rapamycin complex 1 (mTORC1) activity as quantified by phosphorylation of its targets S6, 4E-BP1, S6K1 and CAD.	formic acid	17-24	ribosomal protein S6 kinase B1	Homo sapiens	153-157
32621911-7	2020	Compared with liraglutide group, treatment with rapamycin, a specific inhibitor of mTOR, compatibly augmented GLP-1 receptor level, inhibited phosphorylation of mTOR/p70S6K and expression of p62 as well as increased level of LC3-II/LC3-I ratio and Beclin-1, suggesting that there is an interaction between GLP-1 and mTOR/p70S6K signaling in the regulation of autophagy.	Sirolimus	48-57	ribosomal protein S6 kinase B1	Homo sapiens	166-172
32621911-7	2020	Compared with liraglutide group, treatment with rapamycin, a specific inhibitor of mTOR, compatibly augmented GLP-1 receptor level, inhibited phosphorylation of mTOR/p70S6K and expression of p62 as well as increased level of LC3-II/LC3-I ratio and Beclin-1, suggesting that there is an interaction between GLP-1 and mTOR/p70S6K signaling in the regulation of autophagy.	Sirolimus	48-57	ribosomal protein S6 kinase B1	Homo sapiens	321-327
32707053-9	2020	Moreover, the expression of Rab31-induced p-p70S6K was almost inhibited by rapamycin, a well-established inhibitor of mTOR.	Sirolimus	75-84	ribosomal protein S6 kinase B1	Homo sapiens	44-50
32911610-7	2020	In MTC-derived TT cells, COX4 silencing inhibited p70S6K/pS6 and p-ERK signaling, and was associated with decreased oxygen consumption and ATP production.	Mitomycin	3-6	ribosomal protein S6 kinase B1	Homo sapiens	50-56
32893519-6	2020	RESULTS: Telmisartan decreased VSMC proliferation, which was accompanied by decreased phosphorylations of mammalian target of rapamycin (mTOR) at Ser2448 (p-mTOR-Ser2448) and p70 S6 kinase (p70S6K) at Thr389 (p-p70S6K-Thr389) in dose- and time-dependent manners.	Telmisartan	9-20	ribosomal protein S6 kinase B1	Homo sapiens	175-188
32893519-6	2020	RESULTS: Telmisartan decreased VSMC proliferation, which was accompanied by decreased phosphorylations of mammalian target of rapamycin (mTOR) at Ser2448 (p-mTOR-Ser2448) and p70 S6 kinase (p70S6K) at Thr389 (p-p70S6K-Thr389) in dose- and time-dependent manners.	Telmisartan	9-20	ribosomal protein S6 kinase B1	Homo sapiens	190-196
32893519-6	2020	RESULTS: Telmisartan decreased VSMC proliferation, which was accompanied by decreased phosphorylations of mammalian target of rapamycin (mTOR) at Ser2448 (p-mTOR-Ser2448) and p70 S6 kinase (p70S6K) at Thr389 (p-p70S6K-Thr389) in dose- and time-dependent manners.	Telmisartan	9-20	ribosomal protein S6 kinase B1	Homo sapiens	211-217
32893519-8	2020	Co-treatment with compound C, a specific AMPK inhibitor, or ectopic expression of the dn-AMPKalpha1 gene, significantly reversed telmisartan-inhibited VSMC proliferation, p-mTOR-Ser2448 and p-p70S6K-Thr389 levels.	Telmisartan	129-140	ribosomal protein S6 kinase B1	Homo sapiens	192-198
32893519-9	2020	Among the ARBs tested (including losartan and fimasartan), only telmisartan increased p-AMPK-Thr172 and decreased p-mTOR-Ser2448, p-p70S6K-Thr389, and VSMC proliferation.	Telmisartan	64-75	ribosomal protein S6 kinase B1	Homo sapiens	132-138
32893519-12	2020	CONCLUSION: These results demonstrated that telmisartan-activated AMPK inhibited basal and PDGF-stimulated VSMC proliferation, at least in part, by downregulating the mTOR/p70S6K signaling axis in a PPARgamma-independent manner.	Telmisartan	44-55	ribosomal protein S6 kinase B1	Homo sapiens	172-178
32553736-8	2020	In addition, quercetin treatment reduced the phosphorylated levels of mammalian target of rapamycin (mTOR) and p70 ribosomal S6 kinase (p70S6K) in spinal dorsal horn of db/db mice.	Quercetin	13-22	ribosomal protein S6 kinase B1	Homo sapiens	111-134
32553736-8	2020	In addition, quercetin treatment reduced the phosphorylated levels of mammalian target of rapamycin (mTOR) and p70 ribosomal S6 kinase (p70S6K) in spinal dorsal horn of db/db mice.	Quercetin	13-22	ribosomal protein S6 kinase B1	Homo sapiens	136-142
32983965-3	2020	Doxorubicin and 602 interacted to rapidly activate ATM and c-MET, inactivate mTOR, AKT, and p70 S6K, enhance the expression of Beclin1 and reduce the levels of K-RAS and N-RAS.	Doxorubicin	0-11	ribosomal protein S6 kinase B1	Homo sapiens	92-99
32599128-7	2020	Rapamycin attenuated HG-induced tau hyperphosphorylation via the AKT/AMPK/GSK-3beta pathways and p70S6K in SH-SY5Y cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	97-103
33223507-12	2020	SRT2183 decreased the accumulation of p-Akt, p-mTOR and p-70s6k, and activated the p38 MAPK signaling pathway.	SRT2183	0-7	ribosomal protein S6 kinase B1	Homo sapiens	56-63
33050000-4	2020	Gingerenone A (Gin A) is a compound derived from ginger roots and a dual inhibitor of JAK2 and p70 S6 kinase (S6K1).	gingerenone A	0-13	ribosomal protein S6 kinase B1	Homo sapiens	110-114
33050000-4	2020	Gingerenone A (Gin A) is a compound derived from ginger roots and a dual inhibitor of JAK2 and p70 S6 kinase (S6K1).	gingerenone A	15-20	ribosomal protein S6 kinase B1	Homo sapiens	110-114
33036162-5	2020	Pterostilbene-induced autophagy in T24 cells was paralleled by inhibition of class I PI3K/mTOR/p70S6K as well as activation of MEK/ERK (a RAS target) and class III PI3K pathways.	pterostilbene	0-13	ribosomal protein S6 kinase B1	Homo sapiens	95-101
32400050-0	2020	A novel role for alpha-viniferin in suppressing angiogenesis by blocking the VEGFR-2/p70S6K signaling pathway.	alpha-viniferin	17-32	ribosomal protein S6 kinase B1	Homo sapiens	85-91
32998286-3	2020	p70 S6 kinase 1 (S6K1) is a serine/threonine kinase that phosphorylates insulin receptor substrate 1 (IRS-1)S1101 and desensitizes the insulin receptor (IR).	Serine	28-34	ribosomal protein S6 kinase B1	Homo sapiens	17-21
33101053-6	2020	Acute treatment with ATPgammaS produced insulin mimetic roles; increased phosphorylation of PKB (aka AKT), S6K1 and ERK and enhanced GLUT4-mediated glucose uptake in the absence of exogenous insulin.	adenosine 5'-O-(3-thiotriphosphate)	21-30	ribosomal protein S6 kinase B1	Homo sapiens	107-111
33101053-7	2020	The increases in PKB and S6K1 phosphorylation were completely prevented by pre-incubation with broad spectrum purinergic receptor (P2R) blockers PPADs and suramin but not by P2 x 4 or P2 x 7 blockers 5-BDBD or A-438079, respectively.	pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid	145-150	ribosomal protein S6 kinase B1	Homo sapiens	25-29
33101053-7	2020	The increases in PKB and S6K1 phosphorylation were completely prevented by pre-incubation with broad spectrum purinergic receptor (P2R) blockers PPADs and suramin but not by P2 x 4 or P2 x 7 blockers 5-BDBD or A-438079, respectively.	Suramin	155-162	ribosomal protein S6 kinase B1	Homo sapiens	25-29
33101053-7	2020	The increases in PKB and S6K1 phosphorylation were completely prevented by pre-incubation with broad spectrum purinergic receptor (P2R) blockers PPADs and suramin but not by P2 x 4 or P2 x 7 blockers 5-BDBD or A-438079, respectively.	5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro(3,2-e)-1,4-diazepin-2-one	200-206	ribosomal protein S6 kinase B1	Homo sapiens	25-29
33101053-7	2020	The increases in PKB and S6K1 phosphorylation were completely prevented by pre-incubation with broad spectrum purinergic receptor (P2R) blockers PPADs and suramin but not by P2 x 4 or P2 x 7 blockers 5-BDBD or A-438079, respectively.	3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine	210-218	ribosomal protein S6 kinase B1	Homo sapiens	25-29
32693121-11	2020	Meanwhile, Cd treatment dramatically decreased mTORC1, S6K1, 4E-BP1, S6, ULK1S555 and ULK1S757 phosphorylation, suggesting that mTORC1 activity was inhibited and inactive mTORC1 prevents ULK1 activation by phosphorylating ULK1 at SerS555 and Ser757.	Cadmium	11-13	ribosomal protein S6 kinase B1	Homo sapiens	55-59
32485185-6	2020	Furthermore, A-24 downregulated the phosphorylation of Akt at Ser473 and mTOR at Ser2448 in PI3K/Akt/mTOR pathway, and its downstream substrates p-p70S6K and p-4EBP1 in a dose-dependent manner.	a-24	13-17	ribosomal protein S6 kinase B1	Homo sapiens	147-153
32678390-3	2020	The exposure of adipocytes to H2O2 (generated by glucose oxidase) resulted in an elevated level of ROS, a reduced content of GSH and an increase in JNK activation, concomitantly with a decrease in insulin-stimulated PI3K, Akt and p70S6K activation and cellular glucose uptake.	Hydrogen Peroxide	30-34	ribosomal protein S6 kinase B1	Homo sapiens	230-236
32867828-10	2020	Conversely, upregulation of SLC7A5 or tryptophan supplementation enhanced mTOR-P70S6K signals which promoted the protein translation of MMP3 and MMP13 in RA FLS.	Tryptophan	38-48	ribosomal protein S6 kinase B1	Homo sapiens	79-85
32804918-11	2020	Treatment with omipalisib decreased expression of p-AKT, p-4EBP1, p-p70S6K, p-S6, and p-ERK, therefore disrupting the activation of PI3K/AKT/mTOR and ERK signaling.	omipalisib	15-25	ribosomal protein S6 kinase B1	Homo sapiens	68-74
32531316-11	2020	Co-administration significantly enhanced the anti-tumor effects than use of any one drug, and significantly reduced the phosphorylation of AKT and p70S6K compared to treatment with rapamycin alone.	Sirolimus	181-190	ribosomal protein S6 kinase B1	Homo sapiens	147-153
32454290-12	2020	Briefly, these results indicated that berberine repressed human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt, and provided a molecular basis for the treatment of gastric cancer.	Berberine	38-47	ribosomal protein S6 kinase B1	Homo sapiens	173-179
32360572-8	2020	SIGNIFICANCE: Hyperoside attenuated pregnancy loss through regulating mTOR/S6K and TLR4/MyD88/NF-kB signaling pathways, which may provide a potential drug candidate for recurrent pregnancy loss therapy.	hyperoside	14-24	ribosomal protein S6 kinase B1	Homo sapiens	75-78
32922169-6	2020	The current study showed that IL-13 increased the expression levels of p-mTOR, p-S6K1, and p-Akt, and that rapamycin blocked IL-13-induced down-regulation of miR-143, suppressed the IL-13Ralpha1 expression and up-regulated the expressions of filaggrin, loricrin, and involucrin in HaCaT cells.	Sirolimus	107-116	ribosomal protein S6 kinase B1	Homo sapiens	81-85
32404543-6	2020	Latifolin also suppressed the activation of Akt and S6K1 and attenuated the increase in SA-beta-gal activity after H2O2 exposure.	latifolin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	52-56
31993937-13	2020	CONCLUSION: Our results establish a key role for the lipid desaturase SCD1 and delineate an OA-PLD-mTOR/p70S6K signaling pathway in TNBC-derived MDA-MB-231 cell migration.	Oleic Acids	92-94	ribosomal protein S6 kinase B1	Homo sapiens	104-110
32377724-8	2020	Smad2 and Smad3 phosphorylation induced by TGF-beta2 were reduced by H-RN, and phosphorylation of Akt, mTOR and P70S6K induced by TGF-beta2 were also notably reduced by H-RN in LECs.	h-rn	169-173	ribosomal protein S6 kinase B1	Homo sapiens	112-118
32842681-7	2020	We discovered that OXY exerted its anti-inflammatory role in IL-1beta-induced HMC3 cells by suppressing IL-1beta-induced activation of the PI3K/AKT/p70S6K pathway.	puag-haad	19-22	ribosomal protein S6 kinase B1	Homo sapiens	148-154
32842681-11	2020	These findings suggest that the possible anti-inflammatory mechanisms of OXY in IL-1beta-induced HMC3 cells are mainly through its ability to suppress the PI3K/AKT/p70S6K and ERK1/2 MAPK signal transduction cascades.	puag-haad	73-76	ribosomal protein S6 kinase B1	Homo sapiens	164-170
32727781-5	2020	In addition, CTAB reduced the levels of metastasis-related proteins including c-Met, phosphoinositide 3-kinase (PI3K), Akt, mammalian target of rapamycin (mTOR), ribosomal protein S6 kinase (p70S6K), Twist, N-cadherin, and Vimentin.	Cetrimonium	13-17	ribosomal protein S6 kinase B1	Homo sapiens	191-197
32450522-10	2020	These findings suggest that imoxin may protect against DEX-induced skeletal muscle atrophy by alleviating muscle specific E3 ubiquitin ligases and imoxin alone may promote protein synthesis via Akt/mTOR/S6K1 axis in muscle cells.	imoxin	28-34	ribosomal protein S6 kinase B1	Homo sapiens	203-207
32450522-10	2020	These findings suggest that imoxin may protect against DEX-induced skeletal muscle atrophy by alleviating muscle specific E3 ubiquitin ligases and imoxin alone may promote protein synthesis via Akt/mTOR/S6K1 axis in muscle cells.	Dexamethasone	55-58	ribosomal protein S6 kinase B1	Homo sapiens	203-207
32454290-0	2020	Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways.	Berberine	0-9	ribosomal protein S6 kinase B1	Homo sapiens	135-141
32360572-7	2020	In addition, hyperoside treatment downregulated the expressions of phosphorylated mammalian target of rapamycin (mTOR), phosphorylated p70S6 Kinase (S6K) and inhibited the expressions of Toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88) and NF-kB p-p65 in pregnancy loss animal models.	hyperoside	13-23	ribosomal protein S6 kinase B1	Homo sapiens	149-152
32407957-6	2020	Treated neurons modified their mitochondrial dynamics increasing the mitochondrial fusion and, consistently with the increase of cellular ATP content, they activated cellular mTORC1 dependent p70S6 K anabolism.	Adenosine Triphosphate	138-141	ribosomal protein S6 kinase B1	Homo sapiens	192-199
32278762-8	2020	RESULTS: Curcumol reduced the expression of phosphorylated signal transducer and activator of transcription 3 (p-STAT3) via JAK1, JAK2, and Src pathways and inhibited hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis via mTOR/p70S6K/eIF4E and MAPK pathways.	curcumol	9-17	ribosomal protein S6 kinase B1	Homo sapiens	239-245
32678390-3	2020	The exposure of adipocytes to H2O2 (generated by glucose oxidase) resulted in an elevated level of ROS, a reduced content of GSH and an increase in JNK activation, concomitantly with a decrease in insulin-stimulated PI3K, Akt and p70S6K activation and cellular glucose uptake.	Glucose	49-56	ribosomal protein S6 kinase B1	Homo sapiens	230-236
32630532-0	2020	The (+)-Brevipolide H Displays Anticancer Activity against Human Castration-Resistant Prostate Cancer: The Role of Oxidative Stress and Akt/mTOR/p70S6K-Dependent Pathways in G1 Checkpoint Arrest and Apoptosis.	brevipolide	8-19	ribosomal protein S6 kinase B1	Homo sapiens	145-151
32630532-5	2020	Consequently, (+)-brevipolide H inhibited the signaling pathway of Akt/mTOR/p70S6K.	brevipolide	18-29	ribosomal protein S6 kinase B1	Homo sapiens	76-82
32580379-5	2020	The mammalian target of rapamycin/ribosomal S6 kinase (mTOR/S6K) pathway is blocked in these conditions, and we provide evidence that this is mediated by modulation of both the 5" AMP-activated protein kinase (AMPK) and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathways.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	60-63
32575795-10	2020	Western blot data revealed that BA-5 treatment decreased the phosphorylation of AKT/p70s6k without affecting the MAPK pathway and increased cleaved PARP and cleaved caspase-7 in both HCC and HCC-SR cells.	Barium	32-34	ribosomal protein S6 kinase B1	Homo sapiens	84-90
32606745-0	2020	p70S6K Promotes Acquired Resistance of Erlotinib Through Induction of Epithelial-Mesenchymal Transition in Non-Small Cell Lung Carcinoma.	Erlotinib Hydrochloride	39-48	ribosomal protein S6 kinase B1	Homo sapiens	0-6
32606745-8	2020	Results: HCC827 cells with acquired resistance to erlotinib underwent epithelial-mesenchymal transition and exhibited enhanced p70S6K signaling compared to parental sensitive cells.	Erlotinib Hydrochloride	50-59	ribosomal protein S6 kinase B1	Homo sapiens	127-133
32606745-9	2020	Moreover, in erlotinib resistant cells, downregulation of p70S6K expression using either siRNA or shRNA reversed EMT and partially overcame erlotinib resistance.	Erlotinib Hydrochloride	13-22	ribosomal protein S6 kinase B1	Homo sapiens	58-64
32606745-9	2020	Moreover, in erlotinib resistant cells, downregulation of p70S6K expression using either siRNA or shRNA reversed EMT and partially overcame erlotinib resistance.	Erlotinib Hydrochloride	140-149	ribosomal protein S6 kinase B1	Homo sapiens	58-64
32606745-10	2020	Meanwhile, in erlotinib sensitive cells, overexpression of p70S6K promoted EMT and induced erlotinib resistance.	Erlotinib Hydrochloride	14-23	ribosomal protein S6 kinase B1	Homo sapiens	59-65
32606745-10	2020	Meanwhile, in erlotinib sensitive cells, overexpression of p70S6K promoted EMT and induced erlotinib resistance.	Erlotinib Hydrochloride	91-100	ribosomal protein S6 kinase B1	Homo sapiens	59-65
32606745-11	2020	Upregulation of p70S6K signaling in erlotinib resistant cells was caused by reduced GSK3beta-mediated protein degradation of mTOR and raptor.	Erlotinib Hydrochloride	36-45	ribosomal protein S6 kinase B1	Homo sapiens	16-22
32606745-14	2020	Conclusion: Our findings suggest that p70S6K-induced EMT plays an important role in the acquired resistance of erlotinib and provides a novel therapeutic rationale of targeting p70S6K in NSCLC therapy.	Erlotinib Hydrochloride	111-120	ribosomal protein S6 kinase B1	Homo sapiens	38-44
32606745-14	2020	Conclusion: Our findings suggest that p70S6K-induced EMT plays an important role in the acquired resistance of erlotinib and provides a novel therapeutic rationale of targeting p70S6K in NSCLC therapy.	Erlotinib Hydrochloride	111-120	ribosomal protein S6 kinase B1	Homo sapiens	177-183
32240637-12	2020	Moreover, activation of mTOR/p70S6K pathway by MHY1485 abolished the effects of Rab1A knockdown on cell proliferation and apoptosis.	4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine	47-54	ribosomal protein S6 kinase B1	Homo sapiens	29-35
32347294-0	2020	Small molecule H89 renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	15-18	ribosomal protein S6 kinase B1	Homo sapiens	50-54
32347294-2	2020	mTORC1 phosphorylates S6K1 at Thr 389, whereas mTORC2 phosphorylates AKT at Ser 473 to promote cell growth.	Threonine	30-33	ribosomal protein S6 kinase B1	Homo sapiens	22-26
32347294-6	2020	Here, we report that H89 (N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide), a well-characterized ATP-mimetic kinase inhibitor, renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors across multiple cell lines.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	21-24	ribosomal protein S6 kinase B1	Homo sapiens	170-174
32347294-6	2020	Here, we report that H89 (N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide), a well-characterized ATP-mimetic kinase inhibitor, renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors across multiple cell lines.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	26-85	ribosomal protein S6 kinase B1	Homo sapiens	170-174
32347294-7	2020	Moreover, H89 prevented the dephosphorylation of AKT and S6K1 under nutrient depleted conditions.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	10-13	ribosomal protein S6 kinase B1	Homo sapiens	57-61
32316234-8	2020	It is of note that we identify PP1C and PP2A as the protein phosphatases for phosphorylated Thr-389 of p70S6K essential for kinase activation in cells.	Threonine	92-95	ribosomal protein S6 kinase B1	Homo sapiens	103-109
32630532-11	2020	In addition, suppression of Akt/mTOR/p70S6K pathway associated with downregulation of G1 phase cyclins contributes to (+)-brevipolide H-mediated anticancer activity, which ultimately causes mitochondrial dysfunction and cell apoptosis.	brevipolide	122-133	ribosomal protein S6 kinase B1	Homo sapiens	37-43
32239160-5	2020	Furthermore, the Akt/mTOR/p70S6K pathway was significantly inhibited by carbon ion radiation in both breast cancer cell lines.	Carbon	72-78	ribosomal protein S6 kinase B1	Homo sapiens	26-32
32239160-6	2020	These results indicate that carbon ion radiation kills MDA-MB-231 and MCF-7 breast cancer cells more effectively than X-ray radiation, which might result from the inhibition of the Akt/mTOR/p70S6K pathway.	Carbon	28-34	ribosomal protein S6 kinase B1	Homo sapiens	190-196
32546957-7	2020	The phosphorylation levels of Akt and P70S6K in both cell lines were significantly down-regulated with leflunomide treatment.	Leflunomide	103-114	ribosomal protein S6 kinase B1	Homo sapiens	38-44
33103038-11	2020	Conclusion: Adiponectin attenuated the high-glucose-induced premature senescence of VSMCs via increasing telomerase activity of VSMCs, which was achieved by activation of AMPK/TSC2/mTOR/S6K1 signaling and inhibition of PI3K/Akt/mTOR/S6K1 signaling.	Glucose	44-51	ribosomal protein S6 kinase B1	Homo sapiens	186-190
33103038-11	2020	Conclusion: Adiponectin attenuated the high-glucose-induced premature senescence of VSMCs via increasing telomerase activity of VSMCs, which was achieved by activation of AMPK/TSC2/mTOR/S6K1 signaling and inhibition of PI3K/Akt/mTOR/S6K1 signaling.	Glucose	44-51	ribosomal protein S6 kinase B1	Homo sapiens	233-237
33479660-0	2020	Computer-aided discovery of phenylpyrazole based amides as potent S6K1 inhibitors.	3-Phenyl-1H-pyrazole	28-42	ribosomal protein S6 kinase B1	Homo sapiens	66-70
33479660-0	2020	Computer-aided discovery of phenylpyrazole based amides as potent S6K1 inhibitors.	Amides	49-55	ribosomal protein S6 kinase B1	Homo sapiens	66-70
33479660-2	2020	In this study, computational analysis of five thiophene urea-based S6K1 inhibitors was performed.	Urea	56-60	ribosomal protein S6 kinase B1	Homo sapiens	67-71
33479660-3	2020	Molecular docking showed that the five compounds formed hydrogen bonds with residues Glu173 and Leu175 of S6K1 and hydrophobic interactions with residues Val105, Leu97 and Met225, and these interactions were key elements for the inhibitory potency of the compounds.	Hydrogen	56-64	ribosomal protein S6 kinase B1	Homo sapiens	106-110
32035621-6	2020	Insulin treatment upregulates the phosphorylation of ribosomal protein S6 kinase B1 (RPS6KB1) and AKT serine/threonine kinase 1 (AKT1), which was suppressed by tunicamycin.	Tunicamycin	160-171	ribosomal protein S6 kinase B1	Homo sapiens	53-83
32035621-6	2020	Insulin treatment upregulates the phosphorylation of ribosomal protein S6 kinase B1 (RPS6KB1) and AKT serine/threonine kinase 1 (AKT1), which was suppressed by tunicamycin.	Tunicamycin	160-171	ribosomal protein S6 kinase B1	Homo sapiens	85-92
32067279-9	2020	Mitogen-activated protein kinase kinase (MEK) mediated the phosphorylation of p70S6K induced by Abeta-M.	abeta-m	96-103	ribosomal protein S6 kinase B1	Homo sapiens	78-84
32273810-0	2020	Anticancer activity of THMPP: Downregulation of PI3K/ S6K1 in breast cancer cell line.	thmpp	23-28	ribosomal protein S6 kinase B1	Homo sapiens	54-58
32235536-10	2020	Furthermore, the levels of phosphorylated Akt and phosphorylated p70S6K were decreased through galangin treatment, suggesting that the Akt/p70S6K pathways might be involved in the apoptosis.	galangin	95-103	ribosomal protein S6 kinase B1	Homo sapiens	65-71
32273810-8	2020	Gene expression analysis has shown that THMPP was able to downregulate the expression of PI3K/S6K1 genes, possibly via EGFR signaling pathway in both the cell lines, MCF-7 and SkBr3.	thmpp	40-45	ribosomal protein S6 kinase B1	Homo sapiens	94-98
32235536-10	2020	Furthermore, the levels of phosphorylated Akt and phosphorylated p70S6K were decreased through galangin treatment, suggesting that the Akt/p70S6K pathways might be involved in the apoptosis.	galangin	95-103	ribosomal protein S6 kinase B1	Homo sapiens	139-145
32235767-12	2020	Pirfenidone suppressed mRNA levels of genes that contribute to extracellular matrix production, as well as basal and TGF-beta1-induced collagen I protein production, which was associated with inhibition of the rapamycin-sensitive mTOR/p70S6K pathway in p-hIFs.	pirfenidone	0-11	ribosomal protein S6 kinase B1	Homo sapiens	235-241
32322665-0	2020	miR-140-3p Inhibits Cutaneous Melanoma Progression by Disrupting AKT/p70S6K and JNK Pathways through ABHD2.	mir-140-3p	0-10	ribosomal protein S6 kinase B1	Homo sapiens	69-75
32309446-12	2020	GLP-1 reduced fat load and increased fatty acid beta-oxidation by activated autophagy to regulate the hepatic lipid pathway through mTOR/p70S6K signaling pathway.	Fatty Acids	37-47	ribosomal protein S6 kinase B1	Homo sapiens	137-143
32235767-13	2020	Thus, pirfenidone inhibits the proliferation of intestinal fibroblasts and suppresses collagen I production through the TGF-beta1/mTOR/p70S6K signaling pathway, which might be a novel and safe anti-fibrotic strategy to treat intestinal fibrosis.	pirfenidone	6-17	ribosomal protein S6 kinase B1	Homo sapiens	135-141
32155920-4	2020	OMEO induced protective autophagy, associated with downregulation of the mTOR/p70S6K pathway, and activated caspase-8 and caspase-9-dependent apoptosis.	omeo	0-4	ribosomal protein S6 kinase B1	Homo sapiens	78-84
32178474-4	2020	Among different chemotherapeutic agents tested, only pemetrexed increased PD-L1 levels by activating both mTOR/P70S6K and STAT3 pathways.	Pemetrexed	53-63	ribosomal protein S6 kinase B1	Homo sapiens	111-117
31598652-7	2020	Further, these cells showed dose-dependent downregulation of p53, Sesn2, and phosphorylated-AMPK with concomitant increase in phosphorylated-p70S6K level than paraquat-treated cells.	Paraquat	159-167	ribosomal protein S6 kinase B1	Homo sapiens	141-147
32155920-9	2020	Strikingly, we found that OMEO also induces p38 MAPK-mediated caspase-dependent cleavage of p70S6K, a protein reported to be overexpressed in colon cancer and associated with drug resistance.	omeo	26-30	ribosomal protein S6 kinase B1	Homo sapiens	92-98
32155920-10	2020	Our findings suggest that OMEO inhibits colon cancer through p38 MAPK-mediated protective autophagy and apoptosis associated with caspase-dependent cleavage of p70S6K.	omeo	26-30	ribosomal protein S6 kinase B1	Homo sapiens	160-166
32108266-4	2020	Both rapamycin and BCH blunted 2-DG uptake, irrespective of insulin administration, and this occurred in parallel with a decline in mTOR, 4E-BP1, and p70S6K phosphorylation status, but little effect on AKT phosphorylation.	Sirolimus	5-14	ribosomal protein S6 kinase B1	Homo sapiens	150-156
31931362-10	2020	In vitro, our results showed that DHA could downregulate the mammalian target of rapamycin/ribosomal protein S6 kinase beta-1 (mTOR/S6K1) signaling pathway, promote cell autophagy, and ameliorate cell proliferation in aIgA1-induced HMCs.	artenimol	34-37	ribosomal protein S6 kinase B1	Homo sapiens	132-136
31931362-10	2020	In vitro, our results showed that DHA could downregulate the mammalian target of rapamycin/ribosomal protein S6 kinase beta-1 (mTOR/S6K1) signaling pathway, promote cell autophagy, and ameliorate cell proliferation in aIgA1-induced HMCs.	Sirolimus	81-90	ribosomal protein S6 kinase B1	Homo sapiens	132-136
32521868-0	2020	A study of zederone for the inhibition on ovarian cancer cell proliferation through mTOR/p70s6K signalling pathway.	zederone	11-19	ribosomal protein S6 kinase B1	Homo sapiens	89-95
31879363-2	2020	Nuclear translocation of YBX1 is facilitated by YBX1 phosphorylation at serine 102 by AKT, p70S6K, and p90RSK, and the phosphorylated YBX1 (pYBX1) promotes expression of genes related to drug resistance and cell growth.	Serine	72-78	ribosomal protein S6 kinase B1	Homo sapiens	91-97
31879363-7	2020	Furthermore, treatment with everolimus, an mTORC1 inhibitor, or TAS0612, a novel multikinase inhibitor of AKT, p70S6K, and p90RSK, suppressed YBX1 phosphorylation and overcame antiestrogen resistance in vitro and in vivo IHC analysis revealed that expression of pYBX1 and YBX1 was augmented in patients who experienced recurrence during treatment with adjuvant endocrine therapies.	CHEMBL4650277	64-71	ribosomal protein S6 kinase B1	Homo sapiens	111-117
31894316-11	2020	Cardamonin inhibited cell proliferation and decreased the phosphorylation of mTOR and S6K1, as well as the protein level of raptor, in the mTOR inhibitor-resistant cells.	cardamonin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	86-90
31520398-7	2020	We then demonstrated that the propofol-induced reduction of alpha-synuclein aggregation was associated with increased mammalian target of rapamycin/ribosomal protein S6 kinase beta-1 signaling pathway activity and reduction of the excessive autophagy occurring after acute ischemic stroke.	Propofol	30-38	ribosomal protein S6 kinase B1	Homo sapiens	148-182
32098126-0	2020	Benzoxazole Derivative K313 Induces Cell Cycle Arrest, Apoptosis and Autophagy Blockage and Suppresses mTOR/p70S6K Pathway in Nalm-6 and Daudi Cells.	Benzoxazoles	0-11	ribosomal protein S6 kinase B1	Homo sapiens	108-114
32098126-0	2020	Benzoxazole Derivative K313 Induces Cell Cycle Arrest, Apoptosis and Autophagy Blockage and Suppresses mTOR/p70S6K Pathway in Nalm-6 and Daudi Cells.	palladium chloride	23-27	ribosomal protein S6 kinase B1	Homo sapiens	108-114
32098126-6	2020	We also found that K313 led to the downregulation of p-p70S6K protein, which plays an important role in cell survival and cell cycle progression.	palladium chloride	19-23	ribosomal protein S6 kinase B1	Homo sapiens	55-61
32098126-8	2020	In conclusion, K313 decreases cell viability without affecting normal healthy PBMCs, induces cell cycle arrest and apoptosis, reduces p-p70S6K protein levels, and mediates strong autophagy inhibition.	palladium chloride	15-19	ribosomal protein S6 kinase B1	Homo sapiens	136-142
31926250-6	2020	KEY FINDINGS: We found that metformin could synergistically sensitize AML cells to Ara-C via inhibiting mTORC1/P70S6K pathway.	Metformin	28-37	ribosomal protein S6 kinase B1	Homo sapiens	111-117
31926250-6	2020	KEY FINDINGS: We found that metformin could synergistically sensitize AML cells to Ara-C via inhibiting mTORC1/P70S6K pathway.	Cytarabine	83-88	ribosomal protein S6 kinase B1	Homo sapiens	111-117
31926250-8	2020	SIGNIFICANCE: We firstly found the synergistic anti-tumor effect of Ara-C/metformin in AML through inhibiting mTORC1/P70S6K pathway.	Cytarabine	68-73	ribosomal protein S6 kinase B1	Homo sapiens	117-123
31926250-8	2020	SIGNIFICANCE: We firstly found the synergistic anti-tumor effect of Ara-C/metformin in AML through inhibiting mTORC1/P70S6K pathway.	Metformin	74-83	ribosomal protein S6 kinase B1	Homo sapiens	117-123
31955628-8	2020	The phosphorylation of mTOR, p70S6K, and 4E-BP1 markedly decreased in cells exposed to caffeine after ethanol pretreatment, associated with a decrease of the mitochondrial membrane potential (DeltaPsim).	Caffeine	87-95	ribosomal protein S6 kinase B1	Homo sapiens	29-35
31955628-8	2020	The phosphorylation of mTOR, p70S6K, and 4E-BP1 markedly decreased in cells exposed to caffeine after ethanol pretreatment, associated with a decrease of the mitochondrial membrane potential (DeltaPsim).	Ethanol	102-109	ribosomal protein S6 kinase B1	Homo sapiens	29-35
32111101-0	2020	ZnO Nanoparticles Induced Caspase-Dependent Apoptosis in Gingival Squamous Cell Carcinoma through Mitochondrial Dysfunction and p70S6K Signaling Pathway.	Zinc Oxide	0-3	ribosomal protein S6 kinase B1	Homo sapiens	128-134
32111101-12	2020	Collectively, these results suggest that ZnO-NPs induce apoptosis through the mitochondrial oxidative damage and p70S6K signaling pathway in human GSCC.	Zinc Oxide	41-44	ribosomal protein S6 kinase B1	Homo sapiens	113-119
31863766-7	2020	Moreover, rapamycin attenuated thrombin-stimulated p70S6K phosphorylation.	Sirolimus	10-19	ribosomal protein S6 kinase B1	Homo sapiens	51-57
31369714-5	2020	It was observed that the LPA-induced DNA synthesis was attenuated by inhibitors of protein kinase C (PKC; staurosporine, calphostin C and bisindolylmaleimide), phosphoinositide 3-kinase (PI3K; wortmannin, and LY294002), and ribosomal p70S6 kinase (p70S6K; rapamycin).	lysophosphatidic acid	25-28	ribosomal protein S6 kinase B1	Homo sapiens	234-246
31863779-6	2020	Mechanically, AT-533 inhibited the activation of VEGFR-2 and the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK, in HUVECs, and the viability of breast cancer cells and the HIF-1alpha/VEGF signaling pathway under hypoxia.	at-533	14-20	ribosomal protein S6 kinase B1	Homo sapiens	105-111
31926250-0	2020	Inhibition of mTORC1/P70S6K pathway by Metformin synergistically sensitizes Acute Myeloid Leukemia to Ara-C.	Metformin	39-48	ribosomal protein S6 kinase B1	Homo sapiens	21-27
32096202-15	2020	OGD/R challenged SH SY5Y cell autophagy was also repressed by melatonin, as evidenced by the decreased levels of LC-II and beclin-1 and the increased phosphorylation of mammalian target of rapamycin (mTOR), p70 ribosomal protein S6 kinase (p70S6K), and eukaryotic initiation factor 4E binding protein 1 (4E-BP-1).	Melatonin	62-71	ribosomal protein S6 kinase B1	Homo sapiens	207-238
31926250-0	2020	Inhibition of mTORC1/P70S6K pathway by Metformin synergistically sensitizes Acute Myeloid Leukemia to Ara-C.	Cytarabine	102-107	ribosomal protein S6 kinase B1	Homo sapiens	21-27
31633292-0	2020	Mesoporous silica induces hippocampal neurons cell autophagy through AMPK/mTOR/P70S6K signaling pathway.	mesoporous silica	0-17	ribosomal protein S6 kinase B1	Homo sapiens	79-85
31633292-4	2020	Treatment with the mammalian target of rapamycin (mTOR) inhibitor AZD8055, the phosphorylation level of mTOR and P70S6K reduced and increased levels of p-AMPK meaning that the adenosine-activated protein kinase (AMPK)/mTOR/P70S6K pathway is involved in SBA-15 induced autophagy of HT22.	Adenosine	176-185	ribosomal protein S6 kinase B1	Homo sapiens	113-119
31633292-4	2020	Treatment with the mammalian target of rapamycin (mTOR) inhibitor AZD8055, the phosphorylation level of mTOR and P70S6K reduced and increased levels of p-AMPK meaning that the adenosine-activated protein kinase (AMPK)/mTOR/P70S6K pathway is involved in SBA-15 induced autophagy of HT22.	Adenosine	176-185	ribosomal protein S6 kinase B1	Homo sapiens	223-229
31633292-5	2020	These results suggested that mesoporous silica material SBA-15 might affect central nervous cells via oxidative stress activation of the AMPK/mTOR/P70S6K pathway, which provides a theoretical basis for safe administration of such materials in patients.	mesoporous silica	29-46	ribosomal protein S6 kinase B1	Homo sapiens	147-153
31633292-5	2020	These results suggested that mesoporous silica material SBA-15 might affect central nervous cells via oxidative stress activation of the AMPK/mTOR/P70S6K pathway, which provides a theoretical basis for safe administration of such materials in patients.	SBA-15	56-62	ribosomal protein S6 kinase B1	Homo sapiens	147-153
32096202-15	2020	OGD/R challenged SH SY5Y cell autophagy was also repressed by melatonin, as evidenced by the decreased levels of LC-II and beclin-1 and the increased phosphorylation of mammalian target of rapamycin (mTOR), p70 ribosomal protein S6 kinase (p70S6K), and eukaryotic initiation factor 4E binding protein 1 (4E-BP-1).	Melatonin	62-71	ribosomal protein S6 kinase B1	Homo sapiens	240-246
31267531-10	2020	Inactivation of AKT/mTOR/p70S6K by AKT inhibitor (GSK690693) attenuated miR-10b-induced DDP resistance in esophageal cancer cells.	GSK690693	50-59	ribosomal protein S6 kinase B1	Homo sapiens	25-31
31267531-0	2020	microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARgamma in esophageal cancer.	Cisplatin	21-30	ribosomal protein S6 kinase B1	Homo sapiens	65-71
31782083-5	2020	We also present evidence that eIF4E interacts with the amino terminal domain of S6K1 in a phospho-dependent manner, and this interaction is instrumental in overriding Rapamycin inhibition of S6K1.	Amino Acids	55-60	ribosomal protein S6 kinase B1	Homo sapiens	80-84
31782083-5	2020	We also present evidence that eIF4E interacts with the amino terminal domain of S6K1 in a phospho-dependent manner, and this interaction is instrumental in overriding Rapamycin inhibition of S6K1.	Sirolimus	167-176	ribosomal protein S6 kinase B1	Homo sapiens	80-84
31782083-5	2020	We also present evidence that eIF4E interacts with the amino terminal domain of S6K1 in a phospho-dependent manner, and this interaction is instrumental in overriding Rapamycin inhibition of S6K1.	Sirolimus	167-176	ribosomal protein S6 kinase B1	Homo sapiens	191-195
31369714-5	2020	It was observed that the LPA-induced DNA synthesis was attenuated by inhibitors of protein kinase C (PKC; staurosporine, calphostin C and bisindolylmaleimide), phosphoinositide 3-kinase (PI3K; wortmannin, and LY294002), and ribosomal p70S6 kinase (p70S6K; rapamycin).	lysophosphatidic acid	25-28	ribosomal protein S6 kinase B1	Homo sapiens	248-254
31267531-10	2020	Inactivation of AKT/mTOR/p70S6K by AKT inhibitor (GSK690693) attenuated miR-10b-induced DDP resistance in esophageal cancer cells.	Cisplatin	88-91	ribosomal protein S6 kinase B1	Homo sapiens	25-31
31817918-0	2019	Natural Naphthohydroquinone Dimer Rubioncolin C Exerts Anti-Tumor Activity by Inducing Apoptotic and Autophagic Cell Death and Inhibiting the NF-kappaB and Akt/mTOR/P70S6K Pathway in Human Cancer Cells.	1,4-naphthohydroquinone	8-27	ribosomal protein S6 kinase B1	Homo sapiens	165-171
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	0-23	ribosomal protein S6 kinase B1	Homo sapiens	125-131
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	25-29	ribosomal protein S6 kinase B1	Homo sapiens	125-131
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	nitrosobenzylmethylamine	67-71	ribosomal protein S6 kinase B1	Homo sapiens	125-131
31669255-6	2020	Pathway analysis combined with western blot-based validation revealed enhanced AKT/mTOR/p70S6K signaling as demonstrated by increased acute phosphorylation of AKT (Ser473) and p70S6K (Thr389).	seryl-seryl-seryl-arginine	164-167	ribosomal protein S6 kinase B1	Homo sapiens	88-94
31669255-6	2020	Pathway analysis combined with western blot-based validation revealed enhanced AKT/mTOR/p70S6K signaling as demonstrated by increased acute phosphorylation of AKT (Ser473) and p70S6K (Thr389).	peptide T amide	184-190	ribosomal protein S6 kinase B1	Homo sapiens	88-94
31669255-6	2020	Pathway analysis combined with western blot-based validation revealed enhanced AKT/mTOR/p70S6K signaling as demonstrated by increased acute phosphorylation of AKT (Ser473) and p70S6K (Thr389).	peptide T amide	184-190	ribosomal protein S6 kinase B1	Homo sapiens	176-182
31669255-8	2020	In summary, our findings extend current knowledge of 11,12-EET signaling events and emphasize the importance of the AKT/mTOR/p70S6K pathway in hepatic 11,12-EET signaling.	11,12-epoxy-5,8,14-eicosatrienoic acid	151-160	ribosomal protein S6 kinase B1	Homo sapiens	125-131
31992742-8	2020	JPH203 inhibited phosphorylation of MAPK / Erk, AKT, p70S6K and 4EBP-1.	2-amino-3-(4-((5-amino-2-phenylbenzo(d)oxazol-7-yl)methoxy)-3,5-dichlorophenyl)propanoic acid	0-6	ribosomal protein S6 kinase B1	Homo sapiens	53-70
31611063-6	2020	Interestingly, this autophagy promotion concurred with enhanced anabolic activation via AKT-mammalian target of rapamycin (mTOR)-p70S6K signaling cascade and enhanced antioxidant capacity such as copper zinc superoxide dismutase (CuZnSOD), glutathione peroxidase (GPX), and peroxiredoxin 3 (PRX3), known to be as antagonists of autophagy.	Sirolimus	112-121	ribosomal protein S6 kinase B1	Homo sapiens	129-135
31653348-6	2020	Mechanistic studies of LC3-II, p62 and phosphorylation of p70S6K in HepG2 cells revealed that MTX treatment induced mTOR-dependent autophagy activation, which was further confirmed by the autophagic flux assay using lysosomal inhibitor chloroquine (CQ).	Mitoxantrone	94-97	ribosomal protein S6 kinase B1	Homo sapiens	58-64
31557635-10	2020	GM-CSF activated p-Akt and increased expressions of p70S6K and c-Jun, which were blocked by LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	92-100	ribosomal protein S6 kinase B1	Homo sapiens	52-58
31896113-12	2020	The KHE pattern of expression [PTEN (-), TSC2 (-), p-mTOR (+), p-P70S6K (+), and p-4EBP1 (+)] suggested that sirolimus may be a good therapeutic choice.	Sirolimus	109-118	ribosomal protein S6 kinase B1	Homo sapiens	65-71
33289438-5	2020	Furthermore, PSB significantly reduced the expression of p-AKT, p-p70S6K, beta-catenin, and p-ERK1/2 proteins in SW620 cells, and this effect was reversed by the corresponding signaling pathway agonists.	protosappanin B	13-16	ribosomal protein S6 kinase B1	Homo sapiens	66-72
31878201-8	2019	In contrast, a PI3K/mTOR inhibitor omipalisib blocked the phosphorylation of Akt and both S6K/S6 and 4E-BP/eIF4E branches, and additively decreased the growth of TSC2-null cells with rapamycin.	omipalisib	35-45	ribosomal protein S6 kinase B1	Homo sapiens	90-106
31908533-0	2019	Baohuoside I Inhibits the Proliferation of Pancreatic Cancer Cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling.	baohuoside I	0-12	ribosomal protein S6 kinase B1	Homo sapiens	76-80
31974627-9	2020	The present results showed that LY294002 downregulated the expression of PI3K, CYP2E1, AKT, mTOR and P70S6K (P<0.05).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	32-40	ribosomal protein S6 kinase B1	Homo sapiens	101-107
32000660-10	2020	After 48 h of treatment with aspirin, the phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) and ribosomal protein S6 kinase B1 (S6K1) was reduced, cell proliferation has been inhibited.	Aspirin	29-36	ribosomal protein S6 kinase B1	Homo sapiens	136-166
32000660-10	2020	After 48 h of treatment with aspirin, the phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) and ribosomal protein S6 kinase B1 (S6K1) was reduced, cell proliferation has been inhibited.	Aspirin	29-36	ribosomal protein S6 kinase B1	Homo sapiens	168-172
31959810-7	2020	Furthermore, the combination of radiation with treatment of everolimus, an mTOR-S6K1 pathway inhibitor, sensitised CD44high/CD24low MCF7 cells to a greater extent than MCF7 cells.	everolimus	60-70	ribosomal protein S6 kinase B1	Homo sapiens	80-84
31696568-6	2020	In contrast, inactivation of autophagy by 3-methyladenine or Bafilomycin A1 could attenuate OPG-mediated inhibition of OC differentiation via the AMPK/mTOR/p70S6K signalling pathway.	3-methyladenine	42-57	ribosomal protein S6 kinase B1	Homo sapiens	156-162
31942845-2	2020	70 kDa ribosomal protein S6 kinase (p70S6K), as a significant downstream effector of mTOR, mediates protein synthesis, RNA processing, glucose homeostasis, cell growth and apoptosis.	Glucose	135-142	ribosomal protein S6 kinase B1	Homo sapiens	36-42
31841452-6	2020	Further experiments showed that alpha-KG down-regulated the expression of M1-polarized marker genes and inhibited the activities of mammalian target of rapamycin complex 1 (mTORC1)/p70 ribosomal protein S6 kinase (p70S6K) signaling pathway in M1-polarized MH-S cells.	Sirolimus	152-161	ribosomal protein S6 kinase B1	Homo sapiens	214-220
31634459-9	2019	Matrine pre-treatment significantly reduced collagen content, increased smooth muscle myosin heavy chain 11 (MYH11) and Poldip2 expression, decreased expressions of collagen I, beta1-integrin, phsphoinositide-3-kinase (PI3K) and nuclear phosphorylated p70S6k, and reduced phosphorylation levels of protein kinase B (Akt) and mechanistic target of rapamycin (mTOR) in HCSMCs exposed to AGEs in a concentration dependent manner.	matrine	0-7	ribosomal protein S6 kinase B1	Homo sapiens	252-258
31836786-5	2019	By using a planar surface immunoassay for PI3K/AKT signaling pathway components, we revealed that both melatonin and Bmal1 increased phosphorylation of AKT, ERK-1/2, PDK1, mTOR, PTEN, GSK-3alphabeta, and p70S6K.	Melatonin	103-112	ribosomal protein S6 kinase B1	Homo sapiens	204-210
31817918-5	2019	Further experiments demonstrated that rubioncolin C induced apoptotic and autophagic cell death and inhibited the Akt/mTOR/P70S6K signaling pathway in HCT116 and HepG2 cells.	Carbon	38-51	ribosomal protein S6 kinase B1	Homo sapiens	123-129
30560585-7	2019	Moreover, miR-99a-5p/mTOR axis regulated S6K1 phosphorylation.	mir-99a	10-17	ribosomal protein S6 kinase B1	Homo sapiens	41-45
31553107-10	2019	Inhibition of p70S6K /p85S6K by rapamycin also reduced the expressions of STAT3 and cyclin D1.	Sirolimus	32-41	ribosomal protein S6 kinase B1	Homo sapiens	14-20
31658358-6	2019	Importantly, the enhanced PI3K, Akt, mTOR and S6K expression by miR-365 inhibitor (anti-miR-365) was abrogated by treatment with LY294002, a PI3K inhibitor.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	129-137	ribosomal protein S6 kinase B1	Homo sapiens	46-49
31695068-4	2019	Ribosomal protein S6 kinase 1 (S6K1) is a major downstream signalling molecule of mTOR, and its activity is reduced by rapamycin suggesting that deregulation of S6K1 activity may be beneficial in HD.	Sirolimus	119-128	ribosomal protein S6 kinase B1	Homo sapiens	31-35
31711501-3	2019	The aim of the present study was to clarify whether liposaccharide (LPS) could induce depressive-like behaviors in mice via sequentially activating small GTPase RagA, mammalian target of rapamycin (mTOR), and p70S6K.	liposaccharide	52-66	ribosomal protein S6 kinase B1	Homo sapiens	209-215
31695068-4	2019	Ribosomal protein S6 kinase 1 (S6K1) is a major downstream signalling molecule of mTOR, and its activity is reduced by rapamycin suggesting that deregulation of S6K1 activity may be beneficial in HD.	Sirolimus	119-128	ribosomal protein S6 kinase B1	Homo sapiens	161-165
31374291-8	2019	This activation is likely based on a mTOR/S6K1/PI3K/ERK negative feedback loop, which is presumed to counteract the inhibitory effect of SC144 on tumor aggressiveness.	SC 144	137-142	ribosomal protein S6 kinase B1	Homo sapiens	42-46
31388935-6	2019	siRNA validation of cheminformatics-based predicted AEE788 targets has further revealed the mTOR interactive RPS6K members (RPS6KA3, RPS6KA6, RPS6KB1, and RPS6KL1) as synthetic lethal targets for rapalog combination treatment.	rapalog	196-203	ribosomal protein S6 kinase B1	Homo sapiens	142-149
31592623-5	2019	The ERK pathway (phosphorylation of ERK1/2 [Thr202/Tyr204], RSK [Ser380], and p70S6K [Thr421/Ser424]) was markedly activated immediately after resistance exercise, without any effect of CHO supplementation.	bis(2,3,3,3-tetrachloropropyl) ether	86-92	ribosomal protein S6 kinase B1	Homo sapiens	78-84
31592623-5	2019	The ERK pathway (phosphorylation of ERK1/2 [Thr202/Tyr204], RSK [Ser380], and p70S6K [Thr421/Ser424]) was markedly activated immediately after resistance exercise, without any effect of CHO supplementation.	seryl-seryl-seryl-arginine	93-96	ribosomal protein S6 kinase B1	Homo sapiens	78-84
31341030-0	2019	Glibenclamide targets sulfonylurea receptor 1 to inhibit p70S6K activity and upregulate KLF4 expression to suppress non-small-cell lung carcinoma.	Glyburide	0-13	ribosomal protein S6 kinase B1	Homo sapiens	57-63
31341030-7	2019	Additionally, glibenclamide inhibited p70S6K, and overexpression of p70S6K partially reversed the growth-inhibiting effect of glibenclamide.	Glyburide	14-27	ribosomal protein S6 kinase B1	Homo sapiens	38-44
31341030-7	2019	Additionally, glibenclamide inhibited p70S6K, and overexpression of p70S6K partially reversed the growth-inhibiting effect of glibenclamide.	Glyburide	126-139	ribosomal protein S6 kinase B1	Homo sapiens	68-74
31341030-12	2019	Targeting SUR1 with glibenclamide inhibited NSCLC through downregulation of p70S6K activity and subsequent upregulationof the expression of the tumor suppressor gene KLF4.	Glyburide	20-33	ribosomal protein S6 kinase B1	Homo sapiens	76-82
31454653-5	2019	Our investigations revealed that garcimultiflorone K suppressed EPCs angiogenesis through Akt, mTOR, p70S6K, and eNOS signaling cascades.	garcimultiflorone k	33-52	ribosomal protein S6 kinase B1	Homo sapiens	101-107
31519767-10	2019	Together, our study demonstrates that elevated expression of HK2 promotes autophagy through inhibiting the mTOR-S6K signaling pathway and results in resistance of MCF-7 breast cancer cells toward tamoxifen; thus, our results uncovered, for the first time, HK2 as a potential therapeutic target for overcoming tamoxifen resistance.	Tamoxifen	309-318	ribosomal protein S6 kinase B1	Homo sapiens	112-115
30982374-11	2019	BEZ235 had significant inhibitory effects on all signaling molecules (p-Akt, p-mTOR, and p-p70S6K) in the mTOR pathway.	dactolisib	0-6	ribosomal protein S6 kinase B1	Homo sapiens	91-97
31762815-11	2019	DHA significantly reduced phosphorylation of Akt, mTOR, p70S6K, 4E-BP1 in HUVECs.	artenimol	0-3	ribosomal protein S6 kinase B1	Homo sapiens	56-62
31460901-17	2019	Compared with matrine or acitretin, matrine plus acitretin significantly down-regulated the phosphorylation of phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway (P < 0.05) and its downstream p-p70S6K (P < 0.05).	matrine	36-43	ribosomal protein S6 kinase B1	Homo sapiens	244-250
31632969-7	2019	Investigating the effect of the inhibitors on the metabolic (mTORC1) activity we found that ceranib-2 reduced the phosphorylation of p70 S6K in PBL, and that both inhibitors, ceranib-2 and SKI-II, reduced the phosphorylation of p70 S6K in BJAB cells.	Aligeron	92-101	ribosomal protein S6 kinase B1	Homo sapiens	133-140
31632969-7	2019	Investigating the effect of the inhibitors on the metabolic (mTORC1) activity we found that ceranib-2 reduced the phosphorylation of p70 S6K in PBL, and that both inhibitors, ceranib-2 and SKI-II, reduced the phosphorylation of p70 S6K in BJAB cells.	Aligeron	92-101	ribosomal protein S6 kinase B1	Homo sapiens	228-235
31534118-10	2019	In Akt2, p70S6K and 4EBP1 overexpression groups, CPCs-Ex promoted CVB3-induced apoptosis, VP1 expression and cleavage of caspase-3.	cpcs	49-53	ribosomal protein S6 kinase B1	Homo sapiens	9-15
31545234-8	2019	Moreover, phosphorylated AMP-activated protein kinase (AMPK) and p70S6 kinase (p70s6k) expression were obviously promoted by CA in vitro and in vivo.	Adenosine Monophosphate	10-28	ribosomal protein S6 kinase B1	Homo sapiens	79-85
31460901-17	2019	Compared with matrine or acitretin, matrine plus acitretin significantly down-regulated the phosphorylation of phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway (P < 0.05) and its downstream p-p70S6K (P < 0.05).	Acitretin	49-58	ribosomal protein S6 kinase B1	Homo sapiens	244-250
31404320-5	2019	The aim of the present study was to investigate the effects of rapamycin and doxorubicin on K562 cell proliferation following the combination treatment, and further focus on confirming whether rapamycin enhanced the antitumor effects of doxorubicin by downregulating the mTOR/ribosomal protein S6 kinase (p70S6K) pathway.	Doxorubicin	237-248	ribosomal protein S6 kinase B1	Homo sapiens	305-311
31404320-0	2019	Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	118-124
31404320-0	2019	Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway.	Doxorubicin	44-55	ribosomal protein S6 kinase B1	Homo sapiens	118-124
31404320-5	2019	The aim of the present study was to investigate the effects of rapamycin and doxorubicin on K562 cell proliferation following the combination treatment, and further focus on confirming whether rapamycin enhanced the antitumor effects of doxorubicin by downregulating the mTOR/ribosomal protein S6 kinase (p70S6K) pathway.	Sirolimus	193-202	ribosomal protein S6 kinase B1	Homo sapiens	305-311
31455352-12	2019	Cardamonin inhibited the expression of HIF-1alpha at mRNA and protein levels by repressing the mTOR/p70S6K pathway, and subsequently enhanced mitochondrial oxidative phosphorylation and induced reactive oxygen species (ROS) accumulation.	cardamonin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	100-106
31140729-0	2019	Bortezomib attenuates renal interstitial fibrosis in kidney transplantation via regulating the EMT induced by TNF-alpha-Smurf1-Akt-mTOR-P70S6K pathway.	Bortezomib	0-10	ribosomal protein S6 kinase B1	Homo sapiens	136-142
31534497-12	2019	Another significant finding was that docetaxel treatment repressed KLF5 expression through AMPK/mTOR/p70S6K signaling pathway resulting in increased BECN1, induction of cell autophagy, and promotion of cell survival in castration-resistant prostate cancer cells.	Docetaxel	37-46	ribosomal protein S6 kinase B1	Homo sapiens	101-107
31331001-7	2019	Combined with doxorubicin, melatonin inhibited the activation of p70S6K and modulated the expression of breast cancer, angiogenesis and clock genes.	Doxorubicin	14-25	ribosomal protein S6 kinase B1	Homo sapiens	65-71
31331001-7	2019	Combined with doxorubicin, melatonin inhibited the activation of p70S6K and modulated the expression of breast cancer, angiogenesis and clock genes.	Melatonin	27-36	ribosomal protein S6 kinase B1	Homo sapiens	65-71
31028998-6	2019	More importantly, metformin induced G2/M cell cycle phase arrest in RA-FLS via the IGF-IR/PI3K/AKT/ m-TOR pathway and inhibited m-TOR phosphorylation through both the IGF-IR/PI3K/AKT signaling pathways thereby further upregulating and down-regulating p70s6k and 4E-BP1 phosphorylation, respectively; however, metformin was found not to induce apoptosis in RA-FLSs.	Metformin	18-27	ribosomal protein S6 kinase B1	Homo sapiens	251-268
31028998-7	2019	In summary, these results demonstrate that metformin can effectively inhibit RA-FLS proliferation through inducing cell cycle and upregulating and down-regulating p70s6k and 4E-BP1 phosphorylation.	Metformin	43-52	ribosomal protein S6 kinase B1	Homo sapiens	163-180
31081172-10	2019	mTOR was re-phosphorylated and existed as mTOR complex 1 (mTORC1), which was supported by phosphorylation of S6K1 at Thr 389 in neurons.	Threonine	117-120	ribosomal protein S6 kinase B1	Homo sapiens	109-113
31081172-12	2019	However, the administration of mTORC1/2 inhibitor PP242 could recover the phosphorylation of S6K1, which suggested that mTORC2 was involved in the regulation of mTORC1 activity.	PP242	50-55	ribosomal protein S6 kinase B1	Homo sapiens	93-97
31387554-0	2019	Identification of a novel S6K1 inhibitor, rosmarinic acid methyl ester, for treating cisplatin-resistant cervical cancer.	Cisplatin	85-94	ribosomal protein S6 kinase B1	Homo sapiens	26-30
31387554-11	2019	Furthermore, we observed that combination treatment with RAME and cisplatin greatly enhanced the anti-tumor effect in cisplatin-resistant cervical cancer cells, which was likely due to mTOR/S6K1 inhibition-mediated autophagy and apoptosis.	Cisplatin	66-75	ribosomal protein S6 kinase B1	Homo sapiens	190-194
31387554-11	2019	Furthermore, we observed that combination treatment with RAME and cisplatin greatly enhanced the anti-tumor effect in cisplatin-resistant cervical cancer cells, which was likely due to mTOR/S6K1 inhibition-mediated autophagy and apoptosis.	Cisplatin	118-127	ribosomal protein S6 kinase B1	Homo sapiens	190-194
31387554-12	2019	CONCLUSIONS: Our findings suggest that inhibition of S6K1 by RAME can induce autophagy and apoptosis in cervical cancer cells, and provide a potential option for cervical cancer treatment, particularly when combined with cisplatin.	Cisplatin	221-230	ribosomal protein S6 kinase B1	Homo sapiens	53-57
31383843-7	2019	The intracellular calcium-dependent PKCalpha/mammalian target of the rapamycin (mTOR) signaling pathway triggered by cP1P regulated HIF1alpha translation via S6K1, which is critical for HIF1 activation.	Calcium	18-25	ribosomal protein S6 kinase B1	Homo sapiens	158-162
31383843-7	2019	The intracellular calcium-dependent PKCalpha/mammalian target of the rapamycin (mTOR) signaling pathway triggered by cP1P regulated HIF1alpha translation via S6K1, which is critical for HIF1 activation.	Sirolimus	69-78	ribosomal protein S6 kinase B1	Homo sapiens	158-162
31404320-9	2019	Rapamycin and doxorubicin also reduced the phosphorylation levels of mTOR and p70S6K.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	78-84
31404320-9	2019	Rapamycin and doxorubicin also reduced the phosphorylation levels of mTOR and p70S6K.	Doxorubicin	14-25	ribosomal protein S6 kinase B1	Homo sapiens	78-84
31404320-12	2019	These results suggested that rapamycin could enhance the antitumor effects of doxorubicin on K562 cells by downregulating mTOR/p70S6K signaling.	Sirolimus	29-38	ribosomal protein S6 kinase B1	Homo sapiens	127-133
31404320-12	2019	These results suggested that rapamycin could enhance the antitumor effects of doxorubicin on K562 cells by downregulating mTOR/p70S6K signaling.	Doxorubicin	78-89	ribosomal protein S6 kinase B1	Homo sapiens	127-133
30887599-3	2019	Interestingly, epimagnolin suppressed EGF-induced Akt phosphorylation strongly at Ser473 and weakly at Thr308 without alteration of phosphorylation of MAPK/ERK kinases (MEKs), extracellular signal-regulated kinase (ERKs), and RSK1, resulting in abrogation of the phosphorylation of GSK3beta at Ser9 and p70S6K at Thr389.	magnolin	15-26	ribosomal protein S6 kinase B1	Homo sapiens	303-309
31180515-0	2019	Salidroside protects SH-SY5Y from pathogenic alpha-synuclein by promoting cell autophagy via mediation of mTOR/p70S6K signaling.	rhodioloside	0-11	ribosomal protein S6 kinase B1	Homo sapiens	111-117
31180515-8	2019	Furthermore, the results suggested that the underlying mechanism for the SAL-induced protection of PD model neurons may involve the preservation of autophagy, which attenuates the phosphorylation of alpha-syn in neurons predominantly via mTOR/p70S6K, and is independent of the PI3K/Akt signaling pathway.	rhodioloside	73-76	ribosomal protein S6 kinase B1	Homo sapiens	243-249
31180558-9	2019	Additionally, bupivacaine inhibited protein kinase B (Akt)/mammalian target of rapamycin (mTOR)/S6 kinase (S6K) signaling, which is a negative regulator of autophagic activity.	Bupivacaine	14-25	ribosomal protein S6 kinase B1	Homo sapiens	107-110
31180558-11	2019	The findings indicated that application of clinically relevant concentrations of bupivacaine upregulated autophagic activity via inhibition of Akt/mTOR/S6K signaling.	Bupivacaine	81-92	ribosomal protein S6 kinase B1	Homo sapiens	152-155
30887599-10	2019	Taken together, our results indicate that epimagnolin potentiates as chemopreventive or therapeutic agents by direct active pocket targeting of mTOR kinase, resulting in sensitizing cancer cells harboring enhanced phosphorylation of the mTORC2-Akt-p70S6k signaling pathway.	magnolin	42-53	ribosomal protein S6 kinase B1	Homo sapiens	248-254
31051157-0	2019	Alpha ketoglutarate exerts a pro-osteogenic effect in osteoblast cell lines through activation of JNK and mTOR/S6K1/S6 signaling pathways.	Ketoglutaric Acids	0-19	ribosomal protein S6 kinase B1	Homo sapiens	111-115
31051157-9	2019	Our findings suggest that AKG salt activates the JNK and mTOR/S6K1/S6 signaling pathways to promote differentiation of osteoblasts, independently of GPR99 activation.	Salts	30-34	ribosomal protein S6 kinase B1	Homo sapiens	62-66
31030945-6	2019	The mechanistic study revealed that beta3-AR knockdown and SR59230A inhibited the phosphorylation and thereby the activation of the mTOR/p70S6K pathway.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	59-67	ribosomal protein S6 kinase B1	Homo sapiens	137-143
30753544-3	2019	RESULTS: Metformin added to peripheral blood mononuclear cells from healthy volunteers enhanced in vitro cellular metabolism while inhibiting the mammalian target of rapamycin targets p70S6K and 4EBP1, with decreased cytokine production and cellular proliferation and increased phagocytosis activity.	Metformin	9-18	ribosomal protein S6 kinase B1	Homo sapiens	184-200
30956113-3	2019	Here, we show that transmembrane 4 L six family member 5 (TM4SF5) translocates from plasma membrane to lysosome upon arginine sufficiency and senses arginine, culminating in mTORC1/S6K1 activation.	Arginine	117-125	ribosomal protein S6 kinase B1	Homo sapiens	181-185
30956113-3	2019	Here, we show that transmembrane 4 L six family member 5 (TM4SF5) translocates from plasma membrane to lysosome upon arginine sufficiency and senses arginine, culminating in mTORC1/S6K1 activation.	Arginine	149-157	ribosomal protein S6 kinase B1	Homo sapiens	181-185
30956113-7	2019	Therefore, we propose that lysosomal TM4SF5 senses and enables arginine efflux for mTORC1/S6K1 activation, and arginine-auxotroph in hepatocellular carcinoma may be targeted by blocking the arginine sensing using anti-TM4SF5 reagents.	Arginine	63-71	ribosomal protein S6 kinase B1	Homo sapiens	90-94
31006841-0	2019	Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells.	Curcumin	0-8	ribosomal protein S6 kinase B1	Homo sapiens	86-92
31006841-12	2019	CONCLUSIONS: Curcumin can induce protective autophagy of human ovarian cancer cells by inhibiting the AKT/mTOR/p70S6K pathway, indicating the synergistic effects of curcumin and autophagy inhibition as a possible strategy to overcome the limits of current therapies in the eradication of epithelial ovarian cancer.	Curcumin	13-21	ribosomal protein S6 kinase B1	Homo sapiens	111-117
30506723-8	2019	Yet, importantly, PO-296 inhibited the phosphorylation of signal transducer and activator of transcription 5 (STAT5), increased the phosphorylation of p70S6K, but did not affect the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mitogen-activated protein kinase pathway.	po-296	18-24	ribosomal protein S6 kinase B1	Homo sapiens	151-157
30822534-5	2019	Phosphorylation of ERK1/2, P90RSK, and S6 were downregulated by exposure to a 200 nM dose of oxibendazole in both types of cells, while the expression of phosphorylated JNK, AKT, and P70S6K was upregulated.	oxibendazole	93-105	ribosomal protein S6 kinase B1	Homo sapiens	183-189
31934028-7	2019	Other proteins kinases such as pAMPK, BAX, and p-p70S6K also proved the involvement of autophagy in the process of developing tamoxifen resistance.	Tamoxifen	126-135	ribosomal protein S6 kinase B1	Homo sapiens	49-55
31033201-6	2019	PEM stimulation also augmented phosphorylation of AMPK, p70S6K, AKT and p53 in most cases.	Pemetrexed	0-3	ribosomal protein S6 kinase B1	Homo sapiens	56-62
30761631-6	2019	Supplementation of leucine improved the phosphorylation of mammalian target of rapamycin (mTOR), eukaryotic initiation factor 4E-binding protein 1 (4EBP1) and substrates ribosomal protein S6 kinase 1 (p70S6K).	Leucine	19-26	ribosomal protein S6 kinase B1	Homo sapiens	201-207
31205560-0	2019	Cytochalasin H Inhibits Angiogenesis via the Suppression of HIF-1alpha Protein Accumulation and VEGF Expression through PI3K/AKT/P70S6K and ERK1/2 Signaling Pathways in Non-Small Cell Lung Cancer Cells.	cytochalasin H	0-14	ribosomal protein S6 kinase B1	Homo sapiens	129-135
31133888-7	2019	Low-dose rapamycin (0.1 nM) normalized respiration with the magnitude of this normalization greater for AD-A LCLs, suggesting that the mammalian target of rapamycin complex 1 (mTORC1) pathway may have a different dynamic range for regulating mitochondrial activity in individuals with ASD with and without mitochondrial dysfunction, potentially related to S6K1 (S6 kinase beta-1) regulation.	Sirolimus	9-18	ribosomal protein S6 kinase B1	Homo sapiens	356-360
31133888-7	2019	Low-dose rapamycin (0.1 nM) normalized respiration with the magnitude of this normalization greater for AD-A LCLs, suggesting that the mammalian target of rapamycin complex 1 (mTORC1) pathway may have a different dynamic range for regulating mitochondrial activity in individuals with ASD with and without mitochondrial dysfunction, potentially related to S6K1 (S6 kinase beta-1) regulation.	Sirolimus	9-18	ribosomal protein S6 kinase B1	Homo sapiens	362-378
30900779-5	2019	The results showed that TOR, S6K1 and 4E-BP1 mRNA expressions in the medium with Leu concentration of 2 mM were significantly higher than that in 0.2 mM group (p &lt; 0.05).	Leucine	81-84	ribosomal protein S6 kinase B1	Homo sapiens	29-44
30728070-13	2019	After ACY-1215 treatment, increased chromatin accessibility was observed in regions associated with T-cell effector function and memory phenotypes, while condensed chromatin was found in regions encoding the mTOR downstream molecules AKT, SGK1 and S6K.	ricolinostat	6-14	ribosomal protein S6 kinase B1	Homo sapiens	248-251
30864709-0	2019	Butyrate inhibits the proliferation and induces the apoptosis of colorectal cancer HCT116 cells via the deactivation of mTOR/S6K1 signaling mediated partly by SIRT1 downregulation.	Butyrates	0-8	ribosomal protein S6 kinase B1	Homo sapiens	125-129
30864709-8	2019	Butyrate treatment also enhanced the inhibition of SIRT1 silencing on cell proliferation and activity of mTOR/S6K1.	Butyrates	0-8	ribosomal protein S6 kinase B1	Homo sapiens	110-114
30864709-9	2019	The activation of mTOR/S6K1 signaling and upregulation of cell proliferation mediated by overexpression of SIRT1 were blocked by butyrate.	Butyrates	129-137	ribosomal protein S6 kinase B1	Homo sapiens	23-27
30864709-10	2019	These data suggested that butyrate inhibited proliferation and induced apoptosis in HCT116 cells by deactivating mTOR/S6K1 signaling, possibly through its inhibition of SIRT1.	Butyrates	26-34	ribosomal protein S6 kinase B1	Homo sapiens	118-122
30923227-11	2019	Furthermore, CB2R dysfunction significantly attenuated the cardiac protective effects of rapamycin both in vivo and in vitro Finally, we found that CB2R-mediated autophagy was induced by AMPK-mTOR-p70S6K signaling pathway.	Sirolimus	89-98	ribosomal protein S6 kinase B1	Homo sapiens	197-203
30720062-5	2019	Western blot analysis demonstrated that treatment with metformin increased the phosphorylation of AMPK, and decreased the phosphorylation of AKT, mTOR and p70S6k.	Metformin	55-64	ribosomal protein S6 kinase B1	Homo sapiens	155-161
30739792-4	2019	Mechanistically, ribavirin suppresses Akt/mTOR and eIF4E/p70S6K signaling pathways in ovarian cancer cells.	Ribavirin	17-26	ribosomal protein S6 kinase B1	Homo sapiens	57-63
30552925-3	2019	We have previously shown that 4E-BP1 resistance to rapamycin was overcome by the stoichiometric abundance of S6K1.	Sirolimus	51-60	ribosomal protein S6 kinase B1	Homo sapiens	109-113
30552925-4	2019	Now we present evidence that the TOS-bearing amino terminal domain of S6K1 is sufficient to relieve the rapamycin resistance of 4E-BP1 as TOS deleted variants of S6K1, active or inactive with regard to S6K1 activity failed to bring about relief of 4E-BP1 resistance to rapamycin.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	70-74
30552925-6	2019	The data presented in this study identifies eIF4E and not Raptor as a cellular factor responsible to regulate rapamycin sensitivity of 4E-BP1 suggesting that the phosphorylation dynamics and rapamycin sensitivity of 4E-BP1 and S6K1 are regulated independently.	Sirolimus	110-119	ribosomal protein S6 kinase B1	Homo sapiens	227-231
30845773-8	2019	[Pt(O,O"-acac)(gamma-acac)(DMS)] inhibited the phosphorylation of mammalian target of rapmycin (mTOR), p70S6K, and AKT, and increased the phosphorylation of c-Jun N-terminal kinase (JNK1/2), a kinase activity pattern consistent with autophagy induction.	pt(o,o"-acac)	1-14	ribosomal protein S6 kinase B1	Homo sapiens	103-109
30845773-8	2019	[Pt(O,O"-acac)(gamma-acac)(DMS)] inhibited the phosphorylation of mammalian target of rapmycin (mTOR), p70S6K, and AKT, and increased the phosphorylation of c-Jun N-terminal kinase (JNK1/2), a kinase activity pattern consistent with autophagy induction.	gamma-acac)	15-26	ribosomal protein S6 kinase B1	Homo sapiens	103-109
30845773-8	2019	[Pt(O,O"-acac)(gamma-acac)(DMS)] inhibited the phosphorylation of mammalian target of rapmycin (mTOR), p70S6K, and AKT, and increased the phosphorylation of c-Jun N-terminal kinase (JNK1/2), a kinase activity pattern consistent with autophagy induction.	dimethyl sulfide	27-30	ribosomal protein S6 kinase B1	Homo sapiens	103-109
30146703-9	2019	Contribution of mTOR signaling pathway in metformin-induced effect was shown by the inhibition of phosphorylation of S6K1 and 4E-BP1, the downstream targets of mTOR.	Metformin	42-51	ribosomal protein S6 kinase B1	Homo sapiens	117-121
31114162-12	2019	The activation of rhHMGB1-induced Akt-mTOR-P70S6K and ERK-CREB signalling pathways was inhibited by ALO.	alloin	100-103	ribosomal protein S6 kinase B1	Homo sapiens	43-49
31114162-14	2019	Conclusion: ALO- induced HGC-27 cell apoptosis by down-regulating expressions of HMGB1 and RAGE, inhibiting HMGB1 release and then suppressing rhHMGB1-induced activation of Akt-mTOR-P70S6K and ERK-P90RSK-CREB signalling pathways.	alloin	12-15	ribosomal protein S6 kinase B1	Homo sapiens	182-188
31089421-5	2019	Results: A NaHS (sodium hydrosulfide) injection simultaneously increased the diameter of M. pectoralis major (i.e., fast-twitch glycolytic fibres) and activated the mammalian target of the rapamycin (mTOR)/p70S6 kinase (p70S6K) pathway.	sodium bisulfide	11-15	ribosomal protein S6 kinase B1	Homo sapiens	220-226
31089421-5	2019	Results: A NaHS (sodium hydrosulfide) injection simultaneously increased the diameter of M. pectoralis major (i.e., fast-twitch glycolytic fibres) and activated the mammalian target of the rapamycin (mTOR)/p70S6 kinase (p70S6K) pathway.	sodium bisulfide	17-36	ribosomal protein S6 kinase B1	Homo sapiens	220-226
31089421-6	2019	Dexamethasone (DEX) inhibited protein synthesis, downregulated mTOR and p70S6K phosphorylation, and suppressed the expression of the cystathionine gamma-lyase (CSE) protein in myoblasts.	Dexamethasone	0-13	ribosomal protein S6 kinase B1	Homo sapiens	72-78
31089421-6	2019	Dexamethasone (DEX) inhibited protein synthesis, downregulated mTOR and p70S6K phosphorylation, and suppressed the expression of the cystathionine gamma-lyase (CSE) protein in myoblasts.	Dexamethasone	15-18	ribosomal protein S6 kinase B1	Homo sapiens	72-78
31089421-11	2019	However, PAG abrogated the stimulatory effects of insulin on protein synthesis and the activity of the mTOR/p70S6K pathway.	propargylglycine	9-12	ribosomal protein S6 kinase B1	Homo sapiens	108-114
30798466-10	2019	At the molecular level, 0.5-mM L-valine increased (P &lt; 0.05) the mRNA levels for Ras, ERK1/2, and p70S6K, and the abundances of mTOR, p-4EBP1, total 4EBP1, p-ERK1/2, and total ERK1/2 proteins.	Valine	31-39	ribosomal protein S6 kinase B1	Homo sapiens	101-107
30906437-6	2019	In addition, western blot analysis revealed that the expression levels of Thr-389-phosphorylated p70S6 kinase (p-p70S6K) and phosphorylated Akt (p-Akt) were significantly increased by HG when compared with mannitol treatment.	Threonine	74-77	ribosomal protein S6 kinase B1	Homo sapiens	113-119
30906437-6	2019	In addition, western blot analysis revealed that the expression levels of Thr-389-phosphorylated p70S6 kinase (p-p70S6K) and phosphorylated Akt (p-Akt) were significantly increased by HG when compared with mannitol treatment.	Mannitol	206-214	ribosomal protein S6 kinase B1	Homo sapiens	113-119
30906437-7	2019	Notably, rapamycin significantly inhibited HG-induced p-p70S6K expression, but did not significantly impact p-Akt expression.	Sirolimus	9-18	ribosomal protein S6 kinase B1	Homo sapiens	56-62
30906437-8	2019	However, KU0063794 significantly inhibited the HG-induced p-p70S6K and p-Akt expression levels.	Ku 0063794	9-18	ribosomal protein S6 kinase B1	Homo sapiens	60-66
30320921-7	2019	Delphinidin decreased the phosphorylation of proliferative signaling molecules, including ERK1/2, AKT, P70S6K, and S6, while increasing the phosphorylation of P38 MAPK and P90RSK.	delphinidin	0-11	ribosomal protein S6 kinase B1	Homo sapiens	103-109
30650200-6	2019	Further, OSI-027 almost completely blocked the phosphorylation of the mTORC1 substrates, S6K1, S6 and 4EBP1, and the mTORC2 substrate, AKT, at Ser-473.	OSI 027	9-16	ribosomal protein S6 kinase B1	Homo sapiens	89-107
30557609-5	2019	Mechanistically, DHA induced autophagy by regulating the activity of AMPK/mTOR/p70S6k signaling pathway, which accelerated the degradation of ferritin, increased the labile iron pool, promoted the accumulation of cellular ROS and eventually led to ferroptotic cell death.	artenimol	17-20	ribosomal protein S6 kinase B1	Homo sapiens	79-85
30557609-5	2019	Mechanistically, DHA induced autophagy by regulating the activity of AMPK/mTOR/p70S6k signaling pathway, which accelerated the degradation of ferritin, increased the labile iron pool, promoted the accumulation of cellular ROS and eventually led to ferroptotic cell death.	ros	222-225	ribosomal protein S6 kinase B1	Homo sapiens	79-85
30483732-0	2019	Astragaloside IV ameliorates high glucose-induced renal tubular epithelial-mesenchymal transition by blocking mTORC1/p70S6K signaling in HK-2 cells.	astragaloside	0-13	ribosomal protein S6 kinase B1	Homo sapiens	117-123
30342037-9	2019	AURKA knockdown or inhibition with alisertib reduced levels of phosphorylated RPS6KB1 (at T389) and increased levels of proteins that induce apoptosis, including BIM, cleaved PARP, and cleaved caspase 3.	MLN 8237	35-44	ribosomal protein S6 kinase B1	Homo sapiens	78-85
30342037-13	2019	Alisertib reduced phosphorylation of RPS6KB1 and Ki-67 and increased levels of cleaved caspase 3 in tumor tissues.	MLN 8237	0-9	ribosomal protein S6 kinase B1	Homo sapiens	37-44
30483732-8	2019	The results suggested that the EMT of HK-2 cells and the mTORC1/p70S6K pathway were activated by high glucose.	Glucose	102-109	ribosomal protein S6 kinase B1	Homo sapiens	64-70
30304547-10	2019	The phosphorylation of Src, PI3K, Akt, mammalian target of rapamycin (mTOR) and p70S6K significantly decreased in UUO kidneys from tamoxifen-treated animals.	Tamoxifen	131-140	ribosomal protein S6 kinase B1	Homo sapiens	80-86
30342268-0	2019	Exogenous Tetranectin Protects Against 1-Methyl-4-Phenylpyridine-Induced Neurotoxicity by Inhibiting Apoptosis and Autophagy Through Ribosomal Protein S6 Kinase Beta-1.	1-Methyl-4-phenylpyridinium	39-64	ribosomal protein S6 kinase B1	Homo sapiens	133-167
30304547-11	2019	Tamoxifen dose-dependently suppressed the TGF-beta1-induced expression of alpha-SMA and CTGF, and phosphorylation of Src, PI3K, Akt, mTOR and p70S6K in HK-2 cells.	Tamoxifen	0-9	ribosomal protein S6 kinase B1	Homo sapiens	142-148
30304547-13	2019	Moreover, inhibition of the PI3K/Akt and mTOR/p70S6K pathways was observed in HK-2 cells co-treated with PP1 (a Src kinase inhibitor) and tamoxifen.	Tamoxifen	138-147	ribosomal protein S6 kinase B1	Homo sapiens	46-52
30304547-14	2019	CONCLUSIONS: The anti-fibrotic effects of tamoxifen are associated with the suppression of Src kinase function via ER-alpha, followed by inhibition of the PI3K/Akt and mTOR/p70S6K signalling pathways.	Tamoxifen	42-51	ribosomal protein S6 kinase B1	Homo sapiens	173-179
30103008-7	2018	Costunolide also repressed phosphorylation of mTOR and its downstream kinases p70S6K and 4E-BP1.	costunolide	0-11	ribosomal protein S6 kinase B1	Homo sapiens	78-95
30468278-10	2019	Therefore, our data provide evidence that bufalin induces autophagy in MGC803 cells via both Akt/mTOR/p70S6K and ERK signaling pathways, and Cbl-b-mediated suppression of mTOR and activation of ERK1/2 might play an important role.	bufalin	42-49	ribosomal protein S6 kinase B1	Homo sapiens	102-108
30373500-5	2019	RESULTS: Ketamine could dose-dependently promote the apoptosis of rat hippocampal neurons with upregulation of p-mTOR and its downstream regulators (p-4E-BP-1 and p-p70S6K).	Ketamine	9-17	ribosomal protein S6 kinase B1	Homo sapiens	165-171
30266538-7	2018	Our results demonstrated that dictamnine reduced HIF-1alpha protein synthesis by downregulating the mTOR/p70S6K/eIF4E and MAPK pathways, and reduced the expression of Slug by inhibiting the GSK-3beta/Slug signaling pathway.	dictamnine	30-40	ribosomal protein S6 kinase B1	Homo sapiens	105-111
31904760-10	2019	The relative gene expression of ribosomal protein S6 kinase B1 (S6K1) was increased after whey protein compared with maltodextrin consumption.	maltodextrin	117-129	ribosomal protein S6 kinase B1	Homo sapiens	32-62
31904760-10	2019	The relative gene expression of ribosomal protein S6 kinase B1 (S6K1) was increased after whey protein compared with maltodextrin consumption.	maltodextrin	117-129	ribosomal protein S6 kinase B1	Homo sapiens	64-68
30272296-6	2018	miRNA-300 inhibited the luciferase activity of FOXO1 by targeting its 3"-untranslated region (UTR), and overexpression of miR-300 upregulated the protein levels of phospho-AKT, phospho-4E-BP1, phospho-S6K1, SNAIL and MMP2.	mirna-300	0-9	ribosomal protein S6 kinase B1	Homo sapiens	201-205
30581390-9	2018	Western blot analysis indicated DT-13 significantly decreased the phosphorylation of PDK1, Akt, mTOR as well as p70S6K, suggesting the pro-apoptotic and anti-metastatic effects of DT-13 on prostate cancer cells might be attributed to the blockade of PI3K/Akt pathway.	DT-13	32-37	ribosomal protein S6 kinase B1	Homo sapiens	112-118
29478280-10	2018	The effect of miR-139-5p was mediated by PI3K inhibition, as suggested by the decrease in proliferation and phosphorylation of AKT and p70 S6K after treatment with the direct PI3K inhibitor LY294002.	mir-139-5p	14-24	ribosomal protein S6 kinase B1	Homo sapiens	135-142
29478280-10	2018	The effect of miR-139-5p was mediated by PI3K inhibition, as suggested by the decrease in proliferation and phosphorylation of AKT and p70 S6K after treatment with the direct PI3K inhibitor LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	190-198	ribosomal protein S6 kinase B1	Homo sapiens	135-142
30272296-6	2018	miRNA-300 inhibited the luciferase activity of FOXO1 by targeting its 3"-untranslated region (UTR), and overexpression of miR-300 upregulated the protein levels of phospho-AKT, phospho-4E-BP1, phospho-S6K1, SNAIL and MMP2.	mir-300	122-129	ribosomal protein S6 kinase B1	Homo sapiens	201-205
29964224-3	2018	Our team has reported that ALA-PDT suppressed the cell growth in SZ95 sebocytes by mTOR-p70 S6K signaling.	Alanine	27-30	ribosomal protein S6 kinase B1	Homo sapiens	88-95
30078088-11	2018	Mechanistically, adenosine increased pAMPK and reduced pS6K which was prevented by dipyridamole.	Adenosine	17-26	ribosomal protein S6 kinase B1	Homo sapiens	55-59
30078088-11	2018	Mechanistically, adenosine increased pAMPK and reduced pS6K which was prevented by dipyridamole.	Dipyridamole	83-95	ribosomal protein S6 kinase B1	Homo sapiens	55-59
30300626-10	2018	Western blotting showed that chrysophanol down-regulated ERK1/2, AKT, P70S6K, and S6 in both cell lines.	chrysophanic acid	29-41	ribosomal protein S6 kinase B1	Homo sapiens	70-76
30486505-0	2018	FAK and S6K1 Inhibitor, Neferine, Dually Induces Autophagy and Apoptosis in Human Neuroblastoma Cells.	neferine	24-32	ribosomal protein S6 kinase B1	Homo sapiens	8-12
30486505-8	2018	Furthermore, neferine provoked autophagy and apoptosis in IMR32 cells, confirmed by p-FAK, and p-S6K1 reduction, LC3-II accumulation, Beclin-1 overexpression, and cleaved caspase-3/PARP improvement.	neferine	13-21	ribosomal protein S6 kinase B1	Homo sapiens	97-101
30555320-0	2018	Para-Toluenesulfonamide Induces Anti-tumor Activity Through Akt-Dependent and -Independent mTOR/p70S6K Pathway: Roles of Lipid Raft and Cholesterol Contents.	4-toluenesulfonamide	0-23	ribosomal protein S6 kinase B1	Homo sapiens	96-102
30555320-13	2018	In conclusion, the data suggest that PTS is an effective anti-tumor agent with in vitro and in vivo efficacies through inhibition of both Akt-dependent and -independent mTOR/p70S6K pathways.	4-toluenesulfonamide	37-40	ribosomal protein S6 kinase B1	Homo sapiens	174-180
30423811-6	2018	In NVP-BEZ235-treated SCC-4 and SCC-25 cells, the phosphorylation of 70-kDa ribosomal S6 kinase (p70S6K), but not mTOR, decreased within 24 h. NVP-BEZ235 inhibited OSCC-cell proliferation, migration, and invasion possibly by directly deregulating the phosphorylation of p70S6K.	dactolisib	7-13	ribosomal protein S6 kinase B1	Homo sapiens	97-103
30423811-6	2018	In NVP-BEZ235-treated SCC-4 and SCC-25 cells, the phosphorylation of 70-kDa ribosomal S6 kinase (p70S6K), but not mTOR, decreased within 24 h. NVP-BEZ235 inhibited OSCC-cell proliferation, migration, and invasion possibly by directly deregulating the phosphorylation of p70S6K.	dactolisib	7-13	ribosomal protein S6 kinase B1	Homo sapiens	270-276
30423811-7	2018	The phospho-p70S6K inhibitor mimicked the effects of NVP-BEZ235 for preventing proliferation and weakening the migratory and invasion abilities of SCC-4 and SCC-25 cells.	dactolisib	57-63	ribosomal protein S6 kinase B1	Homo sapiens	12-18
29524195-5	2018	Furthermore, maternal selenium supplementation promoted breast muscle yield; increased serum insulin and IGF-I concentration; upregulated AKT, mammalian target of rapamycin (mTOR), P70S6K, Myf5, MyoD, MyoG, and SelW mRNA levels; and improved the phosphorylation of AKT at Serine 473 residue, mTOR at Serine 2448 residue, and FOXO at Serine 256 residue in skeletal muscles of the offspring.	Selenium	22-30	ribosomal protein S6 kinase B1	Homo sapiens	181-187
30003927-6	2018	Nx potentiated growth inhibitory effects of IR by down regulating ribosomal protein S6K (RPS6KB1), CyclinD1, Chk1 and HIF-1 alpha and prolonging G2/M checkpoint block.	nx	0-2	ribosomal protein S6 kinase B1	Homo sapiens	89-96
30610801-0	2018	Influence of carboplatin on the proliferation and apoptosis of ovarian cancer cells through mTOR/p70s6k signaling pathway.	Carboplatin	13-24	ribosomal protein S6 kinase B1	Homo sapiens	97-103
30610801-1	2018	PURPOSE: To investigate the influence of carboplatin on the proliferation and apoptosis of ovarian cancer cells through mTOR/P70S6K signaling pathway.	Carboplatin	41-52	ribosomal protein S6 kinase B1	Homo sapiens	125-131
30610801-3	2018	After cells were treated with different concentrations of carboplatin, the mRNA and protein expressions of mTOR, p70S6K and 4E-BP1 were detected via RT-PCR and Western blotting.	Carboplatin	58-69	ribosomal protein S6 kinase B1	Homo sapiens	113-130
30610801-8	2018	Carboplatin significantly reduced the mRNA expression of mTOR (p&lt;0.01), whereas the mRNA expressions of p70S6K and 4E-BP1 in carboplatin-treated cells were increased in a dose-dependent manner (p&lt;0.01).	Carboplatin	128-139	ribosomal protein S6 kinase B1	Homo sapiens	107-124
30610801-12	2018	Carboplatin could rapidly inhibit the expression of mTOR, and the phosphorylation of its major downstream effectors p70S6K and 4E-binding protein 1 (4E-BP1) arrested cells in G0/G1 phase and induced ovarian cancer cell apoptosis.	Carboplatin	0-11	ribosomal protein S6 kinase B1	Homo sapiens	116-122
30035335-0	2018	Quercetin-3-methyl ether inhibits esophageal carcinogenesis by targeting the AKT/mTOR/p70S6K and MAPK pathways.	quercetin 3-O-methyl ether	0-24	ribosomal protein S6 kinase B1	Homo sapiens	86-92
30416856-9	2018	Western blot analysis indicated p-mTOR, p70s6K and 4E-BP1 were severely inhibited by combination of MPL with either PLD or gemcitabine.	gemcitabine	123-134	ribosomal protein S6 kinase B1	Homo sapiens	40-57
30416863-12	2018	Levels of p-mTOR (Ser2448) and p-p70S6K (Thr389) increased in URI-overexpressing cells treated with the mTOR inhibitor rapamycin but decreased in URI-silenced cells.	Sirolimus	119-128	ribosomal protein S6 kinase B1	Homo sapiens	33-39
30416863-13	2018	The inhibitory effect of URI silencing on mTOR and p70S6K phosphorylation was antagonized by the autophagy inhibitor 3-methyladenine.	3-methyladenine	117-132	ribosomal protein S6 kinase B1	Homo sapiens	51-57
30119206-4	2018	We found LY294002 obviously restrained cell proliferation in dose-dependent and time-dependent manners by inhibiting PI3K/Akt/mTOR/p70S6K signaling pathway, whereas triggered mTORC2-medicated phosphorylation of Akt (Ser473)/PRAS40 (Thr246) in ECa109 and EC9706 cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	9-17	ribosomal protein S6 kinase B1	Homo sapiens	131-137
30175263-7	2018	Leucine could also activate mammalian target of rapamycin complex 1 (mTORC1) signaling (P &lt; 0.05), as evidenced by the increased phosphorylation levels of ribosomal protein S6 kinase 1 (S6K1) and ribosomal protein S6 (S6).	Leucine	0-7	ribosomal protein S6 kinase B1	Homo sapiens	189-193
30054913-1	2018	KEY POINTS: It has been suggested that leucine is primarily responsible for the increase in muscle protein synthesis after protein ingestion because leucine uniquely activates the mTOR-p70S6K signalling cascade.	Leucine	39-46	ribosomal protein S6 kinase B1	Homo sapiens	185-191
30054913-1	2018	KEY POINTS: It has been suggested that leucine is primarily responsible for the increase in muscle protein synthesis after protein ingestion because leucine uniquely activates the mTOR-p70S6K signalling cascade.	Leucine	149-156	ribosomal protein S6 kinase B1	Homo sapiens	185-191
30054913-4	2018	ABSTRACT: It has been suggested that leucine is primarily responsible for the increase in muscle protein synthesis (MPS) after protein ingestion because leucine uniquely activates the mTOR-p70S6K signalling cascade.	Leucine	37-44	ribosomal protein S6 kinase B1	Homo sapiens	189-195
30054913-4	2018	ABSTRACT: It has been suggested that leucine is primarily responsible for the increase in muscle protein synthesis (MPS) after protein ingestion because leucine uniquely activates the mTOR-p70S6K signalling cascade.	Leucine	153-160	ribosomal protein S6 kinase B1	Homo sapiens	189-195
29879497-8	2018	Our current study is the first to demonstrate the anti-angiogenesis mechanism of Neferine by inducing autophagy via mTOR/p70S6K pathway inhibition and suppressing M2-macrophage polarization.	neferine	81-89	ribosomal protein S6 kinase B1	Homo sapiens	121-127
30072096-6	2018	In A431 cells and primary cSCC cells, GDC-0084 blocked phosphorylation of key PI3K-Akt-mTOR components, including p85, Akt, S6K1 and S6.	GDC-0084	38-46	ribosomal protein S6 kinase B1	Homo sapiens	124-128
32002963-10	2018	Cardamonin inhibited the phosphorylation of mTOR and ribosome S6 protein kinase 1 (S6K1) as well as the protein level of regulatory associated protein of mTOR (Raptor).	cardamonin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	62-81
29981794-9	2018	Mechanism of actions studies suggest that sorafenib inhibited viral translation through dephosphorylation of several key proteins, including eIF4E and p70S6K, leading to a reduction in viral protein production and overall viral replication.	Sorafenib	42-51	ribosomal protein S6 kinase B1	Homo sapiens	151-157
29702026-2	2018	In the current study, we extend our previous evidence and demonstrate that a mechanism by which dietary BDPP protects against SD-mediated cognitive impairment is via mechanisms that involve phosphorylation of the mammalian target of rapamycin complex 1 and its direct downstream targets, including the eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and the ribosomal protein S6 kinase beta-1 (p70S6K).	bdpp	104-108	ribosomal protein S6 kinase B1	Homo sapiens	389-423
29702026-2	2018	In the current study, we extend our previous evidence and demonstrate that a mechanism by which dietary BDPP protects against SD-mediated cognitive impairment is via mechanisms that involve phosphorylation of the mammalian target of rapamycin complex 1 and its direct downstream targets, including the eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and the ribosomal protein S6 kinase beta-1 (p70S6K).	bdpp	104-108	ribosomal protein S6 kinase B1	Homo sapiens	425-431
29761845-9	2018	The formononetin-mediated regulation of cell proliferation and apoptosis involved decreased phosphorylation of ERK1/2, P90RSK, AKT, P70S6K, and S6 proteins, and increased phosphorylation of P38 protein in ES2 and OV90 cells.	formononetin	4-16	ribosomal protein S6 kinase B1	Homo sapiens	132-138
32002963-12	2018	The inhibitory effect of cardamonin on the phosphorylation of mTOR and S6K1 was eliminated by Raptor knockdown with siRNA, whereas this effect of cardamonin was stronger than that of rapamycin and AZD8055 in Raptor over-expression cells.	cardamonin	25-35	ribosomal protein S6 kinase B1	Homo sapiens	71-75
32002963-10	2018	Cardamonin inhibited the phosphorylation of mTOR and ribosome S6 protein kinase 1 (S6K1) as well as the protein level of regulatory associated protein of mTOR (Raptor).	cardamonin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	83-87
30111763-0	2018	Rutacecarpine Inhibits Angiogenesis by Targeting the VEGFR2 and VEGFR2-Mediated Akt/mTOR/p70s6k Signaling Pathway.	rutacecarpine	0-13	ribosomal protein S6 kinase B1	Homo sapiens	89-95
30186180-11	2018	Krukovine treatment also suppressed the C-RAF, ERK, AKT, PI3K, p70s6k, and mTOR phosphorylation in H460 and A549.	Krukovine	0-9	ribosomal protein S6 kinase B1	Homo sapiens	63-69
29626349-4	2018	The array data indicated that both EGF and carvedilol increased phosphorylation of ERK"s cytosolic target P70S6 K while its nuclear target ELK-1 were activated only by EGF; Furthermore, EGF-induced phosphorylation of ELK-1 and c-Jun was attenuated by carvedilol.	Carvedilol	43-53	ribosomal protein S6 kinase B1	Homo sapiens	106-113
30219159-13	2018	Furthermore, in vitro studies revealed that the inhibitory effect of rapamycin on the angiogenic ability of HUVECs and its significant inhibitory effects on the protein level of HIF-1alpha and the phosphorylation of proteins involved in the mTORC1 pathway, including mTOR, raptor and p70S6K (P &lt; 0.05), were enhanced by cotreatment with SRT1720 and rapamycin (P &lt; 0.05).	Sirolimus	69-78	ribosomal protein S6 kinase B1	Homo sapiens	284-290
29457836-4	2018	Chronic-plus-binge ethanol feeding led to hyperactivation of mTORC1, as evidenced by increased phosphorylation of mTOR and its downstream kinase S6 kinase 1 (S6K1) in hepatocytes.	Ethanol	19-26	ribosomal protein S6 kinase B1	Homo sapiens	145-156
29457836-4	2018	Chronic-plus-binge ethanol feeding led to hyperactivation of mTORC1, as evidenced by increased phosphorylation of mTOR and its downstream kinase S6 kinase 1 (S6K1) in hepatocytes.	Ethanol	19-26	ribosomal protein S6 kinase B1	Homo sapiens	158-162
29457836-10	2018	Chronic-plus-binge ethanol feeding led to activation of SREBP-1 and lipin 1 through S6K1-dependent and independent mechanisms.	Ethanol	19-26	ribosomal protein S6 kinase B1	Homo sapiens	84-88
29956761-9	2018	The phosphorylation of protein kinase B and mechanistic target of rapamycin were significantly inhibited in MKN-28 cells treated with aclidinium bromide; and the activity of the downstream proteins such as p70S6K and Cyclin D1 were also significantly decreased.	aclidinium bromide	134-152	ribosomal protein S6 kinase B1	Homo sapiens	206-212
30108651-6	2018	Bufadienolides also inhibit the mammalian target of rapamycin (mTOR) signaling pathway, which is evidenced by the data that bufadienolides inhibit type I insulin-like growth factor- (IGF-1-) activated phosphorylation of mTOR by a concentration- and time-dependent way, as well as phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1).	Bufanolides	0-14	ribosomal protein S6 kinase B1	Homo sapiens	316-320
30050147-0	2018	Flavonoids inhibit cell proliferation and induce apoptosis and autophagy through downregulation of PI3Kgamma mediated PI3K/AKT/mTOR/p70S6K/ULK signaling pathway in human breast cancer cells.	Flavonoids	0-10	ribosomal protein S6 kinase B1	Homo sapiens	132-138
30050147-7	2018	Importantly, treatment with these flavonoids decreased the levels of PI3Kgamma-p110, phospho-PI3K, phospho-AKT, phospho-mTOR, phospho-p70S6K, and phospho-ULK.	Flavonoids	34-44	ribosomal protein S6 kinase B1	Homo sapiens	134-140
30050147-8	2018	Pretreatment with PI3Kgamma specific inhibitor AS605240 potentiated flavonoids-mediated inactivation of AKT, mTOR, p70S6K, ULK, and apoptosis.	5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione	47-55	ribosomal protein S6 kinase B1	Homo sapiens	115-121
30050147-8	2018	Pretreatment with PI3Kgamma specific inhibitor AS605240 potentiated flavonoids-mediated inactivation of AKT, mTOR, p70S6K, ULK, and apoptosis.	Flavonoids	68-78	ribosomal protein S6 kinase B1	Homo sapiens	115-121
30050147-9	2018	Taken together, these findings represent a novel mechanism by which downregulation of PI3Kgamma-p110 and consequent interruption of PI3K/AKT/mTOR/p70S6K/ULK signaling pathway might play a critical functional role in these flavonoids-induced cell cycle arrest at G2/M phase, apoptosis, and autophagy.	Flavonoids	222-232	ribosomal protein S6 kinase B1	Homo sapiens	146-152
30073169-9	2018	Activation of the mTORC1/S6K pathway was attenuated by 10-6 M U0126, an MEK/ERK inhibitor, and 10-6 M calphostin C, a PKC inhibitor, indicating that the MEK/ERK/TSC2 axis acts as a mediator.	calphostin C	102-114	ribosomal protein S6 kinase B1	Homo sapiens	25-28
30073169-10	2018	In agreement, 80 nM PMA (a PKC activator) mimicked the effect of LPS on the activation of the MEK/ERK/TSC2/mTORC1/S6K pathway, monocyte adhesion to ECV cells and actin cytoskeleton rearrangement.	Tetradecanoylphorbol Acetate	20-23	ribosomal protein S6 kinase B1	Homo sapiens	114-117
30073169-9	2018	Activation of the mTORC1/S6K pathway was attenuated by 10-6 M U0126, an MEK/ERK inhibitor, and 10-6 M calphostin C, a PKC inhibitor, indicating that the MEK/ERK/TSC2 axis acts as a mediator.	U 0126	62-67	ribosomal protein S6 kinase B1	Homo sapiens	25-28
29980168-7	2018	RESULTS: Anethole suppressed the adipogenic differentiation of hMSCs through down-regulation of Akt-mTOR-p70S6K-PPARgamma and up-regulation of AMPK.	anethole	9-17	ribosomal protein S6 kinase B1	Homo sapiens	105-121
29980168-9	2018	Anethole also rescued AMPK activity and reduced activation of mTOR-p70S6K-PPARgamma under oxidative conditions in presence of exogenous hydrogen peroxide.	anethole	0-8	ribosomal protein S6 kinase B1	Homo sapiens	67-73
29674181-0	2018	High glucose forces a positive feedback loop connecting ErbB4 expression and mTOR/S6K pathway to aggravate the formation of tau hyperphosphorylation in differentiated SH-SY5Y cells.	Glucose	5-12	ribosomal protein S6 kinase B1	Homo sapiens	82-85
30087714-8	2018	In addition, Western blot results revealed that TOFA decreased the phosphorylation of proteinkinaseB(Akt), Mammalian target of rapamycin (mTOR) and p70 ribosomal protein S6 kinase (p70S6K).	5-(tetradecyloxy)-2-furancarboxylic acid	48-52	ribosomal protein S6 kinase B1	Homo sapiens	148-179
30087714-8	2018	In addition, Western blot results revealed that TOFA decreased the phosphorylation of proteinkinaseB(Akt), Mammalian target of rapamycin (mTOR) and p70 ribosomal protein S6 kinase (p70S6K).	5-(tetradecyloxy)-2-furancarboxylic acid	48-52	ribosomal protein S6 kinase B1	Homo sapiens	181-187
30317760-14	2018	These results specify that lipid synthesis involved in the mTOR/S6K1/SREBP-1c pathways are mainly associated to palmitic acid in HepG2 cells, whereas other signaling pathway may mediate oleic acid-induced lipid synthesis.	Palmitic Acid	112-125	ribosomal protein S6 kinase B1	Homo sapiens	64-68
30317760-9	2018	Rapamycin alleviated lipid deposition caused by oleic acid and palmitic acid and inhibited their induction of increased expression of mTOR, S6K1, and SREBP-1c.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	140-144
30317760-10	2018	QRT-PCR and Western blot results showed that mRNA and protein expressions of mTOR, S6K1, and SREBP-1c in oleic acid and palmitic acid group were significantly higher than the control group (P &lt; 0.05).	Oleic Acid	105-115	ribosomal protein S6 kinase B1	Homo sapiens	83-87
30317760-10	2018	QRT-PCR and Western blot results showed that mRNA and protein expressions of mTOR, S6K1, and SREBP-1c in oleic acid and palmitic acid group were significantly higher than the control group (P &lt; 0.05).	Palmitic Acid	120-133	ribosomal protein S6 kinase B1	Homo sapiens	83-87
30317760-12	2018	Conclusion: Oleic acid and palmitic acid can induce lipid deposition in HepG2 cells and increase expression of every component of mTOR/S6K1/SREBP-1c pathway; however, Oleic acid-induced lipid deposition is more pronounced, and the mTOR, S6K1, and SREBP-1c pathway change is more obvious in palmitic acid.	Oleic Acid	12-22	ribosomal protein S6 kinase B1	Homo sapiens	135-139
30317760-12	2018	Conclusion: Oleic acid and palmitic acid can induce lipid deposition in HepG2 cells and increase expression of every component of mTOR/S6K1/SREBP-1c pathway; however, Oleic acid-induced lipid deposition is more pronounced, and the mTOR, S6K1, and SREBP-1c pathway change is more obvious in palmitic acid.	Oleic Acid	12-22	ribosomal protein S6 kinase B1	Homo sapiens	237-241
30317760-12	2018	Conclusion: Oleic acid and palmitic acid can induce lipid deposition in HepG2 cells and increase expression of every component of mTOR/S6K1/SREBP-1c pathway; however, Oleic acid-induced lipid deposition is more pronounced, and the mTOR, S6K1, and SREBP-1c pathway change is more obvious in palmitic acid.	Palmitic Acid	27-40	ribosomal protein S6 kinase B1	Homo sapiens	135-139
30317760-12	2018	Conclusion: Oleic acid and palmitic acid can induce lipid deposition in HepG2 cells and increase expression of every component of mTOR/S6K1/SREBP-1c pathway; however, Oleic acid-induced lipid deposition is more pronounced, and the mTOR, S6K1, and SREBP-1c pathway change is more obvious in palmitic acid.	Palmitic Acid	27-40	ribosomal protein S6 kinase B1	Homo sapiens	237-241
30317760-12	2018	Conclusion: Oleic acid and palmitic acid can induce lipid deposition in HepG2 cells and increase expression of every component of mTOR/S6K1/SREBP-1c pathway; however, Oleic acid-induced lipid deposition is more pronounced, and the mTOR, S6K1, and SREBP-1c pathway change is more obvious in palmitic acid.	Oleic Acid	167-177	ribosomal protein S6 kinase B1	Homo sapiens	135-139
30317760-12	2018	Conclusion: Oleic acid and palmitic acid can induce lipid deposition in HepG2 cells and increase expression of every component of mTOR/S6K1/SREBP-1c pathway; however, Oleic acid-induced lipid deposition is more pronounced, and the mTOR, S6K1, and SREBP-1c pathway change is more obvious in palmitic acid.	Oleic Acid	167-177	ribosomal protein S6 kinase B1	Homo sapiens	237-241
30108651-6	2018	Bufadienolides also inhibit the mammalian target of rapamycin (mTOR) signaling pathway, which is evidenced by the data that bufadienolides inhibit type I insulin-like growth factor- (IGF-1-) activated phosphorylation of mTOR by a concentration- and time-dependent way, as well as phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1).	Bufanolides	124-138	ribosomal protein S6 kinase B1	Homo sapiens	316-320
29909423-11	2018	In addition, the expression of p-AKT, p-mTOR, and p70S6K decreased in the prucalopride-treated group, and the expression of autophagy marker protein LC3-II/I and Beclin1 significantly increased, whereas the expression of p62 protein decreased.	prucalopride	74-86	ribosomal protein S6 kinase B1	Homo sapiens	50-56
30317760-14	2018	These results specify that lipid synthesis involved in the mTOR/S6K1/SREBP-1c pathways are mainly associated to palmitic acid in HepG2 cells, whereas other signaling pathway may mediate oleic acid-induced lipid synthesis.	Oleic Acid	186-196	ribosomal protein S6 kinase B1	Homo sapiens	64-68
29805556-0	2018	Asiatic acid inhibits proliferation, migration and induces apoptosis by regulating Pdcd4 via the PI3K/Akt/mTOR/p70S6K signaling pathway in human colon carcinoma cells.	asiatic acid	0-12	ribosomal protein S6 kinase B1	Homo sapiens	111-117
29760955-5	2018	In the in vitro study, treatment with NVP-BEZ235 alone attenuated cell proliferation and suppressed p-p70S6K and p-4E-BP1 expression in FaDu cells.	dactolisib	42-48	ribosomal protein S6 kinase B1	Homo sapiens	102-108
29805658-0	2018	Bufalin induces apoptosis in human esophageal carcinoma ECA109 cells by inhibiting the activation of the mTOR/p70S6K pathway.	bufalin	0-7	ribosomal protein S6 kinase B1	Homo sapiens	110-116
29805658-1	2018	The present study examined whether bufalin could induce human esophageal carcinoma ECA109 cells apoptosis via inhibiting the activation of mechanistic target of rapamycin (mTOR)/p70 S6 kinase (p70S6K) pathway is discussed in this article.	bufalin	35-42	ribosomal protein S6 kinase B1	Homo sapiens	193-199
29805658-2	2018	The present study used the esophageal squamous cell carcinoma ECA109 cell line to assess the apoptosis-inducing effects of bufalin via inhibition of the mTOR/p70S6K pathways.	bufalin	123-130	ribosomal protein S6 kinase B1	Homo sapiens	158-164
29805658-7	2018	The levels of p-p70S6K and cIAP-1 were significantly higher in the wtmTOR-transfected group than in the control and empty vector-transfected groups, and then reduced following addition of bufalin; however, BAD expression was significantly lower in the wtmTOR-transfected group.	bufalin	188-195	ribosomal protein S6 kinase B1	Homo sapiens	16-22
29805658-9	2018	In conclusion, the findings of the present study demonstrated that bufalin induced apoptosis in esophageal carcinoma cells via the inhibition of the mTOR/p70S6K pathway and indicated that treatment with bufalin could be combined with chemotherapy to overcome the resistance of esophageal carcinoma cells to chemotherapeutic-induced apoptosis.	bufalin	67-74	ribosomal protein S6 kinase B1	Homo sapiens	154-160
29805658-9	2018	In conclusion, the findings of the present study demonstrated that bufalin induced apoptosis in esophageal carcinoma cells via the inhibition of the mTOR/p70S6K pathway and indicated that treatment with bufalin could be combined with chemotherapy to overcome the resistance of esophageal carcinoma cells to chemotherapeutic-induced apoptosis.	bufalin	203-210	ribosomal protein S6 kinase B1	Homo sapiens	154-160
29872406-9	2018	Further mechanistic studies revealed that TGC increased silent information regulator 1 (Sirt1) expression to reduce the phosphorylation of the mammalian target of rapamycin and its downstream effectors P70S6K and 4EBP1.	Sirolimus	163-172	ribosomal protein S6 kinase B1	Homo sapiens	202-218
29760955-9	2018	Collectively, these data demonstrate that NVP-BEZ235 inhibits HSCC growth through phospho-p70S6K suppression and has a synergistic effect with Cisplatin in treating HSCC.	dactolisib	46-52	ribosomal protein S6 kinase B1	Homo sapiens	90-96
29538717-10	2018	Finally, in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus, sorafenib decreased phosphorylation of the ribosomal protein and mTOR effector S6K in an additive manner.	Everolimus	80-90	ribosomal protein S6 kinase B1	Homo sapiens	171-174
29738527-11	2018	S6K1, a downstream effector of mammalian target of rapamycin (mTOR), serves as a negative feedback mediator that phosphorylates insulin receptor substrate 1 at serine residues (IRS-1pSer).	Serine	160-166	ribosomal protein S6 kinase B1	Homo sapiens	0-4
29538717-10	2018	Finally, in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus, sorafenib decreased phosphorylation of the ribosomal protein and mTOR effector S6K in an additive manner.	Sorafenib	92-101	ribosomal protein S6 kinase B1	Homo sapiens	171-174
29743930-0	2018	LXRalpha participates in the mTOR/S6K1/SREBP-1c signaling pathway during sodium palmitate-induced lipogenesis in HepG2 cells.	Palmitic Acid	73-89	ribosomal protein S6 kinase B1	Homo sapiens	34-38
29743930-6	2018	Sodium palmitate stimulated the expression of genes encoding mTOR, S6K1, LXRalpha, SREBP-1c and SREBP-1c target enzymes (FAS and ACC1) in HepG2 cells.	Palmitic Acid	0-16	ribosomal protein S6 kinase B1	Homo sapiens	67-81
26911848-5	2018	Rosiglitazone inhibited the phosphorylation of mammalian target of rapamycin p70S6K.	Rosiglitazone	0-13	ribosomal protein S6 kinase B1	Homo sapiens	77-83
31938342-0	2018	Ouabain-induced apoptosis and inhibition of viability of tubulointerstitial cells by regulating NKA/pSrc/pERK/pAkt/pS6k/caspase 3 may contribute to lupus nephritis development.	Ouabain	0-7	ribosomal protein S6 kinase B1	Homo sapiens	115-119
29743930-11	2018	Conclusions: mTOR/S6K1 regulates the SREBP-1c signaling pathway through LXRalpha in sodium palmitate-induced HepG2 cells, suggesting LXRalpha might be a potential therapeutic target for NAFLD.	Palmitic Acid	84-100	ribosomal protein S6 kinase B1	Homo sapiens	18-22
31938342-9	2018	Moreover, pSrc, pERK, pAkt, pS6K and caspase 3 expressions were elevated after 100 nM ouabain treatment.	Ouabain	86-93	ribosomal protein S6 kinase B1	Homo sapiens	28-32
31938342-10	2018	In conclusion, ouabain may contribute to LN etiology by inhibiting human proximal tubular cell viability and promoting cells apoptosis through regulating NKA, pSrc, pERK, pAkt, pS6K and caspase 3.	Ouabain	15-22	ribosomal protein S6 kinase B1	Homo sapiens	177-181
29728793-9	2018	Taken together, these findings suggest that metformin functions as a neuroprotective agent following SCI by promoting autophagy and inhibiting apoptosis by regulating the mTOR/P70S6K signaling pathway.	Metformin	44-53	ribosomal protein S6 kinase B1	Homo sapiens	176-182
29496905-11	2018	Our results suggest that leflunomide sensitizes the insulin receptor by inhibiting S6K1 activity in vitro, and that leflunomide could be potentially useful for treating patients with both RA and diabetes.	Leflunomide	25-36	ribosomal protein S6 kinase B1	Homo sapiens	83-87
29524402-0	2018	Ghrelin promotes human non-small cell lung cancer A549 cell proliferation through PI3K/Akt/mTOR/P70S6K and ERK signaling pathways.	Ghrelin	0-7	ribosomal protein S6 kinase B1	Homo sapiens	96-102
29524402-4	2018	Ghrelin induced the rapid phosphorylation of phosphatidylinositol 3-kinase (PI3K), Akt, ERK, mammalian target of rapamycin (mTOR) and P70S6K.	Ghrelin	0-7	ribosomal protein S6 kinase B1	Homo sapiens	134-140
29524402-6	2018	Moreover, GHSR siRNA inhibited phosphorylation of PI3K, Akt, ERK, mTOR and P70S6K induced by ghrelin.	Ghrelin	93-100	ribosomal protein S6 kinase B1	Homo sapiens	75-81
29524402-7	2018	Akt and mTOR/P70S6K phosphorylation was inhibited by LY 294002 but not by PD98059.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	53-62	ribosomal protein S6 kinase B1	Homo sapiens	13-19
29524402-8	2018	These results indicate that ghrelin promotes A549 cell proliferation via GHSR-dependent PI3K/Akt/mTOR/P70S6K and ERK signaling pathways.	Ghrelin	28-35	ribosomal protein S6 kinase B1	Homo sapiens	102-108
29444470-11	2018	In addition, the hepatic phosphorylated mammalian target of rapamycin (mTOR) and P70S6K protein expressions were significantly downregulated and endothelial nitric oxide synthase (eNOS) expression upregulated by sirolimus.	Sirolimus	212-221	ribosomal protein S6 kinase B1	Homo sapiens	81-87
29854093-6	2018	In contrast, SNP (sodium nitroprusside), an NO donor, increased NO concentrations, enhanced protein synthesis, and upregulated mTOR and p70S6K phosphorylation, regardless of L-NAME treatment.	Nitroprusside	18-38	ribosomal protein S6 kinase B1	Homo sapiens	136-142
29652799-4	2018	Furthermore, inhibiting p70 S6K through treatment with the FDA approved drug rapamycin prevents RVFV pathogenesis in a mouse model of infection.	Sirolimus	77-86	ribosomal protein S6 kinase B1	Homo sapiens	24-31
29652799-6	2018	Treatment with the p70 S6K inhibitor PF-4708671 resulted in decreased phosphorylation of translational proteins and reduced RVFV titers.	pyrazofurin	37-39	ribosomal protein S6 kinase B1	Homo sapiens	19-26
29484434-7	2018	Western blot analysis revealed that the expression of mTOR, p-p70S6K and p-4EBP1 decreased following celastrol treatment.	celastrol	101-110	ribosomal protein S6 kinase B1	Homo sapiens	62-68
29247557-9	2018	Our results demonstrated that combined treatment with rapamycin and melatonin blocked the negative feedback loop from the specific downstream effector of mTOR activation S6K1 to Akt signalling, which decreased cell viability, proliferation and clonogenic capacity.	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	170-174
29247557-9	2018	Our results demonstrated that combined treatment with rapamycin and melatonin blocked the negative feedback loop from the specific downstream effector of mTOR activation S6K1 to Akt signalling, which decreased cell viability, proliferation and clonogenic capacity.	Melatonin	68-77	ribosomal protein S6 kinase B1	Homo sapiens	170-174
29541215-0	2018	Wogonoside inhibits cell growth and induces mitochondrial-mediated autophagy-related apoptosis in human colon cancer cells through the PI3K/AKT/mTOR/p70S6K signaling pathway.	wogonoside	0-10	ribosomal protein S6 kinase B1	Homo sapiens	149-155
29541215-6	2018	In conclusion, these results demonstrated that wogonoside inhibits cell growth and induces mitochondrial mediated autophagy-related apoptosis in human colon cancer cells through modulation of the PI3K/Akt/mTOR/p70S6K signaling pathway.	wogonoside	47-57	ribosomal protein S6 kinase B1	Homo sapiens	210-216
29175753-8	2018	Of note, blockade of ROS/NFkappaB/mTOR/P70S6K signaling cascade prevented PDGF-BB-evoked VSMC phenotypic transformation, proliferation and migration.	Reactive Oxygen Species	21-24	ribosomal protein S6 kinase B1	Homo sapiens	39-45
29175753-10	2018	These results suggest that CA impedes PDGF-BB-induced VSMC phenotypic switching, proliferation, migration and neointima formation via inhibition of ROS/NFkappaB/mTOR/P70S6K signaling cascade.	Reactive Oxygen Species	148-151	ribosomal protein S6 kinase B1	Homo sapiens	166-172
29780826-7	2018	Moreover, silibinin dose-dependently downregulated the phosphorylation levels of mTOR at Ser-2448, p70S6K at Thr-389, and 4E-BP1 at Thr-37/46.	Silybin	10-19	ribosomal protein S6 kinase B1	Homo sapiens	99-105
29155324-8	2018	Stress also downregulated intestinal amino acid transporter, ACE2/B0AT-1, and activity of intestinal mammalian target of rapamycin (mTOR) and p70 S6 kinase (p70S6K), resulting in decrease in alpha-defensins, changes in intestinal microbial contents, and perturbation of tryptophan metabolism with activation of the kynurenine pathway.	Tryptophan	270-280	ribosomal protein S6 kinase B1	Homo sapiens	142-155
29155324-8	2018	Stress also downregulated intestinal amino acid transporter, ACE2/B0AT-1, and activity of intestinal mammalian target of rapamycin (mTOR) and p70 S6 kinase (p70S6K), resulting in decrease in alpha-defensins, changes in intestinal microbial contents, and perturbation of tryptophan metabolism with activation of the kynurenine pathway.	Tryptophan	270-280	ribosomal protein S6 kinase B1	Homo sapiens	157-163
29155324-8	2018	Stress also downregulated intestinal amino acid transporter, ACE2/B0AT-1, and activity of intestinal mammalian target of rapamycin (mTOR) and p70 S6 kinase (p70S6K), resulting in decrease in alpha-defensins, changes in intestinal microbial contents, and perturbation of tryptophan metabolism with activation of the kynurenine pathway.	Kynurenine	315-325	ribosomal protein S6 kinase B1	Homo sapiens	142-155
29155324-8	2018	Stress also downregulated intestinal amino acid transporter, ACE2/B0AT-1, and activity of intestinal mammalian target of rapamycin (mTOR) and p70 S6 kinase (p70S6K), resulting in decrease in alpha-defensins, changes in intestinal microbial contents, and perturbation of tryptophan metabolism with activation of the kynurenine pathway.	Kynurenine	315-325	ribosomal protein S6 kinase B1	Homo sapiens	157-163
28357809-9	2018	In fact, treatment with temsirolimus maintained high Beclin-1, p62, and microtubule-associated protein 1A/1B-light chain 3 expression and inhibited the p70S6K expression.	temsirolimus	24-36	ribosomal protein S6 kinase B1	Homo sapiens	152-158
29472548-3	2018	Overexpression of Arg-II induces re-distribution of lysosome and mTOR but not of tuberous sclerosis complex (TSC) from perinuclear area to cell periphery, dissociation of TSC from lysosome and activation of mTORC1-ribosomal protein S6 kinase 1 (S6K1) pathway.	arg-ii	18-24	ribosomal protein S6 kinase B1	Homo sapiens	245-249
29472548-8	2018	Taken together, our study demonstrates that Myo1b mediates the effect of Arg-II in activating mTORC1-S6K1 through promoting peripheral lysosomal positioning, that results in spatial separation and thus dissociation of TSC from lysosome, leading to hyperactive mTORC1-S6K1 signaling linking to cellular senescence/apoptosis.	arg-ii	73-79	ribosomal protein S6 kinase B1	Homo sapiens	101-105
29472548-8	2018	Taken together, our study demonstrates that Myo1b mediates the effect of Arg-II in activating mTORC1-S6K1 through promoting peripheral lysosomal positioning, that results in spatial separation and thus dissociation of TSC from lysosome, leading to hyperactive mTORC1-S6K1 signaling linking to cellular senescence/apoptosis.	arg-ii	73-79	ribosomal protein S6 kinase B1	Homo sapiens	267-271
29472557-6	2018	Metformin reduced cyclin D1 expression and RB, STAT3, STAT5, ERK1/2 and p70S6K phosphorylation.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	72-78
29467620-11	2018	The dual-luciferase reporter assay also showed that p70S6K was a target gene of miR-429; miR-429 overexpression down-regulated expression and phosphorylation levels of p70S6K, and also decreased phosphorylation levels of S6 and increased BTB permeability.	btb	238-241	ribosomal protein S6 kinase B1	Homo sapiens	52-58
29562450-10	2018	Conclusion: Novel pan-FGFR inhibitor BGJ398 substantially suppressed KG-1 cell growth and induced apoptosis by inhibiting the expression of FGFR1, p-AKT, p-S6K and regulating apoptosis-related proteins.	infigratinib	37-43	ribosomal protein S6 kinase B1	Homo sapiens	154-159
29467620-11	2018	The dual-luciferase reporter assay also showed that p70S6K was a target gene of miR-429; miR-429 overexpression down-regulated expression and phosphorylation levels of p70S6K, and also decreased phosphorylation levels of S6 and increased BTB permeability.	btb	238-241	ribosomal protein S6 kinase B1	Homo sapiens	168-174
29270715-5	2018	Furthermore, p70S6K knockdown and the specific mTOR inhibitor rapamycin decreased the expression levels of p-p70S6K and alpha-SMA in cultured fibroblasts from grade T3 pterygium.	Sirolimus	62-71	ribosomal protein S6 kinase B1	Homo sapiens	107-115
33052635-10	2018	Western blot analysis showed that PDCD4 overexpression or PI3K inhibition by LY294002 significantly reduced the expression of phospho-PI3K, phospho-Akt, phospho-mammalian target of rapamycin and phospho-p70s6k, but not their total protein levels.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	77-85	ribosomal protein S6 kinase B1	Homo sapiens	203-209
29270715-5	2018	Furthermore, p70S6K knockdown and the specific mTOR inhibitor rapamycin decreased the expression levels of p-p70S6K and alpha-SMA in cultured fibroblasts from grade T3 pterygium.	alpha-sma	120-129	ribosomal protein S6 kinase B1	Homo sapiens	13-19
28856713-4	2018	Phosphorylation of p70 S6 kinase (p70S6K), an mTOR-regulated marker of protein translation initiation, was significantly increased following mechanical stretching alone but returned to the baseline after 4 h. Leucine supplementation further increased p70S6K phosphorylation, with a greater increase observed in the stretched cells than in the non-stretched cells.	Leucine	209-216	ribosomal protein S6 kinase B1	Homo sapiens	19-32
29175753-0	2018	Chicoric acid prevents PDGF-BB-induced VSMC dedifferentiation, proliferation and migration by suppressing ROS/NFkappaB/mTOR/P70S6K signaling cascade.	chicoric acid	0-13	ribosomal protein S6 kinase B1	Homo sapiens	124-130
29175753-0	2018	Chicoric acid prevents PDGF-BB-induced VSMC dedifferentiation, proliferation and migration by suppressing ROS/NFkappaB/mTOR/P70S6K signaling cascade.	Reactive Oxygen Species	106-109	ribosomal protein S6 kinase B1	Homo sapiens	124-130
29175753-5	2018	Mechanistically, PDGF-BB-treated VSMCs exhibited higher mammalian target of rapamycin (mTOR) and P70S6K phosphorylation, which was attenuated by CA pretreatment, diphenyleneiodonium chloride (DPI), reactive oxygen species (ROS) scavenger N-acetyl-l-cysteine (NAC) and nuclear factor-kappaB (NFkappaB) inhibitor Bay117082.	pdgf-bb	17-24	ribosomal protein S6 kinase B1	Homo sapiens	97-103
29175753-5	2018	Mechanistically, PDGF-BB-treated VSMCs exhibited higher mammalian target of rapamycin (mTOR) and P70S6K phosphorylation, which was attenuated by CA pretreatment, diphenyleneiodonium chloride (DPI), reactive oxygen species (ROS) scavenger N-acetyl-l-cysteine (NAC) and nuclear factor-kappaB (NFkappaB) inhibitor Bay117082.	vsmcs	33-38	ribosomal protein S6 kinase B1	Homo sapiens	97-103
28856713-4	2018	Phosphorylation of p70 S6 kinase (p70S6K), an mTOR-regulated marker of protein translation initiation, was significantly increased following mechanical stretching alone but returned to the baseline after 4 h. Leucine supplementation further increased p70S6K phosphorylation, with a greater increase observed in the stretched cells than in the non-stretched cells.	Leucine	209-216	ribosomal protein S6 kinase B1	Homo sapiens	34-40
29175753-5	2018	Mechanistically, PDGF-BB-treated VSMCs exhibited higher mammalian target of rapamycin (mTOR) and P70S6K phosphorylation, which was attenuated by CA pretreatment, diphenyleneiodonium chloride (DPI), reactive oxygen species (ROS) scavenger N-acetyl-l-cysteine (NAC) and nuclear factor-kappaB (NFkappaB) inhibitor Bay117082.	diphenyleneiodonium	162-190	ribosomal protein S6 kinase B1	Homo sapiens	97-103
28856713-4	2018	Phosphorylation of p70 S6 kinase (p70S6K), an mTOR-regulated marker of protein translation initiation, was significantly increased following mechanical stretching alone but returned to the baseline after 4 h. Leucine supplementation further increased p70S6K phosphorylation, with a greater increase observed in the stretched cells than in the non-stretched cells.	Leucine	209-216	ribosomal protein S6 kinase B1	Homo sapiens	251-257
28856713-5	2018	Notably, the expression of L-type amino acid transporter 1 (LAT1), a stimulator of the mTOR pathway, was also increased by mechanical stretching, and siRNA-mediated knockdown partially attenuated leucine-induced p70S6K phosphorylation.	Leucine	196-203	ribosomal protein S6 kinase B1	Homo sapiens	212-218
29207097-0	2018	The anticancer effects of Cucurbitacin I inhibited cell growth of human non-small cell lung cancer through PI3K/AKT/p70S6K pathway.	cucurbitacin I	26-40	ribosomal protein S6 kinase B1	Homo sapiens	116-122
29207097-3	2018	Furthermore, Cucurbitacin I suppressed phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), phosphorylation (p)-AKT and p-p70S6K pathway in NSCLC.	cucurbitacin I	13-27	ribosomal protein S6 kinase B1	Homo sapiens	124-130
29207097-5	2018	In conclusion, the present results indicated that Cucurbitacin I inhibited cell growth of human NSCLC through PI3K/AKT/p70S6K signaling pathway.	cucurbitacin I	50-64	ribosomal protein S6 kinase B1	Homo sapiens	119-125
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	30-33	ribosomal protein S6 kinase B1	Homo sapiens	101-108
29305864-0	2018	Fenofibrate inhibits mTOR-p70S6K signaling and simultaneously induces cell death in human prostate cancer cells.	Fenofibrate	0-11	ribosomal protein S6 kinase B1	Homo sapiens	26-32
29305864-8	2018	Mechanistically, fenofibrate-induced cell death was associated with decreased p-p70S6K and the mammalian target of rapamycin (mTOR) phosphorylation levels.	Fenofibrate	17-28	ribosomal protein S6 kinase B1	Homo sapiens	80-86
29305864-9	2018	When further exploring the upstream mediators of mTOR/p70S6K, we found that fenofibrate increased p38 MAPK and AMPK phosphorylation but did not significantly change the phosphorylation levels of PI3K, AKT, and JNK.	Fenofibrate	76-87	ribosomal protein S6 kinase B1	Homo sapiens	54-60
29305864-11	2018	These findings suggested that fenofibrate indeed significantly inhibited the proliferation of PC-3 cells via apoptotic action, which is associated with the inactivation of the mTOR/p70S6K-dependent cell survival pathway.	Fenofibrate	30-41	ribosomal protein S6 kinase B1	Homo sapiens	181-187
29248464-9	2018	We also verified that signaling proteins including AKT, P70S6K, S6, and ERK1/2 and their targets were significantly reduced in HTR8/SVneo cells by DA treatment.	decanoic acid	147-149	ribosomal protein S6 kinase B1	Homo sapiens	56-62
29926658-5	2018	Mammalian target of rapamycin(mTOR)-P70S6 kinase (P70S6K) signaling agonist phosphatidic acid and inhibitor rapamycin were used in Rsv treated VSMCs.	Phosphatidic Acids	76-93	ribosomal protein S6 kinase B1	Homo sapiens	50-56
29926658-10	2018	CONCLUSIONS: Rosuvastatin could inhibit Hcy induced VSMCs dedifferentiation via suppressing ERS, which might be regulated by mTOR-P70S6K signaling.	Rosuvastatin Calcium	13-25	ribosomal protein S6 kinase B1	Homo sapiens	130-136
29926658-10	2018	CONCLUSIONS: Rosuvastatin could inhibit Hcy induced VSMCs dedifferentiation via suppressing ERS, which might be regulated by mTOR-P70S6K signaling.	Homocysteine	40-43	ribosomal protein S6 kinase B1	Homo sapiens	130-136
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	186-189	ribosomal protein S6 kinase B1	Homo sapiens	101-108
30184535-9	2018	Butein increased the phosphorylation of AMPKalphaThr-172, TSC2Ser-1387 and ULK1Ser-317 and inhibited the phosphorylation of mTORSer-2448 and its downstream target p70S6K and increased autophagy flux that correlated with the suppression of the IL-1beta mediated expression of IL-6 in normal and OA chondrocytes.	butein	0-6	ribosomal protein S6 kinase B1	Homo sapiens	163-169
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	57-62	ribosomal protein S6 kinase B1	Homo sapiens	123-127
29617677-12	2018	CZ415 disrupted assembling of mTORC1 (mTOR-Raptor association) and mTORC2 (mTOR-Rictor-GbetaL association) in TPC-1 cells, which led to de-phosphorylation of the mTORC1 substrates (S6K1 and 4E-BP1) and the mTORC2 substrate AKT (Ser-473).	CZ415	0-5	ribosomal protein S6 kinase B1	Homo sapiens	181-196
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	182-187	ribosomal protein S6 kinase B1	Homo sapiens	123-127
28986166-7	2018	Sildenafil also increased plasma cyclic guanosine-3",5"-monophosphate (cGMP) and catecholamine concentrations (p&lt;0.05), and consequently activated the expressions of vasodilator-stimulated phosphoprotein (VASP) and p70 ribosomal S6 kinase 1 (S6K1) (p&lt;0.05).	Sildenafil Citrate	0-10	ribosomal protein S6 kinase B1	Homo sapiens	232-243
28300280-3	2018	Here, we show that the inhibitory effect of rapamycin on hsBAFF-promoted B cell proliferation/survival is also related to blocking hsBAFF-stimulated phosphorylation of Akt, S6K1, and 4E-BP1, as well as expression of survivin in normal and B-lymphoid (Raji and Daudi) cells.	Sirolimus	44-53	ribosomal protein S6 kinase B1	Homo sapiens	173-177
28817179-10	2018	CoCl2 upregulated HIF-1alpha and decreased the phosphorylation of mTOR/p70S6K.	cobaltous chloride	0-5	ribosomal protein S6 kinase B1	Homo sapiens	71-77
28817179-12	2018	Also, YC-1 enhanced the phosphorylation of mTOR and p70S6K suppressed by CoCl2 , demonstrating that CoCl2 -induced autophagy via mTOR/p70S6K is mediated by HIF-1alpha.	cobaltous chloride	73-78	ribosomal protein S6 kinase B1	Homo sapiens	52-58
28817179-12	2018	Also, YC-1 enhanced the phosphorylation of mTOR and p70S6K suppressed by CoCl2 , demonstrating that CoCl2 -induced autophagy via mTOR/p70S6K is mediated by HIF-1alpha.	cobaltous chloride	73-78	ribosomal protein S6 kinase B1	Homo sapiens	134-140
28817179-12	2018	Also, YC-1 enhanced the phosphorylation of mTOR and p70S6K suppressed by CoCl2 , demonstrating that CoCl2 -induced autophagy via mTOR/p70S6K is mediated by HIF-1alpha.	cobaltous chloride	100-105	ribosomal protein S6 kinase B1	Homo sapiens	52-58
28817179-12	2018	Also, YC-1 enhanced the phosphorylation of mTOR and p70S6K suppressed by CoCl2 , demonstrating that CoCl2 -induced autophagy via mTOR/p70S6K is mediated by HIF-1alpha.	cobaltous chloride	100-105	ribosomal protein S6 kinase B1	Homo sapiens	134-140
28817179-13	2018	Taken together, these finding suggest that CoCl2 -induced autophagy mediated by the mTOR/p70S6K pathway plays a protective role against hypoxic stress in HDPCs.	cobaltous chloride	43-48	ribosomal protein S6 kinase B1	Homo sapiens	89-95
28986166-7	2018	Sildenafil also increased plasma cyclic guanosine-3",5"-monophosphate (cGMP) and catecholamine concentrations (p&lt;0.05), and consequently activated the expressions of vasodilator-stimulated phosphoprotein (VASP) and p70 ribosomal S6 kinase 1 (S6K1) (p&lt;0.05).	Sildenafil Citrate	0-10	ribosomal protein S6 kinase B1	Homo sapiens	245-249
29262896-9	2017	CONCLUSION: The sinomenine can inhibit Jeko-1 cell proliferation, which may be realized through down-regulating the phosphorylation level of p-Akt, p-mTOR, and p-P70S6K, thus inhibiting the Akt signaling pathway and promoting the cell apoptosis.	sinomenine	16-26	ribosomal protein S6 kinase B1	Homo sapiens	162-168
29024814-5	2017	In K-Ras-WT cells, BKM120 decreased the phosphorylation of Akt, its downstream effector kinase p70S6K, and the translational repressor 4E-BP1.	NVP-BKM120	19-25	ribosomal protein S6 kinase B1	Homo sapiens	95-101
29024631-0	2017	Luteoloside induces G0/G1 arrest and pro-death autophagy through the ROS-mediated AKT/mTOR/p70S6K signalling pathway in human non-small cell lung cancer cell lines.	luteolin-7-glucoside	0-11	ribosomal protein S6 kinase B1	Homo sapiens	91-97
29024631-0	2017	Luteoloside induces G0/G1 arrest and pro-death autophagy through the ROS-mediated AKT/mTOR/p70S6K signalling pathway in human non-small cell lung cancer cell lines.	Reactive Oxygen Species	69-72	ribosomal protein S6 kinase B1	Homo sapiens	91-97
29024631-7	2017	These results demonstrated that luteoloside induced autophagy in lung cancer cell lines by inhibiting the pathway at p-Akt (Ser473), p-mTOR and p-p70S6K (Thr389).	luteolin-7-glucoside	32-43	ribosomal protein S6 kinase B1	Homo sapiens	146-152
29024631-10	2017	In addition, the results showed that ROS served as an upstream effector of the PI3K/AKT/mTOR/p70S6K pathway.	Reactive Oxygen Species	37-40	ribosomal protein S6 kinase B1	Homo sapiens	93-99
29024631-11	2017	Taken together, the present study provides new insights into the molecular mechanisms underlying luteoloside-mediated cell death in NSCLC cells and supports luteoloside as a potential anti-cancer agent for targeting NSCLC through the induction of autophagy, inhibition of proliferation and PI3K/AKT/mTOR/p70S6K signalling.	luteolin-7-glucoside	157-168	ribosomal protein S6 kinase B1	Homo sapiens	304-310
28711603-7	2017	Moreover, overexpression of Brg1 restored miR-139-5p-induced downregulation of Akt and p70S6K phosphorylation.	mir-139-5p	42-52	ribosomal protein S6 kinase B1	Homo sapiens	87-93
29186197-7	2017	Meanwhile, protein levels of the mammalian target of rapamycin (mTOR) and the 70-kDa ribosomal protein, S6 kinase1 (p70S6K), were also up-regulated in FTY720-treated animals, and the nonspecific SphK inhibitor, N,N-dimethylsphingosine (DMS), was found to cause a reverse effect.	N,N-dimethylsphingosine	211-234	ribosomal protein S6 kinase B1	Homo sapiens	116-122
29186197-7	2017	Meanwhile, protein levels of the mammalian target of rapamycin (mTOR) and the 70-kDa ribosomal protein, S6 kinase1 (p70S6K), were also up-regulated in FTY720-treated animals, and the nonspecific SphK inhibitor, N,N-dimethylsphingosine (DMS), was found to cause a reverse effect.	N,N-dimethylsphingosine	236-239	ribosomal protein S6 kinase B1	Homo sapiens	116-122
28877935-7	2017	We found that a clinically applicable Akt/p70S6K dual inhibitor, LY2780301, drastically decreased proliferation of hMECs with ErbB2-induced p70S6K activation via Cyclin B1 inhibition and cell-cycle blockade at G0-G1 phase, while it did not significantly reverse the abnormal acinar morphology of these hMECs.	ly2780301	65-74	ribosomal protein S6 kinase B1	Homo sapiens	42-48
28877935-7	2017	We found that a clinically applicable Akt/p70S6K dual inhibitor, LY2780301, drastically decreased proliferation of hMECs with ErbB2-induced p70S6K activation via Cyclin B1 inhibition and cell-cycle blockade at G0-G1 phase, while it did not significantly reverse the abnormal acinar morphology of these hMECs.	ly2780301	65-74	ribosomal protein S6 kinase B1	Homo sapiens	140-146
29375709-0	2018	Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway.	puerarin	0-8	ribosomal protein S6 kinase B1	Homo sapiens	69-75
29375709-7	2018	The expression levels of p-mTOR and p-p70S6K proteins were downregulated, while no change was observed in the expression levels of mTOR and p70S6K proteins when T-24 and EJ cells were treated by puerarin.	puerarin	195-203	ribosomal protein S6 kinase B1	Homo sapiens	38-44
29375709-9	2018	These effects may be due to the puerarin-induced downregulation of proteins in the mTOR/p70S6K signaling pathway, and the present study may provide the experimental basis for puerarin to be considered as a promising novel anti-tumor drug for the treatment of bladder cancer.	puerarin	32-40	ribosomal protein S6 kinase B1	Homo sapiens	88-94
29375709-9	2018	These effects may be due to the puerarin-induced downregulation of proteins in the mTOR/p70S6K signaling pathway, and the present study may provide the experimental basis for puerarin to be considered as a promising novel anti-tumor drug for the treatment of bladder cancer.	puerarin	175-183	ribosomal protein S6 kinase B1	Homo sapiens	88-94
29467934-9	2018	The inhibition of p70S6K/p-rpS6 pathway was accompanied with reduced cellular ATP level and increase of p-AMPK in S1 cells.	Adenosine Triphosphate	78-81	ribosomal protein S6 kinase B1	Homo sapiens	18-24
29472733-8	2017	The mRNA expression of AR and IGF-I and the phosphorylation of mTOR, p70S6K, and 4EBP1 were significantly increased in DHT+SED and SHAM+EX and were significantly enhanced in DHT+EX compared with either DHT or exercise alone.	Dihydrotestosterone	119-122	ribosomal protein S6 kinase B1	Homo sapiens	69-75
29472733-8	2017	The mRNA expression of AR and IGF-I and the phosphorylation of mTOR, p70S6K, and 4EBP1 were significantly increased in DHT+SED and SHAM+EX and were significantly enhanced in DHT+EX compared with either DHT or exercise alone.	Dihydrotestosterone	174-177	ribosomal protein S6 kinase B1	Homo sapiens	69-75
29472733-8	2017	The mRNA expression of AR and IGF-I and the phosphorylation of mTOR, p70S6K, and 4EBP1 were significantly increased in DHT+SED and SHAM+EX and were significantly enhanced in DHT+EX compared with either DHT or exercise alone.	Dihydrotestosterone	174-177	ribosomal protein S6 kinase B1	Homo sapiens	69-75
29344155-12	2017	The results showed that the expression of p-ERK and p-P70S6K was downregulated in the cells treated with U0126, while the expression of CD133 remained unaltered.	U 0126	105-110	ribosomal protein S6 kinase B1	Homo sapiens	54-60
29157832-9	2017	Moreover, pachymic acid increased the expression of proteins related to autophagy such as LC3-II and Beclin1 and decreased the levels of mTor phosphorylation and p70S6K in the aged cells.	pachymic acid	10-23	ribosomal protein S6 kinase B1	Homo sapiens	162-168
28249781-5	2017	6-Gingerol activated AMPK, but inhibited PI3K/AKT phosphorylation with reduced P70S6K expression and also suppressed the mTOR phosphorylation.	gingerol	0-10	ribosomal protein S6 kinase B1	Homo sapiens	79-85
28220552-7	2017	In HBdMECs treated with 100 microM Ketamine, time-dependent activation of the mTOR pathway occurred, with significantly increased levels of the phosphorylated forms of mTOR at 30 min and of S6RP and p70S6 kinase (p70S6K) at 6 h. The increased level of p-S6RP returned to baseline within 2 days after ketamine exposure.	Ketamine	35-43	ribosomal protein S6 kinase B1	Homo sapiens	199-211
28220552-7	2017	In HBdMECs treated with 100 microM Ketamine, time-dependent activation of the mTOR pathway occurred, with significantly increased levels of the phosphorylated forms of mTOR at 30 min and of S6RP and p70S6 kinase (p70S6K) at 6 h. The increased level of p-S6RP returned to baseline within 2 days after ketamine exposure.	Ketamine	35-43	ribosomal protein S6 kinase B1	Homo sapiens	213-219
28220552-7	2017	In HBdMECs treated with 100 microM Ketamine, time-dependent activation of the mTOR pathway occurred, with significantly increased levels of the phosphorylated forms of mTOR at 30 min and of S6RP and p70S6 kinase (p70S6K) at 6 h. The increased level of p-S6RP returned to baseline within 2 days after ketamine exposure.	Ketamine	300-308	ribosomal protein S6 kinase B1	Homo sapiens	213-219
29085506-6	2017	Metformin significantly decreased E2-stimulated cell proliferation; an effect that was rescued in the presence of compound C. Metformin treatment markedly increased the phosphorylation of AMPK while decreasing p70S6K phosphorylation, indicating that metformin exerts its effects through stimulation of AMPK and subsequent inhibition of the mammalian target of rapamycin (mTOR) signaling pathway.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	210-216
29163161-9	2017	The anti-apoptotic effect of TXL was abrogated by rapamycin, an inhibitor of p70s6k.	Sirolimus	50-59	ribosomal protein S6 kinase B1	Homo sapiens	77-83
29180484-8	2017	Phosphorylation of p70S6K at Thr 389, a marker of mammalian target of rapamycin (mTOR) signaling, was increased in all groups, with the 8H group showing the highest magnitude.	Threonine	29-32	ribosomal protein S6 kinase B1	Homo sapiens	19-25
29180484-8	2017	Phosphorylation of p70S6K at Thr 389, a marker of mammalian target of rapamycin (mTOR) signaling, was increased in all groups, with the 8H group showing the highest magnitude.	8h	136-138	ribosomal protein S6 kinase B1	Homo sapiens	19-25
29075038-8	2017	Overall, our results revealed that PPD stimulated angiogenesis via HIF-1alpha-mediated VEGF expression by activating p70S6K through PI3K/Akt/mTOR and Raf/MEK/ERK signaling cascades, which suggests that the compound has potential use in wound healing therapy in patients suffering from DFUs.	protopanaxadiol	35-38	ribosomal protein S6 kinase B1	Homo sapiens	117-123
29085506-6	2017	Metformin significantly decreased E2-stimulated cell proliferation; an effect that was rescued in the presence of compound C. Metformin treatment markedly increased the phosphorylation of AMPK while decreasing p70S6K phosphorylation, indicating that metformin exerts its effects through stimulation of AMPK and subsequent inhibition of the mammalian target of rapamycin (mTOR) signaling pathway.	Metformin	126-135	ribosomal protein S6 kinase B1	Homo sapiens	210-216
28963126-7	2017	Rapamycin decreased basal and EGF stimulated HIF-1alpha and enhanced MAPK (ERK1/2) activation, while MAPK (ERK/12) inhibition downregulated HIF-1alpha expression and the phosphorylation of p70S6K.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	189-195
28750271-0	2017	Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.	ly2780301	48-57	ribosomal protein S6 kinase B1	Homo sapiens	59-65
28750271-1	2017	BACKGROUND: LY2780301, a dual inhibitor of protein kinase B (AKT) and the downstream effector p70 ribosomal protein S6 kinase (p70S6K), may inhibit progression in tumours relying on phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signalling pathway activation.	ly2780301	12-21	ribosomal protein S6 kinase B1	Homo sapiens	94-125
28750271-1	2017	BACKGROUND: LY2780301, a dual inhibitor of protein kinase B (AKT) and the downstream effector p70 ribosomal protein S6 kinase (p70S6K), may inhibit progression in tumours relying on phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signalling pathway activation.	ly2780301	12-21	ribosomal protein S6 kinase B1	Homo sapiens	127-133
28963126-8	2017	EGF stimulation of p70S6K was also independent of p-AKT Inhibition of the mTORC1 pathway with rapamycin abolished phosphorylation of p70S6K but had no effect on VEGF-A secretion, indicating that EGF-stimulated VEGF-A secretion did not require mTORC1 pathway activation.	Sirolimus	94-103	ribosomal protein S6 kinase B1	Homo sapiens	19-25
28963126-8	2017	EGF stimulation of p70S6K was also independent of p-AKT Inhibition of the mTORC1 pathway with rapamycin abolished phosphorylation of p70S6K but had no effect on VEGF-A secretion, indicating that EGF-stimulated VEGF-A secretion did not require mTORC1 pathway activation.	Sirolimus	94-103	ribosomal protein S6 kinase B1	Homo sapiens	133-139
28852098-8	2017	Importantly, selinexor decreased AXL and GAS6 levels in CAL62 and HTH83 cells and suppressed the phosphorylation of downstream targets of AXL signaling such as AKT and P70S6K.	selinexor	13-22	ribosomal protein S6 kinase B1	Homo sapiens	168-174
28792981-7	2017	To illustrate the underlying mechanism of RPS6KB1 phosphorylation in NSCLC, LY2584702 was employed to inhibit the RPS6KB1 phosphorylation specifically both in lung adenocarcinoma cell line A549 and squamous cell carcinoma cell line SK-MES-1.	LY2584702	76-85	ribosomal protein S6 kinase B1	Homo sapiens	42-49
29207653-0	2017	Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1alpha and hypoxia-mediated mitophagy.	Melatonin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	89-95
29207653-0	2017	Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1alpha and hypoxia-mediated mitophagy.	Sorafenib	19-28	ribosomal protein S6 kinase B1	Homo sapiens	89-95
29207653-6	2017	Melatonin downregulated the HIF-1alpha protein synthesis through the inhibition of the mammalian target of rapamycin complex 1 (mTORC1)/ribosomal protein S6 kinase beta-1 (p70S6K)/ribosomal protein S6 (RP-S6) pathway, although the indole enhanced Akt phosphorylation by the mTORC1/C2 negative feedback.	Melatonin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	136-170
29207653-6	2017	Melatonin downregulated the HIF-1alpha protein synthesis through the inhibition of the mammalian target of rapamycin complex 1 (mTORC1)/ribosomal protein S6 kinase beta-1 (p70S6K)/ribosomal protein S6 (RP-S6) pathway, although the indole enhanced Akt phosphorylation by the mTORC1/C2 negative feedback.	Melatonin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	172-178
28623128-8	2017	At the molecular level, LY3023414 blocked PI3K-AKT-mTOR activation in skin SCC cells, as it dephosphorylated PI3K-AKT-mTOR substrates: P85, AKT and S6K1.	LY3023414	24-33	ribosomal protein S6 kinase B1	Homo sapiens	148-152
28792981-7	2017	To illustrate the underlying mechanism of RPS6KB1 phosphorylation in NSCLC, LY2584702 was employed to inhibit the RPS6KB1 phosphorylation specifically both in lung adenocarcinoma cell line A549 and squamous cell carcinoma cell line SK-MES-1.	LY2584702	76-85	ribosomal protein S6 kinase B1	Homo sapiens	114-121
28831455-2	2017	One potential and current model that explains Akt activation induced by the mTOR inhibitor rapamycin is the relief of mTORC1/p70S6K-mediated feedback inhibition of IRS-1/PI3K/Akt signaling, although this has not been experimentally proven.	Sirolimus	91-100	ribosomal protein S6 kinase B1	Homo sapiens	125-131
28646031-2	2017	Studies of muscle cells have suggested that leucine alters the insulin response for glucose transport by activating an insulin-negative feedback loop driven by the mammalian target of rapamycin/p70 ribosomal S6 kinase (mTOR/p70S6K) pathway.	Glucose	84-91	ribosomal protein S6 kinase B1	Homo sapiens	224-230
28765952-9	2017	Rapamycin, an mTOR inhibitor, suppressed the expression and activity of mTOR and p70S6K, however enhanced expression of SIRT1, LXRalpha, and CCR7.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	81-87
28656204-1	2017	The aim of this study was to investigate the effects of bufalin on the mammalian target of rapamycin (mTOR/p70S6 kinase (p70S6K) signaling pathway and cell apoptosis in orthotopically transplanted tumors in nude mice.	bufalin	56-63	ribosomal protein S6 kinase B1	Homo sapiens	121-127
28286973-5	2017	Moreover, introduction of constitutively active AKT1 abolished the inhibitory effect of curcumin on cell proliferation, migration, and restored the phosphorylation levels of 4E-BP1 and S6K1, suggesting that curcumin functions via suppressing IGF2-mediated AKT/mTOR signaling pathway.	Curcumin	207-215	ribosomal protein S6 kinase B1	Homo sapiens	185-189
27857021-9	2017	Further study revealed that metformin could suppress the expression of insulin-like growth factor 1 receptor and its downstream proteins, phosphoinositide 3-kinase (PI3K), protein kinase B (AKT/PKB), phosphorylation of AKT (pAKT), mammalian target of rapamycin (mTOR), p70S6K, and PKM2.	Metformin	28-37	ribosomal protein S6 kinase B1	Homo sapiens	269-275
28714804-0	2017	Cellular proliferation and differentiation induced by single-layer molybdenum disulfide and mediation mechanisms of proteins via the Akt-mTOR-p70S6K signaling pathway.	molybdenum disulfide	67-87	ribosomal protein S6 kinase B1	Homo sapiens	142-148
28507275-7	2017	Importantly, treatment of AZD8055, an mTOR inhibitor, leads to the decreased phosphorylation levels of mTOR downstream molecules RPS6KB1 at Thr421/Ser424 and AKT at Ser473.	(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	26-33	ribosomal protein S6 kinase B1	Homo sapiens	129-136
28263966-7	2017	Collectively, we uncover that nickel exposure results in DNMT3b induction and MEG3 promoter hypermethylation and expression inhibition, further reduces its binding to c-Jun and in turn increasing c-Jun inhibition of PHLPP1 transcription, leading to the Akt/p70S6K/S6 axis activation, and HIF-1alpha protein translation, as well as malignant transformation of human bronchial epithelial cells.	Nickel	30-36	ribosomal protein S6 kinase B1	Homo sapiens	257-263
28263966-6	2017	Moreover, HIF-1alpha protein translation was upregulated via activating the Akt/p70S6K/S6 axis resultant from PHLPP1 inhibition in nickel responses.	Nickel	131-137	ribosomal protein S6 kinase B1	Homo sapiens	80-86
28489607-6	2017	Further, TSA induced 5" AMP-activated protein kinase (p-AMPK) (T172) and inhibited mammalian target of rapamycin complex 1 (mTORC1) activity as estimated by phosphorylated ribosomal protein S6 kinase beta-1 (p-p70S6K) levels, thereby suggesting that TSA-mediated AMPK activation and inhibition of mTORC1 pathway might be associated with autophagy induction.	trichostatin A	9-12	ribosomal protein S6 kinase B1	Homo sapiens	172-206
28534996-0	2017	Ginsenoside Rd regulates the Akt/mTOR/p70S6K signaling cascade and suppresses angiogenesis and breast tumor growth.	Ginsenosides	0-11	ribosomal protein S6 kinase B1	Homo sapiens	38-44
28489607-6	2017	Further, TSA induced 5" AMP-activated protein kinase (p-AMPK) (T172) and inhibited mammalian target of rapamycin complex 1 (mTORC1) activity as estimated by phosphorylated ribosomal protein S6 kinase beta-1 (p-p70S6K) levels, thereby suggesting that TSA-mediated AMPK activation and inhibition of mTORC1 pathway might be associated with autophagy induction.	trichostatin A	9-12	ribosomal protein S6 kinase B1	Homo sapiens	210-216
28254579-7	2017	These altered autophagic responses could not be attributed to alterations in the mTOR/p70S6K pathway, since resveratrol-induced inhibition of S6 phosphorylation was not abrogated by chelating cytosolic Ca2+ or by knocking out IP3Rs.	Resveratrol	108-119	ribosomal protein S6 kinase B1	Homo sapiens	86-92
28663724-8	2017	Moreover, the phosphorylated mammalian target of rapamycin (mTOR) and p70 ribosomal S6 kinase (p70S6k) protein levels were decreased by GSK1016790A; these changes were sensitive to 740 Y-P and CC.	N-(1-((4-(2-(((2,4-dichlorophenyl)sulfonyl)amino)-3-hydroxypropanoyl)-1-piperazinyl)carbonyl)-3-methylbutyl)-1-benzothiophene-2-carboxamide	136-147	ribosomal protein S6 kinase B1	Homo sapiens	70-93
28663724-8	2017	Moreover, the phosphorylated mammalian target of rapamycin (mTOR) and p70 ribosomal S6 kinase (p70S6k) protein levels were decreased by GSK1016790A; these changes were sensitive to 740 Y-P and CC.	N-(1-((4-(2-(((2,4-dichlorophenyl)sulfonyl)amino)-3-hydroxypropanoyl)-1-piperazinyl)carbonyl)-3-methylbutyl)-1-benzothiophene-2-carboxamide	136-147	ribosomal protein S6 kinase B1	Homo sapiens	95-101
28581447-8	2017	Under basal conditions, adenosine stimulated NO production, eNOS phosphorylation at serine 1177 from 5 minutes to 4 hours and inhibited eNOS phosphorylation at threonine 495 from 5 minutes to 6 hours, but increased phosphorylation of ERK1/2, p38MAPK, and p70S6K only after exposure for 5 minutes.	Adenosine	24-33	ribosomal protein S6 kinase B1	Homo sapiens	255-261
27714811-5	2017	Further, quercetin inhibited phosphorylation of AKT, P70S6K and S6 proteins whereas, it increased phosphorylation of ERK1/2, P38, JNK and P90RSK proteins in JAR and JEG3 cells.	Quercetin	9-18	ribosomal protein S6 kinase B1	Homo sapiens	53-59
28822191-6	2017	Polydatin can cause S phase arrest for HeLa cells, promote cell apoptosis and decrease the mRNA and protein expression levels of PI3K, AKT, mTOR and P70S6K.	polydatin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	149-155
28588499-7	2017	Results: KE intake did not affect muscle glycogen resynthesis, but more rapidly lowered post-exercise AMPK phosphorylation and resulted in higher mTORC1 activation, as evidenced by the higher phosphorylation of its main downstream targets S6K1 and 4E-BP1.	ke	9-11	ribosomal protein S6 kinase B1	Homo sapiens	239-254
28559962-0	2017	Icariside II promotes the osteogenic differentiation of canine bone marrow mesenchymal stem cells via the PI3K/AKT/mTOR/S6K1 signaling pathways.	baohuoside I	0-12	ribosomal protein S6 kinase B1	Homo sapiens	120-124
28559962-10	2017	Treatment with wortmannin or rapamycin attenuated the expression of p-Akt, p-S6K1, and osteogenesis proteins/genes.	Wortmannin	15-25	ribosomal protein S6 kinase B1	Homo sapiens	77-81
28559962-10	2017	Treatment with wortmannin or rapamycin attenuated the expression of p-Akt, p-S6K1, and osteogenesis proteins/genes.	Sirolimus	29-38	ribosomal protein S6 kinase B1	Homo sapiens	77-81
28302721-7	2017	Moreover, Notch1, HIF-1alpha, and IGF-1R/Akt/ERK/S6K1 activated each other to induce EMT in the CdCl2-exposed A549 cells.	Cadmium Chloride	96-101	ribosomal protein S6 kinase B1	Homo sapiens	49-53
28302721-8	2017	These results suggest that Notch1, along with HIF-1alpha and IGF-1R/Akt/ERK/S6K1 signaling pathways, promotes malignant progression stimulated by prolonged cadmium exposure in this lung adenocarcinoma model.	Cadmium	156-163	ribosomal protein S6 kinase B1	Homo sapiens	76-80
29069736-10	2017	TFQ treatment is able to inactivate mTOR signaling pathway with the regulation of mTOR, 4EBP1 and P70S6K.	4-(2,2,2-TRIFLUOROETHYL)-L-PHENYLALANINE	0-3	ribosomal protein S6 kinase B1	Homo sapiens	98-104
28402274-5	2017	Taken together, our results suggested that GM showed beneficial effect on CP-induced liver injury through NF-kappaB-mediated inflammation and PI3K/Akt/mTOR/p70S6K/4EBP1 axis-mediated autophagy in vivo and in vitro.	gm	43-45	ribosomal protein S6 kinase B1	Homo sapiens	156-162
28427224-7	2017	Ponatinib reduced merlin-deficient HSC viability in a dose-dependent manner by decreasing phosphorylation of PDGFRalpha/beta, AKT, p70S6K, MEK1/2, ERK1/2 and STAT3.	ponatinib	0-9	ribosomal protein S6 kinase B1	Homo sapiens	131-137
28389629-0	2017	Inhibition of p70 S6 kinase (S6K1) activity by A77 1726, the active metabolite of leflunomide, induces autophagy through TAK1-mediated AMPK and JNK activation.	Leflunomide	82-93	ribosomal protein S6 kinase B1	Homo sapiens	29-33
28389629-2	2017	Here we report that feedback activation of mTOR in the PI-3 kinase pathway by two p70 S6 kinase (S6K1) inhibitors (PF-4708671 and A77 1726, the active metabolite of an immunosuppressive drug leflunomide) or by S6K1 knockdown did not suppress but rather induced autophagy.	Leflunomide	191-202	ribosomal protein S6 kinase B1	Homo sapiens	97-101
28283889-4	2017	Here, we demonstrate that CF3DODA-Me induced apoptosis, degraded Sp1, inhibited the expression of multiple drivers of the blebbishield emergency program such as VEGFR2, p70S6K, and N-Myc through activation of caspase-3, inhibited reactive oxygen species; and inhibited K-Ras activation to abolish transformation from blebbishields as well as transformation in soft agar.	cf3doda-me	26-36	ribosomal protein S6 kinase B1	Homo sapiens	169-175
30345409-9	2017	The putative toxicity pathway for cytotoxicity of these metals and metal mixtures identified by LASSO is composed of phospho-RPS6KB1, phospho-p53, cleaved CASP3, phospho-MAPK8, IL-10, and Hif-1alpha.	Metals	56-61	ribosomal protein S6 kinase B1	Homo sapiens	125-132
27606834-7	2017	In a dose-dependent manner, naringenin decreased phosphorylation of ERK1/2, P70S6K, S6, and P38 in PC3 cells, and reduced phosphorylation of ERK1/2, P53, P38, and JNK proteins in LNCaP cells.	naringenin	28-38	ribosomal protein S6 kinase B1	Homo sapiens	76-82
28406985-8	2017	To further explore the underlying mechanism, we found that metformin treatment could significantly damp the expression of 4EBP1 and S6K1 in KYSE 450 cells in vitro and in vivo, furthermore, the p-4EBP1 and p-S6K1 expression in KYSE 450 cells were also inhibited greatly in vitro and in vivo.	Metformin	59-68	ribosomal protein S6 kinase B1	Homo sapiens	132-136
28212891-9	2017	Although SFN promotes Nrf2 accumulation to upregulate cytoprotective genes (e.g., heme oxygenase-1 and thioredoxin-1), downregulation of endogenous Nrf2 by target-specific siRNA reveals an Nrf2-independent effect for SFN-mediated inhibition of mTOR/p70S6K/S6 signaling and suppression of VSMC proliferation.	sulforaphane	9-12	ribosomal protein S6 kinase B1	Homo sapiens	249-255
28315428-0	2017	p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells.	Cisplatin	67-76	ribosomal protein S6 kinase B1	Homo sapiens	58-62
28315428-3	2017	Since suppression of ribosomal protein S6 kinase1 (S6K1) phosphorylation reverses the resistance to BCR-ABL inhibitor in CML cells and S6K1 inhibitors augment cisplatin toxicity in lung cancer cells, we speculated that combination of S6K1 inhibitor and cisplatin may be beneficial for eliminating BC CML cells.	Cisplatin	159-168	ribosomal protein S6 kinase B1	Homo sapiens	135-139
28315428-3	2017	Since suppression of ribosomal protein S6 kinase1 (S6K1) phosphorylation reverses the resistance to BCR-ABL inhibitor in CML cells and S6K1 inhibitors augment cisplatin toxicity in lung cancer cells, we speculated that combination of S6K1 inhibitor and cisplatin may be beneficial for eliminating BC CML cells.	Cisplatin	159-168	ribosomal protein S6 kinase B1	Homo sapiens	135-139
28315428-3	2017	Since suppression of ribosomal protein S6 kinase1 (S6K1) phosphorylation reverses the resistance to BCR-ABL inhibitor in CML cells and S6K1 inhibitors augment cisplatin toxicity in lung cancer cells, we speculated that combination of S6K1 inhibitor and cisplatin may be beneficial for eliminating BC CML cells.	Cisplatin	253-262	ribosomal protein S6 kinase B1	Homo sapiens	51-55
28315428-4	2017	To our surprise, S6K1 inhibition decreased cisplatin-induced DNA damage and cell death only in p53-/- BC CML cells but not in p53+/+ BC CML cells.	Cisplatin	43-52	ribosomal protein S6 kinase B1	Homo sapiens	17-21
28315428-7	2017	Our results confirmed that S6K1 inhibition reversed cisplatin toxicity is dependent on p53 expression in CML cells.	Cisplatin	52-61	ribosomal protein S6 kinase B1	Homo sapiens	27-31
28315428-10	2017	Taken together, our results suggest that p53/PDK1/S6K1 is a novel pathway regulating cisplatin toxicity in BC CML cells.	Cisplatin	85-94	ribosomal protein S6 kinase B1	Homo sapiens	50-54
28446743-13	2017	Rapamycin inhibited the phosphorylation of p70s6k.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	43-49
28581447-11	2017	Our data demonstrated that adenosine prevents hypothermic injury to the endothelium by activating ERK1/2, eNOS, p70S6K, and p38MAPK signaling pathways at early time points.	Adenosine	27-36	ribosomal protein S6 kinase B1	Homo sapiens	112-118
28406985-8	2017	To further explore the underlying mechanism, we found that metformin treatment could significantly damp the expression of 4EBP1 and S6K1 in KYSE 450 cells in vitro and in vivo, furthermore, the p-4EBP1 and p-S6K1 expression in KYSE 450 cells were also inhibited greatly in vitro and in vivo.	Metformin	59-68	ribosomal protein S6 kinase B1	Homo sapiens	208-212
28364098-9	2017	Delphinidin inhibited the expression of proteins in mTOR signaling pathway, including AKT, mTOR, eIF4E and p70s6k.	delphinidin	0-11	ribosomal protein S6 kinase B1	Homo sapiens	107-113
28004151-11	2017	Inhibition of mTORC1-S6K1 signalling improved GSIS and restored mTORC2 activity in islets from patients with type 2 diabetes as well as in islets isolated from diabetic db/db mice and mice fed a high-fat/high-sucrose diet.	Sucrose	209-216	ribosomal protein S6 kinase B1	Homo sapiens	21-25
28413468-6	2017	In addition, sunitinib activated ERK1/2 and inhibited mTOR/p70S6K signaling.	Sunitinib	13-22	ribosomal protein S6 kinase B1	Homo sapiens	59-65
28112362-9	2017	The expression of PTEN was upregulated, while that of p-AKT, p-mTOR and p-p70S6K was downregulated by propranolol; these effects were partly reversed by the overexpression of miR-382.	Propranolol	102-113	ribosomal protein S6 kinase B1	Homo sapiens	74-80
28386356-0	2017	Folic acid inhibits dedifferentiation of PDGF-BB-induced vascular smooth muscle cells by suppressing mTOR/P70S6K signaling.	Folic Acid	0-10	ribosomal protein S6 kinase B1	Homo sapiens	106-112
28386356-15	2017	CONCLUSION: Folic acid inhibits dedifferentiation of PDGF-BB-induced VSMCs by suppressing mTOR/P70S6K signaling.	Folic Acid	12-22	ribosomal protein S6 kinase B1	Homo sapiens	95-101
28785288-4	2017	Furthermore, NnV inhibited the phosphorylation of PI3K, PDK1, Akt, mTOR, p70S6K, and 4EBP1, whereas it enhanced the expression of p-PTEN.	(1r,5as,6r)-1,2,5,5a,6,7-Hexahydrophenazine-1,6-Dicarboxylic Acid	13-16	ribosomal protein S6 kinase B1	Homo sapiens	73-90
27669541-7	2017	We found that sucrose-induced active autophagy in OA chondrocytes in vitro was dependent on the activation of AKT/mTOR/P70S6K signaling pathways but was independent of reactive oxygen species (ROS) production.	Sucrose	14-21	ribosomal protein S6 kinase B1	Homo sapiens	119-125
27669541-10	2017	In conclusion, sucrose attenuated IL-1beta induced apoptosis and the expression of catabolic mediators by inducing autophagy, and the autophagy in part was mediated through the activation of AKT/mTOR/P70S6K signaling pathway in human OA chondrocytes.	Sucrose	15-22	ribosomal protein S6 kinase B1	Homo sapiens	200-206
27433879-12	2017	Cisplatin treatment inhibited the phosphorylation of mTOR/P70S6K, and its phosphorylated strips were almost completely inhibited in the 100 mumol/L for 48 hours with cisplatin treatment.	Cisplatin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	58-64
27433879-12	2017	Cisplatin treatment inhibited the phosphorylation of mTOR/P70S6K, and its phosphorylated strips were almost completely inhibited in the 100 mumol/L for 48 hours with cisplatin treatment.	Cisplatin	166-175	ribosomal protein S6 kinase B1	Homo sapiens	58-64
28243129-0	2017	Polydatin regulates proliferation, apoptosis and autophagy in multiple myeloma cells through mTOR/p70s6k pathway.	polydatin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	98-104
28243129-13	2017	Furthermore, inhibition of the mTOR/p70s6k signaling pathway by rapamycin significantly induced autophagy and apoptosis and inhibited cell viability (P&lt;0.05).	Sirolimus	64-73	ribosomal protein S6 kinase B1	Homo sapiens	36-42
28036295-5	2017	Reversely, forced-activation of mTOR by adding SC79 or exogenous expressing a constitutively active S6K1 (T389E) attenuated AT406-induced cytotoxicity against HCC cells.	N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide	124-129	ribosomal protein S6 kinase B1	Homo sapiens	100-104
27856287-4	2017	Spinal local application of AMPK agonist metformin (25mug) prevented the long term potentiation (LTP) induction and the activation of mTOR/p70S6K signal pathway, and significantly attenuated the acute thermal hyperalgesia and mechanical allodynia following single oxaliplatin treatment.	Metformin	41-50	ribosomal protein S6 kinase B1	Homo sapiens	139-145
27856287-5	2017	Importantly, we found that incubation of low concentration oxaliplatin at dose of 6.6nM (the detected concentration in CSF following a single intraperitoneal injection of oxaliplatin) also significantly inhibited the AMPKalpha activation and increased the amplitude of sEPSCs, the number of action potential, and the expression of p-mTOR and p-p70S6K in spinal cord slices.	Oxaliplatin	59-70	ribosomal protein S6 kinase B1	Homo sapiens	344-350
27856287-8	2017	Local application of metformin significantly decreased the mTOR and p70S6K activation induced by tetanus stimulation or oxaliplatin (i.p.).	Metformin	21-30	ribosomal protein S6 kinase B1	Homo sapiens	68-74
27856287-8	2017	Local application of metformin significantly decreased the mTOR and p70S6K activation induced by tetanus stimulation or oxaliplatin (i.p.).	Oxaliplatin	120-131	ribosomal protein S6 kinase B1	Homo sapiens	68-74
27856287-9	2017	These results suggested that the decreased AMPKalpha activity via negatively regulating mTOR/p70S6K signal pathway enhanced the synaptic plasticity and contributed to acute pain induced by low concentration of oxaliplatin entering CNS.	Oxaliplatin	210-221	ribosomal protein S6 kinase B1	Homo sapiens	93-99
27128966-8	2017	The activation of GSK3beta correlated with the inhibitory phosphorylation by Akt as well as p70S6K through AMPK activation in response to metformin.	Metformin	138-147	ribosomal protein S6 kinase B1	Homo sapiens	92-98
27829579-8	2017	Importantly, we found that curcumin reduced Akt, mTOR and P70S6K phosphorylation, effectively suppressing the activity of the Akt/mTOR pathway in HKCs.	Curcumin	27-35	ribosomal protein S6 kinase B1	Homo sapiens	58-64
28395342-6	2017	In addition, FGF2 increases phosphorylation of AKT, P70S6K, S6, ERK1/2, JNK, P38, and P90RSK in a time-dependent manner, and increases in their expression was suppressed by Wortmannin (a phosphatidylinositol 3-kinase [PI3K] inhibitor), U0126 (an ERK1/2 inhibitor), SP600125 (a JNK inhibitor), and SB203580 (a P38 inhibitor) based on western blot analyses.	Wortmannin	173-183	ribosomal protein S6 kinase B1	Homo sapiens	52-58
28487599-8	2017	Furthermore, rapamycin, a specific inhibitor of the mTOR/p70S6K signaling pathway, decreased the levels of Ki-67 and Bcl-2/Bax ratio, inhibited cell proliferation, and promoted apoptosis in EC cells.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	57-63
27709782-6	2017	In addition, erinacine A time-dependent induction of cell death and inhibitory invasiveness was associated with sustained phosphorylation of the PI3K/mTOR/p70S6K and ROCK1/LIMK2/Cofilin pathways.	erinacine A	13-24	ribosomal protein S6 kinase B1	Homo sapiens	155-161
27709782-7	2017	Furthermore, we demonstrated that erinacine A-induced HCT-116 and DLD-1 cells viability and anti-invasion properties by up-regulating the activation of PI3K/mTOR/p70S6K and production of ROS.	erinacine A	34-45	ribosomal protein S6 kinase B1	Homo sapiens	162-168
27709782-8	2017	Experiments involving specific inhibitors demonstrated that the differential expression of cofilin-1 (COFL1) and profilin-1 (PROF1) during erinacine A treatment could be involved in the mechanisms of HCT-116 and DLD-1 cells death and decreased aggressiveness, which occurred via ROCK1/LIMK2/Cofilin expression, with activation of the PI3K/mTOR/p70S6K signalling pathway.	erinacine A	139-150	ribosomal protein S6 kinase B1	Homo sapiens	344-350
27709782-9	2017	These findings elucidate the mechanism of erinacine A inhibiting the aggressive status of cells by activating PI3K/mTOR/p70S6K downstream signalling and the novel protein targets COF1 and PROF1; this could be a good molecular strategy to limit the aggressiveness of CRC cells.	erinacine A	42-53	ribosomal protein S6 kinase B1	Homo sapiens	120-126
27838742-0	2017	Delicaflavone induces autophagic cell death in lung cancer via Akt/mTOR/p70S6K signaling pathway.	delicaflavone	0-13	ribosomal protein S6 kinase B1	Homo sapiens	72-78
27838742-5	2017	Delicaflavone downregulated the expression of phospho-Akt, phospho-mTOR, and phospho-p70S6K in a time- and dose-dependent manner, suggesting that it induced autophagy by inhibiting the Akt/mTOR/p70S6K pathway in A549 and PC-9 cells.	delicaflavone	0-13	ribosomal protein S6 kinase B1	Homo sapiens	85-91
27838742-5	2017	Delicaflavone downregulated the expression of phospho-Akt, phospho-mTOR, and phospho-p70S6K in a time- and dose-dependent manner, suggesting that it induced autophagy by inhibiting the Akt/mTOR/p70S6K pathway in A549 and PC-9 cells.	delicaflavone	0-13	ribosomal protein S6 kinase B1	Homo sapiens	194-200
27838742-6	2017	Delicaflavone is a potential anticancer agent that can induce autophagic cell death in human non-small cell lung cancer via the Akt/mTOR/p70S6K signaling pathway.	delicaflavone	0-13	ribosomal protein S6 kinase B1	Homo sapiens	137-143
27838742-8	2017	Delicaflavone induced autophagic cell death via Akt/mTOR/p70S6K signaling pathway.	delicaflavone	0-13	ribosomal protein S6 kinase B1	Homo sapiens	57-63
27838742-12	2017	Delicaflavone induced autophagic cell death via Akt/mTOR/p70S6K signaling pathway.	delicaflavone	0-13	ribosomal protein S6 kinase B1	Homo sapiens	57-63
28199842-3	2017	Here, we show that PHD2 is phosphorylated on serine 125 (S125) by the mechanistic target of rapamycin (mTOR) downstream kinase P70S6K and that this phosphorylation increases its ability to degrade HIF1alpha.	Serine	45-51	ribosomal protein S6 kinase B1	Homo sapiens	127-133
27171670-6	2017	Western blot analysis revealed that ERK1/2, P90RSK, AKT, and P70S6K were increased significantly in JEG-3 cells by chrysophanol.	chrysophanic acid	115-127	ribosomal protein S6 kinase B1	Homo sapiens	61-67
27959445-6	2017	We also found that delphinidin specifically decreased the CoCl2- and EGF-induced HIF-1alpha protein expression by blocking the ERK and PI3K/Akt/mTOR/p70S6K signaling pathways, whereas the p38-mediated pathways were not involved.	delphinidin	19-30	ribosomal protein S6 kinase B1	Homo sapiens	149-155
27959445-6	2017	We also found that delphinidin specifically decreased the CoCl2- and EGF-induced HIF-1alpha protein expression by blocking the ERK and PI3K/Akt/mTOR/p70S6K signaling pathways, whereas the p38-mediated pathways were not involved.	cobaltous chloride	58-63	ribosomal protein S6 kinase B1	Homo sapiens	149-155
27993682-10	2017	Consistent with a role for mTORC1/S6K1 signaling promoting trastuzumab resistance, all cell lines were sensitive to S6K1 inactivation with significant growth inhibition following treatment with the mTORC1 inhibitor rapamycin.	Sirolimus	215-224	ribosomal protein S6 kinase B1	Homo sapiens	116-120
27393705-5	2017	RESULTS: A kinome-level screen and Kds analyses against a panel of 102 human kinase targets showed that Del binds to three lipid (PIK3CG, PIK3C2B, and PIK3CA) and six serine/threonine (PIM1, PIM3, mTOR, S6K1, PLK2, and AURKB) kinases, five of which belong to the PI3K/Akt/mTOR pathway.	Serine	167-173	ribosomal protein S6 kinase B1	Homo sapiens	203-207
27393705-5	2017	RESULTS: A kinome-level screen and Kds analyses against a panel of 102 human kinase targets showed that Del binds to three lipid (PIK3CG, PIK3C2B, and PIK3CA) and six serine/threonine (PIM1, PIM3, mTOR, S6K1, PLK2, and AURKB) kinases, five of which belong to the PI3K/Akt/mTOR pathway.	Threonine	174-183	ribosomal protein S6 kinase B1	Homo sapiens	203-207
28061838-1	2017	BACKGROUND: Cryptotanshinone (CPT), a fat-soluble phenanthraquinone from Salvia miltiorrhiza Bunge, has been demonstrated to inhibit phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1), a couple of direct downstream effectors of the mammalian target of rapamycin complex 1 (mTORC1), resulting in cancer cell arrested in G0 phase and subsequent inhibition of proliferation.	cryptotanshinone	12-28	ribosomal protein S6 kinase B1	Homo sapiens	169-173
28061838-1	2017	BACKGROUND: Cryptotanshinone (CPT), a fat-soluble phenanthraquinone from Salvia miltiorrhiza Bunge, has been demonstrated to inhibit phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1), a couple of direct downstream effectors of the mammalian target of rapamycin complex 1 (mTORC1), resulting in cancer cell arrested in G0 phase and subsequent inhibition of proliferation.	cryptotanshinone	30-33	ribosomal protein S6 kinase B1	Homo sapiens	169-173
28854418-7	2017	Erinacine A induction of apoptosis was accompanied by sustained phosphorylation of FAK/AKT/p70S6K and the PAK1 pathways, as well as the generation of ROS.	erinacine A	0-11	ribosomal protein S6 kinase B1	Homo sapiens	91-97
28854418-8	2017	Furthermore, the induction of apoptosis and anti-invasion properties by erinacine A could involve the differential expression of the 14-3-3 sigma protein (1433S) and microtubule-associated tumor suppressor candidate 2 (MTUS2), with the activation of the FAK/AKT/p70S6K and PAK1 signaling pathways.	erinacine A	72-83	ribosomal protein S6 kinase B1	Homo sapiens	262-268
28854418-9	2017	CONCLUSIONS: These results lead us to speculate that erinacine A may generate an apoptotic cascade in TSGH 9201 cells by activating the FAK/AKT/p70S6K/PAK1 pathway and upregulating proteins 1433S and MTUS2, providing a new mechanism underlying the anti-cancer effects of erinacine A in human gastric cancer cells.	erinacine A	53-64	ribosomal protein S6 kinase B1	Homo sapiens	144-150
27135475-10	2017	At +3 hours, mTOR and S6K1 phosphorylation was higher for placebo than for alcohol.	Alcohols	75-82	ribosomal protein S6 kinase B1	Homo sapiens	22-26
27840152-8	2016	SR9009 treatment prevented CCl4-induced P70S6K phosphorylation but did not affect CCl4-induced changes in AMPK, ATG proteins or P62.	SR9009	0-6	ribosomal protein S6 kinase B1	Homo sapiens	40-46
27780861-3	2016	Here we show that p70S6K1 (S6K1), a downstream target of mechanistic target of rapamycin (mTOR), phosphorylates PIPKIgamma90 at Thr-553 and Ser-555 and that S6K1-mediated PIPKIgamma90 phosphorylation is essential for cell migration and invasion.	Threonine	128-131	ribosomal protein S6 kinase B1	Homo sapiens	21-25
27780861-3	2016	Here we show that p70S6K1 (S6K1), a downstream target of mechanistic target of rapamycin (mTOR), phosphorylates PIPKIgamma90 at Thr-553 and Ser-555 and that S6K1-mediated PIPKIgamma90 phosphorylation is essential for cell migration and invasion.	Threonine	128-131	ribosomal protein S6 kinase B1	Homo sapiens	27-31
27780861-3	2016	Here we show that p70S6K1 (S6K1), a downstream target of mechanistic target of rapamycin (mTOR), phosphorylates PIPKIgamma90 at Thr-553 and Ser-555 and that S6K1-mediated PIPKIgamma90 phosphorylation is essential for cell migration and invasion.	Serine	140-143	ribosomal protein S6 kinase B1	Homo sapiens	21-25
27780861-3	2016	Here we show that p70S6K1 (S6K1), a downstream target of mechanistic target of rapamycin (mTOR), phosphorylates PIPKIgamma90 at Thr-553 and Ser-555 and that S6K1-mediated PIPKIgamma90 phosphorylation is essential for cell migration and invasion.	Serine	140-143	ribosomal protein S6 kinase B1	Homo sapiens	27-31
27438654-1	2016	The p70 ribosomal S6 kinase (p70S6K) is a downstream substrate that is phosphorylated and activated by the mammalian target of rapamycin complex and regulates multiple cellular processes associated with pulmonary fibrogenesis.	Sirolimus	127-136	ribosomal protein S6 kinase B1	Homo sapiens	4-27
27438654-1	2016	The p70 ribosomal S6 kinase (p70S6K) is a downstream substrate that is phosphorylated and activated by the mammalian target of rapamycin complex and regulates multiple cellular processes associated with pulmonary fibrogenesis.	Sirolimus	127-136	ribosomal protein S6 kinase B1	Homo sapiens	29-35
27840152-12	2016	The autophagy activator rapamycin and the autophagy inhibitor wortmannin each decreased HSC activation, P70S6K phosphorylation and HSC proliferation.	Wortmannin	62-72	ribosomal protein S6 kinase B1	Homo sapiens	104-110
27167250-6	2016	S6K1, a major downstream target of mTORC1, was also activated by carbachol in a temporal profile similar to that of the Akt activation.	Carbachol	65-74	ribosomal protein S6 kinase B1	Homo sapiens	0-4
27167250-7	2016	This carbachol-stimulated S6K1 activation was abrogated by LY294002 or the mTORC1 inhibitor rapamycin, supporting the notion that mAChRs mediate S6K1 activation via the PI3K-Akt-mTORC1 pathway.	Carbachol	5-14	ribosomal protein S6 kinase B1	Homo sapiens	26-30
27167250-7	2016	This carbachol-stimulated S6K1 activation was abrogated by LY294002 or the mTORC1 inhibitor rapamycin, supporting the notion that mAChRs mediate S6K1 activation via the PI3K-Akt-mTORC1 pathway.	Carbachol	5-14	ribosomal protein S6 kinase B1	Homo sapiens	145-149
27167250-7	2016	This carbachol-stimulated S6K1 activation was abrogated by LY294002 or the mTORC1 inhibitor rapamycin, supporting the notion that mAChRs mediate S6K1 activation via the PI3K-Akt-mTORC1 pathway.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	59-67	ribosomal protein S6 kinase B1	Homo sapiens	26-30
27167250-7	2016	This carbachol-stimulated S6K1 activation was abrogated by LY294002 or the mTORC1 inhibitor rapamycin, supporting the notion that mAChRs mediate S6K1 activation via the PI3K-Akt-mTORC1 pathway.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	59-67	ribosomal protein S6 kinase B1	Homo sapiens	145-149
27167250-7	2016	This carbachol-stimulated S6K1 activation was abrogated by LY294002 or the mTORC1 inhibitor rapamycin, supporting the notion that mAChRs mediate S6K1 activation via the PI3K-Akt-mTORC1 pathway.	Sirolimus	92-101	ribosomal protein S6 kinase B1	Homo sapiens	26-30
27167250-7	2016	This carbachol-stimulated S6K1 activation was abrogated by LY294002 or the mTORC1 inhibitor rapamycin, supporting the notion that mAChRs mediate S6K1 activation via the PI3K-Akt-mTORC1 pathway.	Sirolimus	92-101	ribosomal protein S6 kinase B1	Homo sapiens	145-149
27054578-4	2016	Using reverse phase protein array (RPPA) and immunoblot analysis, we identified that AZD1208 resulted in suppression of mTOR signaling, including inhibition of protein phosphorylation of mTOR (Ser2448), p70S6K (Thr389), S6 (Ser235/236), and 4E-BP1 (Ser65).	AZD1208	85-92	ribosomal protein S6 kinase B1	Homo sapiens	203-209
27404348-6	2016	Metformin activated the AMPK/mTOR signaling pathway as shown by increased p-AMPK and decreased p-p70S6K.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	97-103
27916907-0	2016	Metformin Inhibits TGF-beta1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	97-103
27634387-8	2016	Oxygen consumption is elevated in S6K1-depeleted HeLa cells and FL5.12 cells.	Oxygen	0-6	ribosomal protein S6 kinase B1	Homo sapiens	34-38
27634387-9	2016	In addition, S6K1 depletion leads to enhancement of ATP production in cytoplasm and mitochondria.	Adenosine Triphosphate	52-55	ribosomal protein S6 kinase B1	Homo sapiens	13-17
27916907-10	2016	CONCLUSION: Metformin abolishes TGF-beta1-induced EMT in cervical carcinoma cells by inhibiting mTOR/p70s6k signaling to down-regulate PKM2 expression.	Metformin	12-21	ribosomal protein S6 kinase B1	Homo sapiens	101-107
27916907-9	2016	Metformin decreased the p-p70s6k expression and the blockade of mTOR/p70s6k signaling decreased PKM2 expression.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	26-32
27742835-6	2016	We found that inhibition of p70S6K, downstream of TORC1, resulted in diminished Ser(P)-IRS-2 and prolonged Tyr(P)-IRS-2 as well.	Serine	80-83	ribosomal protein S6 kinase B1	Homo sapiens	28-34
27742835-6	2016	We found that inhibition of p70S6K, downstream of TORC1, resulted in diminished Ser(P)-IRS-2 and prolonged Tyr(P)-IRS-2 as well.	Tyrosine	107-110	ribosomal protein S6 kinase B1	Homo sapiens	28-34
27553280-6	2016	Hyp-Gly increased the phosphorylation of Akt, mTOR, and p70S6K in myoblasts, whereas the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibited their phosphorylation by Hyp-Gly.	hydroxyprolyl-glycine	0-7	ribosomal protein S6 kinase B1	Homo sapiens	56-62
27769069-8	2016	Overexpression of Myr-Akt (constitutively active Akt) completely abolished SPS-7-induced inhibitory effect on mTOR/p70S6K/4EBP1 signaling and c-Myc protein expression, suggesting that PI3K/Akt serves as a key upstream regulator.	arginyl-threonyl-prolyl-prolyl-prolyl-seryl-glycine	75-80	ribosomal protein S6 kinase B1	Homo sapiens	115-121
27769069-11	2016	In conclusion, the data suggest that SPS-7 is not an immunosuppressant while induces anticancer effect against HRPC through inhibition of Akt/mTOR/p70S6K pathwaysthat down-regulate protein levels of both c-Myc and cyclin D1, leading to G1 arrest of cell cycle and subsequent apoptosis.	arginyl-threonyl-prolyl-prolyl-prolyl-seryl-glycine	37-42	ribosomal protein S6 kinase B1	Homo sapiens	147-153
27626202-6	2016	Mechanistically, pevonedistat led to P-eIF2a dephosphorylation causing atypical proteotoxic/ER stress from failure to halt protein translation via the UPR and upregulation of mTOR/p70S6K.	pevonedistat	17-29	ribosomal protein S6 kinase B1	Homo sapiens	180-186
27481223-7	2016	This reduction in protein degradation led to an increased amount of p70 S6 kinase (p70S6k), which was abolished in the presence of mAChR antagonist scopolamine.	Scopolamine	148-159	ribosomal protein S6 kinase B1	Homo sapiens	68-81
27481223-7	2016	This reduction in protein degradation led to an increased amount of p70 S6 kinase (p70S6k), which was abolished in the presence of mAChR antagonist scopolamine.	Scopolamine	148-159	ribosomal protein S6 kinase B1	Homo sapiens	83-89
27769241-7	2016	RESULTS: Here we studied the molecular mechanism of berberine in cell culture model with TDP-43 proteinopathies, and found that berberine is able to reverse the processing of insoluble TDP-43 aggregates formation through deregulation of mTOR/p70S6K signal and activation of autophagic degradation pathway.	Berberine	128-137	ribosomal protein S6 kinase B1	Homo sapiens	242-248
27769241-11	2016	Here we demonstrated that berberine is able to reverse the processing of insoluble TDP-43 aggregates formation through deregulation of mTOR/p70S6K signal and activation of autophagic degradation pathway.	Berberine	26-35	ribosomal protein S6 kinase B1	Homo sapiens	140-146
27590857-9	2016	Furthermore, the protein expression of phospho-p70S6K (Ser 417) also increased.	Serine	55-58	ribosomal protein S6 kinase B1	Homo sapiens	47-53
27590857-11	2016	Furthermore, the expression of phospho-mTOR (Ser 2448) and phospho-p70S6K (Ser 417) were also blocked.	Serine	75-78	ribosomal protein S6 kinase B1	Homo sapiens	67-73
27439478-7	2016	In vivo, LY3023414 demonstrated high bioavailability and dose-dependent dephosphorylation of PI3K/AKT/mTOR pathway downstream substrates such as AKT, S6K, S6RP, and 4E-BP1 for 4 to 6 hours, reflecting the drug"s half-life of 2 hours.	LY3023414	9-18	ribosomal protein S6 kinase B1	Homo sapiens	153-159
27155955-6	2016	The increased phosphorylation of eIF-4 E binding protein 1 (4E-BP1) and ribosomal protein S6 kinase 1 (S6K1) in Ala-Gln treatment were associated with phosphorylation of the mTOR in liver and skeletal muscle.	alanylglutamine	112-119	ribosomal protein S6 kinase B1	Homo sapiens	103-107
27667455-8	2016	H-89 not only blocked polyploidization, but also decreased the phosphorylation of S6K1 at Thr421/Ser424 and increased the phosphorylation of S6K1 at Thr389.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	0-4	ribosomal protein S6 kinase B1	Homo sapiens	82-86
27667455-8	2016	H-89 not only blocked polyploidization, but also decreased the phosphorylation of S6K1 at Thr421/Ser424 and increased the phosphorylation of S6K1 at Thr389.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	0-4	ribosomal protein S6 kinase B1	Homo sapiens	141-145
27667455-9	2016	Molecular docking and kinase activity assay showed that H-89 occupied the ATP binding sites of S6K1 and inhibited its activity.	Adenosine Triphosphate	74-77	ribosomal protein S6 kinase B1	Homo sapiens	95-99
27667455-12	2016	Therefore, these data indicated that H-89 blocked the SP600125-induced polyploidization of CMK cells mainly by changing S6K1 phosphorylation state, rather than its inhibitory effect on PKA.	pyrazolanthrone	54-62	ribosomal protein S6 kinase B1	Homo sapiens	120-124
27667455-13	2016	Conclusion H-89 can block the polyploidization of SP600125-induced CMK cells by regulating S6K1 phosphorylation state.	pyrazolanthrone	50-58	ribosomal protein S6 kinase B1	Homo sapiens	91-95
27667458-8	2016	Moreover, SP600125 increased the phosphorylation of S6K1 Thr421/Ser424 and decreased the phosphorylation of Thr389 in Dami cells.	pyrazolanthrone	10-18	ribosomal protein S6 kinase B1	Homo sapiens	52-56
27667458-14	2016	Conclusion SP600125-induced polyploidization of megakaryocytic leukemia cell lines is dependent on the effect of SP600125 on phosphorylation of S6K1 in cell lines at the different differentiation stages.	pyrazolanthrone	11-19	ribosomal protein S6 kinase B1	Homo sapiens	144-148
27667458-14	2016	Conclusion SP600125-induced polyploidization of megakaryocytic leukemia cell lines is dependent on the effect of SP600125 on phosphorylation of S6K1 in cell lines at the different differentiation stages.	pyrazolanthrone	113-121	ribosomal protein S6 kinase B1	Homo sapiens	144-148
27612557-5	2016	There were at least 2932 proteins responding to Danu treatment, including AURKB, p70S6K, and RPL15, and 603 functional proteins and 245 canonical signaling pathways were involved in regulating cell proliferation, metabolism, apoptosis, and autophagy.	danusertib	48-52	ribosomal protein S6 kinase B1	Homo sapiens	81-87
27612557-7	2016	Our verification experiments confirmed that Danu negatively regulated AURKB/p70S6K/RPL15 axis with the involvement of PI3K/Akt/mTOR, AMPK, and p38 MAPK signaling pathways, leading to the induction of apoptosis and autophagy in human leukemia cells.	danusertib	44-48	ribosomal protein S6 kinase B1	Homo sapiens	76-82
27586268-8	2016	Further studies demonstrated that the combined administration of 5-FU and beta-carotene significantly down-regulated the protein levels of Cav-1, p-AKT, p-NF-kappaB, p-mTOR and p-p70S6K in Eca109 cells more effectively than did 5-FU alone.	Fluorouracil	65-69	ribosomal protein S6 kinase B1	Homo sapiens	179-185
27586268-8	2016	Further studies demonstrated that the combined administration of 5-FU and beta-carotene significantly down-regulated the protein levels of Cav-1, p-AKT, p-NF-kappaB, p-mTOR and p-p70S6K in Eca109 cells more effectively than did 5-FU alone.	beta Carotene	74-87	ribosomal protein S6 kinase B1	Homo sapiens	179-185
27680387-5	2016	It was further observed that BA145 induced autophagy by targeting mTOR kinase (IC50 1 muM), leading to reduced expression of p-mTOR, p-p70S6K (T389), p-4EBP (T37/46) and p-S6 (S240/244).	ba145	29-34	ribosomal protein S6 kinase B1	Homo sapiens	135-141
27553280-8	2016	The peptide/histidine transporter 1 (PHT1) was highly expressed in both myoblasts and myotubes, and co-administration of histidine inhibited Hyp-Gly-induced phosphorylation of p70S6K in myoblasts and myotubes.	Histidine	12-21	ribosomal protein S6 kinase B1	Homo sapiens	176-182
27553280-8	2016	The peptide/histidine transporter 1 (PHT1) was highly expressed in both myoblasts and myotubes, and co-administration of histidine inhibited Hyp-Gly-induced phosphorylation of p70S6K in myoblasts and myotubes.	Glycine	145-148	ribosomal protein S6 kinase B1	Homo sapiens	176-182
27396756-4	2016	Here we show that CPX inhibited the phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1), two downstream effector molecules of mTOR complex 1 (mTORC1), in a spectrum of human tumor cells, indicating that CPX inhibits mTORC1 signaling.	Ciclopirox	18-21	ribosomal protein S6 kinase B1	Homo sapiens	72-76
27396756-4	2016	Here we show that CPX inhibited the phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1), two downstream effector molecules of mTOR complex 1 (mTORC1), in a spectrum of human tumor cells, indicating that CPX inhibits mTORC1 signaling.	Ciclopirox	256-259	ribosomal protein S6 kinase B1	Homo sapiens	72-76
27246734-6	2016	Western blot revealed that the expression of Beclin-1 and LC3B-II was enhanced, and the phosphorylation levels of the mammalian target of rapamycin (mTOR) protein and p70S6K were reduced by metformin after SCI.	Metformin	190-199	ribosomal protein S6 kinase B1	Homo sapiens	167-173
27542212-11	2016	We propose that PP and Niclo should be further investigated as potential therapeutics for the treatment of tumors or diseases carrying the constitutive activation of the PI3K/P70S6K signalling axis.	Niclosamide	23-28	ribosomal protein S6 kinase B1	Homo sapiens	175-181
27246734-9	2016	Hence, metformin attenuated SCI by inhibiting apoptosis and inflammation and enhancing the autophagy via the mTOR/p70S6K signalling pathway.	Metformin	7-16	ribosomal protein S6 kinase B1	Homo sapiens	114-120
27632912-8	2016	Similarly, apple extract-induced phosphorylation of the mTOR/p70S6K/S6RP/eIF4B/eIF4E pathway was blocked by pretreatment with PD98059, a specific ERK inhibitor.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	126-133	ribosomal protein S6 kinase B1	Homo sapiens	61-67
27163752-5	2016	Intraplantar injection of 5% formalin was associated with significant activation of mTOR, as well as p70 ribosomal S6 protein (p70S6K), its downstream effector, in the rACC.	Formaldehyde	29-37	ribosomal protein S6 kinase B1	Homo sapiens	127-133
27365393-4	2016	Here, we identified Ser(36) as the major p70S6k phosphorylation site, along with a low frequency site at Thr(40), using an in vitro phosphorylation assay combined with mass spectrometry.	Serine	20-23	ribosomal protein S6 kinase B1	Homo sapiens	41-47
27553905-6	2016	Moreover, sulforaphane treatment significantly attenuated rotenone-inhibited mTOR-mediated p70S6K and 4E-BP1 signalling pathway, as well as neuronal apoptosis.	sulforaphane	10-22	ribosomal protein S6 kinase B1	Homo sapiens	91-97
27553905-6	2016	Moreover, sulforaphane treatment significantly attenuated rotenone-inhibited mTOR-mediated p70S6K and 4E-BP1 signalling pathway, as well as neuronal apoptosis.	Rotenone	58-66	ribosomal protein S6 kinase B1	Homo sapiens	91-97
27291151-3	2016	We showed that GDC-0349 inhibited proliferation of established and primary human HNSCC cells bearing high-level of p-AKT/p-S6K.	GDC-0349	15-23	ribosomal protein S6 kinase B1	Homo sapiens	121-126
27491285-8	2016	S6K1 inhibitor PF-4708671 was particularly effective for reducing migration and proliferation of PC3 cell line.	PF-4708671	15-25	ribosomal protein S6 kinase B1	Homo sapiens	0-4
27235588-0	2016	IL-2, IL-4, IFN-gamma or TNF-alpha enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells.	baff	44-48	ribosomal protein S6 kinase B1	Homo sapiens	113-117
27235588-5	2016	These findings indicate that IL-2, IL-4, IFN-gamma or TNF-alpha enhances BAFF-stimulated cell viability/survival by activating Erk1/2 and S6K1 signaling in neoplastic B-lymphoid cells.	baff	73-77	ribosomal protein S6 kinase B1	Homo sapiens	138-142
27235588-6	2016	Our data suggest that modulation of IL-2, IL-4, IFN-gamma and/or TNF-alpha levels, or inhibitors of Erk1/2 or S6K1 may be a new approach to prevent BAFF-induced aggressive B-cell malignancies.	baff	148-152	ribosomal protein S6 kinase B1	Homo sapiens	110-114
27295130-3	2016	Western blotting and immunofluorescence revealed that zinc exhibited insulin-like glucose transporting effects by activating key markers that are involved in the insulin signaling cascade (including Akt, GLUT4 and GSK3beta), and downregulating members of the insulin signaling feedback cascade such as mammalian target of rapamycin (mTOR) and ribosomal protein S6 kinase (S6K1).	Glucose	82-89	ribosomal protein S6 kinase B1	Homo sapiens	372-376
26143260-8	2016	Inhibition of S6K by a specific chemical inhibitor, PF-4708671 inhibited dopaminergic neuronal differentiation of hNSCs.	pyrazofurin	52-54	ribosomal protein S6 kinase B1	Homo sapiens	14-17
26305116-10	2016	Metformin at 50 mM significantly reduced the phosphorylation of mTOR and p70S6K, by 49.0 and 62.1%, respectively.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	73-79
26994515-7	2016	Within 30 min after treatment with 20 muM naringenin, the abundance of phosphorylated EKR1/2, P70S6K, P90RSK and S6K proteins increased, and then returned to basal levels by 120 min whereas the abundance of AKT increased gradually to 120 min post-treatment.	naringenin	42-52	ribosomal protein S6 kinase B1	Homo sapiens	94-100
26994515-7	2016	Within 30 min after treatment with 20 muM naringenin, the abundance of phosphorylated EKR1/2, P70S6K, P90RSK and S6K proteins increased, and then returned to basal levels by 120 min whereas the abundance of AKT increased gradually to 120 min post-treatment.	naringenin	42-52	ribosomal protein S6 kinase B1	Homo sapiens	97-100
26994515-8	2016	However, the phosphorylation of AKT, P70S6K, P90RSK and S6K was reduced in naringenin-induced pTr cells pre-treated with a PI3K inhibitor (LY294002).	naringenin	75-85	ribosomal protein S6 kinase B1	Homo sapiens	37-43
26994515-8	2016	However, the phosphorylation of AKT, P70S6K, P90RSK and S6K was reduced in naringenin-induced pTr cells pre-treated with a PI3K inhibitor (LY294002).	naringenin	75-85	ribosomal protein S6 kinase B1	Homo sapiens	40-43
26994515-8	2016	However, the phosphorylation of AKT, P70S6K, P90RSK and S6K was reduced in naringenin-induced pTr cells pre-treated with a PI3K inhibitor (LY294002).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	139-147	ribosomal protein S6 kinase B1	Homo sapiens	37-43
26994515-8	2016	However, the phosphorylation of AKT, P70S6K, P90RSK and S6K was reduced in naringenin-induced pTr cells pre-treated with a PI3K inhibitor (LY294002).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	139-147	ribosomal protein S6 kinase B1	Homo sapiens	40-43
26994515-9	2016	Also, a MEK1/2 inhibitor (U0126) significantly decreased naringenin-induced phosphorylation of ERK1/2, P70S6K and S6K proteins in pTr cells.	U 0126	26-31	ribosomal protein S6 kinase B1	Homo sapiens	103-109
26994515-9	2016	Also, a MEK1/2 inhibitor (U0126) significantly decreased naringenin-induced phosphorylation of ERK1/2, P70S6K and S6K proteins in pTr cells.	U 0126	26-31	ribosomal protein S6 kinase B1	Homo sapiens	106-109
26994515-9	2016	Also, a MEK1/2 inhibitor (U0126) significantly decreased naringenin-induced phosphorylation of ERK1/2, P70S6K and S6K proteins in pTr cells.	naringenin	57-67	ribosomal protein S6 kinase B1	Homo sapiens	103-109
26994515-9	2016	Also, a MEK1/2 inhibitor (U0126) significantly decreased naringenin-induced phosphorylation of ERK1/2, P70S6K and S6K proteins in pTr cells.	naringenin	57-67	ribosomal protein S6 kinase B1	Homo sapiens	106-109
27227776-9	2016	The phosphorylation levels of mTOR and p70S6K were decreased by DEX treatment (P&lt;0.05).	Dexamethasone	64-67	ribosomal protein S6 kinase B1	Homo sapiens	39-45
27279570-7	2016	Rifaximin treatment also resulted in a concentration-dependent decrease in the phosphorylation of Akt, mTOR, p38MAPK and inhibition of hypoxia-inducible factor 1-alpha (HIF-1alpha), p70S6K and NF-kappaB.	Rifaximin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	182-188
27295130-6	2016	In conclusion, zinc might enhance glucose consumption by modulating insulin signaling pathways including Akt-GLUT4, GSK3beta, mTOR and S6K1.	Glucose	34-41	ribosomal protein S6 kinase B1	Homo sapiens	135-139
27277722-0	2016	Grifolin induces autophagic cell death by inhibiting the Akt/mTOR/S6K pathway in human ovarian cancer cells.	grifolin	0-8	ribosomal protein S6 kinase B1	Homo sapiens	66-69
27277722-11	2016	The present study indicated that grifolin could induce autophagic cell death in human ovarian cancer by inhibiting the Akt/mTOR/S6K pathway.	grifolin	33-41	ribosomal protein S6 kinase B1	Homo sapiens	128-131
27251440-0	2016	Quinones Derived from Polychlorinated Biphenyls Induce ROS-Dependent Autophagy by Evoking an Autophagic Flux and Inhibition of mTOR/p70S6k.	Quinones	0-8	ribosomal protein S6 kinase B1	Homo sapiens	132-138
27251440-0	2016	Quinones Derived from Polychlorinated Biphenyls Induce ROS-Dependent Autophagy by Evoking an Autophagic Flux and Inhibition of mTOR/p70S6k.	Polychlorinated Biphenyls	22-47	ribosomal protein S6 kinase B1	Homo sapiens	132-138
27251440-0	2016	Quinones Derived from Polychlorinated Biphenyls Induce ROS-Dependent Autophagy by Evoking an Autophagic Flux and Inhibition of mTOR/p70S6k.	ros	55-58	ribosomal protein S6 kinase B1	Homo sapiens	132-138
27251440-3	2016	In the present study, we found that an active, quinone-type PCB metabolite (PCB29-pQ) treatment causes an autophagic response through mTOR/p70S6k inhibition in HepG2 and MDA-MB-231 cells.	quinone	47-54	ribosomal protein S6 kinase B1	Homo sapiens	139-145
27251440-3	2016	In the present study, we found that an active, quinone-type PCB metabolite (PCB29-pQ) treatment causes an autophagic response through mTOR/p70S6k inhibition in HepG2 and MDA-MB-231 cells.	Polychlorinated Biphenyls	60-63	ribosomal protein S6 kinase B1	Homo sapiens	139-145
27251440-3	2016	In the present study, we found that an active, quinone-type PCB metabolite (PCB29-pQ) treatment causes an autophagic response through mTOR/p70S6k inhibition in HepG2 and MDA-MB-231 cells.	2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	76-84	ribosomal protein S6 kinase B1	Homo sapiens	139-145
27006450-5	2016	Aldosterone (10(-9) to 10(-7) M) increased Akt/mTOR/Raptor to activate p70S6K and increase proliferation, viability, and apoptosis resistance in PASMCs.	Aldosterone	0-11	ribosomal protein S6 kinase B1	Homo sapiens	71-77
27191261-3	2016	p70 S6 kinase (p70S6K), which is a downstream effector of phosphatidylinositol 3-kinase/Akt, is frequently constitutively active in ovarian carcinoma.	Phosphatidylinositols	58-78	ribosomal protein S6 kinase B1	Homo sapiens	0-13
27191261-3	2016	p70 S6 kinase (p70S6K), which is a downstream effector of phosphatidylinositol 3-kinase/Akt, is frequently constitutively active in ovarian carcinoma.	Phosphatidylinositols	58-78	ribosomal protein S6 kinase B1	Homo sapiens	15-21
27053525-7	2016	Following 90 min of recovery the activity of S6 kinase 1 (S6K1) was greater than at rest in all four trials (Placebo&lt;Leucine&lt;BCAA&lt;EAA; P &lt; 0.05 time x supplement), with a ninefold increase in the EAA trial.	Amino Acids, Essential	139-142	ribosomal protein S6 kinase B1	Homo sapiens	45-56
27053525-7	2016	Following 90 min of recovery the activity of S6 kinase 1 (S6K1) was greater than at rest in all four trials (Placebo&lt;Leucine&lt;BCAA&lt;EAA; P &lt; 0.05 time x supplement), with a ninefold increase in the EAA trial.	Amino Acids, Essential	139-142	ribosomal protein S6 kinase B1	Homo sapiens	58-62
27243769-7	2016	Meanwhile, Stel B inhibited the expression of PI3K-p110, and the phosphorylation of PDK1, Akt, mTOR, p70S6K as well as GSK-3beta, suggesting the correlation of blocking PI3K/Akt/mTOR pathway with the above antitumor activities.	stellettin B	11-17	ribosomal protein S6 kinase B1	Homo sapiens	101-107
27105488-4	2016	We found that sorafenib downregulated AIB1 protein expression by inhibiting AIB1 mRNA translation through simultaneously blocking eIF4E and mTOR/p70S6K/RP-S6 signaling.	Sorafenib	14-23	ribosomal protein S6 kinase B1	Homo sapiens	145-151
27144582-6	2016	The results show that both 8 weeks of leucine supplementation and aerobic training elevated the activity of mTOR (mammalian target of rapamycin) and its downstream target p70S6K and 4E-BP1, inhibited the ubiquitin-proteasome system, and increased fiber cross-sectional area (CSA) in white gastrocnemius muscle.	Leucine	38-45	ribosomal protein S6 kinase B1	Homo sapiens	171-188
27133039-1	2016	Focal adhesion kinase (FAK) and human p70 ribosomal S6 kinase (S6K1) are non-receptor protein tyrosine plays a vital role in cell signaling pathways, such as cell proliferation, survival, and migration.	Tyrosine	94-102	ribosomal protein S6 kinase B1	Homo sapiens	63-67
26355638-6	2016	CONCLUSION: RT attenuated DEX-induced muscle atrophy through a combination of increases in mTOR and p70S6K protein levels and a low increase in MuRF-1 protein level.	Dexamethasone	26-29	ribosomal protein S6 kinase B1	Homo sapiens	100-106
26669511-10	2016	Collectively, these findings establish a clear relationship between cation-selective transporter expression, the AMPK-mTOR-pS6K signaling cascade, and the antiproliferative activity of metformin in breast cancer.	Metformin	185-194	ribosomal protein S6 kinase B1	Homo sapiens	123-127
26984670-0	2016	5-Caffeoylquinic acid inhibits invasion of non-small cell lung cancer cells through the inactivation of p70S6K and Akt activity: Involvement of p53 in differential regulation of signaling pathways.	5'-O-caffeoylquinic acid	0-21	ribosomal protein S6 kinase B1	Homo sapiens	104-110
26984670-4	2016	Anti-invasive activity of 5-CQA in A549 cells was mediated by the inactivation of p70(S6K)-dependent signaling pathway.	Chlorogenic Acid	26-31	ribosomal protein S6 kinase B1	Homo sapiens	82-85
27098396-0	2016	AKT/TSC2/p70S6K signaling pathway is involved in quinocetone-induced death-promoting autophagy in HepG2 cells.	quinocetone	49-60	ribosomal protein S6 kinase B1	Homo sapiens	9-15
30123617-11	2016	Moreover, we demonstrated that rasfonin inhibited the phosphorylation of both 4E-binding protein 1 (4E-BP1) and S6 kinase 1 (S6K1), two main substrates of mammalian target of rapamycin (mTOR).	rasfonin	31-39	ribosomal protein S6 kinase B1	Homo sapiens	112-123
30123617-11	2016	Moreover, we demonstrated that rasfonin inhibited the phosphorylation of both 4E-binding protein 1 (4E-BP1) and S6 kinase 1 (S6K1), two main substrates of mammalian target of rapamycin (mTOR).	rasfonin	31-39	ribosomal protein S6 kinase B1	Homo sapiens	125-129
26724922-2	2016	To reveal the critical structures of leucine molecule to activate mTORC1, we examined the structure-activity relationships of leucine derivatives in HeLa S3 cells for cellular uptake and for the induction of phosphorylation of p70 ribosomal S6 kinase 1 (p70S6K), a downstream effector of mTORC1.	Leucine	37-44	ribosomal protein S6 kinase B1	Homo sapiens	227-252
27070592-5	2016	In addition, suppression of mTOR activity by rapamycin decreased the level of activity of p70S6K, induced upregulation of p53 and caspase 3, and led to increase of apoptosis in K562R(IMT) cells.	Sirolimus	45-54	ribosomal protein S6 kinase B1	Homo sapiens	90-96
26724922-2	2016	To reveal the critical structures of leucine molecule to activate mTORC1, we examined the structure-activity relationships of leucine derivatives in HeLa S3 cells for cellular uptake and for the induction of phosphorylation of p70 ribosomal S6 kinase 1 (p70S6K), a downstream effector of mTORC1.	Leucine	37-44	ribosomal protein S6 kinase B1	Homo sapiens	254-260
26724922-2	2016	To reveal the critical structures of leucine molecule to activate mTORC1, we examined the structure-activity relationships of leucine derivatives in HeLa S3 cells for cellular uptake and for the induction of phosphorylation of p70 ribosomal S6 kinase 1 (p70S6K), a downstream effector of mTORC1.	Leucine	126-133	ribosomal protein S6 kinase B1	Homo sapiens	227-252
26995153-10	2016	Crucially, strong inhibition has been shown with lithium via the proteic scaffold PP2A/beta-arrestin/AKT, and with the rapid antidepressant effect of ketamine via p70S6K.	Ketamine	150-158	ribosomal protein S6 kinase B1	Homo sapiens	163-169
26948085-8	2016	Moreover, hyperoside dose-dependently inhibited the phosphorylation of Akt, mTOR, p70S6K and 4E-BP1, but increased the phosphorylation of ERK1/2 in A549 cells.	hyperoside	10-20	ribosomal protein S6 kinase B1	Homo sapiens	82-99
26948085-12	2016	The autophagy is induced through inhibiting the Akt/mTOR/p70S6K signal pathways, which contributes to anticancer actions of hyperoside.	hyperoside	124-134	ribosomal protein S6 kinase B1	Homo sapiens	57-63
27279985-0	2016	Quinazoline derivative compound (11d) as a novel angiogenesis inhibitor inhibiting VEGFR2 and blocking VEGFR2-mediated Akt/mTOR /p70s6k signaling pathway.	Quinazolines	0-11	ribosomal protein S6 kinase B1	Homo sapiens	129-135
26400569-6	2016	Nephrin per se was sufficient to induce phosphorylation of p70S6K in an phosphatidylinositol 3-kinase-dependent but IR/Src-independent manner, which was not augmented by exogenous insulin.	Phosphatidylinositols	72-92	ribosomal protein S6 kinase B1	Homo sapiens	59-65
27279985-7	2016	CONCLUSION: The mechanism underlying the anti-angiogenic activity of the quinazoline derivative 11d: possibly involves the inhibition of VEGFR2 and the downregulation of VEGF, VEGFR2, and the VEGFR2-mediated Akt/mTOR/p70s6k signaling pathway.	Quinazolines	73-84	ribosomal protein S6 kinase B1	Homo sapiens	217-223
27136013-0	2016	L-Glutamate deficiency can trigger proliferation inhibition via down regulation of the mTOR/S6K1 pathway in pig intestinal epithelial cells.	Glutamic Acid	0-11	ribosomal protein S6 kinase B1	Homo sapiens	92-96
26910280-6	2016	Bakuchiol also inhibited EGF-induced signaling pathways downstream of Hck, Blk and p38 MAPK, including the MEK/ERKs, p38 MAPK/MSK1 and AKT/p70S6K pathways.	bakuchiol	0-9	ribosomal protein S6 kinase B1	Homo sapiens	139-145
26740621-5	2016	In contrast, rapamycin preferentially inhibits the phosphorylation of p70(S6k) and blocks 35% of translation.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	74-77
26629768-12	2016	Finally, sorafenib induced programmed cell death by attenuation and activation of Akt/mTOR/p70S6K and JNK signaling.	Sorafenib	9-18	ribosomal protein S6 kinase B1	Homo sapiens	91-97
27135362-8	2016	These hypotheses were tested in vivo; as a proof-of-principle, we demonstrated that metformin inhibits the p70S6K-rpS6 axis in a PP2A-phosphatase dependent manner.	Metformin	84-93	ribosomal protein S6 kinase B1	Homo sapiens	107-113
26898122-10	2016	Moreover, MGO induces p38-dependent COX-2 protein expression as well as the phosphorylations of extracellular signal-regulated kinase, c-Jun N-terminal kinase (JNK), and Akt/mammalian target of rapamycin (mTOR)/p70S6K; however, inhibition of JNK and Akt/mTOR/p70S6K phosphorylations further activates COX-2 protein expression.	Pyruvaldehyde	10-13	ribosomal protein S6 kinase B1	Homo sapiens	211-217
26898122-10	2016	Moreover, MGO induces p38-dependent COX-2 protein expression as well as the phosphorylations of extracellular signal-regulated kinase, c-Jun N-terminal kinase (JNK), and Akt/mammalian target of rapamycin (mTOR)/p70S6K; however, inhibition of JNK and Akt/mTOR/p70S6K phosphorylations further activates COX-2 protein expression.	Pyruvaldehyde	10-13	ribosomal protein S6 kinase B1	Homo sapiens	259-265
26915414-6	2016	Ingenuity Pathway Analysis(TM) (IPA) suggested that curcumin may exert its anticancer effects over multiple critical biological pathways including the EIF2, eIF4/p70S6K, mTOR signaling and mitochondrial dysfunction pathways.	Curcumin	52-60	ribosomal protein S6 kinase B1	Homo sapiens	162-168
26704080-6	2016	Phosphorylation of downstream targets of PI3K (AKT and p70S6K) and MAPKs (ERK1/2 and JNK) signaling was suppressed by treatment of ES2 cells with delphinidin.	delphinidin	146-157	ribosomal protein S6 kinase B1	Homo sapiens	55-61
26757927-0	2016	Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition.	evodiamine	0-10	ribosomal protein S6 kinase B1	Homo sapiens	107-111
26698565-5	2016	Phosphorylation of AKT, p70S6K, ERK1/2, JNK1/2, and p90RSK was inactivated by coumestrol treatment in a dose- and time-dependent manner as determined in western blot analyses.	Coumestrol	78-88	ribosomal protein S6 kinase B1	Homo sapiens	24-30
26698565-6	2016	Moreover, PI3K inhibitors enhanced effects of coumestrol to decrease phosphorylation of AKT, p70S6K, S6, and ERK1/2.	Coumestrol	46-56	ribosomal protein S6 kinase B1	Homo sapiens	93-99
26565813-7	2016	Concordantly, simvastatin strongly suppressed PI3K/Akt/mTOR pathway by enhancing PTEN expression and by further sequentially dephosphorylating downstream cascades including Akt, mTOR, p70S6K, S6RP and 4E-BP1.	Simvastatin	14-25	ribosomal protein S6 kinase B1	Homo sapiens	184-190
26566903-6	2016	Specific inhibition of the S6K with the small molecule inhibitor LY-2584702 decreased TGF-alpha and platelet-derived growth factor-beta-induced proliferation of lung fibroblasts in vitro.	LY2584702	65-75	ribosomal protein S6 kinase B1	Homo sapiens	27-30
26566903-7	2016	Administration of S6K inhibitors to TGF-alpha mice prevented the development of extensive subpleural fibrosis and alterations in lung mechanics, and attenuated the increase in total lung hydroxyproline.	Hydroxyproline	187-201	ribosomal protein S6 kinase B1	Homo sapiens	18-21
26771549-0	2016	The p70S6K Specific Inhibitor PF-4708671 Impedes Non-Small Cell Lung Cancer Growth.	PF-4708671	30-40	ribosomal protein S6 kinase B1	Homo sapiens	4-10
26506538-6	2016	The increasing of p-Akt-T308, p-Akt-S473, p-S6K1, p-S6, and p-4E-BP1 since 1h MC-LR exposure indicated that Akt/S6K1 cascade had been activated as early as 1h MC-LR treatment.	Hydrogen	75-77	ribosomal protein S6 kinase B1	Homo sapiens	112-116
26506538-6	2016	The increasing of p-Akt-T308, p-Akt-S473, p-S6K1, p-S6, and p-4E-BP1 since 1h MC-LR exposure indicated that Akt/S6K1 cascade had been activated as early as 1h MC-LR treatment.	cyanoginosin LR	78-83	ribosomal protein S6 kinase B1	Homo sapiens	44-48
26506538-6	2016	The increasing of p-Akt-T308, p-Akt-S473, p-S6K1, p-S6, and p-4E-BP1 since 1h MC-LR exposure indicated that Akt/S6K1 cascade had been activated as early as 1h MC-LR treatment.	cyanoginosin LR	78-83	ribosomal protein S6 kinase B1	Homo sapiens	112-116
26506538-6	2016	The increasing of p-Akt-T308, p-Akt-S473, p-S6K1, p-S6, and p-4E-BP1 since 1h MC-LR exposure indicated that Akt/S6K1 cascade had been activated as early as 1h MC-LR treatment.	Hydrogen	156-158	ribosomal protein S6 kinase B1	Homo sapiens	112-116
26506538-6	2016	The increasing of p-Akt-T308, p-Akt-S473, p-S6K1, p-S6, and p-4E-BP1 since 1h MC-LR exposure indicated that Akt/S6K1 cascade had been activated as early as 1h MC-LR treatment.	cyanoginosin LR	159-164	ribosomal protein S6 kinase B1	Homo sapiens	112-116
26506538-7	2016	And, PI3K/Akt inhibitor (LY294002) blocked MC-LR-induced Akt/S6K1 activation and proliferation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	25-33	ribosomal protein S6 kinase B1	Homo sapiens	61-65
26506538-7	2016	And, PI3K/Akt inhibitor (LY294002) blocked MC-LR-induced Akt/S6K1 activation and proliferation.	cyanoginosin LR	43-48	ribosomal protein S6 kinase B1	Homo sapiens	61-65
26506538-9	2016	Our study indicated that MC-LR exposure promoted HL7702 cell proliferation and the main mechanism was the activation of Akt/S6K1 cascade.	cyanoginosin LR	25-30	ribosomal protein S6 kinase B1	Homo sapiens	124-128
27997894-12	2016	CONCLUSION: Zedoarondiol inhibits PDGF-BB-induced VSMCs proliferation via AMPK-mediated down-regulation of the mTOR/p70S6K pathway and up-regulation of the p53/p21 pathway.	zedoarondiol	12-24	ribosomal protein S6 kinase B1	Homo sapiens	116-122
26643070-0	2016	Pioglitazone, a PPARgamma agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.	Pioglitazone	0-12	ribosomal protein S6 kinase B1	Homo sapiens	164-170
26643070-6	2016	In particular, PIO at 30muM concentration activates AMPK to induce raptor phosphorylation, which diminishes PDGF-induced mTOR activity as evidenced by decreased phosphorylation of p70S6K, 4E-BP1, and S6 and increased accumulation of p27(kip1), a cell cycle inhibitor.	Pioglitazone	15-18	ribosomal protein S6 kinase B1	Homo sapiens	180-186
26757927-5	2016	Further investigation of the mechanism underlying these effects revealed that evodiamine plus erlotinib might downregulate Mcl-1 expression through the mTOR/S6K1 control of its translation.	Erlotinib Hydrochloride	94-103	ribosomal protein S6 kinase B1	Homo sapiens	157-161
26573768-7	2016	Furthermore, curcumin suppressed the activation of AKT, mTOR and P70S6K proteins.	Curcumin	13-21	ribosomal protein S6 kinase B1	Homo sapiens	65-71
26657290-8	2016	Further mechanistic characterization with proteomic analysis revealed that auranofin inhibits expression and/or phosphorylation of multiple key nodes in the PI3K/AKT/mTOR pathway, including S6, 4EBP1, Rictor, p70S6K, mTOR, TSC2, AKT and GSK3.	Auranofin	75-84	ribosomal protein S6 kinase B1	Homo sapiens	209-215
26752047-6	2016	Western blotting showed that rapamycin inhibited mechanistic target of rapamycin (mTOR), p70s6k and IkappaBalpha phosphorylation triggered by ox-LDL.	Sirolimus	29-38	ribosomal protein S6 kinase B1	Homo sapiens	89-95
27997894-11	2016	In addition, zedoarondiol activated AMPK and ACC, inhibited the phosphorylation of mTOR and p70S6K, increased the expression of p53 and p21, and decreased the expression of CDK2 and cyclin E. Compound C (an AMPK inhibitor) abrogated, whereas 5-aminoimidazole-4-carboxamide 1-beta-ribofuranoside (AICAR, an AMPK activator) enhanced zedoarondiol-mediated inhibition of VSMCs proliferation and DNA synthesis.	zedoarondiol	13-25	ribosomal protein S6 kinase B1	Homo sapiens	92-98
27595116-0	2016	Downregulation of p70S6K Enhances Cell Sensitivity to Rapamycin in Esophageal Squamous Cell Carcinoma.	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	18-24
27595116-1	2016	It has been demonstrated that mTOR/p70S6K pathway was abnormally activated in many cancers and rapamycin and its analogs can restrain tumor growth through inhibiting this pathway, but some tumors including esophageal squamous cell carcinoma (ESCC) appear to be insensitive to rapamycin in recent studies.	Sirolimus	95-104	ribosomal protein S6 kinase B1	Homo sapiens	35-41
27595116-3	2016	The results showed that, after downregulating the expression of p70S6K and p-p70S6K by p70S6K siRNA, the inhibitory effects of rapamycin on cell proliferation, cell cycle, and tumor growth were significantly enhanced in vitro and in vivo.	Sirolimus	127-136	ribosomal protein S6 kinase B1	Homo sapiens	64-70
27595116-3	2016	The results showed that, after downregulating the expression of p70S6K and p-p70S6K by p70S6K siRNA, the inhibitory effects of rapamycin on cell proliferation, cell cycle, and tumor growth were significantly enhanced in vitro and in vivo.	Sirolimus	127-136	ribosomal protein S6 kinase B1	Homo sapiens	77-83
27595116-3	2016	The results showed that, after downregulating the expression of p70S6K and p-p70S6K by p70S6K siRNA, the inhibitory effects of rapamycin on cell proliferation, cell cycle, and tumor growth were significantly enhanced in vitro and in vivo.	Sirolimus	127-136	ribosomal protein S6 kinase B1	Homo sapiens	77-83
27595116-5	2016	These results indicated that p-p70S6K may participate in the invasion and metastasis in the development of ESCC and downregulation of the expression of p-p70S6K could improve the sensitivity of cells to rapamycin in ESCC.	Sirolimus	203-212	ribosomal protein S6 kinase B1	Homo sapiens	31-37
27595116-5	2016	These results indicated that p-p70S6K may participate in the invasion and metastasis in the development of ESCC and downregulation of the expression of p-p70S6K could improve the sensitivity of cells to rapamycin in ESCC.	Sirolimus	203-212	ribosomal protein S6 kinase B1	Homo sapiens	154-160
26943752-0	2016	Resveratrol Potentiates Growth Inhibitory Effects of Rapamycin in PTEN-deficient Lipoma Cells by Suppressing p70S6 Kinase Activity.	Resveratrol	0-11	ribosomal protein S6 kinase B1	Homo sapiens	109-121
26943752-5	2016	PTEN expression and AKT phosphorylation were not significantly changed, whereas p70S6 kinase (p70S6K) phosphorylation was reduced in PTEN-deficient lipoma cells after resveratrol incubation.	Resveratrol	167-178	ribosomal protein S6 kinase B1	Homo sapiens	80-92
26943752-5	2016	PTEN expression and AKT phosphorylation were not significantly changed, whereas p70S6 kinase (p70S6K) phosphorylation was reduced in PTEN-deficient lipoma cells after resveratrol incubation.	Resveratrol	167-178	ribosomal protein S6 kinase B1	Homo sapiens	94-100
26943752-6	2016	Rapamycin/resveratrol co-incubation significantly decreased viability further at lower doses of resveratrol and resulted in decreased p70S6K phosphorylation compared to rapamycin incubation alone, suggesting that resveratrol potentiated the growth inhibitory effects of rapamycin by reducing p70S6K activation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	134-140
26943752-6	2016	Rapamycin/resveratrol co-incubation significantly decreased viability further at lower doses of resveratrol and resulted in decreased p70S6K phosphorylation compared to rapamycin incubation alone, suggesting that resveratrol potentiated the growth inhibitory effects of rapamycin by reducing p70S6K activation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	292-298
26943752-6	2016	Rapamycin/resveratrol co-incubation significantly decreased viability further at lower doses of resveratrol and resulted in decreased p70S6K phosphorylation compared to rapamycin incubation alone, suggesting that resveratrol potentiated the growth inhibitory effects of rapamycin by reducing p70S6K activation.	Resveratrol	10-21	ribosomal protein S6 kinase B1	Homo sapiens	134-140
26943752-6	2016	Rapamycin/resveratrol co-incubation significantly decreased viability further at lower doses of resveratrol and resulted in decreased p70S6K phosphorylation compared to rapamycin incubation alone, suggesting that resveratrol potentiated the growth inhibitory effects of rapamycin by reducing p70S6K activation.	Resveratrol	10-21	ribosomal protein S6 kinase B1	Homo sapiens	292-298
26757927-0	2016	Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition.	Erlotinib Hydrochloride	63-72	ribosomal protein S6 kinase B1	Homo sapiens	107-111
26757927-5	2016	Further investigation of the mechanism underlying these effects revealed that evodiamine plus erlotinib might downregulate Mcl-1 expression through the mTOR/S6K1 control of its translation.	evodiamine	78-88	ribosomal protein S6 kinase B1	Homo sapiens	157-161
26523512-9	2015	mTOR/p70S6K protein expression levels were also markedly reduced by propofol but the effects were reversed with pcDNA-HOTAIR.	Propofol	68-76	ribosomal protein S6 kinase B1	Homo sapiens	5-11
26523512-11	2015	CONCLUSION: Propofol inhibited tumor size, cell viability and promoted cell apoptosis via inhibiting mTOR/p70S6K pathway mediated by HOTAIR in cervical cancer.	Propofol	12-20	ribosomal protein S6 kinase B1	Homo sapiens	106-112
26432159-0	2015	Roles of oxidative stress and the ERK1/2, PTEN and p70S6K signaling pathways in arsenite-induced autophagy.	arsenite	80-88	ribosomal protein S6 kinase B1	Homo sapiens	51-57
26565025-5	2015	Blocking TGF-beta receptor I with SB431542 completely blunted the phosphorylation of mTOR, p70S6K, and 4EBP1.	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	34-42	ribosomal protein S6 kinase B1	Homo sapiens	91-108
26432159-8	2015	The current study further showed that arsenite decreased phosphatase and tensin homologue (PTEN) levels and increased phospho-p70S6 kinase (p-p70S6K) in SV-HUC-1 cells.	arsenite	38-46	ribosomal protein S6 kinase B1	Homo sapiens	142-148
26432159-9	2015	However, both kinase inhibitor U0126 and the DNA (cytosine-5-)-methyltransferase 1 (DNMT1) inhibitor 5-aza-deoxycytidine abolished the effect of arsenite on expressions of PTEN and p-p70S6K.	U 0126	31-36	ribosomal protein S6 kinase B1	Homo sapiens	183-189
26432159-9	2015	However, both kinase inhibitor U0126 and the DNA (cytosine-5-)-methyltransferase 1 (DNMT1) inhibitor 5-aza-deoxycytidine abolished the effect of arsenite on expressions of PTEN and p-p70S6K.	Azacitidine	101-106	ribosomal protein S6 kinase B1	Homo sapiens	183-189
26432159-9	2015	However, both kinase inhibitor U0126 and the DNA (cytosine-5-)-methyltransferase 1 (DNMT1) inhibitor 5-aza-deoxycytidine abolished the effect of arsenite on expressions of PTEN and p-p70S6K.	Deoxycytidine	107-120	ribosomal protein S6 kinase B1	Homo sapiens	183-189
26432159-9	2015	However, both kinase inhibitor U0126 and the DNA (cytosine-5-)-methyltransferase 1 (DNMT1) inhibitor 5-aza-deoxycytidine abolished the effect of arsenite on expressions of PTEN and p-p70S6K.	arsenite	145-153	ribosomal protein S6 kinase B1	Homo sapiens	183-189
26432159-10	2015	These results show that autophagy induced by arsenite exposure is mediated by oxidative stress, which regulates activation of the PTEN, p70S6K and ERK1/2 signaling pathways.	arsenite	45-53	ribosomal protein S6 kinase B1	Homo sapiens	136-142
29767001-14	2015	Moreover, the expression of mTOR, S6K1 increased as the level of dietary leucine was elevated from 1.37 to 2.17%.	Leucine	73-80	ribosomal protein S6 kinase B1	Homo sapiens	34-38
26636335-9	2015	Vice versa, everolimus constantly decreased pp70S6K and combination treatment more strongly decreased pp70S6K than lovastatin alone, or attenuated lovastatin-induced p70S6K activation: in BON1 cells lovastatin-induced EGFR inhibition was least pronounced, possibly explaining the low efficacy and consequent absent additive effect.	Everolimus	12-22	ribosomal protein S6 kinase B1	Homo sapiens	45-51
26393424-0	2015	CCN1 acutely increases nitric oxide production via integrin alphavbeta3-Akt-S6K-phosphorylation of endothelial nitric oxide synthase at the serine 1177 signaling axis.	Nitric Oxide	23-35	ribosomal protein S6 kinase B1	Homo sapiens	76-79
26304716-6	2015	Finally, metformin-mediated AMPK/mTOR/p70S6K was identified as a possible upstream pathway controlling translational regulation of Wee1 and Rad51.	Metformin	9-18	ribosomal protein S6 kinase B1	Homo sapiens	38-44
26393424-0	2015	CCN1 acutely increases nitric oxide production via integrin alphavbeta3-Akt-S6K-phosphorylation of endothelial nitric oxide synthase at the serine 1177 signaling axis.	Serine	140-146	ribosomal protein S6 kinase B1	Homo sapiens	76-79
26393424-7	2015	Consistently, CCN1 increased the phosphorylation of Akt-Ser(473) and S6K-Thr(389).	Threonine	73-76	ribosomal protein S6 kinase B1	Homo sapiens	69-72
26393424-12	2015	In conclusion, CCN1 acutely increases NO production via activation of a signaling axis in integrin alphavbeta3-Akt-S6K-eNOS-Ser(1177) phosphorylation, suggesting an important role for CCN1 in vasodilation.	Serine	124-127	ribosomal protein S6 kinase B1	Homo sapiens	115-118
26884863-8	2015	The levels of p-S6K1 were significantly decreased by incubation with LY294002, but the effect could be reversed by E2 in combination with LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	69-77	ribosomal protein S6 kinase B1	Homo sapiens	16-20
26884863-8	2015	The levels of p-S6K1 were significantly decreased by incubation with LY294002, but the effect could be reversed by E2 in combination with LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	138-146	ribosomal protein S6 kinase B1	Homo sapiens	16-20
26344902-0	2015	Palmitate activates mTOR/p70S6K through AMPK inhibition and hypophosphorylation of raptor in skeletal muscle cells: Reversal by oleate is similar to metformin.	Palmitates	0-9	ribosomal protein S6 kinase B1	Homo sapiens	25-31
26887615-0	2015	[Sensitivity of esophageal squamous cell carcinoma cells to rapamycin can be improved by siRNA-interfered expression of p70S6K].	Sirolimus	60-69	ribosomal protein S6 kinase B1	Homo sapiens	120-126
26887615-7	2015	The results of tumor formation test in vivo showed that the inhibitory effect of rapamycin on tumor growth was stronger after the cells were transfected with p70S6K-siRNA, and the inhibition rate was 96.5%.	Sirolimus	81-90	ribosomal protein S6 kinase B1	Homo sapiens	158-164
26887615-8	2015	CONCLUSION: ESCC cells with different differentiation have different sensitivity to rapamycin, and p70S6K-siRNA can improve the sensitivity of cells to rapamycin in vitro and in vivo.	Sirolimus	152-161	ribosomal protein S6 kinase B1	Homo sapiens	99-105
26344902-9	2015	To understand this more, we show activation of AMPK by metformin also prevented palmitate-induced changes in the phosphorylations of raptor and p70S6K, confirming that the mTORC1/p70S6K signaling pathway is responsive to AMPK activity.	Metformin	55-64	ribosomal protein S6 kinase B1	Homo sapiens	144-150
26344902-9	2015	To understand this more, we show activation of AMPK by metformin also prevented palmitate-induced changes in the phosphorylations of raptor and p70S6K, confirming that the mTORC1/p70S6K signaling pathway is responsive to AMPK activity.	Metformin	55-64	ribosomal protein S6 kinase B1	Homo sapiens	179-185
26344902-6	2015	Palmitate decreased the phosphorylation of raptor and 4E-BP1 while increasing the phosphorylation of p70S6K.	Palmitates	0-9	ribosomal protein S6 kinase B1	Homo sapiens	101-107
26344902-9	2015	To understand this more, we show activation of AMPK by metformin also prevented palmitate-induced changes in the phosphorylations of raptor and p70S6K, confirming that the mTORC1/p70S6K signaling pathway is responsive to AMPK activity.	Palmitates	80-89	ribosomal protein S6 kinase B1	Homo sapiens	144-150
26362858-0	2015	Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	69-75
26344902-9	2015	To understand this more, we show activation of AMPK by metformin also prevented palmitate-induced changes in the phosphorylations of raptor and p70S6K, confirming that the mTORC1/p70S6K signaling pathway is responsive to AMPK activity.	Palmitates	80-89	ribosomal protein S6 kinase B1	Homo sapiens	179-185
26344902-12	2015	Our findings indicate that palmitate activates mTORC1/p70S6K signaling by AMPK inhibition and phosphorylation of raptor.	Palmitates	27-36	ribosomal protein S6 kinase B1	Homo sapiens	54-60
26342977-4	2015	Mammary abundance of phosphorylated S6K1 was measured as an indicator of mammalian target of rapamycin complex 1 (mTORC1) activity and was found not to be affected by the complete EAA mix but was increased by the mixture lacking Lys.	Lysine	229-232	ribosomal protein S6 kinase B1	Homo sapiens	36-40
26823699-0	2015	Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling.	Oleanolic Acid	0-14	ribosomal protein S6 kinase B1	Homo sapiens	80-83
26823699-5	2015	Furthermore, Akt, mTOR and S6K protein expression was greatly inhibited in T24 cells under oleanolic acid treatment.	Oleanolic Acid	91-105	ribosomal protein S6 kinase B1	Homo sapiens	27-30
26823699-7	2015	Taken together, we provided evidences that oleanolic acid was Akt/mTOR/S6K and ERK1/2 signaling-targeting anti-tumor agent.	Oleanolic Acid	43-57	ribosomal protein S6 kinase B1	Homo sapiens	71-74
26823699-8	2015	These findings represent new evidences that oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling, and oleanolic acid may be used to prevent human bladder cancer.	Oleanolic Acid	44-58	ribosomal protein S6 kinase B1	Homo sapiens	124-127
26381178-0	2015	PF-4708671, a specific inhibitor of p70 ribosomal S6 kinase 1, activates Nrf2 by promoting p62-dependent autophagic degradation of Keap1.	pyrazofurin	0-2	ribosomal protein S6 kinase B1	Homo sapiens	50-61
26381178-2	2015	PF-4708671 is a specific inhibitor of S6K1, and prevents S6K1-mediated phosphorylation of the S6 protein.	PF-4708671	0-10	ribosomal protein S6 kinase B1	Homo sapiens	38-42
26381178-2	2015	PF-4708671 is a specific inhibitor of S6K1, and prevents S6K1-mediated phosphorylation of the S6 protein.	PF-4708671	0-10	ribosomal protein S6 kinase B1	Homo sapiens	57-61
26213322-9	2015	Of importance, RT-PCR and Western blotting demonstrated that high glucose inhibited DNA-damage-inducible transcript 4 (DDIT4) and TSC1/TSC2, up-regulated Rheb/mTOR/p70S6K and enhanced expression of the apoptosis regulating proteins, such as phospho-Bcl-2, cytochrome C and cleaved caspase.	Glucose	66-73	ribosomal protein S6 kinase B1	Homo sapiens	164-170
26188279-11	2015	Inhibition of mTOR (p70S6K) signaling with the combination of TMZ and NVP-BEZ235 can be augmented beyond that achieved using each agent individually.	dactolisib	74-80	ribosomal protein S6 kinase B1	Homo sapiens	20-26
26208432-7	2015	We observed induction of the key mTOR downstream targets S6K1, S6RP and 4E-BP1 in-patient derived CSCs by tamoxifen on protein level.	Tamoxifen	106-115	ribosomal protein S6 kinase B1	Homo sapiens	57-78
26169935-5	2015	Leucine alone stimulated ribosomal protein s6 kinase 1 (S6K1) phosphorylation ~280% more than placebo and EAA-Leu after exercise.	Leucine	0-7	ribosomal protein S6 kinase B1	Homo sapiens	56-60
26282490-10	2015	These results show that DHTS inhibited HIF-1alpha protein synthesis by downregulating the mTOR/p70S6K/4E-BP1 and MEK/ERK pathways.	dhts	24-28	ribosomal protein S6 kinase B1	Homo sapiens	95-101
26664784-7	2015	This phenotype is not due to modifications in the activity of the phosphoinositide 3 kinase (PI3K)-Akt pathway, but to reduced phosphorylation of the S6K residues Ser(411) and Thr(389).	Serine	163-166	ribosomal protein S6 kinase B1	Homo sapiens	150-153
26243309-4	2015	Aschantin inhibited epidermal growth factor (EGF)-induced full activation of Akt by phosphorylation at Ser473/Thr308, resulting in inhibition of the mTORC2/Akt and Akt/mTORC1/p70S6K signaling pathways and activation of GSK3beta by abrogation of Akt-mediated GSK3beta phosphorylation at Ser9.	aschantin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	175-181
26169935-7	2015	Kinase activity of S6K1 reflected that of S6K1 phosphorylation; 60 min after exercise, the activity was elevated 3.3- and 4.2-fold with intake of leucine alone and with EAAs, respectively (P &lt; 0.05).	Leucine	146-153	ribosomal protein S6 kinase B1	Homo sapiens	19-23
26722438-0	2015	Berberine regulates proliferation, collagen synthesis and cytokine secretion of cardiac fibroblasts via AMPK-mTOR-p70S6K signaling pathway.	Berberine	0-9	ribosomal protein S6 kinase B1	Homo sapiens	114-120
26255117-7	2015	Exposure to beta-glucans increased apoptosis, necrosis, oxidative stress, mRNA expression of p53, p27 and Bax; the activity of AMP-activated protein-kinase, Forkhead transcription factor FOXO3a, Bax and caspase-3; and decreased the activity of p70S6K in MCF-7 cells.	beta-Glucans	12-24	ribosomal protein S6 kinase B1	Homo sapiens	244-250
26722438-9	2015	Mechanistically, the phosphorylation level of AMPK was increased; and the phosphorylation levels of mTOR and p70S6K were decreased in berberine treatment group.	Berberine	134-143	ribosomal protein S6 kinase B1	Homo sapiens	109-115
26722438-10	2015	CONCLUSION: These results illustrated that the protective effects of berberine on cellular behaviors of cardiac fibroblasts were at least in part due to activate AMPK signaling pathway and downregulate mTOR/p70S6K signaling pathway.	Berberine	69-78	ribosomal protein S6 kinase B1	Homo sapiens	207-213
26251974-4	2015	Furthermore, the inhibition of Akt or mTOR with an antagonist (wortmannin or rapamycin) suppressed the stretch-induced increase in glucose consumption, lactate levels, intracellular ATP levels and the expression of mitochondrial ATP synthase and LDHA, indicating the significance of the Akt/mTOR/p70s6k pathway in regulating osteoblastic energy metabolism in response to mechanical stretch.	Wortmannin	63-73	ribosomal protein S6 kinase B1	Homo sapiens	296-302
26251974-4	2015	Furthermore, the inhibition of Akt or mTOR with an antagonist (wortmannin or rapamycin) suppressed the stretch-induced increase in glucose consumption, lactate levels, intracellular ATP levels and the expression of mitochondrial ATP synthase and LDHA, indicating the significance of the Akt/mTOR/p70s6k pathway in regulating osteoblastic energy metabolism in response to mechanical stretch.	Sirolimus	77-86	ribosomal protein S6 kinase B1	Homo sapiens	296-302
26251974-5	2015	Thus, we concluded that cyclic stretch regulates energy metabolism in MG-63 cells partially through the Akt/mTOR/p70s6k signaling pathway.	Magnesium	70-72	ribosomal protein S6 kinase B1	Homo sapiens	113-119
26294741-7	2015	Analysis using a phospho-kinase array revealed that AZD4547 blocks FGFR2 downstream signaling, such as p38, ERK1/2, JNK, p70S6K, and PLCgamma.	AZD4547	52-59	ribosomal protein S6 kinase B1	Homo sapiens	121-127
26046470-8	2015	Reduced intracellular sirolimus concentration was followed by increased p70S6k phosphorylation suggesting preservation of the mTOR-signaling pathway.	Sirolimus	22-31	ribosomal protein S6 kinase B1	Homo sapiens	72-78
26391180-0	2015	Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	130-136
26329846-6	2015	SC06 also suppressed the phosphorylation of 4E-BP1 and P70S6K, two typical substrates in the mTORC1 signaling pathway.	sc06	0-4	ribosomal protein S6 kinase B1	Homo sapiens	55-61
26313261-5	2015	In time-course experiments, 8-chloroadenosine treatment rapidly activated AMPK, measured by AMPK and ACC phosphorylation, and subsequently caused dephosphorylation of p70S6K and ribosomal protein RPS6 in the sensitive cell lines.	8-chloroadenosine	28-45	ribosomal protein S6 kinase B1	Homo sapiens	167-173
25889895-14	2015	We thus conclude that SL0101 and BI-D1870 induce distinct off-target effects in mTORC1-p70S6K signaling, and thus, the functions previously ascribed to RSK based on these inhibitors should be reassessed.	SL0101	22-28	ribosomal protein S6 kinase B1	Homo sapiens	87-93
25889895-14	2015	We thus conclude that SL0101 and BI-D1870 induce distinct off-target effects in mTORC1-p70S6K signaling, and thus, the functions previously ascribed to RSK based on these inhibitors should be reassessed.	BI D1870	33-41	ribosomal protein S6 kinase B1	Homo sapiens	87-93
25449851-3	2015	We explore these reports and the possibility that activation of the mTOR/p70S6K kinase pathway may represent a ROS-mediated response to mitochondrial stress leading to the activation of senescence.	ros	111-114	ribosomal protein S6 kinase B1	Homo sapiens	73-79
26367731-9	2015	p-mTOR, p-p70S6K and p-4E-BP1 were expressed in the cytoplasm of SW1990 cells and those proteins were significantly reduced with rapamycin (p &lt; 0.05).	Sirolimus	129-138	ribosomal protein S6 kinase B1	Homo sapiens	10-16
26002629-5	2015	Coincidently, rapamycin markedly blocked Cd-induced phosphorylation of Akt, S6K1 and 4E-BP1 in the cells.	Sirolimus	14-23	ribosomal protein S6 kinase B1	Homo sapiens	76-91
26002629-5	2015	Coincidently, rapamycin markedly blocked Cd-induced phosphorylation of Akt, S6K1 and 4E-BP1 in the cells.	Cadmium	41-43	ribosomal protein S6 kinase B1	Homo sapiens	76-91
26002629-8	2015	Furthermore, downregulation of S6K1, ectopic expression of constitutively hypophosphorylated 4E-BP1 or dominant negative Akt, or co-treatment with Akt inhibitor also potentiated the rapamycin"s inhibitory effect.	Sirolimus	182-191	ribosomal protein S6 kinase B1	Homo sapiens	31-35
26068063-8	2015	Autophagy signaling molecules AMPK, TSC2 and ULK1 were inactivated while those of mTOR and p70s6K were activated by l-NAME, the effects of which were ablated by metallothionein.	NG-Nitroarginine Methyl Ester	116-122	ribosomal protein S6 kinase B1	Homo sapiens	91-97
26105008-9	2015	Whereas p-mTOR was not significantly decreased by NAC after EX or REC, phosphorylation of the downstream protein synthesis target kinase p70S6K was blunted by 48% at PI with NAC compared with CON (P &lt; 0.05).	Acetylcysteine	174-177	ribosomal protein S6 kinase B1	Homo sapiens	137-143
26105008-11	2015	ROS also played a role in normal p70S6K phosphorylation in response to insulin stimulation in human skeletal muscle.	Reactive Oxygen Species	0-3	ribosomal protein S6 kinase B1	Homo sapiens	33-39
25971373-5	2015	Phosphorylation of p70S6K at threonine 389 and AMPK at threonine 172 of the catalytic alpha subunit were concomitantly increased by mechanical stretch.	Threonine	29-38	ribosomal protein S6 kinase B1	Homo sapiens	19-25
25971373-5	2015	Phosphorylation of p70S6K at threonine 389 and AMPK at threonine 172 of the catalytic alpha subunit were concomitantly increased by mechanical stretch.	Threonine	55-64	ribosomal protein S6 kinase B1	Homo sapiens	19-25
25971373-6	2015	Stimulation of the mTOR pathway by adding leucine and insulin increased the phosphorylation of p70S6K without inactivation of AMPK.	Leucine	42-49	ribosomal protein S6 kinase B1	Homo sapiens	95-101
25971373-8	2015	Activation of AMPK by the addition of 5-amino-4-imidazolecarboxamide ribonucleoside reduced the phosphorylation of p70S6K in response to mechanical stretch.	5-amino-4-imidazolecarboxamide ribonucleoside	38-83	ribosomal protein S6 kinase B1	Homo sapiens	115-121
25977334-0	2015	Secalonic Acid-D Represses HIF1alpha/VEGF-Mediated Angiogenesis by Regulating the Akt/mTOR/p70S6K Signaling Cascade.	secalonic acid	0-14	ribosomal protein S6 kinase B1	Homo sapiens	91-97
25964188-10	2015	Moreover, addition of extracellular ATP to the cell culture media could reverse SC-III3-caused activation of AMPK-TSC2-mTOR-p70s6k pathway, autophagy and cell viability decrease in HepG2 cells.	Adenosine Triphosphate	36-39	ribosomal protein S6 kinase B1	Homo sapiens	124-130
26148118-6	2015	A significant correlation (p = 0.005) was found between everolimus IC50 values and p70S6K phosphorylation, but not with AKT or ERK phosphorylation, consistent with the mTOR pathway being a principal target.	Everolimus	56-66	ribosomal protein S6 kinase B1	Homo sapiens	83-89
25939952-5	2015	Furthermore, autophagy, apoptosis and necrosis induction were dependent on reactive oxygen species-c-Jun N-terminal kinase-protein 53 (ROS-JNK-p53) loop mediated phosphatidylinositide 3-kinases/protein kinase B/mammalian target of rapamycin/p70S6 kinase (PI3K/AKT/mTOR/p70S6K) pathway.	Reactive Oxygen Species	75-98	ribosomal protein S6 kinase B1	Homo sapiens	269-275
25939952-5	2015	Furthermore, autophagy, apoptosis and necrosis induction were dependent on reactive oxygen species-c-Jun N-terminal kinase-protein 53 (ROS-JNK-p53) loop mediated phosphatidylinositide 3-kinases/protein kinase B/mammalian target of rapamycin/p70S6 kinase (PI3K/AKT/mTOR/p70S6K) pathway.	Reactive Oxygen Species	135-138	ribosomal protein S6 kinase B1	Homo sapiens	269-275
25813876-6	2015	The mTOR complex (C)1/S6K1 blocker rapamycin inhibited the phosphorylation of IRS-1 at Ser636 in cells overexpressing alpha-Syn, suggesting that mTORC1/S6K1 activation by alpha-Syn causes feedback inhibition of insulin signaling via suppression of IRS-1 function.	Sirolimus	35-44	ribosomal protein S6 kinase B1	Homo sapiens	22-26
25813876-6	2015	The mTOR complex (C)1/S6K1 blocker rapamycin inhibited the phosphorylation of IRS-1 at Ser636 in cells overexpressing alpha-Syn, suggesting that mTORC1/S6K1 activation by alpha-Syn causes feedback inhibition of insulin signaling via suppression of IRS-1 function.	Sirolimus	35-44	ribosomal protein S6 kinase B1	Homo sapiens	152-156
25813876-7	2015	alpha-Syn overexpression also inhibited PP2A activity, while the PP2A agonist C2 ceramide suppressed both S6K1 activation and IRS-1 Ser636 phosphorylation upon alpha-Syn overexpression.	N-acetylsphingosine	78-89	ribosomal protein S6 kinase B1	Homo sapiens	106-110
25838035-5	2015	BCAAs may induce insulin resistance via the mammalian target of rapamycin complex 1 (mTORC1) and ribosomal protein S6 kinase beta 1 (S6k1)-associated pathways.	bcaas	0-5	ribosomal protein S6 kinase B1	Homo sapiens	97-131
25471732-0	2015	Inhibition of S6K1 enhances dichloroacetate-induced cell death.	Dichloroacetic Acid	28-43	ribosomal protein S6 kinase B1	Homo sapiens	14-18
25471732-3	2015	In the present study, we investigated the effects of S6 kinase 1 (S6K1) inhibition on DCA-induced cell death and the underlying mechanisms in breast cancer cells.	Dichloroacetic Acid	86-89	ribosomal protein S6 kinase B1	Homo sapiens	53-64
25471732-3	2015	In the present study, we investigated the effects of S6 kinase 1 (S6K1) inhibition on DCA-induced cell death and the underlying mechanisms in breast cancer cells.	Dichloroacetic Acid	86-89	ribosomal protein S6 kinase B1	Homo sapiens	66-70
25471732-8	2015	RESULTS: PF4708671, a selective inhibitor of S6K1, and knockdown of S6K1 with specific siRNA enhanced DCA-induced cell death.	Dichloroacetic Acid	102-105	ribosomal protein S6 kinase B1	Homo sapiens	68-72
25471732-12	2015	CONCLUSIONS: Based on these findings, we propose that inhibition of S6K1, in combination with the glycolytic inhibitor, DCA, provides effective cancer therapy.	Dichloroacetic Acid	120-123	ribosomal protein S6 kinase B1	Homo sapiens	68-72
25912861-3	2015	Infusion of complete and imbalanced EAA solutions increased mammalian target of rapamycin (mTOR) signaling in the mammary glands, as evidenced by higher ribosomal S6 kinase 1 (S6K1) phosphorylation compared with saline infusion.	Amino Acids, Essential	36-39	ribosomal protein S6 kinase B1	Homo sapiens	176-180
25838035-5	2015	BCAAs may induce insulin resistance via the mammalian target of rapamycin complex 1 (mTORC1) and ribosomal protein S6 kinase beta 1 (S6k1)-associated pathways.	bcaas	0-5	ribosomal protein S6 kinase B1	Homo sapiens	133-137
26114294-0	2015	Phenformin Induces Cell Cycle Change, Apoptosis, and Mesenchymal-Epithelial Transition and Regulates the AMPK/mTOR/p70s6k and MAPK/ERK Pathways in Breast Cancer Cells.	Phenformin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	115-121
25921843-9	2015	Compared to baseline, metformin significantly improved metabolic parameters and insulin sensitivity, increased SIRT1 gene/protein expression and SIRT1 promoter chromatin accessibility, elevated mTOR gene expression with concomitant reduction in p70S6K phosphorylation in subjects" PBMCs, and modified the plasma N-glycan profile.	Metformin	22-31	ribosomal protein S6 kinase B1	Homo sapiens	245-251
25921843-9	2015	Compared to baseline, metformin significantly improved metabolic parameters and insulin sensitivity, increased SIRT1 gene/protein expression and SIRT1 promoter chromatin accessibility, elevated mTOR gene expression with concomitant reduction in p70S6K phosphorylation in subjects" PBMCs, and modified the plasma N-glycan profile.	n-glycan	312-320	ribosomal protein S6 kinase B1	Homo sapiens	245-251
25921843-10	2015	Compared to placebo, metformin increased SIRT1 protein expression and reduced p70S6K phosphorylation (a proxy of mTOR activity).	Metformin	21-30	ribosomal protein S6 kinase B1	Homo sapiens	78-84
26114294-6	2015	Phenformin induced cell cycle change and apoptosis in breast cancer cells via the AMPK/mTOR/p70s6k and MAPK/ERK pathways.	Phenformin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	92-98
25903132-8	2015	Knockdown of S6K in hippocampal neurons by RNAi led to loss of dendritic spines, an effect that mimics neuronal activity blockade by tetrodotoxin.	Tetrodotoxin	133-145	ribosomal protein S6 kinase B1	Homo sapiens	13-16
25817233-11	2015	Co-treatment with metformin or AICAR decreased the TNF-alpha-induced intracellular TG, accompanied by significantly enhanced AMPK and ACC phosphorylation, suppressed mTOR and p70S6K phosphorylation, and reduced SREBP-1 and FAS expressions.	Metformin	18-27	ribosomal protein S6 kinase B1	Homo sapiens	175-181
25903132-3	2015	Upon extracellular stimulation, mammalian target of rapamycin phosphorylates S6K at Thr-389.	Threonine	84-87	ribosomal protein S6 kinase B1	Homo sapiens	77-80
25903132-4	2015	S6K also undergoes phosphorylation at other sites, including four serine residues in the autoinhibitory domain.	Serine	66-72	ribosomal protein S6 kinase B1	Homo sapiens	0-3
25903132-6	2015	Here we demonstrated that S6K in neuron was phosphorylated at Ser-411 within the autoinhibitory domain by cyclin-dependent kinase 5.	Serine	62-65	ribosomal protein S6 kinase B1	Homo sapiens	26-29
25903132-10	2015	These findings reveal the importance of cyclin-dependent kinase 5-mediated phosphorylation of S6K at Ser-411 in spine morphogenesis driven by BDNF and neuronal activity.	Serine	101-104	ribosomal protein S6 kinase B1	Homo sapiens	94-97
25988388-5	2015	The suppression of HIF-1alpha and VEGF by rapamycin was associated with dephosphorylation of mTOR and the downstream effector ribosomal protein S6 kinase (P70S6K) and 4E-binding protein-1 (4E-BP1) of mTORC1.	Sirolimus	42-51	ribosomal protein S6 kinase B1	Homo sapiens	155-161
25972244-2	2015	Using immunohistological staining, we investigated the value of the mTOR targets p70-S6 kinase (S6K) 1 and 2 as biomarkers for tamoxifen benefit in two independent clinical trials comparing adjuvant tamoxifen with no tamoxifen or 5 years versus 2 years of tamoxifen treatment.	Tamoxifen	127-136	ribosomal protein S6 kinase B1	Homo sapiens	96-108
25972244-5	2015	Nuclear accumulation of S6K1 was indicative of a reduced tamoxifen effect (hazard ratio (HR): 1.07, 95% CI: 0.53-2.81, P=0.84), compared with a significant benefit from tamoxifen treatment in patients without tumor S6K1 nuclear accumulation (HR: 0.42, 95% CI: 0.29-0.62, P&lt;0.00001).	Tamoxifen	57-66	ribosomal protein S6 kinase B1	Homo sapiens	24-28
25972244-6	2015	Also S6K1 and S6K2 activation, indicated by pS6K-t389 expression, was associated with low benefit from tamoxifen (HR: 0.97, 95% CI: 0.50-1.87, P=0.92).	Tamoxifen	103-112	ribosomal protein S6 kinase B1	Homo sapiens	5-9
25972244-6	2015	Also S6K1 and S6K2 activation, indicated by pS6K-t389 expression, was associated with low benefit from tamoxifen (HR: 0.97, 95% CI: 0.50-1.87, P=0.92).	Tamoxifen	103-112	ribosomal protein S6 kinase B1	Homo sapiens	44-48
25972244-8	2015	In conclusion, the mTOR-activated kinases S6K1 and S6K2 interfere with proliferation and response to tamoxifen.	Tamoxifen	101-110	ribosomal protein S6 kinase B1	Homo sapiens	42-46
25993039-16	2015	LBH589 increased LDH and phospho-p70S6K consumption.	Panobinostat	0-6	ribosomal protein S6 kinase B1	Homo sapiens	33-39
26189302-7	2015	Furthermore, all these changes may be due to the activation of AMPK activity by resveratrol treatment, and we also found that the p70S6K and s6 activities, downstream factors of AMPK, were also blocked by resveratrol.	Resveratrol	205-216	ribosomal protein S6 kinase B1	Homo sapiens	130-136
26113875-4	2015	It was observed that galangin and myricetin inhibited secretion of the key angiogenesis mediator vascular endothelial growth factor (VEGF) and decreased levels of p-Akt, p-70S6K and hypoxia-inducible factor-1alpha (HIF-1alpha) proteins in A2780/CP70 and OVCAR-3 cells.	myricetin	34-43	ribosomal protein S6 kinase B1	Homo sapiens	170-177
25903737-7	2015	Pre-treatment with inhibitors of the pathway, LY294002 and rapamycin, decreased the expression of p-Akt and p70S6K and alleviated the morphological changes induced by IL-1beta in hippocampal neurons.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	46-54	ribosomal protein S6 kinase B1	Homo sapiens	108-114
25903737-7	2015	Pre-treatment with inhibitors of the pathway, LY294002 and rapamycin, decreased the expression of p-Akt and p70S6K and alleviated the morphological changes induced by IL-1beta in hippocampal neurons.	Sirolimus	59-68	ribosomal protein S6 kinase B1	Homo sapiens	108-114
25970614-1	2015	Cucurbitacins, the natural triterpenoids possessing many biological activities, have been reported to suppress the mTORC1/p70S6K pathway and to induce autophagy.	Cucurbitacins	0-13	ribosomal protein S6 kinase B1	Homo sapiens	122-128
25970614-1	2015	Cucurbitacins, the natural triterpenoids possessing many biological activities, have been reported to suppress the mTORC1/p70S6K pathway and to induce autophagy.	triterpenoids	27-40	ribosomal protein S6 kinase B1	Homo sapiens	122-128
25659819-4	2015	Rapamycin inhibits the phosphorylation of S6K at nano-molar concentrations in MDA-MB-231 cells; however, micro-molar concentrations of rapamycin are required to inhibit phosphorylation of 4E-BP1 - the phosphorylation of which liberates eIF4E to initiate translation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	42-45
25659819-4	2015	Rapamycin inhibits the phosphorylation of S6K at nano-molar concentrations in MDA-MB-231 cells; however, micro-molar concentrations of rapamycin are required to inhibit phosphorylation of 4E-BP1 - the phosphorylation of which liberates eIF4E to initiate translation.	Sirolimus	135-144	ribosomal protein S6 kinase B1	Homo sapiens	42-45
25659819-6	2015	Data are provided demonstrating that G1 cell cycle arrest induced by rapamycin is due to up-regulation of TGF-beta signaling and down-regulation of Rb phosphorylation via phosphorylation of the mTORC1 substrates S6K and 4E-BP1 respectively.	Sirolimus	69-78	ribosomal protein S6 kinase B1	Homo sapiens	212-215
26113875-5	2015	Transient transfection experiments showed that galangin and myricetin inhibited secretion of VEGF by the Akt/p70S6K/ HIF-1alpha pathway.	myricetin	60-69	ribosomal protein S6 kinase B1	Homo sapiens	109-115
28352705-8	2015	Expression levels of AKT, mTOR, P70S6K mRNAs, and phosphorylated proteins decreased significantly after action of puerarin at different concentrations.	puerarin	114-122	ribosomal protein S6 kinase B1	Homo sapiens	32-38
26387199-10	2015	(2) Feno significantly inhibited the increase of the protein expressions of p-Akt, p-mTOR and p-p70S6K in ISO induced cardiomyocyte hypertrophy, which could be blocked by PPAR-alpha RNAi.	Fenofibrate	4-8	ribosomal protein S6 kinase B1	Homo sapiens	96-102
25588160-7	2015	Moreover, phosphorylated AKT (p-AKT) and 70 kDa ribosomal protein S6-kinase (p-p70S6K) were also inhibited by the gefitinib and SF1126 combination, which may be responsible for the apoptosis.	Gefitinib	114-123	ribosomal protein S6 kinase B1	Homo sapiens	79-85
25588160-8	2015	Gefitinib combined with SF1126 could induce cell apoptosis in TNBC cells and this effect was mediated through the EGFR-PI3K-AKT-mTOR-p70S6K pathway.	Gefitinib	0-9	ribosomal protein S6 kinase B1	Homo sapiens	133-139
25588160-8	2015	Gefitinib combined with SF1126 could induce cell apoptosis in TNBC cells and this effect was mediated through the EGFR-PI3K-AKT-mTOR-p70S6K pathway.	SF 1126	24-30	ribosomal protein S6 kinase B1	Homo sapiens	133-139
25663935-8	2015	Furthermore, treatment with rapamycin, a specific inhibitor of the mammalian target of rapamycin/p70S6K cascade, resulted in decreased FOXP1 expression in the MCF7 cells, but not in the MDA-MB-231 cells, which were resistant to rapamycin-induced inhibition.	Sirolimus	28-37	ribosomal protein S6 kinase B1	Homo sapiens	97-103
25512366-0	2015	S6K is a morphogenic protein with a mechanism involving Filamin-A phosphorylation and phosphatidic acid binding.	Phosphatidic Acids	86-103	ribosomal protein S6 kinase B1	Homo sapiens	0-3
25512366-6	2015	Equally important is that S6K is itself regulated by phospholipids, specifically phosphatidic acid, whereby 300 nM 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), but not the control 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), binds directly to S6K and causes an ~ 2.9-fold increase in S6K catalytic activity.	Phospholipids	53-66	ribosomal protein S6 kinase B1	Homo sapiens	26-29
25512366-6	2015	Equally important is that S6K is itself regulated by phospholipids, specifically phosphatidic acid, whereby 300 nM 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), but not the control 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), binds directly to S6K and causes an ~ 2.9-fold increase in S6K catalytic activity.	Phospholipids	53-66	ribosomal protein S6 kinase B1	Homo sapiens	246-249
25512366-6	2015	Equally important is that S6K is itself regulated by phospholipids, specifically phosphatidic acid, whereby 300 nM 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), but not the control 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), binds directly to S6K and causes an ~ 2.9-fold increase in S6K catalytic activity.	Phospholipids	53-66	ribosomal protein S6 kinase B1	Homo sapiens	246-249
25512366-6	2015	Equally important is that S6K is itself regulated by phospholipids, specifically phosphatidic acid, whereby 300 nM 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), but not the control 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), binds directly to S6K and causes an ~ 2.9-fold increase in S6K catalytic activity.	Phosphatidic Acids	81-98	ribosomal protein S6 kinase B1	Homo sapiens	26-29
25512366-6	2015	Equally important is that S6K is itself regulated by phospholipids, specifically phosphatidic acid, whereby 300 nM 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), but not the control 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), binds directly to S6K and causes an ~ 2.9-fold increase in S6K catalytic activity.	dioleoylphosphatidic acid	115-150	ribosomal protein S6 kinase B1	Homo sapiens	26-29
25512366-6	2015	Equally important is that S6K is itself regulated by phospholipids, specifically phosphatidic acid, whereby 300 nM 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), but not the control 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), binds directly to S6K and causes an ~ 2.9-fold increase in S6K catalytic activity.	dioleoylphosphatidic acid	152-156	ribosomal protein S6 kinase B1	Homo sapiens	26-29
25512366-6	2015	Equally important is that S6K is itself regulated by phospholipids, specifically phosphatidic acid, whereby 300 nM 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), but not the control 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), binds directly to S6K and causes an ~ 2.9-fold increase in S6K catalytic activity.	1,2-oleoylphosphatidylcholine	179-219	ribosomal protein S6 kinase B1	Homo sapiens	26-29
25512366-6	2015	Equally important is that S6K is itself regulated by phospholipids, specifically phosphatidic acid, whereby 300 nM 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), but not the control 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), binds directly to S6K and causes an ~ 2.9-fold increase in S6K catalytic activity.	1,2-oleoylphosphatidylcholine	221-225	ribosomal protein S6 kinase B1	Homo sapiens	26-29
25512366-8	2015	This reliance of S6K on phosphatidic acid (PA), a curvature-inducing phospholipid, explained the extra-large perimeter of cells that overexpressed S6K.	Phosphatidic Acids	24-41	ribosomal protein S6 kinase B1	Homo sapiens	17-20
25512366-8	2015	This reliance of S6K on phosphatidic acid (PA), a curvature-inducing phospholipid, explained the extra-large perimeter of cells that overexpressed S6K.	Phosphatidic Acids	24-41	ribosomal protein S6 kinase B1	Homo sapiens	147-150
25512366-8	2015	This reliance of S6K on phosphatidic acid (PA), a curvature-inducing phospholipid, explained the extra-large perimeter of cells that overexpressed S6K.	Phosphatidic Acids	43-45	ribosomal protein S6 kinase B1	Homo sapiens	17-20
25512366-8	2015	This reliance of S6K on phosphatidic acid (PA), a curvature-inducing phospholipid, explained the extra-large perimeter of cells that overexpressed S6K.	Phosphatidic Acids	43-45	ribosomal protein S6 kinase B1	Homo sapiens	147-150
25512366-8	2015	This reliance of S6K on phosphatidic acid (PA), a curvature-inducing phospholipid, explained the extra-large perimeter of cells that overexpressed S6K.	Phospholipids	69-81	ribosomal protein S6 kinase B1	Homo sapiens	17-20
25512366-8	2015	This reliance of S6K on phosphatidic acid (PA), a curvature-inducing phospholipid, explained the extra-large perimeter of cells that overexpressed S6K.	Phospholipids	69-81	ribosomal protein S6 kinase B1	Homo sapiens	147-150
25647149-10	2015	The downstream targets of this pathway, phospho-p70S6K and phospho-S6RP, were also inhibited by paclitaxel in 10A, 10AT and 10ATG3B cells, but minimally inhibited in 10CA1a cells, suggestive of chemoresistance in 10CA1a cells.	Paclitaxel	96-106	ribosomal protein S6 kinase B1	Homo sapiens	48-54
25423127-6	2015	Contraction of muscle in CON mice increased the phosphorylation of mTORC1 (mammalian target of rapamycin [mTOR] complex 1) substrates S6K1 (70-kd ribosomal protein S6 kinase 1) Thr (8-fold), S6K1 ThrSer (7-fold) and 4E-BP1 Ser (11-fold).	Threonine	177-180	ribosomal protein S6 kinase B1	Homo sapiens	134-138
25423127-6	2015	Contraction of muscle in CON mice increased the phosphorylation of mTORC1 (mammalian target of rapamycin [mTOR] complex 1) substrates S6K1 (70-kd ribosomal protein S6 kinase 1) Thr (8-fold), S6K1 ThrSer (7-fold) and 4E-BP1 Ser (11-fold).	thrser	196-202	ribosomal protein S6 kinase B1	Homo sapiens	134-138
25423127-6	2015	Contraction of muscle in CON mice increased the phosphorylation of mTORC1 (mammalian target of rapamycin [mTOR] complex 1) substrates S6K1 (70-kd ribosomal protein S6 kinase 1) Thr (8-fold), S6K1 ThrSer (7-fold) and 4E-BP1 Ser (11-fold).	Serine	199-202	ribosomal protein S6 kinase B1	Homo sapiens	134-138
25416439-5	2015	ATO was shown to inhibit the expression or activation of Akt downstream factors, including glycogen synthase kinase (GSK)-3beta, mammalian target of rapamycin (mTOR), ribosomal protein S6 kinase (S6K), and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), which regulate cell apoptosis and were upregulated or activated by sorafenib.	Arsenic Trioxide	0-3	ribosomal protein S6 kinase B1	Homo sapiens	196-199
25605643-6	2015	In ER, AMPK activity was elevated immediately after both endurance and resistance exercise (~90%, P &lt; 0.05) but was unchanged in R. Thr(389) phosphorylation of S6K1 was increased severalfold immediately after exercise (P &lt; 0.05) in both trials and increased further throughout recovery.	Threonine	135-138	ribosomal protein S6 kinase B1	Homo sapiens	163-167
25767889-6	2015	Phosphorylation-deficient mutations in regulatory motifs of Ypk3 abrogate Rps6 phosphorylation, and complementation of ypk3Delta cells with human S6 kinase restores Rps6 phosphorylation in a rapamycin-sensitive manner.	Sirolimus	191-200	ribosomal protein S6 kinase B1	Homo sapiens	146-155
25578563-0	2015	PKD1 is downregulated in non-small cell lung cancer and mediates the feedback inhibition of mTORC1-S6K1 axis in response to phorbol ester.	Phorbol Esters	124-137	ribosomal protein S6 kinase B1	Homo sapiens	99-103
25578563-8	2015	Furthermore, the PI3K inhibitors LY294002, BKM120 and MEK inhibitors U0126, PD0325901 blocked the enhanced S6K1 activity induced by Kb.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	33-41	ribosomal protein S6 kinase B1	Homo sapiens	107-111
25578563-8	2015	Furthermore, the PI3K inhibitors LY294002, BKM120 and MEK inhibitors U0126, PD0325901 blocked the enhanced S6K1 activity induced by Kb.	NVP-BKM120	43-49	ribosomal protein S6 kinase B1	Homo sapiens	107-111
25578563-8	2015	Furthermore, the PI3K inhibitors LY294002, BKM120 and MEK inhibitors U0126, PD0325901 blocked the enhanced S6K1 activity induced by Kb.	U 0126	69-74	ribosomal protein S6 kinase B1	Homo sapiens	107-111
25578563-8	2015	Furthermore, the PI3K inhibitors LY294002, BKM120 and MEK inhibitors U0126, PD0325901 blocked the enhanced S6K1 activity induced by Kb.	mirdametinib	76-85	ribosomal protein S6 kinase B1	Homo sapiens	107-111
26622578-3	2015	In the present study, it was identified that the administration of a combination of ABT263 [navitoclax; a Bcl-2/Bcl-extra large (Bcl-xL) inhibitor] and PF4708671 (an S6K1 inhibitor) markedly increased apoptotic cell death in the BT474 breast cancer cells compared with the administration of either agent alone.	navitoclax	92-102	ribosomal protein S6 kinase B1	Homo sapiens	166-170
26622578-3	2015	In the present study, it was identified that the administration of a combination of ABT263 [navitoclax; a Bcl-2/Bcl-extra large (Bcl-xL) inhibitor] and PF4708671 (an S6K1 inhibitor) markedly increased apoptotic cell death in the BT474 breast cancer cells compared with the administration of either agent alone.	PF-4708671	152-161	ribosomal protein S6 kinase B1	Homo sapiens	166-170
25653074-5	2015	Moreover, in cultured primary myocytes from patients with OB/T2D, the synthetic BRS-3 agonist, [D-Try6,beta-Ala11,Phe13,Nle14]bombesin6-14, significantly increased the phosphorylation levels of mitogen-activated protein kinase (MAPK), p90RSK1, protein kinase B (PKB) and p70s6K.	beta-ala11	103-113	ribosomal protein S6 kinase B1	Homo sapiens	271-277
25698201-0	2015	P70S6 kinase phosphorylation: a new site to assess pharmacodynamy of sirolimus.	Sirolimus	69-78	ribosomal protein S6 kinase B1	Homo sapiens	0-12
25698201-1	2015	BACKGROUND: The phosphorylation of p70S6 kinase (p70S6K) represents an important target for sensitive detection on pharmacodynamic effects of sirolimus, but the methods of assessing p70S6K phosphorylation are still unclear.	Sirolimus	142-151	ribosomal protein S6 kinase B1	Homo sapiens	35-47
25698201-1	2015	BACKGROUND: The phosphorylation of p70S6 kinase (p70S6K) represents an important target for sensitive detection on pharmacodynamic effects of sirolimus, but the methods of assessing p70S6K phosphorylation are still unclear.	Sirolimus	142-151	ribosomal protein S6 kinase B1	Homo sapiens	49-55
25698201-9	2015	The p70S6K phosphorylation in patients receiving a sirolimus (19.5 +- 7.7) was significantly lower than in HC (50.1 +- 11.3, P &lt; 0.001), tacrolimus (37.7 +- 15.7, P &lt; 0.001) or cyclosporine treated patients (41.7 +- 11.7, P &lt; 0.001).	Sirolimus	51-60	ribosomal protein S6 kinase B1	Homo sapiens	4-10
25698201-9	2015	The p70S6K phosphorylation in patients receiving a sirolimus (19.5 +- 7.7) was significantly lower than in HC (50.1 +- 11.3, P &lt; 0.001), tacrolimus (37.7 +- 15.7, P &lt; 0.001) or cyclosporine treated patients (41.7 +- 11.7, P &lt; 0.001).	Cyclosporine	183-195	ribosomal protein S6 kinase B1	Homo sapiens	4-10
25698201-13	2015	Assessment of p70S6K phosphorylation may play an adjunct role to on pharmacodynamically guide and individualize sirolimus based on immunosuppression.	Sirolimus	112-121	ribosomal protein S6 kinase B1	Homo sapiens	14-20
25659153-0	2015	Tanshinone IIA inhibits HIF-1alpha and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.	tanshinone	0-10	ribosomal protein S6 kinase B1	Homo sapiens	87-93
25498902-4	2015	Our initial findings in wild type cells showed nelfinavir inhibited mTORC1 signalling and upregulated autophagy, as determined by decreased rpS6 and S6K1 phosphorylation, and SQTSM1 protein expression, respectively.	Nelfinavir	47-57	ribosomal protein S6 kinase B1	Homo sapiens	149-153
25491146-6	2015	When added alone to serum-starved DU145 cells, EPA transiently activates signaling events, including p70S6K phosphorylation.	Eicosapentaenoic Acid	47-50	ribosomal protein S6 kinase B1	Homo sapiens	101-107
25428129-6	2015	Interestingly, mTOR was activated rapidly during tunicamycin treatment, as indicated by phosphorylation of both mTOR and p70S6K.	Tunicamycin	49-60	ribosomal protein S6 kinase B1	Homo sapiens	121-127
25491146-7	2015	However, when added 15 minutes prior to LPA, EPA suppresses LPA-induced activating phosphorylations of ERK, FAK, and p70S6K, and expression of the matricellular protein CCN1.	Eicosapentaenoic Acid	45-48	ribosomal protein S6 kinase B1	Homo sapiens	117-123
25491146-7	2015	However, when added 15 minutes prior to LPA, EPA suppresses LPA-induced activating phosphorylations of ERK, FAK, and p70S6K, and expression of the matricellular protein CCN1.	lysophosphatidic acid	60-63	ribosomal protein S6 kinase B1	Homo sapiens	117-123
26732119-7	2015	Furthermore, our study demonstrated that SB365 increased the phosphorylation of ERK and inhibited the phosphorylation of mTOR and p70S6K, suggesting that their roles in the effects of SB365 on autophagy.	sb365	41-46	ribosomal protein S6 kinase B1	Homo sapiens	130-136
25832358-5	2015	Mechanistically, PQQ was found to be a strong PI3K-Akt-mTOR-p70S6K cascade inhibitor in Human promyelocytic leukemia HL-60 cells.	PQQ Cofactor	17-20	ribosomal protein S6 kinase B1	Homo sapiens	60-66
25311616-0	2014	Phosphoproteomics reveals resveratrol-dependent inhibition of Akt/mTORC1/S6K1 signaling.	Resveratrol	26-37	ribosomal protein S6 kinase B1	Homo sapiens	73-77
25553480-3	2015	Specifically, leucine activates the mammalian target of rapamycin (mTOR) signaling pathway, including the 70 kDa ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor (eIF) 4E-binding protein 1 (4EBP1) to stimulate protein synthesis in skeletal muscle and adipose tissue and to promote mitochondrial biogenesis, resulting in enhanced cellular respiration and energy partitioning.	Leucine	14-21	ribosomal protein S6 kinase B1	Homo sapiens	144-148
25976336-2	2015	METHODS/MATERIALS: Expressions of mTOR and its target molecules p70S6K and 4E-BP1 were determined in cisplatin-sensitive and -resistant cells A2780 and A2780cis, respectively, using Western blotting.	Cisplatin	101-110	ribosomal protein S6 kinase B1	Homo sapiens	64-81
25976336-6	2015	The levels of phosphorylated mTOR (p-mTOR), p70S6K, and 4E-BP1 were significantly increased in A2780cis cells compared to A2780 cells, which might be implicated in cisplatin-induced chemoresistance.	Cisplatin	164-173	ribosomal protein S6 kinase B1	Homo sapiens	44-50
25164962-4	2015	Sequential treatment of Taxol or cisplatin, followed by MK-2206, induced a synergistic inhibition of cell proliferation and effectively promoted cell death, either by inhibiting the phosphorylation of Akt and its downstream effectors 4E-BP1 and p70S6K in SKOV3 cells or by restoring p53 levels, which were downregulated after Taxol or cisplatin treatment, in ES2 cells.	Paclitaxel	24-29	ribosomal protein S6 kinase B1	Homo sapiens	245-251
25164962-4	2015	Sequential treatment of Taxol or cisplatin, followed by MK-2206, induced a synergistic inhibition of cell proliferation and effectively promoted cell death, either by inhibiting the phosphorylation of Akt and its downstream effectors 4E-BP1 and p70S6K in SKOV3 cells or by restoring p53 levels, which were downregulated after Taxol or cisplatin treatment, in ES2 cells.	Cisplatin	33-42	ribosomal protein S6 kinase B1	Homo sapiens	245-251
25164962-4	2015	Sequential treatment of Taxol or cisplatin, followed by MK-2206, induced a synergistic inhibition of cell proliferation and effectively promoted cell death, either by inhibiting the phosphorylation of Akt and its downstream effectors 4E-BP1 and p70S6K in SKOV3 cells or by restoring p53 levels, which were downregulated after Taxol or cisplatin treatment, in ES2 cells.	MK 2206	56-63	ribosomal protein S6 kinase B1	Homo sapiens	245-251
26278147-2	2015	Expressions of mTOR and its target molecules p70S6K and 4E-BP1 were determined in A2780cis and COC1/DDP and the parental cells A2780 and COC1 that are sensitive to cisplatin using Western blotting.	Cisplatin	164-173	ribosomal protein S6 kinase B1	Homo sapiens	45-62
25099702-8	2015	Interleukin-2 production in mitogen-stimulated CD3(+) T cells correlated with the degree of p70S6K phosphorylation in everolimus-treated patients.	Everolimus	118-128	ribosomal protein S6 kinase B1	Homo sapiens	92-98
25587030-7	2014	Without affecting Akt phosphorylation, PMA increased phosphorylation of S6K (T389) and S6 (S240/244), and that was completely prevented by rapamycin.	Tetradecanoylphorbol Acetate	39-42	ribosomal protein S6 kinase B1	Homo sapiens	72-75
25587030-7	2014	Without affecting Akt phosphorylation, PMA increased phosphorylation of S6K (T389) and S6 (S240/244), and that was completely prevented by rapamycin.	Sirolimus	139-148	ribosomal protein S6 kinase B1	Homo sapiens	72-75
25587030-8	2014	Yet, T421/S424 and S235/236 (p-S6K and p-S6, respectively) phosphorylation became rapamycin-insensitive in the presence of PMA.	Sirolimus	82-91	ribosomal protein S6 kinase B1	Homo sapiens	29-34
25587030-8	2014	Yet, T421/S424 and S235/236 (p-S6K and p-S6, respectively) phosphorylation became rapamycin-insensitive in the presence of PMA.	Tetradecanoylphorbol Acetate	123-126	ribosomal protein S6 kinase B1	Homo sapiens	29-34
25778879-6	2015	Moreover, the results showed that Dex reduced the activity of mTOR pathway, as determined by decreased phosphorylation levels of mTOR, Akt, P70S6K and 4E-BP1 in resistant cells.	Dexamethasone	34-37	ribosomal protein S6 kinase B1	Homo sapiens	140-157
25803131-5	2015	Expression of activated forms of AKT, p70 S6K and mTOR or inhibition of JNK and p38 MAPK suppressed the interaction between FTY720 and pemetrexed.	Pemetrexed	135-145	ribosomal protein S6 kinase B1	Homo sapiens	38-45
25146548-5	2015	The activities of mTOR, protein kinase B (Akt) and p70 ribosomal S6 kinase (p70 S6k) upon OPRM1 activation by morphine were measured by immunoblotting their phosphorylation status.	Morphine	110-118	ribosomal protein S6 kinase B1	Homo sapiens	51-74
25146548-5	2015	The activities of mTOR, protein kinase B (Akt) and p70 ribosomal S6 kinase (p70 S6k) upon OPRM1 activation by morphine were measured by immunoblotting their phosphorylation status.	Morphine	110-118	ribosomal protein S6 kinase B1	Homo sapiens	76-83
25146548-8	2015	Morphine significantly rescued mTOR signaling by reversal of Abeta oligomers" effect on mTOR and its upstream signaling molecule Akt, as well as its downstream molecule p70 S6k.	Morphine	0-8	ribosomal protein S6 kinase B1	Homo sapiens	169-176
26064108-9	2015	Our results also indicated that p70S6K and 4EBP1 kinases participated in controlling cortisol secretion via OX1 receptor in H295R cells, which implied important role of p70S6K and 4EBP1 kinases in regulating adrenal function induced by orexin-A.	Hydrocortisone	85-93	ribosomal protein S6 kinase B1	Homo sapiens	169-185
25404012-4	2015	Top canonical pathways that were inhibited upon erlotinib treatment in sensitive cells, but not in the resistant cells include EGFR, insulin receptor, hepatocyte growth factor, mitogen-activated protein kinase, mechanistic target of rapamycin, ribosomal protein S6 kinase beta 1, and Janus kinase/signal transducer and activator of transcription signaling.	Erlotinib Hydrochloride	48-57	ribosomal protein S6 kinase B1	Homo sapiens	244-278
25486532-3	2014	We found that SP600125 induced the polyploidization of Dami and CMK cells, concomitant with the phosphorylation of ribosomal protein S6 kinase 1 (S6K1) at Thr421/Ser424 and dephosphorylation at Thr389.	pyrazolanthrone	14-22	ribosomal protein S6 kinase B1	Homo sapiens	146-150
25486532-4	2014	The polyploidization was partially blocked by H-89, a cAMP-dependent protein kinase (PKA) inhibitor, through direct binding to S6K1, leading to dephosphorylation at Thr421/Ser424 and phosphorylation at Thr389, independent of PKA.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	46-50	ribosomal protein S6 kinase B1	Homo sapiens	127-131
25486532-4	2014	The polyploidization was partially blocked by H-89, a cAMP-dependent protein kinase (PKA) inhibitor, through direct binding to S6K1, leading to dephosphorylation at Thr421/Ser424 and phosphorylation at Thr389, independent of PKA.	Cyclic AMP	54-58	ribosomal protein S6 kinase B1	Homo sapiens	127-131
25486532-5	2014	Overexpression of a rapamycin-resistant mutant of S6K1 further enhanced the inhibitory effect of LY294002 on the SP600125-induced polyploidization of Dami and CMK cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	97-105	ribosomal protein S6 kinase B1	Homo sapiens	50-54
25486532-5	2014	Overexpression of a rapamycin-resistant mutant of S6K1 further enhanced the inhibitory effect of LY294002 on the SP600125-induced polyploidization of Dami and CMK cells.	pyrazolanthrone	113-121	ribosomal protein S6 kinase B1	Homo sapiens	50-54
25486532-7	2014	Additionally, SP600125 induced the polyploidization of HEL cells, which are derived from a patient with erythroleukemia, and phosphorylation at Thr389 of S6K1 was detected.	pyrazolanthrone	14-22	ribosomal protein S6 kinase B1	Homo sapiens	154-158
24667175-6	2014	We also found an increase in phosphorylated AMPK following a decrease in all phosphorylated forms of AKT, mTOR and S6K after the treatment with celastrol.	celastrol	144-153	ribosomal protein S6 kinase B1	Homo sapiens	115-118
24919855-0	2014	First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-kappaBeta and p70s6k, in patients with advanced solid tumors.	PBI-05204	24-33	ribosomal protein S6 kinase B1	Homo sapiens	97-103
24919855-1	2014	BACKGROUND: PBI-05204, a Nerium oleander extract (NOE) containing the cardiac glycoside oleandrin, inhibits the alpha-3 subunit of Na-K ATPase, as well as FGF-2 export, Akt and p70S6K, hence attenuating mTOR activity.	pbi	12-15	ribosomal protein S6 kinase B1	Homo sapiens	177-183
25035961-9	2014	Then, an inhibitory effect of PP242 on metastasis was observed in gastric cancer cell AGS, along with the cytoskeletal rearrangements and suppression of the phosphorylation of PI3K downstream factors including AKT, mTOR, and P70S6K.	PP242	30-35	ribosomal protein S6 kinase B1	Homo sapiens	225-231
25230779-13	2014	Therefore, CD133 may inhibit 5-FU-induced apoptosis by regulating the expression of P-gp and Bcl-2 family mediated by phosphoinositide 3-kinase/Akt/p70S6K pathway in GC cells.	Fluorouracil	29-33	ribosomal protein S6 kinase B1	Homo sapiens	148-154
25429619-6	2014	Collectively, our results show that ROS inhibited autophagy by downregulating the p70S6K/p53/ULK1 axis in selenite-treated NB4 cells.	Reactive Oxygen Species	36-39	ribosomal protein S6 kinase B1	Homo sapiens	82-88
25429619-6	2014	Collectively, our results show that ROS inhibited autophagy by downregulating the p70S6K/p53/ULK1 axis in selenite-treated NB4 cells.	Selenious Acid	106-114	ribosomal protein S6 kinase B1	Homo sapiens	82-88
25349966-7	2014	RESULTS: Treatment with MK-2206 suppressed AKT and S6K1 but not 4E-BP1 phosphorylation in all cell lines.	MK 2206	24-31	ribosomal protein S6 kinase B1	Homo sapiens	51-55
25383959-0	2014	Celastrol stimulates hypoxia-inducible factor-1 activity in tumor cells by initiating the ROS/Akt/p70S6K signaling pathway and enhancing hypoxia-inducible factor-1alpha protein synthesis.	celastrol	0-9	ribosomal protein S6 kinase B1	Homo sapiens	98-104
25383959-5	2014	Instead, Celastrol induced the accumulation of the HIF-1alpha protein by inducing ROS and activating Akt/p70S6K signaling to promote HIF-1alpha translation.	celastrol	9-18	ribosomal protein S6 kinase B1	Homo sapiens	105-111
24943256-8	2014	DMH1 reversed starvation- and AICAR-induced inhibition of Akt, mammalian target of rapamycin (mTOR) and p70S6 kinase (S6K), and reversed rapamycin-induced inhibition of mTOR and S6K.	DMH-1	0-4	ribosomal protein S6 kinase B1	Homo sapiens	118-121
24943256-8	2014	DMH1 reversed starvation- and AICAR-induced inhibition of Akt, mammalian target of rapamycin (mTOR) and p70S6 kinase (S6K), and reversed rapamycin-induced inhibition of mTOR and S6K.	DMH-1	0-4	ribosomal protein S6 kinase B1	Homo sapiens	178-181
24943256-8	2014	DMH1 reversed starvation- and AICAR-induced inhibition of Akt, mammalian target of rapamycin (mTOR) and p70S6 kinase (S6K), and reversed rapamycin-induced inhibition of mTOR and S6K.	AICA ribonucleotide	30-35	ribosomal protein S6 kinase B1	Homo sapiens	118-121
24943256-8	2014	DMH1 reversed starvation- and AICAR-induced inhibition of Akt, mammalian target of rapamycin (mTOR) and p70S6 kinase (S6K), and reversed rapamycin-induced inhibition of mTOR and S6K.	AICA ribonucleotide	30-35	ribosomal protein S6 kinase B1	Homo sapiens	178-181
24916432-7	2014	The initiation of nicotine-induced locomotor sensitization was accompanied by the increased phosphorylated level of mTORC1 downstream target proteins including p-p70s6k and p-4EBP in the BLA, but not CeA.	Nicotine	18-26	ribosomal protein S6 kinase B1	Homo sapiens	162-168
24916432-9	2014	Increased p-p70s6k and p-4EBP were also observed in the expression of nicotine sensitization, which was demonstrated to be inhibited by systemic rapamycin administration.	Nicotine	70-78	ribosomal protein S6 kinase B1	Homo sapiens	12-18
24916432-9	2014	Increased p-p70s6k and p-4EBP were also observed in the expression of nicotine sensitization, which was demonstrated to be inhibited by systemic rapamycin administration.	Sirolimus	145-154	ribosomal protein S6 kinase B1	Homo sapiens	12-18
25270513-6	2014	The phosphorylation levels of P70S6K increased after PDL exposure but those increases were suppressed by the topical RPM.	Sirolimus	117-120	ribosomal protein S6 kinase B1	Homo sapiens	30-36
25200811-6	2014	In addition, the protein levels of activated S6 kinase 1 (S6K1) were significantly reduced following treatment with everolimus, and the phosphorylation of factor 4E binding protein 1 (4EBP1) was suppressed following combination treatment.	Everolimus	116-126	ribosomal protein S6 kinase B1	Homo sapiens	45-56
25200811-6	2014	In addition, the protein levels of activated S6 kinase 1 (S6K1) were significantly reduced following treatment with everolimus, and the phosphorylation of factor 4E binding protein 1 (4EBP1) was suppressed following combination treatment.	Everolimus	116-126	ribosomal protein S6 kinase B1	Homo sapiens	58-62
25270513-8	2014	CONCLUSION: Topical application of 1% RPM can significantly and systematically suppress the PDL-induced early stage of angiogenesis via inhibition of the AKT/mTOR/P70S6K pathway in a rodent model.	Sirolimus	38-41	ribosomal protein S6 kinase B1	Homo sapiens	163-169
25104091-6	2014	At the molecular level, our results demonstrated that treatment with betulin was also associated with activation of AMP kinase and inhibition of mTOR/p70S6K/pS6 signaling in these cells.	betulin	69-76	ribosomal protein S6 kinase B1	Homo sapiens	150-156
25379021-7	2014	Surprisingly, Selumetinib was able to inhibit phosphorylation of p70 S6 kinase (p70S6K) and its downstream target ribosomal protein S6 (RPS6) in sensitive cell lines.	AZD 6244	14-25	ribosomal protein S6 kinase B1	Homo sapiens	65-78
25379021-7	2014	Surprisingly, Selumetinib was able to inhibit phosphorylation of p70 S6 kinase (p70S6K) and its downstream target ribosomal protein S6 (RPS6) in sensitive cell lines.	AZD 6244	14-25	ribosomal protein S6 kinase B1	Homo sapiens	80-86
25379021-11	2014	Pharmacological inhibition of p70S6K using the PI3K/mTOR inhibitor NVP-BEZ235, the specific mTOR inhibitor Rapamycin and the specific p70S6K inhibitor PF-4708671 potentiated Selumetinib effects in resistant cells.	dactolisib	67-77	ribosomal protein S6 kinase B1	Homo sapiens	30-36
25379021-11	2014	Pharmacological inhibition of p70S6K using the PI3K/mTOR inhibitor NVP-BEZ235, the specific mTOR inhibitor Rapamycin and the specific p70S6K inhibitor PF-4708671 potentiated Selumetinib effects in resistant cells.	Sirolimus	107-116	ribosomal protein S6 kinase B1	Homo sapiens	30-36
25379021-11	2014	Pharmacological inhibition of p70S6K using the PI3K/mTOR inhibitor NVP-BEZ235, the specific mTOR inhibitor Rapamycin and the specific p70S6K inhibitor PF-4708671 potentiated Selumetinib effects in resistant cells.	PF-4708671	151-161	ribosomal protein S6 kinase B1	Homo sapiens	30-36
25379021-11	2014	Pharmacological inhibition of p70S6K using the PI3K/mTOR inhibitor NVP-BEZ235, the specific mTOR inhibitor Rapamycin and the specific p70S6K inhibitor PF-4708671 potentiated Selumetinib effects in resistant cells.	PF-4708671	151-161	ribosomal protein S6 kinase B1	Homo sapiens	134-140
25379021-11	2014	Pharmacological inhibition of p70S6K using the PI3K/mTOR inhibitor NVP-BEZ235, the specific mTOR inhibitor Rapamycin and the specific p70S6K inhibitor PF-4708671 potentiated Selumetinib effects in resistant cells.	AZD 6244	174-185	ribosomal protein S6 kinase B1	Homo sapiens	30-36
25379021-12	2014	In addition, biological inhibition of p70S6K using siRNA rendered responsiveness to Selumetinib in resistant cell lines.	AZD 6244	84-95	ribosomal protein S6 kinase B1	Homo sapiens	38-44
25379021-14	2014	We can conclude that p70S6K and its downstream target RPS6 are potential biomarkers of resistance to Selumetinib in colorectal cancer.	AZD 6244	101-112	ribosomal protein S6 kinase B1	Homo sapiens	21-27
25169428-3	2014	In addition, we observed that sulforaphane suppression of TPA-induced S6K1 and ERK1/2 activation played a critical role in attenuating PDCD4 poly-ubiquitination and Pdcd4 mRNA downregulation.	sulforaphane	30-42	ribosomal protein S6 kinase B1	Homo sapiens	70-74
25379019-3	2014	Here, we report that A77 1726, the active metabolite of leflunomide, inhibited the phosphorylation of ribosomal protein S6 and two other substrates of S6K1, insulin receptor substrate-1 and carbamoyl phosphate synthetase 2, in an A375 melanoma cell line.	Leflunomide	56-67	ribosomal protein S6 kinase B1	Homo sapiens	151-185
25379019-5	2014	In vitro kinase assay revealed that leflunomide and A77 1726 inhibited S6K1 activity with IC50 values of approximately 55 and 80 muM, respectively.	Leflunomide	36-47	ribosomal protein S6 kinase B1	Homo sapiens	71-75
25379021-0	2014	Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.	AZD 6244	14-25	ribosomal protein S6 kinase B1	Homo sapiens	83-89
25379021-0	2014	Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.	AZD 6244	27-34	ribosomal protein S6 kinase B1	Homo sapiens	83-89
25220053-0	2014	The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation.	Glutamine	34-43	ribosomal protein S6 kinase B1	Homo sapiens	11-15
25154549-2	2014	It is also known that the mammalian target of rapamycin (mTOR)/p70 S6 kinase 1 (S6K1) and MAPK/p90 ribosomal S6 kinase (RSK) signaling pathways coordinately regulate phosphorylated-ERalpha at Ser(167) (p-Ser(167) -ERalpha).	Serine	192-195	ribosomal protein S6 kinase B1	Homo sapiens	80-85
25088800-5	2014	Meanwhile, AMP treatment suppressed Akt-mammalian target of rapamycin (mTOR) pathway as evidenced by dose- and time-dependent decrease of the phosphorylation of Akt, mTOR and ribosomal protein S6 kinase (p70S6K), whereas Akt activator insulin-like growth factor-1 (IGF-1) pretreatment partially restored Akt-mTOR pathway inhibited by AMP and decreased AMP-inuduced autophagy, signifying that AMP activated autophagy via inhibition of the Akt-mTOR pathway.	ampelopsin	11-14	ribosomal protein S6 kinase B1	Homo sapiens	204-210
25088800-5	2014	Meanwhile, AMP treatment suppressed Akt-mammalian target of rapamycin (mTOR) pathway as evidenced by dose- and time-dependent decrease of the phosphorylation of Akt, mTOR and ribosomal protein S6 kinase (p70S6K), whereas Akt activator insulin-like growth factor-1 (IGF-1) pretreatment partially restored Akt-mTOR pathway inhibited by AMP and decreased AMP-inuduced autophagy, signifying that AMP activated autophagy via inhibition of the Akt-mTOR pathway.	ampelopsin	334-337	ribosomal protein S6 kinase B1	Homo sapiens	204-210
25088800-5	2014	Meanwhile, AMP treatment suppressed Akt-mammalian target of rapamycin (mTOR) pathway as evidenced by dose- and time-dependent decrease of the phosphorylation of Akt, mTOR and ribosomal protein S6 kinase (p70S6K), whereas Akt activator insulin-like growth factor-1 (IGF-1) pretreatment partially restored Akt-mTOR pathway inhibited by AMP and decreased AMP-inuduced autophagy, signifying that AMP activated autophagy via inhibition of the Akt-mTOR pathway.	ampelopsin	334-337	ribosomal protein S6 kinase B1	Homo sapiens	204-210
25154549-2	2014	It is also known that the mammalian target of rapamycin (mTOR)/p70 S6 kinase 1 (S6K1) and MAPK/p90 ribosomal S6 kinase (RSK) signaling pathways coordinately regulate phosphorylated-ERalpha at Ser(167) (p-Ser(167) -ERalpha).	Serine	204-207	ribosomal protein S6 kinase B1	Homo sapiens	80-85
25088800-5	2014	Meanwhile, AMP treatment suppressed Akt-mammalian target of rapamycin (mTOR) pathway as evidenced by dose- and time-dependent decrease of the phosphorylation of Akt, mTOR and ribosomal protein S6 kinase (p70S6K), whereas Akt activator insulin-like growth factor-1 (IGF-1) pretreatment partially restored Akt-mTOR pathway inhibited by AMP and decreased AMP-inuduced autophagy, signifying that AMP activated autophagy via inhibition of the Akt-mTOR pathway.	ampelopsin	334-337	ribosomal protein S6 kinase B1	Homo sapiens	204-210
25490832-3	2014	The expressions of Akt/mTOR/p70 S6K in these cases were detected using the SP method of immunohisto- chemistry.	TFF2 protein, human	75-77	ribosomal protein S6 kinase B1	Homo sapiens	28-35
24243494-4	2014	PDGFR, VEGF-C, mToR, and PS6K expression was significantly reduced (p = 0.002, p = 0.035, p = 0.025, and p = 0.033, respectively) after ADT, whereas expression of EGFR, c-erbB-2, and CA9 was not influenced by ADT.	adt	136-139	ribosomal protein S6 kinase B1	Homo sapiens	25-29
25034385-8	2014	Acute stimulation of myotubes with testosterone reduced phosphorylation of S6K1 and p38 MAPK.	Testosterone	35-47	ribosomal protein S6 kinase B1	Homo sapiens	75-79
25232497-0	2014	Monepantel induces autophagy in human ovarian cancer cells through disruption of the mTOR/p70S6K signalling pathway.	monepantel	0-10	ribosomal protein S6 kinase B1	Homo sapiens	90-96
25146167-8	2014	Treatment of the human meningioma cell line HBL-52 with the PI3K inhibitor LY294002 resulted in reduction of p-AKT, p-p70S6K and p-ERK1/2 protein levels.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	75-83	ribosomal protein S6 kinase B1	Homo sapiens	118-124
25137351-7	2014	The study indicated that butein may repress MMP-9 and uPA proteolytic activities and subsequently inhibit cancer metastasis via Akt/mTOR/p70S6K translational machinery.	butein	25-31	ribosomal protein S6 kinase B1	Homo sapiens	137-143
24714080-0	2014	Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	88-92
24714080-6	2014	However, metformin inhibited the mTOR/S6K1 pathway in 253J and RT4 cells, which usually regulates protein translation; moreover, knockdown of S6K1 effectively reduced the levels of c-FLIPL, indicating that metformin downregulates c-FLIP through inhibition of the mTOR/S6K1 pathway.	Metformin	9-18	ribosomal protein S6 kinase B1	Homo sapiens	38-42
24714080-6	2014	However, metformin inhibited the mTOR/S6K1 pathway in 253J and RT4 cells, which usually regulates protein translation; moreover, knockdown of S6K1 effectively reduced the levels of c-FLIPL, indicating that metformin downregulates c-FLIP through inhibition of the mTOR/S6K1 pathway.	Metformin	9-18	ribosomal protein S6 kinase B1	Homo sapiens	142-146
24714080-6	2014	However, metformin inhibited the mTOR/S6K1 pathway in 253J and RT4 cells, which usually regulates protein translation; moreover, knockdown of S6K1 effectively reduced the levels of c-FLIPL, indicating that metformin downregulates c-FLIP through inhibition of the mTOR/S6K1 pathway.	Metformin	9-18	ribosomal protein S6 kinase B1	Homo sapiens	142-146
24714080-6	2014	However, metformin inhibited the mTOR/S6K1 pathway in 253J and RT4 cells, which usually regulates protein translation; moreover, knockdown of S6K1 effectively reduced the levels of c-FLIPL, indicating that metformin downregulates c-FLIP through inhibition of the mTOR/S6K1 pathway.	Metformin	206-215	ribosomal protein S6 kinase B1	Homo sapiens	142-146
25078151-2	2014	The crystal structures of the S6K1 kinase domain in complexes with staurosporine and the S6K1-specific inhibitor PF-4708671 have been reported.	Staurosporine	67-80	ribosomal protein S6 kinase B1	Homo sapiens	30-34
25078151-2	2014	The crystal structures of the S6K1 kinase domain in complexes with staurosporine and the S6K1-specific inhibitor PF-4708671 have been reported.	PF-4708671	113-123	ribosomal protein S6 kinase B1	Homo sapiens	30-34
25078151-2	2014	The crystal structures of the S6K1 kinase domain in complexes with staurosporine and the S6K1-specific inhibitor PF-4708671 have been reported.	PF-4708671	113-123	ribosomal protein S6 kinase B1	Homo sapiens	89-93
25034385-13	2014	Furthermore, testosterone treatment elicits additional alterations in serine/threonine kinase signaling, including the ribosomal protein S6K1 and p38 MAPK.	Testosterone	13-25	ribosomal protein S6 kinase B1	Homo sapiens	137-141
25061101-3	2014	Elevated phospho-p70S6K, also known as RPS6KB1 (ribosomal protein S6 kinase, 70kDa, polypeptide 1) (T389), an mTORC1 activation marker, predicted Flu resistance in a panel of B-cell lines, isogenic Flu-resistant (FluR) derivatives, and primary human CLL cells.	fludarabine	146-149	ribosomal protein S6 kinase B1	Homo sapiens	17-23
25061101-3	2014	Elevated phospho-p70S6K, also known as RPS6KB1 (ribosomal protein S6 kinase, 70kDa, polypeptide 1) (T389), an mTORC1 activation marker, predicted Flu resistance in a panel of B-cell lines, isogenic Flu-resistant (FluR) derivatives, and primary human CLL cells.	fludarabine	146-149	ribosomal protein S6 kinase B1	Homo sapiens	39-46
25061101-3	2014	Elevated phospho-p70S6K, also known as RPS6KB1 (ribosomal protein S6 kinase, 70kDa, polypeptide 1) (T389), an mTORC1 activation marker, predicted Flu resistance in a panel of B-cell lines, isogenic Flu-resistant (FluR) derivatives, and primary human CLL cells.	fludarabine	146-149	ribosomal protein S6 kinase B1	Homo sapiens	48-97
25061101-3	2014	Elevated phospho-p70S6K, also known as RPS6KB1 (ribosomal protein S6 kinase, 70kDa, polypeptide 1) (T389), an mTORC1 activation marker, predicted Flu resistance in a panel of B-cell lines, isogenic Flu-resistant (FluR) derivatives, and primary human CLL cells.	fludarabine	198-201	ribosomal protein S6 kinase B1	Homo sapiens	17-23
25061101-3	2014	Elevated phospho-p70S6K, also known as RPS6KB1 (ribosomal protein S6 kinase, 70kDa, polypeptide 1) (T389), an mTORC1 activation marker, predicted Flu resistance in a panel of B-cell lines, isogenic Flu-resistant (FluR) derivatives, and primary human CLL cells.	fludarabine	198-201	ribosomal protein S6 kinase B1	Homo sapiens	39-46
25061101-3	2014	Elevated phospho-p70S6K, also known as RPS6KB1 (ribosomal protein S6 kinase, 70kDa, polypeptide 1) (T389), an mTORC1 activation marker, predicted Flu resistance in a panel of B-cell lines, isogenic Flu-resistant (FluR) derivatives, and primary human CLL cells.	fludarabine	198-201	ribosomal protein S6 kinase B1	Homo sapiens	48-97
25061101-3	2014	Elevated phospho-p70S6K, also known as RPS6KB1 (ribosomal protein S6 kinase, 70kDa, polypeptide 1) (T389), an mTORC1 activation marker, predicted Flu resistance in a panel of B-cell lines, isogenic Flu-resistant (FluR) derivatives, and primary human CLL cells.	flur	213-217	ribosomal protein S6 kinase B1	Homo sapiens	17-23
25061101-3	2014	Elevated phospho-p70S6K, also known as RPS6KB1 (ribosomal protein S6 kinase, 70kDa, polypeptide 1) (T389), an mTORC1 activation marker, predicted Flu resistance in a panel of B-cell lines, isogenic Flu-resistant (FluR) derivatives, and primary human CLL cells.	flur	213-217	ribosomal protein S6 kinase B1	Homo sapiens	39-46
25061101-3	2014	Elevated phospho-p70S6K, also known as RPS6KB1 (ribosomal protein S6 kinase, 70kDa, polypeptide 1) (T389), an mTORC1 activation marker, predicted Flu resistance in a panel of B-cell lines, isogenic Flu-resistant (FluR) derivatives, and primary human CLL cells.	flur	213-217	ribosomal protein S6 kinase B1	Homo sapiens	48-97
25061101-12	2014	IMPLICATIONS: This study provides the first evidence for mTORC1/p70S6K-dependent regulation of pyrimidine biosynthesis in a relevant disease setting.	pyrimidine	95-105	ribosomal protein S6 kinase B1	Homo sapiens	64-70
24859886-0	2014	Loss of SNAIL inhibits cellular growth and metabolism through the miR-128-mediated RPS6KB1/HIF-1alpha/PKM2 signaling pathway in prostate cancer cells.	mir-128	66-73	ribosomal protein S6 kinase B1	Homo sapiens	83-90
24714080-6	2014	However, metformin inhibited the mTOR/S6K1 pathway in 253J and RT4 cells, which usually regulates protein translation; moreover, knockdown of S6K1 effectively reduced the levels of c-FLIPL, indicating that metformin downregulates c-FLIP through inhibition of the mTOR/S6K1 pathway.	Metformin	206-215	ribosomal protein S6 kinase B1	Homo sapiens	142-146
24714080-8	2014	Taken together, our results indicate that metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through downregulation of c-FLIP, which is mediated by the mTOR/S6K1 pathway, but independent of AMPK; furthermore, these findings provide a rationale for the combined application of metformin with TRAIL in the treatment of bladder cancer.	Metformin	42-51	ribosomal protein S6 kinase B1	Homo sapiens	181-185
25149531-6	2014	In addition, cells treated with rapamycin showed a significant increase in p-Akt and a decrease in p-p70S6K that was associated with a decrease expression of vimentin and a slight increase expression in N-cadherin.	Sirolimus	32-41	ribosomal protein S6 kinase B1	Homo sapiens	101-107
25153728-0	2014	The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1alpha and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.	Paclitaxel	35-45	ribosomal protein S6 kinase B1	Homo sapiens	111-114
25153728-6	2014	Treatment with sMEK1 and paclitaxel reduced phosphorylation of ribosomal S6 kinase (S6K) and 4E-binding protein (4E-BP), two critical downstream targets of the mTOR-signaling pathway.	Paclitaxel	25-35	ribosomal protein S6 kinase B1	Homo sapiens	84-87
25153728-7	2014	Furthermore, both sMEK1 and paclitaxel significantly inhibited the expression of signaling components downstream of S6K/4E-BP, such as hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF), both in vitro and in vivo.	Paclitaxel	28-38	ribosomal protein S6 kinase B1	Homo sapiens	116-119
25324684-14	2014	Compared to untreated MCMV-infected control cells, rapamycin treatment resulted in a significant decrease in the cleaved caspase 3 levels as well as a significant decrease in the ratio of phosphorylated mammalian target of rapamycin (mTOR) to total mTOR and in the ratio of phosphorylated P70S6K to total P70S6K.	Sirolimus	51-60	ribosomal protein S6 kinase B1	Homo sapiens	289-295
25324684-14	2014	Compared to untreated MCMV-infected control cells, rapamycin treatment resulted in a significant decrease in the cleaved caspase 3 levels as well as a significant decrease in the ratio of phosphorylated mammalian target of rapamycin (mTOR) to total mTOR and in the ratio of phosphorylated P70S6K to total P70S6K.	Sirolimus	51-60	ribosomal protein S6 kinase B1	Homo sapiens	305-311
25107987-7	2014	Additionally, the fold change in the phosphorylation of p70S6K (Thr389) at 2 h post exercise was correlated with the dose of whey protein consumed (r = 0.51, P &lt; 001) and was found to be significantly correlated with intramuscular leucine content (r = 0.32, P = 0.026).	Leucine	234-241	ribosomal protein S6 kinase B1	Homo sapiens	56-62
25110431-12	2014	Aspirin suppressed mTOR downstream signaling, evidenced by the reduced phosphorylation of the mTOR substrates 4E binding protein 1, serine/threonine kinase P70S6K and S6 ribosomal protein and inhibited glycogen synthase kinase 3 activity.	Aspirin	0-7	ribosomal protein S6 kinase B1	Homo sapiens	156-162
24875536-0	2014	Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways.	Reactive Oxygen Species	99-102	ribosomal protein S6 kinase B1	Homo sapiens	126-132
24875536-5	2014	In addition, reactive oxygen species (ROS) served as an upstream of PI3K/AKT/mTOR/p70S6K and JNK signaling pathways.	Reactive Oxygen Species	13-36	ribosomal protein S6 kinase B1	Homo sapiens	82-88
24875536-5	2014	In addition, reactive oxygen species (ROS) served as an upstream of PI3K/AKT/mTOR/p70S6K and JNK signaling pathways.	Reactive Oxygen Species	38-41	ribosomal protein S6 kinase B1	Homo sapiens	82-88
24994913-3	2014	In this report, we provide evidence that in the presence of glucose, exendin-4 stimulates rodent islet cell DNA replication via the activation of ribosomal protein S6 kinase 1 (S6K1) and that this is mediated by the protein kinase B (PKB)-dependent activation of mTOR complex 1 (mTORC1).	Glucose	60-67	ribosomal protein S6 kinase B1	Homo sapiens	177-181
24979463-6	2014	AKT-inhibition with MK-2206 led to increased apoptosis and to a decrease of pS6K in ARID1A-depleted MCF7 cells but not in the controls.	MK 2206	20-27	ribosomal protein S6 kinase B1	Homo sapiens	76-80
24887566-0	2014	Mollugin induces tumor cell apoptosis and autophagy via the PI3K/AKT/mTOR/p70S6K and ERK signaling pathways.	rubimaillin	0-8	ribosomal protein S6 kinase B1	Homo sapiens	74-80
24859886-9	2014	Furthermore, down-expression of miR-128 partially restored the effect of si-SNAIL on the suppression of cellular growth, metabolism, and RPS6KB1/HIF-1alpha/PKM2 signaling pathway.	mir-128	32-39	ribosomal protein S6 kinase B1	Homo sapiens	137-144
24859886-10	2014	To our knowledge, it is the first time to demonstrate that SNAIL/miR-128/RPS6KB1 pathway plays a critical role in the progression of PCa.	mir-128	65-72	ribosomal protein S6 kinase B1	Homo sapiens	73-80
24686084-5	2014	In addressing its biological molecular mechanism, GABARBP was found to effectively inhibit the phosphorylation of down-stream PI3K components, such as PDK1, Akt, mTOR, TSC-2, p70S6K, and 4E-BP1 by directly binding with VEGFR-2.	gabarbp	50-57	ribosomal protein S6 kinase B1	Homo sapiens	175-181
24824653-7	2014	Phosphorylation of p70S6K-Thr(389) was greater in WHEY vs. WHEY + NEAA (P = 0.02).	Threonine	26-29	ribosomal protein S6 kinase B1	Homo sapiens	19-25
24650522-0	2014	Ceramide inhibits insulin-stimulated Akt phosphorylation through activation of Rheb/mTORC1/S6K signaling in skeletal muscle.	Ceramides	0-8	ribosomal protein S6 kinase B1	Homo sapiens	91-94
24650522-5	2014	The mechanism by which C2-ceramide impairs signaling would seem to involve a negative feedback of activated S6K via phosphorylation of insulin receptor substrate-1 at Ser636/639, since S6K inhibitor can block this phenomenon.	N-acetylsphingosine	23-34	ribosomal protein S6 kinase B1	Homo sapiens	108-111
24650522-5	2014	The mechanism by which C2-ceramide impairs signaling would seem to involve a negative feedback of activated S6K via phosphorylation of insulin receptor substrate-1 at Ser636/639, since S6K inhibitor can block this phenomenon.	N-acetylsphingosine	23-34	ribosomal protein S6 kinase B1	Homo sapiens	185-188
24833778-7	2014	Ibuprofen treatment prevented sustained elevation of MEK-ERK signaling at 3 h (p-ERK1/2, p-RSK, p-Mnk1, p-p70S6K Thr421/Ser424) and 24 h (p-ERK1/2) postexercise, and this was associated with suppressed phosphorylation of ribosomal protein S6 (Ser235/236 and Ser240/244).	Ibuprofen	0-9	ribosomal protein S6 kinase B1	Homo sapiens	106-112
24859482-0	2014	Celastrol inhibits the HIF-1alpha pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells.	celastrol	0-9	ribosomal protein S6 kinase B1	Homo sapiens	64-70
24859482-8	2014	Markedly, we found that suppression of HIF-1alpha accumulation by celastrol correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E) and extracellular signal-regulated kinase (ERK), pathways known to regulate HIF-1alpha expression at the translational level.	celastrol	66-75	ribosomal protein S6 kinase B1	Homo sapiens	205-211
24682932-8	2014	Western blot and reverse transcription PCR (RT-PCR) analysis showed that the expressions of mTOR, 4E-BP1, and p70S6K were all significantly decreased in K562 cells after rapamycin + celecoxib treatment (P &lt; 0.05).	Sirolimus	170-179	ribosomal protein S6 kinase B1	Homo sapiens	110-116
24682932-8	2014	Western blot and reverse transcription PCR (RT-PCR) analysis showed that the expressions of mTOR, 4E-BP1, and p70S6K were all significantly decreased in K562 cells after rapamycin + celecoxib treatment (P &lt; 0.05).	Celecoxib	182-191	ribosomal protein S6 kinase B1	Homo sapiens	110-116
24935000-8	2014	Akt and p70S6K, targets of everolimus, were activated in Cakires compared to drug sensitive cells.	Everolimus	27-37	ribosomal protein S6 kinase B1	Homo sapiens	8-14
24936148-7	2014	These effects of S100A4 were abolished by treatment with either the specific PI3K/Akt inhibitor LY294002, or the specific mTOR/p70S6K inhibitor rapamycin.	Sirolimus	144-153	ribosomal protein S6 kinase B1	Homo sapiens	127-133
24901052-4	2014	The combination of mitomycin C and rapamycin inactivated p70 S6 ribosomal kinase (S6K1) and dephosphorylated Bad, leading to dissociation of Bcl-xL from Bak, which resulted in Bak oligomerization, mitochondria dysfunction and cytochrome c release.	Mitomycin	19-30	ribosomal protein S6 kinase B1	Homo sapiens	57-86
24901052-4	2014	The combination of mitomycin C and rapamycin inactivated p70 S6 ribosomal kinase (S6K1) and dephosphorylated Bad, leading to dissociation of Bcl-xL from Bak, which resulted in Bak oligomerization, mitochondria dysfunction and cytochrome c release.	Sirolimus	35-44	ribosomal protein S6 kinase B1	Homo sapiens	57-86
24922651-4	2014	RESULTS: SAHA reduced growth of the three cell lines by inhibiting protein kinase B AKT and mTOR/p70S6K cascade activation.	Vorinostat	9-13	ribosomal protein S6 kinase B1	Homo sapiens	97-103
24682932-9	2014	In conclusion, rapamycin combined with celecoxib could induce cell cycle arrest and apoptosis and decrease the expressions of mTOR, 4E-BP1, and p70S6K.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	144-150
24682932-9	2014	In conclusion, rapamycin combined with celecoxib could induce cell cycle arrest and apoptosis and decrease the expressions of mTOR, 4E-BP1, and p70S6K.	Celecoxib	39-48	ribosomal protein S6 kinase B1	Homo sapiens	144-150
24675012-0	2014	Fisetin inhibits human melanoma cell growth through direct binding to p70S6K and mTOR: findings from 3-D melanoma skin equivalents and computational modeling.	fisetin	0-7	ribosomal protein S6 kinase B1	Homo sapiens	70-76
24675012-11	2014	Our studies characterized, for the first time, the differential interactions of any botanical agent with kinases involved in melanoma growth and demonstrate that fisetin inhibits mTOR and p70S6K through direct binding while the observed inhibitory effect of fisetin on AKT is mediated indirectly, through targeting interrelated pathways.	fisetin	162-169	ribosomal protein S6 kinase B1	Homo sapiens	188-194
25034786-4	2014	Moreover, clioquinol inhibited the catalytic activity of the mTOR complex 1, thus suppressing phosphorylation of P70S6K and 4E-BP1, two major proteins associated with autophagy in the mTORC1 signaling pathway.	Clioquinol	10-20	ribosomal protein S6 kinase B1	Homo sapiens	113-130
24922651-5	2014	SAHA combined with LY or rapamycin, or both, synergistically reduced p-p70S6K and p-4E-BP1 levels.	Vorinostat	0-4	ribosomal protein S6 kinase B1	Homo sapiens	71-77
23564320-11	2014	We have found that, H3-Thr45 phosphorylation correlates to S6K activation in response to mitogens and TPA-induced cell differentiation of leukaemic cell lines U937, HL60 and THP1.	Tetradecanoylphorbol Acetate	102-105	ribosomal protein S6 kinase B1	Homo sapiens	59-62
24932295-7	2014	Resveratrol was also found to significantly attenuate the phosphorylation of the downstream molecules, p70S6K and 4EBP1.	Resveratrol	0-11	ribosomal protein S6 kinase B1	Homo sapiens	103-119
24974584-4	2014	Treatment with artemisinin was also associated with activation of AMP kinase and inhibition of mTOR/p70S6K/pS6 signaling in SHSY5Y cells.	artemisinin	15-26	ribosomal protein S6 kinase B1	Homo sapiens	100-106
24858012-8	2014	In MCF-7 cells metformin decreased the activation of IRbeta, Akt and ERK1/2, increased p-AMPK, FOXO3a, p27, Bax and cleaved caspase-3, and decreased phosphorylation of p70S6K and Bcl-2 protein expression.	Metformin	15-24	ribosomal protein S6 kinase B1	Homo sapiens	168-174
24851866-7	2014	Application of either LY294002 or wortmannin inhibited the activation of both S6K1 and Akt.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	22-30	ribosomal protein S6 kinase B1	Homo sapiens	78-90
24851866-7	2014	Application of either LY294002 or wortmannin inhibited the activation of both S6K1 and Akt.	Wortmannin	34-44	ribosomal protein S6 kinase B1	Homo sapiens	78-90
24630930-10	2014	Inhibition of PI3K and mTOR by LY295002 and rapamycin, respectively, decreases the phosphorylation of downstream targets (i.e. GSK3beta and p70S6K) and leads to an increase of catalase expression only in MCF-7 but not in Resox cells.	ly295002	31-39	ribosomal protein S6 kinase B1	Homo sapiens	140-146
24630930-10	2014	Inhibition of PI3K and mTOR by LY295002 and rapamycin, respectively, decreases the phosphorylation of downstream targets (i.e. GSK3beta and p70S6K) and leads to an increase of catalase expression only in MCF-7 but not in Resox cells.	Sirolimus	44-53	ribosomal protein S6 kinase B1	Homo sapiens	140-146
24691032-10	2014	Phosphorylation of mTOR (Ser(2448)) and S6K1 (Thr(389)) was also increased in CON but inhibited in RAP.	Threonine	46-49	ribosomal protein S6 kinase B1	Homo sapiens	40-44
24652283-3	2014	Here we show that the acetylation of the C-terminal region (CTR) of S6K1 blocks mTORC1-dependent Thr-389 phosphorylation, an essential phosphorylation site for S6K1 activity.	Threonine	97-100	ribosomal protein S6 kinase B1	Homo sapiens	68-72
24652283-3	2014	Here we show that the acetylation of the C-terminal region (CTR) of S6K1 blocks mTORC1-dependent Thr-389 phosphorylation, an essential phosphorylation site for S6K1 activity.	Threonine	97-100	ribosomal protein S6 kinase B1	Homo sapiens	160-164
24652283-5	2014	An S6K1 mutant lacking acetylation sites in its CTR shows enhanced Thr-389 phosphorylation and kinase activity, whereas the acetylation-mimetic S6K1 mutant exhibits decreased Thr-389 phosphorylation and kinase activity.	Threonine	67-70	ribosomal protein S6 kinase B1	Homo sapiens	3-7
24652283-5	2014	An S6K1 mutant lacking acetylation sites in its CTR shows enhanced Thr-389 phosphorylation and kinase activity, whereas the acetylation-mimetic S6K1 mutant exhibits decreased Thr-389 phosphorylation and kinase activity.	Threonine	175-178	ribosomal protein S6 kinase B1	Homo sapiens	144-148
24508654-11	2014	Both rapamycin and cardamonin decreased the phosphorylation of mTOR and p70S6K in two kinds of transfected cells.	Sirolimus	5-14	ribosomal protein S6 kinase B1	Homo sapiens	72-78
24922651-5	2014	SAHA combined with LY or rapamycin, or both, synergistically reduced p-p70S6K and p-4E-BP1 levels.	Lysine	19-21	ribosomal protein S6 kinase B1	Homo sapiens	71-77
24922651-5	2014	SAHA combined with LY or rapamycin, or both, synergistically reduced p-p70S6K and p-4E-BP1 levels.	Sirolimus	25-34	ribosomal protein S6 kinase B1	Homo sapiens	71-77
24810050-13	2014	We conclude that by activating mTOR/S6K glucose causes feedback IR, preventable by rapamycin.	Glucose	40-47	ribosomal protein S6 kinase B1	Homo sapiens	36-39
24607408-11	2014	Furthermore, calanquinone A induced the activation of AMP-activated protein kinase (AMPK) and the inhibition of p70S6K activity.	calanquinone A	13-27	ribosomal protein S6 kinase B1	Homo sapiens	112-118
24860943-0	2014	Long term exposure to L-arginine accelerates endothelial cell senescence through arginase-II and S6K1 signaling.	Arginine	22-32	ribosomal protein S6 kinase B1	Homo sapiens	97-101
24860943-6	2014	While acute L-arginine treatment enhances endothelial NO production accompanied with superoxide production and activation of S6K1 but no up-regulation of arginase-II, chronic L-arginine supplementation causes endothelial senescence, up-regulation of the adhesion molecule expression, and eNOS-uncoupling (decreased NO and enhanced superoxide production), which are associated with S6K1 activation and up-regulation of arginase-II.	Arginine	12-22	ribosomal protein S6 kinase B1	Homo sapiens	125-129
24860943-6	2014	While acute L-arginine treatment enhances endothelial NO production accompanied with superoxide production and activation of S6K1 but no up-regulation of arginase-II, chronic L-arginine supplementation causes endothelial senescence, up-regulation of the adhesion molecule expression, and eNOS-uncoupling (decreased NO and enhanced superoxide production), which are associated with S6K1 activation and up-regulation of arginase-II.	Arginine	12-22	ribosomal protein S6 kinase B1	Homo sapiens	381-385
24860943-6	2014	While acute L-arginine treatment enhances endothelial NO production accompanied with superoxide production and activation of S6K1 but no up-regulation of arginase-II, chronic L-arginine supplementation causes endothelial senescence, up-regulation of the adhesion molecule expression, and eNOS-uncoupling (decreased NO and enhanced superoxide production), which are associated with S6K1 activation and up-regulation of arginase-II.	Arginine	175-185	ribosomal protein S6 kinase B1	Homo sapiens	381-385
24860943-7	2014	Silencing either S6K1 or arginase-II inhibits up-regulation/activation of each other, prevents endothelial dysfunction, adhesion molecule expression, and senescence under the chronic L-arginine supplementation condition.	Arginine	183-193	ribosomal protein S6 kinase B1	Homo sapiens	17-21
24860943-8	2014	These results demonstrate that S6K1 and arginase-II form a positive circuit mediating the detrimental effects of chronic L-arginine supplementation on endothelial cells.	Arginine	121-131	ribosomal protein S6 kinase B1	Homo sapiens	31-35
24471788-0	2014	Salidroside exerts angiogenic and cytoprotective effects on human bone marrow-derived endothelial progenitor cells via Akt/mTOR/p70S6K and MAPK signalling pathways.	rhodioloside	0-11	ribosomal protein S6 kinase B1	Homo sapiens	128-134
24677687-2	2014	Reviewed are also specific interactions between mTOR/S6K1 and ROS-DNA damage signaling pathways.	ros	62-65	ribosomal protein S6 kinase B1	Homo sapiens	53-57
24677687-8	2014	While the primary target of each of these agents may be different the data obtained on several human cancer cell lines, WI-38 fibroblasts and normal lymphocytes suggest common downstream mechanism in which the decline in mTOR/S6K1 signaling and translation rate is coupled with a reduction of oxidative phosphorylation and ROS that leads to decreased oxidative DNA damage.	ros	323-326	ribosomal protein S6 kinase B1	Homo sapiens	226-230
24508654-11	2014	Both rapamycin and cardamonin decreased the phosphorylation of mTOR and p70S6K in two kinds of transfected cells.	cardamonin	19-29	ribosomal protein S6 kinase B1	Homo sapiens	72-78
24607448-11	2014	Adiponectin upregulated TSC2 expression and downregulated mTOR and S6K1 phosphorylation in beta-GP-treated VSMCs.	beta-glycerophosphoric acid	91-98	ribosomal protein S6 kinase B1	Homo sapiens	67-71
24607448-11	2014	Adiponectin upregulated TSC2 expression and downregulated mTOR and S6K1 phosphorylation in beta-GP-treated VSMCs.	vsmcs	107-112	ribosomal protein S6 kinase B1	Homo sapiens	67-71
24631374-8	2014	We found that the autophagy inhibitor 3-methyladenine administered after Rap treatment completely reverted the increased phosphorylation of eIF2alpha and p70S6K inactivation, and blocked the formation of autophagosome-like structures restoring the UPR.	3-methyladenine	38-53	ribosomal protein S6 kinase B1	Homo sapiens	154-160
24626348-4	2014	Short-term GS-HCl treatment also decreased phosphorylation of p70S6K and S6, translation-related proteins.	gs-hcl	11-17	ribosomal protein S6 kinase B1	Homo sapiens	62-68
24612393-8	2014	PKC-mediated adenosine diphosphate (ADP) secretion was essential for thrombin-stimulated mTORC1 activation, as (i) ADP rescued p70S6K phosphorylation in the presence of a PKC inhibitor and (ii) P2Y(12) antagonism prevented thrombin-mediated mTORC1 activation.	Adenosine Diphosphate	13-34	ribosomal protein S6 kinase B1	Homo sapiens	127-133
24612393-8	2014	PKC-mediated adenosine diphosphate (ADP) secretion was essential for thrombin-stimulated mTORC1 activation, as (i) ADP rescued p70S6K phosphorylation in the presence of a PKC inhibitor and (ii) P2Y(12) antagonism prevented thrombin-mediated mTORC1 activation.	Adenosine Diphosphate	36-39	ribosomal protein S6 kinase B1	Homo sapiens	127-133
24612393-8	2014	PKC-mediated adenosine diphosphate (ADP) secretion was essential for thrombin-stimulated mTORC1 activation, as (i) ADP rescued p70S6K phosphorylation in the presence of a PKC inhibitor and (ii) P2Y(12) antagonism prevented thrombin-mediated mTORC1 activation.	Adenosine Diphosphate	115-118	ribosomal protein S6 kinase B1	Homo sapiens	127-133
24595305-5	2014	p70 S6K Thr(389) phosphorylation increased above EB only with combined exercise and protein intake (~2-7 fold, P &lt; 0.05).	Threonine	8-11	ribosomal protein S6 kinase B1	Homo sapiens	0-7
24599950-6	2014	Activation of the AMP-activated protein kinase/mammalian target of rapamycin/p70S6K pathway, but not the PI3K/AKT pathway, occurred in autophagy induced by cucurbitacin I, which was accompanied by decreased hypoxia-inducible factor 1alpha.	cucurbitacin I	156-170	ribosomal protein S6 kinase B1	Homo sapiens	77-83
24580843-4	2014	We found that everolimus inhibits mTOR complex 1 (mTORC1) by disassociating Raptor from mTOR, thereby preventing class I-induced phosphorylation of mTOR, p70S6K, S6RP and 4E-BP1, and resultant class I-stimulated cell migration and proliferation.	Everolimus	14-24	ribosomal protein S6 kinase B1	Homo sapiens	154-160
24370994-1	2014	We have recently reported that beta-caryophyllene oxide (CPO) can induce apoptosis, suppress tumor growth, and inhibit metastasis through the suppression of signal transducer and activator of transcription 3, PI3K/AKT/mTOR/S6K1 signaling cascades and ROS-mediated MAPKs activation.	caryophyllene oxide	31-55	ribosomal protein S6 kinase B1	Homo sapiens	223-227
24370994-1	2014	We have recently reported that beta-caryophyllene oxide (CPO) can induce apoptosis, suppress tumor growth, and inhibit metastasis through the suppression of signal transducer and activator of transcription 3, PI3K/AKT/mTOR/S6K1 signaling cascades and ROS-mediated MAPKs activation.	caryophyllene oxide	57-60	ribosomal protein S6 kinase B1	Homo sapiens	223-227
24513322-5	2014	Mechanistically, pomiferin triacetate appeared as a general inhibitor of the PI3K-Akt-mTOR-p70(S6K) cascade.	4-(5-acetyloxy-8,8-dimethyl-6-(3-methylbut-2-en-1-yl)-4-oxo-4,8-dihydropyrano(2,3-f)chromen-3-yl)-1,2-phenylene diacetate	17-37	ribosomal protein S6 kinase B1	Homo sapiens	95-98
24519751-0	2014	Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.	perifosine	0-10	ribosomal protein S6 kinase B1	Homo sapiens	20-24
24519751-6	2014	Our data demonstrated that perifosine blocked p70S6K1 (S6K1) activation, thus disrupting S6K1-Gli1 association and subsequent Gli1 activation.	perifosine	27-37	ribosomal protein S6 kinase B1	Homo sapiens	49-53
24519751-6	2014	Our data demonstrated that perifosine blocked p70S6K1 (S6K1) activation, thus disrupting S6K1-Gli1 association and subsequent Gli1 activation.	perifosine	27-37	ribosomal protein S6 kinase B1	Homo sapiens	55-59
24519751-7	2014	The reduction of S6K1 or Gli1 expression by target siRNAs inhibited PTCH1 expression and enhanced gemcitabine-induced cytotoxicity in pancreatic cancer cells.	gemcitabine	98-109	ribosomal protein S6 kinase B1	Homo sapiens	17-21
24578415-3	2014	GABA inhibits the selective autophagy pathways, mitophagy and pexophagy, through Sch9, the homolog of the mammalian kinase, S6K1, leading to oxidative stress, all of which can be mitigated by the Tor1 inhibitor, rapamycin.	gamma-Aminobutyric Acid	0-4	ribosomal protein S6 kinase B1	Homo sapiens	124-128
24578415-3	2014	GABA inhibits the selective autophagy pathways, mitophagy and pexophagy, through Sch9, the homolog of the mammalian kinase, S6K1, leading to oxidative stress, all of which can be mitigated by the Tor1 inhibitor, rapamycin.	sch9	81-85	ribosomal protein S6 kinase B1	Homo sapiens	124-128
24464048-10	2014	Furthermore, both OSU-CG5 and resveratrol induced dose-dependent energy restriction in the cells: they suppressed glucose uptake and Akt phosphorylation, decreased the levels of p-mTOR and p-p70S6K, increased the levels of ER stress response proteins GRP78 and GADD153, and increased the level of beta-TrCP, which led to the downregulation of cyclin D1 and Sp1.	OSU-CG5	18-25	ribosomal protein S6 kinase B1	Homo sapiens	191-197
24464048-10	2014	Furthermore, both OSU-CG5 and resveratrol induced dose-dependent energy restriction in the cells: they suppressed glucose uptake and Akt phosphorylation, decreased the levels of p-mTOR and p-p70S6K, increased the levels of ER stress response proteins GRP78 and GADD153, and increased the level of beta-TrCP, which led to the downregulation of cyclin D1 and Sp1.	Resveratrol	30-41	ribosomal protein S6 kinase B1	Homo sapiens	191-197
24378576-8	2014	Temsirolimus strongly inhibited the phosphorylation of p70s6k, a downstream molecule of mTOR, in all MPM cell lines and led to an increase in the levels of cleaved caspase-3 in the H226 and Y-meso14 cells.	temsirolimus	0-12	ribosomal protein S6 kinase B1	Homo sapiens	55-61
24333213-7	2014	Rather, we found that suppression of HIF-1alpha accumulation by cucurbitacin B correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1) and extracellular signal-regulated kinase-1/2 (ERK1/2), a pathway known to regulate HIF-1alpha expression at the translational level.	cucurbitacin B	64-78	ribosomal protein S6 kinase B1	Homo sapiens	207-213
23686889-0	2014	Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades.	brassinin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	105-109
23686889-2	2014	Here, we investigated the effects of brassinin (BSN), a phytoalexin first identified as a constituent of cabbage, on the PI3K/Akt/mTOR/S6K1 activation, cellular proliferation, and apoptosis in PC-3 human prostate cancer.	brassinin	37-46	ribosomal protein S6 kinase B1	Homo sapiens	135-139
23686889-2	2014	Here, we investigated the effects of brassinin (BSN), a phytoalexin first identified as a constituent of cabbage, on the PI3K/Akt/mTOR/S6K1 activation, cellular proliferation, and apoptosis in PC-3 human prostate cancer.	brassinin	48-51	ribosomal protein S6 kinase B1	Homo sapiens	135-139
23813779-0	2014	Tanshinone IIA induces autophagic cell death via activation of AMPK and ERK and inhibition of mTOR and p70 S6K in KBM-5 leukemia cells.	tanshinone	0-14	ribosomal protein S6 kinase B1	Homo sapiens	103-110
23813779-5	2014	Conversely, autophagy inhibitor 3-methyladenine partly reversed the cytotoxicity and the phosphorylation of AMPK, mTOR and p70 S6K induced by Tan IIA in KBM-5 leukemia cells.	3-methyladenine	32-47	ribosomal protein S6 kinase B1	Homo sapiens	123-130
24566141-0	2014	Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1.	evodiamine	0-10	ribosomal protein S6 kinase B1	Homo sapiens	109-113
24566141-5	2014	On the other hand, evodiamine inhibited the mTOR/S6K1 pathway, which usually regulates protein translation; moreover, knockdown of S6K1 with small interfering RNA (siRNA) effectively reduced Mcl-1 levels, indicating evodiamine downregulates c-FLIP through inhibition of mTOR/S6K1 pathway.	evodiamine	19-29	ribosomal protein S6 kinase B1	Homo sapiens	49-53
24566141-5	2014	On the other hand, evodiamine inhibited the mTOR/S6K1 pathway, which usually regulates protein translation; moreover, knockdown of S6K1 with small interfering RNA (siRNA) effectively reduced Mcl-1 levels, indicating evodiamine downregulates c-FLIP through inhibition of mTOR/S6K1 pathway.	evodiamine	19-29	ribosomal protein S6 kinase B1	Homo sapiens	131-135
24566141-5	2014	On the other hand, evodiamine inhibited the mTOR/S6K1 pathway, which usually regulates protein translation; moreover, knockdown of S6K1 with small interfering RNA (siRNA) effectively reduced Mcl-1 levels, indicating evodiamine downregulates c-FLIP through inhibition of mTOR/S6K1 pathway.	evodiamine	19-29	ribosomal protein S6 kinase B1	Homo sapiens	131-135
24566141-5	2014	On the other hand, evodiamine inhibited the mTOR/S6K1 pathway, which usually regulates protein translation; moreover, knockdown of S6K1 with small interfering RNA (siRNA) effectively reduced Mcl-1 levels, indicating evodiamine downregulates c-FLIP through inhibition of mTOR/S6K1 pathway.	evodiamine	216-226	ribosomal protein S6 kinase B1	Homo sapiens	131-135
24566141-5	2014	On the other hand, evodiamine inhibited the mTOR/S6K1 pathway, which usually regulates protein translation; moreover, knockdown of S6K1 with small interfering RNA (siRNA) effectively reduced Mcl-1 levels, indicating evodiamine downregulates c-FLIP through inhibition of mTOR/S6K1 pathway.	evodiamine	216-226	ribosomal protein S6 kinase B1	Homo sapiens	131-135
24566141-6	2014	Taken together, our results indicate that evodiamine induces apoptosis and enhances TRAIL-induced apoptosis possibly through mTOR/S6K1-mediated downregulation of Mcl-1; furthermore, these findings provide a rationale for the combined application of evodiamine with TRAIL in the treatment of bladder cancer.	evodiamine	42-52	ribosomal protein S6 kinase B1	Homo sapiens	130-134
24462769-8	2014	In addition, chronic treatment with rapamycin, a condition known to interfere with assembly of mTORC2, reduces the interaction between Gbetagamma and mTOR and the phosphorylation of AKT; whereas overexpression of Galphai interfered with the effect of Gbetagamma as promoter of p70S6K and AKT phosphorylation.	Sirolimus	36-45	ribosomal protein S6 kinase B1	Homo sapiens	277-283
24462769-8	2014	In addition, chronic treatment with rapamycin, a condition known to interfere with assembly of mTORC2, reduces the interaction between Gbetagamma and mTOR and the phosphorylation of AKT; whereas overexpression of Galphai interfered with the effect of Gbetagamma as promoter of p70S6K and AKT phosphorylation.	gbetagamma	135-145	ribosomal protein S6 kinase B1	Homo sapiens	277-283
24363397-5	2014	AZD1208 causes cell cycle arrest and apoptosis in MOLM-16 cells, accompanied by a dose-dependent reduction in phosphorylation of Bcl-2 antagonist of cell death, 4EBP1, p70S6K, and S6, as well as increases in cleaved caspase 3 and p27.	AZD1208	0-7	ribosomal protein S6 kinase B1	Homo sapiens	168-174
24505341-10	2014	Furthermore, hyperthermia potentiated the effect of metformin to activate AMPK and inactivate mTOR and S6K.	Metformin	52-61	ribosomal protein S6 kinase B1	Homo sapiens	103-106
24066853-8	2014	Artesunate, but not dexamethasone, inhibited phospho-Akt and phospho-p70(S6K) protein abundance.	Artesunate	0-10	ribosomal protein S6 kinase B1	Homo sapiens	69-72
24066853-11	2014	Our study provides a basis for the future development of artesunate as a novel anti-AWR agent that targets ASM hyperplasia via the PI3K/Akt/p70(S6K) pathway and suggests that artesunate may be used as combination therapy with glucocorticoids.	Artesunate	57-67	ribosomal protein S6 kinase B1	Homo sapiens	140-143
24307199-6	2014	In addition, 3-BrP caused glutathione-dependent stimulation of p38 mitogen-activated protein kinase (MAPK), mitogen-induced extracellular kinase (MEK)/extracellular signal-regulated kinase (ERK), and protein kinase B (Akt)/mammalian target of rapamycin/p70S6K phosphorylation or activation, as well as rapid LKB-1/AMP kinase (AMPK) activation, which was later followed by Akt-mediated inactivation.	bromopyruvate	13-18	ribosomal protein S6 kinase B1	Homo sapiens	253-259
24307199-6	2014	In addition, 3-BrP caused glutathione-dependent stimulation of p38 mitogen-activated protein kinase (MAPK), mitogen-induced extracellular kinase (MEK)/extracellular signal-regulated kinase (ERK), and protein kinase B (Akt)/mammalian target of rapamycin/p70S6K phosphorylation or activation, as well as rapid LKB-1/AMP kinase (AMPK) activation, which was later followed by Akt-mediated inactivation.	Glutathione	26-37	ribosomal protein S6 kinase B1	Homo sapiens	253-259
24287118-0	2014	Ghrelin protects human umbilical vein endothelial cells against high glucose-induced apoptosis via mTOR/P70S6K signaling pathway.	Glucose	69-76	ribosomal protein S6 kinase B1	Homo sapiens	104-110
24287118-6	2014	Ghrelin stimulated the rapid phosphorylation of mammalian target of rapamycin (mTOR), P70S6K and S6.	Ghrelin	0-7	ribosomal protein S6 kinase B1	Homo sapiens	86-92
24287118-7	2014	The GHS-R1a-specific antagonist [D-Lys3]-GHRP-6 abolished the anti-apoptotic effect and inhibited the activation of mTOR, P70S6K, S6 induced by ghrelin.	[d-lys3]-ghrp	32-45	ribosomal protein S6 kinase B1	Homo sapiens	122-128
24287118-7	2014	The GHS-R1a-specific antagonist [D-Lys3]-GHRP-6 abolished the anti-apoptotic effect and inhibited the activation of mTOR, P70S6K, S6 induced by ghrelin.	Ghrelin	144-151	ribosomal protein S6 kinase B1	Homo sapiens	122-128
24287118-10	2014	Taken together, our results demonstrate that ghrelin produces a protective effect on HUVECs through activating GHS-R1a and mTOR/P70S6K signaling pathway mediates the effect of ghrelin.	Ghrelin	45-52	ribosomal protein S6 kinase B1	Homo sapiens	128-134
24287118-10	2014	Taken together, our results demonstrate that ghrelin produces a protective effect on HUVECs through activating GHS-R1a and mTOR/P70S6K signaling pathway mediates the effect of ghrelin.	Ghrelin	176-183	ribosomal protein S6 kinase B1	Homo sapiens	128-134
24447434-0	2014	Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.	Tamoxifen	32-41	ribosomal protein S6 kinase B1	Homo sapiens	15-22
24447434-0	2014	Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.	Tamoxifen	122-131	ribosomal protein S6 kinase B1	Homo sapiens	15-22
24447434-10	2014	Applying a conservative level of significance, p-p70S6K remained significantly associated with tamoxifen resistance.	Tamoxifen	95-104	ribosomal protein S6 kinase B1	Homo sapiens	49-55
24447434-11	2014	Patients with p-p70S6K negative tumors derived significant benefit from tamoxifen (HR 0.24, P &lt; 0.0001), while patients whose tumor did express p-p70S6K did not (HR = 1.02, P =0.95), P for interaction 0.004.	Tamoxifen	72-81	ribosomal protein S6 kinase B1	Homo sapiens	16-22
24438088-1	2014	BACKGROUND: Recent studies have shown that glucosamine inhibits the proliferation of various human cancer cell lines and downregulates the activity of COX-2, HIF-1alpha, p70S6K, and transglutaminase 2.	Glucosamine	43-54	ribosomal protein S6 kinase B1	Homo sapiens	170-176
24438088-2	2014	Because the IGF-1R/Akt pathway is a common upstream regulator of p70S6K, HIF-1alpha, and COX-2, we hypothesized that glucosamine inhibits cancer cell proliferation through this pathway.	Glucosamine	117-128	ribosomal protein S6 kinase B1	Homo sapiens	65-71
24568519-7	2014	Moreover, recovery of the mTOR pathway by overexpression of S6K desensitized the chondrosarcoma cells to cisplatin, suggesting the miR-100-mediated sensitization to cisplatin dependent on inhibition of mTOR.	Cisplatin	105-114	ribosomal protein S6 kinase B1	Homo sapiens	60-63
24568519-7	2014	Moreover, recovery of the mTOR pathway by overexpression of S6K desensitized the chondrosarcoma cells to cisplatin, suggesting the miR-100-mediated sensitization to cisplatin dependent on inhibition of mTOR.	Cisplatin	165-174	ribosomal protein S6 kinase B1	Homo sapiens	60-63
24605337-5	2014	We have accordingly attempted to relate the growth inhibitory effects of bupivacaine with the status of S6K1 activity and we present evidence that decrease in cell growth and proliferation by bupivacaine is mediated through inactivation of S6 kinase 1 in a concentration and time dependent manner.	Bupivacaine	192-203	ribosomal protein S6 kinase B1	Homo sapiens	104-108
24688409-5	2014	Moreover, the protein levels of mTORC1 downstream indicators pS6K and p4EBP-1 were reduced by thapsigargin treatment at different concentrations and times, which should be responsible for the reduced cyclin D1 expressions.	Thapsigargin	94-106	ribosomal protein S6 kinase B1	Homo sapiens	61-65
24476474-8	2014	Phosphorylation of mTOR and p70S6k was elevated to a larger extent following 1 h of recovery with leucine in the supplement (120% vs. 49% (p &lt; 0.05) and 59- vs. 8-fold (p &lt; 0.05) for EAA and EAA-Leu, respectively).	Leucine	98-105	ribosomal protein S6 kinase B1	Homo sapiens	28-34
24476474-8	2014	Phosphorylation of mTOR and p70S6k was elevated to a larger extent following 1 h of recovery with leucine in the supplement (120% vs. 49% (p &lt; 0.05) and 59- vs. 8-fold (p &lt; 0.05) for EAA and EAA-Leu, respectively).	Excitatory Amino Acids	189-192	ribosomal protein S6 kinase B1	Homo sapiens	28-34
24476474-8	2014	Phosphorylation of mTOR and p70S6k was elevated to a larger extent following 1 h of recovery with leucine in the supplement (120% vs. 49% (p &lt; 0.05) and 59- vs. 8-fold (p &lt; 0.05) for EAA and EAA-Leu, respectively).	Excitatory Amino Acids	197-200	ribosomal protein S6 kinase B1	Homo sapiens	28-34
24476474-8	2014	Phosphorylation of mTOR and p70S6k was elevated to a larger extent following 1 h of recovery with leucine in the supplement (120% vs. 49% (p &lt; 0.05) and 59- vs. 8-fold (p &lt; 0.05) for EAA and EAA-Leu, respectively).	Leucine	201-204	ribosomal protein S6 kinase B1	Homo sapiens	28-34
24267781-8	2014	RESULTS: In the ischemic myocardium, a high cholesterol diet partly attenuated the autophagy, as determined by an increase in phosphorylated mammalian target of rapamycin (p-mTOR) and a decrease in p70 S6 kinase (P70S6K), lysosome-associated membrane protein (LAMP)-2, and autophagy-related gene 12-5 conjugate (ATG 12-5; P &lt; .05).	Cholesterol	44-55	ribosomal protein S6 kinase B1	Homo sapiens	198-211
24267781-8	2014	RESULTS: In the ischemic myocardium, a high cholesterol diet partly attenuated the autophagy, as determined by an increase in phosphorylated mammalian target of rapamycin (p-mTOR) and a decrease in p70 S6 kinase (P70S6K), lysosome-associated membrane protein (LAMP)-2, and autophagy-related gene 12-5 conjugate (ATG 12-5; P &lt; .05).	Cholesterol	44-55	ribosomal protein S6 kinase B1	Homo sapiens	213-219
23783244-5	2014	Levels of several signaling proteins increased significantly while leucine-induced phosphorylation of mTOR and downstream proteins, 4e-BP1 and S6K1, was completely suppressed.	Leucine	67-74	ribosomal protein S6 kinase B1	Homo sapiens	143-147
24287118-0	2014	Ghrelin protects human umbilical vein endothelial cells against high glucose-induced apoptosis via mTOR/P70S6K signaling pathway.	Ghrelin	0-7	ribosomal protein S6 kinase B1	Homo sapiens	104-110
25087956-0	2014	Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6K signaling pathway.	Eugenol	0-7	ribosomal protein S6 kinase B1	Homo sapiens	107-113
25295069-5	2014	The antiadipogenic effect of Oligonol appears to originate from its ability to inhibit the Akt and mammalian target of rapamycin (mTOR) signaling pathway by diminishing the phosphorylation of ribosomal protein S6 kinase (p70S6K), a downstream target of mTOR and forkhead box protein O1 (Foxo1).	oligonol	29-37	ribosomal protein S6 kinase B1	Homo sapiens	221-227
24076964-0	2014	Regulation of matrix metalloproteinase-1, -3, and -9 in Mycobacterium tuberculosis-dependent respiratory networks by the rapamycin-sensitive PI3K/p70(S6K) cascade.	Sirolimus	121-130	ribosomal protein S6 kinase B1	Homo sapiens	146-153
24732927-4	2014	Moreover, novel mechanisms for energy balance regulation involving gastric-brain communication are described including the role of the gastric intracellular mTOR/S6K1 pathway mediating the interaction among ghrelin, nesfatin and endocannabinoid gastric systems to modulate metabolism.	Ghrelin	207-214	ribosomal protein S6 kinase B1	Homo sapiens	162-166
24732927-4	2014	Moreover, novel mechanisms for energy balance regulation involving gastric-brain communication are described including the role of the gastric intracellular mTOR/S6K1 pathway mediating the interaction among ghrelin, nesfatin and endocannabinoid gastric systems to modulate metabolism.	nesfatin	216-224	ribosomal protein S6 kinase B1	Homo sapiens	162-166
24750786-3	2014	Metformin exerts anticancer effects by primarily blocking the pivotal LKB1/AMPK/mTOR/S6K1 pathway-dependent cell growth, induces selective lethal effects on GSC by impairing the GSC-initiating spherogenesis and inhibits the proliferation of CD133+ cells, while having a low or null effect on differentiated glioblastoma cells and normal human stem cells.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	85-89
25075425-0	2014	4",6-dihydroxy-4-methoxyisoaurone inhibits the HIF-1alpha pathway through inhibition of Akt/mTOR/p70S6K/4E-BP1 phosphorylation.	4',6-dihydroxy-4-methoxyisoaurone	0-33	ribosomal protein S6 kinase B1	Homo sapiens	97-103
25075425-8	2014	Taken together, our results suggested that ISOA is an effective inhibitor of HIF-1 through targeting Akt/mTOR/p70S6K/4E-BP1 pathway, thereby, providing new perspectives into the mechanism of its anticancer activity.	isoa	43-47	ribosomal protein S6 kinase B1	Homo sapiens	110-116
24239466-3	2014	RESULTS: A high concentration of rapamycin (10 muM) blocked both S6K1 and elF4E phosphorylation and inhibited cell proliferation in T24 and 5637 cells.	Sirolimus	33-42	ribosomal protein S6 kinase B1	Homo sapiens	65-69
24239466-5	2014	Cells silenced for S6K1 or elF4E expression exhibited significantly reduced cell migration and invasion compared with those of the control but inhibition of both S6K1 and elF4E phosphorylation by rapamycin reduced cell migration and invasion more than siRNA transfection against S6K1 or elF4E in 5637 and T24 cells.	Sirolimus	196-205	ribosomal protein S6 kinase B1	Homo sapiens	162-166
24239466-5	2014	Cells silenced for S6K1 or elF4E expression exhibited significantly reduced cell migration and invasion compared with those of the control but inhibition of both S6K1 and elF4E phosphorylation by rapamycin reduced cell migration and invasion more than siRNA transfection against S6K1 or elF4E in 5637 and T24 cells.	Sirolimus	196-205	ribosomal protein S6 kinase B1	Homo sapiens	162-166
24391749-0	2013	Evodiamine inhibits insulin-stimulated mTOR-S6K activation and IRS1 serine phosphorylation in adipocytes and improves glucose tolerance in obese/diabetic mice.	evodiamine	0-10	ribosomal protein S6 kinase B1	Homo sapiens	44-47
24030871-7	2014	RAPA markedly inhibited cell proliferation, induced G1 cell cycle arrest, and reduced phosphorylation of p70 S6 protein kinase (p70S6K) and 4E-BP1 in GC cells, particularly when used in combination with LY294002 or TSA.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	203-211	ribosomal protein S6 kinase B1	Homo sapiens	128-134
24030871-7	2014	RAPA markedly inhibited cell proliferation, induced G1 cell cycle arrest, and reduced phosphorylation of p70 S6 protein kinase (p70S6K) and 4E-BP1 in GC cells, particularly when used in combination with LY294002 or TSA.	trichostatin A	215-218	ribosomal protein S6 kinase B1	Homo sapiens	105-126
24391749-9	2013	These results suggest evodiamine improves glucose tolerance and prevents the progress of insulin resistance associated with obese/diabetic states, at least in part, through inhibition of mTOR-S6K signaling and IRS1 serine phosphorylation in adipocytes.	evodiamine	22-32	ribosomal protein S6 kinase B1	Homo sapiens	192-195
24391749-3	2013	There is a significant decrease in the mammalian target of rapamycin (mTOR) and ribosomal S6 protein kinase (S6K) signaling in white adipose tissue (WAT) in KK-Ay mice treated with evodiamine, in which glucose tolerance is improved.	evodiamine	181-191	ribosomal protein S6 kinase B1	Homo sapiens	109-112
24391749-3	2013	There is a significant decrease in the mammalian target of rapamycin (mTOR) and ribosomal S6 protein kinase (S6K) signaling in white adipose tissue (WAT) in KK-Ay mice treated with evodiamine, in which glucose tolerance is improved.	Glucose	202-209	ribosomal protein S6 kinase B1	Homo sapiens	109-112
24096035-0	2013	Ascofuranone suppresses EGF-induced HIF-1alpha protein synthesis by inhibition of the Akt/mTOR/p70S6K pathway in MDA-MB-231 breast cancer cells.	ascofuranone	0-12	ribosomal protein S6 kinase B1	Homo sapiens	95-101
23389114-3	2013	Since epidemiologic as well as rodent tumor studies indicate that sulforaphane (SFN), a constituent of many edible cruciferous vegetables, might be a potent inhibitor of mammary carcinogenesis, we analyzed the response of four breast cancer cell lines representing different abnormalities in ErbB2/ER-PI3K-Akt-mTOR-S6K1[corrected] signaling pathway to this compound.	sulforaphane	66-78	ribosomal protein S6 kinase B1	Homo sapiens	315-319
23438827-0	2013	Myricetin induces apoptosis in HepG2 cells through Akt/p70S6K/bad signaling and mitochondrial apoptotic pathway.	myricetin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	55-61
23389114-5	2013	Cell viability and ultrastructure, protein synthesis, autophagy induction and phosphorylation status of Akt and S6K1 kinases upon SFN treatment were determined.	sulforaphane	130-133	ribosomal protein S6 kinase B1	Homo sapiens	112-116
24089522-9	2013	Mutation of Ser-83 diminished p70S6K-induced phosphorylation of TRIB2.	Serine	12-15	ribosomal protein S6 kinase B1	Homo sapiens	30-36
23389114-9	2013	CONCLUSION: These results indicate that SFN is a potent inhibitor of the viability of breast cancer cells representing different activity of the ErbB2/ER-PI3K-Akt-mTOR-S6K1 [corrected] pro-survival pathway and suggest that it targets downstream elements of the pathway.	sulforaphane	40-43	ribosomal protein S6 kinase B1	Homo sapiens	168-172
23794518-7	2013	Meanwhile, lapatinib inhibited the phosphorylation of HER2, AKT, mTOR, and p70S6K, whereas that of AMPK was activated.	Lapatinib	11-20	ribosomal protein S6 kinase B1	Homo sapiens	75-81
24261856-0	2013	alpha-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway.	a-santalol	0-14	ribosomal protein S6 kinase B1	Homo sapiens	160-166
24261856-7	2013	Western blot analysis indicated that alpha-santalol inhibited VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including AKT, ERK, FAK, Src, mTOR, and pS6K in HUVEC, PC-3 and LNCaP cells.	a-santalol	37-51	ribosomal protein S6 kinase B1	Homo sapiens	183-187
24261856-11	2013	Furthermore, alpha-santalol reduced the cell viability and induced apoptosis in PC-3 cells, which were correlated with the downregulation of AKT, mTOR and P70S6K expressions.	a-santalol	13-27	ribosomal protein S6 kinase B1	Homo sapiens	155-161
24261856-13	2013	CONCLUSION: alpha-santalol inhibits angiogenesis by targeting VEGFR2 regulated AKT/mTOR/P70S6K signaling pathway, and could be used as a potential drug candidate for cancer therapy.	a-santalol	12-26	ribosomal protein S6 kinase B1	Homo sapiens	88-94
23974517-9	2013	Moreover, fucoxanthin dose-dependently decreased the levels of phosphorylated Akt and its downstream proteins p53, p70S6K, and mTOR, and increases the expression of PTEN in HeLa cells.	fucoxanthin	10-21	ribosomal protein S6 kinase B1	Homo sapiens	115-121
24331535-8	2013	Furthermore, resveratrol induced significant dephosphorylation of Akt, mTOR, p70S6K, and 4E-BP1, but enhanced specific phosphorylation of p38-MAPK which could be blocked by SB203580.	Resveratrol	13-24	ribosomal protein S6 kinase B1	Homo sapiens	77-83
24331535-8	2013	Furthermore, resveratrol induced significant dephosphorylation of Akt, mTOR, p70S6K, and 4E-BP1, but enhanced specific phosphorylation of p38-MAPK which could be blocked by SB203580.	SB 203580	173-181	ribosomal protein S6 kinase B1	Homo sapiens	77-83
24331535-10	2013	CONCLUSION: Our findings have suggested that resveratrol induces cell cycle arrest, apoptosis, and autophagy in T-ALL cells through inhibiting Akt/mTOR/p70S6K/4E-BP1 and activating p38-MAPK signaling pathways.	Resveratrol	45-56	ribosomal protein S6 kinase B1	Homo sapiens	152-158
23982212-4	2013	The common feature pharmacophore hypothesis and GFA regression model of S6K1 inhibitors were first developed and applied in a virtual screen of the Specs database for retrieving S6K1 inhibitors.	gfa	48-51	ribosomal protein S6 kinase B1	Homo sapiens	72-76
23982212-4	2013	The common feature pharmacophore hypothesis and GFA regression model of S6K1 inhibitors were first developed and applied in a virtual screen of the Specs database for retrieving S6K1 inhibitors.	gfa	48-51	ribosomal protein S6 kinase B1	Homo sapiens	178-182
23891858-5	2013	CIL-102 dose-dependent induction of apoptosis and inhibitory invasiveness were accompanied by sustained phosphorylation of JNK1/2 and p70S6K as well as generation of the reactive oxygen species.	1-(4-(furo(2,3-b)quinolin-4-ylamino)phenyl)ethanone	0-7	ribosomal protein S6 kinase B1	Homo sapiens	134-140
23958494-4	2013	The effect of AZA in HepG2 cells has been proven to derive from activation of Ras/ERK/TSC2, leading to activation of mTOR/p70S6K in a sustained manner.	Azathioprine	14-17	ribosomal protein S6 kinase B1	Homo sapiens	122-128
23958494-5	2013	p70S6K phosphorylates IRS-1 in serine 307 which leads to the uncoupling between IRS-1 and p85 (the regulatory subunit of PI3K) and therefore causing the lack of response of HepG2 to IGF-1.	Serine	31-37	ribosomal protein S6 kinase B1	Homo sapiens	0-6
24124380-11	2013	In vitro treatment with rapamycin, RAD001, and AZD8055 reduced cell growth, cell migration, and phospho-p70S6K expression significantly in G-415 and TGBC-2TKB cancer cells (P &lt; 0.001).	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	104-110
24124380-11	2013	In vitro treatment with rapamycin, RAD001, and AZD8055 reduced cell growth, cell migration, and phospho-p70S6K expression significantly in G-415 and TGBC-2TKB cancer cells (P &lt; 0.001).	(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	47-54	ribosomal protein S6 kinase B1	Homo sapiens	104-110
24089446-11	2013	nab-Rapamycin significantly inhibited mTOR targets S6K and 4EBP1.	nab-rapamycin	0-13	ribosomal protein S6 kinase B1	Homo sapiens	51-64
23841933-4	2013	Here, we report that BDNF-induced p70S6K activation is dependent on glucose, but not amino acids, sufficiency in cultured cortical neurons.	Glucose	68-75	ribosomal protein S6 kinase B1	Homo sapiens	34-40
24073294-13	2013	Inhibition of ERK1/2 by U0126 also abolished activity of p70S6K both in vitro and in vivo models.	U 0126	24-29	ribosomal protein S6 kinase B1	Homo sapiens	57-63
23814023-4	2013	In breast cancer cells (MCF-7 and BT474), everolimus inhibited the mTOR downstream activity by limiting phosphorylation of p70S6K and 4EBP1, which resulted in p-Ser473-AKT activation.	Everolimus	42-52	ribosomal protein S6 kinase B1	Homo sapiens	123-139
24303161-8	2013	P-mTOR and p-p70S6k were significantly increased above rest in EAA + Carb (P = 0.03, P = 0.007) 140 min after last sprint, but not in placebo.	Amino Acids, Essential	63-66	ribosomal protein S6 kinase B1	Homo sapiens	13-19
24303161-8	2013	P-mTOR and p-p70S6k were significantly increased above rest in EAA + Carb (P = 0.03, P = 0.007) 140 min after last sprint, but not in placebo.	Carbohydrates	69-73	ribosomal protein S6 kinase B1	Homo sapiens	13-19
24058693-0	2013	Contribution of S6K1/MAPK signaling pathways in the response to oxidative stress: activation of RSK and MSK by hydrogen peroxide.	Hydrogen Peroxide	111-128	ribosomal protein S6 kinase B1	Homo sapiens	16-20
24058693-4	2013	Here, we investigated the initial contribution of S6K1/MAPK signaling pathways in the cell response to oxidative stress produced by hydrogen peroxide (H2O2).	Hydrogen Peroxide	132-149	ribosomal protein S6 kinase B1	Homo sapiens	50-54
24058693-4	2013	Here, we investigated the initial contribution of S6K1/MAPK signaling pathways in the cell response to oxidative stress produced by hydrogen peroxide (H2O2).	Hydrogen Peroxide	151-155	ribosomal protein S6 kinase B1	Homo sapiens	50-54
24058693-9	2013	We demonstrated that H2O2 stimulated phosphorylation of RSK and MSK kinases at residues that are homologous to Thr389 in S6K1.	Hydrogen Peroxide	21-25	ribosomal protein S6 kinase B1	Homo sapiens	121-125
23793038-6	2013	The findings showed that LY294002 attenuated DEHP-induced up-regulation of the selected genes (pi3k, akt, mtor and p70s6k) involved in PI3K-AKT-mTOR signaling pathway at both mRNA and protein levels thus inhibited the cell abnormal proliferation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	25-33	ribosomal protein S6 kinase B1	Homo sapiens	115-121
23793038-6	2013	The findings showed that LY294002 attenuated DEHP-induced up-regulation of the selected genes (pi3k, akt, mtor and p70s6k) involved in PI3K-AKT-mTOR signaling pathway at both mRNA and protein levels thus inhibited the cell abnormal proliferation.	Diethylhexyl Phthalate	45-49	ribosomal protein S6 kinase B1	Homo sapiens	115-121
23764197-7	2013	Lovastatin exposure induced lower RhoC, bcl-2, matrix metalloproteinase-9 (MMP-9), survivin, Akt, bcl-xL, vascular endothelial growth factor (VEGF), and p-p70s6k expression in OVCAR3 compared to the control, but higher caspase-3 and Bax expression.	Lovastatin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	155-161
23864113-0	2013	Rosiglitazone inhibits insulin-like growth factor-1-induced polycystic kidney disease cell growth and p70S6 kinase activation.	Rosiglitazone	0-13	ribosomal protein S6 kinase B1	Homo sapiens	102-114
23864113-9	2013	Moreover, rosiglitazone (at the same concentration) was shown to inhibit the IGF-1-induced activation of p70S6K.	Rosiglitazone	10-23	ribosomal protein S6 kinase B1	Homo sapiens	105-111
23864113-14	2013	This effect of rosiglitazone was demonstrated to be partially due to the inhibition of IGF-1-induced activation of p70S6K.	Rosiglitazone	15-28	ribosomal protein S6 kinase B1	Homo sapiens	115-121
23643747-4	2013	This effect was abolished by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).	Sirolimus	29-38	ribosomal protein S6 kinase B1	Homo sapiens	182-186
23643747-4	2013	This effect was abolished by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).	pf470867	116-124	ribosomal protein S6 kinase B1	Homo sapiens	169-180
23643747-4	2013	This effect was abolished by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).	pf470867	116-124	ribosomal protein S6 kinase B1	Homo sapiens	182-186
23643747-7	2013	These results show that haloperidol promotes mTORC1- and S6K1-dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs.	Haloperidol	24-35	ribosomal protein S6 kinase B1	Homo sapiens	57-61
23942996-0	2013	S6K1 inhibition enhances tamoxifen-induced cell death in MCF-7 cells through translational inhibition of Mcl-1 and survivin.	Tamoxifen	25-34	ribosomal protein S6 kinase B1	Homo sapiens	0-4
23942996-2	2013	We examined whether tamoxifen"s effect can be modulated by S6K1 inhibition.	Tamoxifen	20-29	ribosomal protein S6 kinase B1	Homo sapiens	59-63
23942996-3	2013	S6K1 inhibition by PF4708671, a selective inhibitor of S6K1, acts synergistically with tamoxifen in S6K1-high MCF-7 cells.	PF-4708671	19-28	ribosomal protein S6 kinase B1	Homo sapiens	0-4
23942996-3	2013	S6K1 inhibition by PF4708671, a selective inhibitor of S6K1, acts synergistically with tamoxifen in S6K1-high MCF-7 cells.	PF-4708671	19-28	ribosomal protein S6 kinase B1	Homo sapiens	55-59
23942996-3	2013	S6K1 inhibition by PF4708671, a selective inhibitor of S6K1, acts synergistically with tamoxifen in S6K1-high MCF-7 cells.	PF-4708671	19-28	ribosomal protein S6 kinase B1	Homo sapiens	55-59
23942996-3	2013	S6K1 inhibition by PF4708671, a selective inhibitor of S6K1, acts synergistically with tamoxifen in S6K1-high MCF-7 cells.	Tamoxifen	87-96	ribosomal protein S6 kinase B1	Homo sapiens	0-4
23942996-4	2013	Similarly, the knockdown of S6K1 with small interfering RNA (siRNA) significantly sensitized MCF-7 cells to tamoxifen.	Tamoxifen	108-117	ribosomal protein S6 kinase B1	Homo sapiens	28-32
23942996-7	2013	These results showed that inhibition of S6K1 acts synergistically with tamoxifen, via translational modulation of Mcl-1 and survivin.	Tamoxifen	71-80	ribosomal protein S6 kinase B1	Homo sapiens	40-44
23942996-8	2013	Based on these findings, we propose that targeting S6K1 may be an effective strategy to overcome tamoxifen resistance in breast cancer.	Tamoxifen	97-106	ribosomal protein S6 kinase B1	Homo sapiens	51-55
23877919-5	2013	We found that eupatilin inhibited PI3K activity, causing a direct effect on phosphorylation of the downstream kinases Akt and p70S6K.	eupatilin	14-23	ribosomal protein S6 kinase B1	Homo sapiens	126-132
23922674-9	2013	This coincides with the constitutive activation of one of the downstream effectors of the mTORC1 signaling pathway, namely p-p70S6K (Thr 389).	Threonine	133-136	ribosomal protein S6 kinase B1	Homo sapiens	125-131
23874880-7	2013	Ku-0063794 at the IC50 concentration effectively inhibited both mTOR and p70S6K phosphorylation levels; the latter is an mTORC1 substrate and did not upregulate Akt ser473 phosphorylation which would be induced by rapamycin and resulted in partial inhibition of FOXO1 phosphorylation.	Ku 0063794	0-10	ribosomal protein S6 kinase B1	Homo sapiens	73-79
23680031-10	2013	Intracellular free calcium accumulated immediately following resveratrol addition, which led to the activation of phospho-AMPK and phospho-Raptor, and a reduction in the amount of phospho-p70S6K.	Calcium	19-26	ribosomal protein S6 kinase B1	Homo sapiens	188-194
23680031-10	2013	Intracellular free calcium accumulated immediately following resveratrol addition, which led to the activation of phospho-AMPK and phospho-Raptor, and a reduction in the amount of phospho-p70S6K.	Resveratrol	61-72	ribosomal protein S6 kinase B1	Homo sapiens	188-194
23670050-4	2013	We showed that a novel AKT inhibitor, AZD5363, inhibits the AKT downstream pathway by reducing p-MTOR and p-RPS6KB/p70S6K.	capivasertib	38-45	ribosomal protein S6 kinase B1	Homo sapiens	115-121
23975168-0	2013	Low amount of salinomycin greatly increases Akt activation, but reduces activated p70S6K levels.	salinomycin	14-25	ribosomal protein S6 kinase B1	Homo sapiens	82-88
23788636-8	2013	Phosphorylations of AMP-activated protein kinasealpha (AMPKalpha)-Thr(172) and p70S6K-Thr(389), both PP2A substrates, were also increased in both N1KD and GSI-treated cells and responded to okadaic acid treatment.	Threonine	86-89	ribosomal protein S6 kinase B1	Homo sapiens	79-85
23788636-8	2013	Phosphorylations of AMP-activated protein kinasealpha (AMPKalpha)-Thr(172) and p70S6K-Thr(389), both PP2A substrates, were also increased in both N1KD and GSI-treated cells and responded to okadaic acid treatment.	2-(5-Chlorothiophen-2-Yl)-N-[(3s)-1-(4-{2-[(Dimethylamino)methyl]-1h-Imidazol-1-Yl}-2-Fluorophenyl)-2-Oxopyrrolidin-3-Yl]ethanesulfonamide	155-158	ribosomal protein S6 kinase B1	Homo sapiens	79-85
23709654-9	2013	In vitro data revealed that metformin inhibited cancer cell growth, activated cAMP-inducible protein kinase (5"-AMP-activated protein kinase [AMPK]), and down-regulated p70S6K/pS6.	Metformin	28-37	ribosomal protein S6 kinase B1	Homo sapiens	169-175
23709654-10	2013	Metformin potentiated H2O2-inducible activation of AMPK but attenuated pERK and p70S6K.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	80-86
23709654-14	2013	In vitro data suggest that p70S6K/pS6 is likely a molecular target of metformin in DTC cells.	Metformin	70-79	ribosomal protein S6 kinase B1	Homo sapiens	27-33
23709654-14	2013	In vitro data suggest that p70S6K/pS6 is likely a molecular target of metformin in DTC cells.	dtc	83-86	ribosomal protein S6 kinase B1	Homo sapiens	27-33
23319394-8	2013	BEZ235 monotherapy also inhibited the phosphorylation of Akt and p70S6K/S6RP, downstream molecules of PI3K and mTOR, respectively, as well as suppressing tumor-cell proliferation and angiogenesis of PC-9/HGF tumors.	dactolisib	0-6	ribosomal protein S6 kinase B1	Homo sapiens	65-71
23580233-9	2013	Moreover, the effect of Mono-Pt involved the AKT1-MTOR-RPS6KB1 pathway and MAPK1 (ERK2)/MAPK3 (ERK1) signaling, since the MTOR inhibitor rapamycin increased, while the MAPK1/3 inhibitor U0126 decreased Mono-Pt-induced autophagic cell death.	monoplatin	24-31	ribosomal protein S6 kinase B1	Homo sapiens	55-62
23726918-4	2013	Curcumin enhanced Erk1/2 predominantly in Ras-activated cells, but inhibited Akt and its downstream molecules (mTOR and S6K1) regardless of these oncogene activations.	Curcumin	0-8	ribosomal protein S6 kinase B1	Homo sapiens	120-124
23481040-9	2013	Apoptotic activity of the proteasome inhibitor bortezomib was also related to Bax activation and P70S6K downregulation.	Bortezomib	47-57	ribosomal protein S6 kinase B1	Homo sapiens	97-103
23608221-9	2013	In addition, ghrelin stimulated the phosphorylation of Akt downstream effectors, such as glycogen synthase kinase (GSK)-3beta, mammalian target of rapamycin (mTOR), and p70(S6K).	Ghrelin	13-20	ribosomal protein S6 kinase B1	Homo sapiens	173-176
23588860-7	2013	HS-173 blocked the PI3K/Akt signalling pathway by decreasing the activation of Akt, mTOR and P70S6K.	ethyl 6-(5-(phenylsulfonamido)pyridin-3-yl)imidazo(1,2-a)pyridine-3-carboxylate	0-6	ribosomal protein S6 kinase B1	Homo sapiens	93-99
23608221-13	2013	Our data also suggest that PI3K/Akt-mediated inactivation of GSK-3beta and activation of mTOR/p70(S6K) contribute to the proliferative effect of ghrelin.	Ghrelin	145-152	ribosomal protein S6 kinase B1	Homo sapiens	94-101
23819061-4	2013	Rapamycin, an inhibitor of mTOR complex 1, reduced the level of HIF-1 alpha and blocked phosphorylation of ribosomal protein S6 kinase 1 (S6K), a transcriptional regulator of mTOR, demonstrating that hypoxia activates mTOR/S6K/HIF-1 alpha signaling in CCA.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	138-141
23984518-6	2013	Western blotting demonstrated that OP-B inhibited the phosphorylation of Akt and its" downstream vital protein, such as mTOR and p70S6K.	ophiopogonin B	35-39	ribosomal protein S6 kinase B1	Homo sapiens	129-135
23819061-4	2013	Rapamycin, an inhibitor of mTOR complex 1, reduced the level of HIF-1 alpha and blocked phosphorylation of ribosomal protein S6 kinase 1 (S6K), a transcriptional regulator of mTOR, demonstrating that hypoxia activates mTOR/S6K/HIF-1 alpha signaling in CCA.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	223-226
23690929-5	2013	Both temsirolimus and everolimus inhibited the phosphorylation of p70S6K and 4E-BP1, which are downstream targets of the mTOR pathway, and reduced the viability of EGFR mutant lung cancer cells, PC-9, and HCC827, even in the presence of HGF in vitro.	temsirolimus	5-17	ribosomal protein S6 kinase B1	Homo sapiens	66-83
23690929-5	2013	Both temsirolimus and everolimus inhibited the phosphorylation of p70S6K and 4E-BP1, which are downstream targets of the mTOR pathway, and reduced the viability of EGFR mutant lung cancer cells, PC-9, and HCC827, even in the presence of HGF in vitro.	Everolimus	22-32	ribosomal protein S6 kinase B1	Homo sapiens	66-83
23435355-7	2013	In contrast, the protein levels of sterol regulatory element-binding protein 1 (SREBP1), mammalian target of rapamycin (mTOR) and S6 kinase (S6K) were all reduced when hepatocytes were treated with BA for up to 24h.	betulinic acid	198-200	ribosomal protein S6 kinase B1	Homo sapiens	141-144
23584166-4	2013	Here we show that administration of the TRPV1 agonist, capsaicin, induces phosphorylation of mTOR, p70S6K, S6, Erk1/2 and p38 MAPK, but not Akt, AMPK or GSK3beta.	Capsaicin	55-64	ribosomal protein S6 kinase B1	Homo sapiens	99-105
23515290-10	2013	TGF-beta and PGE2 induce activation of PI3K/AKT/mammalian target of rapamycin pathway as indicated by increased AKT, p70S6K, and S6 phosphorylation.	Dinoprostone	13-17	ribosomal protein S6 kinase B1	Homo sapiens	117-123
23515290-11	2013	Rapamycin completely blocked the effects of TGF-beta and PGE2 on phosphorylation of p70S6K and S6 but not on AKT phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	84-90
23515290-11	2013	Rapamycin completely blocked the effects of TGF-beta and PGE2 on phosphorylation of p70S6K and S6 but not on AKT phosphorylation.	Dinoprostone	57-61	ribosomal protein S6 kinase B1	Homo sapiens	84-90
22898570-11	2013	In human fibroblasts deficient in leucine catabolic steps, we observed regulation consistent with sustaining a more efficient MAP4K3 and mTOR-S6K1 signaling.	Leucine	34-41	ribosomal protein S6 kinase B1	Homo sapiens	142-146
23427297-13	2013	Together, these data suggest that tandutinib is a novel potent therapeutic agent that can target the Akt/mTOR/p70S6K signaling pathway to inhibit tumor growth and angiogenesis.	tandutinib	34-44	ribosomal protein S6 kinase B1	Homo sapiens	110-116
23645731-5	2013	Upon curcumin treatment, AKT activation was substantially suppressed, with subsequent reduction of activities of mammalian target of rapamycin (mTOR) and its downstream molecules S6 kinase-1 (S6K1) and elF4E-binding protein-1 (4E-BP1), but constitutive activity of extracellular signal-regulated kinase (ERK1/2) was clearly enhanced.	Curcumin	5-13	ribosomal protein S6 kinase B1	Homo sapiens	179-190
23645731-5	2013	Upon curcumin treatment, AKT activation was substantially suppressed, with subsequent reduction of activities of mammalian target of rapamycin (mTOR) and its downstream molecules S6 kinase-1 (S6K1) and elF4E-binding protein-1 (4E-BP1), but constitutive activity of extracellular signal-regulated kinase (ERK1/2) was clearly enhanced.	Curcumin	5-13	ribosomal protein S6 kinase B1	Homo sapiens	192-196
23188704-8	2013	Besides, cisplatin treatment activated the mammalian target of rapamycin (mTOR) pathway as shown by increased phosphorylation of Akt1, mTOR, S6K, and 4E-BP1, together with the elevated Livin.	Cisplatin	9-18	ribosomal protein S6 kinase B1	Homo sapiens	144-156
23354299-9	2013	Sorafenib treatment was associated with the down-regulation of phosphorylated mammalian target of rapamycin and its downstream substrate p70S6K.	Sorafenib	0-9	ribosomal protein S6 kinase B1	Homo sapiens	137-143
23429703-0	2013	Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1.	pyrimidine	23-33	ribosomal protein S6 kinase B1	Homo sapiens	81-85
23429703-4	2013	mTORC1 signaling posttranslationally regulated this metabolic pathway via its downstream target ribosomal protein S6 kinase 1 (S6K1), which directly phosphorylates S1859 on CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, dihydroorotase), the enzyme that catalyzes the first three steps of de novo pyrimidine synthesis.	pyrimidine	317-327	ribosomal protein S6 kinase B1	Homo sapiens	127-131
23314035-0	2013	Resveratrol inhibits human nasopharyngeal carcinoma cell growth via             blocking pAkt/p70S6K signaling pathways.	Resveratrol	0-11	ribosomal protein S6 kinase B1	Homo sapiens	94-100
23314035-8	2013	In addition,             resveratrol treatment also significantly decreased the phosphorylation levels             of Akt1, p70S6K and p-4E-BP-1 and the protein expression of several cyclins involved             in cell cycle regulation.	Resveratrol	25-36	ribosomal protein S6 kinase B1	Homo sapiens	124-130
23314035-10	2013	Collectively, our findings suggest that resveratrol exerts potent anti-prolife-rative             and pro-apoptotic effects on human NPC cells possibly through interfering with             the pAkt1/p70S6K signaling pathways, thus it may potentially be developed as an             effective agent for chemoprevention and chemotherapy of human NPC.	Resveratrol	40-51	ribosomal protein S6 kinase B1	Homo sapiens	199-205
23591341-9	2013	Cisplatin treatment inhibited the phosphorylation of mTOR/P70S6K, which was most significant at the concentration of 100 mumol/L for 48 h. Cisplatin also induced cell viability loss, which was 12% and 45% at the concentrations of 50, and 100 mumol/L for 24 h. This effect could be enhanced by rapamycin (F=74.890,P&lt;0.01).	Cisplatin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	58-64
23591341-9	2013	Cisplatin treatment inhibited the phosphorylation of mTOR/P70S6K, which was most significant at the concentration of 100 mumol/L for 48 h. Cisplatin also induced cell viability loss, which was 12% and 45% at the concentrations of 50, and 100 mumol/L for 24 h. This effect could be enhanced by rapamycin (F=74.890,P&lt;0.01).	Cisplatin	139-148	ribosomal protein S6 kinase B1	Homo sapiens	58-64
23591341-9	2013	Cisplatin treatment inhibited the phosphorylation of mTOR/P70S6K, which was most significant at the concentration of 100 mumol/L for 48 h. Cisplatin also induced cell viability loss, which was 12% and 45% at the concentrations of 50, and 100 mumol/L for 24 h. This effect could be enhanced by rapamycin (F=74.890,P&lt;0.01).	Sirolimus	293-302	ribosomal protein S6 kinase B1	Homo sapiens	58-64
23535839-3	2013	Using the UK taxotere as adjuvant chemotherapy trial (TACT), we tested the hypothesis that activation of AKT or downstream markers, p70S6K or p90RSK, identifies patients with reduced benefit from taxane chemotherapy.	taxane	196-202	ribosomal protein S6 kinase B1	Homo sapiens	132-138
22828916-5	2013	Consistently, the mTOR inhibitor everolimus inhibited phosphorylation of S6K and cell growth equally in both lines.	Everolimus	33-43	ribosomal protein S6 kinase B1	Homo sapiens	73-76
23830390-3	2013	Our recent observation that rapamycin continues to inhibit S6K1 in the absence of either phosphorylation, together with the evidence that phosphorylation at activation loop may occur prior to that of hydrophobic motif raises serious questions about the proposed mechanism of rapamycin inhibition.	Sirolimus	28-37	ribosomal protein S6 kinase B1	Homo sapiens	59-63
23387849-8	2013	This OSS-activation of Smad1/5 induced its association with and activation of runt-related transcription factor-2 (Runx2), leading to activations of mammalian target of rapamycin (mTOR) and p70S6 kinase (p70S6K), a pathway critical for EC proliferation in response to OSS.	OSS	5-8	ribosomal protein S6 kinase B1	Homo sapiens	190-202
23387849-8	2013	This OSS-activation of Smad1/5 induced its association with and activation of runt-related transcription factor-2 (Runx2), leading to activations of mammalian target of rapamycin (mTOR) and p70S6 kinase (p70S6K), a pathway critical for EC proliferation in response to OSS.	OSS	5-8	ribosomal protein S6 kinase B1	Homo sapiens	204-210
23387849-8	2013	This OSS-activation of Smad1/5 induced its association with and activation of runt-related transcription factor-2 (Runx2), leading to activations of mammalian target of rapamycin (mTOR) and p70S6 kinase (p70S6K), a pathway critical for EC proliferation in response to OSS.	OSS	268-271	ribosomal protein S6 kinase B1	Homo sapiens	204-210
23537100-12	2013	CCI-779 inhibited the phosphorylation of mTOR (Ser2448), p70S6K (Thr389), S6 (Ser240/244), and 4EBP1 (Thr37/46) in different grades and the expressions of p70S6K, S6, and 4EBP1.	temsirolimus	0-7	ribosomal protein S6 kinase B1	Homo sapiens	57-63
23537100-12	2013	CCI-779 inhibited the phosphorylation of mTOR (Ser2448), p70S6K (Thr389), S6 (Ser240/244), and 4EBP1 (Thr37/46) in different grades and the expressions of p70S6K, S6, and 4EBP1.	temsirolimus	0-7	ribosomal protein S6 kinase B1	Homo sapiens	155-161
23394126-3	2013	Compound 28 (XL388) inhibited cellular phosphorylation of mTOR complex 1 (p-p70S6K, pS6, and p-4E-BP1) and mTOR complex 2 (pAKT (S473)) substrates.	XL388	13-18	ribosomal protein S6 kinase B1	Homo sapiens	76-82
23497499-8	2013	RESULTS: Sorafenib decreased phospho-MEK, phospho-ERK1/2, phospho-p70S6K and phospho-4EBP-1 expression in PDAC cells.	Sorafenib	9-18	ribosomal protein S6 kinase B1	Homo sapiens	66-72
23449430-0	2013	Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	148-157
23376066-0	2013	Inhibition of S6K1 enhances glucose deprivation-induced cell death via downregulation of anti-apoptotic proteins in MCF-7 breast cancer cells.	Glucose	28-35	ribosomal protein S6 kinase B1	Homo sapiens	14-18
23376066-4	2013	In the present study, we investigated the effects of S6 kinase 1 (S6K1) inhibition on glucose deprivation-induced cell death and the underlying mechanisms in MCF-7 breast cancer cells.	Glucose	86-93	ribosomal protein S6 kinase B1	Homo sapiens	53-64
23376066-4	2013	In the present study, we investigated the effects of S6 kinase 1 (S6K1) inhibition on glucose deprivation-induced cell death and the underlying mechanisms in MCF-7 breast cancer cells.	Glucose	86-93	ribosomal protein S6 kinase B1	Homo sapiens	66-70
23376066-5	2013	PF4708671, a selective inhibitor of S6K1, and knockdown of S6K1 with specific siRNA enhanced cell death induced under glucose deprivation conditions.	PF-4708671	0-9	ribosomal protein S6 kinase B1	Homo sapiens	36-40
23376066-6	2013	Moreover, inhibition of S6K1 led to apoptosis in glucose-starved MCF-7 cells via downregulation of the anti-apoptotic proteins, Mcl-1 and survivin.	Glucose	49-56	ribosomal protein S6 kinase B1	Homo sapiens	24-28
23376066-7	2013	Further experiments revealed that sorafenib, shown to be involved in Mcl-1 and survivin downregulation via mTOR/S6K1 inhibition significantly promotes cell death under glucose deprivation conditions.	Sorafenib	34-43	ribosomal protein S6 kinase B1	Homo sapiens	112-116
23376066-8	2013	These findings collectively suggest that S6K1 plays an important role in tumor cell survival under stress conditions, and thus inhibition of S6K1 may be an effective strategy for sensitizing cells to glucose deprivation.	Glucose	200-207	ribosomal protein S6 kinase B1	Homo sapiens	41-45
23376066-8	2013	These findings collectively suggest that S6K1 plays an important role in tumor cell survival under stress conditions, and thus inhibition of S6K1 may be an effective strategy for sensitizing cells to glucose deprivation.	Glucose	200-207	ribosomal protein S6 kinase B1	Homo sapiens	141-145
23325107-0	2013	Curcumin ameliorates the neurodegenerative pathology in A53T alpha-synuclein cell model of Parkinson"s disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy.	Curcumin	0-8	ribosomal protein S6 kinase B1	Homo sapiens	146-152
23325107-5	2013	We further found that curcumin, a natural compound derived from the curry spice turmeric and with low toxicity in normal cells, could efficiently reduce the accumulation of A53T alpha-synuclein through downregulation of the mTOR/p70S6K signaling and recovery of macroautophagy which was suppressed.	Curcumin	22-30	ribosomal protein S6 kinase B1	Homo sapiens	229-235
23364979-5	2013	Furthermore, we also found that TGF-beta1-induced mTOR and p70S6K phosphorylation were significantly down-regulated by rapamycin.	Sirolimus	119-128	ribosomal protein S6 kinase B1	Homo sapiens	59-65
23364979-7	2013	CONCLUSION: These results indicate that rapamycin effectively suppresses TGF-beta1-induced type III collagen and fibronectin levels in primary human lung fibroblasts partly through the mTOR/p70S6K pathway.	Sirolimus	40-49	ribosomal protein S6 kinase B1	Homo sapiens	190-196
23178462-8	2013	In the LKB1 wild-type cells, 2-DG dramatically suppressed the phosphorylation of two mTOR targets, 4E-BP1 and S6K, whereas the LKB1 mutant A549 and H460 cells were highly resistant to 2-DG-induced inhibition on mTOR activity.	Deoxyglucose	29-33	ribosomal protein S6 kinase B1	Homo sapiens	110-113
22887478-5	2013	We also observed that EB can significantly enhance the apoptotic effects of a specific pharmacological Akt inhibitor when used in combination and also caused broad inhibition of all the three kinases in Akt/mTOR/S6K1 signaling axis in PC-3 cells.	embelin	22-24	ribosomal protein S6 kinase B1	Homo sapiens	212-216
23422279-5	2013	Next, we found that ICV infusion of E(2) increased phosphorylation of the downstream mTOR targets S6K (Thr-421) and 4E-BP1 in the dorsal hippocampus 5 min after infusion, and that this phosphorylation was blocked by dorsal hippocampal infusion of inhibitors of ERK, PI3K, and mTOR.	Threonine	103-106	ribosomal protein S6 kinase B1	Homo sapiens	98-101
23261705-4	2013	Pharmacological inhibition of MTORC1 with rapamycin abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6.	Sirolimus	42-51	ribosomal protein S6 kinase B1	Homo sapiens	111-118
23184810-7	2013	In addition, the JNK antagonist SP600125, but not the p38 inhibitor SB203580, prevents TNF-induced activation of S6 kinase, suggesting that pentoxifylline and propentofylline may regulate mTORC activity in spinal astrocytes partially through inhibition of the JNK pathway.	pyrazolanthrone	32-40	ribosomal protein S6 kinase B1	Homo sapiens	113-122
23142281-3	2013	IPD-196 effectively inhibited the phosphorylation of downstream PI3K effectors such as Akt, mTOR, p70S6K, and 4E-BP1, and its antiproliferative effect was more potent than that of sorafenib or LY294002.	IPD-196	0-7	ribosomal protein S6 kinase B1	Homo sapiens	98-104
23184810-7	2013	In addition, the JNK antagonist SP600125, but not the p38 inhibitor SB203580, prevents TNF-induced activation of S6 kinase, suggesting that pentoxifylline and propentofylline may regulate mTORC activity in spinal astrocytes partially through inhibition of the JNK pathway.	Pentoxifylline	140-154	ribosomal protein S6 kinase B1	Homo sapiens	113-122
23184810-7	2013	In addition, the JNK antagonist SP600125, but not the p38 inhibitor SB203580, prevents TNF-induced activation of S6 kinase, suggesting that pentoxifylline and propentofylline may regulate mTORC activity in spinal astrocytes partially through inhibition of the JNK pathway.	propentofylline	159-174	ribosomal protein S6 kinase B1	Homo sapiens	113-122
23151908-7	2013	Next, we examined the PI3K/Akt/mTOR signaling pathway and found that OP-B inhibited             phosphorylation of Akt (Ser473, Thr308) in NCI-H157 cells and also inhibited several             key components of the pathway in NCI-H460 cells, such as p-Akt(Ser473, Thr308),             p-p70S6K (Thr389).	ophiopogonin B	69-73	ribosomal protein S6 kinase B1	Homo sapiens	287-293
23420667-7	2013	During the prolonged treatment with AZD8055, the phosphorylation of mammalian target of rapamycin (mTOR) C1 substrates p70S6K and phosphorylation of the mTORC2 substrate Akt were deregulated, suggesting that the activity of mTOR was downregulated.	(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	36-43	ribosomal protein S6 kinase B1	Homo sapiens	119-125
23273915-6	2013	Furthermore, we found that S6K1 short isoforms bind and activate mTORC1, elevating 4E-BP1 phosphorylation, cap-dependent translation, and Mcl-1 protein levels.	cap	107-110	ribosomal protein S6 kinase B1	Homo sapiens	27-31
23273915-7	2013	Both a phosphorylation-defective 4E-BP1 mutant and the mTORC1 inhibitor rapamycin partially blocked the oncogenic effects of S6K1 short isoforms, suggesting that these are mediated by mTORC1 and 4E-BP1.	Sirolimus	72-81	ribosomal protein S6 kinase B1	Homo sapiens	125-129
22391570-2	2013	We investigated S6K1, a protein kinase that drives glycolysis in leukemia cells, as a target for counteracting glucose-dependent survival induced by BCR-ABL.	Glucose	111-118	ribosomal protein S6 kinase B1	Homo sapiens	16-20
22391570-5	2013	Instead, loss of S6K1 triggered compensatory activation of fatty-acid oxidation, a metabolic program that can support glucose-independent cell survival.	Fatty Acids	59-69	ribosomal protein S6 kinase B1	Homo sapiens	17-21
22391570-5	2013	Instead, loss of S6K1 triggered compensatory activation of fatty-acid oxidation, a metabolic program that can support glucose-independent cell survival.	Glucose	118-125	ribosomal protein S6 kinase B1	Homo sapiens	17-21
22391570-6	2013	Fatty-acid oxidation in response to S6K1 inactivation required the expression of the fatty-acid transporter carnitine palmitoyl transferase 1c, which was recently linked to rapamycin resistance in cancer.	Fatty Acids	0-10	ribosomal protein S6 kinase B1	Homo sapiens	36-40
22391570-6	2013	Fatty-acid oxidation in response to S6K1 inactivation required the expression of the fatty-acid transporter carnitine palmitoyl transferase 1c, which was recently linked to rapamycin resistance in cancer.	Sirolimus	173-182	ribosomal protein S6 kinase B1	Homo sapiens	36-40
22391570-7	2013	Finally, addition of an inhibitor of fatty-acid oxidation significantly enhanced cytotoxicity in response to S6K1 inactivation.	Fatty Acids	37-47	ribosomal protein S6 kinase B1	Homo sapiens	109-113
23302650-12	2013	We showed that CrT1-activated AMPK activation was followed by modulating the mammalian target of rapamycin/p70S6K pathway and was inactivated by treating cells with compound C. Treatment with CrT1 and aminoimidazole carboxamide ribonucleotide (AICAR) synergistically activated AMPK.	AICA ribonucleotide	201-242	ribosomal protein S6 kinase B1	Homo sapiens	107-113
23470740-3	2013	The percentage-phosphorylated S6K1 and growth hormone (GH) concentration was significantly increased by the GABA administration.	gamma-Aminobutyric Acid	108-112	ribosomal protein S6 kinase B1	Homo sapiens	30-34
24350295-5	2013	However, silencing the key components and addition of metyrapone had different effects on downstream substrates 4EBP1 and p70S6K of mTOR.	Metyrapone	54-64	ribosomal protein S6 kinase B1	Homo sapiens	122-128
23316499-0	2013	Rapid activation of FAK/mTOR/p70S6K/PAK1-signaling controls the early testosterone-induced actin reorganization in colon cancer cells.	Testosterone	70-82	ribosomal protein S6 kinase B1	Homo sapiens	29-35
22902995-8	2013	HS-104 inhibited the expression of the downstream proteins of PI3K including p-AKT, p-mTOR and p-p70S6K in VEGF-induced HUVECs.	HS-104	0-6	ribosomal protein S6 kinase B1	Homo sapiens	97-103
23248098-0	2013	Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis.	Resveratrol	8-19	ribosomal protein S6 kinase B1	Homo sapiens	122-125
23000445-7	2013	Wogonoside also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.	wogonoside	0-10	ribosomal protein S6 kinase B1	Homo sapiens	86-99
24335168-4	2013	Treatment with metformin was also associated with activation of AMP kinase and inhibition of mTOR/p70S6K/pS6 signaling in both cells.	Metformin	15-24	ribosomal protein S6 kinase B1	Homo sapiens	98-104
23000445-7	2013	Wogonoside also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.	wogonoside	0-10	ribosomal protein S6 kinase B1	Homo sapiens	101-107
22705322-3	2013	We aimed to evaluate (pThr389)S6K1 and total S6K1 levels in human and rat fat depots as candidate markers of altered glucose metabolism.	pthr389	22-29	ribosomal protein S6 kinase B1	Homo sapiens	30-34
22705322-11	2013	In human preadipocytes, high glucose medium led to increased (pThr389)S6K1/total S6K1 levels in comparison with normal glucose medium, which was significantly decreased under rosiglitazone administration.	Glucose	29-36	ribosomal protein S6 kinase B1	Homo sapiens	70-74
22705322-11	2013	In human preadipocytes, high glucose medium led to increased (pThr389)S6K1/total S6K1 levels in comparison with normal glucose medium, which was significantly decreased under rosiglitazone administration.	Glucose	29-36	ribosomal protein S6 kinase B1	Homo sapiens	81-85
22705322-11	2013	In human preadipocytes, high glucose medium led to increased (pThr389)S6K1/total S6K1 levels in comparison with normal glucose medium, which was significantly decreased under rosiglitazone administration.	pthr389	62-69	ribosomal protein S6 kinase B1	Homo sapiens	70-74
22705322-11	2013	In human preadipocytes, high glucose medium led to increased (pThr389)S6K1/total S6K1 levels in comparison with normal glucose medium, which was significantly decreased under rosiglitazone administration.	Rosiglitazone	175-188	ribosomal protein S6 kinase B1	Homo sapiens	70-74
22705322-11	2013	In human preadipocytes, high glucose medium led to increased (pThr389)S6K1/total S6K1 levels in comparison with normal glucose medium, which was significantly decreased under rosiglitazone administration.	Rosiglitazone	175-188	ribosomal protein S6 kinase B1	Homo sapiens	81-85
23129808-2	2013	The branched-chain amino acid leucine is an essential nutrient that stimulates mTORC1 to promote protein synthesis by activating p70 S6 kinase 1 (S6K1).	branched-chain amino acid leucine	4-37	ribosomal protein S6 kinase B1	Homo sapiens	133-144
23129808-2	2013	The branched-chain amino acid leucine is an essential nutrient that stimulates mTORC1 to promote protein synthesis by activating p70 S6 kinase 1 (S6K1).	branched-chain amino acid leucine	4-37	ribosomal protein S6 kinase B1	Homo sapiens	146-150
23129808-3	2013	Here we show that the protein tyrosine phosphatase SHP-2 is required for leucine-induced activation of S6K1 in skeletal myoblasts.	Leucine	73-80	ribosomal protein S6 kinase B1	Homo sapiens	103-107
23129808-4	2013	In response to leucine, S6K1 activation is inhibited in myoblasts either lacking SHP-2 expression or overexpressing a catalytically inactive mutant of SHP-2.	Leucine	15-22	ribosomal protein S6 kinase B1	Homo sapiens	24-28
23129808-5	2013	Activation of S6K1 by leucine requires the mobilization of intracellular calcium (Ca(2+)), which we show is mediated by SHP-2 in an inositol-1,4,5-trisphosphate-dependent manner.	Leucine	22-29	ribosomal protein S6 kinase B1	Homo sapiens	14-18
23129808-5	2013	Activation of S6K1 by leucine requires the mobilization of intracellular calcium (Ca(2+)), which we show is mediated by SHP-2 in an inositol-1,4,5-trisphosphate-dependent manner.	Calcium	73-80	ribosomal protein S6 kinase B1	Homo sapiens	14-18
23129808-5	2013	Activation of S6K1 by leucine requires the mobilization of intracellular calcium (Ca(2+)), which we show is mediated by SHP-2 in an inositol-1,4,5-trisphosphate-dependent manner.	Inositol 1,4,5-Trisphosphate	132-160	ribosomal protein S6 kinase B1	Homo sapiens	14-18
23565163-4	2013	The mTORC1-downstream p70 ribosomal protein S6 kinase (S6K1), which is activated by insulin, can phosphorylate IRS1 at serine 307 in vitro and is considered the physiological protein kinase.	Serine	119-125	ribosomal protein S6 kinase B1	Homo sapiens	55-59
22674285-11	2013	Ardisianone also inhibited Akt and mTOR/p70S6K pathways and induced a fast downregulation of survivin, leading to activation of mitochondria-involved caspase cascades.	Ardisianone	0-11	ribosomal protein S6 kinase B1	Homo sapiens	40-46
22674285-14	2013	CONCLUSIONS: The data suggest that the ardisianone induces apoptosis in human prostate cancers through mitochondrial damage stress, leading to the inhibition of mTOR/p70S6K pathway, downregulation of Bcl-2 family members, degradation of survivin, and activation of caspase cascades.	Ardisianone	39-50	ribosomal protein S6 kinase B1	Homo sapiens	166-172
23045529-5	2012	Hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1) and its effector kinase S6 kinase 1 (S6K1) is known to trigger multisite seryl phosphorylation of insulin receptor substrate 1 (IRS1), leading to its ubiquitination and degradation.	seryl	143-148	ribosomal protein S6 kinase B1	Homo sapiens	94-105
23041229-5	2012	Surprisingly 2-DG causes cell line-specific decrease in LKB-1/AMPK phosphorylation/activation, and also causes Akt/mTOR/p70S6K and MEK/ERK activation, which is prevented by co-treatment with ATO.	Deoxyglucose	13-17	ribosomal protein S6 kinase B1	Homo sapiens	120-126
23316499-5	2013	Pharmacological inhibition of FAK-sensitive phosphatidylinositide-3-kinase (PI-3K), a known element of mAR-signaling, fully abrogated the testosterone-induced actin reorganization and the activation of mTOR, p70S6K and PAK1.	Testosterone	138-150	ribosomal protein S6 kinase B1	Homo sapiens	208-214
23045529-5	2012	Hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1) and its effector kinase S6 kinase 1 (S6K1) is known to trigger multisite seryl phosphorylation of insulin receptor substrate 1 (IRS1), leading to its ubiquitination and degradation.	seryl	143-148	ribosomal protein S6 kinase B1	Homo sapiens	107-111
22871496-7	2012	Phosphorylation of RPS6KB1 and RPS6 were decreased (P &lt; 0.05) by everolimus, but RPS6KB1, RPS6, eIF4B and PPARG expressions were not affected.	Everolimus	68-78	ribosomal protein S6 kinase B1	Homo sapiens	19-26
22941374-10	2012	Additionally, in gefitinib-resistant cell lines, the combination of gefitinib and everolimus not only showed stronger inhibition of phosphorylated mTOR and phosphorylated p70S6K expression than either drug alone but also reduced the levels of p-Akt and p-MAPK in both cell lines.	Gefitinib	68-77	ribosomal protein S6 kinase B1	Homo sapiens	171-177
22909393-9	2012	In examining its mechanism, SB365 was found to effectively suppress the phosphorylation of PI3K downstream factors, such as Akt, mTOR and p70S6K both in vitro and in vivo.	sb365	28-33	ribosomal protein S6 kinase B1	Homo sapiens	138-144
22941374-10	2012	Additionally, in gefitinib-resistant cell lines, the combination of gefitinib and everolimus not only showed stronger inhibition of phosphorylated mTOR and phosphorylated p70S6K expression than either drug alone but also reduced the levels of p-Akt and p-MAPK in both cell lines.	Everolimus	82-92	ribosomal protein S6 kinase B1	Homo sapiens	171-177
22689083-6	2012	Activation of autophagy with rapamycin resulted in increased wogonin-mediated autophagy via inhibition of mTOR/P70S6K pathway.	Sirolimus	29-38	ribosomal protein S6 kinase B1	Homo sapiens	111-117
22903553-11	2012	Furthermore, as expected, sMEK1 plus gemcitabine markedly reduced the phosphorylation of p70S6K and the phosphorylation of 4E-BP1, which is one of the best characterized targets of the mTOR complex cascade.	gemcitabine	37-48	ribosomal protein S6 kinase B1	Homo sapiens	89-95
22875710-7	2012	Treatment of U87MG human GBM cells with KM-233 caused a time dependent change in the phosphorylation profiles of MEK, ERK1/2, Akt, BAD, STAT3, and p70S6K.	KM-233	40-46	ribosomal protein S6 kinase B1	Homo sapiens	147-153
23022044-6	2012	Thioridazine suppressed phosphorylation of the signaling regulators downstream of the focal adhesion kinase (FAK) through alphavbeta3 integrin, which also include Akt, phosphoinositide-dependent protein kinase 1 (PDK-1), mammalian target of rapamycin (mTOR), ribosomal protein S6 kinase (p70S6K), but had no effect on VEGF-stimulated extracellular signal-regulated kinase (ERK) phosphorylation.	Thioridazine	0-12	ribosomal protein S6 kinase B1	Homo sapiens	288-294
22929805-10	2012	Moreover, the phosphorylation levels of mTOR, extracellular signal-regulated kinase (ERK), p70S6K, RP-S6, 4E-BP1, and eIF4E were significantly suppressed by sorafenib.	Sorafenib	157-166	ribosomal protein S6 kinase B1	Homo sapiens	91-97
22929805-12	2012	CONCLUSIONS: Sorafenib-mediated inhibition of HIF-1alpha synthesis is associated with previously undefined pathways in which mTOR/p70S6K/4E-BP1 and ERK phosphorylation are downregulated.	Sorafenib	13-22	ribosomal protein S6 kinase B1	Homo sapiens	130-136
22988110-8	2012	The comparative treatment of tyrosine kinase inhibitor (TKI) drugs revealed only imatinib, the standard of care in CML, was inhibitory to BCR-ABL leading to down-regulation of pERK and pS6K and inhibiting cell proliferation.	Imatinib Mesylate	81-89	ribosomal protein S6 kinase B1	Homo sapiens	185-189
22285179-4	2012	Moreover, rapamycin inhibited AKT/mTOR signalling by dephosphorylation of the downstream target p70S6 kinase (p70S6K).	Sirolimus	10-19	ribosomal protein S6 kinase B1	Homo sapiens	96-108
22787141-0	2012	S6K1 in the central nervous system regulates energy expenditure via MC4R/CRH pathways in response to deprivation of an essential amino acid.	Amino Acids, Essential	119-139	ribosomal protein S6 kinase B1	Homo sapiens	0-4
22285179-4	2012	Moreover, rapamycin inhibited AKT/mTOR signalling by dephosphorylation of the downstream target p70S6 kinase (p70S6K).	Sirolimus	10-19	ribosomal protein S6 kinase B1	Homo sapiens	110-116
22285179-8	2012	In conclusion, we demonstrate that rapamycin effectively inhibits HB growth both in vitro and in vivo by blocking AKT/mTOR signalling at the level of p70S6K and that rapamycin should be considered to treat HB patients especially those to be indicated for liver transplantation to benefit from its anti-tumourigenic and immunosuppressive properties.	Sirolimus	35-44	ribosomal protein S6 kinase B1	Homo sapiens	150-156
22863900-0	2012	Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	53-59
23384908-3	2012	The expressions of mTOR, 4E-BP1 and p70S6K at protein and mRNA level in K562 cells with rapamycin treatment were detected by Western blot and RT-PCR.	Sirolimus	88-97	ribosomal protein S6 kinase B1	Homo sapiens	36-42
22993301-0	2012	Caffeine induces apoptosis of osteosarcoma cells by inhibiting AKT/mTOR/S6K, NF-kappaB and MAPK pathways.	Caffeine	0-8	ribosomal protein S6 kinase B1	Homo sapiens	72-75
22460505-6	2012	Furthermore, as expected, thioridazine successfully inhibited phosphorylation of Akt, phosphorylation of 4E-BP1 and phosphorylation of p70S6K, which is one of the best characterized targets of the mTOR complex cascade.	Thioridazine	26-38	ribosomal protein S6 kinase B1	Homo sapiens	135-141
22460505-7	2012	These results suggest that thioridazine effectively suppresses tumor growth activity by targeting the PI3K/Akt/mTOR/p70S6K signaling pathway.	Thioridazine	27-39	ribosomal protein S6 kinase B1	Homo sapiens	116-122
22993301-4	2012	Caffeine inhibited proliferation of HOS cells and suppressed NF-kappaB, AKT, mTOR/S6K and ERK activities.	Caffeine	0-8	ribosomal protein S6 kinase B1	Homo sapiens	82-85
22641227-10	2012	Sorafenib/AZD6244 potently inhibited angiogenesis and phosphorylation             of VEGFR-2, PDGFR-beta and ERK, p90RSK, p70S6K, cdk-2 and retinoblastoma.	Sorafenib	0-9	ribosomal protein S6 kinase B1	Homo sapiens	122-128
22137265-8	2012	Addition of 100 and 350 muM Arg to culture medium dose-dependently increased (a) protein synthesis and decreased protein degradation and (b) the abundance of total and phosphorylated mTOR, p70S6K and 4EBP1 proteins.	Arginine	28-31	ribosomal protein S6 kinase B1	Homo sapiens	189-205
22843885-6	2012	Phosphorylation of mTORC1 substrate, p70S6K at thr389 was reduced by rapamycin and pretreatment with rapamycin abrogated platelet-derived growth factor (PDGF)-induced activation of S6K, as well as that of mTORC2 substrate pAKT(Ser473).	Sirolimus	69-78	ribosomal protein S6 kinase B1	Homo sapiens	37-43
22843885-6	2012	Phosphorylation of mTORC1 substrate, p70S6K at thr389 was reduced by rapamycin and pretreatment with rapamycin abrogated platelet-derived growth factor (PDGF)-induced activation of S6K, as well as that of mTORC2 substrate pAKT(Ser473).	Sirolimus	101-110	ribosomal protein S6 kinase B1	Homo sapiens	37-43
22170854-0	2012	Liquiritigenin inhibits serum-induced HIF-1alpha and VEGF expression via the AKT/mTOR-p70S6K signalling pathway in HeLa cells.	liquiritigenin	0-14	ribosomal protein S6 kinase B1	Homo sapiens	86-92
22641227-10	2012	Sorafenib/AZD6244 potently inhibited angiogenesis and phosphorylation             of VEGFR-2, PDGFR-beta and ERK, p90RSK, p70S6K, cdk-2 and retinoblastoma.	AZD 6244	10-17	ribosomal protein S6 kinase B1	Homo sapiens	122-128
22170854-8	2012	Mechanistically, we demonstrated that LQ inhibited HIF-1alpha and VEGF expression involved in blocking the protein kinase B (PKB/Akt) signalling pathway, and the mechanisms correlated with dephosphorylation of the mammalian target of rapamycin (mTOR) and its effector ribosomal protein S6 kinase (p70S6K).	liquiritigenin	38-40	ribosomal protein S6 kinase B1	Homo sapiens	297-303
22689575-3	2012	Bafilomycin, an inhibitor of V-ATPase, inhibited EGF-stimulated DNA synthesis and mammalian target of rapamycin complex 1 (mTORC1) activation as indicated by a decrease in eukaryotic initiation factor 4E-binding 1 (4E-BP1) phosphorylation and p70 ribosomal S6 protein kinase (p70S6K) phosphorylation and kinase activity.	bafilomycin	0-11	ribosomal protein S6 kinase B1	Homo sapiens	243-274
22683950-4	2012	Through G-protein-coupled receptors, serotonin at physiologically relevant concentrations activated Src/PI3K/AKT/mTOR/p70S6K phosphorylation signaling, and this activation was similar to that seen with VEGF.	Serotonin	37-46	ribosomal protein S6 kinase B1	Homo sapiens	118-124
22781553-5	2012	RESULTS: AT13148 caused substantial blockade of AKT, p70S6K, PKA, ROCK, and SGK substrate phosphorylation and induced apoptosis in a concentration and time-dependent manner in cancer cells with clinically relevant genetic defects in vitro and in vivo.	AT13148	9-16	ribosomal protein S6 kinase B1	Homo sapiens	53-59
22614071-0	2012	Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced             apoptosis in gastric cancer cells with HER2 amplification.	Fluorouracil	58-70	ribosomal protein S6 kinase B1	Homo sapiens	23-26
22614071-8	2012	In summary, inhibition of the mTOR/S6K signal may be a key molecular event in enhancing fluorouracil-induced apoptosis specifically in gastric cancer cells with HER2 amplification.	Fluorouracil	88-100	ribosomal protein S6 kinase B1	Homo sapiens	35-38
22689575-3	2012	Bafilomycin, an inhibitor of V-ATPase, inhibited EGF-stimulated DNA synthesis and mammalian target of rapamycin complex 1 (mTORC1) activation as indicated by a decrease in eukaryotic initiation factor 4E-binding 1 (4E-BP1) phosphorylation and p70 ribosomal S6 protein kinase (p70S6K) phosphorylation and kinase activity.	bafilomycin	0-11	ribosomal protein S6 kinase B1	Homo sapiens	276-282
22705730-11	2012	Moreover, atorvastatin (10 mumol/L) stimulated the phosphorylation of 4E-BP1 and p70S6K, the substrates of mTOR, in the cortical neurons.	Atorvastatin	10-22	ribosomal protein S6 kinase B1	Homo sapiens	81-87
22673193-5	2012	Downregulation of mTOR/S6K1 reduced Mcl-1 protein expression, consequently promoting sensitization to cisplatin.	Cisplatin	102-111	ribosomal protein S6 kinase B1	Homo sapiens	23-27
22722716-8	2012	DMSO also suppressed p-eIF2alpha/p-EIF2S1, ATF4, p-AKT1, p-MTOR and p-p70s6k/p-RPS6KB2 expression as assessed by western blotting.	Dimethyl Sulfoxide	0-4	ribosomal protein S6 kinase B1	Homo sapiens	70-76
22367610-9	2012	A higher ATP level could activate the mammalian target of rapamycin (mTOR), which drives the translation initiation and elongation by phosphorylating eukaryotic initiation factor 4E binding protein 1 (4EBP1) and S6 kinase 1 (S6K1).	Adenosine Triphosphate	9-12	ribosomal protein S6 kinase B1	Homo sapiens	212-223
22367610-9	2012	A higher ATP level could activate the mammalian target of rapamycin (mTOR), which drives the translation initiation and elongation by phosphorylating eukaryotic initiation factor 4E binding protein 1 (4EBP1) and S6 kinase 1 (S6K1).	Adenosine Triphosphate	9-12	ribosomal protein S6 kinase B1	Homo sapiens	225-229
22406476-8	2012	RESULTS: Aspirin reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1.	Aspirin	9-16	ribosomal protein S6 kinase B1	Homo sapiens	86-101
22389381-7	2012	Treatment with metformin was associated with inhibition of mTOR/p70S6K/pS6 signaling and downregulation of pERK in both TT and MZ-CRC-1 cells.	Metformin	15-24	ribosomal protein S6 kinase B1	Homo sapiens	64-70
22442136-6	2012	The effects of EtOH and Leu were associated with coordinate changes in the phosphorylation state of mTOR, raptor, and their downstream targets 4EBP1 and S6K1.	Ethanol	15-19	ribosomal protein S6 kinase B1	Homo sapiens	153-157
22442136-6	2012	The effects of EtOH and Leu were associated with coordinate changes in the phosphorylation state of mTOR, raptor, and their downstream targets 4EBP1 and S6K1.	Leucine	24-27	ribosomal protein S6 kinase B1	Homo sapiens	153-157
22419707-12	2012	TSH induced phosphorylation of protein kinase S6K1, whereas TSHR blocking antibodies inhibited the phosphorylation of the protein kinase S6K1.	Thyrotropin	0-3	ribosomal protein S6 kinase B1	Homo sapiens	46-50
22294050-7	2012	everolimus (20 nM) significantly             reduced protein levels of the mTOR downstream effector p70-S6K compared with radiation             and vehicle (p=0.05, ANOVA) and significantly suppressed phospho-p70-S6K levels             compared with all other treatments (p&lt;0.001, ANOVA).	Everolimus	0-10	ribosomal protein S6 kinase B1	Homo sapiens	100-107
22294050-7	2012	everolimus (20 nM) significantly             reduced protein levels of the mTOR downstream effector p70-S6K compared with radiation             and vehicle (p=0.05, ANOVA) and significantly suppressed phospho-p70-S6K levels             compared with all other treatments (p&lt;0.001, ANOVA).	Everolimus	0-10	ribosomal protein S6 kinase B1	Homo sapiens	209-216
22450127-0	2012	Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.	pyrazolopyrimidines	0-19	ribosomal protein S6 kinase B1	Homo sapiens	32-38
22209892-6	2012	Intriguingly, p70 S6 kinase 1 (S6K1) was activated by DOX, which was prevented by resveratrol.	Doxorubicin	54-57	ribosomal protein S6 kinase B1	Homo sapiens	31-35
22209892-6	2012	Intriguingly, p70 S6 kinase 1 (S6K1) was activated by DOX, which was prevented by resveratrol.	Resveratrol	82-93	ribosomal protein S6 kinase B1	Homo sapiens	31-35
22209892-7	2012	Knocking down S6K1 with small interfering RNA diminished DOX-induced autophagy and cardiotoxicity, but resveratrol failed to exert an additive effect.	Doxorubicin	57-60	ribosomal protein S6 kinase B1	Homo sapiens	14-18
22209892-8	2012	In addition, S6K1 overexpression impaired the ability of resveratrol to antagonize DOX-induced autophagy and cardiomyocyte death.	Resveratrol	57-68	ribosomal protein S6 kinase B1	Homo sapiens	13-17
22209892-8	2012	In addition, S6K1 overexpression impaired the ability of resveratrol to antagonize DOX-induced autophagy and cardiomyocyte death.	Doxorubicin	83-86	ribosomal protein S6 kinase B1	Homo sapiens	13-17
22209892-9	2012	Taken together, our data indicate that the protective effect of resveratrol against DOX cardiotoxicity largely depends on its ability to suppress DOX-induced autophagy via the inhibition of S6K1.	Resveratrol	64-75	ribosomal protein S6 kinase B1	Homo sapiens	190-194
22209892-9	2012	Taken together, our data indicate that the protective effect of resveratrol against DOX cardiotoxicity largely depends on its ability to suppress DOX-induced autophagy via the inhibition of S6K1.	Doxorubicin	146-149	ribosomal protein S6 kinase B1	Homo sapiens	190-194
22391631-4	2012	Although less than HP, p70 ribosomal S6 kinase 1 (S6K1) and eukaryotic initiation factor (eIF) 4E binding protein 1 (4EBP1) association with regulatory associated protein of mammalian target of rapamycin was greater in LP+L than LP, resulting in higher S6K1 and 4EBP1 phosphorylation.	Leucine	219-220	ribosomal protein S6 kinase B1	Homo sapiens	50-54
21204993-5	2012	The phosphorylation of p70S6K (Thr(421) /Ser(424) ), rpS6 (Ser(240/244) and Ser(235/236) ) and MAPK p38 as increased (~2-16 fold) after both exercise protocols.	Threonine	31-34	ribosomal protein S6 kinase B1	Homo sapiens	23-29
21204993-6	2012	However, the phosphorylation of MAPK Erk1/2 and p70S6K at Thr(389) increased only after 5 x 10 RM.	Threonine	58-61	ribosomal protein S6 kinase B1	Homo sapiens	48-54
21204993-7	2012	The increase in the phosphorylation of p70S6K (Thr(421) /Ser(424) ), rpS6 (Ser(235/236) ) and Erk1/2 were higher after 5 x 10 RM (P&lt;0.05).	Threonine	47-50	ribosomal protein S6 kinase B1	Homo sapiens	39-45
21204993-7	2012	The increase in the phosphorylation of p70S6K (Thr(421) /Ser(424) ), rpS6 (Ser(235/236) ) and Erk1/2 were higher after 5 x 10 RM (P&lt;0.05).	Serine	57-60	ribosomal protein S6 kinase B1	Homo sapiens	39-45
22342124-0	2012	Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.	pyrazolopyrimidines	37-56	ribosomal protein S6 kinase B1	Homo sapiens	60-66
22342124-2	2012	High throughput screening versus p70S6K led to the identification of aminopyrimidine 3a as active inhibitor.	aminopyrimidine 3a	69-87	ribosomal protein S6 kinase B1	Homo sapiens	33-39
22127230-7	2012	Phosphorylation of p70(S6k) increased to a larger extent (~2-fold; P &lt; 0.05) in the early recovery period with BCAA supplementation, whereas the expression of genes regulating mTOR activity was not influenced by BCAA.	Amino Acids, Branched-Chain	114-118	ribosomal protein S6 kinase B1	Homo sapiens	23-26
22182451-5	2012	SNX-2112 induced autophagy in a time- and dose-dependent manner via Akt/mTOR/p70S6K inhibition.	SNX 2112	0-8	ribosomal protein S6 kinase B1	Homo sapiens	77-83
22499437-6	2012	Perifosine treatment suppressed the phosphorylation of Akt downstream targets such as GSK3alpha/beta, MDM2, and p70S6K and induced apoptosis.	perifosine	0-10	ribosomal protein S6 kinase B1	Homo sapiens	112-118
22562408-0	2012	Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks.	caffeic acid phenethyl ester	0-28	ribosomal protein S6 kinase B1	Homo sapiens	111-117
22562408-10	2012	In summary, our results suggest that CAPE administration may be useful as an adjuvant therapy for prostate and potentially other types of cancers that are driven by the p70S6K and Akt signaling networks.	caffeic acid phenethyl ester	37-41	ribosomal protein S6 kinase B1	Homo sapiens	169-175
22383528-6	2012	We then showed that in fro/fro fibroblasts, the reduced ceramide was associated with decreased phosphorylation of protein phosphatase 2A (PP2A) and increased phosphorylation of its substrate Akt-p, together with PI3K, PDK1, mTOR (mammalian target of rapamycin), and p70S6K, although PTEN was unaffected.	Ceramides	56-64	ribosomal protein S6 kinase B1	Homo sapiens	266-272
22322152-9	2012	Studies of mechanism revealed that E Platinum suppressed activation of mTOR and p70S6K by decreasing phosphorylation of Akt, ERK1/2, JNK and p38 involved in mitogen-activated protein kinase signaling.	Platinum	37-45	ribosomal protein S6 kinase B1	Homo sapiens	80-86
22227406-11	2012	Rapamycin, a specific inhibitor of mammalian TOR signaling attenuated PTTH-stimulated phosphorylation of 4E-BP and S6K of the glands, and greatly inhibited PTTH-stimulated ecdysteroidogenesis.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	115-118
22109717-0	2012	Ascochlorin inhibits growth factor-induced HIF-1alpha activation and tumor-angiogenesis through the suppression of EGFR/ERK/p70S6K signaling pathway in human cervical carcinoma cells.	ascochlorin	0-11	ribosomal protein S6 kinase B1	Homo sapiens	124-130
22311299-0	2012	Glucagon-like peptide 1 (GLP-1) can reverse AMP-activated protein kinase (AMPK) and S6 kinase (P70S6K) activities induced by fluctuations in glucose levels in hypothalamic areas involved in feeding behaviour.	Glucose	141-148	ribosomal protein S6 kinase B1	Homo sapiens	95-101
22311299-5	2012	Therefore, we investigated the coordinated effects of glucose and GLP-1 on the expression and activity of AMPK and p70S6K in the areas involved in the control of feeding.	Glucose	54-61	ribosomal protein S6 kinase B1	Homo sapiens	115-121
22574368-0	2012	[Rapamycin inhibits the proliferation of prostate cancer cell line 22RV1 and activity of S6K1].	Sirolimus	1-10	ribosomal protein S6 kinase B1	Homo sapiens	89-94
22574368-4	2012	RESULTS: Rapamycin significantly inhibited the proliferation of the prostate cancer 22RV1 cells and the activity of S6K1 in a dose- dependent manner, most obviously at 400 nmol/L (P&lt;0.01).	Sirolimus	9-18	ribosomal protein S6 kinase B1	Homo sapiens	116-120
22190165-11	2012	Sorafenib/rapamycin combination resulted in downregulation of pAkt, pmTOR, p-p70S6K, p4EBP1, pGSK3beta, Mcl1, and Bcl-Xl.	Sirolimus	10-19	ribosomal protein S6 kinase B1	Homo sapiens	77-83
22406476-13	2012	Rectal mucosal samples from patients given aspirin had reduced phosphorylation of S6K1 and S6.	Aspirin	43-50	ribosomal protein S6 kinase B1	Homo sapiens	82-86
22139427-7	2012	With increasing concentration of cucurmosin,             the expression of EGFR, p-PI3K, Akt, p-Akt, mTOR, p-mTOR, P70S6K-alpha, p-P70S6K-alpha,             4E-BP1 and p-4E-BP1 at the protein level was decreased, whereas the expression             of p-Bad and caspase-9 was elevated.	cucurmosin	33-43	ribosomal protein S6 kinase B1	Homo sapiens	115-127
22050182-6	2012	Western blot analysis showed that rosiglitazone significantly lowered phosphorylated ERK1/2 (extracellular-signal-regulated kinase 1/2), Akt (also known as protein kinase B), mTOR (mammalian target of rapamycin), p70S6K (70 kDa S6 kinase) and 4EBP1 (eukaryotic initiation factor 4E-binding protein) levels in Ang II-treated VSMCs.	Rosiglitazone	34-47	ribosomal protein S6 kinase B1	Homo sapiens	213-219
22376175-0	2012	Rapamycin inhibition of baculovirus recombinant (BVr) ribosomal protein S6 kinase (S6K1) is mediated by an event other than phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	83-87
22171948-4	2012	Treatment with the mTOR inhibitor rapamycin blocked activation of P70S6K and S6, but it also increased activation of AKT and failed to induce cell death.	Sirolimus	34-43	ribosomal protein S6 kinase B1	Homo sapiens	66-72
22142888-9	2012	Chloroquine and RAD001 inhibited phosphorylation of mTOR and its downstream target, S6K1.	Chloroquine	0-11	ribosomal protein S6 kinase B1	Homo sapiens	84-88
22310719-4	2012	MG132 caused the phosphorylation of GSK3beta at Ser(9) and, to a lesser extent, Thr(390), the dephosphorylation of p70S6K at Thr(389), and the phosphorylation of p70S6K at Thr(421) and Ser(424).	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	0-5	ribosomal protein S6 kinase B1	Homo sapiens	115-121
22310719-4	2012	MG132 caused the phosphorylation of GSK3beta at Ser(9) and, to a lesser extent, Thr(390), the dephosphorylation of p70S6K at Thr(389), and the phosphorylation of p70S6K at Thr(421) and Ser(424).	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	0-5	ribosomal protein S6 kinase B1	Homo sapiens	162-168
22310719-4	2012	MG132 caused the phosphorylation of GSK3beta at Ser(9) and, to a lesser extent, Thr(390), the dephosphorylation of p70S6K at Thr(389), and the phosphorylation of p70S6K at Thr(421) and Ser(424).	Threonine	125-128	ribosomal protein S6 kinase B1	Homo sapiens	115-121
22310719-4	2012	MG132 caused the phosphorylation of GSK3beta at Ser(9) and, to a lesser extent, Thr(390), the dephosphorylation of p70S6K at Thr(389), and the phosphorylation of p70S6K at Thr(421) and Ser(424).	Threonine	125-128	ribosomal protein S6 kinase B1	Homo sapiens	115-121
22310719-5	2012	The specific p38 inhibitor SB203080 reduced the p-GSK3beta(Ser9) and autophagy through the phosphorylation of p70S6K(Thr389); however, it augmented the levels of p-ERK, p-GSK3beta(Thr390), and p-70S6K(Thr421/Ser424) induced by MG132, and increased apoptotic cell death.	sb203080	27-35	ribosomal protein S6 kinase B1	Homo sapiens	110-116
22310719-5	2012	The specific p38 inhibitor SB203080 reduced the p-GSK3beta(Ser9) and autophagy through the phosphorylation of p70S6K(Thr389); however, it augmented the levels of p-ERK, p-GSK3beta(Thr390), and p-70S6K(Thr421/Ser424) induced by MG132, and increased apoptotic cell death.	sb203080	27-35	ribosomal protein S6 kinase B1	Homo sapiens	193-200
22281494-0	2012	Improved insulin sensitivity by rapamycin is associated with reduction of mTOR and S6K1 activities in L6 myotubes.	Sirolimus	32-41	ribosomal protein S6 kinase B1	Homo sapiens	83-87
22190165-11	2012	Sorafenib/rapamycin combination resulted in downregulation of pAkt, pmTOR, p-p70S6K, p4EBP1, pGSK3beta, Mcl1, and Bcl-Xl.	Sorafenib	0-9	ribosomal protein S6 kinase B1	Homo sapiens	77-83
22251921-9	2012	WC-26, SV119, RHM-138 and siramesine increased the synthesis and processing of microtubule-associated protein light chain 3, an autophagosome marker, and decreased the expression levels of the downstream effectors of mammalian target of rapamycin (mTOR), p70S6K and 4EBP1, suggesting that sigma-2 ligands induce autophagy, probably by inhibition of the mTOR pathway.	Lu 28-179	26-36	ribosomal protein S6 kinase B1	Homo sapiens	255-271
22281494-2	2012	Pretreatment with 5mug/ml of tunicamycin or 600nM thapsigargin for 3h decreased insulin-mediated tyrosine phosphorylation of IRS-1 and glucose uptake, and increased the level of mTOR/S6K1 phosphorylation in L6 myotubes.	Tunicamycin	29-40	ribosomal protein S6 kinase B1	Homo sapiens	183-187
22281494-2	2012	Pretreatment with 5mug/ml of tunicamycin or 600nM thapsigargin for 3h decreased insulin-mediated tyrosine phosphorylation of IRS-1 and glucose uptake, and increased the level of mTOR/S6K1 phosphorylation in L6 myotubes.	Thapsigargin	50-62	ribosomal protein S6 kinase B1	Homo sapiens	183-187
22281494-2	2012	Pretreatment with 5mug/ml of tunicamycin or 600nM thapsigargin for 3h decreased insulin-mediated tyrosine phosphorylation of IRS-1 and glucose uptake, and increased the level of mTOR/S6K1 phosphorylation in L6 myotubes.	Tritium	67-69	ribosomal protein S6 kinase B1	Homo sapiens	183-187
22281494-3	2012	However, the inhibition of mTOR activity by rapamycin (inhibitor of several intracellular pathways including S6K1 pathways) reversed the ER stress-reduced tyrosine phosphorylation of IRS-1 and glucose uptake.	Sirolimus	44-53	ribosomal protein S6 kinase B1	Homo sapiens	109-113
22281494-3	2012	However, the inhibition of mTOR activity by rapamycin (inhibitor of several intracellular pathways including S6K1 pathways) reversed the ER stress-reduced tyrosine phosphorylation of IRS-1 and glucose uptake.	Tyrosine	155-163	ribosomal protein S6 kinase B1	Homo sapiens	109-113
22281494-3	2012	However, the inhibition of mTOR activity by rapamycin (inhibitor of several intracellular pathways including S6K1 pathways) reversed the ER stress-reduced tyrosine phosphorylation of IRS-1 and glucose uptake.	Glucose	193-200	ribosomal protein S6 kinase B1	Homo sapiens	109-113
22281494-7	2012	Moreover, S6K1 RNAi-mediated knockdown preserved insulin-stimulated Akt phosphorylation and glucose uptake in ER-stressed L6 myotubes, which was blocked by the phosphatidylinositol 3-kinase inhibitor wortmannin.	Glucose	92-99	ribosomal protein S6 kinase B1	Homo sapiens	10-14
22281494-7	2012	Moreover, S6K1 RNAi-mediated knockdown preserved insulin-stimulated Akt phosphorylation and glucose uptake in ER-stressed L6 myotubes, which was blocked by the phosphatidylinositol 3-kinase inhibitor wortmannin.	Wortmannin	200-210	ribosomal protein S6 kinase B1	Homo sapiens	10-14
22281494-8	2012	Taken together, these results suggest that rapamycin improved ER stress-induced insulin resistance via inhibition of mTOR/S6K1 hyperphosphorylation in L6 myotubes.	Sirolimus	43-52	ribosomal protein S6 kinase B1	Homo sapiens	122-126
22408430-2	2012	mTORC1 is sensitive to rapamycin, activates S6K1 and 4EBP1, which are involved in mRNA translation.	Sirolimus	23-32	ribosomal protein S6 kinase B1	Homo sapiens	44-58
22078465-5	2012	Carboplatin effectively inhibited the activation of mTOR signaling cascade, which includes mTOR, 4E-BP1, p70S6K, HIF-1alpha, and VEGF.	Carboplatin	0-11	ribosomal protein S6 kinase B1	Homo sapiens	105-111
21793913-5	2012	DA6034 treatment facilitated the phosphorylation of mTOR that led to an increase in the activity of S6K1, indicating its ability to activate mTOR and S6K1.	recoflavone	0-6	ribosomal protein S6 kinase B1	Homo sapiens	100-104
21793913-5	2012	DA6034 treatment facilitated the phosphorylation of mTOR that led to an increase in the activity of S6K1, indicating its ability to activate mTOR and S6K1.	recoflavone	0-6	ribosomal protein S6 kinase B1	Homo sapiens	150-154
22139847-6	2012	Accordingly, the loss of p38alpha leads to ROS accumulation in response to H(2)O(2), which causes cell death and inactivation of mTOR/p70S6K signaling.	Reactive Oxygen Species	43-46	ribosomal protein S6 kinase B1	Homo sapiens	134-140
22139847-6	2012	Accordingly, the loss of p38alpha leads to ROS accumulation in response to H(2)O(2), which causes cell death and inactivation of mTOR/p70S6K signaling.	Water	75-80	ribosomal protein S6 kinase B1	Homo sapiens	134-140
22139847-8	2012	Therefore, our results reveal a novel homeostatic role for p38alpha in response to oxidative stress, where ROS removal is favored by antioxidant enzymes up-regulation, allowing cell survival and mTOR/p70S6K activation.	Reactive Oxygen Species	107-110	ribosomal protein S6 kinase B1	Homo sapiens	200-206
22028412-8	2012	From these results, we conclude that activation of mTOR/p70S6K by ANG II in vascular endothelium may contribute to impairment of insulin-stimulated vasodilation through phosphorylation of IRS-1 at Ser(636/639).	Serine	197-200	ribosomal protein S6 kinase B1	Homo sapiens	56-62
22223345-9	2012	In addition, PA inhibited key enzymes involved in protein synthesis such as mammalian target of rapamycin (mTOR), 70 kDa ribosomal protein S6 kinase (p70S6K), and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1).	pomolic acid	13-15	ribosomal protein S6 kinase B1	Homo sapiens	150-156
22687422-0	2012	Tributylhexadecylphosphonium bromide, a novel nuclear factor of activated T cells signaling inhibitor, blocks interleukin-2 induction associated with inhibition of p70 ribosomal protein S6 kinase phosphorylation.	tributylhexadecylphosphonium bromide	0-36	ribosomal protein S6 kinase B1	Homo sapiens	164-195
22687422-6	2012	Unlike CsA, THPB did not affect dephosphorylation of NFAT1, but suppressed phosphorylation of p70 ribosomal protein S6 kinase (p70S6K).	tributylhexadecylphosphonium bromide	12-16	ribosomal protein S6 kinase B1	Homo sapiens	94-125
22687422-6	2012	Unlike CsA, THPB did not affect dephosphorylation of NFAT1, but suppressed phosphorylation of p70 ribosomal protein S6 kinase (p70S6K).	tributylhexadecylphosphonium bromide	12-16	ribosomal protein S6 kinase B1	Homo sapiens	127-133
22687422-7	2012	These results suggest that THPB may be a novel type of NFAT signaling inhibitor that acts in association with inhibition of p70S6K phosphorylation.	tributylhexadecylphosphonium bromide	27-31	ribosomal protein S6 kinase B1	Homo sapiens	124-130
22931089-3	2012	We have investigated the link between PA, TLR2/4 and ribosomal S6 kinase 1 (S6K1) in C2C12 myotubes.	Palmitic Acid	38-40	ribosomal protein S6 kinase B1	Homo sapiens	76-80
22931089-4	2012	Incubation with agonists of either TLR2 or TLR4, and with a high concentration of PA, increased S6K1 phosphorylation.	Palmitic Acid	82-84	ribosomal protein S6 kinase B1	Homo sapiens	96-100
22931089-6	2012	By using the SB202190 inhibitor, p38 MAPK (mitogen-activated protein kinase) was found to be a key mediator of PA-induced phosphorylation of S6K1.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	13-21	ribosomal protein S6 kinase B1	Homo sapiens	141-145
22931089-6	2012	By using the SB202190 inhibitor, p38 MAPK (mitogen-activated protein kinase) was found to be a key mediator of PA-induced phosphorylation of S6K1.	Palmitic Acid	111-113	ribosomal protein S6 kinase B1	Homo sapiens	141-145
22931089-7	2012	Downregulation of either tlr2 or tlr4 gene expression by small interfering RNAs prevented the activation of both p38 MAPK and S6K1 by FSL-1, LPS or PA.	Palmitic Acid	148-150	ribosomal protein S6 kinase B1	Homo sapiens	126-130
22931089-9	2012	As PA induced the same intracellular signalling, a novel atypical pathway for PA is induced at the cellular membrane level and results in a higher phosphorylation state of S6K1.	Palmitic Acid	3-5	ribosomal protein S6 kinase B1	Homo sapiens	172-176
22931089-9	2012	As PA induced the same intracellular signalling, a novel atypical pathway for PA is induced at the cellular membrane level and results in a higher phosphorylation state of S6K1.	Palmitic Acid	78-80	ribosomal protein S6 kinase B1	Homo sapiens	172-176
23006739-6	2012	In addition, GDC-0941 blocked the feedback of PI3K/Akt through S6K1, resulting in decreased Akt activity by rapamycin activation.	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	13-21	ribosomal protein S6 kinase B1	Homo sapiens	63-67
23006739-6	2012	In addition, GDC-0941 blocked the feedback of PI3K/Akt through S6K1, resulting in decreased Akt activity by rapamycin activation.	Sirolimus	108-117	ribosomal protein S6 kinase B1	Homo sapiens	63-67
21977024-3	2012	Although excessive activation of mTOR/S6K1 induces cardiac INS resistance via serine phosphorylation of INS receptor substrates (IRS-1/2), it also renders cardioprotection via increased Ang II receptor 2 (AT2R) upregulation and adaptive hypertrophy.	Serine	78-84	ribosomal protein S6 kinase B1	Homo sapiens	38-42
21977024-6	2012	Conversely, alcohol-mediated inhibition of mTOR/S6K1, down-regulation of INS receptor and growth-inhibitory mir-200 family, and upregulation of mir-212 that promotes fetal gene program may exacerbate CRS-related cardiomyopathy.	Alcohols	12-19	ribosomal protein S6 kinase B1	Homo sapiens	48-52
23275900-7	2012	Both RAPA and LY294002 reduced levels of phospho-AKT, phospho-mTOR, phospho-p70S6k and phospho-4EBP1 expression (P &lt;0.05).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	14-22	ribosomal protein S6 kinase B1	Homo sapiens	76-82
21983747-5	2012	Consistent with this, Western blotting demonstrated that everolimus reduced activation and expression of G1-phase cell cycle progression factors, including p70S6K and cyclin D, respectively, decreased levels of proliferating cell nuclear antigen, and attenuated growth factor/serum-induced phosphorylation of the cell cycle phase transition intermediate, retinoblastoma protein.	Everolimus	57-67	ribosomal protein S6 kinase B1	Homo sapiens	156-162
21993902-7	2012	Moreover, treatment of             CML cell line (K562) with rapamycin resulted in a decrease of phosphorylation             of mTOR, 4E-BP1 and p70S6K.	Sirolimus	61-70	ribosomal protein S6 kinase B1	Homo sapiens	145-151
22523661-8	2012	Exaggerated leucine-mediated mTORC1-S6K1 signalling induced by infant formulas may thus explain increased adipogenesis and generation of lifelong elevated adipocyte numbers.	Leucine	12-19	ribosomal protein S6 kinase B1	Homo sapiens	36-40
22028412-6	2012	An inhibitor of mTOR, rapamycin, attenuated the ANG II-stimulated phosphorylation of p70S6K and phosphorylation of IRS-1 (Ser(636/639)) and blocked the ability of ANG II to impair insulin-stimulated phosphorylation of eNOS, nitric oxide production, and mesenteric-arteriole vasodilation.	Sirolimus	22-31	ribosomal protein S6 kinase B1	Homo sapiens	85-91
21909688-8	2012	These effects correlate with the ability of bortezomib to cause dephosphorylation of phospho-Akt, phospho-p70S6K, and phospho-S6RP, thus inactivating a pathway known to be required for HIF-1alpha protein expression at the translational level.	Bortezomib	44-54	ribosomal protein S6 kinase B1	Homo sapiens	106-112
23094058-0	2012	Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways.	Quercetin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	110-116
23094058-8	2012	Furthermore, quercetin reduced the cell viability and induced apoptosis in prostate cancer cells, which were correlated with the downregulation of AKT, mTOR and P70S6K expressions.	Quercetin	13-22	ribosomal protein S6 kinase B1	Homo sapiens	161-167
23094058-9	2012	Collectively the findings in the present study suggest that quercetin inhibits tumor growth and angiogenesis by targeting VEGF-R2 regulated AKT/mTOR/P70S6K signaling pathway, and could be used as a potential drug candidate for cancer therapy.	Quercetin	60-69	ribosomal protein S6 kinase B1	Homo sapiens	149-155
22848442-9	2012	In trophoblast JAR cells, treatment with arginine and its metabolites enhanced Stat3, PKB, and S6K1 activation and facilitated cellular adhesion activity.	Arginine	41-49	ribosomal protein S6 kinase B1	Homo sapiens	95-99
21717457-5	2011	Both OSU03012 and PI103 downregulated phosphorylation of Akt and inhibited the downstream targets glycogen synthase kinase-3beta (GSK3beta) and p70 S6 kinase-1 (S6K1), as well as downregulated the expression of cyclin D1 and Mycn protein.	OSU 03012	5-13	ribosomal protein S6 kinase B1	Homo sapiens	161-165
22457718-7	2012	BITC treatment decreased phosphorylation of mTOR and its downstream targets (P70s6k and 4E-BP1) in cultured MDA-MB-231 and MCF-7 cells and MDA-MB-231 xenografts, but activation of mTOR by transient overexpression of its positive regulator Rheb failed to confer protection against BITC-induced autophagy.	benzyl isothiocyanate	0-4	ribosomal protein S6 kinase B1	Homo sapiens	77-94
22500211-5	2012	Both metformin and ionizing radiation activated AMPK leading to inactivation of mTOR and suppression of its downstream effectors such as S6K1 and 4EBP1, a crucial signaling pathway for proliferation and survival of cancer cells, in vitro as well as in the in vivo tumors.	Metformin	5-14	ribosomal protein S6 kinase B1	Homo sapiens	137-151
21764510-3	2011	Combining adriamycin and torisel inhibited the phosphorylation of 4EBP-1 and p70S6K, the proteins involved in mTOR pathway, increased expression of gammaH2AX indicative of DNA damage, triggered cell cycle arrest at G2/M and apoptosis.	Doxorubicin	10-20	ribosomal protein S6 kinase B1	Homo sapiens	77-83
21964931-9	2011	The use of small molecule inhibitors LY294002 or rapamycin to inhibit PI3K/Akt and p70(S6K) activities, respectively, resulted in diminished HIF-1alpha activation and subsequent VEGF expression.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	37-45	ribosomal protein S6 kinase B1	Homo sapiens	83-86
21964931-9	2011	The use of small molecule inhibitors LY294002 or rapamycin to inhibit PI3K/Akt and p70(S6K) activities, respectively, resulted in diminished HIF-1alpha activation and subsequent VEGF expression.	Sirolimus	49-58	ribosomal protein S6 kinase B1	Homo sapiens	83-86
21889928-7	2011	In addition, lonidamine elicits ERK and Akt/mTOR pathway activation, as indicated by increased ERK, Akt, p70S6K and rpS6 phosphorylation, and these effects are reduced by co-treatment with ATO.	lonidamine	13-23	ribosomal protein S6 kinase B1	Homo sapiens	105-111
21889928-7	2011	In addition, lonidamine elicits ERK and Akt/mTOR pathway activation, as indicated by increased ERK, Akt, p70S6K and rpS6 phosphorylation, and these effects are reduced by co-treatment with ATO.	Arsenic Trioxide	189-192	ribosomal protein S6 kinase B1	Homo sapiens	105-111
21740967-6	2011	Over the past few years, we have reported, in regards to the catalytic action of PLD, that PA is a chemoattractant agent that binds to and signals inside the cell through the ribosomal S6 kinases (S6K).	Phosphatidic Acids	91-93	ribosomal protein S6 kinase B1	Homo sapiens	175-200
22132975-2	2011	Deoxyribose (dR; a downstream TPase-product) addition to endothelial cells may stimulate FAK and p70/S6k signaling, which can be inhibited by rapamycin.	Deoxyribose	0-11	ribosomal protein S6 kinase B1	Homo sapiens	101-104
22132975-2	2011	Deoxyribose (dR; a downstream TPase-product) addition to endothelial cells may stimulate FAK and p70/S6k signaling, which can be inhibited by rapamycin.	Sirolimus	142-151	ribosomal protein S6 kinase B1	Homo sapiens	101-104
21885991-8	2011	Up4A-stimulated phosphorylation and kinase activity of S6 kinase (S6K) and Erk1/2 were inhibited by PD98059, whereas phosphorylation and kinase activity of S6K, but not Erk1/2, were inhibited by rapamycin.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	100-107	ribosomal protein S6 kinase B1	Homo sapiens	55-64
21885991-8	2011	Up4A-stimulated phosphorylation and kinase activity of S6 kinase (S6K) and Erk1/2 were inhibited by PD98059, whereas phosphorylation and kinase activity of S6K, but not Erk1/2, were inhibited by rapamycin.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	100-107	ribosomal protein S6 kinase B1	Homo sapiens	66-69
21885991-8	2011	Up4A-stimulated phosphorylation and kinase activity of S6 kinase (S6K) and Erk1/2 were inhibited by PD98059, whereas phosphorylation and kinase activity of S6K, but not Erk1/2, were inhibited by rapamycin.	Sirolimus	195-204	ribosomal protein S6 kinase B1	Homo sapiens	55-64
21885991-8	2011	Up4A-stimulated phosphorylation and kinase activity of S6 kinase (S6K) and Erk1/2 were inhibited by PD98059, whereas phosphorylation and kinase activity of S6K, but not Erk1/2, were inhibited by rapamycin.	Sirolimus	195-204	ribosomal protein S6 kinase B1	Homo sapiens	66-69
21885991-10	2011	Up4A-stimulated activation of S6K, but not Erk1/2, was also prevented by LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	73-81	ribosomal protein S6 kinase B1	Homo sapiens	30-33
21885991-11	2011	Furthermore, Up4A-stimulated phosphorylation and kinase activity of S6K and Erk1/2 were inhibited by the P2 receptor antagonist, suramin, but not by the P2X receptor antagonist, Ip5I.	Suramin	129-136	ribosomal protein S6 kinase B1	Homo sapiens	68-71
21949121-9	2011	AZD8055 was shown to inhibit phosphorylation of the autophagy-initiating kinase ULK1 at Ser(757) and inhibited known targets of mTORC1 (p-mTOR Ser(2448), p70S6K, p-S6, p4EBP1) and mTORC2 (p-mTOR Ser(2481), p-AKT Ser(473)).	(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	0-7	ribosomal protein S6 kinase B1	Homo sapiens	154-160
21908613-4	2011	First, increasing the levels of PIP(3) in Sin1(-/-) MEFs by (i) expression of a constitutively active PI3K or (ii) relief of a negative feedback loop on PI3K by prolonged inhibition of mTORC1 or S6K is sufficient to rescue hydrophobic motif phosphorylation of Akt.	piperidine	32-35	ribosomal protein S6 kinase B1	Homo sapiens	195-198
21764510-3	2011	Combining adriamycin and torisel inhibited the phosphorylation of 4EBP-1 and p70S6K, the proteins involved in mTOR pathway, increased expression of gammaH2AX indicative of DNA damage, triggered cell cycle arrest at G2/M and apoptosis.	temsirolimus	25-32	ribosomal protein S6 kinase B1	Homo sapiens	77-83
21725613-5	2011	NVP-BEZ235 decreased the levels of p-Akt and p-p70S6K and inhibited cell proliferation in all HCC cell lines in a dose-dependent manner.	dactolisib	4-10	ribosomal protein S6 kinase B1	Homo sapiens	47-53
21637925-7	2011	Finally, we demonstrate that sepiapterin markedly suppresses VEGF-A-induced p70S6K phosphorylation and VEGFR-2 expression, resulting in inhibition of VEGF-A-induced cell proliferation and migration.	sepiapterin	29-40	ribosomal protein S6 kinase B1	Homo sapiens	76-82
21637925-0	2011	Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70S6K-dependent VEGFR-2 expression.	sepiapterin	0-11	ribosomal protein S6 kinase B1	Homo sapiens	101-107
21906315-8	2011	Furthermore, the results indicated that, although 4-hydroxytamoxifen used primarily pathway #1 to down-regulate the phosphorylation of 4E-BP1 and up-regulate the expression of p27, it also secondarily down-regulated the phosphorylation of S6K1.	hydroxytamoxifen	50-68	ribosomal protein S6 kinase B1	Homo sapiens	239-243
21637925-3	2011	Sepiapterin induction of cell proliferation and migration in SKOV-3 cells is accompanied by ERK, Akt and p70S6K activation.	sepiapterin	0-11	ribosomal protein S6 kinase B1	Homo sapiens	105-111
21742783-3	2011	In vitro cigarette smoke extract (CSE) and one of its components, acrolein, inhibit the mammalian target of rapamycin (mTOR)/p70S6K pathway in human endothelial cells, and chemical inhibition of this pathway by rapamycin resulted in elevated MMP-1.	Acrolein	66-74	ribosomal protein S6 kinase B1	Homo sapiens	125-131
21906315-9	2011	In contrast, the deficiency of D-(+)-glucose or L-leucine used primarily pathway #2 to down-regulate the phosphorylation of S6K1, but they also secondarily down-regulated the phosphorylation of 4E-BP1 and up-regulated the expression of p27.	Glucose	31-44	ribosomal protein S6 kinase B1	Homo sapiens	124-128
21906315-9	2011	In contrast, the deficiency of D-(+)-glucose or L-leucine used primarily pathway #2 to down-regulate the phosphorylation of S6K1, but they also secondarily down-regulated the phosphorylation of 4E-BP1 and up-regulated the expression of p27.	Leucine	48-57	ribosomal protein S6 kinase B1	Homo sapiens	124-128
21746787-15	2011	These data indicate that the increase in myofibrillar MPS for C+P could, potentially, be mediated through p70S6K, downstream of mTOR, which in turn may suppress the rise in eEF2 on translation elongation.	Carbon	62-63	ribosomal protein S6 kinase B1	Homo sapiens	106-112
21168492-7	2011	In parallel, IGF-II increases phosphorylation of AKT and p70S6K, while metformin increases AMPK phosphorylation and decreases p70S6K phosphorylation.	Metformin	71-80	ribosomal protein S6 kinase B1	Homo sapiens	126-132
21168492-8	2011	The effects of metformin on PR A/B and p70S6K are partially reversed by an AMPK inhibitor.	Metformin	15-24	ribosomal protein S6 kinase B1	Homo sapiens	39-45
21717584-6	2011	Mammalian target of rapamycin complex 1 (mTORC1), which is negatively regulated by AMPK and plays a central role in cell growth and proliferation, was inhibited by metformin, as manifested by dephosphorylation of its downstream targets 40S ribosomal S6 kinase 1 (S6K1) (T389), the eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) (T37/46) and S6 (S235/236) in C666-1 cells.	Metformin	164-173	ribosomal protein S6 kinase B1	Homo sapiens	263-267
21602475-3	2011	Once activated by insulin, mTOR/p70S6K phosphorylates insulin receptor substrate-1 (IRS-1) on serine residues, resulting in its inhibition and reduction of insulin signaling.	Serine	94-100	ribosomal protein S6 kinase B1	Homo sapiens	32-38
21673091-6	2011	OSI-027 inhibits phosphorylation of the mTORC1 substrates 4E-BP1 and S6K1 as well as the mTORC2 substrate AKT in diverse cancer models in vitro and in vivo.	OSI 027	0-7	ribosomal protein S6 kinase B1	Homo sapiens	69-73
21602475-11	2011	Mimicking AMPK activators in the presence of insulin, rapamycin inhibited p70S6K and reduced IRS-1 phosphorylation on serine, resulting in the overphosphorylation of PKB/Akt and AS160.	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	74-80
21803746-5	2011	PDGFRbeta-upregulated, PLX4032-resistant (PPRM) cell lines show dual phospho (p)-ERK and p-AKT upregulation, and their growth inhibitory responses to specific small molecule inhibitors correlated with p-ERK, p-AKT, and p-p70S6K levels.	Vemurafenib	23-30	ribosomal protein S6 kinase B1	Homo sapiens	221-227
20857402-6	2011	Homocysteine also induced transient phosphorylation of ERK, Akt, and p70 ribosomal S6 kinase (p70S6K).	Homocysteine	0-12	ribosomal protein S6 kinase B1	Homo sapiens	69-92
21614555-4	2011	Western blot analysis of phosphorylated proteins showed that exposure to prazosin increased the levels of phospho-p53 and phospho-adenosine monophosphate-activated protein kinase (AMPK) but dramatically decreased the levels of phospho-mammalian target of rapamycin (mTOR), phospho-protein kinase B (Akt), and phospho-ribosomal protein S6 kinase (p70S6K).	Prazosin	73-81	ribosomal protein S6 kinase B1	Homo sapiens	346-352
20683653-11	2011	AMP-kinase was stimulated by MF approximately equally in MCF-7, TAM-R, and LTED cells, while inhibition by biguanide of p-S6K as a downstream target of mTOR was strongest in TAM-R cells.	Biguanides	107-116	ribosomal protein S6 kinase B1	Homo sapiens	120-125
20951021-7	2011	Western blotting and immunoprecipitation demonstrated that denbinobin causes more efficient inhibition of IGF-1-induced activation of IGF-1R and its downstream signaling targets, including , extracellular signal-regulated kinase, Akt, mTOR, p70S6K, 4EBP and cyclin D1.	denbinobin	59-69	ribosomal protein S6 kinase B1	Homo sapiens	241-253
21702994-6	2011	Phosphorylation of mTOR and p70S6K was transiently increased following leucine exposure, independently to insulin.	Leucine	71-78	ribosomal protein S6 kinase B1	Homo sapiens	28-34
21464613-10	2011	NVP-BEZ235 and GSK2126458 inhibited AKT signaling but NVP-BEZ235 showed greater effects than GSK2126458 on p70S6K and rpS6 signaling with effects resembling those of rapamycin.	dactolisib	58-64	ribosomal protein S6 kinase B1	Homo sapiens	107-113
21464613-10	2011	NVP-BEZ235 and GSK2126458 inhibited AKT signaling but NVP-BEZ235 showed greater effects than GSK2126458 on p70S6K and rpS6 signaling with effects resembling those of rapamycin.	omipalisib	93-103	ribosomal protein S6 kinase B1	Homo sapiens	107-113
21455575-4	2011	Furthermore, 5-FU inhibited the phosphorylation of Akt and p70 S6K, while the knockdown of IGFBP3 reduced the levels of poly (ADP-ribose) polymerase cleaved by 5-FU in PC3 cells.	Fluorouracil	13-17	ribosomal protein S6 kinase B1	Homo sapiens	59-66
21089180-4	2011	Chrysophanic acid treatment in SNU-C5 cells inhibited EGF-induced phosphorylation of EGFR and suppressed activation of downstream signaling molecules, such as AKT, extracellular signal-regulated kinase (ERK) and the mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase (p70S6K).	chrysophanic acid	0-17	ribosomal protein S6 kinase B1	Homo sapiens	282-288
21321360-6	2011	Importantly, lenalidomide decreased the percentage and clonogenicity of SP cells, and also induced phosphorylation changes in Akt, GSK-3alpha/beta, MEK1, c-Jun, p53, and p70S6K in SP cells.	Lenalidomide	13-25	ribosomal protein S6 kinase B1	Homo sapiens	170-176
21268130-4	2011	The phosphorylation of AKT and its downstream targets, 70-kDa ribosomal protein S6 kinase (p70S6K) and translation initiation factor 4B (eIF4B), are increased in the arsenite treated cells, indicating that long-term arsenite treatment activates AKT-p70S6K signaling pathway.	arsenite	166-174	ribosomal protein S6 kinase B1	Homo sapiens	91-97
21268130-4	2011	The phosphorylation of AKT and its downstream targets, 70-kDa ribosomal protein S6 kinase (p70S6K) and translation initiation factor 4B (eIF4B), are increased in the arsenite treated cells, indicating that long-term arsenite treatment activates AKT-p70S6K signaling pathway.	arsenite	166-174	ribosomal protein S6 kinase B1	Homo sapiens	249-255
21268130-4	2011	The phosphorylation of AKT and its downstream targets, 70-kDa ribosomal protein S6 kinase (p70S6K) and translation initiation factor 4B (eIF4B), are increased in the arsenite treated cells, indicating that long-term arsenite treatment activates AKT-p70S6K signaling pathway.	arsenite	216-224	ribosomal protein S6 kinase B1	Homo sapiens	91-97
21510936-4	2011	Our results showed that in human neuroblastoma cells, PA exposure can reduce H(2)O(2)-induced apoptosis and can increase tau protein phosphorylation on Ser214 via p70(S6K) activation.	Phosphatidic Acids	54-56	ribosomal protein S6 kinase B1	Homo sapiens	163-170
21536668-8	2011	In contrast, ATRA suppressed phosphorylation of ribosomal S6 kinase (S6K) and its downstream targets S6 and eIF4B.	Tretinoin	13-17	ribosomal protein S6 kinase B1	Homo sapiens	69-72
21228102-4	2011	Both GSK3 inhibitors reduced the phosphorylation of the mTOR downstream target, p70(S6K), indicating that GSK3 inhibition in podocytes is able to cause similar effects as treatment with rapamycin.	Sirolimus	186-195	ribosomal protein S6 kinase B1	Homo sapiens	84-87
21329734-9	2011	Both rapamycin co-treatment and p70S6K knockdown inhibited visfatin-induced GSK3beta phosphorylation at Ser-9 and nuclear translocation of beta-catenin.	Serine	104-107	ribosomal protein S6 kinase B1	Homo sapiens	32-38
20857402-6	2011	Homocysteine also induced transient phosphorylation of ERK, Akt, and p70 ribosomal S6 kinase (p70S6K).	Homocysteine	0-12	ribosomal protein S6 kinase B1	Homo sapiens	94-100
20857402-8	2011	In conclusion, homocysteine-induced differential activation of Ras/ERK and PI3K/Akt/p70S6K signaling pathways and consequent expression of cyclins A and D1 are dependent on beta1 integrin.	Homocysteine	15-27	ribosomal protein S6 kinase B1	Homo sapiens	84-90
21282364-0	2011	Leucine deprivation increases hepatic insulin sensitivity via GCN2/mTOR/S6K1 and AMPK pathways.	Leucine	0-7	ribosomal protein S6 kinase B1	Homo sapiens	72-76
21191105-6	2011	PGF(2alpha) stimulated time- and dose-dependent increases in the phosphorylation of extracellular receptor kinase (ERK)1/2 (Thr202/Tyr204), p70S6 kinase (p70S6K) (Thr389 and Thr421/Ser424), and eukaryotic initiation factor 4G (eIF4G) (Ser1108) without influencing Akt (Ser473).	Prostaglandins F	0-3	ribosomal protein S6 kinase B1	Homo sapiens	140-152
21191105-6	2011	PGF(2alpha) stimulated time- and dose-dependent increases in the phosphorylation of extracellular receptor kinase (ERK)1/2 (Thr202/Tyr204), p70S6 kinase (p70S6K) (Thr389 and Thr421/Ser424), and eukaryotic initiation factor 4G (eIF4G) (Ser1108) without influencing Akt (Ser473).	Prostaglandins F	0-3	ribosomal protein S6 kinase B1	Homo sapiens	154-160
21191105-7	2011	Pretreatment with the phosphoinositide 3-kinase (PI3K) inhibitor LY294002 and the ERK inhibitor PD98059 blocked F prostanoid receptor signaling responses, whereas rapamycin blocked heightened p70S6K/eIF4G phosphorylation without influencing ERK1/2 phosphorylation.	Sirolimus	163-172	ribosomal protein S6 kinase B1	Homo sapiens	192-198
21282364-4	2011	RESULTS: We show that leucine deprivation improves hepatic insulin sensitivity by sequentially activating general control nonderepressible (GCN)2 and decreasing mammalian target of rapamycin/S6K1 signaling.	Leucine	22-29	ribosomal protein S6 kinase B1	Homo sapiens	191-195
21081844-0	2011	Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition.	Caffeine	0-8	ribosomal protein S6 kinase B1	Homo sapiens	73-79
25961241-7	2011	The IGF1R inhibitor picropodophyllin inhibited growth of all MCF-7 cells but only in the long-term oestrogen/insulin-deprived cells was this paralleled by reduction in phosphorylated p70S6K, a downstream target of mTOR.	picropodophyllin	20-36	ribosomal protein S6 kinase B1	Homo sapiens	183-189
20558053-1	2011	Although activation of the mammalian target of rapamycin complex/p70 S6 kinase (S6K1) pathway by leucine is efficient to stimulate muscle protein synthesis, it can also exert inhibition on the early steps of insulin signaling leading to insulin resistance.	Leucine	97-104	ribosomal protein S6 kinase B1	Homo sapiens	80-84
20558053-5	2011	Tyrosine phosphorylation of IRbeta, IRS1 and PI3 kinase activity were reduced in LEU group 30 min after feeding (-36%, -36% and -38% respectively, P&lt;.05) whereas S6K1, S6rp and 4EBP1 phosphorylations were similar.	Leucine	81-84	ribosomal protein S6 kinase B1	Homo sapiens	165-169
21345206-6	2011	HMbeta supplementation induced muscle hypertrophy in the extensor digitorum longus (EDL) and soleus muscles and increased serum insulin levels, the expression of the mammalian target of rapamycin (mTOR) and phosphorylation of p70S6K in the EDL muscle.	hmbeta	0-6	ribosomal protein S6 kinase B1	Homo sapiens	226-232
21081844-6	2011	In contrast, ERK1/2 (Thr202/204) was increased by caffeine, suggesting an inhibition of the Akt/mTOR/p70S6K pathway and activation of the ERK1/2 pathway.	Caffeine	50-58	ribosomal protein S6 kinase B1	Homo sapiens	101-107
21223797-3	2010	RESULTS: Tamoxifen leads to apoptosis of the cells and reduction in survivin expression, as well as a dramatic reduction in the activated form of p70S6K.	Tamoxifen	9-18	ribosomal protein S6 kinase B1	Homo sapiens	146-152
20930115-5	2011	LXA(4) increased phosphorylation of Akt, p70(S6K) but not ERK1/2.	N-(1H-benzimidazol-2-ylmethyl)-2-methoxyacetamide	0-3	ribosomal protein S6 kinase B1	Homo sapiens	45-48
21185721-0	2011	Potent and selective thiophene urea-templated inhibitors of S6K.	thiophene urea	21-35	ribosomal protein S6 kinase B1	Homo sapiens	60-63
21185721-2	2011	We describe a novel thiophene urea class of S6K inhibitors.	thiophene urea	20-34	ribosomal protein S6 kinase B1	Homo sapiens	44-47
20851763-4	2011	Using serum starved SK-N-SH neuroblastoma cells, we show that the muscarinic receptor agonists carbachol and pilocarpine enhance the activation of the mTOR substrate p70 S6 Kinase (S6K) and its target ribosomal protein S6 (S6) in a VEGFR2 dependent manner.	Carbachol	95-104	ribosomal protein S6 kinase B1	Homo sapiens	181-184
20851763-4	2011	Using serum starved SK-N-SH neuroblastoma cells, we show that the muscarinic receptor agonists carbachol and pilocarpine enhance the activation of the mTOR substrate p70 S6 Kinase (S6K) and its target ribosomal protein S6 (S6) in a VEGFR2 dependent manner.	Pilocarpine	109-120	ribosomal protein S6 kinase B1	Homo sapiens	181-184
20851763-7	2011	Treatments with the phosphatase inhibitors sodium orthovanadate and okadaic acid increase S6, Akt and to a lesser extent S6K phosphorylation, indicating that tyrosine and serine/threonine dephosphorylation also regulates their activity.	Sodium orthovanadate	43-63	ribosomal protein S6 kinase B1	Homo sapiens	121-124
20851763-7	2011	Treatments with the phosphatase inhibitors sodium orthovanadate and okadaic acid increase S6, Akt and to a lesser extent S6K phosphorylation, indicating that tyrosine and serine/threonine dephosphorylation also regulates their activity.	Okadaic Acid	68-80	ribosomal protein S6 kinase B1	Homo sapiens	121-124
21698202-7	2011	The leucine (2.5-5 mM)-induced phosphorylation of S6K1 on the other hand was repressed by low concentrations of both tunicamycin and thapsigargin.	Leucine	4-11	ribosomal protein S6 kinase B1	Homo sapiens	50-54
21698202-7	2011	The leucine (2.5-5 mM)-induced phosphorylation of S6K1 on the other hand was repressed by low concentrations of both tunicamycin and thapsigargin.	Tunicamycin	117-128	ribosomal protein S6 kinase B1	Homo sapiens	50-54
21698202-7	2011	The leucine (2.5-5 mM)-induced phosphorylation of S6K1 on the other hand was repressed by low concentrations of both tunicamycin and thapsigargin.	Thapsigargin	133-145	ribosomal protein S6 kinase B1	Homo sapiens	50-54
21698202-13	2011	Blocking PKB using a specific inhibitor had the same effect on both PRAS40 and leucine-induced phosphorylation of S6K1.	Leucine	79-86	ribosomal protein S6 kinase B1	Homo sapiens	114-118
21079551-5	2010	To inhibit this pathway, we used sirolimus, which repressed p70S6K phosphorylation and reduced BK virus large T antigen expression in a dose-dependent manner.	Sirolimus	33-42	ribosomal protein S6 kinase B1	Homo sapiens	60-66
21079551-7	2010	The combination of sirolimus and leflunomide inhibited BK virus genome replication, large T antigen expression, PDK1, Akt, mammalian target of rapamycin, and p70S6K phosphorylation.	Sirolimus	19-28	ribosomal protein S6 kinase B1	Homo sapiens	158-164
21079551-7	2010	The combination of sirolimus and leflunomide inhibited BK virus genome replication, large T antigen expression, PDK1, Akt, mammalian target of rapamycin, and p70S6K phosphorylation.	Leflunomide	33-44	ribosomal protein S6 kinase B1	Homo sapiens	158-164
20497028-5	2010	Hyperbaric O2 treatment stimulated significantly increased mRNA expression of fibroblast growth factor (FGF)-2 as well as protein expression levels of Akt, p70(S6K), phosphorylated ERK, nuclear factor (NF)-kappaB, protein kinase C (PKC)alpha, and phosphorylated c-Jun N-terminal kinase (JNK).	Oxygen	11-13	ribosomal protein S6 kinase B1	Homo sapiens	160-163
19936974-4	2010	The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K.	Paraffin	46-54	ribosomal protein S6 kinase B1	Homo sapiens	36-42
20980505-5	2011	Instead, HCMV-induced PABP accumulation resulted from new protein synthesis and was sensitive to the mTORC1-selective inhibitor rapamycin, which interferes with phosphorylation of the mTORC1 substrate p70 S6K and the translational repressor 4E-BP1.	Sirolimus	128-137	ribosomal protein S6 kinase B1	Homo sapiens	201-208
20826199-7	2010	Likewise, levels of phosphorylated mTOR and p70S6K were significantly enhanced in the CA3 following morphine CPP.	Morphine	100-108	ribosomal protein S6 kinase B1	Homo sapiens	44-50
20826199-4	2010	Here, we tested the role of PI3K/Akt-mTOR-p70S6K signaling pathway in morphine-induced CPP in the hippocampus.	Morphine	70-78	ribosomal protein S6 kinase B1	Homo sapiens	42-48
20528801-7	2010	Phosphorylation of p70(S6k) was unaffected by resistance exercise alone; however, BCAA intake increased (P&lt;0.05) this phosphorylation in both legs following exercise.	Amino Acids, Branched-Chain	82-86	ribosomal protein S6 kinase B1	Homo sapiens	23-26
20844469-6	2010	In contrast, phospho-mTOR and phospho-p70S6K (Thr421Ser424) expressions were higher in SCC from CP.	thr421ser424	46-58	ribosomal protein S6 kinase B1	Homo sapiens	38-44
20528801-10	2010	CONCLUSION: The present findings indicate that resistance exercise and BCAA exert both separate and combined effects on the p70(S6k) phosphorylation in an Akt-independent manner.	Amino Acids, Branched-Chain	71-75	ribosomal protein S6 kinase B1	Homo sapiens	124-131
20473536-6	2010	Compared with the control group, dietary supplementation with 0.55% L-leucine for 2 weeks increased (P&lt;0.05): (1) the phosphorylated levels of S6K1 and 4E-BP1; (2) protein synthesis in skeletal muscle, liver, the heart, kidney, pancreas, spleen, and stomach; and (3) daily weight gain by 61%.	Leucine	68-77	ribosomal protein S6 kinase B1	Homo sapiens	146-150
20629079-9	2010	Dasatinib reduced the phosphorylation of AKT, mTOR, p70S6K, and S6 kinase expression.	Dasatinib	0-9	ribosomal protein S6 kinase B1	Homo sapiens	52-58
20941752-8	2010	Our results indicated that inactivation of PI-3K, Akt, or p70S6K could inhibit silica-induced overexpression of cyclin D1 and cyclin-dependent kinase 4 (CDK4) and decreased expression of E2F-4.	Silicon Dioxide	79-85	ribosomal protein S6 kinase B1	Homo sapiens	58-64
20728939-3	2010	Rapamycin inhibited the phosphorylation of the 70-kDa ribosomal protein S6 kinase (p70S6K) and the 4E binding protein 1 (4EBP-1), and suppressed the mitogen activated protein kinase (MAPK) pathway by decreasing phosphorylation of c-Jun N-terminal kinase (JNK).	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	83-89
20941752-3	2010	This study showed that silica exposure induced phosphorylation of p70S6 kinase (p70S6K) and Akt in human embryo lung fibroblasts (HELFs).	Silicon Dioxide	23-29	ribosomal protein S6 kinase B1	Homo sapiens	66-78
20656472-4	2010	Treatment of HK2 cells, mouse Tsc-deficient cells and human VHL-deficient cells (786-O) with rapamycin resulted in decrease in p70S6K phosphorylation at Thr(389), and increase in the expression of NF-YA and OGG1 proteins.	Sirolimus	93-102	ribosomal protein S6 kinase B1	Homo sapiens	127-133
20941752-3	2010	This study showed that silica exposure induced phosphorylation of p70S6 kinase (p70S6K) and Akt in human embryo lung fibroblasts (HELFs).	Silicon Dioxide	23-29	ribosomal protein S6 kinase B1	Homo sapiens	80-86
20941752-5	2010	Moreover, pretreatment of cells with rapamycin, a specific p70S6K inhibitor, could inhibit silica-induced cell cycle alteration, AP-1 activation, and phosphorylation of p70S6K, but had no effect on Akt phosphorylation.	Sirolimus	37-46	ribosomal protein S6 kinase B1	Homo sapiens	59-65
20941752-5	2010	Moreover, pretreatment of cells with rapamycin, a specific p70S6K inhibitor, could inhibit silica-induced cell cycle alteration, AP-1 activation, and phosphorylation of p70S6K, but had no effect on Akt phosphorylation.	Sirolimus	37-46	ribosomal protein S6 kinase B1	Homo sapiens	169-175
20941752-5	2010	Moreover, pretreatment of cells with rapamycin, a specific p70S6K inhibitor, could inhibit silica-induced cell cycle alteration, AP-1 activation, and phosphorylation of p70S6K, but had no effect on Akt phosphorylation.	Silicon Dioxide	91-97	ribosomal protein S6 kinase B1	Homo sapiens	59-65
20941752-5	2010	Moreover, pretreatment of cells with rapamycin, a specific p70S6K inhibitor, could inhibit silica-induced cell cycle alteration, AP-1 activation, and phosphorylation of p70S6K, but had no effect on Akt phosphorylation.	Silicon Dioxide	91-97	ribosomal protein S6 kinase B1	Homo sapiens	169-175
20682696-1	2010	OBJECTIVE: Branched-chain amino acids, such as leucine and glucose, stimulate protein synthesis and increase the phosphorylation and activity of the mammalian target of rapamycin (mTOR) and its downstream target p70S6 kinase (p70S6K).	Amino Acids, Branched-Chain	11-37	ribosomal protein S6 kinase B1	Homo sapiens	212-224
20682696-1	2010	OBJECTIVE: Branched-chain amino acids, such as leucine and glucose, stimulate protein synthesis and increase the phosphorylation and activity of the mammalian target of rapamycin (mTOR) and its downstream target p70S6 kinase (p70S6K).	Amino Acids, Branched-Chain	11-37	ribosomal protein S6 kinase B1	Homo sapiens	226-232
20682696-1	2010	OBJECTIVE: Branched-chain amino acids, such as leucine and glucose, stimulate protein synthesis and increase the phosphorylation and activity of the mammalian target of rapamycin (mTOR) and its downstream target p70S6 kinase (p70S6K).	Leucine	47-54	ribosomal protein S6 kinase B1	Homo sapiens	212-224
20682696-1	2010	OBJECTIVE: Branched-chain amino acids, such as leucine and glucose, stimulate protein synthesis and increase the phosphorylation and activity of the mammalian target of rapamycin (mTOR) and its downstream target p70S6 kinase (p70S6K).	Leucine	47-54	ribosomal protein S6 kinase B1	Homo sapiens	226-232
20682696-1	2010	OBJECTIVE: Branched-chain amino acids, such as leucine and glucose, stimulate protein synthesis and increase the phosphorylation and activity of the mammalian target of rapamycin (mTOR) and its downstream target p70S6 kinase (p70S6K).	Glucose	59-66	ribosomal protein S6 kinase B1	Homo sapiens	212-224
20682696-1	2010	OBJECTIVE: Branched-chain amino acids, such as leucine and glucose, stimulate protein synthesis and increase the phosphorylation and activity of the mammalian target of rapamycin (mTOR) and its downstream target p70S6 kinase (p70S6K).	Glucose	59-66	ribosomal protein S6 kinase B1	Homo sapiens	226-232
20656472-4	2010	Treatment of HK2 cells, mouse Tsc-deficient cells and human VHL-deficient cells (786-O) with rapamycin resulted in decrease in p70S6K phosphorylation at Thr(389), and increase in the expression of NF-YA and OGG1 proteins.	Threonine	153-156	ribosomal protein S6 kinase B1	Homo sapiens	127-133
20861369-4	2010	We found that exposure to a cocaine-related cue induced reinstatement to cocaine seeking and increased phosphorylation of p70s6 kinase (p70s6k) and ribosomal protein s6 (rps6), measures of mTOR activity, in the nucleus accumbens (NAc) core but not shell.	Cocaine	28-35	ribosomal protein S6 kinase B1	Homo sapiens	122-134
20429048-4	2010	In addition, the phosphorylation of mTOR and p70 ribosomal S6 kinase (S6K) enhanced by palmitate was attenuated in PKCTheta-deficient C2C12 myotubes and in C2C12 myotubes treated with PKCTheta pseudosubstrate.	Palmitates	87-96	ribosomal protein S6 kinase B1	Homo sapiens	59-68
20429048-4	2010	In addition, the phosphorylation of mTOR and p70 ribosomal S6 kinase (S6K) enhanced by palmitate was attenuated in PKCTheta-deficient C2C12 myotubes and in C2C12 myotubes treated with PKCTheta pseudosubstrate.	Palmitates	87-96	ribosomal protein S6 kinase B1	Homo sapiens	70-73
20429048-5	2010	Taken together, our results suggested that palmitate-induced insulin resistance in C2C12 myotubes is mediated by PKCTheta/mTOR/S6K pathway.	Palmitates	43-52	ribosomal protein S6 kinase B1	Homo sapiens	127-130
20861369-4	2010	We found that exposure to a cocaine-related cue induced reinstatement to cocaine seeking and increased phosphorylation of p70s6 kinase (p70s6k) and ribosomal protein s6 (rps6), measures of mTOR activity, in the nucleus accumbens (NAc) core but not shell.	Cocaine	28-35	ribosomal protein S6 kinase B1	Homo sapiens	136-142
20861369-6	2010	Finally, stimulation of NAc core p70s6k and rps6 phosphorylation by NMDA enhanced cue-induced reinstatement, an effect reversed by rapamycin pretreatment.	N-Methylaspartate	68-72	ribosomal protein S6 kinase B1	Homo sapiens	33-39
20861369-6	2010	Finally, stimulation of NAc core p70s6k and rps6 phosphorylation by NMDA enhanced cue-induced reinstatement, an effect reversed by rapamycin pretreatment.	Sirolimus	131-140	ribosomal protein S6 kinase B1	Homo sapiens	33-39
20501660-8	2010	Inhibitors of this pathway suppressed hyaluronan synthesis and HAS2 expression in MCF-7 cells, suggesting that the reduced hyaluronan synthesis by MbetaCD is due to down-regulation of HAS2, mediated by the phosphoinositide 3-kinase-Akt-mTOR-p70S6K pathway.	methyl-beta-cyclodextrin	147-154	ribosomal protein S6 kinase B1	Homo sapiens	241-247
20460585-5	2010	A marked increase in p70S6K Thr(389) and rpS6 Ser-235/236 phosphorylation was observed concomitantly with an up-regulation of protein synthesis rate.	Threonine	28-31	ribosomal protein S6 kinase B1	Homo sapiens	21-27
20460585-6	2010	Treatment with rapamycin prevented p70S6K phosphorylation and rescued cell size control in AMPK-deficient cells.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	35-41
20660299-3	2010	LH/hCG treatment showed a time-dependent stimulation of T-I cell proliferation and phosphorylation of protein kinase B (AKT), ERK1/2, and ribosomal protein (rp)S6 kinase 1 (S6K1), and its downstream effector, rpS6.	Luteinizing Hormone	0-2	ribosomal protein S6 kinase B1	Homo sapiens	138-177
20660299-6	2010	Furthermore, the AKT-specific inhibitor abolished forskolin (FSK)-stimulated phosphorylation of AKT, tuberin, S6K1, and rpS6.	Colforsin	50-59	ribosomal protein S6 kinase B1	Homo sapiens	110-114
20660299-6	2010	Furthermore, the AKT-specific inhibitor abolished forskolin (FSK)-stimulated phosphorylation of AKT, tuberin, S6K1, and rpS6.	Colforsin	61-64	ribosomal protein S6 kinase B1	Homo sapiens	110-114
20660299-8	2010	Pharmacologic targeting of mTORC1 with rapamycin also abrogated hCG or FSK-induced phosphorylation of S6K1, rpS6, and eukaryotic initiation factor 4E binding protein 1.	Sirolimus	39-48	ribosomal protein S6 kinase B1	Homo sapiens	102-106
20660299-8	2010	Pharmacologic targeting of mTORC1 with rapamycin also abrogated hCG or FSK-induced phosphorylation of S6K1, rpS6, and eukaryotic initiation factor 4E binding protein 1.	Colforsin	71-74	ribosomal protein S6 kinase B1	Homo sapiens	102-106
20167228-7	2010	The Abeta(25-35)-infusion decreased the levels of Akt, mTOR and p70S6k phosphorylation, which could be rescued by DHEA-treatment in a sigma(1) receptor-dependent manner.	Dehydroepiandrosterone	114-118	ribosomal protein S6 kinase B1	Homo sapiens	64-70
20167228-9	2010	These findings suggest that DHEA prevents the Abeta(25-35)-impaired survival and dendritic growth of newborn neurons through a sigma(1) receptor-mediated modulation of PI3K-Akt-mTOR-p70S6k signaling.	Dehydroepiandrosterone	28-32	ribosomal protein S6 kinase B1	Homo sapiens	182-188
20434451-9	2010	Triptolide-induced autophagy has a pro-death effect, requires autophagy-specific genes, atg5 or beclin1, and is associated with the inactivation of the Protein kinase B (Akt)/mammalian target of Rapamycin/p70S6K pathway and the up-regulation of the Extracellular Signal-Related Kinase (ERK)1/2 pathway.	triptolide	0-10	ribosomal protein S6 kinase B1	Homo sapiens	205-211
20599721-0	2010	S6K1 is acetylated at lysine 516 in response to growth factor stimulation.	Lysine	22-28	ribosomal protein S6 kinase B1	Homo sapiens	0-4
20599721-2	2010	S6K1 is activated by the phosphorylation of multiple serine and threonine residues in response to stimulation by a variety of growth factors and cytokines.	Serine	53-59	ribosomal protein S6 kinase B1	Homo sapiens	0-4
20599721-2	2010	S6K1 is activated by the phosphorylation of multiple serine and threonine residues in response to stimulation by a variety of growth factors and cytokines.	Threonine	64-73	ribosomal protein S6 kinase B1	Homo sapiens	0-4
20599721-3	2010	In addition to phosphorylation, we have recently shown that S6K1 is also targeted by lysine acetylation.	Lysine	85-91	ribosomal protein S6 kinase B1	Homo sapiens	60-64
20599721-4	2010	Here, using tandem mass spectrometry we have mapped acetylation of S6K1 to lysine 516, a site close to the C-terminus of the kinase that is highly conserved amongst vertebrate S6K1 orthologues.	Lysine	75-81	ribosomal protein S6 kinase B1	Homo sapiens	67-71
20599721-4	2010	Here, using tandem mass spectrometry we have mapped acetylation of S6K1 to lysine 516, a site close to the C-terminus of the kinase that is highly conserved amongst vertebrate S6K1 orthologues.	Lysine	75-81	ribosomal protein S6 kinase B1	Homo sapiens	176-180
20599721-8	2010	We propose that K516 acetylation may serve to modulate important kinase-independent functions of S6K1 in response to growth factor signalling.	Vitamin K 1	16-20	ribosomal protein S6 kinase B1	Homo sapiens	97-101
20554786-7	2010	We found that in 15 cultures (67.5%), everolimus significantly reduced cell viability (by approximately 30%; P&lt;0.05 versus control), inhibited p70S6K activity (-30%), and blocked IGF1 proliferative effects.	Everolimus	38-48	ribosomal protein S6 kinase B1	Homo sapiens	146-152
20623096-13	2010	Further, extracellular PA serves as a neutrophil chemoattractant; PA enters the cell and activates the mTOR/S6K pathway (specifically, S6K).	Phosphatidic Acids	23-25	ribosomal protein S6 kinase B1	Homo sapiens	108-111
20623096-13	2010	Further, extracellular PA serves as a neutrophil chemoattractant; PA enters the cell and activates the mTOR/S6K pathway (specifically, S6K).	Phosphatidic Acids	23-25	ribosomal protein S6 kinase B1	Homo sapiens	135-138
20623096-13	2010	Further, extracellular PA serves as a neutrophil chemoattractant; PA enters the cell and activates the mTOR/S6K pathway (specifically, S6K).	Phosphatidic Acids	66-68	ribosomal protein S6 kinase B1	Homo sapiens	108-111
20623096-13	2010	Further, extracellular PA serves as a neutrophil chemoattractant; PA enters the cell and activates the mTOR/S6K pathway (specifically, S6K).	Phosphatidic Acids	66-68	ribosomal protein S6 kinase B1	Homo sapiens	135-138
20623096-14	2010	A clear connection between PLD with the mTOR/S6K pathway has been established, in that PA binds to mTOR and also binds to S6K independently of mTOR.	Phosphatidic Acids	87-89	ribosomal protein S6 kinase B1	Homo sapiens	45-48
20623096-14	2010	A clear connection between PLD with the mTOR/S6K pathway has been established, in that PA binds to mTOR and also binds to S6K independently of mTOR.	Phosphatidic Acids	87-89	ribosomal protein S6 kinase B1	Homo sapiens	122-125
20382746-7	2010	The mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) inhibition with rapamycin inhibited IFN- and EGF-induced protein synthesis, suggesting that IFN-induced protein synthesis is modulated by mTOR/S6K1 activation.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	54-58
20439463-4	2010	mTOR inhibitor rapamycin or NS5A knockdown blocked S6K1 and 4EBP1 phosphorylation increase in NS5A-Huh7 and HCV replicon cells, suggesting that NS5A specifically regulated mTOR activation.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	51-65
20382746-7	2010	The mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) inhibition with rapamycin inhibited IFN- and EGF-induced protein synthesis, suggesting that IFN-induced protein synthesis is modulated by mTOR/S6K1 activation.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	203-207
20484410-3	2010	Here we show in PC Cl3 rat thyroid cells that TSH/cAMP, like insulin, activates the mammalian target of rapamycin (mTOR)-raptor complex (mTORC1) leading to phosphorylation of S6K1 and 4E-BP1.	Thyrotropin	46-49	ribosomal protein S6 kinase B1	Homo sapiens	175-190
20484410-3	2010	Here we show in PC Cl3 rat thyroid cells that TSH/cAMP, like insulin, activates the mammalian target of rapamycin (mTOR)-raptor complex (mTORC1) leading to phosphorylation of S6K1 and 4E-BP1.	Cyclic AMP	50-54	ribosomal protein S6 kinase B1	Homo sapiens	175-190
20351317-11	2010	In contrast, activation of AMPK inhibited LH-stimulated MTOR/S6K1 signaling and progesterone secretion.	Luteinizing Hormone	42-44	ribosomal protein S6 kinase B1	Homo sapiens	61-65
20427478-6	2010	More importantly, upregulation of p70S6K signaling impaired insulin-stimulated phosphorylation of Akt Ser(473) and p70S6K in IR(+/+) and Rec B but not in Rec A cell lines.	Serine	102-105	ribosomal protein S6 kinase B1	Homo sapiens	34-40
20114074-8	2010	Importantly, using AMPK-alpha1(-/-)alpha2(-/-) MEFs we show that thapsigargin application triggers autophagy in the absence of AMPK and does not involve complete mTOR inhibition, as detected by p70S6K phosphorylation.	Thapsigargin	65-77	ribosomal protein S6 kinase B1	Homo sapiens	194-200
20698768-6	2010	Disruption of p70 S6K-mediated translation by rapamycin or siRNA knockdown in undifferentiated hESCs does not alter cell viability or expression of the pluripotency markers Oct4 and Nanog.	Sirolimus	46-55	ribosomal protein S6 kinase B1	Homo sapiens	14-21
20230819-5	2010	Inhibition of PI3K or mTOR/p70S6K by wortmannin and rapamycin, respectively, increased apoptosis and inhibited phosphorylation of Akt and p70S6K induced by single-dose oxidative stress.	Wortmannin	37-47	ribosomal protein S6 kinase B1	Homo sapiens	27-33
20230819-5	2010	Inhibition of PI3K or mTOR/p70S6K by wortmannin and rapamycin, respectively, increased apoptosis and inhibited phosphorylation of Akt and p70S6K induced by single-dose oxidative stress.	Wortmannin	37-47	ribosomal protein S6 kinase B1	Homo sapiens	138-144
20230819-5	2010	Inhibition of PI3K or mTOR/p70S6K by wortmannin and rapamycin, respectively, increased apoptosis and inhibited phosphorylation of Akt and p70S6K induced by single-dose oxidative stress.	Sirolimus	52-61	ribosomal protein S6 kinase B1	Homo sapiens	27-33
20230819-5	2010	Inhibition of PI3K or mTOR/p70S6K by wortmannin and rapamycin, respectively, increased apoptosis and inhibited phosphorylation of Akt and p70S6K induced by single-dose oxidative stress.	Sirolimus	52-61	ribosomal protein S6 kinase B1	Homo sapiens	138-144
20363874-3	2010	The AMPK activator metformin stimulated AMPK Thr172 phosphorylation and inhibited IGF-I-stimulated phosphorylation of Akt/tuberous sclerosis 2 (TSC2)/mammalian target of rapamycin (mTOR)/p70S6 kinase (p70S6K).	Metformin	19-28	ribosomal protein S6 kinase B1	Homo sapiens	201-207
20029971-11	2010	Collectively, these results indicate that the basal level of intracellular calcium gates BDNF-induced activation of p70S6K and protein synthesis through CaM.	Calcium	75-82	ribosomal protein S6 kinase B1	Homo sapiens	116-122
20423992-0	2010	AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.	AT 7867	0-6	ribosomal protein S6 kinase B1	Homo sapiens	49-62
20423992-3	2010	This ATP-competitive small molecule potently inhibits both AKT and p70S6K activity at the cellular level, as measured by inhibition of GSK3beta and S6 ribosomal protein phosphorylation, and also causes growth inhibition in a range of human cancer cell lines as a single agent.	Adenosine Triphosphate	5-8	ribosomal protein S6 kinase B1	Homo sapiens	67-73
20051528-6	2010	The changes in p70(S6K) activity induced by insulin and leucine correlated with changes in phosphorylation of Thr(389), the mTOR phosphorylation site on p70(S6K), and of Ser(2448) on mTOR, both related to mTOR activity.	Threonine	110-113	ribosomal protein S6 kinase B1	Homo sapiens	19-22
20142804-3	2010	Here, we show that hydrogen peroxide (H(2)O(2)), a major oxidant generated when oxidative stress occurs, induced apoptosis of neuronal cells (PC12 cells and primary murine neurons), by inhibiting the mammalian target of rapamycin (mTOR)-mediated phosphorylation of ribosomal p70 S6 kinase (S6K1) and eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1).	Hydrogen Peroxide	19-36	ribosomal protein S6 kinase B1	Homo sapiens	290-294
20142804-3	2010	Here, we show that hydrogen peroxide (H(2)O(2)), a major oxidant generated when oxidative stress occurs, induced apoptosis of neuronal cells (PC12 cells and primary murine neurons), by inhibiting the mammalian target of rapamycin (mTOR)-mediated phosphorylation of ribosomal p70 S6 kinase (S6K1) and eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1).	Hydrogen Peroxide	38-46	ribosomal protein S6 kinase B1	Homo sapiens	290-294
20051528-0	2010	Activation of the cardiac mTOR/p70(S6K) pathway by leucine requires PDK1 and correlates with PRAS40 phosphorylation.	Leucine	51-58	ribosomal protein S6 kinase B1	Homo sapiens	31-34
20051528-6	2010	The changes in p70(S6K) activity induced by insulin and leucine correlated with changes in phosphorylation of Thr(389), the mTOR phosphorylation site on p70(S6K), and of Ser(2448) on mTOR, both related to mTOR activity.	Serine	170-173	ribosomal protein S6 kinase B1	Homo sapiens	19-22
20051528-5	2010	In wild-type hearts, both leucine and insulin increased p70(S6K) activity whereas, in contrast to insulin, leucine was unable to activate PKB/Akt.	Leucine	26-33	ribosomal protein S6 kinase B1	Homo sapiens	56-59
20051528-6	2010	The changes in p70(S6K) activity induced by insulin and leucine correlated with changes in phosphorylation of Thr(389), the mTOR phosphorylation site on p70(S6K), and of Ser(2448) on mTOR, both related to mTOR activity.	Leucine	56-63	ribosomal protein S6 kinase B1	Homo sapiens	19-22
20051528-6	2010	The changes in p70(S6K) activity induced by insulin and leucine correlated with changes in phosphorylation of Thr(389), the mTOR phosphorylation site on p70(S6K), and of Ser(2448) on mTOR, both related to mTOR activity.	Leucine	56-63	ribosomal protein S6 kinase B1	Homo sapiens	157-160
20051528-10	2010	Moreover, the introduction in PDK1 of the L155E mutation, which is known to preserve the insulin-induced and PKB/Akt-dependent phosphorylation of mTOR/p70(S6K), suppressed all leucine effects, including phosphorylation of mTOR, PRAS40, and p70(S6K).	Leucine	176-183	ribosomal protein S6 kinase B1	Homo sapiens	155-158
20051528-10	2010	Moreover, the introduction in PDK1 of the L155E mutation, which is known to preserve the insulin-induced and PKB/Akt-dependent phosphorylation of mTOR/p70(S6K), suppressed all leucine effects, including phosphorylation of mTOR, PRAS40, and p70(S6K).	Leucine	176-183	ribosomal protein S6 kinase B1	Homo sapiens	244-247
20051528-11	2010	We conclude that the leucine-induced stimulation of the cardiac PRAS40/mTOR/p70(S6K) pathway requires PDK1 in a way that differs from that of insulin.	Leucine	21-28	ribosomal protein S6 kinase B1	Homo sapiens	76-79
20168088-4	2010	Rapamycin administration caused a significant reduction of 70 kDa S6 kinase (p70S6K) phosphorylation and a significant increase of the autophagic proteins Beclin 1 and microtubule-associated protein 1 light chain 3 (LC3), as of monodansylcadaverine (MDC) labeling in the lesioned side.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	77-83
20298436-3	2010	Leucine enhances mTOR-mediated phosphorylation of S6K1 and 4E-BP, thereby promoting protein synthesis.	Leucine	0-7	ribosomal protein S6 kinase B1	Homo sapiens	50-64
20099302-11	2010	Serotonin could override rapamycin by an mTOR-independent pathway and activate common downstream signals such as p70S6K and 4E-BP1.	Serotonin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	113-130
19887493-5	2010	Western blot analysis showed that PDGF-BB-induced phosphorylation of Akt, p70S6K, and p38 was inhibited by piceatannol, but not resveratrol.	3,3',4,5'-tetrahydroxystilbene	107-118	ribosomal protein S6 kinase B1	Homo sapiens	74-80
19642865-4	2010	Under feeder-free culture conditions, rapamycin (an mTOR inhibitor) potently inhibited the activities of mTOR and p70S6K in undifferentiated hESCs; however, LY294002 (a PI3K inhibitor) and an AKT inhibitor had no effects.	Sirolimus	38-47	ribosomal protein S6 kinase B1	Homo sapiens	114-120
20309890-4	2010	Thus, by using Tris-acetate 3-15% polyacrylamide gels, it is possible to simultaneously analyze proteins, in the mass range of 10-500 kDa, such as HERC1 (532 kDa), HERC2 (528 kDa), mTOR (289 kDa), Clathrin heavy chain (192 kDa), RSK (90 kDa), S6K (70 kDa), beta-actin (42 kDa), Ran (24 kDa) and LC3 (18 kDa).	Tris acetate	15-27	ribosomal protein S6 kinase B1	Homo sapiens	243-246
20203102-0	2010	Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes.	Glucose	108-115	ribosomal protein S6 kinase B1	Homo sapiens	33-37
20203102-3	2010	Acute inhibition of mTORC1/S6K1 by rapamycin increases insulin signaling and glucose uptake in myocytes and adipocytes, but whether these effects can be maintained under chronic inhibition of mTORC1 or S6K1 remains unclear.	Sirolimus	35-44	ribosomal protein S6 kinase B1	Homo sapiens	27-31
20203102-3	2010	Acute inhibition of mTORC1/S6K1 by rapamycin increases insulin signaling and glucose uptake in myocytes and adipocytes, but whether these effects can be maintained under chronic inhibition of mTORC1 or S6K1 remains unclear.	Glucose	77-84	ribosomal protein S6 kinase B1	Homo sapiens	27-31
20203102-5	2010	Both chronic inhibition of mTORC1 by rapamycin or knockdown of either mTOR, raptor, or S6K1 reduced inhibitory serine phosphorylation of IRS-1, while increasing its insulin-stimulated tyrosine phosphorylation and associated PI3K activity.	Serine	111-117	ribosomal protein S6 kinase B1	Homo sapiens	87-91
20203102-5	2010	Both chronic inhibition of mTORC1 by rapamycin or knockdown of either mTOR, raptor, or S6K1 reduced inhibitory serine phosphorylation of IRS-1, while increasing its insulin-stimulated tyrosine phosphorylation and associated PI3K activity.	Tyrosine	184-192	ribosomal protein S6 kinase B1	Homo sapiens	87-91
20203102-7	2010	Unexpectedly, insulin-induced activation of Akt2 and glucose transporter 4 expression were reduced after chronic disruption of the mTORC1/S6K1 pathway, impairing insulin-mediated glucose uptake despite increased PI3K activation.	Glucose	53-60	ribosomal protein S6 kinase B1	Homo sapiens	138-142
20203102-8	2010	In conclusion, these data indicate that both mTORC1 and S6K1 are key elements of the negative feedback loop but inhibit insulin-induced PI3K activity through phosphorylation of specific serine residues in IRS-1.	Serine	186-192	ribosomal protein S6 kinase B1	Homo sapiens	56-60
20203102-9	2010	However, this study also shows that chronic inhibition of the mTORC1/S6K1 pathway uncouples IRS-1/PI3K signaling from insulin-induced glucose transport due to impaired activation of Akt2 and blunted glucose transporter 4 expression.	Glucose	134-141	ribosomal protein S6 kinase B1	Homo sapiens	69-73
20138837-0	2010	Lipid raft cholesterol and genistein inhibit the cell viability of prostate cancer cells via the partial contribution of EGFR-Akt/p70S6k pathway and down-regulation of androgen receptor.	Cholesterol	11-22	ribosomal protein S6 kinase B1	Homo sapiens	130-136
19940100-9	2010	These results indicate that leucine activates contraction-stimulated glucose transport and inhibits insulin-stimulated glucose transport in skeletal muscle by activating mammalian target of rapamycin (mTOR)/p70S6K signaling.	Leucine	28-35	ribosomal protein S6 kinase B1	Homo sapiens	207-213
20160026-8	2010	Celastrol suppressed the VEGF-induced activation of AKT, mammalian target of rapamycin (mTOR), and ribosomal protein S6 kinase (P70S6K).	celastrol	0-9	ribosomal protein S6 kinase B1	Homo sapiens	128-134
20160026-9	2010	Additionally, we found that Celastrol inhibited the proliferation of prostate cancer cells and induced apoptosis, and these effects correlated with the extent of inhibition of AKT/mTOR/P70S6K signaling.	celastrol	28-37	ribosomal protein S6 kinase B1	Homo sapiens	185-191
20160026-10	2010	Taken together, our results suggest that Celastrol targets the AKT/mTOR/P70S6K pathway, which leads to suppression of tumor growth and angiogenesis.	celastrol	41-50	ribosomal protein S6 kinase B1	Homo sapiens	72-78
20187284-0	2010	Increased p70s6k phosphorylation during intake of a protein-carbohydrate drink following resistance exercise in the fasted state.	Carbohydrates	60-72	ribosomal protein S6 kinase B1	Homo sapiens	10-16
19815051-0	2010	The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.	Sirolimus	4-13	ribosomal protein S6 kinase B1	Homo sapiens	101-107
19815051-0	2010	The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.	Everolimus	33-43	ribosomal protein S6 kinase B1	Homo sapiens	101-107
19881535-5	2010	Short-term imatinib treatment of Bcr-Abl-positive cells caused dephosphorylation of p70S6-K and S6-protein without inactivation of Akt.	Imatinib Mesylate	11-19	ribosomal protein S6 kinase B1	Homo sapiens	84-91
19961954-7	2010	Acetylation of S6K1 and 2 is increased upon the inhibition of class I/II histone deacetylases (HDACs) by trichostatin-A, while the enhancement of S6K1 acetylation by nicotinamide suggests the additional involvement of sirtuin deacetylases in S6K deacetylation.	trichostatin A	105-119	ribosomal protein S6 kinase B1	Homo sapiens	15-25
19961954-7	2010	Acetylation of S6K1 and 2 is increased upon the inhibition of class I/II histone deacetylases (HDACs) by trichostatin-A, while the enhancement of S6K1 acetylation by nicotinamide suggests the additional involvement of sirtuin deacetylases in S6K deacetylation.	trichostatin A	105-119	ribosomal protein S6 kinase B1	Homo sapiens	15-19
19961954-7	2010	Acetylation of S6K1 and 2 is increased upon the inhibition of class I/II histone deacetylases (HDACs) by trichostatin-A, while the enhancement of S6K1 acetylation by nicotinamide suggests the additional involvement of sirtuin deacetylases in S6K deacetylation.	Niacinamide	166-178	ribosomal protein S6 kinase B1	Homo sapiens	15-25
19961954-7	2010	Acetylation of S6K1 and 2 is increased upon the inhibition of class I/II histone deacetylases (HDACs) by trichostatin-A, while the enhancement of S6K1 acetylation by nicotinamide suggests the additional involvement of sirtuin deacetylases in S6K deacetylation.	Niacinamide	166-178	ribosomal protein S6 kinase B1	Homo sapiens	15-19
19965918-9	2010	RESULTS: In 28 cultures (70%), Everolimus significantly reduced cell viability (by approximately 40%; P &lt; 0.05 vs. control), promoted apoptosis (+30%; P &lt; 0.05 vs. control), inhibited p70S6K activity (-20%), and blocked IGF-I proliferative and antiapoptotic effects.	Everolimus	31-41	ribosomal protein S6 kinase B1	Homo sapiens	190-196
19766294-6	2010	RESULTS: DL-homocysteine and NMDA time-dependently increased: i) the phosphorylation of ERK1/2, p38 MAPK, Akt and p70S6K (ANOVA, p&lt;0.0001); ii) the synthesis, secretion and activation of MMP-2.	N-Methylaspartate	29-33	ribosomal protein S6 kinase B1	Homo sapiens	114-120
19995915-0	2010	mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.	Threonine	47-56	ribosomal protein S6 kinase B1	Homo sapiens	17-21
19995915-6	2010	We identified several phosphorylation sites in Rictor and found that Thr1135 is directly phosphorylated by S6K1 in vitro and in vivo, in a rapamycin-sensitive manner.	Sirolimus	139-148	ribosomal protein S6 kinase B1	Homo sapiens	107-111
21326806-7	2010	Phospholipase D (PLD) and its product, phosphatidic acid (PA) have been implicated as an activator of mTOR signaling, including the direct phosphorylative activation of p70S6K atthreonine 389.	Phosphatidic Acids	39-56	ribosomal protein S6 kinase B1	Homo sapiens	169-175
21326806-7	2010	Phospholipase D (PLD) and its product, phosphatidic acid (PA) have been implicated as an activator of mTOR signaling, including the direct phosphorylative activation of p70S6K atthreonine 389.	Phosphatidic Acids	58-60	ribosomal protein S6 kinase B1	Homo sapiens	169-175
21326806-7	2010	Phospholipase D (PLD) and its product, phosphatidic acid (PA) have been implicated as an activator of mTOR signaling, including the direct phosphorylative activation of p70S6K atthreonine 389.	atthreonine	176-187	ribosomal protein S6 kinase B1	Homo sapiens	169-175
21326806-11	2010	Cor-relatively, there are overexpressions of nuclear p-Akt (Ser 473) and nuclear p-p70S6K (Thr 389) in ULMS and STUMP (p&lt;0.05).	Threonine	91-94	ribosomal protein S6 kinase B1	Homo sapiens	83-89
19723512-8	2010	Antroquinonol induced the assembly of tuberous sclerosis complex (TSC)-1/TSC2, leading to the blockade of cellular protein synthesis through inhibition of protein phosphorylation including mTOR (Ser(2448)), p70(S6K) (Thr(421)/Ser(424) and Thr(389)) and 4E-BP1 (Thr(37)/Thr(46) and Thr(70)).	antroquinonol	0-13	ribosomal protein S6 kinase B1	Homo sapiens	207-210
20068168-2	2010	However, sensitivity to rapamycin is reduced by Akt activation that results from the ablative effects of rapamycin on a p70 S6K-induced negative feedback loop that blunts phosphoinositide 3-kinase (PI3K)-mediated support for Akt activity.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	120-127
20068168-2	2010	However, sensitivity to rapamycin is reduced by Akt activation that results from the ablative effects of rapamycin on a p70 S6K-induced negative feedback loop that blunts phosphoinositide 3-kinase (PI3K)-mediated support for Akt activity.	Sirolimus	105-114	ribosomal protein S6 kinase B1	Homo sapiens	120-127
20019183-6	2010	Rapamycin inhibited S6K at mTOR-sensitive phosphorylation sites in response to strain and hypoxia.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	20-23
19951696-8	2010	The phosphorylation of P70S6K, downstream of mTOR signaling, and AKT were further reduced by pretreatment with N-acetyl-l-cysteine (NAC), an ROS scavenger, whereas the phosphorylation of ERK1/2 and the conversion of LC3 I to LC3 II were further enhanced.	Acetylcysteine	111-130	ribosomal protein S6 kinase B1	Homo sapiens	23-29
19951696-8	2010	The phosphorylation of P70S6K, downstream of mTOR signaling, and AKT were further reduced by pretreatment with N-acetyl-l-cysteine (NAC), an ROS scavenger, whereas the phosphorylation of ERK1/2 and the conversion of LC3 I to LC3 II were further enhanced.	Reactive Oxygen Species	141-144	ribosomal protein S6 kinase B1	Homo sapiens	23-29
19766294-4	2010	MATERIALS AND METHODS: VSMC exposed to DL-homocysteine or NMDA (100 micromol/L for both; 5 min-8 hours), were investigated by measuring: i) phosphorylation of ERK1/2, p38MAPK (signaling molecules of MAPK pathway) and Akt and p70S6K (signaling molecules of PI3-K pathway) by western blot; ii) synthesis and secretion of MMP-2 (western blot); iii) activation of MMP-2 (gelatin zimography).	vsmc	23-27	ribosomal protein S6 kinase B1	Homo sapiens	225-231
19766294-6	2010	RESULTS: DL-homocysteine and NMDA time-dependently increased: i) the phosphorylation of ERK1/2, p38 MAPK, Akt and p70S6K (ANOVA, p&lt;0.0001); ii) the synthesis, secretion and activation of MMP-2.	DL-Homocysteine	9-24	ribosomal protein S6 kinase B1	Homo sapiens	114-120
20028854-6	2010	AZD8055 inhibits the phosphorylation of mTORC1 substrates p70S6K and 4E-BP1 as well as phosphorylation of the mTORC2 substrate AKT and downstream proteins.	(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	0-7	ribosomal protein S6 kinase B1	Homo sapiens	58-75
20563709-1	2010	Most of the cellular responses to phosphatidylinositol 3-kinase activation and phosphatidylinositol 3,4,5-trisphosphate production are mediated by the activation of a group of AGC kinases comprising PKB, S6K, RSK, SGK and PKC isoforms, which play essential roles in regulating physiological processes related to cell growth, proliferation, survival and metabolism.	Phosphatidylinositols	34-54	ribosomal protein S6 kinase B1	Homo sapiens	204-207
20563709-1	2010	Most of the cellular responses to phosphatidylinositol 3-kinase activation and phosphatidylinositol 3,4,5-trisphosphate production are mediated by the activation of a group of AGC kinases comprising PKB, S6K, RSK, SGK and PKC isoforms, which play essential roles in regulating physiological processes related to cell growth, proliferation, survival and metabolism.	phosphatidylinositol 3,4,5-triphosphate	79-119	ribosomal protein S6 kinase B1	Homo sapiens	204-207
19567381-7	2010	Similar to rapamycin, everolimus and zotarolimus abrogated TNF-alpha-induced p70S6K phosphorylation under these conditions.	Everolimus	22-32	ribosomal protein S6 kinase B1	Homo sapiens	77-83
19567381-7	2010	Similar to rapamycin, everolimus and zotarolimus abrogated TNF-alpha-induced p70S6K phosphorylation under these conditions.	zotarolimus	37-48	ribosomal protein S6 kinase B1	Homo sapiens	77-83
19889638-3	2010	Application of OSS (0.5 +/- 4 dynes/cm(2)) to MG63 cells induced sustained activation of phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR/p70S6K (p70S6 kinase) signaling cascades and hence cell proliferation, which was accompanied by increased expression of cyclins A and D1, cyclin-dependent protein kinases-2, -4, and -6, and bone formation-related genes (c-fos, Egr-1, and Cox-2) and decreased expression of p21(CIP1) and p27(KIP1).	OSS	15-18	ribosomal protein S6 kinase B1	Homo sapiens	135-141
19889638-4	2010	OSS-induced activation of PI3K/Akt/mTOR/p70S6K and cell proliferation were inhibited by specific antibodies or small interference RNAs of alpha(v)beta(3) and beta(1) integrins and by dominant-negative mutants of Shc (Shc-SH2) and focal adhesion kinase (FAK) (FAK(F397Y)).	OSS	0-3	ribosomal protein S6 kinase B1	Homo sapiens	40-46
19889638-6	2010	OSS also induced sustained activation of ERK, which was inhibited by the specific PI3K inhibitor LY294002 and was required for OSS-induced activation of mTOR/p70S6K and proliferation in MG63 cells.	OSS	0-3	ribosomal protein S6 kinase B1	Homo sapiens	158-164
19889638-6	2010	OSS also induced sustained activation of ERK, which was inhibited by the specific PI3K inhibitor LY294002 and was required for OSS-induced activation of mTOR/p70S6K and proliferation in MG63 cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	97-105	ribosomal protein S6 kinase B1	Homo sapiens	158-164
19889638-6	2010	OSS also induced sustained activation of ERK, which was inhibited by the specific PI3K inhibitor LY294002 and was required for OSS-induced activation of mTOR/p70S6K and proliferation in MG63 cells.	OSS	127-130	ribosomal protein S6 kinase B1	Homo sapiens	158-164
19910069-6	2010	Sorafenib-induced elevation of the insulin-like growth factor receptor 1 (IGF-1R), phospho-c-Raf Ser338, phospho-MEK Ser217/221 and phospho-ERK Thr202/Tyr204 was attenuated by co-treating cells with anti-human IGF-1R antibody or over-expression of activated mutant p70S6K.	Sorafenib	0-9	ribosomal protein S6 kinase B1	Homo sapiens	265-271
19845851-10	2010	Upon rapamycin and CCI-779 treatment, the phosphorylation level of mTOR and p70S6K in HCC cell lines was significantly reduced, indicating that both drugs can suppress mTOR activity in HCC cells.	Sirolimus	5-14	ribosomal protein S6 kinase B1	Homo sapiens	76-82
19845851-10	2010	Upon rapamycin and CCI-779 treatment, the phosphorylation level of mTOR and p70S6K in HCC cell lines was significantly reduced, indicating that both drugs can suppress mTOR activity in HCC cells.	temsirolimus	19-26	ribosomal protein S6 kinase B1	Homo sapiens	76-82
19951696-8	2010	The phosphorylation of P70S6K, downstream of mTOR signaling, and AKT were further reduced by pretreatment with N-acetyl-l-cysteine (NAC), an ROS scavenger, whereas the phosphorylation of ERK1/2 and the conversion of LC3 I to LC3 II were further enhanced.	Acetylcysteine	132-135	ribosomal protein S6 kinase B1	Homo sapiens	23-29
19797661-3	2009	Deletion of S6K1 induced gene expression patterns similar to those seen in CR or with pharmacological activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK), a conserved regulator of the metabolic response to CR.	Adenosine Monophosphate	116-139	ribosomal protein S6 kinase B1	Homo sapiens	12-16
19923913-5	2009	Selective inhibition of the PI3K-AKT-mTOR pathway using pharmacologic inhibitors (LY294002, AKT inhibitor VIII, Rapamycin) significantly attenuated expression of p-AKT and p-70S6K, respectively and radiosensitized SKBR3 cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	82-90	ribosomal protein S6 kinase B1	Homo sapiens	172-179
19923913-5	2009	Selective inhibition of the PI3K-AKT-mTOR pathway using pharmacologic inhibitors (LY294002, AKT inhibitor VIII, Rapamycin) significantly attenuated expression of p-AKT and p-70S6K, respectively and radiosensitized SKBR3 cells.	Sirolimus	112-121	ribosomal protein S6 kinase B1	Homo sapiens	172-179
20019839-8	2009	Furthermore, bisindolylmaleimide-V, a specific inhibitor of p70(S6K), stunted survivin expression and induced cell death in CCL2-treated PC3.	bisindolylmaleimide V	13-34	ribosomal protein S6 kinase B1	Homo sapiens	64-67
19801633-0	2009	Cyclin D1 induction by benzo[a]pyrene-7,8-diol-9,10-epoxide via the phosphatidylinositol 3-kinase/Akt/MAPK- and p70s6k-dependent pathway promotes cell transformation and tumorigenesis.	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	23-59	ribosomal protein S6 kinase B1	Homo sapiens	112-118
19801633-6	2009	In addition, we clarified that p70(s6k) is also involved in B[a]PDE-induced cyclin D1 expression because rampamycin pretreatment dramatically reduced cyclin D1 induction by B[a]PDE.	rampamycin	105-115	ribosomal protein S6 kinase B1	Homo sapiens	31-38
20137651-5	2009	investigations on the insulin affection activities of P(70)S6K were carried out by immunoprecipitation, incorporation of [r-(32)P]ATP, tissue cell culture, Western blotting.	[r-(32)p]atp	121-133	ribosomal protein S6 kinase B1	Homo sapiens	54-62
20137651-7	2009	(2) The P(70)S6K activities in the placenta from the insulin stimulation group was significantly elevated, the P(70)S6K activities in the placenta from the rapamycin stimulation group was significantly declined, there were statistical significance when each was compared with control group (P &lt; 0.01).	Sirolimus	156-165	ribosomal protein S6 kinase B1	Homo sapiens	111-119
19648118-9	2009	The 5"-terminal oligopyrimidine tract sequences of CRMP2 and Tau mRNAs strongly contribute to the up-regulation of their translation in the axon in response to the axonal activation of the mTOR-p70S6K pathway.	oligopyrimidine	16-31	ribosomal protein S6 kinase B1	Homo sapiens	194-200
19797661-3	2009	Deletion of S6K1 induced gene expression patterns similar to those seen in CR or with pharmacological activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK), a conserved regulator of the metabolic response to CR.	Adenosine Monophosphate	141-144	ribosomal protein S6 kinase B1	Homo sapiens	12-16
19507250-3	2009	ATRA (0.1-1 microM) upregulated levels of RTP801, a negative regulator of mTORC1, and inhibited mTORC1 signaling as assessed by measurement of the levels of p-p70S6K and p-4E-BP1 in HL60 and NB4 cells.	Tretinoin	0-4	ribosomal protein S6 kinase B1	Homo sapiens	159-165
19507250-4	2009	ATRA (0.1-1 microM) in combination with RAD001 (10 nM) strikingly downregulated the levels of p-70S6K and p-4E-BP1 without affecting the total amount of these proteins.	Tretinoin	0-4	ribosomal protein S6 kinase B1	Homo sapiens	94-101
19789218-8	2009	CA-S6K1 overexpression reversed HIF-1alpha inhibition by rapamycin (a mammalian target of rapamycin/S6K1 inhibitor).	Sirolimus	57-66	ribosomal protein S6 kinase B1	Homo sapiens	3-7
19789218-8	2009	CA-S6K1 overexpression reversed HIF-1alpha inhibition by rapamycin (a mammalian target of rapamycin/S6K1 inhibitor).	Sirolimus	57-66	ribosomal protein S6 kinase B1	Homo sapiens	100-104
19789218-13	2009	Oltipraz inhibits HIF-1alpha activity and HIF-1alpha-dependent tumor growth, which may result from a decrease in HIF-1alpha stability through S6K1 inhibition in combination with an H(2)O(2)-scavenging effect.	oltipraz	0-8	ribosomal protein S6 kinase B1	Homo sapiens	142-146
19539716-4	2009	The findings also show that H(2)O(2) induces the dephosphorylation of the mammalian target of rapamycin (mTOR) at Ser 2481 and the p70 ribosomal protein S6 kinase (p70S6K) at Thr389 in a Bcl-2/E1B 19kDa interacting protein 3 (BNIP3)-dependent manner.	Hydrogen Peroxide	28-36	ribosomal protein S6 kinase B1	Homo sapiens	131-162
19563826-2	2009	Recently, it was found that dithiolethione compounds had the activities to prevent or treat fibrosis, insulin resistance, and mitochondrial protective effects in the liver by a mechanism involving AMP-activated protein kinase (AMPK) and/or 70-kDa ribosomal protein S6 kinase 1 (S6K1).	dithiolethione	28-42	ribosomal protein S6 kinase B1	Homo sapiens	278-282
19563826-5	2009	This review focuses on the interaction between oltipraz and the AMPK-mTOR-S6K1 pathway, which regulates genes that confer hepatocyte protection from intoxication, disrupted energy metabolism, and inflammation.	oltipraz	47-55	ribosomal protein S6 kinase B1	Homo sapiens	74-78
19539716-4	2009	The findings also show that H(2)O(2) induces the dephosphorylation of the mammalian target of rapamycin (mTOR) at Ser 2481 and the p70 ribosomal protein S6 kinase (p70S6K) at Thr389 in a Bcl-2/E1B 19kDa interacting protein 3 (BNIP3)-dependent manner.	Hydrogen Peroxide	28-36	ribosomal protein S6 kinase B1	Homo sapiens	164-170
19706758-6	2009	Temsirolimus inhibited the phosphorylation of p70S6K, a substrate of mTOR.	temsirolimus	0-12	ribosomal protein S6 kinase B1	Homo sapiens	46-52
19108833-7	2009	Resveratrol blocked the oxLDL-induced phosphorylation and activation of the PI3K/Akt/mTOR/p70S6K pathway and strongly inhibited both the DNA synthesis and proliferation of SMC.	Resveratrol	0-11	ribosomal protein S6 kinase B1	Homo sapiens	90-96
19632115-2	2009	Screening hits containing the 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine scaffold were optimized for p70S6K potency and selectivity against related kinases.	4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine	30-77	ribosomal protein S6 kinase B1	Homo sapiens	106-112
19632115-3	2009	Structure-based design employing an active site homology model derived from PKA led to the preparation of benzimidazole 5-substituted compounds 26 and 27 as highly potent inhibitors (K(i) &lt;1nM) of p70S6K, with &gt;100-fold selectivity against PKA, ROCK and GSK3.	benzimidazole	106-119	ribosomal protein S6 kinase B1	Homo sapiens	200-206
19648913-2	2009	We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC).	Dronabinol	245-272	ribosomal protein S6 kinase B1	Homo sapiens	120-126
19648913-2	2009	We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC).	Dronabinol	274-277	ribosomal protein S6 kinase B1	Homo sapiens	120-126
19535330-4	2009	OGD-induced apoptosis was increased by the combined deletion of S6K1 and S6K2 genes, as well as by treatment with rapamycin that inhibits S6K1 activity by acting on the upstream regulator mTOR (mammalian target of rapamycin).	Sirolimus	114-123	ribosomal protein S6 kinase B1	Homo sapiens	138-142
19535330-7	2009	Rescue of either S6K1 or S6K2 expression by adenoviral infection revealed that protective functions were specifically mediated by S6K1, because this isoform selectively promoted resistance to OGD and reduction of ROS levels.	Reactive Oxygen Species	213-216	ribosomal protein S6 kinase B1	Homo sapiens	17-21
19535330-7	2009	Rescue of either S6K1 or S6K2 expression by adenoviral infection revealed that protective functions were specifically mediated by S6K1, because this isoform selectively promoted resistance to OGD and reduction of ROS levels.	Reactive Oxygen Species	213-216	ribosomal protein S6 kinase B1	Homo sapiens	130-134
19535330-9	2009	In summary, this article uncovers a protective role for astrocyte S6K1 against brain ischemia, indicating a functional pathway that senses nutrient and oxygen levels and may be beneficial for neuronal survival.	Oxygen	152-158	ribosomal protein S6 kinase B1	Homo sapiens	66-70
19433130-5	2009	GA treatment downregulated the expression of SRC-3 and then inhibited the activity of Akt kinase and its downstream targets p70 S6 kinase 1 (S6K1) and glycogen synthase kinase 3beta (GSK3beta) without changes in total protein levels of these three proteins, which thus influenced the expression of the apoptosis related gene Bcl-2 in K562 cells.	gambogic acid	0-2	ribosomal protein S6 kinase B1	Homo sapiens	141-145
19220580-7	2009	Phosphorylation of mammalian target-of-rapamycin (mTOR) targets (p70S6K, S6R and 4EBP1) was reduced by sorafenib in sorafenib-sensitive lines but activated in sorafenib-less-sensitive 10-0505 xenograft.	Sorafenib	103-112	ribosomal protein S6 kinase B1	Homo sapiens	65-71
19220580-7	2009	Phosphorylation of mammalian target-of-rapamycin (mTOR) targets (p70S6K, S6R and 4EBP1) was reduced by sorafenib in sorafenib-sensitive lines but activated in sorafenib-less-sensitive 10-0505 xenograft.	Sorafenib	116-125	ribosomal protein S6 kinase B1	Homo sapiens	65-71
19220580-7	2009	Phosphorylation of mammalian target-of-rapamycin (mTOR) targets (p70S6K, S6R and 4EBP1) was reduced by sorafenib in sorafenib-sensitive lines but activated in sorafenib-less-sensitive 10-0505 xenograft.	Sorafenib	116-125	ribosomal protein S6 kinase B1	Homo sapiens	65-71
19220580-8	2009	Sorafenib-induced phosphorylation of c-met, p70S6K and 4EBP1 was significantly reduced when 10-0505 cells were co-treated with anti-human anti-HGF antibody, suggesting that treatment with sorafenib leads to increased HGF secretion and activation of c-met and mTOR targets.	Sorafenib	0-9	ribosomal protein S6 kinase B1	Homo sapiens	44-60
19220580-8	2009	Sorafenib-induced phosphorylation of c-met, p70S6K and 4EBP1 was significantly reduced when 10-0505 cells were co-treated with anti-human anti-HGF antibody, suggesting that treatment with sorafenib leads to increased HGF secretion and activation of c-met and mTOR targets.	Sorafenib	188-197	ribosomal protein S6 kinase B1	Homo sapiens	44-60
19474060-5	2009	Testosterone increases the phosphorylation of mTOR and its downstream targets 40S ribosomal protein S6 kinase 1 (S6K1; also known as RPS6KB1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1).	Testosterone	0-12	ribosomal protein S6 kinase B1	Homo sapiens	82-117
19474060-5	2009	Testosterone increases the phosphorylation of mTOR and its downstream targets 40S ribosomal protein S6 kinase 1 (S6K1; also known as RPS6KB1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1).	Testosterone	0-12	ribosomal protein S6 kinase B1	Homo sapiens	133-140
19474060-6	2009	The S6K1 phosphorylation induced by testosterone was blocked by rapamycin and small interfering RNA to mTOR.	Testosterone	36-48	ribosomal protein S6 kinase B1	Homo sapiens	4-8
19474060-8	2009	ERK1/2 inhibitor PD98059 blocked the testosterone-induced S6K1 phosphorylation, whereas Akt inhibition (Akt-inhibitor-X) had no effect.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	17-24	ribosomal protein S6 kinase B1	Homo sapiens	58-62
19474060-8	2009	ERK1/2 inhibitor PD98059 blocked the testosterone-induced S6K1 phosphorylation, whereas Akt inhibition (Akt-inhibitor-X) had no effect.	Testosterone	37-49	ribosomal protein S6 kinase B1	Homo sapiens	58-62
19474060-9	2009	Testosterone-induced ERK1/2 and S6K1 phosphorylation increases were blocked by either 1,2-bis(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid-acetoxymethylester or by inhibitors of inositol 1,4,5-trisphosphate (IP(3)) pathway: U-73122 and 2-aminoethyl diphenylborate.	Testosterone	0-12	ribosomal protein S6 kinase B1	Homo sapiens	32-36
19474060-9	2009	Testosterone-induced ERK1/2 and S6K1 phosphorylation increases were blocked by either 1,2-bis(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid-acetoxymethylester or by inhibitors of inositol 1,4,5-trisphosphate (IP(3)) pathway: U-73122 and 2-aminoethyl diphenylborate.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	86-159	ribosomal protein S6 kinase B1	Homo sapiens	32-36
19474060-9	2009	Testosterone-induced ERK1/2 and S6K1 phosphorylation increases were blocked by either 1,2-bis(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid-acetoxymethylester or by inhibitors of inositol 1,4,5-trisphosphate (IP(3)) pathway: U-73122 and 2-aminoethyl diphenylborate.	Inositol 1,4,5-Trisphosphate	180-208	ribosomal protein S6 kinase B1	Homo sapiens	32-36
19474060-9	2009	Testosterone-induced ERK1/2 and S6K1 phosphorylation increases were blocked by either 1,2-bis(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid-acetoxymethylester or by inhibitors of inositol 1,4,5-trisphosphate (IP(3)) pathway: U-73122 and 2-aminoethyl diphenylborate.	ip	210-212	ribosomal protein S6 kinase B1	Homo sapiens	32-36
19474060-9	2009	Testosterone-induced ERK1/2 and S6K1 phosphorylation increases were blocked by either 1,2-bis(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid-acetoxymethylester or by inhibitors of inositol 1,4,5-trisphosphate (IP(3)) pathway: U-73122 and 2-aminoethyl diphenylborate.	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	226-233	ribosomal protein S6 kinase B1	Homo sapiens	32-36
19474060-9	2009	Testosterone-induced ERK1/2 and S6K1 phosphorylation increases were blocked by either 1,2-bis(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid-acetoxymethylester or by inhibitors of inositol 1,4,5-trisphosphate (IP(3)) pathway: U-73122 and 2-aminoethyl diphenylborate.	2-aminoethyldiphenylborate	238-265	ribosomal protein S6 kinase B1	Homo sapiens	32-36
19474060-12	2009	Our findings suggest that testosterone activates the mTORC1/S6K1 axis through IP(3)/Ca(2+) and MEK/ERK1/2 to induce cardiomyocyte hypertrophy.	Testosterone	26-38	ribosomal protein S6 kinase B1	Homo sapiens	60-64
19474060-12	2009	Our findings suggest that testosterone activates the mTORC1/S6K1 axis through IP(3)/Ca(2+) and MEK/ERK1/2 to induce cardiomyocyte hypertrophy.	Inositol 1,4,5-Trisphosphate	78-83	ribosomal protein S6 kinase B1	Homo sapiens	60-64
19424604-9	2009	In addition, the mTOR inhibitor rapamycin was found to affect the phosphorylation status of p70S6K in amniotic fluid stem cells.	Sirolimus	32-41	ribosomal protein S6 kinase B1	Homo sapiens	92-98
19557637-6	2009	Because rapamycin targets the mammalian target of rapamycin (mTOR) pathway, we also used our cells to confirm that rapamycin modified the expression of mTOR and effectively suppressed the phosphorylation of two downstream effector molecules in the mTOR pathway, S6K1, and 4E-BP1.	Sirolimus	8-17	ribosomal protein S6 kinase B1	Homo sapiens	262-266
19291795-8	2009	Immunohistochemistry confirmed Ras, phospho-Akt and phospho-p70S6K (Thr 421/ Ser 424) expression in lesions arising from premalignant and tumor cells.	Threonine	68-71	ribosomal protein S6 kinase B1	Homo sapiens	60-66
19291795-8	2009	Immunohistochemistry confirmed Ras, phospho-Akt and phospho-p70S6K (Thr 421/ Ser 424) expression in lesions arising from premalignant and tumor cells.	Serine	77-80	ribosomal protein S6 kinase B1	Homo sapiens	60-66
20157535-6	2009	In a large-scalein vitro kinase screen we identified p70 S6 kinase (S6K1) as a target of resveratrol.	Resveratrol	89-100	ribosomal protein S6 kinase B1	Homo sapiens	68-72
20157535-7	2009	Blocking S6K1 activity by expression of a dominant-negative mutant or RNA interference is sufficient to disrupt autophagy to a similar extent as resveratrol.	Resveratrol	145-156	ribosomal protein S6 kinase B1	Homo sapiens	9-13
20157535-9	2009	These data indicate that S6K1 is important for the full induction of autophagy in mammals and raise the possibility that some of the beneficial effects of resveratrol are due to modulation of S6K1 activity.	Resveratrol	155-166	ribosomal protein S6 kinase B1	Homo sapiens	192-196
19303025-5	2009	In addition, we demonstrated that CAPE activated the mammalian target of rapamycin (mTOR)-p70 S6 ribosomal kinase (S6K) and also stimulated extracellular signal-regulated kinase (ERK).	caffeic acid phenethyl ester	34-38	ribosomal protein S6 kinase B1	Homo sapiens	94-118
19424415-2	2009	Here, we present data suggesting that yeast Tor1 and Sch9 (a homolog of the mammalian kinases Akt and S6K) is a central component of a network that controls a common set of genes implicated in a metabolic switch from the TCA cycle and respiration to glycolysis and glycerol biosynthesis.	Trichloroacetic Acid	221-224	ribosomal protein S6 kinase B1	Homo sapiens	102-105
19552765-8	2009	We found that the suppression of HIF-1 alpha expression by melatonin correlated with dephosphorylation of p70S6K and its direct target RPS6, a pathway known to regulate HIF-1 alpha expression at the translational level.	Melatonin	59-68	ribosomal protein S6 kinase B1	Homo sapiens	106-112
19424415-2	2009	Here, we present data suggesting that yeast Tor1 and Sch9 (a homolog of the mammalian kinases Akt and S6K) is a central component of a network that controls a common set of genes implicated in a metabolic switch from the TCA cycle and respiration to glycolysis and glycerol biosynthesis.	Glycerol	265-273	ribosomal protein S6 kinase B1	Homo sapiens	102-105
19254699-6	2009	In addition, D-glucosamine inhibited HIF-1alpha expression induced by serum stimulation in parallel with inhibition of p70S6K suggesting D-glucosamine inhibits growth factor-induced HIF-1alpha expression, at least in part, through p70S6K inhibition.	Glucosamine	13-26	ribosomal protein S6 kinase B1	Homo sapiens	231-237
19254699-6	2009	In addition, D-glucosamine inhibited HIF-1alpha expression induced by serum stimulation in parallel with inhibition of p70S6K suggesting D-glucosamine inhibits growth factor-induced HIF-1alpha expression, at least in part, through p70S6K inhibition.	Glucosamine	137-150	ribosomal protein S6 kinase B1	Homo sapiens	119-125
19254699-6	2009	In addition, D-glucosamine inhibited HIF-1alpha expression induced by serum stimulation in parallel with inhibition of p70S6K suggesting D-glucosamine inhibits growth factor-induced HIF-1alpha expression, at least in part, through p70S6K inhibition.	Glucosamine	137-150	ribosomal protein S6 kinase B1	Homo sapiens	231-237
19168580-6	2009	Furthermore, Pin1 enhanced the insulin-induced extracellular signal-regulated protein kinase (ERK)1/2 phosphorylation through its interaction with p70S6K, whereas the inhibition of p70S6K activity by rapamycin suppressed insulin-induced ERK1/2 phosphorylation in SK-HEP-1 cells.	Sirolimus	200-209	ribosomal protein S6 kinase B1	Homo sapiens	181-187
19058911-9	2009	BCH treatment decreased the phosphorylation of mTOR, p70S6K and 4EBP1, suggesting that BCH enhanced anti-tumor action of cisplatin by inhibiting mTOR pathway.	bis(cyclohexylammonium)sulfate	0-3	ribosomal protein S6 kinase B1	Homo sapiens	53-69
19058911-9	2009	BCH treatment decreased the phosphorylation of mTOR, p70S6K and 4EBP1, suggesting that BCH enhanced anti-tumor action of cisplatin by inhibiting mTOR pathway.	bis(cyclohexylammonium)sulfate	87-90	ribosomal protein S6 kinase B1	Homo sapiens	53-69
19058911-9	2009	BCH treatment decreased the phosphorylation of mTOR, p70S6K and 4EBP1, suggesting that BCH enhanced anti-tumor action of cisplatin by inhibiting mTOR pathway.	Cisplatin	121-130	ribosomal protein S6 kinase B1	Homo sapiens	53-69
19437488-11	2009	At the molecular level, the lack of S6K1-mediated negative feedback decreased insulin receptor substrate-1 (IRS-1) serine phosphorylation, resulting in activation of survival pathways mediated by phosphatidylinositol 3-kinase/Akt and extracellular signal-regulated kinase (ERK).	Serine	115-121	ribosomal protein S6 kinase B1	Homo sapiens	36-40
19414357-5	2009	Rapamycin resistance was reflected by reduced inhibition of p70S6K and S6RP phosphorylation in MCF10CA1a tumor cells, with RS6P showing the least response to rapamycin in the tumor cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	60-66
19266162-2	2009	We tested the hypothesis that the branched-chain amino acid leucine reduces acute insulin action in primary myotubes via a negative feedback mechanism involving ribosomal protein S6 kinase 1 (S6K1).	branched-chain amino acid leucine	34-67	ribosomal protein S6 kinase B1	Homo sapiens	192-196
19266162-3	2009	The effect of S6K1 on glucose metabolism was determined by applying RNA interference (siRNA).	Glucose	22-29	ribosomal protein S6 kinase B1	Homo sapiens	14-18
19266162-5	2009	Leucine also reduced insulin-stimulated Akt phosphorylation, glucose uptake and glucose incorporation to glycogen (39%, 39% and 37%, respectively), and this reduction was restored after S6K1 silencing.	Leucine	0-7	ribosomal protein S6 kinase B1	Homo sapiens	186-190
19266162-6	2009	Depletion of S6K1 enhanced basal glucose utilization and protected against the development of impaired insulin action, in response to excessive leucine.	Glucose	33-40	ribosomal protein S6 kinase B1	Homo sapiens	13-17
19266162-6	2009	Depletion of S6K1 enhanced basal glucose utilization and protected against the development of impaired insulin action, in response to excessive leucine.	Leucine	144-151	ribosomal protein S6 kinase B1	Homo sapiens	13-17
19266162-7	2009	In conclusion, S6K1 plays an important role in the regulation of insulin action on glucose metabolism in skeletal muscle.	Glucose	83-90	ribosomal protein S6 kinase B1	Homo sapiens	15-19
19065636-4	2009	By using the nocodazole-induced Dami cell model, we found that 4E-BP1 and Thr421/Ser424 of ribosomal S6 kinase 1(S6K1) were phosphorylated mostly at M-phase in cytoplasm and oscillated in nocodazole-induced polyploid Dami cells, concomitant with increased expression of p27 and cyclin D3.	Nocodazole	13-23	ribosomal protein S6 kinase B1	Homo sapiens	113-117
19112158-6	2009	Phosphorylation of p70(S6k) on Thr(389) and S6 in type II fibers was increased three-to fourfold and six- to ninefold (P &lt; 0.05), respectively, 1 and 2 h after exercise, whereas phosphorylation in type I fibers remained unchanged.	Threonine	31-34	ribosomal protein S6 kinase B1	Homo sapiens	23-26
19065636-5	2009	However, phosphorylation of 4E-BP1 and S6K1 on Thr421/Ser424 was significantly decreased in differentiated Dami cells induced by phorbol 12-myristate 13-acetate (PMA), concomitant with increased expression of cyclin D1 and p21 and cyclin D3.	Tetradecanoylphorbol Acetate	162-165	ribosomal protein S6 kinase B1	Homo sapiens	39-43
19065636-7	2009	Moreover, overexpression of rapamycin-resistant form of S6K1 significantly reversed polyploidization of nocodazole-induced Dami cells.	Nocodazole	104-114	ribosomal protein S6 kinase B1	Homo sapiens	56-60
19284655-0	2009	Inhibition of S6K1 accounts partially for the anti-inflammatory effects of the arginase inhibitor L-norvaline.	norvaline	98-109	ribosomal protein S6 kinase B1	Homo sapiens	14-18
19284655-11	2009	The anti-inflammatory properties of L-norvaline are partially attributable to its ability to inhibit S6K1.	norvaline	36-47	ribosomal protein S6 kinase B1	Homo sapiens	101-105
19112174-1	2009	The 40 S ribosomal S6 kinase 1 (S6K1) acts downstream of mTOR (mammalian target of rapamycin) and is sensitive to inhibition by rapamycin.	Sirolimus	83-92	ribosomal protein S6 kinase B1	Homo sapiens	32-36
19112174-5	2009	In this study, we report that overexpression of S6K1 endows breast cancer cells with a proliferative advantage in low serum conditions and enhanced sensitivity to rapamycin.	Sirolimus	163-172	ribosomal protein S6 kinase B1	Homo sapiens	48-52
19112174-6	2009	We investigate the molecular mechanism behind this observation to show that S6K1 regulates estrogen receptor alpha (ERalpha) by phosphorylating it on serine 167, leading to transcriptional activation of ERalpha.	Serine	150-156	ribosomal protein S6 kinase B1	Homo sapiens	76-80
19223503-8	2009	The combination of rapamycin and UCN-01 synergistically inhibited the DLBCL cell proliferation by inducing G1 arrest as well as apoptosis by suppressing the phosphorylation of p70S6K/p85S6K and CDC2 expression.	Sirolimus	19-28	ribosomal protein S6 kinase B1	Homo sapiens	176-182
19223503-8	2009	The combination of rapamycin and UCN-01 synergistically inhibited the DLBCL cell proliferation by inducing G1 arrest as well as apoptosis by suppressing the phosphorylation of p70S6K/p85S6K and CDC2 expression.	7-hydroxystaurosporine	33-39	ribosomal protein S6 kinase B1	Homo sapiens	176-182
18948408-3	2009	In this study, we transduced fully differentiated 3T3-L1 adipocytes with a constitutively active myristoylated Akt that led to hyperactivation of mammalian target of rapamycin and p70 S6 kinase (S6K1), increased serine phosphorylation of IRS-1, and reduction in insulin-stimulated phosphatidylinositol (PI) 3-kinase activity and glucose transport.	Serine	212-218	ribosomal protein S6 kinase B1	Homo sapiens	195-199
18948408-3	2009	In this study, we transduced fully differentiated 3T3-L1 adipocytes with a constitutively active myristoylated Akt that led to hyperactivation of mammalian target of rapamycin and p70 S6 kinase (S6K1), increased serine phosphorylation of IRS-1, and reduction in insulin-stimulated phosphatidylinositol (PI) 3-kinase activity and glucose transport.	Phosphatidylinositols	281-301	ribosomal protein S6 kinase B1	Homo sapiens	195-199
18948408-3	2009	In this study, we transduced fully differentiated 3T3-L1 adipocytes with a constitutively active myristoylated Akt that led to hyperactivation of mammalian target of rapamycin and p70 S6 kinase (S6K1), increased serine phosphorylation of IRS-1, and reduction in insulin-stimulated phosphatidylinositol (PI) 3-kinase activity and glucose transport.	Glucose	329-336	ribosomal protein S6 kinase B1	Homo sapiens	195-199
18948408-5	2009	Reduction in expression of either p85alpha or S6K1 achieved with small interfering RNA in the presence of myristoylated Akt rescued 3T3-L1 adipocytes from the insulin resistance induced by serine phosphorylation of IRS-1 and completely restored insulin-stimulated activation of PI 3-kinase and glucose uptake.	Serine	189-195	ribosomal protein S6 kinase B1	Homo sapiens	46-50
18948408-5	2009	Reduction in expression of either p85alpha or S6K1 achieved with small interfering RNA in the presence of myristoylated Akt rescued 3T3-L1 adipocytes from the insulin resistance induced by serine phosphorylation of IRS-1 and completely restored insulin-stimulated activation of PI 3-kinase and glucose uptake.	Glucose	294-301	ribosomal protein S6 kinase B1	Homo sapiens	46-50
19191576-4	2009	The DNA-damaging agent cisplatin caused a concentration-dependent decrease in the level of full-length p70S6K in small cell lung cancer H69 and non-small cell lung cancer A549 cells with a concomitant increase in the level of an approximately 45 kDa fragment.	Cisplatin	23-32	ribosomal protein S6 kinase B1	Homo sapiens	103-109
19191576-6	2009	Cell-permeable peptide inhibitor and siRNA against caspase-3 inhibited cisplatin-induced proteolytic cleavage of p70S6K.	Cisplatin	71-80	ribosomal protein S6 kinase B1	Homo sapiens	113-119
19191576-9	2009	p70S6K was primarily cleaved at a noncanonical recognition site, Thr-Pro-Val-Asp, after Asp-393.	thr-pro-val-asp	65-80	ribosomal protein S6 kinase B1	Homo sapiens	0-6
19191576-9	2009	p70S6K was primarily cleaved at a noncanonical recognition site, Thr-Pro-Val-Asp, after Asp-393.	Aspartic Acid	77-80	ribosomal protein S6 kinase B1	Homo sapiens	0-6
19191576-11	2009	These results suggest that p70S6K is a novel substrate for caspase-3 and that the proteolytic cleavage of p70S6K is important for cisplatin-induced apoptosis.	Cisplatin	130-139	ribosomal protein S6 kinase B1	Homo sapiens	27-33
19191576-11	2009	These results suggest that p70S6K is a novel substrate for caspase-3 and that the proteolytic cleavage of p70S6K is important for cisplatin-induced apoptosis.	Cisplatin	130-139	ribosomal protein S6 kinase B1	Homo sapiens	106-112
19197153-4	2009	In this review, we discuss the implications of a recent finding that showed differential inhibition of S6K1 and 4E-BP1 by rapamycin, leading to cell-type-specific repression of cap-dependent translation.	Sirolimus	122-131	ribosomal protein S6 kinase B1	Homo sapiens	103-118
19065636-4	2009	By using the nocodazole-induced Dami cell model, we found that 4E-BP1 and Thr421/Ser424 of ribosomal S6 kinase 1(S6K1) were phosphorylated mostly at M-phase in cytoplasm and oscillated in nocodazole-induced polyploid Dami cells, concomitant with increased expression of p27 and cyclin D3.	Nocodazole	188-198	ribosomal protein S6 kinase B1	Homo sapiens	113-117
19065636-5	2009	However, phosphorylation of 4E-BP1 and S6K1 on Thr421/Ser424 was significantly decreased in differentiated Dami cells induced by phorbol 12-myristate 13-acetate (PMA), concomitant with increased expression of cyclin D1 and p21 and cyclin D3.	Tetradecanoylphorbol Acetate	129-160	ribosomal protein S6 kinase B1	Homo sapiens	39-43
19074484-6	2009	The PI3K inhibitor Ly294002 abolished Akt and p70S6K phosphorylation and reversed the dedifferentiated phenotype via induction of sm-calponin, sm-alpha-actin, SM22alpha, and myosin light chain kinase.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	19-27	ribosomal protein S6 kinase B1	Homo sapiens	46-52
18952604-6	2008	This led to phosphorylation of IRS-1 by S6K1 at multiple serine residues including Ser-270, Ser-307, Ser-636, and Ser-1101 in human IRS-1 (Ser-265, Ser-302, Ser-632, and Ser-1097, in rodent IRS-1).	Serine	92-95	ribosomal protein S6 kinase B1	Homo sapiens	40-44
18952604-5	2008	S6K1 was phosphorylated at Thr-389 in response to TNF-alpha.	Threonine	27-30	ribosomal protein S6 kinase B1	Homo sapiens	0-4
18952604-6	2008	This led to phosphorylation of IRS-1 by S6K1 at multiple serine residues including Ser-270, Ser-307, Ser-636, and Ser-1101 in human IRS-1 (Ser-265, Ser-302, Ser-632, and Ser-1097, in rodent IRS-1).	Serine	57-63	ribosomal protein S6 kinase B1	Homo sapiens	40-44
18952604-6	2008	This led to phosphorylation of IRS-1 by S6K1 at multiple serine residues including Ser-270, Ser-307, Ser-636, and Ser-1101 in human IRS-1 (Ser-265, Ser-302, Ser-632, and Ser-1097, in rodent IRS-1).	Serine	83-86	ribosomal protein S6 kinase B1	Homo sapiens	40-44
18952604-6	2008	This led to phosphorylation of IRS-1 by S6K1 at multiple serine residues including Ser-270, Ser-307, Ser-636, and Ser-1101 in human IRS-1 (Ser-265, Ser-302, Ser-632, and Ser-1097, in rodent IRS-1).	Serine	92-95	ribosomal protein S6 kinase B1	Homo sapiens	40-44
18952604-6	2008	This led to phosphorylation of IRS-1 by S6K1 at multiple serine residues including Ser-270, Ser-307, Ser-636, and Ser-1101 in human IRS-1 (Ser-265, Ser-302, Ser-632, and Ser-1097, in rodent IRS-1).	Serine	92-95	ribosomal protein S6 kinase B1	Homo sapiens	40-44
18952604-6	2008	This led to phosphorylation of IRS-1 by S6K1 at multiple serine residues including Ser-270, Ser-307, Ser-636, and Ser-1101 in human IRS-1 (Ser-265, Ser-302, Ser-632, and Ser-1097, in rodent IRS-1).	Serine	92-95	ribosomal protein S6 kinase B1	Homo sapiens	40-44
18952604-6	2008	This led to phosphorylation of IRS-1 by S6K1 at multiple serine residues including Ser-270, Ser-307, Ser-636, and Ser-1101 in human IRS-1 (Ser-265, Ser-302, Ser-632, and Ser-1097, in rodent IRS-1).	Serine	92-95	ribosomal protein S6 kinase B1	Homo sapiens	40-44
18952604-6	2008	This led to phosphorylation of IRS-1 by S6K1 at multiple serine residues including Ser-270, Ser-307, Ser-636, and Ser-1101 in human IRS-1 (Ser-265, Ser-302, Ser-632, and Ser-1097, in rodent IRS-1).	Serine	92-95	ribosomal protein S6 kinase B1	Homo sapiens	40-44
19074484-2	2009	We hypothesized that phosphoinositol-Akt-mammalian target of rapamycin-p70S6 kinase (PI3K/Akt/mTOR/p70S6K) pathway activation regulates VSMC differentiation from MSCs.	phosphoinositol	21-36	ribosomal protein S6 kinase B1	Homo sapiens	99-105
19074484-5	2009	mTOR inhibition with rapamycin at below pharmacological concentrations blocked p70S6K phosphorylation and induced a differentiated contractile phenotype with smooth muscle (sm)-calponin, sm-alpha-actin, and SM protein 22-alpha (SM22alpha) expression.	Sirolimus	21-30	ribosomal protein S6 kinase B1	Homo sapiens	79-85
19098447-3	2009	Safingol inhibited PKCbeta-I, PKC delta and PKC epsilon, and inhibited phosphorylation of critical components of the PI3k/Akt/mTOR pathway (Akt, p70S6k and rS6) and the MAPk pathway (ERK).	safingol	0-8	ribosomal protein S6 kinase B1	Homo sapiens	145-151
19176385-3	2009	Recently, we have shown that curcumin inhibits phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), two downstream effector molecules of the mammalian target of rapamycin complex 1 (mTORC1) in numerous cancer cell lines.	Curcumin	29-37	ribosomal protein S6 kinase B1	Homo sapiens	83-87
19176385-7	2009	This is evidenced by the findings that curcumin was able to inhibit phosphorylation of S6K1 and 4E-BP1 in the cells pretreated with PP2A inhibitor (okadaic acid) or AMPK inhibitor (compound C), or in the cells expressing dominant-negative (dn) PP2A, shRNA to PP2A-A subunit, or dn-AMPKalpha.	Curcumin	39-47	ribosomal protein S6 kinase B1	Homo sapiens	87-102
19176385-7	2009	This is evidenced by the findings that curcumin was able to inhibit phosphorylation of S6K1 and 4E-BP1 in the cells pretreated with PP2A inhibitor (okadaic acid) or AMPK inhibitor (compound C), or in the cells expressing dominant-negative (dn) PP2A, shRNA to PP2A-A subunit, or dn-AMPKalpha.	Okadaic Acid	148-160	ribosomal protein S6 kinase B1	Homo sapiens	87-102
19176385-7	2009	This is evidenced by the findings that curcumin was able to inhibit phosphorylation of S6K1 and 4E-BP1 in the cells pretreated with PP2A inhibitor (okadaic acid) or AMPK inhibitor (compound C), or in the cells expressing dominant-negative (dn) PP2A, shRNA to PP2A-A subunit, or dn-AMPKalpha.	dn-ampkalpha	278-290	ribosomal protein S6 kinase B1	Homo sapiens	87-102
19071109-6	2009	NVP-BEZ235 inhibited phosphorylation of protein kinase B (Akt), P70S6k and 4E-BP-1.	dactolisib	4-10	ribosomal protein S6 kinase B1	Homo sapiens	64-82
18978810-0	2009	Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.	Silybin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	60-66
18978810-6	2009	Rather, we found that suppression of HIF-1alpha accumulation by silibinin correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), a pathway known to regulate HIF-1alpha expression at the translational level.	Silybin	64-73	ribosomal protein S6 kinase B1	Homo sapiens	202-208
19059405-2	2009	In the present study, we show that SP600125 induces a dose-dependent decrease in mTOR activity, as assessed by reduced phosphorylation of the downstream targets S6K1 and S6, and a significant increase in the expression of Redd1.	pyrazolanthrone	35-43	ribosomal protein S6 kinase B1	Homo sapiens	161-165
18781596-7	2009	Finally and most importantly, our data indicate that a decrease in AKT activity followed by a total decrease in p70(S6K) phosphorylation reflecting a decrease in mTOR activity occurs during high oxygen consumption, resulting from high cell density.	Oxygen	195-201	ribosomal protein S6 kinase B1	Homo sapiens	112-115
20066897-6	2009	p-mTOR and S6K expressions were significantly downregulated by rapamycin.	Sirolimus	63-72	ribosomal protein S6 kinase B1	Homo sapiens	11-14
20066897-8	2009	Combined cisplatin and rapamycin treatment resulted in significant downregulated p-mTOR and S6K expression, but no change in ERCC1 expression.	Cisplatin	9-18	ribosomal protein S6 kinase B1	Homo sapiens	92-95
20066897-8	2009	Combined cisplatin and rapamycin treatment resulted in significant downregulated p-mTOR and S6K expression, but no change in ERCC1 expression.	Sirolimus	23-32	ribosomal protein S6 kinase B1	Homo sapiens	92-95
18925875-11	2008	Moreover, rapamycin treatment of HEK (human embryonic kidney)-293, MCF-7 or HeLa cells suppressed phosphorylation of S6K, without affecting SGK1 phosphorylation or activation.	Sirolimus	10-19	ribosomal protein S6 kinase B1	Homo sapiens	117-120
18952604-6	2008	This led to phosphorylation of IRS-1 by S6K1 at multiple serine residues including Ser-270, Ser-307, Ser-636, and Ser-1101 in human IRS-1 (Ser-265, Ser-302, Ser-632, and Ser-1097, in rodent IRS-1).	Serine	92-95	ribosomal protein S6 kinase B1	Homo sapiens	40-44
18952604-9	2008	RNAi knockdown demonstrated an important role for S6K1 in mediating TNF-alpha-induced IRS-1 inhibition that led to impaired insulin-stimulated glucose uptake in adipocytes.	Glucose	143-150	ribosomal protein S6 kinase B1	Homo sapiens	50-54
18952604-11	2008	Expression of a dominant negative S6K1 mutant prevented TNF-induced Ser-270 phosphorylation and IRS-1 protein degradation.	Serine	68-71	ribosomal protein S6 kinase B1	Homo sapiens	34-38
18784743-1	2008	This study found that MS-275, a novel synthetic benzamide histone deacetylase inhibitor (HDACI), blocked Akt/mammalian target of rapamycin (mTOR) signaling in acute myelogenous leukemia (AML) HL60 and acute promyelocytic leukemia (APL) NB4 cells, as assessed by decreased levels of the phosphorylated (p)-Akt, p-p70 ribosomal S6 kinase (p70S6K) and p-S6K by western blot analysis.	entinostat	22-28	ribosomal protein S6 kinase B1	Homo sapiens	310-335
19020730-9	2008	TAE226 inhibited the expression of mTOR, Akt, p70S6K and S6 as well as the phosphorylation of mTOR (Ser2448), Akt (Ser473), p70S6K (Thr389) and S6 (Ser240/244).	TAE226	0-6	ribosomal protein S6 kinase B1	Homo sapiens	46-52
19020730-9	2008	TAE226 inhibited the expression of mTOR, Akt, p70S6K and S6 as well as the phosphorylation of mTOR (Ser2448), Akt (Ser473), p70S6K (Thr389) and S6 (Ser240/244).	TAE226	0-6	ribosomal protein S6 kinase B1	Homo sapiens	124-130
18784743-1	2008	This study found that MS-275, a novel synthetic benzamide histone deacetylase inhibitor (HDACI), blocked Akt/mammalian target of rapamycin (mTOR) signaling in acute myelogenous leukemia (AML) HL60 and acute promyelocytic leukemia (APL) NB4 cells, as assessed by decreased levels of the phosphorylated (p)-Akt, p-p70 ribosomal S6 kinase (p70S6K) and p-S6K by western blot analysis.	entinostat	22-28	ribosomal protein S6 kinase B1	Homo sapiens	337-343
18577697-4	2008	The phosphorylation of PKB Ser(473) and p70(S6k) Thr(389) increased concomitantly with insulin, but whereas raising insulin to 30 mU/l increased the phosphorylation of mTOR Ser(2448), 4E-BP1 Thr(37/46), or GSK3beta Ser(9) and decreased that of eEF2 Thr(56), higher insulin doses to 72 and 167 mU/l did not augment these latter responses.	Threonine	49-52	ribosomal protein S6 kinase B1	Homo sapiens	44-47
18511708-6	2008	Responsiveness to rapamycin correlated with staining for the mTOR target, p-S6K, in the original tumor, but not for p-Akt.	Sirolimus	18-27	ribosomal protein S6 kinase B1	Homo sapiens	74-79
18769144-4	2008	We showed that chemical agents or siRNA inhibiting the activity of ATM, CDK2 and p70s6K kinases blocked degradation of Delta Np63 alpha in HNSCC cells after cisplatin exposure.	Cisplatin	157-166	ribosomal protein S6 kinase B1	Homo sapiens	81-87
18499206-5	2008	In addition, delphinidin treatment resulted in significant inhibition of HGF-activated (i) Ras-ERK MAPKs and (ii) PI3K/AKT/mTOR/p70S6K pathways.	delphinidin	13-24	ribosomal protein S6 kinase B1	Homo sapiens	128-134
18621911-5	2008	Furthermore, 1-butanol inhibited 5-HT activation of S6K1 and S6 protein, downstream effectors of mammalian target of rapamycin (mTOR), by 80 and 72%, respectively, and partially blocked activation of extracellular signal-regulated kinase (ERK) by 30% but had no effect on other associated signaling pathways.	1-Butanol	13-22	ribosomal protein S6 kinase B1	Homo sapiens	52-63
18621911-7	2008	PA also reproduced activations by 5-HT of mTOR, S6K1, and ERK.	Phosphatidic Acids	0-2	ribosomal protein S6 kinase B1	Homo sapiens	48-52
18621911-12	2008	Signaling by PA produces its downstream effects primarily through the mTOR/S6K1 pathway and to a lesser extent through the ERK pathway.	Phosphatidic Acids	13-15	ribosomal protein S6 kinase B1	Homo sapiens	75-79
18504440-7	2008	Cells infected with a recombinant adenovirus expressing constitutively active and rapamycin-resistant mutant of p70 S6 kinase 1 (S6K1) conferred to resistance to rapamycin.	Sirolimus	82-91	ribosomal protein S6 kinase B1	Homo sapiens	129-133
18495226-8	2008	Metformin growth inhibition was partly abolished by the AMPK inhibitor, compound C. Western blotting demonstrated that metformin at cytotoxic concentrations, induced AMPK phosphorylation and decreased p70S6K and S6K phosphorylation, suggesting the mechanism for its anti-proliferative action.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	201-207
18495226-8	2008	Metformin growth inhibition was partly abolished by the AMPK inhibitor, compound C. Western blotting demonstrated that metformin at cytotoxic concentrations, induced AMPK phosphorylation and decreased p70S6K and S6K phosphorylation, suggesting the mechanism for its anti-proliferative action.	Metformin	119-128	ribosomal protein S6 kinase B1	Homo sapiens	201-207
18688088-1	2008	The 70-kDa S6 kinase (p70S6K) is a Ser/Thr (S/T)-directed kinase that plays a crucial role in cell growth, cell differentiation, and cell cycle control.	Serine	35-38	ribosomal protein S6 kinase B1	Homo sapiens	22-28
18688088-1	2008	The 70-kDa S6 kinase (p70S6K) is a Ser/Thr (S/T)-directed kinase that plays a crucial role in cell growth, cell differentiation, and cell cycle control.	Threonine	39-42	ribosomal protein S6 kinase B1	Homo sapiens	22-28
18377870-6	2008	Expression of a constitutively active form of the mTOR target ribosomal protein S6 kinase (S6K) or of translation factor eIF4E reduced apoptosis by glucose limitation, and co-expression of S6K and eIF4E protected beta cells to the same extent as active Akt.	Glucose	148-155	ribosomal protein S6 kinase B1	Homo sapiens	91-94
18356276-10	2008	The progrowth signaling via AKT-mammalian target rapamycin-p70(S6K) and cyclin D1/cyclin-dependent kinase were inhibited, and proapoptotic activity of Bcl-2-associated death promoter was increased by LY294002 treatment.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	200-208	ribosomal protein S6 kinase B1	Homo sapiens	49-52
18622747-10	2008	Phosphorylation of Akt, p70S6K and 4E-BP1 were significantly reduced in the cells treated with LY294002 or RAPA (P&lt;0.01), but we failed to find that 5-aza-dC enhance these effects.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	95-103	ribosomal protein S6 kinase B1	Homo sapiens	24-41
18250144-7	2008	Under the conditions adopted, rapamycin inhibited both mammalian target-of-rapamycin complexes (mTORC1 and mTORC2), as indicated by the reduced amount of raptor and rictor bound to mTOR in immunoprecipitates and by the marked hypophosphorylation of protein S6 kinase I (p70S6K) and Akt, determined by western blotting.	Sirolimus	30-39	ribosomal protein S6 kinase B1	Homo sapiens	270-276
17983653-6	2008	AZD6244 potently down-regulated the levels of phospho-ERK1/2 and its downstream effector, p-p70S6K, in the MV4-11 and MOLM13 cells as measured by Western blot analysis.	AZD 6244	0-7	ribosomal protein S6 kinase B1	Homo sapiens	92-98
17983653-7	2008	Interestingly, when AZD6244 was combined with sunitinib, a FLT3 kinase inhibitor, growth inhibition and apoptosis of both MV4-11 and MOLM13 cells were synergistically enhanced in association with further down-regulation of phospho-ERK1/2 and p-p70S6K in these cells.	AZD 6244	20-27	ribosomal protein S6 kinase B1	Homo sapiens	244-250
17983653-7	2008	Interestingly, when AZD6244 was combined with sunitinib, a FLT3 kinase inhibitor, growth inhibition and apoptosis of both MV4-11 and MOLM13 cells were synergistically enhanced in association with further down-regulation of phospho-ERK1/2 and p-p70S6K in these cells.	Sunitinib	46-55	ribosomal protein S6 kinase B1	Homo sapiens	244-250
18461003-7	2008	Contrary to our hypothesis, 70-kDa ribosomal protein S6 kinase (p70 S6K) threonine (Thr) 389 phosphorylation within the vastus lateralis was attenuated at 180 min post-RE during the HHC trial.	Threonine	73-82	ribosomal protein S6 kinase B1	Homo sapiens	64-71
18461003-7	2008	Contrary to our hypothesis, 70-kDa ribosomal protein S6 kinase (p70 S6K) threonine (Thr) 389 phosphorylation within the vastus lateralis was attenuated at 180 min post-RE during the HHC trial.	Threonine	84-87	ribosomal protein S6 kinase B1	Homo sapiens	64-71
18461003-10	2008	CONCLUSION: p70 S6K Thr 389 phosphorylation was attenuated during the HHC trial despite dramatically greater (&gt;2.5-fold) circulating GH concentrations; this was potentially due to cortisol-induced inhibition of p70 S6K Thr 389 phosphorylation.	Threonine	20-23	ribosomal protein S6 kinase B1	Homo sapiens	12-19
18461003-10	2008	CONCLUSION: p70 S6K Thr 389 phosphorylation was attenuated during the HHC trial despite dramatically greater (&gt;2.5-fold) circulating GH concentrations; this was potentially due to cortisol-induced inhibition of p70 S6K Thr 389 phosphorylation.	Hydrocortisone	183-191	ribosomal protein S6 kinase B1	Homo sapiens	12-19
18461003-10	2008	CONCLUSION: p70 S6K Thr 389 phosphorylation was attenuated during the HHC trial despite dramatically greater (&gt;2.5-fold) circulating GH concentrations; this was potentially due to cortisol-induced inhibition of p70 S6K Thr 389 phosphorylation.	Threonine	222-225	ribosomal protein S6 kinase B1	Homo sapiens	12-19
18058806-9	2008	In the in vitro study, cisplatin at CPI(50) targets both the apoptosis and survival pathway by activating the caspase-cascade; inhibiting Akt, mTOR, p70S6K, and 4EBP1.	Cisplatin	23-32	ribosomal protein S6 kinase B1	Homo sapiens	149-166
18097751-0	2008	Administration of triiodo-L-thyronine into dorsal hippocampus alters phosphorylation of Akt, mammalian target of rapamycin, p70S6 kinase and 4E-BP1 in rats.	Triiodothyronine	18-37	ribosomal protein S6 kinase B1	Homo sapiens	124-136
18435829-0	2008	Leucine induces phosphorylation and activation of p70S6K in cortical neurons via the system L amino acid transporter.	Leucine	0-7	ribosomal protein S6 kinase B1	Homo sapiens	50-56
18435829-5	2008	Leucine also induces phosphorylation of S6 protein, a substrate of p70S6K.	Leucine	0-7	ribosomal protein S6 kinase B1	Homo sapiens	67-73
18425342-10	2008	Taken together, these results suggest that activation of p70S6K contributes to cisplatin resistance in small cell lung cancer H69 cells, and inhibition/downregulation of p70S6K as well as activation of ERK1/2 could circumvent cisplatin resistance.	Cisplatin	79-88	ribosomal protein S6 kinase B1	Homo sapiens	57-63
18425342-3	2008	In the present study, we investigated whether the p70S6K pathway contributes to cisplatin resistance in human small cell lung cancer H69 cells.	Cisplatin	80-89	ribosomal protein S6 kinase B1	Homo sapiens	50-56
18425342-10	2008	Taken together, these results suggest that activation of p70S6K contributes to cisplatin resistance in small cell lung cancer H69 cells, and inhibition/downregulation of p70S6K as well as activation of ERK1/2 could circumvent cisplatin resistance.	Cisplatin	79-88	ribosomal protein S6 kinase B1	Homo sapiens	170-176
18425342-4	2008	The levels of phosphorylated p70S6K and its downstream target S6 but not total p70S6K or S6 were elevated in the H69 cells that acquired resistance to cisplatin (H69/CP) compared to parental H69 cells.	Cisplatin	151-160	ribosomal protein S6 kinase B1	Homo sapiens	29-35
18425342-10	2008	Taken together, these results suggest that activation of p70S6K contributes to cisplatin resistance in small cell lung cancer H69 cells, and inhibition/downregulation of p70S6K as well as activation of ERK1/2 could circumvent cisplatin resistance.	Cisplatin	226-235	ribosomal protein S6 kinase B1	Homo sapiens	170-176
18425342-5	2008	Cisplatin treatment resulted in the activation of p70S6K and downregulation of p70S6K was associated with cisplatin-induced PARP cleavage.	Cisplatin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	50-56
18425342-5	2008	Cisplatin treatment resulted in the activation of p70S6K and downregulation of p70S6K was associated with cisplatin-induced PARP cleavage.	Cisplatin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	79-85
18252807-5	2008	Hyperosmotic stress markedly activated S6K1; S6K1 activation was completely abolished by oltipraz pretreatment.	oltipraz	89-97	ribosomal protein S6 kinase B1	Homo sapiens	39-43
18425342-5	2008	Cisplatin treatment resulted in the activation of p70S6K and downregulation of p70S6K was associated with cisplatin-induced PARP cleavage.	Cisplatin	106-115	ribosomal protein S6 kinase B1	Homo sapiens	79-85
18425342-6	2008	While the ability of cisplatin to induce apoptosis was attenuated in H69/CP cells, inhibition of p70S6K by rapamycin enhanced cisplatin-induced apoptosis in these cells as evident by the increase in cisplatin-induced poly(ADP-ribose) polymerase (PARP) cleavage.	Sirolimus	107-116	ribosomal protein S6 kinase B1	Homo sapiens	97-103
18425342-6	2008	While the ability of cisplatin to induce apoptosis was attenuated in H69/CP cells, inhibition of p70S6K by rapamycin enhanced cisplatin-induced apoptosis in these cells as evident by the increase in cisplatin-induced poly(ADP-ribose) polymerase (PARP) cleavage.	Cisplatin	126-135	ribosomal protein S6 kinase B1	Homo sapiens	97-103
18425342-6	2008	While the ability of cisplatin to induce apoptosis was attenuated in H69/CP cells, inhibition of p70S6K by rapamycin enhanced cisplatin-induced apoptosis in these cells as evident by the increase in cisplatin-induced poly(ADP-ribose) polymerase (PARP) cleavage.	Cisplatin	126-135	ribosomal protein S6 kinase B1	Homo sapiens	97-103
18252807-0	2008	Abrogation of hyperosmotic impairment of insulin signaling by a novel class of 1,2-dithiole-3-thiones through the inhibition of S6K1 activation.	1,2-dithiol-3-thione	79-101	ribosomal protein S6 kinase B1	Homo sapiens	128-132
18252807-5	2008	Hyperosmotic stress markedly activated S6K1; S6K1 activation was completely abolished by oltipraz pretreatment.	oltipraz	89-97	ribosomal protein S6 kinase B1	Homo sapiens	45-49
18252807-7	2008	Transfection of constitutive active mutant S6K1 eliminated the protective effect of oltipraz on GSK3beta phosphorylation, indicating that oltipraz restores insulin signaling by inhibiting S6K1 activation.	oltipraz	84-92	ribosomal protein S6 kinase B1	Homo sapiens	43-47
18252807-7	2008	Transfection of constitutive active mutant S6K1 eliminated the protective effect of oltipraz on GSK3beta phosphorylation, indicating that oltipraz restores insulin signaling by inhibiting S6K1 activation.	oltipraz	84-92	ribosomal protein S6 kinase B1	Homo sapiens	188-192
18252807-7	2008	Transfection of constitutive active mutant S6K1 eliminated the protective effect of oltipraz on GSK3beta phosphorylation, indicating that oltipraz restores insulin signaling by inhibiting S6K1 activation.	oltipraz	138-146	ribosomal protein S6 kinase B1	Homo sapiens	43-47
18252807-7	2008	Transfection of constitutive active mutant S6K1 eliminated the protective effect of oltipraz on GSK3beta phosphorylation, indicating that oltipraz restores insulin signaling by inhibiting S6K1 activation.	oltipraz	138-146	ribosomal protein S6 kinase B1	Homo sapiens	188-192
18252807-8	2008	A variety of synthetic 1,2-dithiole-3-thione derivatives also inhibited S6K1 activity and insulin resistance induced by hyperosmotic stress in HepG2 cells.	1,2-dithiol-3-thione	23-44	ribosomal protein S6 kinase B1	Homo sapiens	72-76
18252807-9	2008	The results of this study demonstrate that a novel class of 1,2-dithiole-3-thiones improve insulin sensitivity under the condition of hyperosmotic stress, which results from the inhibition of S6K1 activation.	1,2-dithiol-3-thione	60-82	ribosomal protein S6 kinase B1	Homo sapiens	192-196
18354181-5	2008	Rapamycin, a specific inhibitor of mTORC1, selectively and completely blocked the FcepsilonRI- and Kit-induced mTORC1-dependent p70S6K phosphorylation and partially blocked the 4E-BP1 phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	128-134
18413730-4	2008	Phosphorylation of TSC1 and S6K1 was induced in response to bile acid stimulation.	Bile Acids and Salts	60-69	ribosomal protein S6 kinase B1	Homo sapiens	28-32
18258606-9	2008	Stimulation of SK-BR-3 with MIC-1 profoundly induces the phosphorylation of mTOR and its downstream substrates, including p70S6K and 4E-BP1.	sk-br-3	15-22	ribosomal protein S6 kinase B1	Homo sapiens	122-139
18381446-0	2008	Mammalian target of rapamycin and S6 kinase 1 positively regulate 6-thioguanine-induced autophagy.	Thioguanine	66-79	ribosomal protein S6 kinase B1	Homo sapiens	34-45
18381446-6	2008	Consistently, short interfering RNA silencing of the 70-kDa ribosomal S6 kinase 1 (S6K1), the downstream effector of mTOR, markedly reduces 6-TG-induced autophagy.	Thioguanine	140-144	ribosomal protein S6 kinase B1	Homo sapiens	83-87
18381446-9	2008	In conclusion, our data indicate that mTOR-S6K1 positively regulates autophagy after MMR processing of 6-TG probably through its negative feedback inhibition of Akt.	Thioguanine	103-107	ribosomal protein S6 kinase B1	Homo sapiens	43-47
18332467-4	2008	A PK/PD model was used to describe the relationship between everolimus concentrations and S6K1 inhibition in PBMCs of cancer patients and in PBMCs and tumors of everolimus-treated CA20948 pancreatic tumor-bearing rats.	Everolimus	60-70	ribosomal protein S6 kinase B1	Homo sapiens	90-94
18332467-9	2008	CONCLUSION: A direct-link PK/PD model predicting the time course of S6K1 inhibition during weekly and daily everolimus administration allowed extrapolation from preclinical studies and first clinical results to select optimal doses and regimens of everolimus to explore in future clinical trials.	Everolimus	108-118	ribosomal protein S6 kinase B1	Homo sapiens	68-72
18332467-9	2008	CONCLUSION: A direct-link PK/PD model predicting the time course of S6K1 inhibition during weekly and daily everolimus administration allowed extrapolation from preclinical studies and first clinical results to select optimal doses and regimens of everolimus to explore in future clinical trials.	Everolimus	248-258	ribosomal protein S6 kinase B1	Homo sapiens	68-72
18320031-8	2008	It was noted that treatment of SIRT1-.transfected cells with Rapamycin, a mTOR inhibitor, reduced the phosphorylation of S6K1 and the expression of Id1, implying that SIRT1-induced phosphorylation of S6K1 may be partly for the decreased expression of p16(INK4A) and promoted phosphorylation of Rb in 2BS.	Sirolimus	61-70	ribosomal protein S6 kinase B1	Homo sapiens	121-125
18021293-8	2008	Treatment with rapamycin, an mTOR inhibitor, blocked Cd-induced phosphorylation of S6K1 and eukaryotic initiation factor 4E binding protein 1, and markedly inhibited Cd-induced apoptosis.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	83-141
18021293-8	2008	Treatment with rapamycin, an mTOR inhibitor, blocked Cd-induced phosphorylation of S6K1 and eukaryotic initiation factor 4E binding protein 1, and markedly inhibited Cd-induced apoptosis.	Cadmium	53-55	ribosomal protein S6 kinase B1	Homo sapiens	83-141
18223253-2	2008	We have previously shown that the mTOR/p70 S6 kinase (p70 S6K) pathway is constitutively activated in BCR-ABL transformed cells and that inhibition of BCR-ABL kinase activity by imatinib mesylate abrogates such activation.	Imatinib Mesylate	178-195	ribosomal protein S6 kinase B1	Homo sapiens	54-61
18262357-3	2008	We observed the effect of MK-801 on the "mammalian target of rapamycin" (mTOR)/70-kDa ribosomal protein S6 kinase (p70S6K) pathway that regulates protein synthesis in the rat frontal cortex.	Dizocilpine Maleate	26-32	ribosomal protein S6 kinase B1	Homo sapiens	115-121
18320031-8	2008	It was noted that treatment of SIRT1-.transfected cells with Rapamycin, a mTOR inhibitor, reduced the phosphorylation of S6K1 and the expression of Id1, implying that SIRT1-induced phosphorylation of S6K1 may be partly for the decreased expression of p16(INK4A) and promoted phosphorylation of Rb in 2BS.	Sirolimus	61-70	ribosomal protein S6 kinase B1	Homo sapiens	200-204
18191814-4	2008	By contrast, gefitinib inhibited in a fast and completely way p-EGFR and partially p-Akt while a 3 days-rapamycin exposure resulted in the inhibition of the expression of both mTor and p70S6K.	Gefitinib	13-22	ribosomal protein S6 kinase B1	Homo sapiens	185-191
18191814-4	2008	By contrast, gefitinib inhibited in a fast and completely way p-EGFR and partially p-Akt while a 3 days-rapamycin exposure resulted in the inhibition of the expression of both mTor and p70S6K.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	185-191
18060476-5	2008	Furthermore, rapamycin, a specific inhibitor of mTOR, blocked the activation of mTOR/p70S6K but not PI3K/Akt.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	85-91
18374093-6	2008	Rapamycin treatment of islets resulted in reduced phosphorylation of p70s6k, a downstream effector molecule of mTOR and increased ERK1/2 phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	69-75
18347658-2	2008	Cellular mechanisms responsible for the development of insulin resistance are unclear, though one proposed mechanism is that nutrient overload chronically increases available energy, over-activating the mammalian target of rapamycin (mTOR) and ribosomal S6 kinase 1 (S6K1) signaling pathway leading to increased phosphorylation of serine residues on insulin receptor substrate-1 (IRS-1).	Serine	331-337	ribosomal protein S6 kinase B1	Homo sapiens	267-271
17971516-10	2008	LY-294002 completely abolished TNF-alpha-induced stimulation of PS as well as phosphorylation of Akt and its downstream targets GSK-3, p70(S6K), and 4E-BP1.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-9	ribosomal protein S6 kinase B1	Homo sapiens	139-142
17971516-11	2008	Rapamycin inhibited TNF-alpha-induced phosphorylation of the mTOR C1 target p70(S6K) without altering TNF-alpha-induced PS and 4E-BP1 phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	76-79
17786026-0	2007	Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy.	Curcumin	62-70	ribosomal protein S6 kinase B1	Homo sapiens	22-28
18160324-0	2008	PGF2alpha-associated vascular smooth muscle hypertrophy is ROS dependent and involves the activation of mTOR, p70S6k, and PTEN.	Dinoprost	0-9	ribosomal protein S6 kinase B1	Homo sapiens	110-116
18160324-0	2008	PGF2alpha-associated vascular smooth muscle hypertrophy is ROS dependent and involves the activation of mTOR, p70S6k, and PTEN.	Reactive Oxygen Species	59-62	ribosomal protein S6 kinase B1	Homo sapiens	110-116
17712061-5	2008	In synaptoneurosomes, atRA rapidly increased phosphorylation of ERK1/2, its target 4E-BP, and p70S6K, and its substrate, ribosome protein S6, indicating activation of MAPK and mammalian target of rapamycin (mTOR).	Tretinoin	22-26	ribosomal protein S6 kinase B1	Homo sapiens	94-100
18787612-2	2008	Downstream signaling from PI3"-K/Akt leads to phosphorylation (p) of mTOR at serine 2448 and to activation of its substrate, p70S6Kinase (p70S6K), phosphorylated on threonine 389.	Threonine	165-174	ribosomal protein S6 kinase B1	Homo sapiens	125-136
18787612-2	2008	Downstream signaling from PI3"-K/Akt leads to phosphorylation (p) of mTOR at serine 2448 and to activation of its substrate, p70S6Kinase (p70S6K), phosphorylated on threonine 389.	Threonine	165-174	ribosomal protein S6 kinase B1	Homo sapiens	125-131
18156399-0	2008	Arginine activates intestinal p70(S6k) and protein synthesis in piglet rotavirus enteritis.	Arginine	0-8	ribosomal protein S6 kinase B1	Homo sapiens	34-37
18156399-2	2008	In this study, we hypothesized that during rotavirus infection, oral Arg, which stimulates p70(S6k) activation, will further stimulate intestinal protein synthesis and mucosal recovery, whereas the p70(S6k) inhibitor rapamycin (Rapa) will inhibit mucosal recovery.	Arginine	69-72	ribosomal protein S6 kinase B1	Homo sapiens	95-98
18156399-2	2008	In this study, we hypothesized that during rotavirus infection, oral Arg, which stimulates p70(S6k) activation, will further stimulate intestinal protein synthesis and mucosal recovery, whereas the p70(S6k) inhibitor rapamycin (Rapa) will inhibit mucosal recovery.	Arginine	69-72	ribosomal protein S6 kinase B1	Homo sapiens	91-98
18156399-10	2008	However, in Arg-treated piglets, p70(S6k) activation occurred over the entire villus.	Arginine	12-15	ribosomal protein S6 kinase B1	Homo sapiens	37-40
18156399-11	2008	Jejunal villi of the Rapa-treated group showed inactivation of p70(S6k) and a decrease in mucosal resistance (reflecting increased permeability), the latter of which was reversed by Arg.	Sirolimus	21-25	ribosomal protein S6 kinase B1	Homo sapiens	67-70
18156399-12	2008	We conclude that, early in rotavirus enteritis, Arg has no impact on diarrhea but augments intestinal protein synthesis in part by p70(S6k) stimulation, while improving intestinal permeability via a mammalian target of rapamycin/p70(S6k)-independent mechanism.	Arginine	48-51	ribosomal protein S6 kinase B1	Homo sapiens	135-138
18156399-12	2008	We conclude that, early in rotavirus enteritis, Arg has no impact on diarrhea but augments intestinal protein synthesis in part by p70(S6k) stimulation, while improving intestinal permeability via a mammalian target of rapamycin/p70(S6k)-independent mechanism.	Arginine	48-51	ribosomal protein S6 kinase B1	Homo sapiens	131-138
18326039-1	2008	S6K1 is a member of the AGC subfamily of serine-threonine protein kinases, whereby catalytic activation requires dual phosphorylation of critical residues in the conserved T-loop (Thr-229) and hydrophobic motif (Thr-389).	Threonine	180-183	ribosomal protein S6 kinase B1	Homo sapiens	0-4
18326039-1	2008	S6K1 is a member of the AGC subfamily of serine-threonine protein kinases, whereby catalytic activation requires dual phosphorylation of critical residues in the conserved T-loop (Thr-229) and hydrophobic motif (Thr-389).	Threonine	212-215	ribosomal protein S6 kinase B1	Homo sapiens	0-4
17980619-2	2008	In addition to its kinase domain, S6K1 contains a C-terminal autoinhibitory domain (AID; residues 399-502), which prevents T-loop and HM phosphorylation; and autoinhibition is relieved on multi-site Ser-Thr phosphorylation of the AID (S411, S418, T421, and S424).	Serine	199-202	ribosomal protein S6 kinase B1	Homo sapiens	34-38
17980619-2	2008	In addition to its kinase domain, S6K1 contains a C-terminal autoinhibitory domain (AID; residues 399-502), which prevents T-loop and HM phosphorylation; and autoinhibition is relieved on multi-site Ser-Thr phosphorylation of the AID (S411, S418, T421, and S424).	Threonine	203-206	ribosomal protein S6 kinase B1	Homo sapiens	34-38
17993646-2	2008	Signaling through the mammalian target of rapamycin (mTOR) has been found to impact insulin sensitivity under various pathological conditions, through serine phosphorylation and inhibition of insulin receptor substrate by the downstream effector of mTOR, ribosomal S6 kinase 1 (S6K1).	Serine	151-157	ribosomal protein S6 kinase B1	Homo sapiens	278-282
17874120-1	2008	The purpose of the present study was to investigate the possible relationship between a change in Thr(389) phosphorylation of p70S6 kinase (p70(S6k)) after a single resistance training session and an increase in skeletal muscle mass following short-term resistance training.	Threonine	98-101	ribosomal protein S6 kinase B1	Homo sapiens	140-147
18094094-7	2008	The observation that the TSC1/TSC2 functions as a negative regulator of the mammalian target of rapamycin (mTOR)/p70 S6 kinase (S6K1) signaling pathway yielded the first rapamycin clinical trial for LAM.	Sirolimus	96-105	ribosomal protein S6 kinase B1	Homo sapiens	128-132
17908691-4	2007	Here, we show that rapamycin activates Akt and induces contractile protein expression in human VSMC in an insulin-like growth factor I-dependent manner, by relieving S6K1-dependent negative regulation of insulin receptor substrate-1 (IRS-1).	Sirolimus	19-28	ribosomal protein S6 kinase B1	Homo sapiens	166-170
17908691-7	2007	Rapamycin inhibits S6K1-dependent IRS-1 serine phosphorylation, increases IRS-1 protein levels, and promotes association of tyrosine-phosphorylated IRS-1 with PI3K.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	19-23
17908691-7	2007	Rapamycin inhibits S6K1-dependent IRS-1 serine phosphorylation, increases IRS-1 protein levels, and promotes association of tyrosine-phosphorylated IRS-1 with PI3K.	Serine	40-46	ribosomal protein S6 kinase B1	Homo sapiens	19-23
17908691-7	2007	Rapamycin inhibits S6K1-dependent IRS-1 serine phosphorylation, increases IRS-1 protein levels, and promotes association of tyrosine-phosphorylated IRS-1 with PI3K.	Tyrosine	124-132	ribosomal protein S6 kinase B1	Homo sapiens	19-23
17908691-8	2007	A rapamycin-resistant S6K1 mutant prevents rapamycin-induced Akt activation and VSMC differentiation.	Sirolimus	2-11	ribosomal protein S6 kinase B1	Homo sapiens	22-26
17919812-5	2007	The underlying mechanism of inhibition of HIF-1alpha expression by resveratrol seems to be associated with both inactivation of p42/p44 MAPK and p70S6K, as well as enhanced degradation of HIF-1alpha protein, resulting in profound decrease in VEGF expression and cell migration.	Resveratrol	67-78	ribosomal protein S6 kinase B1	Homo sapiens	145-151
18031600-8	2007	SF prevented the glutamate-induced decrease in the activity of the PI3K/Akt/p70S6K and the MEK/ERK1/2 pathways.	Glutamic Acid	17-26	ribosomal protein S6 kinase B1	Homo sapiens	76-82
17976640-4	2007	All agonist treatments resulted in S2248 phosphorylation of mTOR and T389 and S421/T424 phosphorylation of S6K1, however only ET-1 and TPA-stimulated mTOR/S6K1 activation was abolished with infection of a dominant negative adenoviral c-Raf (DN-Raf) construct.	Tetradecanoylphorbol Acetate	135-138	ribosomal protein S6 kinase B1	Homo sapiens	107-111
17976640-4	2007	All agonist treatments resulted in S2248 phosphorylation of mTOR and T389 and S421/T424 phosphorylation of S6K1, however only ET-1 and TPA-stimulated mTOR/S6K1 activation was abolished with infection of a dominant negative adenoviral c-Raf (DN-Raf) construct.	Tetradecanoylphorbol Acetate	135-138	ribosomal protein S6 kinase B1	Homo sapiens	155-159
17976640-6	2007	Expression of DN-PKC(delta) or pretreatment of cardiomyocytes with rottlerin, a PKC(delta) specific inhibitor, blocked both ET-1 and insulin stimulated mTOR S2448 and S6K1 T389 phosphorylation.	rottlerin	67-76	ribosomal protein S6 kinase B1	Homo sapiens	167-171
17575014-8	2007	Inhibition of the mammalian target of rapamycin (mTOR) pathway by rapamycin not only inhibited the phosphorylation of p70(S6K) and the expression of cell cycle regulatory proteins but also reduced accumulation of &gt; or =4N cells and BrdU incorporation of &gt;4N cells.	Sirolimus	38-47	ribosomal protein S6 kinase B1	Homo sapiens	118-121
17698034-8	2007	Metformin treatment of the hepatocytes resulted in activation of the AMP-activated kinase, attenuation of the mTOR/S6K1 pathway, reduction of IRS-1 phosphorylation, and a leftward shift in the insulin dose-response curve for PKB activation.	Metformin	0-9	ribosomal protein S6 kinase B1	Homo sapiens	115-119
17698034-9	2007	These data suggest a link between an oversupply of fatty acid to hepatocytes, a disproportionate stimulation of mTOR/S6K1, and resistance to insulin.	Fatty Acids	51-61	ribosomal protein S6 kinase B1	Homo sapiens	117-121
17669398-6	2007	Troglitazone, which has previously been shown to activate AMPK, similarly inhibited MM cell growth, activated AMPK, and decreased ERK and P70S6K phosphorylation.	Troglitazone	0-12	ribosomal protein S6 kinase B1	Homo sapiens	138-144
17624310-0	2007	D-glucosamine inhibits proliferation of human cancer cells through inhibition of p70S6K.	Glucosamine	0-13	ribosomal protein S6 kinase B1	Homo sapiens	81-87
17624310-3	2007	In the present study, we found D-glucosamine inhibited the activity of p70S6K and the proliferation of DU145 prostate cancer cells and MDA-MB-231 breast cancer cells.	Glucosamine	31-44	ribosomal protein S6 kinase B1	Homo sapiens	71-77
17624310-4	2007	D-glucosamine decreased phosphorylation of p70S6K, and its downstream substrates RPS6, and eIF-4B, but not mTOR and 4EBP1 in DU145 cells, suggesting that D-glucosamine induced inhibition of p70S6K is not through the inhibition of mTOR.	Glucosamine	0-13	ribosomal protein S6 kinase B1	Homo sapiens	43-49
17624310-4	2007	D-glucosamine decreased phosphorylation of p70S6K, and its downstream substrates RPS6, and eIF-4B, but not mTOR and 4EBP1 in DU145 cells, suggesting that D-glucosamine induced inhibition of p70S6K is not through the inhibition of mTOR.	Glucosamine	0-13	ribosomal protein S6 kinase B1	Homo sapiens	190-196
17624310-4	2007	D-glucosamine decreased phosphorylation of p70S6K, and its downstream substrates RPS6, and eIF-4B, but not mTOR and 4EBP1 in DU145 cells, suggesting that D-glucosamine induced inhibition of p70S6K is not through the inhibition of mTOR.	Glucosamine	154-167	ribosomal protein S6 kinase B1	Homo sapiens	43-49
17624310-4	2007	D-glucosamine decreased phosphorylation of p70S6K, and its downstream substrates RPS6, and eIF-4B, but not mTOR and 4EBP1 in DU145 cells, suggesting that D-glucosamine induced inhibition of p70S6K is not through the inhibition of mTOR.	Glucosamine	154-167	ribosomal protein S6 kinase B1	Homo sapiens	190-196
17624310-6	2007	These findings suggest that D-glucosamine can inhibit growth of cancer cells through dephosphorylation of p70S6K.	Glucosamine	28-41	ribosomal protein S6 kinase B1	Homo sapiens	106-112
17488244-7	2007	Exercise led to a five- to eightfold increase in Ser(424)/Thr(421) phosphorylation of p70(S6k) up to 30 min after exercise, but no change in Thr(389) phosphorylation.	Serine	49-52	ribosomal protein S6 kinase B1	Homo sapiens	86-93
17488244-7	2007	Exercise led to a five- to eightfold increase in Ser(424)/Thr(421) phosphorylation of p70(S6k) up to 30 min after exercise, but no change in Thr(389) phosphorylation.	Threonine	58-61	ribosomal protein S6 kinase B1	Homo sapiens	86-93
17827708-6	2007	In the obesity-induced insulin resistant condition, JNK and p70S6K are activated and phosphorylate IRS-proteins, which diminishes the insulin-induced tyrosine phosphorylation of IRS-proteins and thereby impairs the PI 3-kinase/AKT activations.	Tyrosine	150-158	ribosomal protein S6 kinase B1	Homo sapiens	60-66
17804710-5	2007	We show that the in vivo proliferative response to chronic TSHR stimulation relies heavily on the activation of the mTOR/S6K1 axis, and that mTOR inhibition during goitrogenic stimulation abrogates the hyperplastic but not the hypertrophic thyrocyte responses to TSH, thus functionally uncoupling these two processes.	Thyrotropin	59-62	ribosomal protein S6 kinase B1	Homo sapiens	121-125
17668885-0	2007	Identification of a novel class of dithiolethiones that prevent hepatic insulin resistance via the adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway.	dithiolethiones	35-50	ribosomal protein S6 kinase B1	Homo sapiens	162-173
17668885-8	2007	Oltipraz treatment inhibited the ability of TNF-alpha to activate p70 ribosomal S6 kinase-1 (S6K1) downstream of mammalian target of rapamycin, thus preventing insulin receptor substrate-1 serine phosphorylation and protecting insulin signals.	oltipraz	0-8	ribosomal protein S6 kinase B1	Homo sapiens	80-97
17668885-8	2007	Oltipraz treatment inhibited the ability of TNF-alpha to activate p70 ribosomal S6 kinase-1 (S6K1) downstream of mammalian target of rapamycin, thus preventing insulin receptor substrate-1 serine phosphorylation and protecting insulin signals.	Serine	189-195	ribosomal protein S6 kinase B1	Homo sapiens	80-97
17668885-9	2007	Moreover, oltipraz activated AMP-activated protein kinase (AMPK), whose inhibition by a dominant negative mutant abolished S6K1 inhibition and protected insulin signaling, indicating that AMPK activation leads to S6K1 inhibition.	oltipraz	10-18	ribosomal protein S6 kinase B1	Homo sapiens	123-127
17668885-9	2007	Moreover, oltipraz activated AMP-activated protein kinase (AMPK), whose inhibition by a dominant negative mutant abolished S6K1 inhibition and protected insulin signaling, indicating that AMPK activation leads to S6K1 inhibition.	oltipraz	10-18	ribosomal protein S6 kinase B1	Homo sapiens	213-217
17334390-1	2007	Rapamycin, a natural product inhibitor of the Raptor-mammalian target of rapamycin complex (mTORC1), is known to induce Protein kinase B (Akt/PKB) Ser-473 phosphorylation in a subset of human cancer cell lines through inactivation of S6K1, stabilization of insulin receptor substrate (IRS)-1, and increased signaling through the insulin/insulin-like growth factor-I/phosphatidylinositol 3-kinase (PI3K) axis.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	234-238
17699852-5	2007	As a known PDK-1 inhibitor, OSU-03012 inhibited the PI3K/Akt pathway with downstream effects on BAD, GSK-3beta, FoxO1a, p70S6K, and MDM-2.	OSU 03012	28-37	ribosomal protein S6 kinase B1	Homo sapiens	120-126
17494629-6	2007	S6K deletion in muscle mimics the effect of the mTOR inhibitor rapamycin on rpS6 and eIF4B phosphorylation without affecting eEF2 phosphorylation.	Sirolimus	63-72	ribosomal protein S6 kinase B1	Homo sapiens	0-3
17427199-8	2007	Moreover, we found in MAPK inhibited cultures and in uPAR silencing cells that p70S6K phosphorylation on residue Thr-389 was significantly reduced, whereas Ser-421/Thr-424 phosphorylation did not change.	Threonine	113-116	ribosomal protein S6 kinase B1	Homo sapiens	79-85
17908691-3	2007	We have previously reported that rapamycin promotes VSMC differentiation by inhibiting the mammalian target of rapamycin (mTOR) target S6K1.	Sirolimus	33-42	ribosomal protein S6 kinase B1	Homo sapiens	135-139
17936702-4	2007	Growth factor stimulation induces disassembly of URI/PP1gamma complexes through S6K1-mediated phosphorylation of URI at serine 371.	Serine	120-126	ribosomal protein S6 kinase B1	Homo sapiens	80-84
17825298-0	2007	mTOR is the rapamycin-sensitive kinase that confers mechanically-induced phosphorylation of the hydrophobic motif site Thr(389) in p70(S6k).	Threonine	119-122	ribosomal protein S6 kinase B1	Homo sapiens	135-138
17825298-1	2007	Mechanical stretch induces phosphorylation of the hydrophobic motif site Thr(389) in p70(S6k) through a rapamycin-sensitive (RS) pathway that involves a unique PI3K-independent mechanism.	Threonine	73-76	ribosomal protein S6 kinase B1	Homo sapiens	89-92
17668885-13	2007	CONCLUSION: Our findings led to the identification of dithiolethione compounds that prevent insulin resistance through a mechanism involving AMPK-mediated S6K1 inhibition and thereby sensitize hepatic insulin response.	dithiolethione	54-68	ribosomal protein S6 kinase B1	Homo sapiens	155-159
17709744-0	2007	Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance.	Serine	24-27	ribosomal protein S6 kinase B1	Homo sapiens	48-52
17709744-4	2007	Here we show that S6K1 directly phosphorylates IRS-1 Ser-1101 in vitro in the C-terminal domain of the protein and that mutation of this site largely blocks the ability of amino acids to suppress IRS-1 tyrosine and Akt phosphorylation.	Serine	53-56	ribosomal protein S6 kinase B1	Homo sapiens	18-22
17709744-4	2007	Here we show that S6K1 directly phosphorylates IRS-1 Ser-1101 in vitro in the C-terminal domain of the protein and that mutation of this site largely blocks the ability of amino acids to suppress IRS-1 tyrosine and Akt phosphorylation.	Tyrosine	202-210	ribosomal protein S6 kinase B1	Homo sapiens	18-22
17505052-5	2007	Although the ability of mTOR to respond to insulin-like growth factor (IGF)-I is not disrupted by sepsis, the ability of leucine to increase 4E-BP1 and S6K1 phosphorylation is greatly attenuated.	Leucine	121-128	ribosomal protein S6 kinase B1	Homo sapiens	152-156
17660033-1	2007	BACKGROUND: Inhibition of P70S6 kinase (P70(S6K)) phosphorylation in activated T cells is 1 of the major mechanisms by which rapamycin exerts its immunosuppressive action.	Sirolimus	125-134	ribosomal protein S6 kinase B1	Homo sapiens	26-29
17660033-5	2007	OUTCOMES &amp; MEASUREMENTS: Basal and stimulated phosphorylation of P70(S6K) was measured by using Western blotting in patients" peripheral-blood mononuclear cells before and 6 to 11 months after conversion to rapamycin-based therapy.	Adenosine Monophosphate	10-13	ribosomal protein S6 kinase B1	Homo sapiens	69-72
17660033-5	2007	OUTCOMES &amp; MEASUREMENTS: Basal and stimulated phosphorylation of P70(S6K) was measured by using Western blotting in patients" peripheral-blood mononuclear cells before and 6 to 11 months after conversion to rapamycin-based therapy.	Sirolimus	211-220	ribosomal protein S6 kinase B1	Homo sapiens	69-72
17660033-7	2007	RESULTS: The potency of rapamycin inhibition of P70(S6K) phosphorylation varied among patients (RAPA blood concentration required to achieve 50% inhibition of P70(S6K) activation for mitogen-activated kinase, 3.14 to 12.14 ng/mL) and failed to correlate with drug trough levels.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	48-51
17660033-7	2007	RESULTS: The potency of rapamycin inhibition of P70(S6K) phosphorylation varied among patients (RAPA blood concentration required to achieve 50% inhibition of P70(S6K) activation for mitogen-activated kinase, 3.14 to 12.14 ng/mL) and failed to correlate with drug trough levels.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	159-162
17660033-8	2007	The combination of tacrolimus and rapamycin limited the inhibitory effect of the latter drug on P70(S6K) activation.	Tacrolimus	19-29	ribosomal protein S6 kinase B1	Homo sapiens	96-99
17660033-8	2007	The combination of tacrolimus and rapamycin limited the inhibitory effect of the latter drug on P70(S6K) activation.	Sirolimus	34-43	ribosomal protein S6 kinase B1	Homo sapiens	96-99
17660033-11	2007	CONCLUSIONS: Long-term rapamycin treatment inhibits P70(S6K) phosphorylation in peripheral-blood mononuclear cells without significant correlation with rapamycin trough levels.	Sirolimus	23-32	ribosomal protein S6 kinase B1	Homo sapiens	52-55
17510244-4	2007	The increase in p70S6K phosphorylation by FSH treatment was abolished by prior exposure to DHT, suggesting that DHT inhibits FSH-mediated activation of mTOR signaling in cultured granulosa cells.	Dihydrotestosterone	91-94	ribosomal protein S6 kinase B1	Homo sapiens	16-22
17510244-4	2007	The increase in p70S6K phosphorylation by FSH treatment was abolished by prior exposure to DHT, suggesting that DHT inhibits FSH-mediated activation of mTOR signaling in cultured granulosa cells.	Dihydrotestosterone	112-115	ribosomal protein S6 kinase B1	Homo sapiens	16-22
17510244-7	2007	These results indicate that reduced p70S6K phosphorylation observed in DHT-treated cells might be the result of reduced TSC2 phosphorylation.	Dihydrotestosterone	71-74	ribosomal protein S6 kinase B1	Homo sapiens	36-42
17634259-1	2007	Our objective was to determine the impact of carbohydrate and/or protein ingestion before and after exercise on ribosomal protein S6 kinase (S6K1) and S6 phosphorylation status in human skeletal muscle tissue.	Carbohydrates	45-57	ribosomal protein S6 kinase B1	Homo sapiens	141-145
17634259-8	2007	In contrast to the CHO treatment (-4 +/- 2%), S6K1 phosphorylation at T(389) was higher following exercise in the CHO+PRO treatment only (+78 +/- 2%, P &lt; 0.01).	cho+pro	114-121	ribosomal protein S6 kinase B1	Homo sapiens	46-50
17634259-9	2007	During recovery, S6K1 phosphorylation at T(389) remained higher in CHO+PRO than in CHO (P &lt; 0.05).	CAV protocol	67-70	ribosomal protein S6 kinase B1	Homo sapiens	17-21
17634259-9	2007	During recovery, S6K1 phosphorylation at T(389) remained higher in CHO+PRO than in CHO (P &lt; 0.05).	Proline	71-74	ribosomal protein S6 kinase B1	Homo sapiens	17-21
17634259-9	2007	During recovery, S6K1 phosphorylation at T(389) remained higher in CHO+PRO than in CHO (P &lt; 0.05).	CAV protocol	83-86	ribosomal protein S6 kinase B1	Homo sapiens	17-21
17517883-2	2007	The binding of S6K1 and 4E-BP1 to raptor requires a TOR signaling (TOS) motif, which contains an essential Phe followed by four alternating acidic and small hydrophobic amino acids.	Phenylalanine	107-110	ribosomal protein S6 kinase B1	Homo sapiens	15-30
17517883-8	2007	Overexpressed PRAS40 suppressed the phosphorylation of S6K1 and 4E-BP1 at their rapamycin-sensitive phosphorylation sites, and reciprocally, overexpression of S6K1 or 4E-BP1 suppressed phosphorylation of PRAS40 (Ser(183)) and its binding to raptor.	Sirolimus	80-89	ribosomal protein S6 kinase B1	Homo sapiens	55-70
17517883-8	2007	Overexpressed PRAS40 suppressed the phosphorylation of S6K1 and 4E-BP1 at their rapamycin-sensitive phosphorylation sites, and reciprocally, overexpression of S6K1 or 4E-BP1 suppressed phosphorylation of PRAS40 (Ser(183)) and its binding to raptor.	Sirolimus	80-89	ribosomal protein S6 kinase B1	Homo sapiens	159-173
17517883-8	2007	Overexpressed PRAS40 suppressed the phosphorylation of S6K1 and 4E-BP1 at their rapamycin-sensitive phosphorylation sites, and reciprocally, overexpression of S6K1 or 4E-BP1 suppressed phosphorylation of PRAS40 (Ser(183)) and its binding to raptor.	Serine	212-215	ribosomal protein S6 kinase B1	Homo sapiens	55-70
17517883-8	2007	Overexpressed PRAS40 suppressed the phosphorylation of S6K1 and 4E-BP1 at their rapamycin-sensitive phosphorylation sites, and reciprocally, overexpression of S6K1 or 4E-BP1 suppressed phosphorylation of PRAS40 (Ser(183)) and its binding to raptor.	Serine	212-215	ribosomal protein S6 kinase B1	Homo sapiens	159-173
17568186-7	2007	Interestingly, cisplatin virtually abolished phosphorylation of p70S6K and 4EBP1 in CGC cells, while phosphorylation was maintained in cisplatin-treated AFPGC cells.	Cisplatin	15-24	ribosomal protein S6 kinase B1	Homo sapiens	64-80
17618850-2	2007	A recent report in Molecular Cell (Urban et al., 2007) now extends this conservation to include Sch9, an AGC protein kinase family member from S. cerevisiae, which appears to be the long sought after yeast ortholog of mammalian S6 kinase 1 (S6K1) and a direct target for the rapamycin-sensitive TOR complex I.	Sirolimus	275-284	ribosomal protein S6 kinase B1	Homo sapiens	228-239
17550782-2	2007	Here we show that S6K-deficient skeletal muscle cells have increased AMP and inorganic phosphate levels relative to ATP and phosphocreatine, causing AMP-activated protein kinase (AMPK) upregulation.	Adenosine Monophosphate	69-72	ribosomal protein S6 kinase B1	Homo sapiens	18-21
17550782-2	2007	Here we show that S6K-deficient skeletal muscle cells have increased AMP and inorganic phosphate levels relative to ATP and phosphocreatine, causing AMP-activated protein kinase (AMPK) upregulation.	Phosphates	77-96	ribosomal protein S6 kinase B1	Homo sapiens	18-21
17550782-2	2007	Here we show that S6K-deficient skeletal muscle cells have increased AMP and inorganic phosphate levels relative to ATP and phosphocreatine, causing AMP-activated protein kinase (AMPK) upregulation.	Adenosine Triphosphate	116-119	ribosomal protein S6 kinase B1	Homo sapiens	18-21
17550782-2	2007	Here we show that S6K-deficient skeletal muscle cells have increased AMP and inorganic phosphate levels relative to ATP and phosphocreatine, causing AMP-activated protein kinase (AMPK) upregulation.	Phosphocreatine	124-139	ribosomal protein S6 kinase B1	Homo sapiens	18-21
17550782-4	2007	Two known AMPK-dependent functions, mitochondrial biogenesis and fatty acid beta-oxidation, are upregulated in S6K-deficient muscle cells, leading to a sharp depletion of lipid content, while glycogen stores are spared.	Fatty Acids	65-75	ribosomal protein S6 kinase B1	Homo sapiens	111-114
17550782-4	2007	Two known AMPK-dependent functions, mitochondrial biogenesis and fatty acid beta-oxidation, are upregulated in S6K-deficient muscle cells, leading to a sharp depletion of lipid content, while glycogen stores are spared.	Glycogen	192-200	ribosomal protein S6 kinase B1	Homo sapiens	111-114
17329620-11	2007	Rapamycin partially inhibited this increase in mTOR-mediated S6K phosphorylation and IRS-1 Ser312 and Ser636 phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	61-64
17408801-8	2007	IRS-4 down-regulation abolished IGF-I-, TPA- and IGF-I plus TPA-stimulated ERK and p70S6K activities.	Tetradecanoylphorbol Acetate	40-43	ribosomal protein S6 kinase B1	Homo sapiens	83-89
17408801-8	2007	IRS-4 down-regulation abolished IGF-I-, TPA- and IGF-I plus TPA-stimulated ERK and p70S6K activities.	Tetradecanoylphorbol Acetate	60-63	ribosomal protein S6 kinase B1	Homo sapiens	83-89
17383120-0	2007	Phosphatidylinositol-3 kinase/Akt/p70S6K/AP-1 signaling pathway mediated benzo(a)pyrene-induced cell cycle alternation via cell cycle regulatory proteins in human embryo lung fibroblasts.	pyrene	81-87	ribosomal protein S6 kinase B1	Homo sapiens	34-40
17452018-2	2007	mTOR exists in two complexes: mTOR Complex1, which is rapamycin-sensitive and phosphorylates S6K1 and initiation factor 4E binding proteins (4E-BPs), and mTOR Complex2, which is rapamycin-insensitive and phosphorylates protein kinase B (PKB, also known as Akt).	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	93-97
17446865-3	2007	We investigated the role of the third, so-called turn motif phosphate, also located in the tail, in the AGC kinases PKB, S6K, RSK, MSK, PRK and PKC.	Phosphates	60-69	ribosomal protein S6 kinase B1	Homo sapiens	121-124
17446865-6	2007	In S6K and MSK, the turn motif phosphate thereby also protects the HM from dephosphorylation.	Phosphates	31-40	ribosomal protein S6 kinase B1	Homo sapiens	3-6
17287212-4	2007	Forced activation of AMPK by AICAR, phenformin, or oligomycin significantly blocked phosphorylation of p70S6K, a downstream target of mTOR, in response to the combination of glucose and amino acids.	AICA ribonucleotide	29-34	ribosomal protein S6 kinase B1	Homo sapiens	103-109
17287212-4	2007	Forced activation of AMPK by AICAR, phenformin, or oligomycin significantly blocked phosphorylation of p70S6K, a downstream target of mTOR, in response to the combination of glucose and amino acids.	Phenformin	36-46	ribosomal protein S6 kinase B1	Homo sapiens	103-109
17287212-4	2007	Forced activation of AMPK by AICAR, phenformin, or oligomycin significantly blocked phosphorylation of p70S6K, a downstream target of mTOR, in response to the combination of glucose and amino acids.	Oligomycins	51-61	ribosomal protein S6 kinase B1	Homo sapiens	103-109
17287212-4	2007	Forced activation of AMPK by AICAR, phenformin, or oligomycin significantly blocked phosphorylation of p70S6K, a downstream target of mTOR, in response to the combination of glucose and amino acids.	Glucose	174-181	ribosomal protein S6 kinase B1	Homo sapiens	103-109
17383120-6	2007	Moreover, pretreatment of cells with rapamycin, a specific p70(S6K) inhibitor, inhibited B(a)P-induced AP-1 activation, cell cycle alteration and phosphorylation of p70(S6K), but had no effect on Akt phosphorylation.	Sirolimus	37-46	ribosomal protein S6 kinase B1	Homo sapiens	63-66
17383120-6	2007	Moreover, pretreatment of cells with rapamycin, a specific p70(S6K) inhibitor, inhibited B(a)P-induced AP-1 activation, cell cycle alteration and phosphorylation of p70(S6K), but had no effect on Akt phosphorylation.	Sirolimus	37-46	ribosomal protein S6 kinase B1	Homo sapiens	59-62
17291499-0	2007	Chronic alcohol consumption alters mammalian target of rapamycin (mTOR), reduces ribosomal p70s6 kinase and p4E-BP1 levels in mouse cerebral cortex.	Alcohols	8-15	ribosomal protein S6 kinase B1	Homo sapiens	91-103
17371247-2	2007	This finding gave rise to the question of the mechanism by which nutrients, such as AAs (amino acids), enter the mTOR (mammalian target of rapamycin)/S6K1 signalling pathway.	Amino Acids	84-87	ribosomal protein S6 kinase B1	Homo sapiens	150-154
17220300-2	2007	Activation of S6K1 involves the phosphorylation of its multiple Ser/Thr residues, including the proline-directed sites (Ser-411, Ser-418, Thr-421, and Ser-424) in the autoinhibitory domain near the C terminus.	Serine	64-67	ribosomal protein S6 kinase B1	Homo sapiens	14-18
17242159-9	2007	This finding indicates that PA binds to and activates p70S6K, even in the absence of mTOR.	Phosphatidic Acids	28-30	ribosomal protein S6 kinase B1	Homo sapiens	54-60
17220300-2	2007	Activation of S6K1 involves the phosphorylation of its multiple Ser/Thr residues, including the proline-directed sites (Ser-411, Ser-418, Thr-421, and Ser-424) in the autoinhibitory domain near the C terminus.	Threonine	68-71	ribosomal protein S6 kinase B1	Homo sapiens	14-18
17220300-2	2007	Activation of S6K1 involves the phosphorylation of its multiple Ser/Thr residues, including the proline-directed sites (Ser-411, Ser-418, Thr-421, and Ser-424) in the autoinhibitory domain near the C terminus.	Serine	120-123	ribosomal protein S6 kinase B1	Homo sapiens	14-18
17220300-2	2007	Activation of S6K1 involves the phosphorylation of its multiple Ser/Thr residues, including the proline-directed sites (Ser-411, Ser-418, Thr-421, and Ser-424) in the autoinhibitory domain near the C terminus.	Proline	96-103	ribosomal protein S6 kinase B1	Homo sapiens	14-18
17220300-2	2007	Activation of S6K1 involves the phosphorylation of its multiple Ser/Thr residues, including the proline-directed sites (Ser-411, Ser-418, Thr-421, and Ser-424) in the autoinhibitory domain near the C terminus.	Serine	120-123	ribosomal protein S6 kinase B1	Homo sapiens	14-18
17220300-2	2007	Activation of S6K1 involves the phosphorylation of its multiple Ser/Thr residues, including the proline-directed sites (Ser-411, Ser-418, Thr-421, and Ser-424) in the autoinhibitory domain near the C terminus.	Threonine	138-141	ribosomal protein S6 kinase B1	Homo sapiens	14-18
17187762-5	2007	Calcium also decreased the level of phosphorylated p70-S6 kinase (S6K), a kinase known to inhibit EF2K.	Calcium	0-7	ribosomal protein S6 kinase B1	Homo sapiens	51-64
17220300-2	2007	Activation of S6K1 involves the phosphorylation of its multiple Ser/Thr residues, including the proline-directed sites (Ser-411, Ser-418, Thr-421, and Ser-424) in the autoinhibitory domain near the C terminus.	Serine	120-123	ribosomal protein S6 kinase B1	Homo sapiens	14-18
17220300-3	2007	Phosphorylation at Thr-389 is also a crucial event in S6K1 activation.	Threonine	19-22	ribosomal protein S6 kinase B1	Homo sapiens	54-58
17220300-4	2007	Here, we report that S6K1 phosphorylation at Ser-411 is required for the rapamycin-sensitive phosphorylation of Thr-389 and the subsequent activation of S6K1.	Serine	45-48	ribosomal protein S6 kinase B1	Homo sapiens	21-25
17220300-4	2007	Here, we report that S6K1 phosphorylation at Ser-411 is required for the rapamycin-sensitive phosphorylation of Thr-389 and the subsequent activation of S6K1.	Serine	45-48	ribosomal protein S6 kinase B1	Homo sapiens	153-157
17220300-4	2007	Here, we report that S6K1 phosphorylation at Ser-411 is required for the rapamycin-sensitive phosphorylation of Thr-389 and the subsequent activation of S6K1.	Threonine	112-115	ribosomal protein S6 kinase B1	Homo sapiens	21-25
17220300-4	2007	Here, we report that S6K1 phosphorylation at Ser-411 is required for the rapamycin-sensitive phosphorylation of Thr-389 and the subsequent activation of S6K1.	Threonine	112-115	ribosomal protein S6 kinase B1	Homo sapiens	153-157
17220300-5	2007	Mutation of Ser-411 to Ala ablated insulin-induced Thr-389 phosphorylation and S6K1 activation, whereas mutation mimicking Ser-411 phosphorylation did not show any effect.	Serine	12-15	ribosomal protein S6 kinase B1	Homo sapiens	79-83
17220300-7	2007	Thus, Ser-411 phosphorylation regulates S6K1 activation via the control of Thr-389 phosphorylation.	Serine	6-9	ribosomal protein S6 kinase B1	Homo sapiens	40-44
17220300-7	2007	Thus, Ser-411 phosphorylation regulates S6K1 activation via the control of Thr-389 phosphorylation.	Threonine	75-78	ribosomal protein S6 kinase B1	Homo sapiens	40-44
17220300-8	2007	In nervous system neurons, Cdk5-p35 kinase associates with S6K1 via the direct interaction between p35 and S6K1 and catalyzes S6K1 phosphorylation specifically at Ser-411.	Serine	163-166	ribosomal protein S6 kinase B1	Homo sapiens	59-63
17220300-8	2007	In nervous system neurons, Cdk5-p35 kinase associates with S6K1 via the direct interaction between p35 and S6K1 and catalyzes S6K1 phosphorylation specifically at Ser-411.	Serine	163-166	ribosomal protein S6 kinase B1	Homo sapiens	107-111
17220300-8	2007	In nervous system neurons, Cdk5-p35 kinase associates with S6K1 via the direct interaction between p35 and S6K1 and catalyzes S6K1 phosphorylation specifically at Ser-411.	Serine	163-166	ribosomal protein S6 kinase B1	Homo sapiens	107-111
17220300-9	2007	Inhibition of the Cdk5 activity or suppression of Cdk5 expression blocked S6K1 phosphorylation at Ser-411 and Thr-389, resulting in S6K1 inactivation.	Serine	98-101	ribosomal protein S6 kinase B1	Homo sapiens	74-78
17220300-9	2007	Inhibition of the Cdk5 activity or suppression of Cdk5 expression blocked S6K1 phosphorylation at Ser-411 and Thr-389, resulting in S6K1 inactivation.	Serine	98-101	ribosomal protein S6 kinase B1	Homo sapiens	132-136
17220300-9	2007	Inhibition of the Cdk5 activity or suppression of Cdk5 expression blocked S6K1 phosphorylation at Ser-411 and Thr-389, resulting in S6K1 inactivation.	Threonine	110-113	ribosomal protein S6 kinase B1	Homo sapiens	132-136
17336708-3	2007	METHODS: We measured basal and in vivo stimulated AKT and P70 S6 kinase (P70(S6K)) phosphorylation in PBMCs from 37 cyclosporine A-treated patients, 10 of whom had Kaposi sarcoma, before and 6 months after conversion to rapamycin therapy.	Cyclosporine	116-130	ribosomal protein S6 kinase B1	Homo sapiens	58-61
17336708-5	2007	Long-term treatment with rapamycin was associated with marked inhibition of basal and stimulated phosphorylation of both AKT and P70(S6K), in parallel with regression of the dermal neoplasm.	Sirolimus	25-34	ribosomal protein S6 kinase B1	Homo sapiens	129-132
17336708-7	2007	Thus, monitoring P70(S6K) phosphorylation can help predict and monitor the biological effectiveness of rapamycin in renal transplant recipients with Kaposi sarcoma and possibly adjust the biologically active doses of the mTOR inhibitor.	Sirolimus	103-112	ribosomal protein S6 kinase B1	Homo sapiens	17-20
17187762-5	2007	Calcium also decreased the level of phosphorylated p70-S6 kinase (S6K), a kinase known to inhibit EF2K.	Calcium	0-7	ribosomal protein S6 kinase B1	Homo sapiens	66-69
17187762-7	2007	Since phosphorylated eEF2 inhibits mRNA translation, calcium elevation appears to inhibit mRNA translation in growth cones by a synergistic mechanism involving regulation of EF2K, S6K, and eEF2 itself.	Calcium	53-60	ribosomal protein S6 kinase B1	Homo sapiens	180-183
16832347-7	2007	Inhibition of p70S6K expression with small interfering RNA oligonucleotides inhibited cell proliferation greater than 50% in the presence of a combination of PMA and serum.	Oligonucleotides	59-75	ribosomal protein S6 kinase B1	Homo sapiens	14-20
17098211-6	2007	Yet, like insulin, they activated mTOR and induced downstream threonine phosphorylation in p70S6K and 4EBP1.	Threonine	62-71	ribosomal protein S6 kinase B1	Homo sapiens	91-107
17237311-6	2007	Likewise, compared with EC, both ES and EW increased formation of the mRNA cap binding complex eIF4F and stimulated phosphorylation of the translational repressor, 4E-BP1, the 70kD ribosomal protein S6 kinase (S6K1), and the mammalian target of rapamycin (mTOR) kinase at serine 2448.	Einsteinium	33-35	ribosomal protein S6 kinase B1	Homo sapiens	210-214
17237311-6	2007	Likewise, compared with EC, both ES and EW increased formation of the mRNA cap binding complex eIF4F and stimulated phosphorylation of the translational repressor, 4E-BP1, the 70kD ribosomal protein S6 kinase (S6K1), and the mammalian target of rapamycin (mTOR) kinase at serine 2448.	NSC334073	40-42	ribosomal protein S6 kinase B1	Homo sapiens	210-214
16952420-3	2007	Therefore, the effects of insulin and rapamycin (an inhibitor of mTOR) on the phosphorylation of mTOR (Ser 2448) and p70(S6K) (Thr 389) as well as on cell proliferation in parental HepG2 cells and HepG2 cells overexpressing constitutively active Akt/PKB (HepG2-CA-Akt/PKB) were studied.	Sirolimus	38-47	ribosomal protein S6 kinase B1	Homo sapiens	121-124
16962100-0	2007	Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.	Acetaldehyde	0-12	ribosomal protein S6 kinase B1	Homo sapiens	56-59
16962100-10	2007	Interestingly, acetaldehyde enhanced p70(S6K) activation and depressed 4E-BP1 phosphorylation, the effect of which was blunted and exaggerated, respectively, by rapamycin.	Acetaldehyde	15-27	ribosomal protein S6 kinase B1	Homo sapiens	37-40
17074751-2	2006	Dexamethasone, a synthetic glucocorticoid that represses protein synthesis, acts to inhibit mTOR signaling as assessed by reduced phosphorylation of the downstream targets S6K1 and 4E-BP1.	Dexamethasone	0-13	ribosomal protein S6 kinase B1	Homo sapiens	172-187
17597835-8	2007	A TSC2 siRNA induced p70S6K phosphorylation at baseline and inhibited p70S6K downregulation by rosiglitazone.	Rosiglitazone	95-108	ribosomal protein S6 kinase B1	Homo sapiens	70-76
16952420-5	2007	Rapamycin treatment partially decreased the phosphorylation of mTOR but completely abolished the phosphorylation of p70(S6K) in the absence as well as presence of insulin in both cell lines.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	116-119
17534123-9	2007	Interestingly, RSVL inhibits the expression of p70S6K and the phosphorylation of pS6RP.	Resveratrol	15-19	ribosomal protein S6 kinase B1	Homo sapiens	47-53
16995874-5	2006	Interestingly, when ZD6474 was combined with sunitinib (SU11248; Sutent, Pfizer, Kalamazoo, MI, USA), a class III and V receptor tyrosine kinase inhibitor, the ZD6474-mediated growth inhibition was potentiated in association with further down-regulation of the mTOR targets p-p70S6K and p-4E-BP-1.	Sunitinib	45-54	ribosomal protein S6 kinase B1	Homo sapiens	276-282
16995874-5	2006	Interestingly, when ZD6474 was combined with sunitinib (SU11248; Sutent, Pfizer, Kalamazoo, MI, USA), a class III and V receptor tyrosine kinase inhibitor, the ZD6474-mediated growth inhibition was potentiated in association with further down-regulation of the mTOR targets p-p70S6K and p-4E-BP-1.	vandetanib	20-26	ribosomal protein S6 kinase B1	Homo sapiens	276-282
16715128-0	2006	Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	65-80
16979140-3	2006	Specifically, resveratrol inhibited the phosphorylation of Akt, p70 S6K, and S6 ribosomal protein on activation residues.	Resveratrol	14-25	ribosomal protein S6 kinase B1	Homo sapiens	64-71
16715128-7	2006	However, only downregulation of raptor mimicked the effect of rapamycin, inhibiting phosphorylation of S6 kinase 1 (S6K1) and 4E-BP1.	Sirolimus	62-71	ribosomal protein S6 kinase B1	Homo sapiens	103-114
16715128-7	2006	However, only downregulation of raptor mimicked the effect of rapamycin, inhibiting phosphorylation of S6 kinase 1 (S6K1) and 4E-BP1.	Sirolimus	62-71	ribosomal protein S6 kinase B1	Homo sapiens	116-120
16715128-8	2006	Cells infected with an adenovirus expressing constitutively active and rapamycin-resistant mutant of p70 S6K1, but not with an adenovirus expressing wild-type S6K1, or a control virus, conferred to resistance to rapamycin.	Sirolimus	71-80	ribosomal protein S6 kinase B1	Homo sapiens	105-109
16715128-13	2006	Rapamycin inhibits IGF-I-stimulated cell motility, through suppression of both S6K1 and 4E-BP1/eIF4E-signaling pathways, as a consequence of inhibition of mTOR kinase activity.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	79-94
17020909-11	2006	CONCLUSION: In summary, our data suggest that chronic alcohol intake interrupted cardiac contractile function and Akt/mTOR/p70s6k signaling.	Alcohols	54-61	ribosomal protein S6 kinase B1	Homo sapiens	123-129
16919239-5	2006	The activity of mammalian target of rapamycin (mTOR) is essential for phosphorylation of S6K1 and the treatment of dermal fibroblasts with rapamycin, a potent inhibitor of mTOR abolished procollagen I production.	Sirolimus	36-45	ribosomal protein S6 kinase B1	Homo sapiens	89-93
17085645-7	2006	In OVCAR-3 and PC-3 cells, the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin/p70S6K and p42/p44 mitogen-activated protein kinase pathways were required for LPA-induced HIF-1alpha and VEGF expressions, whereas only the phosphoinositide 3-kinase/mammalian target of rapamycin/p70S6K pathway was important in SK-Hep1 cells.	lysophosphatidic acid	170-173	ribosomal protein S6 kinase B1	Homo sapiens	91-97
17085645-7	2006	In OVCAR-3 and PC-3 cells, the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin/p70S6K and p42/p44 mitogen-activated protein kinase pathways were required for LPA-induced HIF-1alpha and VEGF expressions, whereas only the phosphoinositide 3-kinase/mammalian target of rapamycin/p70S6K pathway was important in SK-Hep1 cells.	lysophosphatidic acid	170-173	ribosomal protein S6 kinase B1	Homo sapiens	288-294
17121928-0	2006	Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.	Arsenic Trioxide	69-85	ribosomal protein S6 kinase B1	Homo sapiens	52-65
17121928-3	2006	Our data show that p70S6K is rapidly phosphorylated on Thr(421) and Ser(424) and is activated in an As(2)O(3)-inducible manner.	Threonine	55-58	ribosomal protein S6 kinase B1	Homo sapiens	19-25
17121928-3	2006	Our data show that p70S6K is rapidly phosphorylated on Thr(421) and Ser(424) and is activated in an As(2)O(3)-inducible manner.	Serine	68-71	ribosomal protein S6 kinase B1	Homo sapiens	19-25
17121928-3	2006	Our data show that p70S6K is rapidly phosphorylated on Thr(421) and Ser(424) and is activated in an As(2)O(3)-inducible manner.	Arsenic Trioxide	100-109	ribosomal protein S6 kinase B1	Homo sapiens	19-25
17121928-5	2006	p70S6K subsequently phosphorylates the S6 ribosomal protein on Ser(235)/Ser(236) and Ser(240)/Ser(244) to promote initiation of mRNA translation.	Serine	63-66	ribosomal protein S6 kinase B1	Homo sapiens	0-6
17121928-5	2006	p70S6K subsequently phosphorylates the S6 ribosomal protein on Ser(235)/Ser(236) and Ser(240)/Ser(244) to promote initiation of mRNA translation.	Serine	72-75	ribosomal protein S6 kinase B1	Homo sapiens	0-6
17121928-5	2006	p70S6K subsequently phosphorylates the S6 ribosomal protein on Ser(235)/Ser(236) and Ser(240)/Ser(244) to promote initiation of mRNA translation.	Serine	72-75	ribosomal protein S6 kinase B1	Homo sapiens	0-6
17121928-5	2006	p70S6K subsequently phosphorylates the S6 ribosomal protein on Ser(235)/Ser(236) and Ser(240)/Ser(244) to promote initiation of mRNA translation.	Serine	72-75	ribosomal protein S6 kinase B1	Homo sapiens	0-6
16895915-0	2006	Nuclear export of S6K1 II is regulated by protein kinase CK2 phosphorylation at Ser-17.	Serine	80-83	ribosomal protein S6 kinase B1	Homo sapiens	18-22
16895915-9	2006	The localization of the CK2 phosphorylation site was narrowed down to Ser-17 in S6K1 II.	Serine	70-73	ribosomal protein S6 kinase B1	Homo sapiens	80-84
16895915-12	2006	Treatment of cells with the nuclear export inhibitor leptomycin B revealed that the S17E mutant accumulates in the nucleus to the same extent as S6K1 II wild type.	leptomycin B	53-65	ribosomal protein S6 kinase B1	Homo sapiens	145-149
16895915-15	2006	Taken together, this study establishes a functional link between S6K1 II and CK2 signaling, which involves the regulation of S6K1 II nuclear export by CK2-mediated phosphorylation of Ser-17.	Serine	183-186	ribosomal protein S6 kinase B1	Homo sapiens	65-69
16895915-15	2006	Taken together, this study establishes a functional link between S6K1 II and CK2 signaling, which involves the regulation of S6K1 II nuclear export by CK2-mediated phosphorylation of Ser-17.	Serine	183-186	ribosomal protein S6 kinase B1	Homo sapiens	125-129
16949034-4	2006	Celecoxib increased p38 MAP kinase (p38), p44/42 MAP kinase (ERK), and p70S6 kinase (p70S6K) phosphorylation while leaving JNK activation unaffected.	Celecoxib	0-9	ribosomal protein S6 kinase B1	Homo sapiens	71-83
16949034-4	2006	Celecoxib increased p38 MAP kinase (p38), p44/42 MAP kinase (ERK), and p70S6 kinase (p70S6K) phosphorylation while leaving JNK activation unaffected.	Celecoxib	0-9	ribosomal protein S6 kinase B1	Homo sapiens	85-91
16870609-3	2006	mTORC1 (mTOR complex 1) is rapamycin-sensitive and regulates the rate of protein synthesis in part by phosphorylating two well established effectors, S6K1 (p70 ribosomal S6 kinase 1) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1).	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	150-154
16984396-7	2006	The bipartite region of PDIP46/SKAR interacting with ER comprising residues 274-421 encompasses the docking site for S6K1 within the RRM and two serines phosphorylated by S6K1.	Serine	145-152	ribosomal protein S6 kinase B1	Homo sapiens	117-121
16984396-7	2006	The bipartite region of PDIP46/SKAR interacting with ER comprising residues 274-421 encompasses the docking site for S6K1 within the RRM and two serines phosphorylated by S6K1.	Serine	145-152	ribosomal protein S6 kinase B1	Homo sapiens	171-175
16870609-3	2006	mTORC1 (mTOR complex 1) is rapamycin-sensitive and regulates the rate of protein synthesis in part by phosphorylating two well established effectors, S6K1 (p70 ribosomal S6 kinase 1) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1).	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	170-181
16816403-3	2006	The present experiments were performed to determine whether PGF2alpha stimulates the mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase 1 (S6K1) signaling pathway in steroidogenic luteal cells.	Dinoprost	60-69	ribosomal protein S6 kinase B1	Homo sapiens	153-157
16816403-4	2006	We demonstrate that PGF2alpha treatment results in a timeand concentration-dependent stimulation of the phosphorylation and activation of S6K1.	Dinoprost	20-29	ribosomal protein S6 kinase B1	Homo sapiens	138-142
16816403-5	2006	The stimulation of S6K1 in response to PGF2alpha treatment was abolished by the mTOR inhibitor rapamycin.	Dinoprost	39-48	ribosomal protein S6 kinase B1	Homo sapiens	19-23
16816403-5	2006	The stimulation of S6K1 in response to PGF2alpha treatment was abolished by the mTOR inhibitor rapamycin.	Sirolimus	95-104	ribosomal protein S6 kinase B1	Homo sapiens	19-23
16710051-5	2006	We conclude that mTOR/p70(s6k) signaling is essential to intestinal cell migration, is activated by ARG, involves both nuclear and cytoplasmic events, and may play a role in intestinal repair.	Arginine	100-103	ribosomal protein S6 kinase B1	Homo sapiens	22-29
16914728-0	2006	Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis.	Serine	81-87	ribosomal protein S6 kinase B1	Homo sapiens	66-70
16920842-6	2006	Phosphorylation of mammalian target of rapamycin (mTOR) on Ser(2448) or Ser(2481) or 70-kDa ribosomal protein S6 kinase (S6K1) on Thr(389) was not affected by meal feeding or following removal of food.	Threonine	130-133	ribosomal protein S6 kinase B1	Homo sapiens	121-125
16914728-2	2006	Using two cell culture models of the familial hamartoma syndrome, tuberous sclerosis, we show here that Raptor-mTOR and S6K1 are required for phosphorylation of IRS1 at a subset of serine residues frequently associated with insulin resistance, including S307, S312, S527, S616, and S636 (of human IRS1).	Serine	181-187	ribosomal protein S6 kinase B1	Homo sapiens	120-124
16914728-3	2006	Using loss- and gain-of-function S6K1 constructs, we demonstrate a requirement for the catalytic activity of S6K1 in both direct and indirect regulation of IRS1 serine phosphorylation.	Serine	161-167	ribosomal protein S6 kinase B1	Homo sapiens	109-113
16549223-5	2006	Our findings show that (S)-3,5-dihydroxyphenylglycine (DHPG) increases significantly the activation of mTOR and p70S6K (Thr389, controlled by mTOR) in both brain areas.	3,5-dihydroxyphenylglycine	23-53	ribosomal protein S6 kinase B1	Homo sapiens	112-118
16549223-5	2006	Our findings show that (S)-3,5-dihydroxyphenylglycine (DHPG) increases significantly the activation of mTOR and p70S6K (Thr389, controlled by mTOR) in both brain areas.	3,5-dihydroxyphenylglycine	55-59	ribosomal protein S6 kinase B1	Homo sapiens	112-118
16899564-8	2006	PRL-induced phosphorylation of p70S6K and 4E-BP1 was inhibited by rapamycin, but not by okadaic acid (inhibitor of protein phosphatase, PP2A).	Sirolimus	66-75	ribosomal protein S6 kinase B1	Homo sapiens	31-48
16766130-0	2006	Glutamate-dependent translational regulation in cultured Bergmann glia cells: involvement of p70S6K.	Glutamic Acid	0-9	ribosomal protein S6 kinase B1	Homo sapiens	93-99
16550606-5	2006	At physiological concentrations (2.5 microM), curcumin rapidly inhibited phosphorylation of the mammalian target of rapamycin (mTOR) and its downstream effector molecules, p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), in a panel of cell lines (Rh1, Rh30, DU145, MCF-7 and Hela).	Curcumin	46-54	ribosomal protein S6 kinase B1	Homo sapiens	189-193
16787414-8	2006	Thus, we believe that the thiazolidinedione regulates tau phosphorylation through a PPARgamma-dependent/independent mechanism involving an Akt/glycogen synthase kinase-3(GSK-3beta)-independent signalling cascade: PDK1/p70S6K/mTor.	2,4-thiazolidinedione	26-43	ribosomal protein S6 kinase B1	Homo sapiens	218-224
16427044-8	2006	Inhibition of PI-3K with low-dose LY294002, or MAPK with PD98059 also suppressed the mTOR/p70 S6k pathway, and correlated with the blockage of IFN-gamma-induced dephosphorylation of pY-STAT3.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	57-64	ribosomal protein S6 kinase B1	Homo sapiens	90-97
16717100-7	2006	Phosphorylation of p70(S6K), a known target of mTOR, occurred rapidly following T3 treatment and was inhibited by rapamycin and wortmannin.	Sirolimus	114-123	ribosomal protein S6 kinase B1	Homo sapiens	19-26
16717100-7	2006	Phosphorylation of p70(S6K), a known target of mTOR, occurred rapidly following T3 treatment and was inhibited by rapamycin and wortmannin.	Wortmannin	128-138	ribosomal protein S6 kinase B1	Homo sapiens	19-26
16717100-8	2006	In contrast, phosphorylation of the p85 variant of S6K in response to T3 was not blocked by LY294002, wortmannin, or rapamycin, thus supporting a T3-activated pathway independent of PI3K and mTOR.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	92-100	ribosomal protein S6 kinase B1	Homo sapiens	51-54
16717100-8	2006	In contrast, phosphorylation of the p85 variant of S6K in response to T3 was not blocked by LY294002, wortmannin, or rapamycin, thus supporting a T3-activated pathway independent of PI3K and mTOR.	Wortmannin	102-112	ribosomal protein S6 kinase B1	Homo sapiens	51-54
16717100-9	2006	40 S ribosomal protein S6, a target of p70(S6K), and 4E-BP1, a target of mTOR, were both phosphorylated within 15-25 min of T3 treatment and could be inhibited by wortmannin and rapamycin.	Wortmannin	163-173	ribosomal protein S6 kinase B1	Homo sapiens	43-46
16951269-3	2006	The aim of this study was to evaluate the expression and activation of the Akt-mTOR-p70S6K pathway in renal cell carcinoma (RCC), seeking to strengthen the rationale for targeted therapy of RCC using rapamycin or a rapamycin analogue.	Sirolimus	215-224	ribosomal protein S6 kinase B1	Homo sapiens	84-90
16819968-4	2006	Blockade of the mammalian targets of rapamycin (mTOR)/70 kDa ribosomal S6 kinase 1 (S6K1) pathway by the specific inhibitor rapamycin greatly enhanced M. tbc-induced IL-12/IL-23 p40 (p40) and IL-23 p19 (p19) mRNA and IL-23 protein expression.	Sirolimus	124-133	ribosomal protein S6 kinase B1	Homo sapiens	84-88
16611854-13	2006	PGJ2 + RA induced phosphatase and tensin homolog deleted on chromosome 10 (PTEN), whose overexpression repressed the TGFbeta1 gene through S6K1 inhibition, decreasing extracellular signal-regulated kinase 1/2-90-kDa ribosomal S6 kinase 1 and Akt-mTOR phosphorylations.	15-deoxy-delta(12,14)-prostaglandin J2	0-4	ribosomal protein S6 kinase B1	Homo sapiens	139-143
16611854-13	2006	PGJ2 + RA induced phosphatase and tensin homolog deleted on chromosome 10 (PTEN), whose overexpression repressed the TGFbeta1 gene through S6K1 inhibition, decreasing extracellular signal-regulated kinase 1/2-90-kDa ribosomal S6 kinase 1 and Akt-mTOR phosphorylations.	Alitretinoin	7-9	ribosomal protein S6 kinase B1	Homo sapiens	139-143
16763566-2	2006	In response to insulin, eIF4B is phosphorylated on Ser422 by S6K in a rapamycin-sensitive manner.	Sirolimus	70-79	ribosomal protein S6 kinase B1	Homo sapiens	61-64
16424383-7	2006	Rapamycin, a specific S6K1 inhibitor, abolished increased LAM cell growth.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	22-26
16640565-2	2006	The activation process of S6 kinase involves a complex and sequential series of multiple Ser/Thr phosphorylations and is mainly mediated via phosphatidylinositol 3-kinase (PI3K)-3-phosphoinositide-dependent protein kinase-1 (PDK1) and mTor-dependent pathways.	Serine	89-92	ribosomal protein S6 kinase B1	Homo sapiens	26-35
16640565-2	2006	The activation process of S6 kinase involves a complex and sequential series of multiple Ser/Thr phosphorylations and is mainly mediated via phosphatidylinositol 3-kinase (PI3K)-3-phosphoinositide-dependent protein kinase-1 (PDK1) and mTor-dependent pathways.	Threonine	93-96	ribosomal protein S6 kinase B1	Homo sapiens	26-35
16640565-7	2006	Complex formation is inducible by growth factors and leads to S6K tyrosine phosphorylation.	Tyrosine	66-74	ribosomal protein S6 kinase B1	Homo sapiens	62-65
16640565-10	2006	Inhibitors towards tyrosine kinases, such as genistein and PP1, or src-specific SU6656, but not PI3K and mTor inhibitors, lead to a reduction in tyrosine phosphorylation of S6K.	SU 6656	80-86	ribosomal protein S6 kinase B1	Homo sapiens	173-176
16640565-10	2006	Inhibitors towards tyrosine kinases, such as genistein and PP1, or src-specific SU6656, but not PI3K and mTor inhibitors, lead to a reduction in tyrosine phosphorylation of S6K.	Tyrosine	19-27	ribosomal protein S6 kinase B1	Homo sapiens	173-176
16640565-13	2006	Our data indicate that S6 kinase is recruited into a complex with RTKs and src and becomes phosphorylated on tyrosine/s in response to PDGF or serum.	Tyrosine	109-117	ribosomal protein S6 kinase B1	Homo sapiens	23-32
16723377-3	2006	Thrombin, histamine, and U46619 all enhanced EGF-stimulated [3H]-thymidine incorporation as well as late-phase Akt and p70S6K phosphorylation in ASM cultures.	Histamine	10-19	ribosomal protein S6 kinase B1	Homo sapiens	119-125
16611854-8	2006	PGJ2 + RA treatment inhibited the activity of p70 ribosomal S6 kinase-1 (S6K1), abolishing Zf9 phosphorylation at serine as did rapamycin [a mammalian target of rapamycin (mTOR) inhibitor].	15-deoxy-delta(12,14)-prostaglandin J2	0-4	ribosomal protein S6 kinase B1	Homo sapiens	60-77
16611854-8	2006	PGJ2 + RA treatment inhibited the activity of p70 ribosomal S6 kinase-1 (S6K1), abolishing Zf9 phosphorylation at serine as did rapamycin [a mammalian target of rapamycin (mTOR) inhibitor].	Alitretinoin	7-9	ribosomal protein S6 kinase B1	Homo sapiens	60-77
16611854-9	2006	Zf9 dephosphorylation by PGJ2 + RA was reversed by transfection of cells with the plasmid encoding constitutively active S6K1 (CA-S6K1).	15-deoxy-delta(12,14)-prostaglandin J2	25-29	ribosomal protein S6 kinase B1	Homo sapiens	121-125
16611854-9	2006	Zf9 dephosphorylation by PGJ2 + RA was reversed by transfection of cells with the plasmid encoding constitutively active S6K1 (CA-S6K1).	15-deoxy-delta(12,14)-prostaglandin J2	25-29	ribosomal protein S6 kinase B1	Homo sapiens	130-134
16611854-9	2006	Zf9 dephosphorylation by PGJ2 + RA was reversed by transfection of cells with the plasmid encoding constitutively active S6K1 (CA-S6K1).	Alitretinoin	32-34	ribosomal protein S6 kinase B1	Homo sapiens	121-125
16611854-9	2006	Zf9 dephosphorylation by PGJ2 + RA was reversed by transfection of cells with the plasmid encoding constitutively active S6K1 (CA-S6K1).	Alitretinoin	32-34	ribosomal protein S6 kinase B1	Homo sapiens	130-134
16611854-11	2006	TGFbeta1 gene repression by PGJ2 + RA was consistently antagonized by CA-S6K1.	15-deoxy-delta(12,14)-prostaglandin J2	28-32	ribosomal protein S6 kinase B1	Homo sapiens	73-77
16434554-9	2006	After extended exposure to 6% halothane, alterations in two separate responses regulated by the target of rapamycin pathway occur: 1) redistribution of eIF4E from its translation-stimulatory association with eIF4G to its translation-inactive complex with eIF4E-binding protein-1; and 2) decreased phosphorylation of ribosomal protein S6 (rpS6) with a corresponding decrease in active forms of a kinase that phosphorylates rpS6 (p70(S6K1)).	Halothane	30-39	ribosomal protein S6 kinase B1	Homo sapiens	432-436
16195541-10	2006	We conclude from these studies that a parallel PI3K- and reactive oxygen species-dependent Akt/mTOR/S6K1 pathway participates independently from MAPK and Rho/ROCK in the mitogenic effect of 5-HT on pulmonary artery SMCs.	Reactive Oxygen Species	57-80	ribosomal protein S6 kinase B1	Homo sapiens	100-104
16213157-10	2006	The Michaelis constant (Km) values of S6K for ATP and the Biotin-S6 substrate peptide were determined to be 21.4+/-0.29 and 0.9+/-0.48 microM, respectively.	Adenosine Triphosphate	46-49	ribosomal protein S6 kinase B1	Homo sapiens	38-41
16213157-10	2006	The Michaelis constant (Km) values of S6K for ATP and the Biotin-S6 substrate peptide were determined to be 21.4+/-0.29 and 0.9+/-0.48 microM, respectively.	Biotin	58-64	ribosomal protein S6 kinase B1	Homo sapiens	38-41
16213157-11	2006	The Lance assay was further validated with a diverse panel of literature inhibitors, in which the PKC inhibitors staurosporine, Ro-318220, and the PKA inhibitor Balanol potently inhibited S6K.	Staurosporine	113-126	ribosomal protein S6 kinase B1	Homo sapiens	188-191
16213157-11	2006	The Lance assay was further validated with a diverse panel of literature inhibitors, in which the PKC inhibitors staurosporine, Ro-318220, and the PKA inhibitor Balanol potently inhibited S6K.	Ro 31-8220	128-137	ribosomal protein S6 kinase B1	Homo sapiens	188-191
16213157-11	2006	The Lance assay was further validated with a diverse panel of literature inhibitors, in which the PKC inhibitors staurosporine, Ro-318220, and the PKA inhibitor Balanol potently inhibited S6K.	ophiocordin	161-168	ribosomal protein S6 kinase B1	Homo sapiens	188-191
16400626-9	2006	Among the 17q23 genes, RPS6KB1 showed markedly elevated transcript levels as compared to normal cerebellum in five of six DMBs and four of five classic medulloblastomas investigated.	DMBS	122-126	ribosomal protein S6 kinase B1	Homo sapiens	23-30
16613491-11	2006	PFE pretreatment resulted in a dose-dependent inhibition in the phosphorylation of mTOR at Thr2448 and p70S6K at Thr421/Ser424.	Coconut Oil	0-3	ribosomal protein S6 kinase B1	Homo sapiens	103-109
16477012-6	2006	The effects of PDGF/IL-1beta costimulation on contractile marker expression and Akt and p70S6K phosphorylation were blocked by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 and by adenovirus expressing a dominant-negative Akt, and they were mimicked by constitutively active Akt.	Wortmannin	172-182	ribosomal protein S6 kinase B1	Homo sapiens	88-94
16477012-6	2006	The effects of PDGF/IL-1beta costimulation on contractile marker expression and Akt and p70S6K phosphorylation were blocked by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 and by adenovirus expressing a dominant-negative Akt, and they were mimicked by constitutively active Akt.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	187-195	ribosomal protein S6 kinase B1	Homo sapiens	88-94
16449323-7	2006	Western blot analysis of PD98059-treated progenitor cells compared with the control showed a downmodulation of phospho-ERK 1 and phospho-ERK 2 and a minimal influence on p70S6K activation; by contrast, p70S6K activation was completely inhibited in rapamycin-treated cells.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	25-32	ribosomal protein S6 kinase B1	Homo sapiens	170-176
16449323-7	2006	Western blot analysis of PD98059-treated progenitor cells compared with the control showed a downmodulation of phospho-ERK 1 and phospho-ERK 2 and a minimal influence on p70S6K activation; by contrast, p70S6K activation was completely inhibited in rapamycin-treated cells.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	25-32	ribosomal protein S6 kinase B1	Homo sapiens	202-208
16148030-3	2006	Blockade of PI3K-Akt-mTOR-S6K1 signaling by LY-294002, and rapamycin suppressed both thrombin-induced VSMC DNA synthesis and migration.	Lysine	44-46	ribosomal protein S6 kinase B1	Homo sapiens	26-30
16505118-7	2006	In addition, rosiglitazone increased the phosphorylation of AMP-activated protein kinase alpha (AMPKalpha), a downstream kinase target for LKB1, whereas it decreased phosphorylation of p70 ribosomal protein S6 kinase (p70S6K), a downstream target of mammalian target of rapamycin (mTOR).	Rosiglitazone	13-26	ribosomal protein S6 kinase B1	Homo sapiens	185-216
16505118-7	2006	In addition, rosiglitazone increased the phosphorylation of AMP-activated protein kinase alpha (AMPKalpha), a downstream kinase target for LKB1, whereas it decreased phosphorylation of p70 ribosomal protein S6 kinase (p70S6K), a downstream target of mammalian target of rapamycin (mTOR).	Rosiglitazone	13-26	ribosomal protein S6 kinase B1	Homo sapiens	218-224
16505118-10	2006	Taken together, these findings show that rosiglitazone, via up-regulation of the PTEN/AMPK and down-regulation of the Akt/mTOR/p70S6K signal cascades, inhibits NSCLC cell proliferation through PPARgamma-dependent and PPARgamma-independent signals.	Rosiglitazone	41-54	ribosomal protein S6 kinase B1	Homo sapiens	127-133
16286479-5	2006	14,15-EET stimulated Akt and S6K1 phosphorylation in Src- and phosphatidylinositol 3-kinase (PI3K)-dependent manner in HDMVECs.	14,15-epoxy-5,8,11-eicosatrienoic acid	6-9	ribosomal protein S6 kinase B1	Homo sapiens	29-33
16183647-4	2005	In cells treated with the oxidizing agents diamide or phenylarsine oxide, S6K1 phosphorylation increased and became insensitive to nutrient deprivation.	Diamide	43-50	ribosomal protein S6 kinase B1	Homo sapiens	74-78
16428328-3	2006	Geldanamycin, a potent inhibitor of Hsp90, disrupted the in vivo binding of Hsp90 to raptor without affecting the association of raptor and mTOR, and suppressed the phosphorylation by mTOR of the downstream translational regulators p70 S6 kinase (S6K) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1).	geldanamycin	0-12	ribosomal protein S6 kinase B1	Homo sapiens	247-250
16428328-4	2006	The protein kinase activity of S6K as well as the phosphorylation of the substrate, 40S ribosomal protein S6, were lowered in the geldanamycin-treated cells.	geldanamycin	130-142	ribosomal protein S6 kinase B1	Homo sapiens	31-34
16428328-5	2006	These results indicate that Hsp90 is involved in the regulation of protein translation by facilitating the phosphorylation reaction of 4E-BP1 and S6K catalyzed by the mTOR/raptor complex through the association with raptor, and that the mTOR signaling pathway is a novel target of geldanamycin.	geldanamycin	281-293	ribosomal protein S6 kinase B1	Homo sapiens	146-149
15908181-11	2005	In conclusion, adrenaline potentiates insulin-stimulated activation of PKB and p70(S6K) via cAMP and Epac in skeletal muscle.	Epinephrine	15-25	ribosomal protein S6 kinase B1	Homo sapiens	79-86
15908181-11	2005	In conclusion, adrenaline potentiates insulin-stimulated activation of PKB and p70(S6K) via cAMP and Epac in skeletal muscle.	Cyclic AMP	92-96	ribosomal protein S6 kinase B1	Homo sapiens	79-86
15895362-7	2005	The activity of mammalian target of rapamycin (mTOR) is essential for phosphorylation of S6K1 and the treatment malanoma cells with rapamycin, a potent inhibitor of mTOR effectively induced melanogenesis.	Sirolimus	36-45	ribosomal protein S6 kinase B1	Homo sapiens	89-93
16139919-4	2005	RESULTS: The phophatidylinositol 3-kinase (PI3K) inhibitor LY294002 and the mitogen-activated protein kinase inhibitor, UO126, decreased the TGF-beta1-dependent ADAM12 expression and prevented the phosphorylation of p70S6K.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	59-67	ribosomal protein S6 kinase B1	Homo sapiens	216-222
16139919-4	2005	RESULTS: The phophatidylinositol 3-kinase (PI3K) inhibitor LY294002 and the mitogen-activated protein kinase inhibitor, UO126, decreased the TGF-beta1-dependent ADAM12 expression and prevented the phosphorylation of p70S6K.	U 0126	120-125	ribosomal protein S6 kinase B1	Homo sapiens	216-222
16139919-5	2005	In addition, TGF-beta1-induced ADAM12 up-regulation was blocked by the Frap/mTOR inhibitor rapamycin, which abrogated the phosphorylation of p70S6K.	Sirolimus	91-100	ribosomal protein S6 kinase B1	Homo sapiens	141-147
16183647-4	2005	In cells treated with the oxidizing agents diamide or phenylarsine oxide, S6K1 phosphorylation increased and became insensitive to nutrient deprivation.	oxophenylarsine	54-72	ribosomal protein S6 kinase B1	Homo sapiens	74-78
16183647-5	2005	Conversely, the reducing reagent BAL (British anti-Lewisite, also known as 2,3-dimercapto-1-propanol) inhibits S6K1 phosphorylation and stabilizes the interaction of mTOR and raptor to mimic the state of the complex under nutrient-deprived conditions.	Dimercaprol	75-100	ribosomal protein S6 kinase B1	Homo sapiens	111-115
16255777-12	2005	As expected, rapamycin inhibited the phosphorylation of mTOR substrates, p70S6K and 4EBP1, and BAY43-9006 inhibited phosphorylation of ERK, which is dependent on B-Raf activity.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	73-89
16255777-13	2005	We also observed unexpected rapamycin inhibition of the phosphorylation of ERK, as well as BAY43-9006 inhibition of the phosphorylation of mTOR substrates, p70S6K and 4EBP1.	Sorafenib	91-101	ribosomal protein S6 kinase B1	Homo sapiens	156-172
16099428-2	2005	Interestingly, anisomycin-induced p70(S6K) phosphorylation was reduced by SP600125, while insulin-induced p70(S6K) phosphorylation was not.	Anisomycin	15-25	ribosomal protein S6 kinase B1	Homo sapiens	38-41
16254257-0	2005	p-p70S6K (Thr 389) Expression in nodular sclerosing hodgkin"s disease as evidence for receptor tyrosine kinase signaling.	Threonine	10-13	ribosomal protein S6 kinase B1	Homo sapiens	2-8
16099428-2	2005	Interestingly, anisomycin-induced p70(S6K) phosphorylation was reduced by SP600125, while insulin-induced p70(S6K) phosphorylation was not.	pyrazolanthrone	74-82	ribosomal protein S6 kinase B1	Homo sapiens	38-41
15914125-10	2005	Significantly, rapamycin completely inhibited the phosphorylation of p70(S6K), an mTOR-regulated kinase implicated in the control of proliferation, but had no effect on collagen or total protein synthesis.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	73-76
16049009-4	2005	The Class IA phosphatidylinositol (PI) 3-kinase plays a well recognized role in the regulation of S6K1.	Phosphatidylinositols	13-33	ribosomal protein S6 kinase B1	Homo sapiens	98-102
16049009-9	2005	Consistent with this, hVps34 is also inhibited by activation of the AMP-activated kinase, which inhibits mTOR/S6K1 in glucose-starved cells.	Glucose	118-125	ribosomal protein S6 kinase B1	Homo sapiens	110-114
16049009-11	2005	Our data suggest that hVps34 is a nutrient-regulated lipid kinase that integrates amino acid and glucose inputs to mTOR and S6K1.	Glucose	97-104	ribosomal protein S6 kinase B1	Homo sapiens	124-128
16104747-4	2005	This approach lead to the conclusion that several AGC group protein kinases (including PKCalpha, PKCbeta, MSK1, p70 S6K, PDK-1, and MAPKAP-K1alpha) may be best inhibited by bisindolylmaleimides which adopt a compressed approximately C2-symmetric anti conformation; in constrast, GSK3beta may be best inhibited by bisindolylmaleimides whose ground state is a distorted syn conformation.	bisindolylmaleimide	173-193	ribosomal protein S6 kinase B1	Homo sapiens	112-119
16104747-4	2005	This approach lead to the conclusion that several AGC group protein kinases (including PKCalpha, PKCbeta, MSK1, p70 S6K, PDK-1, and MAPKAP-K1alpha) may be best inhibited by bisindolylmaleimides which adopt a compressed approximately C2-symmetric anti conformation; in constrast, GSK3beta may be best inhibited by bisindolylmaleimides whose ground state is a distorted syn conformation.	bisindolylmaleimide	313-333	ribosomal protein S6 kinase B1	Homo sapiens	112-119
16103079-0	2005	15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of PI3K-Akt-mTOR-S6K1 signaling.	15-hydroxy-5,8,11,13-eicosatetraenoic acid	0-34	ribosomal protein S6 kinase B1	Homo sapiens	88-92
16103079-5	2005	Wortmannin and LY294002, two specific inhibitors of phosphatidylinositol 3-kinase (PI3K), blocked both Akt and S6K1 phosphorylation, whereas rapamycin, a specific inhibitor of Akt downstream effector, mammalian target of rapamycin (mTOR), suppressed only S6K1 phosphorylation induced by 15(S)-HETE suggesting that this eicosanoid activates the PI3K-Akt-mTOR-S6K1 signaling in HDMVEC.	Wortmannin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	111-115
16103079-5	2005	Wortmannin and LY294002, two specific inhibitors of phosphatidylinositol 3-kinase (PI3K), blocked both Akt and S6K1 phosphorylation, whereas rapamycin, a specific inhibitor of Akt downstream effector, mammalian target of rapamycin (mTOR), suppressed only S6K1 phosphorylation induced by 15(S)-HETE suggesting that this eicosanoid activates the PI3K-Akt-mTOR-S6K1 signaling in HDMVEC.	Wortmannin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	255-259
16103079-5	2005	Wortmannin and LY294002, two specific inhibitors of phosphatidylinositol 3-kinase (PI3K), blocked both Akt and S6K1 phosphorylation, whereas rapamycin, a specific inhibitor of Akt downstream effector, mammalian target of rapamycin (mTOR), suppressed only S6K1 phosphorylation induced by 15(S)-HETE suggesting that this eicosanoid activates the PI3K-Akt-mTOR-S6K1 signaling in HDMVEC.	Wortmannin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	255-259
16103079-5	2005	Wortmannin and LY294002, two specific inhibitors of phosphatidylinositol 3-kinase (PI3K), blocked both Akt and S6K1 phosphorylation, whereas rapamycin, a specific inhibitor of Akt downstream effector, mammalian target of rapamycin (mTOR), suppressed only S6K1 phosphorylation induced by 15(S)-HETE suggesting that this eicosanoid activates the PI3K-Akt-mTOR-S6K1 signaling in HDMVEC.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	15-23	ribosomal protein S6 kinase B1	Homo sapiens	111-115
16103079-5	2005	Wortmannin and LY294002, two specific inhibitors of phosphatidylinositol 3-kinase (PI3K), blocked both Akt and S6K1 phosphorylation, whereas rapamycin, a specific inhibitor of Akt downstream effector, mammalian target of rapamycin (mTOR), suppressed only S6K1 phosphorylation induced by 15(S)-HETE suggesting that this eicosanoid activates the PI3K-Akt-mTOR-S6K1 signaling in HDMVEC.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	15-23	ribosomal protein S6 kinase B1	Homo sapiens	255-259
16103079-5	2005	Wortmannin and LY294002, two specific inhibitors of phosphatidylinositol 3-kinase (PI3K), blocked both Akt and S6K1 phosphorylation, whereas rapamycin, a specific inhibitor of Akt downstream effector, mammalian target of rapamycin (mTOR), suppressed only S6K1 phosphorylation induced by 15(S)-HETE suggesting that this eicosanoid activates the PI3K-Akt-mTOR-S6K1 signaling in HDMVEC.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	15-23	ribosomal protein S6 kinase B1	Homo sapiens	255-259
16103079-8	2005	Pharmacologic inhibition of PI3K-Akt-mTOR-S6K1 signaling completely suppressed 15(S)-HETE-induced in vivo angiogenesis.	Sulfur	82-85	ribosomal protein S6 kinase B1	Homo sapiens	42-46
16103079-8	2005	Pharmacologic inhibition of PI3K-Akt-mTOR-S6K1 signaling completely suppressed 15(S)-HETE-induced in vivo angiogenesis.	Hydroxyeicosatetraenoic Acids	85-89	ribosomal protein S6 kinase B1	Homo sapiens	42-46
16103079-10	2005	Together, these results show for the first time that 15(S)-HETE stimulates angiogenesis via activation of PI3K-Akt-mTOR-S6K1 signaling.	Hydroxyeicosatetraenoic Acids	55-63	ribosomal protein S6 kinase B1	Homo sapiens	120-124
15905173-3	2005	Expression of a constitutively active, rapamycin- and wortmannin-resistant S6K1 leads to constitutive phosphorylation of mTOR, whereas knock-down of S6K1 using small inhibitory RNA greatly reduces mTOR phosphorylation despite elevated Akt activity.	Wortmannin	54-64	ribosomal protein S6 kinase B1	Homo sapiens	75-79
15905173-3	2005	Expression of a constitutively active, rapamycin- and wortmannin-resistant S6K1 leads to constitutive phosphorylation of mTOR, whereas knock-down of S6K1 using small inhibitory RNA greatly reduces mTOR phosphorylation despite elevated Akt activity.	Wortmannin	54-64	ribosomal protein S6 kinase B1	Homo sapiens	149-153
15905173-4	2005	Importantly, phosphorylation of mTOR by S6K1 occurs at threonine 2446/serine 2448.	Threonine	55-64	ribosomal protein S6 kinase B1	Homo sapiens	40-44
15905173-4	2005	Importantly, phosphorylation of mTOR by S6K1 occurs at threonine 2446/serine 2448.	Serine	70-76	ribosomal protein S6 kinase B1	Homo sapiens	40-44
16018822-8	2005	The effect of sirolimus on activation of mammalian target of rapamycin (mTOR) was measured by phosphorylation of the substrate p70s6k at T389, and activation of RhoA was measured by pull-down assay.	Sirolimus	14-23	ribosomal protein S6 kinase B1	Homo sapiens	127-133
15899889-7	2005	In addition, we show that cellular amino acid status, which modulates p70S6 kinase (S6K1) activity via the TSC/Rheb pathway, regulates Ser-2448 phosphorylation.	Serine	135-138	ribosomal protein S6 kinase B1	Homo sapiens	84-88
15701678-5	2005	INS also promoted phosphorylation of ERK1/2, S6K1, and 4E-BP1 and dephosphorylation of eIF4E.	Insulin	0-3	ribosomal protein S6 kinase B1	Homo sapiens	45-49
15994961-7	2005	Consistent with this observation, the inhibition of phosphorylated-MEK and phosphorylated-p70S6K, the two key signaling molecules responsible for activation of eEF2K, also occurred at least 12 hours after SCH66336 administration.	lonafarnib	205-213	ribosomal protein S6 kinase B1	Homo sapiens	90-96
15988001-6	2005	Tetracycline-inducible expression of REDD1 triggers rapid dephosphorylation of S6K and 4E-BP1 and significantly decreases cellular size.	Tetracycline	0-12	ribosomal protein S6 kinase B1	Homo sapiens	79-93
15882288-10	2005	The p70(S6) kinase pathway leading to cell cycle progression was found to be active, and low concentrations of rapamycin dramatically reduced p70(S6) kinase phosphorylation.	Sirolimus	111-120	ribosomal protein S6 kinase B1	Homo sapiens	4-18
15882288-14	2005	CONCLUSION: Rapamycin inhibits the proliferative response of HRECs to mitogenic stimuli, and causes cell cycle arrest in the early G(1) phase, not only by a nonspecific process due to inhibition of the p70(S6k) pathway, but also by a direct effect on cyclin D3 mRNA stability.	Sirolimus	12-21	ribosomal protein S6 kinase B1	Homo sapiens	202-209
15677443-5	2005	Platelet-derived growth factor (PDGF) stimulated p70S6K phosphorylation, which was blocked by LY294002, an inhibitor of phosphatidylinositol 3-kinase.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	94-102	ribosomal protein S6 kinase B1	Homo sapiens	49-55
15809305-3	2005	Nutrients and growth factors activate S6K1 by inducing the phosphorylation of threonine 389 in the hydrophobic motif of S6K1.	Threonine	78-87	ribosomal protein S6 kinase B1	Homo sapiens	38-42
15809305-3	2005	Nutrients and growth factors activate S6K1 by inducing the phosphorylation of threonine 389 in the hydrophobic motif of S6K1.	Threonine	78-87	ribosomal protein S6 kinase B1	Homo sapiens	120-124
15809305-5	2005	This proposal is not supported, however, by the existence of mutants of S6K1 that are phosphorylated in vivo on Thr(389) in a rapamycin-resistant fashion.	Threonine	112-115	ribosomal protein S6 kinase B1	Homo sapiens	72-76
15809305-7	2005	Phosphorylation of Thr(389) by rictor-mTOR is independent of the TOR signaling motif and depends on removal of the carboxyl terminal domain of S6K1.	Threonine	19-22	ribosomal protein S6 kinase B1	Homo sapiens	143-147
15845392-1	2005	We present immunohistochemical evidence that the mTOR/p70s6k pathway is activated in pancreatic tumors and show that the mTOR inhibitor and rapamycin analog CCI-779 potently suppresses the proliferation of pancreatic cancer cells.	temsirolimus	157-164	ribosomal protein S6 kinase B1	Homo sapiens	54-60
15870625-1	2005	PURPOSE: We hypothesized that creatine supplementation would facilitate muscle anabolism by increasing the expression of growth factors and the phosphorylation of anabolic signaling molecules; we therefore tested the responses of mRNA for IGF-I and IGF-II and the phosphorylation state of components of anabolic signaling pathways p70(s6k) and 4E-BP1 to a bout of high-intensity resistance exercise after 5 d of creatine supplementation.	Creatine	30-38	ribosomal protein S6 kinase B1	Homo sapiens	331-338
15677443-6	2005	Rapamycin blocked phosphorylation of p70S6K but had no affect on PDGF-induced Akt phosphorylation, positioning p70S6K downstream of Akt.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	37-43
15825085-9	2005	Bile acid-induced proliferation is mediated by activation of a protein kinase C/extracellular signal-regulated kinase/p70S6K-dependent pathway.	Bile Acids and Salts	0-9	ribosomal protein S6 kinase B1	Homo sapiens	118-124
15659381-2	2005	We previously identified a conserved TOR signaling (TOS) motif in the N terminus of S6K1 that is required for its mTOR-dependent activation.	Toremifene	37-40	ribosomal protein S6 kinase B1	Homo sapiens	84-88
15659381-7	2005	Furthermore, we have shown that the RSPRR motif significantly suppresses S6K1 phosphorylation at two phosphorylation sites (Thr-389 and Thr-229) that are crucial for S6K1 activation.	Threonine	136-139	ribosomal protein S6 kinase B1	Homo sapiens	166-170
15659381-2	2005	We previously identified a conserved TOR signaling (TOS) motif in the N terminus of S6K1 that is required for its mTOR-dependent activation.	tos	52-55	ribosomal protein S6 kinase B1	Homo sapiens	84-88
15659381-8	2005	Importantly, introducing both the Thr-389 phosphomimetic and RSPRR motif mutations into the catalytically inactive S6K1 mutant S6K1-F5A completely rescues its activity and renders it fully rapamycin resistant.	Threonine	34-37	ribosomal protein S6 kinase B1	Homo sapiens	115-119
15659381-8	2005	Importantly, introducing both the Thr-389 phosphomimetic and RSPRR motif mutations into the catalytically inactive S6K1 mutant S6K1-F5A completely rescues its activity and renders it fully rapamycin resistant.	Threonine	34-37	ribosomal protein S6 kinase B1	Homo sapiens	127-131
15659381-3	2005	Furthermore, our data suggested that the TOS motif suppresses an inhibitory function associated with the C terminus of S6K1.	tos	41-44	ribosomal protein S6 kinase B1	Homo sapiens	119-123
15659381-6	2005	Deletion or mutations within this RSPRR motif partially rescue the kinase activity of the S6K1 TOS motif mutant (S6K1-F5A), and this rescued activity is rapamycin resistant.	Sirolimus	153-162	ribosomal protein S6 kinase B1	Homo sapiens	90-94
15659381-6	2005	Deletion or mutations within this RSPRR motif partially rescue the kinase activity of the S6K1 TOS motif mutant (S6K1-F5A), and this rescued activity is rapamycin resistant.	Sirolimus	153-162	ribosomal protein S6 kinase B1	Homo sapiens	113-117
15659381-7	2005	Furthermore, we have shown that the RSPRR motif significantly suppresses S6K1 phosphorylation at two phosphorylation sites (Thr-389 and Thr-229) that are crucial for S6K1 activation.	Threonine	124-127	ribosomal protein S6 kinase B1	Homo sapiens	73-77
15659381-7	2005	Furthermore, we have shown that the RSPRR motif significantly suppresses S6K1 phosphorylation at two phosphorylation sites (Thr-389 and Thr-229) that are crucial for S6K1 activation.	Threonine	124-127	ribosomal protein S6 kinase B1	Homo sapiens	166-170
15659381-7	2005	Furthermore, we have shown that the RSPRR motif significantly suppresses S6K1 phosphorylation at two phosphorylation sites (Thr-389 and Thr-229) that are crucial for S6K1 activation.	Threonine	136-139	ribosomal protein S6 kinase B1	Homo sapiens	73-77
15632115-6	2005	After serum addition, p70S6K phosphorylation was higher and more resistant to rapamycin treatment in cells overexpressing DGKzeta.	Sirolimus	78-87	ribosomal protein S6 kinase B1	Homo sapiens	22-28
15632115-7	2005	The effect of this DGK isoform on p70S6K hyperphosphorylation required the mTOR PA binding region.	Phosphatidic Acids	80-82	ribosomal protein S6 kinase B1	Homo sapiens	34-40
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	Sirolimus	46-55	ribosomal protein S6 kinase B1	Homo sapiens	148-154
15576463-4	2005	Inhibition of mTOR/S6K1 by rapamycin increased insulin-stimulated glucose transport by as much as 45% in 3T3-L1 adipocytes.	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	19-23
15576463-4	2005	Inhibition of mTOR/S6K1 by rapamycin increased insulin-stimulated glucose transport by as much as 45% in 3T3-L1 adipocytes.	Glucose	66-73	ribosomal protein S6 kinase B1	Homo sapiens	19-23
15576463-5	2005	Activation of mTOR/S6K1 by insulin was associated with a rapamycin-sensitive increase in Ser636/639 phosphorylation of insulin receptor substrate (IRS)-1 but, surprisingly, did not result in impaired IRS-1-associated phosphatidylinositol (PI) 3-kinase activity.	Phosphatidylinositols	217-237	ribosomal protein S6 kinase B1	Homo sapiens	19-23
15576463-8	2005	As in murine cells, rapamycin treatment of human adipocytes inhibited S6K1, blunted Ser636/639 phosphorylation of IRS-1, leading to increased Akt activation and glucose uptake by insulin.	Sirolimus	20-29	ribosomal protein S6 kinase B1	Homo sapiens	70-74
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	Wortmannin	57-67	ribosomal protein S6 kinase B1	Homo sapiens	148-154
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	69-77	ribosomal protein S6 kinase B1	Homo sapiens	148-154
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	U 0126	83-88	ribosomal protein S6 kinase B1	Homo sapiens	148-154
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	Sirolimus	185-194	ribosomal protein S6 kinase B1	Homo sapiens	148-154
15816524-0	2005	ET-18-OCH3 inhibits the phosphorylation and activation of p70 S6 kinase in MCF-7 cells.	edelfosine	0-10	ribosomal protein S6 kinase B1	Homo sapiens	58-71
15501927-8	2005	The activation of p70S6K/S6 pathway was sensitive to inhibition by rapamycin and LY294002, indicating that mTOR and PI3K/Akt are upstream signaling regulators.	Sirolimus	67-76	ribosomal protein S6 kinase B1	Homo sapiens	18-24
15501927-8	2005	The activation of p70S6K/S6 pathway was sensitive to inhibition by rapamycin and LY294002, indicating that mTOR and PI3K/Akt are upstream signaling regulators.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	81-89	ribosomal protein S6 kinase B1	Homo sapiens	18-24
15691882-6	2005	Again, homocysteine thiolactone (50 microM) prevented insulin-mediated MAPK, GSK-3 and p70 S6K phosphorylation and these effects were blocked by glutathione (250 microM).	homocysteine thiolactone	7-31	ribosomal protein S6 kinase B1	Homo sapiens	87-94
15691882-6	2005	Again, homocysteine thiolactone (50 microM) prevented insulin-mediated MAPK, GSK-3 and p70 S6K phosphorylation and these effects were blocked by glutathione (250 microM).	Glutathione	145-156	ribosomal protein S6 kinase B1	Homo sapiens	87-94
15522879-7	2005	Extracellular ATP induced dramatic increases in mTOR and p70 S6K phosphorylation.	Adenosine Triphosphate	14-17	ribosomal protein S6 kinase B1	Homo sapiens	57-64
15522879-8	2005	This activation of the mTOR/p70 S6 kinase (p70 S6K) pathway in response to ATP is because of independent contributions of PI3K/Akt and ERK1/2 pathways, which converge on the level of p70 S6K.	Adenosine Triphosphate	75-78	ribosomal protein S6 kinase B1	Homo sapiens	43-50
15522879-8	2005	This activation of the mTOR/p70 S6 kinase (p70 S6K) pathway in response to ATP is because of independent contributions of PI3K/Akt and ERK1/2 pathways, which converge on the level of p70 S6K.	Adenosine Triphosphate	75-78	ribosomal protein S6 kinase B1	Homo sapiens	183-190
15522879-9	2005	ATP-dependent activation of mTOR and p70 S6K also requires additional signaling inputs perhaps from pathways operating through Galpha or Gbetagamma subunits.	Adenosine Triphosphate	0-3	ribosomal protein S6 kinase B1	Homo sapiens	37-44
15522879-10	2005	Collectively, our data demonstrate that ATP-induced adventitial fibroblast proliferation requires activation and interaction of multiple signaling pathways such as PI3K, Akt, mTOR, p70 S6K, and ERK1/2 and provide evidence for purinergic regulation of the protein translational pathways related to cell proliferation.	Adenosine Triphosphate	40-43	ribosomal protein S6 kinase B1	Homo sapiens	181-188
15371259-7	2005	However, disrupting the actin cytoskeleton with cytochalasin D did block the multiaxial signaling to p70(S6k), with no effect on signaling to PKB/Akt.	Cytochalasin D	48-62	ribosomal protein S6 kinase B1	Homo sapiens	105-108
15816524-4	2005	In this study, we demonstrated that the prototypic ALP, 1-O-octadecyl-2-O-methyl-rac-glycerophosphocholine (ET-18-OCH3), inhibits the activation of p70S6K in MCF-7 cells but does not inhibit the activity of p70S6K.	1-o-octadecyl-2-o-methyl-rac-glycerophosphocholine	56-106	ribosomal protein S6 kinase B1	Homo sapiens	148-154
15816524-4	2005	In this study, we demonstrated that the prototypic ALP, 1-O-octadecyl-2-O-methyl-rac-glycerophosphocholine (ET-18-OCH3), inhibits the activation of p70S6K in MCF-7 cells but does not inhibit the activity of p70S6K.	et-18	108-113	ribosomal protein S6 kinase B1	Homo sapiens	148-154
15816524-4	2005	In this study, we demonstrated that the prototypic ALP, 1-O-octadecyl-2-O-methyl-rac-glycerophosphocholine (ET-18-OCH3), inhibits the activation of p70S6K in MCF-7 cells but does not inhibit the activity of p70S6K.	et-18	108-113	ribosomal protein S6 kinase B1	Homo sapiens	207-213
15816524-7	2005	Phorbol ester-induced activation of p70S6K which was sensitive to the m-Tor inhibitor but not the phosphoinositide 3-kinase inhibitor, was also inhibited by ET-18-OCH3.	Phorbol Esters	0-13	ribosomal protein S6 kinase B1	Homo sapiens	36-42
15816524-7	2005	Phorbol ester-induced activation of p70S6K which was sensitive to the m-Tor inhibitor but not the phosphoinositide 3-kinase inhibitor, was also inhibited by ET-18-OCH3.	et-18	157-162	ribosomal protein S6 kinase B1	Homo sapiens	36-42
15816524-8	2005	Hence the diminished phosphorylation of p70S6K by ET-18-OCH3 is a result of the inhibition of both phosphoinositide 3-kinase-dependent and -independent activation of p70S6K.	edelfosine	50-60	ribosomal protein S6 kinase B1	Homo sapiens	40-46
15816524-8	2005	Hence the diminished phosphorylation of p70S6K by ET-18-OCH3 is a result of the inhibition of both phosphoinositide 3-kinase-dependent and -independent activation of p70S6K.	edelfosine	50-60	ribosomal protein S6 kinase B1	Homo sapiens	166-172
15816524-9	2005	The differential effects of ENE-OCH3, a phosphonocholine analog of ET-18-OCH3, on MCF-7 cell proliferation correlated with its effects on p70S6K activation.	ene-och3	28-36	ribosomal protein S6 kinase B1	Homo sapiens	138-144
15816524-9	2005	The differential effects of ENE-OCH3, a phosphonocholine analog of ET-18-OCH3, on MCF-7 cell proliferation correlated with its effects on p70S6K activation.	phosphonocholine	40-56	ribosomal protein S6 kinase B1	Homo sapiens	138-144
15816524-9	2005	The differential effects of ENE-OCH3, a phosphonocholine analog of ET-18-OCH3, on MCF-7 cell proliferation correlated with its effects on p70S6K activation.	edelfosine	67-77	ribosomal protein S6 kinase B1	Homo sapiens	138-144
15816524-10	2005	The data suggest that the inhibition of p70S6K activation of by ET-18-OCH3 contributes to the antiproliferative effects of ALPs in MCF-7 cells.	edelfosine	64-74	ribosomal protein S6 kinase B1	Homo sapiens	40-46
15623621-6	2004	HepG2 and Hep3B cell lines were treated with rapamycin to see the effect on proliferation and S6K phosphorylation.	Sirolimus	45-54	ribosomal protein S6 kinase B1	Homo sapiens	94-97
15696050-3	2005	We examined the role of the mammalian target of rapamycin and ribosomal p70S6 kinase (p70S6K) in S-1-P-induced SMC migration .	sphingosine 1-phosphate	97-102	ribosomal protein S6 kinase B1	Homo sapiens	72-84
15696050-3	2005	We examined the role of the mammalian target of rapamycin and ribosomal p70S6 kinase (p70S6K) in S-1-P-induced SMC migration .	sphingosine 1-phosphate	97-102	ribosomal protein S6 kinase B1	Homo sapiens	86-92
15696050-7	2005	Phosphorylation of p70S6K was also assayed after S-1-P treatment in the presence and absence of inhibitors of PI3 kinase (wortmannin, WN, and LY294002, LY), Akt (AktI), p38(MAPK) (SB203580), and MEK1 (PD98059).	sphingosine 1-phosphate	49-54	ribosomal protein S6 kinase B1	Homo sapiens	19-25
15696050-9	2005	S-1-P stimulated phosphorylation of ERK1/2, p38(MAPK), and p70S6K, which peaked at 5 minutes for ERK1/2 and p38(MAPK) and10 minutes for p70S6K (2-fold increase over control for each, P &lt; .05).	sphingosine 1-phosphate	0-5	ribosomal protein S6 kinase B1	Homo sapiens	59-65
15696050-9	2005	S-1-P stimulated phosphorylation of ERK1/2, p38(MAPK), and p70S6K, which peaked at 5 minutes for ERK1/2 and p38(MAPK) and10 minutes for p70S6K (2-fold increase over control for each, P &lt; .05).	sphingosine 1-phosphate	0-5	ribosomal protein S6 kinase B1	Homo sapiens	136-142
15696050-10	2005	Rapamycin prevented the phosphorylation of p70S6K at the Thr 389 site (which correlates with enzyme activity), reduced ERK1/2 phosphorylation, but had no effect on the Thr 421/Ser 424 site or on p38(MAPK) phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	43-49
15696050-10	2005	Rapamycin prevented the phosphorylation of p70S6K at the Thr 389 site (which correlates with enzyme activity), reduced ERK1/2 phosphorylation, but had no effect on the Thr 421/Ser 424 site or on p38(MAPK) phosphorylation.	Threonine	57-60	ribosomal protein S6 kinase B1	Homo sapiens	43-49
15696050-11	2005	Wortmannin and LY294002 inhibited phosphorylation of the Thr 389 site of p70S6K.	Wortmannin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	73-79
15696050-11	2005	Wortmannin and LY294002 inhibited phosphorylation of the Thr 389 site of p70S6K.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	15-23	ribosomal protein S6 kinase B1	Homo sapiens	73-79
15696050-11	2005	Wortmannin and LY294002 inhibited phosphorylation of the Thr 389 site of p70S6K.	Threonine	57-60	ribosomal protein S6 kinase B1	Homo sapiens	73-79
15696050-13	2005	CONCLUSIONS: S-1-P-induced SMC migration was completely inhibited by rapamycin, indicating that the p70S6K pathway is involved.	sphingosine 1-phosphate	13-18	ribosomal protein S6 kinase B1	Homo sapiens	100-106
15696050-13	2005	CONCLUSIONS: S-1-P-induced SMC migration was completely inhibited by rapamycin, indicating that the p70S6K pathway is involved.	Sirolimus	69-78	ribosomal protein S6 kinase B1	Homo sapiens	100-106
15696050-15	2005	S-1-P stimulates phosphorylation of p70S6K in a MEK1-dependent, PI3 kinase-dependent, but Akt-independent manner.	sphingosine 1-phosphate	0-5	ribosomal protein S6 kinase B1	Homo sapiens	36-42
15459249-2	2005	Recent results indicate that an inhibitor of the Ras signaling pathway, farnesylthiosalicylic acid (FTS), decreased phosphorylation of the mTOR effectors, PHAS-I and S6K1, in breast cancer cells.	farnesylthiosalicylic acid	72-98	ribosomal protein S6 kinase B1	Homo sapiens	166-170
15459249-2	2005	Recent results indicate that an inhibitor of the Ras signaling pathway, farnesylthiosalicylic acid (FTS), decreased phosphorylation of the mTOR effectors, PHAS-I and S6K1, in breast cancer cells.	farnesylthiosalicylic acid	100-103	ribosomal protein S6 kinase B1	Homo sapiens	166-170
15494402-5	2004	In contrast, glucagon repressed both basal and amino acid-induced signaling through mTOR, as assessed by changes in the phosphorylation of 4E-BP1 and S6K1.	Glucagon	13-21	ribosomal protein S6 kinase B1	Homo sapiens	150-154
15494402-7	2004	Surprisingly, the phosphorylation of two S6K1 substrates, rpS6 and eukaryotic initiation factor 4B, was not repressed but instead was increased by glucagon treatment, regardless of the amino acid concentration.	Glucagon	147-155	ribosomal protein S6 kinase B1	Homo sapiens	41-45
15494402-9	2004	Thus, glucagon represses phosphorylation of 4E-BP1 and S6K1 through the activation of a protein kinase A-LKB-AMPK-mTOR signaling pathway, while simultaneously enhancing phosphorylation of other downstream effectors of mTOR through the activation of the extracellular signal-regulated protein kinase 1-p90(rsk) signaling pathway.	Glucagon	6-14	ribosomal protein S6 kinase B1	Homo sapiens	55-59
15723652-9	2005	Western blot assays revealed that phytosphingosine decreases phosphorylated Akt and p70S6k.	phytosphingosine	34-50	ribosomal protein S6 kinase B1	Homo sapiens	84-90
15623621-10	2004	Rapamycin treatment of HepG2 and Hep3B cell lines markedly inhibited cell proliferation and reduced S6K phosphorylation in both cell lines.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	100-103
15561916-6	2004	Our studies demonstrated that forskolin-generated cAMP resulted in activation of mTOR at basal glucose concentrations as assessed by phosphorylation of S6K1, a downstream effector of mTOR.	Colforsin	30-39	ribosomal protein S6 kinase B1	Homo sapiens	152-156
15627061-2	2004	METHODS: S6K1/2 expression and phosphorylated ribosomal S6 protein (phS6) content have been detected in formalin fixed, paraffin embedded sections of 50 human endometrial adenocarcinomas with different grade of differentiation and in 13 normal endometrial tissues using immunohistochemical approach with following semiquantitative analysis.	Formaldehyde	104-112	ribosomal protein S6 kinase B1	Homo sapiens	9-15
15561916-6	2004	Our studies demonstrated that forskolin-generated cAMP resulted in activation of mTOR at basal glucose concentrations as assessed by phosphorylation of S6K1, a downstream effector of mTOR.	Cyclic AMP	50-54	ribosomal protein S6 kinase B1	Homo sapiens	152-156
15561916-6	2004	Our studies demonstrated that forskolin-generated cAMP resulted in activation of mTOR at basal glucose concentrations as assessed by phosphorylation of S6K1, a downstream effector of mTOR.	Glucose	95-102	ribosomal protein S6 kinase B1	Homo sapiens	152-156
15561916-7	2004	Conversely, an adenylyl cyclase inhibitor partially blocked glucose-induced S6K1 phosphorylation.	Glucose	60-67	ribosomal protein S6 kinase B1	Homo sapiens	76-80
15561916-8	2004	Furthermore, the GLP-1 receptor agonist, Exenatide, dose-dependently enhanced phosphorylation of S6K1 at an intermediate glucose concentration (8 mmol/l) in a rapamycin-sensitive manner.	Exenatide	41-50	ribosomal protein S6 kinase B1	Homo sapiens	97-101
15561916-8	2004	Furthermore, the GLP-1 receptor agonist, Exenatide, dose-dependently enhanced phosphorylation of S6K1 at an intermediate glucose concentration (8 mmol/l) in a rapamycin-sensitive manner.	Glucose	121-128	ribosomal protein S6 kinase B1	Homo sapiens	97-101
15561916-8	2004	Furthermore, the GLP-1 receptor agonist, Exenatide, dose-dependently enhanced phosphorylation of S6K1 at an intermediate glucose concentration (8 mmol/l) in a rapamycin-sensitive manner.	Sirolimus	159-168	ribosomal protein S6 kinase B1	Homo sapiens	97-101
15561916-10	2004	Glyburide, an inhibitor of ATP-sensitive K+ channels (K(ATP) channels), provided partial activation of mTOR at basal glucose concentrations due to the influx of extracellular Ca2+, and diazoxide, an activator of KATP channels, resulted in partial inhibition of S6K1 phosphorylation by 20 mmol/l glucose.	Glyburide	0-9	ribosomal protein S6 kinase B1	Homo sapiens	261-265
15561916-12	2004	BAPTA, a chelator of intracellular Ca2+, resulted in inhibition of glucose-stimulated S6K1 phosphorylation due to a reduction in cytosolic Ca2+ concentrations.	1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid	0-5	ribosomal protein S6 kinase B1	Homo sapiens	86-90
15561916-12	2004	BAPTA, a chelator of intracellular Ca2+, resulted in inhibition of glucose-stimulated S6K1 phosphorylation due to a reduction in cytosolic Ca2+ concentrations.	Glucose	67-74	ribosomal protein S6 kinase B1	Homo sapiens	86-90
15627061-2	2004	METHODS: S6K1/2 expression and phosphorylated ribosomal S6 protein (phS6) content have been detected in formalin fixed, paraffin embedded sections of 50 human endometrial adenocarcinomas with different grade of differentiation and in 13 normal endometrial tissues using immunohistochemical approach with following semiquantitative analysis.	Paraffin	120-128	ribosomal protein S6 kinase B1	Homo sapiens	9-15
15342961-3	2004	The flavonoid naringin prevented the effects of AICAR, okadaic acid, and microcystin on AMPK activation as well as on S6K tail phosphorylation, suggesting AMPK as a mediator of the latter.	Flavonoids	4-13	ribosomal protein S6 kinase B1	Homo sapiens	118-121
15342961-3	2004	The flavonoid naringin prevented the effects of AICAR, okadaic acid, and microcystin on AMPK activation as well as on S6K tail phosphorylation, suggesting AMPK as a mediator of the latter.	naringin	14-22	ribosomal protein S6 kinase B1	Homo sapiens	118-121
15342961-5	2004	Amino acids activated S6K by phosphorylation at Thr-389, but the toxins did not, and AICAR in fact suppressed the activating phosphorylation induced by the amino acids.	Threonine	48-51	ribosomal protein S6 kinase B1	Homo sapiens	22-25
15304500-6	2004	Selective MEK inhibitors attenuated TGFalpha-mediated basal activation of p70S6K (S6K) specifically at Thr-389, indicating that this S6K site is downstream of ERK/MAPK signaling.	Threonine	103-106	ribosomal protein S6 kinase B1	Homo sapiens	74-80
15382039-8	2004	On the one hand, NS398 decreases the expression of HIF-1alpha mRNA and reduces HIF-1alpha synthesis in a COX-2/PGE2 dependent way, which can be restored by addition of exogenous PGE2 that activates the phosphatidylinositol 3-kinase/AKT/p70s6k signaling pathway.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	17-22	ribosomal protein S6 kinase B1	Homo sapiens	236-242
15382039-8	2004	On the one hand, NS398 decreases the expression of HIF-1alpha mRNA and reduces HIF-1alpha synthesis in a COX-2/PGE2 dependent way, which can be restored by addition of exogenous PGE2 that activates the phosphatidylinositol 3-kinase/AKT/p70s6k signaling pathway.	Dinoprostone	111-115	ribosomal protein S6 kinase B1	Homo sapiens	236-242
15382039-8	2004	On the one hand, NS398 decreases the expression of HIF-1alpha mRNA and reduces HIF-1alpha synthesis in a COX-2/PGE2 dependent way, which can be restored by addition of exogenous PGE2 that activates the phosphatidylinositol 3-kinase/AKT/p70s6k signaling pathway.	Dinoprostone	178-182	ribosomal protein S6 kinase B1	Homo sapiens	236-242
15520200-9	2004	Indeed, VEGF-induced proliferation of HUVECs was sensitive to rapamycin, an inhibitor of p70 S6K activation.	Sirolimus	62-71	ribosomal protein S6 kinase B1	Homo sapiens	89-96
15235105-5	2004	In the presence of PI3K inhibitors (Wortmannin), EGF-stimulated trophoblast migration and phosphorylation of AKT and P70S6K (Thr(389) and Thr(421)/Ser(424)) were decreased, while EGF-induced ERK phosphorylation was not affected.	Wortmannin	36-46	ribosomal protein S6 kinase B1	Homo sapiens	117-123
15342917-5	2004	In this study, we show that phorbol esters and activated Ras also induce the phosphorylation of tuberin and collaborates with the nutrient-sensing pathway to regulate mTOR effectors, such as p70 ribosomal S6 kinase 1 (S6K1).	Phorbol Esters	28-42	ribosomal protein S6 kinase B1	Homo sapiens	218-222
15342917-7	2004	RSK1 phosphorylation of Ser-1798 inhibits the tumor suppressor function of the tuberin/hamartin complex, resulting in increased mTOR signaling to S6K1.	Serine	24-27	ribosomal protein S6 kinase B1	Homo sapiens	146-150
15341740-5	2004	We find that serines 383 and 385 of human SKAR are insulin-stimulated and rapamycin-sensitive S6K1 phosphorylation sites.	Serine	13-20	ribosomal protein S6 kinase B1	Homo sapiens	94-98
15341740-6	2004	Quantitative mass spectrometry reveals that serine 383/385 phosphorylation is sensitive to RNA interference (RNAi)-mediated S6K1 reduction, but not S6K2 reduction.	Serine	44-50	ribosomal protein S6 kinase B1	Homo sapiens	124-128
15105162-6	2004	Inhibition of PI(3) kinase or mTOR with LY294002 or rapamycin blocked p70S6K activation, prevented formation of large elongated contractile phenotype myocytes, and blocked accumulation of SM22 and smMHC.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	40-48	ribosomal protein S6 kinase B1	Homo sapiens	70-76
15317677-6	2004	In addition, both of the phosphatidylinositol 3-kinase inhibitors wortmannin and LY-294002 abolished the ANG II-induced increase in protein synthesis, and wortmannin also blocked p70(S6k) phosphorylation.	Wortmannin	66-76	ribosomal protein S6 kinase B1	Homo sapiens	183-186
15317677-6	2004	In addition, both of the phosphatidylinositol 3-kinase inhibitors wortmannin and LY-294002 abolished the ANG II-induced increase in protein synthesis, and wortmannin also blocked p70(S6k) phosphorylation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	81-90	ribosomal protein S6 kinase B1	Homo sapiens	183-186
15317677-6	2004	In addition, both of the phosphatidylinositol 3-kinase inhibitors wortmannin and LY-294002 abolished the ANG II-induced increase in protein synthesis, and wortmannin also blocked p70(S6k) phosphorylation.	Wortmannin	155-165	ribosomal protein S6 kinase B1	Homo sapiens	183-186
15235105-5	2004	In the presence of PI3K inhibitors (Wortmannin), EGF-stimulated trophoblast migration and phosphorylation of AKT and P70S6K (Thr(389) and Thr(421)/Ser(424)) were decreased, while EGF-induced ERK phosphorylation was not affected.	Threonine	125-128	ribosomal protein S6 kinase B1	Homo sapiens	117-123
15235105-6	2004	Expression of an activated AKT (Myr-AKT2) increased basal phospho-p70S6K (Thr(389) and Thr(421)/Ser(424)) content, but failed to stimulate cell migration.	Threonine	74-77	ribosomal protein S6 kinase B1	Homo sapiens	66-72
15235105-8	2004	In addition, there was a concentration-dependent inhibition of cell migration and p70S6K phosphorylation (Thr(389) and Thr(421)/Ser(424)) in the presence of Rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR, a downstream of AKT).	Threonine	106-109	ribosomal protein S6 kinase B1	Homo sapiens	82-88
15235105-8	2004	In addition, there was a concentration-dependent inhibition of cell migration and p70S6K phosphorylation (Thr(389) and Thr(421)/Ser(424)) in the presence of Rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR, a downstream of AKT).	Serine	128-131	ribosomal protein S6 kinase B1	Homo sapiens	82-88
15235105-8	2004	In addition, there was a concentration-dependent inhibition of cell migration and p70S6K phosphorylation (Thr(389) and Thr(421)/Ser(424)) in the presence of Rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR, a downstream of AKT).	Sirolimus	157-166	ribosomal protein S6 kinase B1	Homo sapiens	82-88
14998784-0	2004	Branched-chain amino acids increase p70S6k phosphorylation in human skeletal muscle after resistance exercise.	Amino Acids, Branched-Chain	0-26	ribosomal protein S6 kinase B1	Homo sapiens	36-42
15213227-6	2004	Protein synthesis in wild-type livers was decreased concomitant with increased phosphorylation of eIF2 and decreased phosphorylation of 4E-BP1 and S6K1, translation regulators controlled nutritionally by mammalian target of rapamycin.	Sirolimus	224-233	ribosomal protein S6 kinase B1	Homo sapiens	147-151
15208659-5	2004	LY294002, a PI3K inhibitor, blocked the activation of Akt and p70S6K, indicating that Akt and p70S6K activation is linked to PI3K activation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	ribosomal protein S6 kinase B1	Homo sapiens	62-68
15208659-5	2004	LY294002, a PI3K inhibitor, blocked the activation of Akt and p70S6K, indicating that Akt and p70S6K activation is linked to PI3K activation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	ribosomal protein S6 kinase B1	Homo sapiens	94-100
15208659-7	2004	Rapamycin, a specific inhibitor of FRAP/mTOR (the upstream kinase of p70S6K), also blocked p70S6K activation, indicating the involvement of FRAP/mTOR activation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	69-75
15208659-7	2004	Rapamycin, a specific inhibitor of FRAP/mTOR (the upstream kinase of p70S6K), also blocked p70S6K activation, indicating the involvement of FRAP/mTOR activation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	91-97
15208659-8	2004	LY294002 and rapamycin also blocked the enhancement of Egr-1 level, Cdk5 activity, and myogenin expression, suggesting that upregulation of these factors is coupled to PI3K-p70S6K activation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	ribosomal protein S6 kinase B1	Homo sapiens	173-179
15208659-8	2004	LY294002 and rapamycin also blocked the enhancement of Egr-1 level, Cdk5 activity, and myogenin expression, suggesting that upregulation of these factors is coupled to PI3K-p70S6K activation.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	173-179
15039148-6	2004	Dexamethasone treatment did not alter the basal phosphorylation state of 4E-BP1, p70(S6K), or eIF2alpha; however, it abrogated the stimulatory effect of amino acid infusion on the phosphorylation of 4E-BP1 (P = 0.31) without affecting amino acid-induced phosphorylation of p70(S6K) (P = 0.002) or dephosphorylation of eIF2alpha (P = 0.003).	Dexamethasone	0-13	ribosomal protein S6 kinase B1	Homo sapiens	273-276
15255942-2	2004	We have previously shown that the acetylcholine analog carbachol induces astroglial cell proliferation through activation of muscarinic M3 receptors, and that ethanol strongly inhibits this effect by inhibiting activation of protein kinase C (PKC) zeta and its down-stream effector 70-kDa ribosomal S6 kinase (p70S6K).	Ethanol	159-166	ribosomal protein S6 kinase B1	Homo sapiens	310-316
15255942-5	2004	In addition, exogenous PAs were able to increase DNA synthesis and to activate PKC zeta and p70S6K.	Protactinium	23-26	ribosomal protein S6 kinase B1	Homo sapiens	92-98
14998784-5	2004	Resistance exercise led to a robust increase in p70(S6k) phosphorylation at Ser(424) and/or Thr(421), which persisted 1 and 2 h after exercise.	Serine	76-79	ribosomal protein S6 kinase B1	Homo sapiens	52-55
14998784-6	2004	BCAA ingestion further enhanced p70(S6k) phosphorylation 3.5-fold during recovery.	Amino Acids, Branched-Chain	0-4	ribosomal protein S6 kinase B1	Homo sapiens	36-39
14998784-7	2004	p70(S6k) phosphorylation at Thr(389) was unaltered directly after resistance exercise.	Threonine	28-31	ribosomal protein S6 kinase B1	Homo sapiens	4-7
14998784-11	2004	In conclusion, BCAA, ingested during and after resistance exercise, mediate signal transduction through p70(S6k) in skeletal muscle.	Amino Acids, Branched-Chain	15-19	ribosomal protein S6 kinase B1	Homo sapiens	108-111
15158097-5	2004	On the other hand, cells that had been induced to differentiate and express granulocytic phenotypes, showed an increased ( approximately 6-fold) basal level of p70S6K T(421)/S(424) phosphorylation over immature cells, as well as an increased baseline tyrosyl phosphorylation of the GM-CSF receptor beta subunit (GM-CSF.Rbeta).	cyclo(tyrosyl-tyrosyl)	251-258	ribosomal protein S6 kinase B1	Homo sapiens	160-166
15158097-9	2004	In summary, these findings show the increase in basal phosphorylation of p70S6K upon granulocytic differentiation of myeloid leukemic cells and their responses to GM-CSF that are closely paralleled with tyrosyl phosphorylation of its receptor, and help in pointing to specific cell signaling molecules that are different in leukemic blasts from normal leukocytes.	cyclo(tyrosyl-tyrosyl)	203-210	ribosomal protein S6 kinase B1	Homo sapiens	73-79
15149849-8	2004	Conversely, cytochalasin D and the Rho kinase inhibitor Y-27632, both of which cause stress fiber disruption, increased p70(S6K) activity.	Cytochalasin D	12-26	ribosomal protein S6 kinase B1	Homo sapiens	124-127
15149849-8	2004	Conversely, cytochalasin D and the Rho kinase inhibitor Y-27632, both of which cause stress fiber disruption, increased p70(S6K) activity.	Y 27632	56-63	ribosomal protein S6 kinase B1	Homo sapiens	124-127
14998784-1	2004	The aim of the study was to investigate the effect of resistance exercise alone or in combination with oral intake of branched-chain amino acids (BCAA) on phosphorylation of the 70-kDa S6 protein kinase (p70(S6k)) and mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK1/2), and p38 MAPK in skeletal muscle.	Amino Acids, Branched-Chain	118-144	ribosomal protein S6 kinase B1	Homo sapiens	208-211
14998784-1	2004	The aim of the study was to investigate the effect of resistance exercise alone or in combination with oral intake of branched-chain amino acids (BCAA) on phosphorylation of the 70-kDa S6 protein kinase (p70(S6k)) and mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK1/2), and p38 MAPK in skeletal muscle.	Amino Acids, Branched-Chain	146-150	ribosomal protein S6 kinase B1	Homo sapiens	208-211
15607500-8	2004	Rapa was a highly potent and effective inhibitor of cSMC proliferation (reduction in DNA synthesis by &gt;50% from 0.01 ng/ml), acting through inhibition of 70-kDa S6 kinase (p70S6k).	csmc	52-56	ribosomal protein S6 kinase B1	Homo sapiens	175-181
14993219-3	2004	We show here that deletion of either Tsc1 or Tsc2 or expression of the Rheb (Ras homolog enriched in brain) GTPase leads to hyperphosphorylation of S6K1 at a subset of regulatory sites, particularly those of two essential residues functionally conserved among AGC superfamily serine/threonine kinases, i.e. the activation loop (T-loop; Thr-229) and the hydrophobic motif (H-motif; Thr-389).	Serine	276-282	ribosomal protein S6 kinase B1	Homo sapiens	148-152
14993219-3	2004	We show here that deletion of either Tsc1 or Tsc2 or expression of the Rheb (Ras homolog enriched in brain) GTPase leads to hyperphosphorylation of S6K1 at a subset of regulatory sites, particularly those of two essential residues functionally conserved among AGC superfamily serine/threonine kinases, i.e. the activation loop (T-loop; Thr-229) and the hydrophobic motif (H-motif; Thr-389).	Threonine	336-339	ribosomal protein S6 kinase B1	Homo sapiens	148-152
14993219-3	2004	We show here that deletion of either Tsc1 or Tsc2 or expression of the Rheb (Ras homolog enriched in brain) GTPase leads to hyperphosphorylation of S6K1 at a subset of regulatory sites, particularly those of two essential residues functionally conserved among AGC superfamily serine/threonine kinases, i.e. the activation loop (T-loop; Thr-229) and the hydrophobic motif (H-motif; Thr-389).	Threonine	381-384	ribosomal protein S6 kinase B1	Homo sapiens	148-152
15070696-7	2004	The phosphorylation of the serine/threonine kinase p70S6K at Thr389 and Thr421/Ser424 was down-regulated by rapamycin and/or dexamethasone.	Sirolimus	108-117	ribosomal protein S6 kinase B1	Homo sapiens	51-57
15070696-7	2004	The phosphorylation of the serine/threonine kinase p70S6K at Thr389 and Thr421/Ser424 was down-regulated by rapamycin and/or dexamethasone.	Dexamethasone	125-138	ribosomal protein S6 kinase B1	Homo sapiens	51-57
15070696-8	2004	Strikingly, the combinatorial treatment with rapamycin and dexamethasone suppressed the antiapoptotic effects of exogenously added IGF-I and interleukin 6 (IL-6) as well as their stimulation of p70S6K phosphorylation.	Sirolimus	45-54	ribosomal protein S6 kinase B1	Homo sapiens	194-200
15070696-8	2004	Strikingly, the combinatorial treatment with rapamycin and dexamethasone suppressed the antiapoptotic effects of exogenously added IGF-I and interleukin 6 (IL-6) as well as their stimulation of p70S6K phosphorylation.	Dexamethasone	59-72	ribosomal protein S6 kinase B1	Homo sapiens	194-200
15016873-7	2004	Significantly, rapamycin, an inhibitor commonly used to investigate the mTOR/p70S6K pathway, reduced the in vivo phosphorylation of specific NS5A phosphopeptides, strongly suggesting that p70S6 kinase and potentially related members of this group phosphorylate NS5A inside the cell.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	77-83
15209375-2	2004	One of the most studied signalling events controlled by PtdIns(3,4,5)P3, comprises the activation of a group of AGC family protein kinases, including isoforms of protein kinase B (PKB)/Akt, p70 ribosomal S6 kinase (S6K), serum- and glucocorticoid-induced protein kinase (SGK) and protein kinase C (PKC), which play crucial roles in regulating physiological processes relevant to metabolism, growth, proliferation and survival.	phosphatidylinositol 3,4,5-triphosphate	56-71	ribosomal protein S6 kinase B1	Homo sapiens	204-213
15209375-2	2004	One of the most studied signalling events controlled by PtdIns(3,4,5)P3, comprises the activation of a group of AGC family protein kinases, including isoforms of protein kinase B (PKB)/Akt, p70 ribosomal S6 kinase (S6K), serum- and glucocorticoid-induced protein kinase (SGK) and protein kinase C (PKC), which play crucial roles in regulating physiological processes relevant to metabolism, growth, proliferation and survival.	phosphatidylinositol 3,4,5-triphosphate	56-71	ribosomal protein S6 kinase B1	Homo sapiens	215-218
14684182-4	2004	Recent reports including our study have demonstrated the possible interplay between mTOR and AMPK signaling pathways, supporting a model in which mitochondrial dysfunction caused by the mitochondrial inhibitors or ATP depletion inhibits activation of p70 S6 kinase alpha (p70alpha), a downstream effector of mTOR, by activating AMPK.	Adenosine Triphosphate	214-217	ribosomal protein S6 kinase B1	Homo sapiens	251-270
14871980-9	2004	In contrast, overexpression of S6K1, and phosphorylated Akt independent of phosphatase and tensin homologue deleted from chromosome 10 status, were associated with rapamycin sensitivity.	Sirolimus	164-173	ribosomal protein S6 kinase B1	Homo sapiens	31-35
14871980-11	2004	Rapamycin inhibited the phosphorylation of S6K1, ribosomal S6 protein, and 4E-BP1 in rapamycin-resistant as well as -sensitive cells, indicating that its ability to inhibit the mTOR pathway is not sufficient to confer sensitivity to rapamycin.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	43-47
14769825-3	2004	We studied the role of PLD in the phosphorylation of p70(S6K) and 4E-BP1 induced by lysophosphatidic acid (LPA) and platelet-derived growth factor (PDGF) using fibroblasts deficient in PLD activity and also 1-butanol, which inhibits phosphatidic acid production by PLD.	lysophosphatidic acid	84-105	ribosomal protein S6 kinase B1	Homo sapiens	53-56
14769825-3	2004	We studied the role of PLD in the phosphorylation of p70(S6K) and 4E-BP1 induced by lysophosphatidic acid (LPA) and platelet-derived growth factor (PDGF) using fibroblasts deficient in PLD activity and also 1-butanol, which inhibits phosphatidic acid production by PLD.	lysophosphatidic acid	107-110	ribosomal protein S6 kinase B1	Homo sapiens	53-56
14769825-3	2004	We studied the role of PLD in the phosphorylation of p70(S6K) and 4E-BP1 induced by lysophosphatidic acid (LPA) and platelet-derived growth factor (PDGF) using fibroblasts deficient in PLD activity and also 1-butanol, which inhibits phosphatidic acid production by PLD.	1-Butanol	207-216	ribosomal protein S6 kinase B1	Homo sapiens	53-56
14769825-3	2004	We studied the role of PLD in the phosphorylation of p70(S6K) and 4E-BP1 induced by lysophosphatidic acid (LPA) and platelet-derived growth factor (PDGF) using fibroblasts deficient in PLD activity and also 1-butanol, which inhibits phosphatidic acid production by PLD.	Phosphatidic Acids	88-105	ribosomal protein S6 kinase B1	Homo sapiens	53-56
14717609-6	2004	Specific phospho-Threo recognition by the p70S6K antibody directed to target phospho-Threo residue 389 correlated with ZmS6K activation.	threo	17-22	ribosomal protein S6 kinase B1	Homo sapiens	42-48
14717609-6	2004	Specific phospho-Threo recognition by the p70S6K antibody directed to target phospho-Threo residue 389 correlated with ZmS6K activation.	threo	85-90	ribosomal protein S6 kinase B1	Homo sapiens	42-48
14970836-6	2004	In contrast, rapamycin completely inhibited insulin-stimulated p70 S6K activation, assessed by phosphorylation of p70 S6K and its substrate, S6.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	63-70
14970836-6	2004	In contrast, rapamycin completely inhibited insulin-stimulated p70 S6K activation, assessed by phosphorylation of p70 S6K and its substrate, S6.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	114-121
15228219-0	2004	Tissue-specific regulation of 4E-BP1 and S6K1 phosphorylation by alpha-ketoisocaproate.	alpha-ketoisocaproic acid	65-86	ribosomal protein S6 kinase B1	Homo sapiens	41-45
15228219-1	2004	The indispensable branched-chain amino acid leucine acts as a key regulator of mRNA translation by modulating the phosphorylation of proteins that represent important control points in translation initiation, including the translational repressor, eukaryotic initiation factor (eIF) 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase (S6K1).	branched-chain amino acid leucine	18-51	ribosomal protein S6 kinase B1	Homo sapiens	346-351
15228219-2	2004	In the current study, we compared the effects of L- and D-enantiomers of leucine on the phosphorylation of 4E-BP1 and S6K1.	Leucine	73-80	ribosomal protein S6 kinase B1	Homo sapiens	118-122
15228219-4	2004	Food-deprived (18 h) rats were orally administered 135 mg/100 g body weight L-leucine, D-leucine or alpha-KIC and were sacrificed after 1 h. L-Leucine administration had an obvious stimulatory effect on the phosphorylation of 4E-BP1 and S6K1 in both skeletal muscle and liver while D-leucine was much less effective, indicating that the effect of leucine is stereospecific.	Leucine	141-150	ribosomal protein S6 kinase B1	Homo sapiens	237-241
15228219-7	2004	The results showing that the efficacy of L-leucine and alpha-KIC in stimulating phosphorylation of S6K1 and 4E-BP1 is equivalent in skeletal muscle, may be explained by the conversion of alpha-KIC to L-leucine.	Leucine	41-50	ribosomal protein S6 kinase B1	Homo sapiens	99-114
15228219-7	2004	The results showing that the efficacy of L-leucine and alpha-KIC in stimulating phosphorylation of S6K1 and 4E-BP1 is equivalent in skeletal muscle, may be explained by the conversion of alpha-KIC to L-leucine.	Leucine	200-209	ribosomal protein S6 kinase B1	Homo sapiens	99-114
14684182-4	2004	Recent reports including our study have demonstrated the possible interplay between mTOR and AMPK signaling pathways, supporting a model in which mitochondrial dysfunction caused by the mitochondrial inhibitors or ATP depletion inhibits activation of p70 S6 kinase alpha (p70alpha), a downstream effector of mTOR, by activating AMPK.	Adenosine Triphosphate	214-217	ribosomal protein S6 kinase B1	Homo sapiens	272-280
14684182-5	2004	Leucine may stimulate p70alpha phosphorylation via mTOR pathway, in part, by serving both as a mitochondrial fuel through oxidative carboxylation and an allosteric activation of glutamate dehydrogenase.	Leucine	0-7	ribosomal protein S6 kinase B1	Homo sapiens	22-30
12960228-7	2003	Low doses of LY294002, a phosphatidyl-inositol-3-kinase inhibitor, which abolished cell growth and p70S6K activity but did not influence Akt activity, did not block the insulin-mediated rescue either.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	13-21	ribosomal protein S6 kinase B1	Homo sapiens	99-105
14560955-1	2004	The p70 S6 kinase (p70 S6K) was the first signaling element in mammalian cells shown to be inhibited by rapamycin.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	4-17
14560955-1	2004	The p70 S6 kinase (p70 S6K) was the first signaling element in mammalian cells shown to be inhibited by rapamycin.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	19-26
14560955-2	2004	The activity of the p70 S6K in mammalian cell is upregulated by extracellular amino acids (especially leucine) and by signals from receptor tyrosine kinases (RTKs), primarily through activation of the type 1A PI-3 kinase.	Leucine	102-109	ribosomal protein S6 kinase B1	Homo sapiens	20-27
14560955-3	2004	The amino acid-/rapamycin-sensitive input and the PI-3 kinase input are co-dominant but largely independent, in that deletion of the amino-terminal and carboxy-terminal noncatalytic sequences flanking the p70 S6K catalytic domain renders the kinase insensitive to inhibition by both rapamycin and by withdrawal of amino acids, whereas this p70 S6K mutant remains responsive to activation by RTKs and to inhibition by wortmannin.	Sirolimus	16-25	ribosomal protein S6 kinase B1	Homo sapiens	205-212
14560955-3	2004	The amino acid-/rapamycin-sensitive input and the PI-3 kinase input are co-dominant but largely independent, in that deletion of the amino-terminal and carboxy-terminal noncatalytic sequences flanking the p70 S6K catalytic domain renders the kinase insensitive to inhibition by both rapamycin and by withdrawal of amino acids, whereas this p70 S6K mutant remains responsive to activation by RTKs and to inhibition by wortmannin.	Sirolimus	16-25	ribosomal protein S6 kinase B1	Homo sapiens	340-347
14560955-3	2004	The amino acid-/rapamycin-sensitive input and the PI-3 kinase input are co-dominant but largely independent, in that deletion of the amino-terminal and carboxy-terminal noncatalytic sequences flanking the p70 S6K catalytic domain renders the kinase insensitive to inhibition by both rapamycin and by withdrawal of amino acids, whereas this p70 S6K mutant remains responsive to activation by RTKs and to inhibition by wortmannin.	Sirolimus	283-292	ribosomal protein S6 kinase B1	Homo sapiens	205-212
14560955-3	2004	The amino acid-/rapamycin-sensitive input and the PI-3 kinase input are co-dominant but largely independent, in that deletion of the amino-terminal and carboxy-terminal noncatalytic sequences flanking the p70 S6K catalytic domain renders the kinase insensitive to inhibition by both rapamycin and by withdrawal of amino acids, whereas this p70 S6K mutant remains responsive to activation by RTKs and to inhibition by wortmannin.	Wortmannin	417-427	ribosomal protein S6 kinase B1	Homo sapiens	205-212
14560955-4	2004	At a molecular level, this dual control of p70 S6K activity is attributable to phosphorylation of the two p70 S6K sites: The Ptd Ins 3,4,5P3-dependent kinasel (PDK1) phosphorylates p70 S6K at a Thr on the activation loop, whereas mTOR phosphorylates a Thr located in a hydrophobic motif carboxyterminal to the catalytic domain.	Threonine	194-197	ribosomal protein S6 kinase B1	Homo sapiens	43-50
14560955-4	2004	At a molecular level, this dual control of p70 S6K activity is attributable to phosphorylation of the two p70 S6K sites: The Ptd Ins 3,4,5P3-dependent kinasel (PDK1) phosphorylates p70 S6K at a Thr on the activation loop, whereas mTOR phosphorylates a Thr located in a hydrophobic motif carboxyterminal to the catalytic domain.	Threonine	194-197	ribosomal protein S6 kinase B1	Homo sapiens	106-113
14560955-4	2004	At a molecular level, this dual control of p70 S6K activity is attributable to phosphorylation of the two p70 S6K sites: The Ptd Ins 3,4,5P3-dependent kinasel (PDK1) phosphorylates p70 S6K at a Thr on the activation loop, whereas mTOR phosphorylates a Thr located in a hydrophobic motif carboxyterminal to the catalytic domain.	Threonine	194-197	ribosomal protein S6 kinase B1	Homo sapiens	106-113
14560955-4	2004	At a molecular level, this dual control of p70 S6K activity is attributable to phosphorylation of the two p70 S6K sites: The Ptd Ins 3,4,5P3-dependent kinasel (PDK1) phosphorylates p70 S6K at a Thr on the activation loop, whereas mTOR phosphorylates a Thr located in a hydrophobic motif carboxyterminal to the catalytic domain.	Threonine	252-255	ribosomal protein S6 kinase B1	Homo sapiens	43-50
14560955-4	2004	At a molecular level, this dual control of p70 S6K activity is attributable to phosphorylation of the two p70 S6K sites: The Ptd Ins 3,4,5P3-dependent kinasel (PDK1) phosphorylates p70 S6K at a Thr on the activation loop, whereas mTOR phosphorylates a Thr located in a hydrophobic motif carboxyterminal to the catalytic domain.	Threonine	252-255	ribosomal protein S6 kinase B1	Homo sapiens	106-113
14560955-4	2004	At a molecular level, this dual control of p70 S6K activity is attributable to phosphorylation of the two p70 S6K sites: The Ptd Ins 3,4,5P3-dependent kinasel (PDK1) phosphorylates p70 S6K at a Thr on the activation loop, whereas mTOR phosphorylates a Thr located in a hydrophobic motif carboxyterminal to the catalytic domain.	Threonine	252-255	ribosomal protein S6 kinase B1	Homo sapiens	106-113
14560963-7	2004	mTOR immunopurified from culture cells or tissues phosphorylates in vitro p70 S6 kinase (p70) alpha and p70beta, mainly on Thr412 or Thr401, respectively, located in a Phe-Thr-Tyr motif.	Phenylalanine	168-171	ribosomal protein S6 kinase B1	Homo sapiens	89-99
14560963-7	2004	mTOR immunopurified from culture cells or tissues phosphorylates in vitro p70 S6 kinase (p70) alpha and p70beta, mainly on Thr412 or Thr401, respectively, located in a Phe-Thr-Tyr motif.	Threonine	123-126	ribosomal protein S6 kinase B1	Homo sapiens	89-99
14560963-7	2004	mTOR immunopurified from culture cells or tissues phosphorylates in vitro p70 S6 kinase (p70) alpha and p70beta, mainly on Thr412 or Thr401, respectively, located in a Phe-Thr-Tyr motif.	Tyrosine	176-179	ribosomal protein S6 kinase B1	Homo sapiens	89-99
14971662-3	2004	The present study investigated the vanadate-induced phosphorylation of Akt and p70S6K, two kinases known to be vital for cell survival, growth, transformation, and transition of the cell cycle in mammals.	Vanadates	35-43	ribosomal protein S6 kinase B1	Homo sapiens	79-85
14971662-4	2004	Exposure of mouse epidermal JB6 cells to vanadium led to phosphorylation of Akt and p70S6K in a time- and dose-dependent manner.	Vanadium	41-49	ribosomal protein S6 kinase B1	Homo sapiens	84-90
14971662-7	2004	Furthermore, vanadium-induced p70S6k phosphorylation at Thr389 and Thr421/Ser424 and Akt phosphorylation at Thr308 occurred through a PI-3K-dependent pathway because a PI-3K dominant negative mutant inhibited induction as compared with vector control cells.	Vanadium	13-21	ribosomal protein S6 kinase B1	Homo sapiens	30-36
14971662-8	2004	These results indicate that there was a differential role of aPKC in vanadate-induced phosphorylation of Akt and p70S6k, suggesting that signal transduction pathways leading to the activation of Akt and p70S6k were different.	Vanadates	69-77	ribosomal protein S6 kinase B1	Homo sapiens	113-119
14971662-8	2004	These results indicate that there was a differential role of aPKC in vanadate-induced phosphorylation of Akt and p70S6k, suggesting that signal transduction pathways leading to the activation of Akt and p70S6k were different.	Vanadates	69-77	ribosomal protein S6 kinase B1	Homo sapiens	203-209
14623952-9	2003	Taken together, the present data suggest that the N-methyl-d-aspartate-, phosphatidylinositol 3-kinase-dependent dendritic activation of the mTOR-p70S6K pathway is necessary for the induction phase of protein synthesis-dependent synaptic plasticity.	N-Methylaspartate	50-70	ribosomal protein S6 kinase B1	Homo sapiens	146-152
14623952-9	2003	Taken together, the present data suggest that the N-methyl-d-aspartate-, phosphatidylinositol 3-kinase-dependent dendritic activation of the mTOR-p70S6K pathway is necessary for the induction phase of protein synthesis-dependent synaptic plasticity.	Phosphatidylinositols	73-93	ribosomal protein S6 kinase B1	Homo sapiens	146-152
12937293-7	2003	S6K1 phosphorylation on Thr-389 demonstrated a trend for peak activation at 10 min following exercise (336%, P = 0.06) with ribosomal protein S6 phosphorylation being maximally activated at 15 min of recovery (647%, P &lt; 0.05).	Threonine	24-27	ribosomal protein S6 kinase B1	Homo sapiens	0-4
12907754-8	2003	The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 abolished cell proliferation and activation of p70S6K and Akt; however, PRL-dependent activation of Erk1/2 was not modified.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	51-59	ribosomal protein S6 kinase B1	Homo sapiens	107-113
14602936-7	2003	By using the newly developed TBIO method of PCR-based gene synthesis, error-free synthetic genes for the human protein kinases PKB2, S6K1 and PDK1 were obtained with little or no corrective mutagenesis.	tbio	29-33	ribosomal protein S6 kinase B1	Homo sapiens	133-137
12704019-2	2003	Here we report that isoproterenol phosphorylated the protein S6 kinase (p70S6k) in alveolar epithelial cells, which was inhibited by both rapamycin and the MEK1/2 inhibitor U-0126.	Isoproterenol	20-33	ribosomal protein S6 kinase B1	Homo sapiens	72-78
14516795-0	2003	Hydrogen peroxide mediates arsenite activation of p70(s6k) and extracellular signal-regulated kinase.	Hydrogen Peroxide	0-17	ribosomal protein S6 kinase B1	Homo sapiens	50-57
14516795-0	2003	Hydrogen peroxide mediates arsenite activation of p70(s6k) and extracellular signal-regulated kinase.	arsenite	27-35	ribosomal protein S6 kinase B1	Homo sapiens	50-57
14516795-2	2003	Arsenite treatment resulted in the persistent activation of p70(s6k) and extracellular signal-regulated kinase 1/2 (ERK1/2) which was accompanied by an increase in intracellular ROS production.	arsenite	0-8	ribosomal protein S6 kinase B1	Homo sapiens	60-67
14516795-4	2003	Elimination of H(2)O(2) by catalase or N-acetyl-L-cysteine inhibited the arsenite-induced activation of p70(s6k) and ERK1/2, indicating the possible role of H(2)O(2) in the arsenite activation of the p70(s6k) and the ERK1/2 signaling pathways.	Hydrogen Peroxide	15-23	ribosomal protein S6 kinase B1	Homo sapiens	104-111
14516795-4	2003	Elimination of H(2)O(2) by catalase or N-acetyl-L-cysteine inhibited the arsenite-induced activation of p70(s6k) and ERK1/2, indicating the possible role of H(2)O(2) in the arsenite activation of the p70(s6k) and the ERK1/2 signaling pathways.	Hydrogen Peroxide	15-23	ribosomal protein S6 kinase B1	Homo sapiens	200-207
14516795-4	2003	Elimination of H(2)O(2) by catalase or N-acetyl-L-cysteine inhibited the arsenite-induced activation of p70(s6k) and ERK1/2, indicating the possible role of H(2)O(2) in the arsenite activation of the p70(s6k) and the ERK1/2 signaling pathways.	Acetylcysteine	39-58	ribosomal protein S6 kinase B1	Homo sapiens	104-111
14516795-4	2003	Elimination of H(2)O(2) by catalase or N-acetyl-L-cysteine inhibited the arsenite-induced activation of p70(s6k) and ERK1/2, indicating the possible role of H(2)O(2) in the arsenite activation of the p70(s6k) and the ERK1/2 signaling pathways.	arsenite	73-81	ribosomal protein S6 kinase B1	Homo sapiens	104-111
14516795-4	2003	Elimination of H(2)O(2) by catalase or N-acetyl-L-cysteine inhibited the arsenite-induced activation of p70(s6k) and ERK1/2, indicating the possible role of H(2)O(2) in the arsenite activation of the p70(s6k) and the ERK1/2 signaling pathways.	arsenite	73-81	ribosomal protein S6 kinase B1	Homo sapiens	200-207
14516795-4	2003	Elimination of H(2)O(2) by catalase or N-acetyl-L-cysteine inhibited the arsenite-induced activation of p70(s6k) and ERK1/2, indicating the possible role of H(2)O(2) in the arsenite activation of the p70(s6k) and the ERK1/2 signaling pathways.	Water	15-20	ribosomal protein S6 kinase B1	Homo sapiens	104-111
14516795-4	2003	Elimination of H(2)O(2) by catalase or N-acetyl-L-cysteine inhibited the arsenite-induced activation of p70(s6k) and ERK1/2, indicating the possible role of H(2)O(2) in the arsenite activation of the p70(s6k) and the ERK1/2 signaling pathways.	Water	15-20	ribosomal protein S6 kinase B1	Homo sapiens	200-207
14516795-4	2003	Elimination of H(2)O(2) by catalase or N-acetyl-L-cysteine inhibited the arsenite-induced activation of p70(s6k) and ERK1/2, indicating the possible role of H(2)O(2) in the arsenite activation of the p70(s6k) and the ERK1/2 signaling pathways.	arsenite	173-181	ribosomal protein S6 kinase B1	Homo sapiens	104-111
14516795-6	2003	While the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY294002 completely abrogated arsenite activation of p70(s6k), ERK1/2 activation by arsenite was not affected by these inhibitors, indicating that H(2)O(2) might act as an upstream molecule of PI3K as well as ERK1/2.	Wortmannin	58-68	ribosomal protein S6 kinase B1	Homo sapiens	126-133
14516795-6	2003	While the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY294002 completely abrogated arsenite activation of p70(s6k), ERK1/2 activation by arsenite was not affected by these inhibitors, indicating that H(2)O(2) might act as an upstream molecule of PI3K as well as ERK1/2.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	73-81	ribosomal protein S6 kinase B1	Homo sapiens	126-133
14516795-6	2003	While the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY294002 completely abrogated arsenite activation of p70(s6k), ERK1/2 activation by arsenite was not affected by these inhibitors, indicating that H(2)O(2) might act as an upstream molecule of PI3K as well as ERK1/2.	arsenite	103-111	ribosomal protein S6 kinase B1	Homo sapiens	126-133
13679036-2	2003	Arachidonic acid stimulated phosphorylation of Akt, S6K1, ribosomal protein S6, 4EBP1, and eIF4E in a time-dependent manner in VSMC.	Arachidonic Acid	0-16	ribosomal protein S6 kinase B1	Homo sapiens	52-85
13679036-2	2003	Arachidonic acid stimulated phosphorylation of Akt, S6K1, ribosomal protein S6, 4EBP1, and eIF4E in a time-dependent manner in VSMC.	vsmc	127-131	ribosomal protein S6 kinase B1	Homo sapiens	52-85
13679036-6	2003	LY294002, an inhibitor of PI3K, completely blocked AA-induced phosphorylation of Akt, S6K1, ribosomal protein S6, 4EBP1, and eIF4E, suggesting a role for PI3K in these effects.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	ribosomal protein S6 kinase B1	Homo sapiens	86-119
12812918-11	2003	To begin to test the leucine oxidation hypothesis of mTOR activation, the dose-dependent effects of orally administered leucine on acute activation of S6K1 (an mTOR substrate) and BCKD were compared using the pS293 antibodies.	Leucine	120-127	ribosomal protein S6 kinase B1	Homo sapiens	151-155
14623952-5	2003	Second, we observed that Thr-389-phosphorylated p70 S6 kinase (p70S6K), the main active phosphoform of the mTOR effector p70S6K, was induced in an N-methyl-D-aspartate and phosphatidylinositol 3-kinase-dependent manner throughout the dendrites but not in the cell bodies of CA1 neurons in hippocampal slices after L-LTP induction.	Threonine	25-28	ribosomal protein S6 kinase B1	Homo sapiens	48-61
14623952-5	2003	Second, we observed that Thr-389-phosphorylated p70 S6 kinase (p70S6K), the main active phosphoform of the mTOR effector p70S6K, was induced in an N-methyl-D-aspartate and phosphatidylinositol 3-kinase-dependent manner throughout the dendrites but not in the cell bodies of CA1 neurons in hippocampal slices after L-LTP induction.	Threonine	25-28	ribosomal protein S6 kinase B1	Homo sapiens	63-69
14623952-5	2003	Second, we observed that Thr-389-phosphorylated p70 S6 kinase (p70S6K), the main active phosphoform of the mTOR effector p70S6K, was induced in an N-methyl-D-aspartate and phosphatidylinositol 3-kinase-dependent manner throughout the dendrites but not in the cell bodies of CA1 neurons in hippocampal slices after L-LTP induction.	Threonine	25-28	ribosomal protein S6 kinase B1	Homo sapiens	121-127
14623952-5	2003	Second, we observed that Thr-389-phosphorylated p70 S6 kinase (p70S6K), the main active phosphoform of the mTOR effector p70S6K, was induced in an N-methyl-D-aspartate and phosphatidylinositol 3-kinase-dependent manner throughout the dendrites but not in the cell bodies of CA1 neurons in hippocampal slices after L-LTP induction.	phosphoform	88-99	ribosomal protein S6 kinase B1	Homo sapiens	48-61
14623952-5	2003	Second, we observed that Thr-389-phosphorylated p70 S6 kinase (p70S6K), the main active phosphoform of the mTOR effector p70S6K, was induced in an N-methyl-D-aspartate and phosphatidylinositol 3-kinase-dependent manner throughout the dendrites but not in the cell bodies of CA1 neurons in hippocampal slices after L-LTP induction.	phosphoform	88-99	ribosomal protein S6 kinase B1	Homo sapiens	63-69
14623952-5	2003	Second, we observed that Thr-389-phosphorylated p70 S6 kinase (p70S6K), the main active phosphoform of the mTOR effector p70S6K, was induced in an N-methyl-D-aspartate and phosphatidylinositol 3-kinase-dependent manner throughout the dendrites but not in the cell bodies of CA1 neurons in hippocampal slices after L-LTP induction.	phosphoform	88-99	ribosomal protein S6 kinase B1	Homo sapiens	121-127
14623952-5	2003	Second, we observed that Thr-389-phosphorylated p70 S6 kinase (p70S6K), the main active phosphoform of the mTOR effector p70S6K, was induced in an N-methyl-D-aspartate and phosphatidylinositol 3-kinase-dependent manner throughout the dendrites but not in the cell bodies of CA1 neurons in hippocampal slices after L-LTP induction.	N-Methylaspartate	147-167	ribosomal protein S6 kinase B1	Homo sapiens	48-61
14623952-5	2003	Second, we observed that Thr-389-phosphorylated p70 S6 kinase (p70S6K), the main active phosphoform of the mTOR effector p70S6K, was induced in an N-methyl-D-aspartate and phosphatidylinositol 3-kinase-dependent manner throughout the dendrites but not in the cell bodies of CA1 neurons in hippocampal slices after L-LTP induction.	N-Methylaspartate	147-167	ribosomal protein S6 kinase B1	Homo sapiens	63-69
14623952-5	2003	Second, we observed that Thr-389-phosphorylated p70 S6 kinase (p70S6K), the main active phosphoform of the mTOR effector p70S6K, was induced in an N-methyl-D-aspartate and phosphatidylinositol 3-kinase-dependent manner throughout the dendrites but not in the cell bodies of CA1 neurons in hippocampal slices after L-LTP induction.	N-Methylaspartate	147-167	ribosomal protein S6 kinase B1	Homo sapiens	121-127
14623952-5	2003	Second, we observed that Thr-389-phosphorylated p70 S6 kinase (p70S6K), the main active phosphoform of the mTOR effector p70S6K, was induced in an N-methyl-D-aspartate and phosphatidylinositol 3-kinase-dependent manner throughout the dendrites but not in the cell bodies of CA1 neurons in hippocampal slices after L-LTP induction.	Phosphatidylinositols	172-192	ribosomal protein S6 kinase B1	Homo sapiens	48-61
14623952-5	2003	Second, we observed that Thr-389-phosphorylated p70 S6 kinase (p70S6K), the main active phosphoform of the mTOR effector p70S6K, was induced in an N-methyl-D-aspartate and phosphatidylinositol 3-kinase-dependent manner throughout the dendrites but not in the cell bodies of CA1 neurons in hippocampal slices after L-LTP induction.	Phosphatidylinositols	172-192	ribosomal protein S6 kinase B1	Homo sapiens	63-69
14623952-5	2003	Second, we observed that Thr-389-phosphorylated p70 S6 kinase (p70S6K), the main active phosphoform of the mTOR effector p70S6K, was induced in an N-methyl-D-aspartate and phosphatidylinositol 3-kinase-dependent manner throughout the dendrites but not in the cell bodies of CA1 neurons in hippocampal slices after L-LTP induction.	Phosphatidylinositols	172-192	ribosomal protein S6 kinase B1	Homo sapiens	121-127
14623952-6	2003	A similar dendrite-wide activation of p70S6K was induced in primary hippocampal neurons by depolarization with KCL or glutamate.	Glutamic Acid	118-127	ribosomal protein S6 kinase B1	Homo sapiens	38-44
12704019-2	2003	Here we report that isoproterenol phosphorylated the protein S6 kinase (p70S6k) in alveolar epithelial cells, which was inhibited by both rapamycin and the MEK1/2 inhibitor U-0126.	Sirolimus	138-147	ribosomal protein S6 kinase B1	Homo sapiens	72-78
12704019-2	2003	Here we report that isoproterenol phosphorylated the protein S6 kinase (p70S6k) in alveolar epithelial cells, which was inhibited by both rapamycin and the MEK1/2 inhibitor U-0126.	U 0126	173-179	ribosomal protein S6 kinase B1	Homo sapiens	72-78
12704019-4	2003	Accordingly, we provide here first evidence that isoproterenol regulates Na-K-ATPase via p70S6k in alveolar epithelial cells.	Isoproterenol	49-62	ribosomal protein S6 kinase B1	Homo sapiens	89-95
12906785-7	2003	Rheb also activates S6K1 during amino acid insufficiency via a rapamycin-sensitive mechanism, suggesting that Rheb participates in nutrient signaling through mTOR.	Sirolimus	63-72	ribosomal protein S6 kinase B1	Homo sapiens	20-24
12909616-3	2003	Using adult feline cardiomyocytes, here we report that integrin-interacting Arg-Gly-Asp (RGD) peptides activate S6K1 as observed by band shifting, kinase activity and phosphorylation at Thr-389 and Thr-421/Ser-424 of S6K1, and S6 protein phosphorylation.	Arginine	76-79	ribosomal protein S6 kinase B1	Homo sapiens	112-116
12909616-3	2003	Using adult feline cardiomyocytes, here we report that integrin-interacting Arg-Gly-Asp (RGD) peptides activate S6K1 as observed by band shifting, kinase activity and phosphorylation at Thr-389 and Thr-421/Ser-424 of S6K1, and S6 protein phosphorylation.	Arginine	76-79	ribosomal protein S6 kinase B1	Homo sapiens	217-221
12909616-3	2003	Using adult feline cardiomyocytes, here we report that integrin-interacting Arg-Gly-Asp (RGD) peptides activate S6K1 as observed by band shifting, kinase activity and phosphorylation at Thr-389 and Thr-421/Ser-424 of S6K1, and S6 protein phosphorylation.	Glycine	80-83	ribosomal protein S6 kinase B1	Homo sapiens	112-116
12909616-3	2003	Using adult feline cardiomyocytes, here we report that integrin-interacting Arg-Gly-Asp (RGD) peptides activate S6K1 as observed by band shifting, kinase activity and phosphorylation at Thr-389 and Thr-421/Ser-424 of S6K1, and S6 protein phosphorylation.	Glycine	80-83	ribosomal protein S6 kinase B1	Homo sapiens	217-221
12909616-3	2003	Using adult feline cardiomyocytes, here we report that integrin-interacting Arg-Gly-Asp (RGD) peptides activate S6K1 as observed by band shifting, kinase activity and phosphorylation at Thr-389 and Thr-421/Ser-424 of S6K1, and S6 protein phosphorylation.	Aspartic Acid	84-87	ribosomal protein S6 kinase B1	Homo sapiens	112-116
12909616-3	2003	Using adult feline cardiomyocytes, here we report that integrin-interacting Arg-Gly-Asp (RGD) peptides activate S6K1 as observed by band shifting, kinase activity and phosphorylation at Thr-389 and Thr-421/Ser-424 of S6K1, and S6 protein phosphorylation.	Aspartic Acid	84-87	ribosomal protein S6 kinase B1	Homo sapiens	217-221
12909616-3	2003	Using adult feline cardiomyocytes, here we report that integrin-interacting Arg-Gly-Asp (RGD) peptides activate S6K1 as observed by band shifting, kinase activity and phosphorylation at Thr-389 and Thr-421/Ser-424 of S6K1, and S6 protein phosphorylation.	Threonine	186-189	ribosomal protein S6 kinase B1	Homo sapiens	112-116
14614324-2	2003	Exposure of K562 cells to greater or less than 3.0 mM SB or 3.0 mM SAHA for 24-48 hr resulted in a marked induction of mitchondrial damage (e.g., cytochrome c release) and apoptosis, events associated with downregulation of Bcr/Abl and Raf-1, induction of p21CIP1, inactivation of MEK1/2, ERK1/2, and p70S6K, and a dramatic increase in JNK activation.	Butyric Acid	54-56	ribosomal protein S6 kinase B1	Homo sapiens	301-307
14614324-2	2003	Exposure of K562 cells to greater or less than 3.0 mM SB or 3.0 mM SAHA for 24-48 hr resulted in a marked induction of mitchondrial damage (e.g., cytochrome c release) and apoptosis, events associated with downregulation of Bcr/Abl and Raf-1, induction of p21CIP1, inactivation of MEK1/2, ERK1/2, and p70S6K, and a dramatic increase in JNK activation.	Vorinostat	67-71	ribosomal protein S6 kinase B1	Homo sapiens	301-307
12747804-1	2003	In 1321N1 astrocytoma cells, carbachol stimulation of M3 muscarinic cholinergic receptors, coupled to phospholipase C, evoked a persistent 10-20-fold activation of p70 S6 kinase (S6K1).	Carbachol	29-38	ribosomal protein S6 kinase B1	Homo sapiens	179-183
12914961-4	2003	Interestingly, treating SH-SY5Y cells with retinoic acid greatly increases Ret protein levels and GDNF-induced Ret tyrosine phosphorylation, but does not affect the mitogenic action of GDNF and the activation of the Akt/p70S6K pathway.	Tretinoin	43-56	ribosomal protein S6 kinase B1	Homo sapiens	220-226
12841848-2	2003	In mammalian cells, insulin-induced PI3K (phosphoinositide 3-kinase) activation, generates the lipid second messenger PtdIns(3,4,5) P (3), which is thought to play a key role in triggering the activation of S6K.	ptdins(3,4,5) p	118-133	ribosomal protein S6 kinase B1	Homo sapiens	207-210
12949840-5	2003	Treatment with rapamycin inhibited EGF-induced phosphorylation and activation of ribosomal p70 S6 protein kinase (p70 S6K), an mTOR downstream target, but had no effect on phosphorylation and activation of Akt.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	91-112
12949840-5	2003	Treatment with rapamycin inhibited EGF-induced phosphorylation and activation of ribosomal p70 S6 protein kinase (p70 S6K), an mTOR downstream target, but had no effect on phosphorylation and activation of Akt.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	114-121
12935893-2	2003	We demonstrate that leukocyte chemotaxis is prevented by the macrolide immunosuppressant rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR)/ribosomal p70-S6 kinase (p70S6K) pathway.	Macrolides	61-70	ribosomal protein S6 kinase B1	Homo sapiens	175-188
12935893-2	2003	We demonstrate that leukocyte chemotaxis is prevented by the macrolide immunosuppressant rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR)/ribosomal p70-S6 kinase (p70S6K) pathway.	Macrolides	61-70	ribosomal protein S6 kinase B1	Homo sapiens	190-196
12935893-7	2003	The specificity of the effect of rapamycin was confirmed by the use of the structural analog FK506, which did not have a significant effect on chemotaxis but effectively rescued rapamycin-induced p70S6K inhibition.	Sirolimus	33-42	ribosomal protein S6 kinase B1	Homo sapiens	196-202
12935893-7	2003	The specificity of the effect of rapamycin was confirmed by the use of the structural analog FK506, which did not have a significant effect on chemotaxis but effectively rescued rapamycin-induced p70S6K inhibition.	Tacrolimus	93-98	ribosomal protein S6 kinase B1	Homo sapiens	196-202
12935893-7	2003	The specificity of the effect of rapamycin was confirmed by the use of the structural analog FK506, which did not have a significant effect on chemotaxis but effectively rescued rapamycin-induced p70S6K inhibition.	Sirolimus	178-187	ribosomal protein S6 kinase B1	Homo sapiens	196-202
12747804-2	2003	This response was abolished by chelation of cytosolic Ca2+ and reproduced by the Ca2+ ionophore ionomycin, but was not prevented by down-regulation or inhibition of protein kinase C. Carbachol-stimulated activation and phosphorylation of S6K1 at Thr389 were prevented by rapamycin, an inhibitor of mTOR (mammalian target of rapamycin), or by wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor.	Carbachol	183-192	ribosomal protein S6 kinase B1	Homo sapiens	238-242
12747804-3	2003	Carbachol also stimulated the phosphorylation of eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), a second mTOR-dependent event, with similar potency to its effect on S6K1.	Carbachol	0-9	ribosomal protein S6 kinase B1	Homo sapiens	178-182
12747804-6	2003	By contrast, an inhibitor of epidermal growth factor receptor kinase, AG1478, which prevents carbachol-stimulated ErbB3 transactivation, PI3K recruitment and protein kinase B activation in 1321N1 cells, reduced activation of S6K1 by no more than 30%.	RTKI cpd	70-76	ribosomal protein S6 kinase B1	Homo sapiens	225-229
12747804-6	2003	By contrast, an inhibitor of epidermal growth factor receptor kinase, AG1478, which prevents carbachol-stimulated ErbB3 transactivation, PI3K recruitment and protein kinase B activation in 1321N1 cells, reduced activation of S6K1 by no more than 30%.	Carbachol	93-102	ribosomal protein S6 kinase B1	Homo sapiens	225-229
12740386-5	2003	Rapamycin also caused an inhibition (IC50 0.2 nm) of the in vitro enzymatic activity of p70S6K.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	88-94
12713446-3	2003	Many of the serine/threonine residues that become phosphorylated and contribute to S6K1 activation are conserved in S6K2.	Serine	12-18	ribosomal protein S6 kinase B1	Homo sapiens	83-87
12713446-3	2003	Many of the serine/threonine residues that become phosphorylated and contribute to S6K1 activation are conserved in S6K2.	Threonine	19-28	ribosomal protein S6 kinase B1	Homo sapiens	83-87
12801526-10	2003	IN CONCLUSION: (i) TNF-receptor activation leads to activation of the p70S6K; (ii) TRAF4 is a mediator in this TNF-induced signaling pathway; and (iii) TRAF4 inhibits Fas-induced apoptosis.	ammonium ferrous sulfate	167-170	ribosomal protein S6 kinase B1	Homo sapiens	70-76
12759354-4	2003	Our data demonstrate that p70 S6K is rapidly phosphorylated on threonine 421 and serine 424 and is activated during treatment of cells with IFNalpha or IFNbeta.	Threonine	63-72	ribosomal protein S6 kinase B1	Homo sapiens	26-33
12759354-4	2003	Our data demonstrate that p70 S6K is rapidly phosphorylated on threonine 421 and serine 424 and is activated during treatment of cells with IFNalpha or IFNbeta.	Serine	81-87	ribosomal protein S6 kinase B1	Homo sapiens	26-33
12720544-4	2003	PE also induces activation of p70 ribosomal protein S6 kinases (S6K1 and 2) in adult cardiomyocytes.	Phenylephrine	0-2	ribosomal protein S6 kinase B1	Homo sapiens	30-74
12720544-6	2003	Activation of S6K1/2 by PE was blocked by the broad-spectrum PKC inhibitor bisindolylmaleimide (BIM) I, whereas Go6976, a compound that only inhibits Ca(2+)-dependent PKCs, did not inhibit S6K activation.	Phenylephrine	24-26	ribosomal protein S6 kinase B1	Homo sapiens	14-20
12720544-6	2003	Activation of S6K1/2 by PE was blocked by the broad-spectrum PKC inhibitor bisindolylmaleimide (BIM) I, whereas Go6976, a compound that only inhibits Ca(2+)-dependent PKCs, did not inhibit S6K activation.	bisindolylmaleimide	75-94	ribosomal protein S6 kinase B1	Homo sapiens	14-20
12720544-6	2003	Activation of S6K1/2 by PE was blocked by the broad-spectrum PKC inhibitor bisindolylmaleimide (BIM) I, whereas Go6976, a compound that only inhibits Ca(2+)-dependent PKCs, did not inhibit S6K activation.	bisindolylmaleimide	96-99	ribosomal protein S6 kinase B1	Homo sapiens	14-20
12740386-6	2003	However, the inhibition of activity was not complete, but only a 40-50%, indicating that neutrophil p70S6K activity has a rapamycin-resistant component.	Sirolimus	122-131	ribosomal protein S6 kinase B1	Homo sapiens	100-106
12773160-7	2003	Recent studies from many laboratories have now confirmed our findings in mice, rats and human patients, and have shown that drugs that antagonize S6K activities, such as rapamycin, diminish tumours in TSC-deficient mice and rats.	Sirolimus	170-179	ribosomal protein S6 kinase B1	Homo sapiens	146-149
12668683-6	2003	TSH induced the PDK1-dependent phosphorylation of S6K1 but did not induce Akt/protein kinase B phosphorylation.	Thyrotropin	0-3	ribosomal protein S6 kinase B1	Homo sapiens	50-54
12668683-7	2003	The TSH-induced S6K1 phosphorylation was inhibited by a dominant negative p85alpha regulatory subunit or by the PI3K inhibitors wortmannin and LY294002.	Wortmannin	128-138	ribosomal protein S6 kinase B1	Homo sapiens	16-20
12668683-7	2003	The TSH-induced S6K1 phosphorylation was inhibited by a dominant negative p85alpha regulatory subunit or by the PI3K inhibitors wortmannin and LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	143-151	ribosomal protein S6 kinase B1	Homo sapiens	16-20
12668683-8	2003	Rapamycin inhibited the phosphorylation of S6K1 in the cells treated with either TSH or 8-bromo-cAMP.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	43-47
12668683-8	2003	Rapamycin inhibited the phosphorylation of S6K1 in the cells treated with either TSH or 8-bromo-cAMP.	Thyrotropin	81-84	ribosomal protein S6 kinase B1	Homo sapiens	43-47
12668683-8	2003	Rapamycin inhibited the phosphorylation of S6K1 in the cells treated with either TSH or 8-bromo-cAMP.	8-Bromo Cyclic Adenosine Monophosphate	88-100	ribosomal protein S6 kinase B1	Homo sapiens	43-47
12668683-11	2003	These findings suggest an interaction between TSHR and PI3K, which is stimulated by TSH and cAMP and might involve the downstream S6K1 but not Akt/protein kinase B.	Thyrotropin	46-49	ribosomal protein S6 kinase B1	Homo sapiens	130-134
12818373-1	2003	We have previously suggested that phosphatidylinositol 3-kinase (PI3K)/p70 S6 kinase (p70 S6K) plays an important role in the regulation of neutrophilic differentiation of HL-60 cells on the basis of analysis of transferrin receptor (Trf-R)-positive (Trf-R(+)) and -negative (Trf-R(-)) cells that appear after treatment with dimethyl sulfoxide (DMSO).	Dimethyl Sulfoxide	325-343	ribosomal protein S6 kinase B1	Homo sapiens	86-93
12818373-1	2003	We have previously suggested that phosphatidylinositol 3-kinase (PI3K)/p70 S6 kinase (p70 S6K) plays an important role in the regulation of neutrophilic differentiation of HL-60 cells on the basis of analysis of transferrin receptor (Trf-R)-positive (Trf-R(+)) and -negative (Trf-R(-)) cells that appear after treatment with dimethyl sulfoxide (DMSO).	Dimethyl Sulfoxide	345-349	ribosomal protein S6 kinase B1	Homo sapiens	86-93
12818373-4	2003	Wortmannin, a specific inhibitor of PI3K, partially inhibited G-CSF-induced p70 S6K activity, c-Myc expression, and G-CSF-dependent proliferation, whereas rapamycin, an inhibitor of p70 S6K, completely inhibited p70 S6K activity, c-Myc expression, and G-CSF-dependent proliferation, indicating that the extent of c-Myc inhibition by these inhibitors correlates with a reduction in proliferation, and that c-Myc is downstream from PI3K/p70 S6K.	Wortmannin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	76-83
12611592-3	2003	Amino acids, especially branched-chain amino acids, such as leucine, promote phosphorylation of 4E-BP1 and S6K1, and permit insulin to further increase their phosphorylation.	Amino Acids, Branched-Chain	24-50	ribosomal protein S6 kinase B1	Homo sapiens	107-111
12611592-3	2003	Amino acids, especially branched-chain amino acids, such as leucine, promote phosphorylation of 4E-BP1 and S6K1, and permit insulin to further increase their phosphorylation.	Leucine	60-67	ribosomal protein S6 kinase B1	Homo sapiens	107-111
19079937-11	2003	Leucine has been shown to act as a real mediator by modulating specifically the activities of intracellular kinases linked to the translation of proteins such as phosphatidylinosinol 3" kinase and mammalian target of rapamycin-70 kDa ribosomal protein S6 (p70S6K) kinases.	Leucine	0-7	ribosomal protein S6 kinase B1	Homo sapiens	256-262
12586835-4	2003	In mitotic HeLa cells, when the activity of Cdc2 is high, S6K1 is phosphorylated at multiple Ser/Thr, Pro (S/TP) sites, including Ser(371), Ser(411), Thr(421), and Ser(424).	Serine	93-96	ribosomal protein S6 kinase B1	Homo sapiens	58-62
12747827-2	2003	We recently identified a TOR signaling (TOS) motif in the N terminus of S6K1 and the C terminus of 4E-BP1 and demonstrated that in S6K1, the TOS motif is necessary to facilitate mTOR signaling to phosphorylate and activate S6K1.	Toremifene	25-28	ribosomal protein S6 kinase B1	Homo sapiens	72-76
12747827-2	2003	We recently identified a TOR signaling (TOS) motif in the N terminus of S6K1 and the C terminus of 4E-BP1 and demonstrated that in S6K1, the TOS motif is necessary to facilitate mTOR signaling to phosphorylate and activate S6K1.	Toremifene	25-28	ribosomal protein S6 kinase B1	Homo sapiens	131-135
12747827-2	2003	We recently identified a TOR signaling (TOS) motif in the N terminus of S6K1 and the C terminus of 4E-BP1 and demonstrated that in S6K1, the TOS motif is necessary to facilitate mTOR signaling to phosphorylate and activate S6K1.	Toremifene	25-28	ribosomal protein S6 kinase B1	Homo sapiens	131-135
12747827-2	2003	We recently identified a TOR signaling (TOS) motif in the N terminus of S6K1 and the C terminus of 4E-BP1 and demonstrated that in S6K1, the TOS motif is necessary to facilitate mTOR signaling to phosphorylate and activate S6K1.	tos	40-43	ribosomal protein S6 kinase B1	Homo sapiens	72-76
12747827-2	2003	We recently identified a TOR signaling (TOS) motif in the N terminus of S6K1 and the C terminus of 4E-BP1 and demonstrated that in S6K1, the TOS motif is necessary to facilitate mTOR signaling to phosphorylate and activate S6K1.	tos	40-43	ribosomal protein S6 kinase B1	Homo sapiens	131-135
12747827-2	2003	We recently identified a TOR signaling (TOS) motif in the N terminus of S6K1 and the C terminus of 4E-BP1 and demonstrated that in S6K1, the TOS motif is necessary to facilitate mTOR signaling to phosphorylate and activate S6K1.	tos	40-43	ribosomal protein S6 kinase B1	Homo sapiens	131-135
12747827-2	2003	We recently identified a TOR signaling (TOS) motif in the N terminus of S6K1 and the C terminus of 4E-BP1 and demonstrated that in S6K1, the TOS motif is necessary to facilitate mTOR signaling to phosphorylate and activate S6K1.	tos	141-144	ribosomal protein S6 kinase B1	Homo sapiens	72-76
12747827-2	2003	We recently identified a TOR signaling (TOS) motif in the N terminus of S6K1 and the C terminus of 4E-BP1 and demonstrated that in S6K1, the TOS motif is necessary to facilitate mTOR signaling to phosphorylate and activate S6K1.	tos	141-144	ribosomal protein S6 kinase B1	Homo sapiens	131-135
12747827-2	2003	We recently identified a TOR signaling (TOS) motif in the N terminus of S6K1 and the C terminus of 4E-BP1 and demonstrated that in S6K1, the TOS motif is necessary to facilitate mTOR signaling to phosphorylate and activate S6K1.	tos	141-144	ribosomal protein S6 kinase B1	Homo sapiens	131-135
12747827-3	2003	However, it is unclear how the TOS motif in S6K1 and 4E-BP1 mediates mTOR signaling.	tos	31-34	ribosomal protein S6 kinase B1	Homo sapiens	44-48
12586835-4	2003	In mitotic HeLa cells, when the activity of Cdc2 is high, S6K1 is phosphorylated at multiple Ser/Thr, Pro (S/TP) sites, including Ser(371), Ser(411), Thr(421), and Ser(424).	Threonine	97-100	ribosomal protein S6 kinase B1	Homo sapiens	58-62
12586835-4	2003	In mitotic HeLa cells, when the activity of Cdc2 is high, S6K1 is phosphorylated at multiple Ser/Thr, Pro (S/TP) sites, including Ser(371), Ser(411), Thr(421), and Ser(424).	Proline	102-105	ribosomal protein S6 kinase B1	Homo sapiens	58-62
12586835-4	2003	In mitotic HeLa cells, when the activity of Cdc2 is high, S6K1 is phosphorylated at multiple Ser/Thr, Pro (S/TP) sites, including Ser(371), Ser(411), Thr(421), and Ser(424).	neotetrazolium	109-111	ribosomal protein S6 kinase B1	Homo sapiens	58-62
12586835-4	2003	In mitotic HeLa cells, when the activity of Cdc2 is high, S6K1 is phosphorylated at multiple Ser/Thr, Pro (S/TP) sites, including Ser(371), Ser(411), Thr(421), and Ser(424).	Serine	130-133	ribosomal protein S6 kinase B1	Homo sapiens	58-62
12604610-4	2003	A point mutation of the TOS motif also eliminates all in vitro mTOR-catalyzed 4E-BP1 phosphorylation and abolishes the raptor-dependent component of mTOR-catalyzed p70S6k phosphorylation in vitro.	tos	24-27	ribosomal protein S6 kinase B1	Homo sapiens	164-170
12586835-4	2003	In mitotic HeLa cells, when the activity of Cdc2 is high, S6K1 is phosphorylated at multiple Ser/Thr, Pro (S/TP) sites, including Ser(371), Ser(411), Thr(421), and Ser(424).	Serine	130-133	ribosomal protein S6 kinase B1	Homo sapiens	58-62
12586835-4	2003	In mitotic HeLa cells, when the activity of Cdc2 is high, S6K1 is phosphorylated at multiple Ser/Thr, Pro (S/TP) sites, including Ser(371), Ser(411), Thr(421), and Ser(424).	Threonine	150-153	ribosomal protein S6 kinase B1	Homo sapiens	58-62
12586835-4	2003	In mitotic HeLa cells, when the activity of Cdc2 is high, S6K1 is phosphorylated at multiple Ser/Thr, Pro (S/TP) sites, including Ser(371), Ser(411), Thr(421), and Ser(424).	Serine	130-133	ribosomal protein S6 kinase B1	Homo sapiens	58-62
12586835-5	2003	Concomitant with this, the phosphorylation of the hydrophobic motif site, Thr(389), is reduced resulting in a decrease in the specific activity of S6K1.	Threonine	74-77	ribosomal protein S6 kinase B1	Homo sapiens	147-151
12711332-10	2003	PD098059 and U0126 completely abrogated ERK2 phosphorylation; whereas, LY294002 completely blocked PKB/Akt and p70(S6k) phosphorylation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	71-79	ribosomal protein S6 kinase B1	Homo sapiens	111-118
12429015-0	2003	Activation of S6K1 (p70 ribosomal protein S6 kinase 1) requires an initial calcium-dependent priming event involving formation of a high-molecular-mass signalling complex.	Calcium	75-82	ribosomal protein S6 kinase B1	Homo sapiens	14-18
12711631-8	2003	FTY720 also induced Bad (Ser(136)) and ribosomal p70S6 kinase (p70(S6k)) (Thr(389)) dephosphorylation.	Threonine	74-77	ribosomal protein S6 kinase B1	Homo sapiens	63-70
12554767-4	2003	Akt activation was blocked by wortmannin and LY 294,002, two inhibitors of PI 3-K; by genistein, a protein tyrosine kinase inhibitor and an ER agonist; by AG825, a selective ErbB2 inhibitor; and by the antiestrogens ICI 182,780 and 4-hydroxy-tamoxifen; but not by rapamycin, an inhibitor of the ribosomal protein kinase p70S6K; nor by AG30, a selective epidermal growth factor receptor inhibitor.	ly 294,002	45-55	ribosomal protein S6 kinase B1	Homo sapiens	320-326
12554767-4	2003	Akt activation was blocked by wortmannin and LY 294,002, two inhibitors of PI 3-K; by genistein, a protein tyrosine kinase inhibitor and an ER agonist; by AG825, a selective ErbB2 inhibitor; and by the antiestrogens ICI 182,780 and 4-hydroxy-tamoxifen; but not by rapamycin, an inhibitor of the ribosomal protein kinase p70S6K; nor by AG30, a selective epidermal growth factor receptor inhibitor.	tyrphostin AG825	155-160	ribosomal protein S6 kinase B1	Homo sapiens	320-326
12681504-5	2003	Amino acid-induced S6K1 activation was inhibited by LY294002 (PI3-kinase inhibitor) and rapamycin (inhibitor of the mammalian target of rapamycin, mTOR), suggesting the involvement of an avian homolog of mTOR.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	52-60	ribosomal protein S6 kinase B1	Homo sapiens	19-23
12681504-5	2003	Amino acid-induced S6K1 activation was inhibited by LY294002 (PI3-kinase inhibitor) and rapamycin (inhibitor of the mammalian target of rapamycin, mTOR), suggesting the involvement of an avian homolog of mTOR.	Sirolimus	88-97	ribosomal protein S6 kinase B1	Homo sapiens	19-23
12681504-6	2003	The availability of individual amino acids (methionine or leucine) regulated S6K1 phosphorylation on Thr389 and QM7 protein synthesis.	Methionine	44-54	ribosomal protein S6 kinase B1	Homo sapiens	77-81
12681504-6	2003	The availability of individual amino acids (methionine or leucine) regulated S6K1 phosphorylation on Thr389 and QM7 protein synthesis.	Leucine	58-65	ribosomal protein S6 kinase B1	Homo sapiens	77-81
12429015-5	2003	Calcium-dependent regulation of S6K1 did not specifically target Thr-229 and Thr-389, the key regulatory phosphorylation sites; rather, calcium chelation resulted in a global inhibition of S6K1 phosphorylation.	Calcium	0-7	ribosomal protein S6 kinase B1	Homo sapiens	32-36
12429015-5	2003	Calcium-dependent regulation of S6K1 did not specifically target Thr-229 and Thr-389, the key regulatory phosphorylation sites; rather, calcium chelation resulted in a global inhibition of S6K1 phosphorylation.	Calcium	0-7	ribosomal protein S6 kinase B1	Homo sapiens	189-193
12429015-5	2003	Calcium-dependent regulation of S6K1 did not specifically target Thr-229 and Thr-389, the key regulatory phosphorylation sites; rather, calcium chelation resulted in a global inhibition of S6K1 phosphorylation.	Calcium	136-143	ribosomal protein S6 kinase B1	Homo sapiens	32-36
12429015-5	2003	Calcium-dependent regulation of S6K1 did not specifically target Thr-229 and Thr-389, the key regulatory phosphorylation sites; rather, calcium chelation resulted in a global inhibition of S6K1 phosphorylation.	Calcium	136-143	ribosomal protein S6 kinase B1	Homo sapiens	189-193
12429015-8	2003	We hypothesize that the initial calcium-dependent process is required to release an inhibitory interaction between the C- and N-termini of S6K1, thus allowing phosphorylation of these key domains.	Calcium	32-39	ribosomal protein S6 kinase B1	Homo sapiens	139-143
12429015-12	2003	Consistent with this hypothesis, serum stimulation of S6K1 activity is associated with its incorporation into a calcium-dependent high-molecular-mass complex.	Calcium	112-119	ribosomal protein S6 kinase B1	Homo sapiens	54-58
12370290-1	2002	The mammalian target of rapamycin (mTOR) is a Ser/Thr (S/T) protein kinase, which controls mRNA translation initiation by modulating phosphorylation of the translational regulators PHAS-I and p70(S6K).	Serine	46-49	ribosomal protein S6 kinase B1	Homo sapiens	192-199
12711631-15	2003	Okadaic acid (OA) inhibited the FTY720-induced dephosphorylation of Akt and p70(S6k), suggesting that FTY720 promotes Ser/Thr protein phosphatase (PP) activity.	Okadaic Acid	0-12	ribosomal protein S6 kinase B1	Homo sapiens	80-83
12711631-15	2003	Okadaic acid (OA) inhibited the FTY720-induced dephosphorylation of Akt and p70(S6k), suggesting that FTY720 promotes Ser/Thr protein phosphatase (PP) activity.	Okadaic Acid	14-16	ribosomal protein S6 kinase B1	Homo sapiens	80-83
12558800-3	2003	RESULTS: The treatment of SV40-immortalized human corneal epithelial cells (HCE-T cells) with 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), widely used as an AMPK activator, inhibits p70 S6k activities.	acadesine	94-139	ribosomal protein S6 kinase B1	Homo sapiens	192-199
12558800-3	2003	RESULTS: The treatment of SV40-immortalized human corneal epithelial cells (HCE-T cells) with 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), widely used as an AMPK activator, inhibits p70 S6k activities.	acadesine	141-146	ribosomal protein S6 kinase B1	Homo sapiens	192-199
12558800-4	2003	Altered glucose availability, which regulates AMPK activity, also modulates the activity of p70 S6k.	Glucose	8-15	ribosomal protein S6 kinase B1	Homo sapiens	92-99
12558800-5	2003	AICAR treatment also inhibits phosphorylation of Thr-412 in the p70 S6 kinase (p70 S6k), which is indispensable for the activity.	Threonine	49-52	ribosomal protein S6 kinase B1	Homo sapiens	64-77
12558800-5	2003	AICAR treatment also inhibits phosphorylation of Thr-412 in the p70 S6 kinase (p70 S6k), which is indispensable for the activity.	Threonine	49-52	ribosomal protein S6 kinase B1	Homo sapiens	79-86
12553669-8	2002	We report that p70 S6 kinase (S6K)1 participates in this IF rearrangement since the inhibitor rapamycin or a dominant inhibitory S6K could reduce the Cdc42V12 or bradykinin-induced vimentin collapse.	Sirolimus	94-103	ribosomal protein S6 kinase B1	Homo sapiens	30-33
12553669-8	2002	We report that p70 S6 kinase (S6K)1 participates in this IF rearrangement since the inhibitor rapamycin or a dominant inhibitory S6K could reduce the Cdc42V12 or bradykinin-induced vimentin collapse.	cdc42v12	150-158	ribosomal protein S6 kinase B1	Homo sapiens	30-33
12553669-8	2002	We report that p70 S6 kinase (S6K)1 participates in this IF rearrangement since the inhibitor rapamycin or a dominant inhibitory S6K could reduce the Cdc42V12 or bradykinin-induced vimentin collapse.	cdc42v12	150-158	ribosomal protein S6 kinase B1	Homo sapiens	129-132
12565877-3	2003	N-Acetylleucine amide caused cell cycle arrest at G1 stage in Jurkat cells, a human leukemia T cell line, concomitant with the inhibition of serum-induced p70(S6k) activation and p27 degradation.	N-acetylleucinamide	0-21	ribosomal protein S6 kinase B1	Homo sapiens	159-162
12555062-2	2003	Activation of p70S6K requires sequential phosphorylation of multiple serine and threonine sites often triggered by growth factors and hormones.	Serine	69-75	ribosomal protein S6 kinase B1	Homo sapiens	14-20
12555062-2	2003	Activation of p70S6K requires sequential phosphorylation of multiple serine and threonine sites often triggered by growth factors and hormones.	Threonine	80-89	ribosomal protein S6 kinase B1	Homo sapiens	14-20
12555062-3	2003	Here, we report that paclitaxel, a microtubule-damaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration- and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody.	Paclitaxel	21-31	ribosomal protein S6 kinase B1	Homo sapiens	90-96
12555062-3	2003	Here, we report that paclitaxel, a microtubule-damaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration- and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody.	Paclitaxel	21-31	ribosomal protein S6 kinase B1	Homo sapiens	272-278
12555062-3	2003	Here, we report that paclitaxel, a microtubule-damaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration- and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody.	Threonine	100-109	ribosomal protein S6 kinase B1	Homo sapiens	90-96
12555062-4	2003	Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorylated in p70S6K following treatment with paclitaxel.	Phosphoamino Acids	0-17	ribosomal protein S6 kinase B1	Homo sapiens	173-179
12555062-4	2003	Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorylated in p70S6K following treatment with paclitaxel.	Serine	56-62	ribosomal protein S6 kinase B1	Homo sapiens	173-179
12555062-4	2003	Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorylated in p70S6K following treatment with paclitaxel.	Threonine	64-73	ribosomal protein S6 kinase B1	Homo sapiens	173-179
12555062-4	2003	Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorylated in p70S6K following treatment with paclitaxel.	Serine	121-127	ribosomal protein S6 kinase B1	Homo sapiens	173-179
12555062-4	2003	Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorylated in p70S6K following treatment with paclitaxel.	Threonine	132-141	ribosomal protein S6 kinase B1	Homo sapiens	173-179
12555062-4	2003	Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorylated in p70S6K following treatment with paclitaxel.	Paclitaxel	205-215	ribosomal protein S6 kinase B1	Homo sapiens	173-179
12555062-5	2003	Paclitaxel-induced p70S6K(T421/S424) phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca(++), PI3K, and mammalian target of rapamycin (mTOR).	Paclitaxel	0-10	ribosomal protein S6 kinase B1	Homo sapiens	19-25
12555062-8	2003	Inhibition of PKC and JNK prevents paclitaxel-induced p70S6K inactivation.	Paclitaxel	35-45	ribosomal protein S6 kinase B1	Homo sapiens	54-60
12555062-9	2003	Moreover, the paclitaxel-induced phosphorylation and low activity of p70S6K mainly occurs during mitosis.	Paclitaxel	14-24	ribosomal protein S6 kinase B1	Homo sapiens	69-75
12555062-10	2003	In summary, paclitaxel is able to induce p70S6K(T421/S424) phosphorylation and decrease its activity in mitotic cells via multiple signaling pathways.	Paclitaxel	12-22	ribosomal protein S6 kinase B1	Homo sapiens	41-47
12555062-11	2003	Our data suggest that paclitaxel-induced p70S6K(T421/S424) phosphorylation and kinase inactivation are differentially regulated.	Paclitaxel	22-32	ribosomal protein S6 kinase B1	Homo sapiens	41-47
12555062-12	2003	Our data also indicate that paclitaxel may exert its antitumor effect, at least in part, via inhibition of p70S6K.	Paclitaxel	28-38	ribosomal protein S6 kinase B1	Homo sapiens	107-113
12395317-7	2002	No interference between the MEK/ERK pathway and 4E-BP1 phosphorylation was detected, whereas p70S6K phosphorylation induced by EGF was under a U0126-sensitive regulation.	U 0126	143-148	ribosomal protein S6 kinase B1	Homo sapiens	93-99
12370290-1	2002	The mammalian target of rapamycin (mTOR) is a Ser/Thr (S/T) protein kinase, which controls mRNA translation initiation by modulating phosphorylation of the translational regulators PHAS-I and p70(S6K).	Threonine	50-53	ribosomal protein S6 kinase B1	Homo sapiens	192-199
12183455-2	2002	Phosphorylation of this motif (FLGFT389Y) in p70 S6 kinase (S6K1) is both rapamycin- and wortmannin-sensitive, suggesting a role for both mammalian target of rapamycin- and phosphatidylinositol 3-kinase-dependent pathways.	Sirolimus	74-83	ribosomal protein S6 kinase B1	Homo sapiens	60-64
12403809-26	2002	Instead, we show by using wortmannin and dominant interfering alleles of phosphatidylinositide-3-OH kinase (PI3K) that increased S6K1 activation is contingent upon the suppression of TSC2 function by PI3K in normal cells and is PI3K independent in TSC2-deficient cells.	Wortmannin	26-36	ribosomal protein S6 kinase B1	Homo sapiens	129-133
12183455-2	2002	Phosphorylation of this motif (FLGFT389Y) in p70 S6 kinase (S6K1) is both rapamycin- and wortmannin-sensitive, suggesting a role for both mammalian target of rapamycin- and phosphatidylinositol 3-kinase-dependent pathways.	Wortmannin	89-99	ribosomal protein S6 kinase B1	Homo sapiens	60-64
12183455-4	2002	Interestingly, although PDK1 alone can promote an increase in Thr(389) phosphorylation in both wild type S6K1 and a kinase-inactive mutant of S6K1, the cooperative effect between PDK1 and protein kinase Czeta required S6K1 activity.	Threonine	62-65	ribosomal protein S6 kinase B1	Homo sapiens	105-109
12183455-4	2002	Interestingly, although PDK1 alone can promote an increase in Thr(389) phosphorylation in both wild type S6K1 and a kinase-inactive mutant of S6K1, the cooperative effect between PDK1 and protein kinase Czeta required S6K1 activity.	Threonine	62-65	ribosomal protein S6 kinase B1	Homo sapiens	142-146
12183455-4	2002	Interestingly, although PDK1 alone can promote an increase in Thr(389) phosphorylation in both wild type S6K1 and a kinase-inactive mutant of S6K1, the cooperative effect between PDK1 and protein kinase Czeta required S6K1 activity.	Threonine	62-65	ribosomal protein S6 kinase B1	Homo sapiens	142-146
12193593-5	2002	In addition, 5(S)-HETE stimulated phosphatidylinositol 3-kinase (PI3-kinase) activity and phosphorylation of its downstream targets Akt, p70S6K, and 4E-BP1 and their effector molecules ribosomal protein S6 and eIF4E.	5-hydroxy-6,8,11,14-eicosatetraenoic acid	13-22	ribosomal protein S6 kinase B1	Homo sapiens	137-143
12183455-4	2002	Interestingly, although PDK1 alone can promote an increase in Thr(389) phosphorylation in both wild type S6K1 and a kinase-inactive mutant of S6K1, the cooperative effect between PDK1 and protein kinase Czeta required S6K1 activity.	czeta	203-208	ribosomal protein S6 kinase B1	Homo sapiens	142-146
12183455-4	2002	Interestingly, although PDK1 alone can promote an increase in Thr(389) phosphorylation in both wild type S6K1 and a kinase-inactive mutant of S6K1, the cooperative effect between PDK1 and protein kinase Czeta required S6K1 activity.	czeta	203-208	ribosomal protein S6 kinase B1	Homo sapiens	142-146
12183455-5	2002	Furthermore, Akt, another phosphatidylinositol 3-kinase effector and regulator of S6K1, also increased Thr(389) phosphorylation in a S6K1 activity-dependent manner.	Threonine	103-106	ribosomal protein S6 kinase B1	Homo sapiens	82-86
12183455-5	2002	Furthermore, Akt, another phosphatidylinositol 3-kinase effector and regulator of S6K1, also increased Thr(389) phosphorylation in a S6K1 activity-dependent manner.	Threonine	103-106	ribosomal protein S6 kinase B1	Homo sapiens	133-137
12183455-6	2002	Consistent with this, epidermal growth factor-induced Thr(389) phosphorylation in wild type S6K1 persisted for up to 120 min, whereas kinase-inactive mutants of S6K1 displayed only a reduced and transient increase in Thr(389) phosphorylation.	Threonine	54-57	ribosomal protein S6 kinase B1	Homo sapiens	92-96
12183455-6	2002	Consistent with this, epidermal growth factor-induced Thr(389) phosphorylation in wild type S6K1 persisted for up to 120 min, whereas kinase-inactive mutants of S6K1 displayed only a reduced and transient increase in Thr(389) phosphorylation.	Threonine	217-220	ribosomal protein S6 kinase B1	Homo sapiens	92-96
12183455-6	2002	Consistent with this, epidermal growth factor-induced Thr(389) phosphorylation in wild type S6K1 persisted for up to 120 min, whereas kinase-inactive mutants of S6K1 displayed only a reduced and transient increase in Thr(389) phosphorylation.	Threonine	217-220	ribosomal protein S6 kinase B1	Homo sapiens	161-165
12183455-7	2002	We conclude that S6K1 activity is required for maximal Thr(389) phosphorylation by mitogens and by multiple phosphatidylinositol 3-kinase-dependent inputs including PDK1, PKCzeta, and Akt, and we propose that autophosphorylation is an important regulatory mechanism for phosphorylation of the hydrophobic motif Thr(389) site in S6K1.	Threonine	55-58	ribosomal protein S6 kinase B1	Homo sapiens	17-21
12183455-7	2002	We conclude that S6K1 activity is required for maximal Thr(389) phosphorylation by mitogens and by multiple phosphatidylinositol 3-kinase-dependent inputs including PDK1, PKCzeta, and Akt, and we propose that autophosphorylation is an important regulatory mechanism for phosphorylation of the hydrophobic motif Thr(389) site in S6K1.	Threonine	311-314	ribosomal protein S6 kinase B1	Homo sapiens	17-21
12374740-1	2002	The growth factor-activated AGC protein kinases RSK, S6K, PKB, MSK and SGK are activated by serine/threonine phosphorylation in the activation loop and in the hydrophobic motif, C-terminal to the kinase domain.	Serine	92-98	ribosomal protein S6 kinase B1	Homo sapiens	53-56
12374740-1	2002	The growth factor-activated AGC protein kinases RSK, S6K, PKB, MSK and SGK are activated by serine/threonine phosphorylation in the activation loop and in the hydrophobic motif, C-terminal to the kinase domain.	Threonine	99-108	ribosomal protein S6 kinase B1	Homo sapiens	53-56
12374740-4	2002	Moreover, we demonstrate that RSK2, S6K1, PKBalpha, MSK1 and SGK1 contain a similar phosphate-binding pocket, which they use for intramolecular interaction with their own phosphorylated hydrophobic motif.	Phosphates	84-93	ribosomal protein S6 kinase B1	Homo sapiens	36-50
12384526-0	2002	Ultraviolet-induced phosphorylation of p70(S6K) at Thr(389) and Thr(421)/Ser(424) involves hydrogen peroxide and mammalian target of rapamycin but not Akt and atypical protein kinase C. The p70 S6 kinase (p70(S6k)) is a Ser/Thr kinase that plays an important role in cell growth, transformation, and the transition of the cell cycle in mammalian cells.	Threonine	51-54	ribosomal protein S6 kinase B1	Homo sapiens	39-42
12384526-5	2002	Importantly, UV-induced increases in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) were dramatically inhibited by pretreatment of cells with rapamycin, LY294002, or PD98059, whereas overexpression of dominant-negative mutants of PKClambda/iota and Akt1 did not inhibit p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	165-173	ribosomal protein S6 kinase B1	Homo sapiens	41-44
12384526-0	2002	Ultraviolet-induced phosphorylation of p70(S6K) at Thr(389) and Thr(421)/Ser(424) involves hydrogen peroxide and mammalian target of rapamycin but not Akt and atypical protein kinase C. The p70 S6 kinase (p70(S6k)) is a Ser/Thr kinase that plays an important role in cell growth, transformation, and the transition of the cell cycle in mammalian cells.	Serine	73-76	ribosomal protein S6 kinase B1	Homo sapiens	39-42
12384526-0	2002	Ultraviolet-induced phosphorylation of p70(S6K) at Thr(389) and Thr(421)/Ser(424) involves hydrogen peroxide and mammalian target of rapamycin but not Akt and atypical protein kinase C. The p70 S6 kinase (p70(S6k)) is a Ser/Thr kinase that plays an important role in cell growth, transformation, and the transition of the cell cycle in mammalian cells.	Hydrogen Peroxide	91-108	ribosomal protein S6 kinase B1	Homo sapiens	39-42
12384526-4	2002	The scavenging of UV-generated H(2)O(2) by N-acety-L-cyteine (a general antioxidant) or catalase (a specific H(2)O(2) scavenger) inhibited p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424), whereas pretreatment of cells with sodium formate (an.OH radical scavenger) or superoxide dismutase (an O( minus sign, dot below )(2) radical scavenger) did not show any inhibitory effects.	Hydrogen Peroxide	31-39	ribosomal protein S6 kinase B1	Homo sapiens	143-146
12384526-5	2002	Importantly, UV-induced increases in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) were dramatically inhibited by pretreatment of cells with rapamycin, LY294002, or PD98059, whereas overexpression of dominant-negative mutants of PKClambda/iota and Akt1 did not inhibit p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Threonine	65-68	ribosomal protein S6 kinase B1	Homo sapiens	41-44
12384526-5	2002	Importantly, UV-induced increases in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) were dramatically inhibited by pretreatment of cells with rapamycin, LY294002, or PD98059, whereas overexpression of dominant-negative mutants of PKClambda/iota and Akt1 did not inhibit p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Threonine	78-81	ribosomal protein S6 kinase B1	Homo sapiens	41-44
12384526-5	2002	Importantly, UV-induced increases in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) were dramatically inhibited by pretreatment of cells with rapamycin, LY294002, or PD98059, whereas overexpression of dominant-negative mutants of PKClambda/iota and Akt1 did not inhibit p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Serine	87-90	ribosomal protein S6 kinase B1	Homo sapiens	41-44
12384526-5	2002	Importantly, UV-induced increases in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) were dramatically inhibited by pretreatment of cells with rapamycin, LY294002, or PD98059, whereas overexpression of dominant-negative mutants of PKClambda/iota and Akt1 did not inhibit p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	165-173	ribosomal protein S6 kinase B1	Homo sapiens	286-289
12384526-5	2002	Importantly, UV-induced increases in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) were dramatically inhibited by pretreatment of cells with rapamycin, LY294002, or PD98059, whereas overexpression of dominant-negative mutants of PKClambda/iota and Akt1 did not inhibit p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Threonine	78-81	ribosomal protein S6 kinase B1	Homo sapiens	41-44
12384526-5	2002	Importantly, UV-induced increases in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) were dramatically inhibited by pretreatment of cells with rapamycin, LY294002, or PD98059, whereas overexpression of dominant-negative mutants of PKClambda/iota and Akt1 did not inhibit p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Threonine	78-81	ribosomal protein S6 kinase B1	Homo sapiens	41-44
12384526-5	2002	Importantly, UV-induced increases in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) were dramatically inhibited by pretreatment of cells with rapamycin, LY294002, or PD98059, whereas overexpression of dominant-negative mutants of PKClambda/iota and Akt1 did not inhibit p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Serine	332-335	ribosomal protein S6 kinase B1	Homo sapiens	41-44
12384526-6	2002	These results demonstrated that H(2)O(2), phosphatidylinositol 3-kinase, and mammalian target of rapamycin were important players for UV-induced p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424), whereas Akt and atypical protein kinase C were not involved in this activation.	Hydrogen Peroxide	32-40	ribosomal protein S6 kinase B1	Homo sapiens	149-152
12384526-6	2002	These results demonstrated that H(2)O(2), phosphatidylinositol 3-kinase, and mammalian target of rapamycin were important players for UV-induced p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424), whereas Akt and atypical protein kinase C were not involved in this activation.	Threonine	173-176	ribosomal protein S6 kinase B1	Homo sapiens	149-152
12384526-6	2002	These results demonstrated that H(2)O(2), phosphatidylinositol 3-kinase, and mammalian target of rapamycin were important players for UV-induced p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424), whereas Akt and atypical protein kinase C were not involved in this activation.	Threonine	186-189	ribosomal protein S6 kinase B1	Homo sapiens	149-152
12384526-6	2002	These results demonstrated that H(2)O(2), phosphatidylinositol 3-kinase, and mammalian target of rapamycin were important players for UV-induced p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424), whereas Akt and atypical protein kinase C were not involved in this activation.	Serine	195-198	ribosomal protein S6 kinase B1	Homo sapiens	149-152
12384526-7	2002	The role of H(2)O(2) in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) was further supported by the findings that treatment of cells with H(2)O(2) also caused p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Hydrogen Peroxide	12-20	ribosomal protein S6 kinase B1	Homo sapiens	28-31
12384526-7	2002	The role of H(2)O(2) in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) was further supported by the findings that treatment of cells with H(2)O(2) also caused p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Hydrogen Peroxide	12-20	ribosomal protein S6 kinase B1	Homo sapiens	24-31
12384526-7	2002	The role of H(2)O(2) in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) was further supported by the findings that treatment of cells with H(2)O(2) also caused p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Threonine	52-55	ribosomal protein S6 kinase B1	Homo sapiens	28-31
12384526-7	2002	The role of H(2)O(2) in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) was further supported by the findings that treatment of cells with H(2)O(2) also caused p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Threonine	52-55	ribosomal protein S6 kinase B1	Homo sapiens	24-31
12384526-7	2002	The role of H(2)O(2) in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) was further supported by the findings that treatment of cells with H(2)O(2) also caused p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Serine	74-77	ribosomal protein S6 kinase B1	Homo sapiens	28-31
12384526-7	2002	The role of H(2)O(2) in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) was further supported by the findings that treatment of cells with H(2)O(2) also caused p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Hydrogen Peroxide	150-158	ribosomal protein S6 kinase B1	Homo sapiens	28-31
12384526-7	2002	The role of H(2)O(2) in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) was further supported by the findings that treatment of cells with H(2)O(2) also caused p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Hydrogen Peroxide	150-158	ribosomal protein S6 kinase B1	Homo sapiens	24-31
12384526-7	2002	The role of H(2)O(2) in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) was further supported by the findings that treatment of cells with H(2)O(2) also caused p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Serine	221-224	ribosomal protein S6 kinase B1	Homo sapiens	28-31
12171932-6	2002	On the other hand, LY294002 and wortmannin, specific inhibitors of PI3K, prevented PDGF-BB-induced phosphorylation of Akt and its downstream effector molecules, p70S6K, ribosomal protein S6, 4E-BP1, and eIF4E.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	19-27	ribosomal protein S6 kinase B1	Homo sapiens	161-167
12384526-7	2002	The role of H(2)O(2) in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) was further supported by the findings that treatment of cells with H(2)O(2) also caused p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424).	Serine	221-224	ribosomal protein S6 kinase B1	Homo sapiens	24-31
12171932-6	2002	On the other hand, LY294002 and wortmannin, specific inhibitors of PI3K, prevented PDGF-BB-induced phosphorylation of Akt and its downstream effector molecules, p70S6K, ribosomal protein S6, 4E-BP1, and eIF4E.	Wortmannin	32-42	ribosomal protein S6 kinase B1	Homo sapiens	161-167
12433206-1	2002	The mitogen-stimulated serine/threonine kinase p70S6k plays an important role in the progression of cells from G0/G1 to S phase of the cell cycle by translational up-regulation of a family of mRNA transcripts family of mRNA transcripts which contain polypyrimidine tract at their 5 transcriptional start site.	polypyrimidine	250-264	ribosomal protein S6 kinase B1	Homo sapiens	47-53
12271141-4	2002	Second, the activity of S6K1 was repressed by coexpression of hamartin and tuberin, but the activity of rapamycin-resistant mutants of S6K1 were not affected, implicating mTOR in the TSC-mediated inhibitory effect on S6K1.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	135-139
12271141-4	2002	Second, the activity of S6K1 was repressed by coexpression of hamartin and tuberin, but the activity of rapamycin-resistant mutants of S6K1 were not affected, implicating mTOR in the TSC-mediated inhibitory effect on S6K1.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	135-139
12225947-4	2002	Pretreatment of cells with wortmannin and LY-294002, inhibitors of PI3K, or rapamycin, an inhibitor of the mammalian target of rapamycin kinase and p70S6K, diminished the ANG IV-mediated activation of PDK-1 and PKB-alpha as well as phosphorylation of p70S6K.	Wortmannin	27-37	ribosomal protein S6 kinase B1	Homo sapiens	148-154
12225947-4	2002	Pretreatment of cells with wortmannin and LY-294002, inhibitors of PI3K, or rapamycin, an inhibitor of the mammalian target of rapamycin kinase and p70S6K, diminished the ANG IV-mediated activation of PDK-1 and PKB-alpha as well as phosphorylation of p70S6K.	Wortmannin	27-37	ribosomal protein S6 kinase B1	Homo sapiens	251-257
12225947-4	2002	Pretreatment of cells with wortmannin and LY-294002, inhibitors of PI3K, or rapamycin, an inhibitor of the mammalian target of rapamycin kinase and p70S6K, diminished the ANG IV-mediated activation of PDK-1 and PKB-alpha as well as phosphorylation of p70S6K.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	42-51	ribosomal protein S6 kinase B1	Homo sapiens	148-154
12225947-4	2002	Pretreatment of cells with wortmannin and LY-294002, inhibitors of PI3K, or rapamycin, an inhibitor of the mammalian target of rapamycin kinase and p70S6K, diminished the ANG IV-mediated activation of PDK-1 and PKB-alpha as well as phosphorylation of p70S6K.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	42-51	ribosomal protein S6 kinase B1	Homo sapiens	251-257
12225947-4	2002	Pretreatment of cells with wortmannin and LY-294002, inhibitors of PI3K, or rapamycin, an inhibitor of the mammalian target of rapamycin kinase and p70S6K, diminished the ANG IV-mediated activation of PDK-1 and PKB-alpha as well as phosphorylation of p70S6K.	Sirolimus	76-85	ribosomal protein S6 kinase B1	Homo sapiens	148-154
12225947-4	2002	Pretreatment of cells with wortmannin and LY-294002, inhibitors of PI3K, or rapamycin, an inhibitor of the mammalian target of rapamycin kinase and p70S6K, diminished the ANG IV-mediated activation of PDK-1 and PKB-alpha as well as phosphorylation of p70S6K.	Sirolimus	76-85	ribosomal protein S6 kinase B1	Homo sapiens	251-257
12433206-3	2002	Rapamycin treatment induced a significant dephosphorylation and inactivation of p70S6k in all cancer cell lines, while wortmannin, a specific inhibitor of PI3-K, caused a mild dephosphorylation of p70S6k in AGS, MDA-MB-435S and MB-157.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	80-86
12433206-3	2002	Rapamycin treatment induced a significant dephosphorylation and inactivation of p70S6k in all cancer cell lines, while wortmannin, a specific inhibitor of PI3-K, caused a mild dephosphorylation of p70S6k in AGS, MDA-MB-435S and MB-157.	Wortmannin	119-129	ribosomal protein S6 kinase B1	Homo sapiens	197-203
12433206-4	2002	In addition, SQ20006, methylxanthine phosphodiesterase inhibitor, reduced the phosphorylation of p70S6k in all cancer cells tested.	SQ 20006	13-20	ribosomal protein S6 kinase B1	Homo sapiens	97-103
12433206-5	2002	Consistent with inhibitory effect of rapamycin on p70S6k activity, rapamycin inhibited [3H]-thymidine incorporation and increased the number of cells at G0/G1 phase.	Sirolimus	37-46	ribosomal protein S6 kinase B1	Homo sapiens	50-56
12242656-6	2002	In human growth factor-independent MM cell lines OPM2 and RPMI8226, we show that the PI 3-K inhibitors LY294002 and Wortmannin strongly inhibited cell proliferation, whereas inhibition of the mammalian Target Of Rapamycin (mTOR)/P70-S6-kinase (P70(S6K)) pathway with rapamycin or of the Mitogen-Activated Protein Kinase (MAPK) pathway with PD98059 had minimal effect on proliferation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	103-111	ribosomal protein S6 kinase B1	Homo sapiens	229-232
12242656-6	2002	In human growth factor-independent MM cell lines OPM2 and RPMI8226, we show that the PI 3-K inhibitors LY294002 and Wortmannin strongly inhibited cell proliferation, whereas inhibition of the mammalian Target Of Rapamycin (mTOR)/P70-S6-kinase (P70(S6K)) pathway with rapamycin or of the Mitogen-Activated Protein Kinase (MAPK) pathway with PD98059 had minimal effect on proliferation.	Wortmannin	116-126	ribosomal protein S6 kinase B1	Homo sapiens	229-232
12242656-8	2002	LY294002 inhibited phosphorylation of Akt, FKHRL-1 and P70(S6K) but had no effect on ERK1/2 phosphorylation, indicating that the PI 3-K and MAPK pathways are independent.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	ribosomal protein S6 kinase B1	Homo sapiens	55-58
12242656-11	2002	In three of them including the two patients with PCL, constitutive phosphorylation of Akt, FKHRL-1 and P70(S6K) was present, inhibited by LY294002 and enhanced by IGF-1.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	138-146	ribosomal protein S6 kinase B1	Homo sapiens	103-106
12176053-4	2002	Wortmannin, a specific inhibitor of PI3K, partially inhibited G-CSF-induced p70 S6K activity and G-CSF-dependent proliferation, whereas rapamycin, an inhibitor of p70 S6K, completely inhibited these activities.	Sirolimus	136-145	ribosomal protein S6 kinase B1	Homo sapiens	163-170
12169454-10	2002	Insulin increased the phosphorylation of p70 S6 kinase (p70(S6k)) in both muscle and liver and protein kinase B (PKB/Akt) in muscle, two indicative signal proteins in the phosphatidylinositol (PI) 3-kinase pathway.	Phosphatidylinositols	171-191	ribosomal protein S6 kinase B1	Homo sapiens	56-63
12176053-1	2002	Previously, we suggested that p70 S6 kinase (p70 S6K) plays an important role in the regulation of neutrophilic differentiation of HL-60 cells; this conclusion was based on our analysis of transferrin receptor (Trf-R) positive (Trf-R(+)) and negative (Trf-R(-)) cells that appeared after treatment with dimethyl sulfoxide (Me(2)SO).	Dimethyl Sulfoxide	303-321	ribosomal protein S6 kinase B1	Homo sapiens	30-43
12176053-1	2002	Previously, we suggested that p70 S6 kinase (p70 S6K) plays an important role in the regulation of neutrophilic differentiation of HL-60 cells; this conclusion was based on our analysis of transferrin receptor (Trf-R) positive (Trf-R(+)) and negative (Trf-R(-)) cells that appeared after treatment with dimethyl sulfoxide (Me(2)SO).	Dimethyl Sulfoxide	303-321	ribosomal protein S6 kinase B1	Homo sapiens	45-52
12176053-4	2002	Wortmannin, a specific inhibitor of PI3K, partially inhibited G-CSF-induced p70 S6K activity and G-CSF-dependent proliferation, whereas rapamycin, an inhibitor of p70 S6K, completely inhibited these activities.	Wortmannin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	76-83
12045200-7	2002	Rapamycin, an immunosuppressant, inhibited hyperphosphorylation of S6, p70S6K activation, and DNA synthesis in LAMD-SM cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	71-77
12296652-9	2002	Wortmannin (500 and 1000 nM) significantly decreased PDGF-BB stimulation of meningioma cells (p &lt; 0.001) while it reduced Akt and p70S6K phosphorylation but not mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) phosphorylation.	Wortmannin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	133-139
12172555-4	2002	In Drosophila melanogaster and mammalian cells, loss of Tsc1 and Tsc2 results in a TOR-dependent increase of S6K activity.	Topiramate	83-86	ribosomal protein S6 kinase B1	Homo sapiens	109-112
12080086-4	2002	Expression of S6K1 mutants that possess partial rapamycin-resistant activity or overexpression of eIF4E individually and additively partially rescues the rapamycin-induced decrease in cell size.	Sirolimus	48-57	ribosomal protein S6 kinase B1	Homo sapiens	14-18
12153572-2	2002	They activate p70 ribosomal protein S6 kinase (p70S6K) and acetyl-CoA carboxylase (ACC) involved in protein and fatty acids synthesis, respectively.	Fatty Acids	112-123	ribosomal protein S6 kinase B1	Homo sapiens	14-45
12153572-2	2002	They activate p70 ribosomal protein S6 kinase (p70S6K) and acetyl-CoA carboxylase (ACC) involved in protein and fatty acids synthesis, respectively.	Fatty Acids	112-123	ribosomal protein S6 kinase B1	Homo sapiens	47-53
12023960-8	2002	Its mutation to either Ile or Val severely reduced the efficacy with which NEK6-phosphorylated peptide substrates, and moreover, mutation of the equivalent Leu residue in S6K1 or SGK1 prevented phosphorylation of their hydrophobic motifs by NEK6 in vitro.	Leucine	156-159	ribosomal protein S6 kinase B1	Homo sapiens	171-175
12091463-3	2002	Carbachol induced a dose- and time-dependent activation of p70S6K, as evidenced by increased phosphorylation at Thr-389, Thr-421 and Ser-424, by increased p70S6K activity, and by a shift in its molecular weight.	Carbachol	0-9	ribosomal protein S6 kinase B1	Homo sapiens	59-65
12091463-3	2002	Carbachol induced a dose- and time-dependent activation of p70S6K, as evidenced by increased phosphorylation at Thr-389, Thr-421 and Ser-424, by increased p70S6K activity, and by a shift in its molecular weight.	Carbachol	0-9	ribosomal protein S6 kinase B1	Homo sapiens	155-161
12091463-3	2002	Carbachol induced a dose- and time-dependent activation of p70S6K, as evidenced by increased phosphorylation at Thr-389, Thr-421 and Ser-424, by increased p70S6K activity, and by a shift in its molecular weight.	Threonine	112-115	ribosomal protein S6 kinase B1	Homo sapiens	59-65
12091463-3	2002	Carbachol induced a dose- and time-dependent activation of p70S6K, as evidenced by increased phosphorylation at Thr-389, Thr-421 and Ser-424, by increased p70S6K activity, and by a shift in its molecular weight.	Threonine	121-124	ribosomal protein S6 kinase B1	Homo sapiens	59-65
12091463-3	2002	Carbachol induced a dose- and time-dependent activation of p70S6K, as evidenced by increased phosphorylation at Thr-389, Thr-421 and Ser-424, by increased p70S6K activity, and by a shift in its molecular weight.	Serine	133-136	ribosomal protein S6 kinase B1	Homo sapiens	59-65
12091463-5	2002	Carbachol-induced DNA synthesis was strongly inhibited by rapamycin, suggesting that p70S6K activation plays an important role in carbachol-induced cell proliferation.	Carbachol	0-9	ribosomal protein S6 kinase B1	Homo sapiens	85-91
12091463-5	2002	Carbachol-induced DNA synthesis was strongly inhibited by rapamycin, suggesting that p70S6K activation plays an important role in carbachol-induced cell proliferation.	Carbachol	130-139	ribosomal protein S6 kinase B1	Homo sapiens	85-91
12091463-7	2002	In the same range of concentrations, ethanol also inhibits carbachol-induced activation of PKCzeta and of p70S6K.	Ethanol	37-44	ribosomal protein S6 kinase B1	Homo sapiens	106-112
12091463-7	2002	In the same range of concentrations, ethanol also inhibits carbachol-induced activation of PKCzeta and of p70S6K.	Carbachol	59-68	ribosomal protein S6 kinase B1	Homo sapiens	106-112
12091463-9	2002	These results indicate that activation of the PKCzeta--&gt; p70S6K pathway by M3 mAChRs may play a role in the increased DNA synthesis and may represent a target for ethanol-induced inhibition of astroglial cell proliferation.	Ethanol	166-173	ribosomal protein S6 kinase B1	Homo sapiens	60-66
11940578-4	2002	These treatments resulted in S6K1 activation with Thr-389 phosphorylation as well as mammalian target of rapamycin (mTOR) and S6 protein phosphorylation.	Threonine	50-53	ribosomal protein S6 kinase B1	Homo sapiens	29-33
11940578-5	2002	Thr-421/Ser-424 phosphorylation of S6K1 was observed predominantly in TPA-treated cells.	Threonine	0-3	ribosomal protein S6 kinase B1	Homo sapiens	35-39
11940578-5	2002	Thr-421/Ser-424 phosphorylation of S6K1 was observed predominantly in TPA-treated cells.	Serine	8-11	ribosomal protein S6 kinase B1	Homo sapiens	35-39
11940578-5	2002	Thr-421/Ser-424 phosphorylation of S6K1 was observed predominantly in TPA-treated cells.	Tetradecanoylphorbol Acetate	70-73	ribosomal protein S6 kinase B1	Homo sapiens	35-39
11940578-6	2002	Dominant negative c-Raf expression or a MEK1/2 inhibitor (U0126) treatment showed a profound blocking effect only on the TPA-stimulated phosphorylation of S6K1 and mTOR.	U 0126	58-63	ribosomal protein S6 kinase B1	Homo sapiens	155-159
11940578-6	2002	Dominant negative c-Raf expression or a MEK1/2 inhibitor (U0126) treatment showed a profound blocking effect only on the TPA-stimulated phosphorylation of S6K1 and mTOR.	Tetradecanoylphorbol Acetate	121-124	ribosomal protein S6 kinase B1	Homo sapiens	155-159
11940578-7	2002	Whereas p38 MAPK inhibitors exhibited only partial effect, MAPK-phosphatase-3 expression significantly blocked the TPA-stimulated S6K1 and mTOR phosphorylation.	Tetradecanoylphorbol Acetate	115-118	ribosomal protein S6 kinase B1	Homo sapiens	130-134
11914378-1	2002	A critical step in S6 kinase 1 (S6K1) activation is Thr(229) phosphorylation in the activation loop by the phosphoinositide-dependent protein kinase (PDK1).	Threonine	52-55	ribosomal protein S6 kinase B1	Homo sapiens	19-30
11914378-5	2002	Here we use phosphospecific antibodies to show that Thr(229) is fully phosphorylated in S6K1-E389D(3)E in the absence of mitogens and that regulation of S6K1-E389D(3)E activity by mitogens, rapamycin, or wortmannin parallels Ser(371) phosphorylation.	Threonine	52-55	ribosomal protein S6 kinase B1	Homo sapiens	88-92
11914378-5	2002	Here we use phosphospecific antibodies to show that Thr(229) is fully phosphorylated in S6K1-E389D(3)E in the absence of mitogens and that regulation of S6K1-E389D(3)E activity by mitogens, rapamycin, or wortmannin parallels Ser(371) phosphorylation.	Threonine	52-55	ribosomal protein S6 kinase B1	Homo sapiens	153-157
11914378-5	2002	Here we use phosphospecific antibodies to show that Thr(229) is fully phosphorylated in S6K1-E389D(3)E in the absence of mitogens and that regulation of S6K1-E389D(3)E activity by mitogens, rapamycin, or wortmannin parallels Ser(371) phosphorylation.	Sirolimus	190-199	ribosomal protein S6 kinase B1	Homo sapiens	88-92
11914378-5	2002	Here we use phosphospecific antibodies to show that Thr(229) is fully phosphorylated in S6K1-E389D(3)E in the absence of mitogens and that regulation of S6K1-E389D(3)E activity by mitogens, rapamycin, or wortmannin parallels Ser(371) phosphorylation.	Sirolimus	190-199	ribosomal protein S6 kinase B1	Homo sapiens	153-157
11914378-5	2002	Here we use phosphospecific antibodies to show that Thr(229) is fully phosphorylated in S6K1-E389D(3)E in the absence of mitogens and that regulation of S6K1-E389D(3)E activity by mitogens, rapamycin, or wortmannin parallels Ser(371) phosphorylation.	Wortmannin	204-214	ribosomal protein S6 kinase B1	Homo sapiens	88-92
11914378-5	2002	Here we use phosphospecific antibodies to show that Thr(229) is fully phosphorylated in S6K1-E389D(3)E in the absence of mitogens and that regulation of S6K1-E389D(3)E activity by mitogens, rapamycin, or wortmannin parallels Ser(371) phosphorylation.	Wortmannin	204-214	ribosomal protein S6 kinase B1	Homo sapiens	153-157
11914378-5	2002	Here we use phosphospecific antibodies to show that Thr(229) is fully phosphorylated in S6K1-E389D(3)E in the absence of mitogens and that regulation of S6K1-E389D(3)E activity by mitogens, rapamycin, or wortmannin parallels Ser(371) phosphorylation.	Serine	225-228	ribosomal protein S6 kinase B1	Homo sapiens	88-92
11914378-5	2002	Here we use phosphospecific antibodies to show that Thr(229) is fully phosphorylated in S6K1-E389D(3)E in the absence of mitogens and that regulation of S6K1-E389D(3)E activity by mitogens, rapamycin, or wortmannin parallels Ser(371) phosphorylation.	Serine	225-228	ribosomal protein S6 kinase B1	Homo sapiens	153-157
12032842-7	2002	Finally, transient transfection of a constitutively active Myr-EGFP-AKT-HA construct (in the presence of PD98059) restored C2Ras myogenesis by its ability to activate P70S6K and p38-MAPK.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	105-112	ribosomal protein S6 kinase B1	Homo sapiens	167-173
12032842-8	2002	A crosstalk between P70S6K and p38-MAPK was observed under rapamycin treatment in both insulin or active AKT induced myogenesis.	Sirolimus	59-68	ribosomal protein S6 kinase B1	Homo sapiens	20-26
12054624-1	2002	We report here for the first time that the specific MAPK kinase (MEK) inhibitor, PD-98059, completely knocked out granulocyte-macrophage colony-stimulating factor (GM-CSF)-stimulated MAPK activity but also partially inactivated the ribosomal kinase p70S6K.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	81-89	ribosomal protein S6 kinase B1	Homo sapiens	249-255
12054624-5	2002	Since an upstream activator of p70S6K, phosphatidylinositol (PI)3-kinase, has been associated to cell movement in phagocytic cells, we studied a possible participation of p70S6K in chemotaxis and whether MAPK had an input.	Phosphatidylinositols	39-59	ribosomal protein S6 kinase B1	Homo sapiens	31-37
12054624-6	2002	Our data show that functional chemotaxis was inhibited by rapamycin, a specific p70S6K inhibitor, as well as by PD-98059.	Sirolimus	58-67	ribosomal protein S6 kinase B1	Homo sapiens	80-86
12091463-0	2002	Effect of ethanol on protein kinase Czeta and p70S6 kinase activation by carbachol: a possible mechanism for ethanol-induced inhibition of glial cell proliferation.	Ethanol	10-17	ribosomal protein S6 kinase B1	Homo sapiens	46-58
12091463-0	2002	Effect of ethanol on protein kinase Czeta and p70S6 kinase activation by carbachol: a possible mechanism for ethanol-induced inhibition of glial cell proliferation.	Carbachol	73-82	ribosomal protein S6 kinase B1	Homo sapiens	46-58
12091463-0	2002	Effect of ethanol on protein kinase Czeta and p70S6 kinase activation by carbachol: a possible mechanism for ethanol-induced inhibition of glial cell proliferation.	Ethanol	109-116	ribosomal protein S6 kinase B1	Homo sapiens	46-58
12091463-2	2002	In this study we investigated the activation of p70S6 kinase (p70S6K) by carbachol in 1321 N1 astroctyoma cells.	Carbachol	73-82	ribosomal protein S6 kinase B1	Homo sapiens	48-60
12091463-2	2002	In this study we investigated the activation of p70S6 kinase (p70S6K) by carbachol in 1321 N1 astroctyoma cells.	Carbachol	73-82	ribosomal protein S6 kinase B1	Homo sapiens	62-68
12023032-2	2002	Here, we report that the bisindolylmaleimide derivative Ro 31-6045, previously reported to be inactive as a kinase inhibitor, inhibited S6K activity in vivo with an IC50=8 microM.	bisindolylmaleimide	25-44	ribosomal protein S6 kinase B1	Homo sapiens	136-139
11967149-4	2002	RESULTS: We have identified a conserved TOR signaling (TOS) motif in the N terminus of all known S6 kinases and in the C terminus of the 4E-BPs that is crucial for phosphorylation and regulation S6K1 and 4E-BP1 activities.	Toremifene	40-43	ribosomal protein S6 kinase B1	Homo sapiens	195-210
11967149-4	2002	RESULTS: We have identified a conserved TOR signaling (TOS) motif in the N terminus of all known S6 kinases and in the C terminus of the 4E-BPs that is crucial for phosphorylation and regulation S6K1 and 4E-BP1 activities.	tos	55-58	ribosomal protein S6 kinase B1	Homo sapiens	195-210
11967149-5	2002	Deletion or mutations within the TOS motif significantly inhibit S6K1 activation and the phosphorylation of its hydrophobic motif, Thr389.	tos	33-36	ribosomal protein S6 kinase B1	Homo sapiens	65-69
11967149-7	2002	The TOS motif is essential for S6K1 activation by mTOR, as mutations in this motif mimic the effect of rapamycin on S6K1 phosphorylation, and render S6K1 insensitive to changes in amino acids.	Sirolimus	103-112	ribosomal protein S6 kinase B1	Homo sapiens	31-35
11914378-1	2002	A critical step in S6 kinase 1 (S6K1) activation is Thr(229) phosphorylation in the activation loop by the phosphoinositide-dependent protein kinase (PDK1).	Threonine	52-55	ribosomal protein S6 kinase B1	Homo sapiens	32-36
11914378-2	2002	Thr(229) phosphorylation requires prior phosphorylation of the Ser/Thr-Pro sites in the autoinhibitory domain and Thr(389) in the linker domain, consistent with PDK1 more effectively catalyzing Thr(229) phosphorylation in a variant harboring acidic residues in these positions (S6K1-E389D(3)E).	Threonine	0-3	ribosomal protein S6 kinase B1	Homo sapiens	278-282
11914378-2	2002	Thr(229) phosphorylation requires prior phosphorylation of the Ser/Thr-Pro sites in the autoinhibitory domain and Thr(389) in the linker domain, consistent with PDK1 more effectively catalyzing Thr(229) phosphorylation in a variant harboring acidic residues in these positions (S6K1-E389D(3)E).	Serine	63-66	ribosomal protein S6 kinase B1	Homo sapiens	278-282
11914378-3	2002	S6K1-E389D(3)E has high basal activity and exhibits partial resistance to rapamycin and wortmannin, and its activity can be further augmented by mitogens, effects presumably mediated by Thr(229) phosphorylation.	Sirolimus	74-83	ribosomal protein S6 kinase B1	Homo sapiens	0-4
11914378-3	2002	S6K1-E389D(3)E has high basal activity and exhibits partial resistance to rapamycin and wortmannin, and its activity can be further augmented by mitogens, effects presumably mediated by Thr(229) phosphorylation.	Wortmannin	88-98	ribosomal protein S6 kinase B1	Homo sapiens	0-4
11914378-3	2002	S6K1-E389D(3)E has high basal activity and exhibits partial resistance to rapamycin and wortmannin, and its activity can be further augmented by mitogens, effects presumably mediated by Thr(229) phosphorylation.	Threonine	186-189	ribosomal protein S6 kinase B1	Homo sapiens	0-4
11914378-4	2002	However, PDK1-induced Thr(229) phosphorylation is reported to be constitutive rather than phosphatidylinositide 3,4,5-trisphosphate-dependent, suggesting that S6K1-E389D(3)E activity is mediated through a distinct site.	Threonine	22-25	ribosomal protein S6 kinase B1	Homo sapiens	159-163
11976732-13	2002	The phosphorylation of two downstream effectors of phosphoinositide 3-kinase, Akt and p70S6K, was markedly inhibited in the presence of artesunate.	Artesunate	136-146	ribosomal protein S6 kinase B1	Homo sapiens	86-92
11739559-5	2001	IL-8 expression was attenuated more by the Src kinase inhibitor PP1 than by the p70s6k inhibitor rapamycin.	Sirolimus	97-106	ribosomal protein S6 kinase B1	Homo sapiens	80-86
12489846-2	2002	We reported that the mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR)-p70(S6K) pathways.	U 0126	108-113	ribosomal protein S6 kinase B1	Homo sapiens	308-315
12489846-12	2002	Removal of anchorage substantially sensitized p70(S6K) to PD98059 in MDA-MB231 cells, whereas p70(S6K) in suspended HBC4 cells remained fairly refractory.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	58-65	ribosomal protein S6 kinase B1	Homo sapiens	46-49
12489846-13	2002	U0126 was either without effect or less inhibitory on p70(S6K) in MDA-MB453 and SKBR3, two cell lines in which anoikis sensitivity was not induced.	U 0126	0-5	ribosomal protein S6 kinase B1	Homo sapiens	54-57
11818508-7	2002	BAPTA-AM pretreatment inhibited other insulin-induced phosphorylation events including phosphorylation of Akt, MAPK (ERK1 and 2) and p70 S6K.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	0-8	ribosomal protein S6 kinase B1	Homo sapiens	133-140
11684675-3	2002	Activation of p70S6K is regulated by phosphorylation of seven different residues distributed throughout the protein, a subset of which depends on the activity of p85/p110 phosphatidylinositol 3-kinase (PI3K); in fact, the phosphorylation status of Thr(229) and Thr(389) is intimately linked to PI3K activity.	Threonine	248-251	ribosomal protein S6 kinase B1	Homo sapiens	14-20
11684675-3	2002	Activation of p70S6K is regulated by phosphorylation of seven different residues distributed throughout the protein, a subset of which depends on the activity of p85/p110 phosphatidylinositol 3-kinase (PI3K); in fact, the phosphorylation status of Thr(229) and Thr(389) is intimately linked to PI3K activity.	Threonine	261-264	ribosomal protein S6 kinase B1	Homo sapiens	14-20
12362981-4	2002	The induction of leukemia cell differentiation in response to the analogs of vitamin D was inhibited by LY294002 (phosphatidylinositol 3-kinase inhibitor), PD98059 (inhibitor of MEK1,2, an upstream regulator of extracellular-signal regulated kinase) and rapamycin (p70S6K inhibitor) pointing out that activation of signal transduction pathways unrelated to nVDR is necessary for differentiation.	Vitamin D	77-86	ribosomal protein S6 kinase B1	Homo sapiens	265-271
12362981-4	2002	The induction of leukemia cell differentiation in response to the analogs of vitamin D was inhibited by LY294002 (phosphatidylinositol 3-kinase inhibitor), PD98059 (inhibitor of MEK1,2, an upstream regulator of extracellular-signal regulated kinase) and rapamycin (p70S6K inhibitor) pointing out that activation of signal transduction pathways unrelated to nVDR is necessary for differentiation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	104-112	ribosomal protein S6 kinase B1	Homo sapiens	265-271
12362981-4	2002	The induction of leukemia cell differentiation in response to the analogs of vitamin D was inhibited by LY294002 (phosphatidylinositol 3-kinase inhibitor), PD98059 (inhibitor of MEK1,2, an upstream regulator of extracellular-signal regulated kinase) and rapamycin (p70S6K inhibitor) pointing out that activation of signal transduction pathways unrelated to nVDR is necessary for differentiation.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	156-163	ribosomal protein S6 kinase B1	Homo sapiens	265-271
11967149-7	2002	The TOS motif is essential for S6K1 activation by mTOR, as mutations in this motif mimic the effect of rapamycin on S6K1 phosphorylation, and render S6K1 insensitive to changes in amino acids.	Sirolimus	103-112	ribosomal protein S6 kinase B1	Homo sapiens	116-120
11967149-7	2002	The TOS motif is essential for S6K1 activation by mTOR, as mutations in this motif mimic the effect of rapamycin on S6K1 phosphorylation, and render S6K1 insensitive to changes in amino acids.	Sirolimus	103-112	ribosomal protein S6 kinase B1	Homo sapiens	116-120
11967149-8	2002	Furthermore, only overexpression of S6K1 with an intact TOS motif prevents 4E-BP1 phosphorylation by a common mTOR-regulated modulator of S6K1 and 4E-BP1.	tos	56-59	ribosomal protein S6 kinase B1	Homo sapiens	36-40
11967149-9	2002	CONCLUSIONS: S6K1 and 4E-BP1 contain a conserved five amino acid sequence (TOS motif) that is crucial for their regulation by the mTOR pathway.	tos	75-78	ribosomal protein S6 kinase B1	Homo sapiens	13-28
11792123-5	2001	The utilization of the inhibitors, wortmannin and LY294002, demonstrated a role for phosphatidylinositol 3-kinase (PI3K) whereas rapamycin demonstrated p70 S6-kinase (p70S6K) involvement in the production of IL-10 by these monocytes.	Sirolimus	129-138	ribosomal protein S6 kinase B1	Homo sapiens	152-165
11879570-6	2001	Thus, our results suggest that UVA-induced EGFR signaling may be required for activation of p90(RSK)/p70(S6K), PI-3 kinase, and ERKs but not JNKs or p38 kinase.	uva	31-34	ribosomal protein S6 kinase B1	Homo sapiens	101-108
11709727-4	2001	Wortmannin, LY294002, and rapamycin at concentrations that did not affect MAPK phosphorylation but substantially inhibited PI3K, Akt, and p70(S6K) significantly suppressed the soft agar growth of tumor cell lines that overexpress ErbB2 but not the growth of tumor lines with low ErbB2 expression.	Wortmannin	0-10	ribosomal protein S6 kinase B1	Homo sapiens	138-141
11709727-4	2001	Wortmannin, LY294002, and rapamycin at concentrations that did not affect MAPK phosphorylation but substantially inhibited PI3K, Akt, and p70(S6K) significantly suppressed the soft agar growth of tumor cell lines that overexpress ErbB2 but not the growth of tumor lines with low ErbB2 expression.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	12-20	ribosomal protein S6 kinase B1	Homo sapiens	138-141
11709727-4	2001	Wortmannin, LY294002, and rapamycin at concentrations that did not affect MAPK phosphorylation but substantially inhibited PI3K, Akt, and p70(S6K) significantly suppressed the soft agar growth of tumor cell lines that overexpress ErbB2 but not the growth of tumor lines with low ErbB2 expression.	Sirolimus	26-35	ribosomal protein S6 kinase B1	Homo sapiens	138-141
11272147-1	2001	Recent findings have demonstrated that the branched-chain amino acid leucine can activate the translational regulators, phosphorylated heat- and acid-stable protein regulated by insulin (PHAS-I) and p70 S6 kinase (p70S6k), in an insulin-independent and rapamycin-sensitive manner through mammalian target of rapamycin (mTOR), although the mechanism for this activation is undefined.	branched-chain amino acid leucine	43-76	ribosomal protein S6 kinase B1	Homo sapiens	199-212
11713299-7	2001	Inhibition of mTOR by rapamycin led to fast and complete repression of S6K1, as judged by rpS6 phosphorylation, but to only partial and delayed repression of translational activation of TOP mRNAs.	Sirolimus	22-31	ribosomal protein S6 kinase B1	Homo sapiens	71-75
11551843-0	2001	Elevated IGF-II mRNA and phosphorylation of 4E-BP1 and p70(S6k) in muscle showing clenbuterol-induced anabolism.	Clenbuterol	82-93	ribosomal protein S6 kinase B1	Homo sapiens	59-62
11551843-4	2001	The results showed that the well-documented early effects of clenbuterol on protein metabolism were preceded by elevated levels of IGF-II and H19 transcripts together with increased phosphorylation of eukaryotic initiation factor (eIF)4E binding protein-1 (4E-BP1) and p70(S6k).	Clenbuterol	61-72	ribosomal protein S6 kinase B1	Homo sapiens	273-276
11551843-6	2001	These novel findings indicate that clenbuterol-induced muscle anabolism is potentially mediated, at least in part, by an IGF-II-induced activation of 4E-BP1 and p70(S6k).	Clenbuterol	35-46	ribosomal protein S6 kinase B1	Homo sapiens	165-168
11500301-2	2001	To test the hypothesis that leucine and insulin stimulate translation initiation in human skeletal muscle by phosphorylating 70-kDa ribosomal protein S6 kinase (p70(S6k)), we infused healthy adults with leucine alone (n = 6), insulin alone (n = 6), or both leucine and insulin (n = 6) for 2 h. p70(S6k) and protein kinase B (PKB) serine(473) phosphorylation were measured in vastus lateralis muscles.	Leucine	28-35	ribosomal protein S6 kinase B1	Homo sapiens	161-168
11500301-2	2001	To test the hypothesis that leucine and insulin stimulate translation initiation in human skeletal muscle by phosphorylating 70-kDa ribosomal protein S6 kinase (p70(S6k)), we infused healthy adults with leucine alone (n = 6), insulin alone (n = 6), or both leucine and insulin (n = 6) for 2 h. p70(S6k) and protein kinase B (PKB) serine(473) phosphorylation were measured in vastus lateralis muscles.	Leucine	28-35	ribosomal protein S6 kinase B1	Homo sapiens	165-168
11500301-5	2001	Phosphorylation of p70(S6k) increased 4-fold in response to leucine alone, 8-fold in response to insulin alone, and 18-fold after the leucine + insulin infusion.	Leucine	60-67	ribosomal protein S6 kinase B1	Homo sapiens	23-26
11500301-5	2001	Phosphorylation of p70(S6k) increased 4-fold in response to leucine alone, 8-fold in response to insulin alone, and 18-fold after the leucine + insulin infusion.	Leucine	134-141	ribosomal protein S6 kinase B1	Homo sapiens	23-26
11274216-7	2001	Hence, there is a requirement for the activation of both ERK1/ERK2 and mammalian target of rapamycin/p70(S6K) signal transduction pathways for a full commitment to glucose-induced pancreatic beta-cell mitogenesis.	Glucose	164-171	ribosomal protein S6 kinase B1	Homo sapiens	101-104
11279232-7	2001	In vitro assays indicated that Ser(411) on immunoprecipitated p70(S6K) proteins is phosphorylated by active JNKs and ERKs, but not p38 kinase, and Thr(421)/Ser(424) is phosphorylated by ERK1, but not ERK2, JNKs, or p38 kinase.	Serine	31-34	ribosomal protein S6 kinase B1	Homo sapiens	62-69
11279232-7	2001	In vitro assays indicated that Ser(411) on immunoprecipitated p70(S6K) proteins is phosphorylated by active JNKs and ERKs, but not p38 kinase, and Thr(421)/Ser(424) is phosphorylated by ERK1, but not ERK2, JNKs, or p38 kinase.	Threonine	147-150	ribosomal protein S6 kinase B1	Homo sapiens	62-69
11279232-7	2001	In vitro assays indicated that Ser(411) on immunoprecipitated p70(S6K) proteins is phosphorylated by active JNKs and ERKs, but not p38 kinase, and Thr(421)/Ser(424) is phosphorylated by ERK1, but not ERK2, JNKs, or p38 kinase.	Serine	156-159	ribosomal protein S6 kinase B1	Homo sapiens	62-69
11358856-4	2001	Inhibition of the PI3K downstream target p70S6K by rapamycin, the Raf-MEK-MAPK pathway with PD98059, or the Ras-MEK kinase-p38 pathway with SB203580 had no effect on radiation survival in cells with oncogenic ras.	Sirolimus	51-60	ribosomal protein S6 kinase B1	Homo sapiens	41-47
11879570-3	2001	In this report, we show that UVA stimulation of the epidermal growth factor receptor (EGFR) may lead to activation of p70(S6K)/p90(RSK) through phosphatidyl isositol (PI)-3 kinase and extracellular receptor-activated kinases (ERKs).	phosphatidyl isositol	144-165	ribosomal protein S6 kinase B1	Homo sapiens	122-125
11879570-4	2001	Evidence is provided that phosphorylation and activation of p70(S6K)/p90(RSK) induced by UVA were prevented in Egfr(-/-) cells and were also markedly inhibited by the EGFR-specific tyrosine kinase inhibitors AG1478 and PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	219-227	ribosomal protein S6 kinase B1	Homo sapiens	64-67
11514293-7	2001	In addition, chronic alcohol feeding significantly reduced the extent of p70S6 kinase (p70(S6K)) phosphorylation.	Alcohols	21-28	ribosomal protein S6 kinase B1	Homo sapiens	73-76
11514293-9	2001	These data suggest that a chronic alcohol-induced impairment in myocardial protein synthesis results in part from inhibition in peptide chain initiation secondary to marked changes in eIF4E availability and p70(S6K) phosphorylation.	Alcohols	34-41	ribosomal protein S6 kinase B1	Homo sapiens	207-210
11513750-9	2001	Taken together with earlier data showing that amino acids regulate 4E-BP1 and p70 S6k, the present findings show that 4E-BP1 in particular is regulated in response to the availability of both amino acids and sugars.	Sugars	208-214	ribosomal protein S6 kinase B1	Homo sapiens	78-85
11402043-4	2001	Similarly, TNF significantly up-regulated PAI-1 synthesis when p70(S6K) phosphorylation was inhibited by rapamycin.	Sirolimus	105-114	ribosomal protein S6 kinase B1	Homo sapiens	63-66
11493700-4	2001	Rapamycin inhibited mitochondrial-based p70S6K, which prevented phosphorylation of Ser-136 on BAD and blocked cell survival induced by insulin-like growth factor 1 (IGF-1).	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	40-46
11493700-4	2001	Rapamycin inhibited mitochondrial-based p70S6K, which prevented phosphorylation of Ser-136 on BAD and blocked cell survival induced by insulin-like growth factor 1 (IGF-1).	Serine	83-86	ribosomal protein S6 kinase B1	Homo sapiens	40-46
11493700-5	2001	Moreover, IGF-1-induced phosphorylation of BAD Ser-136 was abolished in p70S6K-deficient cells.	Serine	47-50	ribosomal protein S6 kinase B1	Homo sapiens	72-78
11446769-5	2001	Protein kinase C (PKC) activator TPA also induced the phosphorylation of p70 S6K.	Tetradecanoylphorbol Acetate	33-36	ribosomal protein S6 kinase B1	Homo sapiens	73-80
11446769-6	2001	Both the PI-3K inhibitor wortmannin and PKC inhibitor calphostin C blocked the phosphorylation of p70 S6K mediated by the growth factors.	Wortmannin	25-35	ribosomal protein S6 kinase B1	Homo sapiens	98-105
11446769-8	2001	Furthermore, HGF and KGF increased the rate of corneal epithelial wound healing in an organ culture model, and wortmannin and rapamycin (the p70 S6K inhibitor) blocked corneal epithelial wound healing promoted by the growth factors.	Wortmannin	111-121	ribosomal protein S6 kinase B1	Homo sapiens	141-148
11446769-8	2001	Furthermore, HGF and KGF increased the rate of corneal epithelial wound healing in an organ culture model, and wortmannin and rapamycin (the p70 S6K inhibitor) blocked corneal epithelial wound healing promoted by the growth factors.	Sirolimus	126-135	ribosomal protein S6 kinase B1	Homo sapiens	141-148
11531284-7	2001	Importantly, constitutive phosphorylation of Akt2 and p70 S6K, as found in neoplastic OSE, was also observed in overtly normal OSE from women with predisposing BRCA1 gene mutations.	serine O-sulfate	86-89	ribosomal protein S6 kinase B1	Homo sapiens	54-61
11531284-7	2001	Importantly, constitutive phosphorylation of Akt2 and p70 S6K, as found in neoplastic OSE, was also observed in overtly normal OSE from women with predisposing BRCA1 gene mutations.	serine O-sulfate	127-130	ribosomal protein S6 kinase B1	Homo sapiens	54-61
11404220-2	2001	Here it is shown that phenanthroline, a zinc and heavy metal chelator, inhibited both amino acid- and insulin-stimulated phosphorylation of p70(S6k).	Phenanthrolines	22-36	ribosomal protein S6 kinase B1	Homo sapiens	144-147
11404220-2	2001	Here it is shown that phenanthroline, a zinc and heavy metal chelator, inhibited both amino acid- and insulin-stimulated phosphorylation of p70(S6k).	Metals	55-60	ribosomal protein S6 kinase B1	Homo sapiens	144-147
11279232-5	2001	The p70(S6K) phosphorylation at Ser(411) and Thr(421)/Ser(424) was inhibited by rapamycin, PD98059, or DNM-ERK2 but not by wortmannin, SB202190, DNM-Deltap85, or DNM-p38.	Serine	32-35	ribosomal protein S6 kinase B1	Homo sapiens	4-11
11279232-5	2001	The p70(S6K) phosphorylation at Ser(411) and Thr(421)/Ser(424) was inhibited by rapamycin, PD98059, or DNM-ERK2 but not by wortmannin, SB202190, DNM-Deltap85, or DNM-p38.	Threonine	45-48	ribosomal protein S6 kinase B1	Homo sapiens	4-11
11279232-5	2001	The p70(S6K) phosphorylation at Ser(411) and Thr(421)/Ser(424) was inhibited by rapamycin, PD98059, or DNM-ERK2 but not by wortmannin, SB202190, DNM-Deltap85, or DNM-p38.	Serine	54-57	ribosomal protein S6 kinase B1	Homo sapiens	4-11
11279232-5	2001	The p70(S6K) phosphorylation at Ser(411) and Thr(421)/Ser(424) was inhibited by rapamycin, PD98059, or DNM-ERK2 but not by wortmannin, SB202190, DNM-Deltap85, or DNM-p38.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	91-98	ribosomal protein S6 kinase B1	Homo sapiens	4-11
11344218-7	2001	BCAA also increased the phosphorylation of both eIF4E-BP1 (P &lt; 0.02) and p70(S6K) (P &lt; 0.03), consistent with an action to activate the protein synthetic apparatus.	Amino Acids, Branched-Chain	0-4	ribosomal protein S6 kinase B1	Homo sapiens	76-79
11344218-8	2001	Dexamethasone increased plasma phenylalanine concentration (P &lt; 0.001), prevented the BCAA-induced anabolic shift in forearm protein balance, and inhibited their action on the phosphorylation of p70(S6K).	Dexamethasone	0-13	ribosomal protein S6 kinase B1	Homo sapiens	202-205
11344218-8	2001	Dexamethasone increased plasma phenylalanine concentration (P &lt; 0.001), prevented the BCAA-induced anabolic shift in forearm protein balance, and inhibited their action on the phosphorylation of p70(S6K).	Amino Acids, Branched-Chain	89-93	ribosomal protein S6 kinase B1	Homo sapiens	202-205
11108720-8	2001	Pretreatment of cells with the mitogen-activated protein-extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited S6K2 activation to a greater extent than S6K1.	U 0126	118-123	ribosomal protein S6 kinase B1	Homo sapiens	175-179
11313876-7	2001	Several signaling molecules of the PI3K pathway, including Akt2 and p70 S6K, were constitutively activated in FH-OSE from six of six women but in NFH-OSE from only four of eight women.	serine O-sulfate	113-116	ribosomal protein S6 kinase B1	Homo sapiens	68-75
11313876-7	2001	Several signaling molecules of the PI3K pathway, including Akt2 and p70 S6K, were constitutively activated in FH-OSE from six of six women but in NFH-OSE from only four of eight women.	serine O-sulfate	150-153	ribosomal protein S6 kinase B1	Homo sapiens	68-75
11238774-3	2001	In addition, leucine enhances phosphorylation of the 70-kDa ribosomal protein S6 kinase (S6K1).	Leucine	13-20	ribosomal protein S6 kinase B1	Homo sapiens	89-93
11211609-4	2001	We assessed PS6K dosage in 94 archival paraffin-embedded meningiomas using dual-color fluorescence in situ hybridization.	Paraffin	39-47	ribosomal protein S6 kinase B1	Homo sapiens	12-16
11272147-1	2001	Recent findings have demonstrated that the branched-chain amino acid leucine can activate the translational regulators, phosphorylated heat- and acid-stable protein regulated by insulin (PHAS-I) and p70 S6 kinase (p70S6k), in an insulin-independent and rapamycin-sensitive manner through mammalian target of rapamycin (mTOR), although the mechanism for this activation is undefined.	branched-chain amino acid leucine	43-76	ribosomal protein S6 kinase B1	Homo sapiens	214-220
11272147-1	2001	Recent findings have demonstrated that the branched-chain amino acid leucine can activate the translational regulators, phosphorylated heat- and acid-stable protein regulated by insulin (PHAS-I) and p70 S6 kinase (p70S6k), in an insulin-independent and rapamycin-sensitive manner through mammalian target of rapamycin (mTOR), although the mechanism for this activation is undefined.	Sirolimus	253-262	ribosomal protein S6 kinase B1	Homo sapiens	199-212
11272147-1	2001	Recent findings have demonstrated that the branched-chain amino acid leucine can activate the translational regulators, phosphorylated heat- and acid-stable protein regulated by insulin (PHAS-I) and p70 S6 kinase (p70S6k), in an insulin-independent and rapamycin-sensitive manner through mammalian target of rapamycin (mTOR), although the mechanism for this activation is undefined.	Sirolimus	253-262	ribosomal protein S6 kinase B1	Homo sapiens	214-220
11272147-4	2001	Thus, a minimal model consisting of leucine and glutamine as substrates for oxidative decarboxylation and an activator of GDH, respectively, confirmed the requirement for these two metabolic components and mimicked closely the synergistic interactions achieved by a complete complement of amino acids to activate p70s6k in a rapamycin-sensitive manner.	Leucine	36-43	ribosomal protein S6 kinase B1	Homo sapiens	313-319
11272147-4	2001	Thus, a minimal model consisting of leucine and glutamine as substrates for oxidative decarboxylation and an activator of GDH, respectively, confirmed the requirement for these two metabolic components and mimicked closely the synergistic interactions achieved by a complete complement of amino acids to activate p70s6k in a rapamycin-sensitive manner.	Glutamine	48-57	ribosomal protein S6 kinase B1	Homo sapiens	313-319
11272147-5	2001	Studies using various leucine analogs also confirmed the close association of mitochondrial metabolism and the ability of leucine analogs to activate p70s6k.	Leucine	22-29	ribosomal protein S6 kinase B1	Homo sapiens	150-156
11160203-7	2001	Upstream of p70(S6K), signaling through both Ig receptors depresses PI3K pathway phospholipids below control with time, which is followed by p27(Kip1) induction.	Phospholipids	81-94	ribosomal protein S6 kinase B1	Homo sapiens	16-19
11145615-2	2001	These compounds inhibit the kinase action of PI3K, thus preventing the accumulation of PI(3,4,5)P3 and PI(3,4)P2 (PIs) and subsequent phosphorylation and activation of the downstream effectors of PI3K, Akt and p70(S6K).	Monothiopyrophosphoric acid	114-117	ribosomal protein S6 kinase B1	Homo sapiens	210-213
11114166-5	2000	Inhibition of FRAP nuclear export by LMB coincides with diminished p70(s6k) activation and 4E-BP1 phosphorylation.	leptomycin B	37-40	ribosomal protein S6 kinase B1	Homo sapiens	67-74
10993886-0	2000	Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen.	Salicylates	0-10	ribosomal protein S6 kinase B1	Homo sapiens	66-72
10993886-5	2000	We find that salicylate potently inhibits p70(s6k) activation and phosphorylation in a p38 MAPK-independent manner.	Salicylates	13-23	ribosomal protein S6 kinase B1	Homo sapiens	42-49
10993886-6	2000	Interestingly, low salicylate concentrations (&lt;/=250 microm) inhibit p70(s6k) activation by phorbol myristate acetate, while higher salicylate concentrations (&gt;/=5 mm) are required to block p70(s6k) activation by epidermal growth factor + insulin-like growth factor-1.	Salicylates	19-29	ribosomal protein S6 kinase B1	Homo sapiens	72-79
10993886-6	2000	Interestingly, low salicylate concentrations (&lt;/=250 microm) inhibit p70(s6k) activation by phorbol myristate acetate, while higher salicylate concentrations (&gt;/=5 mm) are required to block p70(s6k) activation by epidermal growth factor + insulin-like growth factor-1.	Tetradecanoylphorbol Acetate	95-120	ribosomal protein S6 kinase B1	Homo sapiens	72-79
10993886-8	2000	Inhibition of p70(s6k) by salicylate occurs within 5 min, is independent of the phosphatidylinositol 3-kinase pathway, and is associated with dephosphorylation of p70(s6k) on its major rapamycin-sensitive site, Thr(389).	Salicylates	26-36	ribosomal protein S6 kinase B1	Homo sapiens	14-21
10993886-8	2000	Inhibition of p70(s6k) by salicylate occurs within 5 min, is independent of the phosphatidylinositol 3-kinase pathway, and is associated with dephosphorylation of p70(s6k) on its major rapamycin-sensitive site, Thr(389).	Salicylates	26-36	ribosomal protein S6 kinase B1	Homo sapiens	163-170
10993886-8	2000	Inhibition of p70(s6k) by salicylate occurs within 5 min, is independent of the phosphatidylinositol 3-kinase pathway, and is associated with dephosphorylation of p70(s6k) on its major rapamycin-sensitive site, Thr(389).	Phosphatidylinositols	80-100	ribosomal protein S6 kinase B1	Homo sapiens	14-21
10993886-8	2000	Inhibition of p70(s6k) by salicylate occurs within 5 min, is independent of the phosphatidylinositol 3-kinase pathway, and is associated with dephosphorylation of p70(s6k) on its major rapamycin-sensitive site, Thr(389).	Threonine	211-214	ribosomal protein S6 kinase B1	Homo sapiens	14-21
10993886-8	2000	Inhibition of p70(s6k) by salicylate occurs within 5 min, is independent of the phosphatidylinositol 3-kinase pathway, and is associated with dephosphorylation of p70(s6k) on its major rapamycin-sensitive site, Thr(389).	Threonine	211-214	ribosomal protein S6 kinase B1	Homo sapiens	163-170
10993886-9	2000	A rapamycin-resistant mutant of p70(s6k) is resistant to salicylate-induced Thr(389) dephosphorylation.	Salicylates	57-67	ribosomal protein S6 kinase B1	Homo sapiens	32-39
10993886-9	2000	A rapamycin-resistant mutant of p70(s6k) is resistant to salicylate-induced Thr(389) dephosphorylation.	Threonine	76-79	ribosomal protein S6 kinase B1	Homo sapiens	32-39
11134159-5	2000	Phosphorylation of P70(S6k) and eIF4E-BP1 was quantified on Western blots after SDS-PAGE.	Sodium Dodecyl Sulfate	80-83	ribosomal protein S6 kinase B1	Homo sapiens	19-26
11162588-3	2001	We found that both FRAP and insulin-activated p70 S6 kinase (p70(s6k)) serine phosphorylated IRS-1 between residues 511 and 772 (IRS-1(511-772)).	Serine	71-77	ribosomal protein S6 kinase B1	Homo sapiens	61-68
11145615-0	2001	Growth factor-stimulated phosphorylation of Akt and p70(S6K) is differentially inhibited by LY294002 and Wortmannin.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	92-100	ribosomal protein S6 kinase B1	Homo sapiens	52-55
11145615-0	2001	Growth factor-stimulated phosphorylation of Akt and p70(S6K) is differentially inhibited by LY294002 and Wortmannin.	Wortmannin	105-115	ribosomal protein S6 kinase B1	Homo sapiens	52-55
11079678-11	2000	Cerivastatin reduced the 3H-thymidine incorporation (164 +/- 11%, p &lt; 0.01), inhibited Cdk2 activation and Rb phosphorylation, but did not prevent p27Kip1 down-regulation, nor p42mapk and p70S6K activation.	cerivastatin	0-12	ribosomal protein S6 kinase B1	Homo sapiens	191-197
11272147-5	2001	Studies using various leucine analogs also confirmed the close association of mitochondrial metabolism and the ability of leucine analogs to activate p70s6k.	Leucine	122-129	ribosomal protein S6 kinase B1	Homo sapiens	150-156
11272147-7	2001	These findings indicate that leucine at physiological concentrations stimulates p70s6k phosphorylation via the mTOR pathway, in part, by serving both as a mitochondrial fuel and an allosteric activator of GDH.	Leucine	29-36	ribosomal protein S6 kinase B1	Homo sapiens	80-86
10987835-10	2000	These results indicate that IGF-I functions through a signal transduction pathway involving PI 3-K and p70(S6k) to prevent the development of sensitivity to kainate neurotoxicity in cerebellar granule cells.	Kainic Acid	157-164	ribosomal protein S6 kinase B1	Homo sapiens	103-110
10971657-5	2000	These deletions also abolished the ability of a rapamycin-resistant mTOR mutant to rescue the activity of p70 alpha from inhibition induced by rapamycin in vivo.	Sirolimus	48-57	ribosomal protein S6 kinase B1	Homo sapiens	106-115
11032423-6	2000	In contrast, in the presence of zinc, EtOH enhanced the stimulatory effect of LPA on p70 S6K activity.	Ethanol	38-42	ribosomal protein S6 kinase B1	Homo sapiens	85-92
11032423-6	2000	In contrast, in the presence of zinc, EtOH enhanced the stimulatory effect of LPA on p70 S6K activity.	lysophosphatidic acid	78-81	ribosomal protein S6 kinase B1	Homo sapiens	85-92
11032423-7	2000	The results indicate that in human fibroblasts, in the presence of zinc, EtOH enhances the stimulatory effects of LPA on DNA synthesis, but not on cell proliferation, by a mechanism probably involving activation of p70 S6K.	Ethanol	73-77	ribosomal protein S6 kinase B1	Homo sapiens	215-222
10981855-4	2000	Rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR), which is an upstream signaling of p70S6K, completely inhibited FCS-induced cell size increases and protein synthesis, but had no effect on SKA mRNA expression.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	111-117
10601311-11	1999	Overexpression of PDK1 in cells induces the phosphorylation of p70 S6 kinase at Thr-412 in unstimulated cells, and a catalytically inactive mutant of PDK1 prevents the phosphorylation of p70 S6K at Thr-412 in insulin-like growth factor 1-stimulated cells.	Threonine	80-83	ribosomal protein S6 kinase B1	Homo sapiens	187-194
10849422-5	2000	We now demonstrate that SCF activates phosphoinositide 3-kinase (PI3-K) and p70 S6 kinase (p70S6K) and that rapamycin, a FRAP/mammalian target of rapamycin-dependent inhibitor of p70S6K, completely inhibited bromodeoxyuridine incorporation induced by SCF in primary cultures of spermatogonia.	Sirolimus	108-117	ribosomal protein S6 kinase B1	Homo sapiens	179-185
10849422-9	2000	Constitutively active v-AKT highly phosphorylated p70S6K, which was totally inhibited by rapamycin.	Sirolimus	89-98	ribosomal protein S6 kinase B1	Homo sapiens	50-56
10893325-3	2000	This investigation revealed that in L6 myoblasts, dexamethasone, a synthetic glucocorticoid, deactivated the ribosomal protein S6 kinase (p70(S6k)) within 4 h, as evidenced by diminished phosphorylation of its physiological substrate, the 40S ribosomal protein S6.	Dexamethasone	50-63	ribosomal protein S6 kinase B1	Homo sapiens	138-145
10893325-4	2000	This deactivation correlated with dephosphorylation of p70(S6k) at Thr(389), whereas phosphorylation of Ser(411) was unaffected.	Threonine	67-70	ribosomal protein S6 kinase B1	Homo sapiens	59-62
10893325-7	2000	Okadaic acid and calyculin A corrected the dexamethasone-induced dephosphorylation of p70(S6k) and 4E-BP1, implicating a PP1- and/or PP2A-like protein phosphatase(s) in the observed phenomena.	Okadaic Acid	0-12	ribosomal protein S6 kinase B1	Homo sapiens	86-93
10893325-7	2000	Okadaic acid and calyculin A corrected the dexamethasone-induced dephosphorylation of p70(S6k) and 4E-BP1, implicating a PP1- and/or PP2A-like protein phosphatase(s) in the observed phenomena.	calyculin A	17-28	ribosomal protein S6 kinase B1	Homo sapiens	86-93
10893325-7	2000	Okadaic acid and calyculin A corrected the dexamethasone-induced dephosphorylation of p70(S6k) and 4E-BP1, implicating a PP1- and/or PP2A-like protein phosphatase(s) in the observed phenomena.	Dexamethasone	43-56	ribosomal protein S6 kinase B1	Homo sapiens	86-93
11200472-8	2000	Fibronectin-induced changes in S6K2 activity were closely correlated with phosphorylation at Ser423, which is homologues to Ser 434 of S6K1.	Serine	93-96	ribosomal protein S6 kinase B1	Homo sapiens	135-139
10753954-0	2000	Nitric oxide increases p21(Waf1/Cip1) expression by a cGMP-dependent pathway that includes activation of extracellular signal-regulated kinase and p70(S6k).	Nitric Oxide	0-12	ribosomal protein S6 kinase B1	Homo sapiens	147-154
10753954-0	2000	Nitric oxide increases p21(Waf1/Cip1) expression by a cGMP-dependent pathway that includes activation of extracellular signal-regulated kinase and p70(S6k).	Cyclic GMP	54-58	ribosomal protein S6 kinase B1	Homo sapiens	147-154
10753954-3	2000	Both ERK and p70(S6k) were phosphorylated in response to the NO donor S-nitroso-N-acetylpenicillamine (SNAP) and the activation was rapid, transient, and preceded increased p21 expresion under defined conditions where serum was present.	S-Nitroso-N-Acetylpenicillamine	70-101	ribosomal protein S6 kinase B1	Homo sapiens	13-20
10753954-4	2000	Addition of a selective inhibitor of ERK phosphorylation (PD98059) prevented the subsequent phosphorylation of p70(S6k) and the increase in p21 protein.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	58-65	ribosomal protein S6 kinase B1	Homo sapiens	115-118
10753954-5	2000	Both cGMP and cAMP activated both ERK and p70(S6k), whereas only selective inhibitors of protein kinase G prevented the activation of the kinases by SNAP.	Cyclic GMP	5-9	ribosomal protein S6 kinase B1	Homo sapiens	46-49
10753954-5	2000	Both cGMP and cAMP activated both ERK and p70(S6k), whereas only selective inhibitors of protein kinase G prevented the activation of the kinases by SNAP.	Cyclic AMP	14-18	ribosomal protein S6 kinase B1	Homo sapiens	46-49
10753954-7	2000	Rapamycin blocked p70(S6k) phosphorylation induced by NO and also inhibited p53 phosphorylation and p21 expression whereas PD98059 only prevented the NO-induced increase in p21 protein without influencing either p53 activation or p21 mRNA expression.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	22-25
12548975-3	2000	However, their analog, the immunosupressant FK-506, can inhibit the proliferation of fibroblast PBL1 without interfering with the activities of P90RSK, P70S6K and MAPK.	Tacrolimus	44-50	ribosomal protein S6 kinase B1	Homo sapiens	152-158
10822168-5	2000	The results indicate that high cellular levels of PCho potentiate insulin- and IGF-I-induced DNA synthesis by MAPK- and p70 S6K-regulated mechanisms.	Phosphorylcholine	50-54	ribosomal protein S6 kinase B1	Homo sapiens	120-127
10702801-9	2000	Unlike the inhibitory effects of TSH on the proliferation of RasV12S35-expressing cells, TSH enhanced RasV12C40-stimulated proliferation by further increasing the activity of p70s6k, an important mediator of the mitogenic effects of TSH and RasV12C40.	Thyrotropin	89-92	ribosomal protein S6 kinase B1	Homo sapiens	175-181
10601235-2	1999	Activation of p70 S6 kinase (p70(S6K)) by growth factors requires multiple signal inputs involving phosphoinositide 3-kinase (PI3K), its effector Akt, and an unidentified kinase that phosphorylates Ser/Thr residues (Ser(411), Ser(418), Ser(424), and Thr(421)) clustered at its autoinhibitory domain.	Serine	198-201	ribosomal protein S6 kinase B1	Homo sapiens	29-32
10601235-2	1999	Activation of p70 S6 kinase (p70(S6K)) by growth factors requires multiple signal inputs involving phosphoinositide 3-kinase (PI3K), its effector Akt, and an unidentified kinase that phosphorylates Ser/Thr residues (Ser(411), Ser(418), Ser(424), and Thr(421)) clustered at its autoinhibitory domain.	Threonine	202-205	ribosomal protein S6 kinase B1	Homo sapiens	29-32
10601235-2	1999	Activation of p70 S6 kinase (p70(S6K)) by growth factors requires multiple signal inputs involving phosphoinositide 3-kinase (PI3K), its effector Akt, and an unidentified kinase that phosphorylates Ser/Thr residues (Ser(411), Ser(418), Ser(424), and Thr(421)) clustered at its autoinhibitory domain.	Serine	216-219	ribosomal protein S6 kinase B1	Homo sapiens	29-32
10601235-2	1999	Activation of p70 S6 kinase (p70(S6K)) by growth factors requires multiple signal inputs involving phosphoinositide 3-kinase (PI3K), its effector Akt, and an unidentified kinase that phosphorylates Ser/Thr residues (Ser(411), Ser(418), Ser(424), and Thr(421)) clustered at its autoinhibitory domain.	Serine	216-219	ribosomal protein S6 kinase B1	Homo sapiens	29-32
10601235-2	1999	Activation of p70 S6 kinase (p70(S6K)) by growth factors requires multiple signal inputs involving phosphoinositide 3-kinase (PI3K), its effector Akt, and an unidentified kinase that phosphorylates Ser/Thr residues (Ser(411), Ser(418), Ser(424), and Thr(421)) clustered at its autoinhibitory domain.	Serine	216-219	ribosomal protein S6 kinase B1	Homo sapiens	29-32
10601235-2	1999	Activation of p70 S6 kinase (p70(S6K)) by growth factors requires multiple signal inputs involving phosphoinositide 3-kinase (PI3K), its effector Akt, and an unidentified kinase that phosphorylates Ser/Thr residues (Ser(411), Ser(418), Ser(424), and Thr(421)) clustered at its autoinhibitory domain.	Threonine	250-253	ribosomal protein S6 kinase B1	Homo sapiens	29-32
10601235-5	1999	Both p70(S6K) Ser(411) and Akt Ser(473) phosphorylation by Ang II appear to involve EGF receptor transactivation and were inhibited by dominant-negative Ras, whereas the phosphorylation of p70(S6K) and ERK but not Akt was sensitive to the MEK inhibitor.	Serine	14-17	ribosomal protein S6 kinase B1	Homo sapiens	9-12
10601276-9	1999	The addition of rapamycin, which inhibits IGF-I-induced p70(s6k) activation, significantly inhibited IGF-I-regulated IGFBP-5 gene expression.	Sirolimus	16-25	ribosomal protein S6 kinase B1	Homo sapiens	56-63
10601311-11	1999	Overexpression of PDK1 in cells induces the phosphorylation of p70 S6 kinase at Thr-412 in unstimulated cells, and a catalytically inactive mutant of PDK1 prevents the phosphorylation of p70 S6K at Thr-412 in insulin-like growth factor 1-stimulated cells.	Threonine	198-201	ribosomal protein S6 kinase B1	Homo sapiens	187-194
10567431-3	1999	We report here that a mammalian recombinant p70alpha polypeptide, extracted in an inactive form from rapamycin-treated cells, can be directly phosphorylated by the mTOR kinase in vitro predominantly at the rapamycin-sensitive site Thr-412.	Sirolimus	101-110	ribosomal protein S6 kinase B1	Homo sapiens	44-52
10567431-3	1999	We report here that a mammalian recombinant p70alpha polypeptide, extracted in an inactive form from rapamycin-treated cells, can be directly phosphorylated by the mTOR kinase in vitro predominantly at the rapamycin-sensitive site Thr-412.	Sirolimus	206-215	ribosomal protein S6 kinase B1	Homo sapiens	44-52
10567431-3	1999	We report here that a mammalian recombinant p70alpha polypeptide, extracted in an inactive form from rapamycin-treated cells, can be directly phosphorylated by the mTOR kinase in vitro predominantly at the rapamycin-sensitive site Thr-412.	Threonine	231-234	ribosomal protein S6 kinase B1	Homo sapiens	44-52
10551813-0	1999	Hydrogen peroxide activates p70(S6k) signaling pathway.	Hydrogen Peroxide	0-17	ribosomal protein S6 kinase B1	Homo sapiens	32-35
10551813-6	1999	However, down-regulation of 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive protein kinase C (PKC) by chronic pretreatment with TPA or a specific PKC inhibitor Ro-31-8220 did not block the activation of p70(S6k) by ROS, indicating that the activation of TPA-responsive PKC was not required for stimulation of p70(S6k) activity by H(2)O(2) in JB6 cells.	Tetradecanoylphorbol Acetate	134-137	ribosomal protein S6 kinase B1	Homo sapiens	213-216
10551813-6	1999	However, down-regulation of 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive protein kinase C (PKC) by chronic pretreatment with TPA or a specific PKC inhibitor Ro-31-8220 did not block the activation of p70(S6k) by ROS, indicating that the activation of TPA-responsive PKC was not required for stimulation of p70(S6k) activity by H(2)O(2) in JB6 cells.	Tetradecanoylphorbol Acetate	134-137	ribosomal protein S6 kinase B1	Homo sapiens	319-322
10551813-7	1999	Exposure of JB6 cells to platelet-derived growth factor or epidermal growth factor led to a rapid increase in H(2)O(2), phosphorylation, and activation of p70(S6k), which were antagonized by the pretreatment of catalase.	Hydrogen Peroxide	110-118	ribosomal protein S6 kinase B1	Homo sapiens	159-162
10551813-8	1999	Taken together, the results suggest that ROS act as a messenger in growth factor-induced p70(S6k) signaling pathway.	Reactive Oxygen Species	41-44	ribosomal protein S6 kinase B1	Homo sapiens	93-96
10545192-0	1999	Phosphatidylinositol 3-kinase requirement in activation of the ras/C-raf-1/MEK/ERK and p70(s6k) signaling cascade by the insulinomimetic agent vanadyl sulfate.	vanadyl sulfate	143-158	ribosomal protein S6 kinase B1	Homo sapiens	87-94
10502303-4	1999	pp52(S6K) was inhibited by fluoride (IC(50) approximately 60 mM), but was relatively insensitive to beta-glycerolphosphate, EGTA, dithiothreitol, spermine, heparin, NaCl, and metal ions such as Mn(2+), Zn(2+), and Ca(2+).	Fluorides	27-35	ribosomal protein S6 kinase B1	Homo sapiens	5-8
10502303-4	1999	pp52(S6K) was inhibited by fluoride (IC(50) approximately 60 mM), but was relatively insensitive to beta-glycerolphosphate, EGTA, dithiothreitol, spermine, heparin, NaCl, and metal ions such as Mn(2+), Zn(2+), and Ca(2+).	Heparin	156-163	ribosomal protein S6 kinase B1	Homo sapiens	5-8
10499523-9	1999	Both AG1478 and PD98059 inhibited ET-1-induced phosphorylation and activation of p70S6K.	RTKI cpd	5-11	ribosomal protein S6 kinase B1	Homo sapiens	81-87
10499523-9	1999	Both AG1478 and PD98059 inhibited ET-1-induced phosphorylation and activation of p70S6K.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	16-23	ribosomal protein S6 kinase B1	Homo sapiens	81-87
10480882-7	1999	Expression of a p70 S6K mutant partially resistant to rapamycin reverses the inhibitory effect of the drug on DNA synthesis, indicating that rapamycin action is via p70 S6K.	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	16-23
10480882-7	1999	Expression of a p70 S6K mutant partially resistant to rapamycin reverses the inhibitory effect of the drug on DNA synthesis, indicating that rapamycin action is via p70 S6K.	Sirolimus	141-150	ribosomal protein S6 kinase B1	Homo sapiens	16-23
10480882-7	1999	Expression of a p70 S6K mutant partially resistant to rapamycin reverses the inhibitory effect of the drug on DNA synthesis, indicating that rapamycin action is via p70 S6K.	Sirolimus	141-150	ribosomal protein S6 kinase B1	Homo sapiens	165-172
10490847-5	1999	Similar to S6K1, S6K2 is activated by mitogens and by constitutively active PI3K, and is inhibited by rapamycin as well as wortmannin.	Sirolimus	102-111	ribosomal protein S6 kinase B1	Homo sapiens	11-15
10490847-5	1999	Similar to S6K1, S6K2 is activated by mitogens and by constitutively active PI3K, and is inhibited by rapamycin as well as wortmannin.	Wortmannin	123-133	ribosomal protein S6 kinase B1	Homo sapiens	11-15
10490848-4	1999	Conceptual translation of the SRK cDNA revealed that the catalytic domain of SRK was highly homologous to that of p70S6K, and that the treatment of wortmannin or rapamycin strongly inhibited the phosphorylation and the activation of SRK, as in p70S6K.	Wortmannin	148-158	ribosomal protein S6 kinase B1	Homo sapiens	114-120
10490848-4	1999	Conceptual translation of the SRK cDNA revealed that the catalytic domain of SRK was highly homologous to that of p70S6K, and that the treatment of wortmannin or rapamycin strongly inhibited the phosphorylation and the activation of SRK, as in p70S6K.	Wortmannin	148-158	ribosomal protein S6 kinase B1	Homo sapiens	244-250
10490848-4	1999	Conceptual translation of the SRK cDNA revealed that the catalytic domain of SRK was highly homologous to that of p70S6K, and that the treatment of wortmannin or rapamycin strongly inhibited the phosphorylation and the activation of SRK, as in p70S6K.	Sirolimus	162-171	ribosomal protein S6 kinase B1	Homo sapiens	114-120
10454535-7	1999	Microinjection of highly specific inhibitors of PI3K or Rac1, or treatment with the p70s6k inhibitor rapamycin, impaired cAMP-stimulated DNA synthesis, demonstrating that PKA-dependent and -independent pathways contribute to cAMP-mediated mitogenesis.	Sirolimus	101-110	ribosomal protein S6 kinase B1	Homo sapiens	84-90
10455142-1	1999	While studying the stress regulation of p70/85 S6 kinase (S6K), we observed that anisomycin and UV light stimulated S6K activity, but that sorbitol inactivated S6K.	Anisomycin	81-91	ribosomal protein S6 kinase B1	Homo sapiens	47-56
10455142-1	1999	While studying the stress regulation of p70/85 S6 kinase (S6K), we observed that anisomycin and UV light stimulated S6K activity, but that sorbitol inactivated S6K.	Anisomycin	81-91	ribosomal protein S6 kinase B1	Homo sapiens	58-61
10455142-1	1999	While studying the stress regulation of p70/85 S6 kinase (S6K), we observed that anisomycin and UV light stimulated S6K activity, but that sorbitol inactivated S6K.	Anisomycin	81-91	ribosomal protein S6 kinase B1	Homo sapiens	116-119
10455142-1	1999	While studying the stress regulation of p70/85 S6 kinase (S6K), we observed that anisomycin and UV light stimulated S6K activity, but that sorbitol inactivated S6K.	Anisomycin	81-91	ribosomal protein S6 kinase B1	Homo sapiens	116-119
10455142-1	1999	While studying the stress regulation of p70/85 S6 kinase (S6K), we observed that anisomycin and UV light stimulated S6K activity, but that sorbitol inactivated S6K.	Sorbitol	139-147	ribosomal protein S6 kinase B1	Homo sapiens	47-56
10455142-1	1999	While studying the stress regulation of p70/85 S6 kinase (S6K), we observed that anisomycin and UV light stimulated S6K activity, but that sorbitol inactivated S6K.	Sorbitol	139-147	ribosomal protein S6 kinase B1	Homo sapiens	58-61
10455142-2	1999	Pretreatment with hyperosmotic stress also prevented the activation of S6K by both 12-O-tetradecanoylphorbol-13-acetate and anisomycin.	Tetradecanoylphorbol Acetate	83-119	ribosomal protein S6 kinase B1	Homo sapiens	71-74
10455142-2	1999	Pretreatment with hyperosmotic stress also prevented the activation of S6K by both 12-O-tetradecanoylphorbol-13-acetate and anisomycin.	Anisomycin	124-134	ribosomal protein S6 kinase B1	Homo sapiens	71-74
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Sorbitol	14-22	ribosomal protein S6 kinase B1	Homo sapiens	75-78
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Sorbitol	14-22	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Sorbitol	14-22	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	75-78
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Serine	111-114	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Serine	111-114	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Threonine	115-118	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Threonine	115-118	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Carbonic Acid	136-140	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Carbonic Acid	136-140	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Threonine	168-171	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Threonine	168-171	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10455142-4	1999	Rapamycin-resistant S6K truncation mutants were similarly resistant to deactivation by sorbitol.	Sorbitol	87-95	ribosomal protein S6 kinase B1	Homo sapiens	20-23
10455142-8	1999	However, calyculin A prevented both rapamycin- and sorbitol-mediated deactivation of S6K.	calyculin A	9-20	ribosomal protein S6 kinase B1	Homo sapiens	85-88
10455142-8	1999	However, calyculin A prevented both rapamycin- and sorbitol-mediated deactivation of S6K.	Sirolimus	36-45	ribosomal protein S6 kinase B1	Homo sapiens	85-88
10455142-8	1999	However, calyculin A prevented both rapamycin- and sorbitol-mediated deactivation of S6K.	Sorbitol	51-59	ribosomal protein S6 kinase B1	Homo sapiens	85-88
10446965-2	1999	Treatment of cells with rapamycin, a selective FRAP Inhibitor, inhibited basal p70s6K kinase activity and induced dephosphorylation of p70s6K and 4E-BP1.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	79-85
10446965-2	1999	Treatment of cells with rapamycin, a selective FRAP Inhibitor, inhibited basal p70s6K kinase activity and induced dephosphorylation of p70s6K and 4E-BP1.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	135-152
10716639-4	2000	Rapamycin kills normal cells more readily in normal than in A-T cells, and inhibits the FRAP target p70 S6 kinase (p70S6K) more readily in normal than in A-T cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	100-113
10716639-4	2000	Rapamycin kills normal cells more readily in normal than in A-T cells, and inhibits the FRAP target p70 S6 kinase (p70S6K) more readily in normal than in A-T cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	115-121
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Wortmannin	136-146	ribosomal protein S6 kinase B1	Homo sapiens	58-61
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Wortmannin	136-146	ribosomal protein S6 kinase B1	Homo sapiens	54-61
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Reactive Oxygen Species	161-164	ribosomal protein S6 kinase B1	Homo sapiens	58-61
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Reactive Oxygen Species	161-164	ribosomal protein S6 kinase B1	Homo sapiens	54-61
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Reactive Oxygen Species	161-164	ribosomal protein S6 kinase B1	Homo sapiens	97-100
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Wortmannin	231-241	ribosomal protein S6 kinase B1	Homo sapiens	58-61
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Wortmannin	231-241	ribosomal protein S6 kinase B1	Homo sapiens	54-61
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Wortmannin	231-241	ribosomal protein S6 kinase B1	Homo sapiens	97-100
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Reactive Oxygen Species	161-164	ribosomal protein S6 kinase B1	Homo sapiens	58-61
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Reactive Oxygen Species	161-164	ribosomal protein S6 kinase B1	Homo sapiens	54-61
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Reactive Oxygen Species	161-164	ribosomal protein S6 kinase B1	Homo sapiens	97-100
10551813-5	1999	In addition, Ca(2+) chelation also inhibited ROS-induced activation of p70(S6k), indicating that Ca(2+) is a mediator of p70(S6k) activation by ROS.	Reactive Oxygen Species	45-48	ribosomal protein S6 kinase B1	Homo sapiens	75-78
10551813-5	1999	In addition, Ca(2+) chelation also inhibited ROS-induced activation of p70(S6k), indicating that Ca(2+) is a mediator of p70(S6k) activation by ROS.	Reactive Oxygen Species	45-48	ribosomal protein S6 kinase B1	Homo sapiens	125-128
10551813-5	1999	In addition, Ca(2+) chelation also inhibited ROS-induced activation of p70(S6k), indicating that Ca(2+) is a mediator of p70(S6k) activation by ROS.	Reactive Oxygen Species	144-147	ribosomal protein S6 kinase B1	Homo sapiens	75-78
10551813-5	1999	In addition, Ca(2+) chelation also inhibited ROS-induced activation of p70(S6k), indicating that Ca(2+) is a mediator of p70(S6k) activation by ROS.	Reactive Oxygen Species	144-147	ribosomal protein S6 kinase B1	Homo sapiens	125-128
10551813-6	1999	However, down-regulation of 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive protein kinase C (PKC) by chronic pretreatment with TPA or a specific PKC inhibitor Ro-31-8220 did not block the activation of p70(S6k) by ROS, indicating that the activation of TPA-responsive PKC was not required for stimulation of p70(S6k) activity by H(2)O(2) in JB6 cells.	Tetradecanoylphorbol Acetate	66-69	ribosomal protein S6 kinase B1	Homo sapiens	213-216
10551813-6	1999	However, down-regulation of 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive protein kinase C (PKC) by chronic pretreatment with TPA or a specific PKC inhibitor Ro-31-8220 did not block the activation of p70(S6k) by ROS, indicating that the activation of TPA-responsive PKC was not required for stimulation of p70(S6k) activity by H(2)O(2) in JB6 cells.	Tetradecanoylphorbol Acetate	66-69	ribosomal protein S6 kinase B1	Homo sapiens	319-322
10551813-6	1999	However, down-regulation of 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive protein kinase C (PKC) by chronic pretreatment with TPA or a specific PKC inhibitor Ro-31-8220 did not block the activation of p70(S6k) by ROS, indicating that the activation of TPA-responsive PKC was not required for stimulation of p70(S6k) activity by H(2)O(2) in JB6 cells.	Tetradecanoylphorbol Acetate	134-137	ribosomal protein S6 kinase B1	Homo sapiens	213-216
10551813-6	1999	However, down-regulation of 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive protein kinase C (PKC) by chronic pretreatment with TPA or a specific PKC inhibitor Ro-31-8220 did not block the activation of p70(S6k) by ROS, indicating that the activation of TPA-responsive PKC was not required for stimulation of p70(S6k) activity by H(2)O(2) in JB6 cells.	Tetradecanoylphorbol Acetate	134-137	ribosomal protein S6 kinase B1	Homo sapiens	319-322
10502303-4	1999	pp52(S6K) was inhibited by fluoride (IC(50) approximately 60 mM), but was relatively insensitive to beta-glycerolphosphate, EGTA, dithiothreitol, spermine, heparin, NaCl, and metal ions such as Mn(2+), Zn(2+), and Ca(2+).	Sodium Chloride	165-169	ribosomal protein S6 kinase B1	Homo sapiens	5-8
10502303-4	1999	pp52(S6K) was inhibited by fluoride (IC(50) approximately 60 mM), but was relatively insensitive to beta-glycerolphosphate, EGTA, dithiothreitol, spermine, heparin, NaCl, and metal ions such as Mn(2+), Zn(2+), and Ca(2+).	Metals	175-180	ribosomal protein S6 kinase B1	Homo sapiens	5-8
10502303-4	1999	pp52(S6K) was inhibited by fluoride (IC(50) approximately 60 mM), but was relatively insensitive to beta-glycerolphosphate, EGTA, dithiothreitol, spermine, heparin, NaCl, and metal ions such as Mn(2+), Zn(2+), and Ca(2+).	Zinc	202-204	ribosomal protein S6 kinase B1	Homo sapiens	5-8
10502303-5	1999	The consensus sequence for substrate phosphorylation was determined to be RXXSXR, which was partially distinct from mammalian p70(S6K) in its requirement for an amino-terminal arginine.	Arginine	176-184	ribosomal protein S6 kinase B1	Homo sapiens	130-133
10502303-6	1999	Phosphorylation of ribosomal protein S6 by p52(S6K) occurred exclusively on serine on at least five tryptic peptides.	Serine	76-82	ribosomal protein S6 kinase B1	Homo sapiens	47-50
10502303-6	1999	Phosphorylation of ribosomal protein S6 by p52(S6K) occurred exclusively on serine on at least five tryptic peptides.	Peptides	108-116	ribosomal protein S6 kinase B1	Homo sapiens	47-50
10551813-1	1999	We investigated a possible role of reactive oxygen species (ROS) in p70(S6k) activation, which plays an important role in the progression of cells from G(0)/G(1) to S phase of the cell cycle by translational up-regulation of a family of mRNA transcripts that encode for components of the protein synthetic machinery.	Reactive Oxygen Species	35-58	ribosomal protein S6 kinase B1	Homo sapiens	72-75
10551813-1	1999	We investigated a possible role of reactive oxygen species (ROS) in p70(S6k) activation, which plays an important role in the progression of cells from G(0)/G(1) to S phase of the cell cycle by translational up-regulation of a family of mRNA transcripts that encode for components of the protein synthetic machinery.	Reactive Oxygen Species	60-63	ribosomal protein S6 kinase B1	Homo sapiens	72-75
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Reactive Oxygen Species	28-31	ribosomal protein S6 kinase B1	Homo sapiens	58-61
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Reactive Oxygen Species	28-31	ribosomal protein S6 kinase B1	Homo sapiens	54-61
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Reactive Oxygen Species	28-31	ribosomal protein S6 kinase B1	Homo sapiens	97-100
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Sirolimus	121-130	ribosomal protein S6 kinase B1	Homo sapiens	58-61
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Sirolimus	121-130	ribosomal protein S6 kinase B1	Homo sapiens	54-61
10490848-4	1999	Conceptual translation of the SRK cDNA revealed that the catalytic domain of SRK was highly homologous to that of p70S6K, and that the treatment of wortmannin or rapamycin strongly inhibited the phosphorylation and the activation of SRK, as in p70S6K.	Sirolimus	162-171	ribosomal protein S6 kinase B1	Homo sapiens	244-250